Clustering O 0 1.986115239560604e-05
of O 0 3.2851577458359316e-08
missense O 0 3.9813916373532265e-05
mutations O 0 9.79047308646841e-06
in O 0 2.764845241642888e-08
the O 0 1.6310973478539381e-06
ataxia B-Disease 1 1.0
- I-Disease 1 0.9999992847442627
telangiectasia I-Disease 1 0.9999997615814209
gene O 0 9.345186299469788e-06
in O 0 2.037832125267869e-09
a O 0 1.9007451612651494e-08
sporadic B-Disease 0 2.0744355424540117e-05
T I-Disease 0 0.1427030712366104
- I-Disease 0 0.0739503800868988
cell I-Disease 0 0.24461276829242706
leukaemia I-Disease 0 0.07722972333431244
. O 0 3.7607094327540835e-08

Ataxia B-Disease 1 1.0
- I-Disease 1 0.9999988079071045
telangiectasia I-Disease 1 0.9999998807907104
( O 0 0.01208591554313898
A B-Disease 1 0.9999994039535522
- I-Disease 1 0.9999898672103882
T I-Disease 1 0.9999992847442627
) O 0 1.220015088954085e-09
is O 0 5.503634215031639e-10
a O 0 2.877895921571394e-09
recessive B-Disease 0 9.088954539038241e-05
multi I-Disease 0 0.00031070882687345147
- I-Disease 1 0.9878143072128296
system I-Disease 0 0.0008991353679448366
disorder I-Disease 0 0.2027243822813034
caused O 0 4.213192639213048e-08
by O 0 1.6156924409482798e-10
mutations O 0 7.329087559071468e-09
in O 0 6.127742063766206e-11
the O 0 6.642979222259981e-11
ATM O 0 1.4030407058385208e-08
gene O 0 9.38696320673671e-09
at O 0 5.61445390179216e-10
11q22 O 0 2.3364056289665314e-07
- O 0 5.43435589861474e-07
q23 O 0 1.0750819683380541e-06
( O 0 1.2955719830287649e-09
ref O 0 4.463883556127257e-07
. O 0 7.948789404466083e-10
3 O 0 1.5648877749185885e-09
) O 0 1.2297057816468282e-09
. O 0 1.2495337209372792e-08

The O 0 2.6138368980355153e-07
risk O 0 5.124246058585413e-07
of O 0 3.2121789672601153e-09
cancer B-Disease 0 8.848565812513698e-06
, O 0 3.0719067289908253e-09
especially O 0 2.58911470041312e-09
lymphoid B-Disease 0 1.484005736074323e-07
neoplasias I-Disease 0 1.244265240529785e-05
, O 0 1.350948797274043e-09
is O 0 1.3766456863351095e-09
substantially O 0 2.6860263346861757e-07
elevated O 0 1.3782083442492876e-05
in O 0 1.987788778023969e-08
A B-Disease 1 0.9999992847442627
- I-Disease 1 0.9999997615814209
T I-Disease 1 1.0
patients O 1 0.9993026256561279
and O 0 1.2864274090418348e-08
has O 0 6.106910888092898e-08
long O 0 6.139329933319004e-09
been O 0 1.566770180261301e-08
associated O 0 4.8142951847296445e-09
with O 0 3.831517325636469e-09
chromosomal O 1 0.9999964237213135
instability O 1 0.999813973903656
. O 0 4.344323372151848e-07

By O 0 1.0551896423294238e-07
analysing O 0 2.356654022150906e-06
tumour B-Disease 1 0.999915361404419
DNA O 0 1.3866135759599274e-06
from O 0 3.5579661439300025e-09
patients O 0 1.1270786615114048e-07
with O 0 1.2737113586069881e-09
sporadic B-Disease 0 1.0150743946724106e-05
T I-Disease 0 0.0017984623555094004
- I-Disease 0 0.00011589502537390217
cell I-Disease 0 0.0032090414315462112
prolymphocytic I-Disease 0 0.008009742945432663
leukaemia I-Disease 0 0.011380159296095371
( O 0 6.198111801580808e-09
T B-Disease 0 7.189785264927195e-06
- I-Disease 0 5.753739969804883e-06
PLL I-Disease 0 2.159853102057241e-05
) O 0 1.016431050437916e-09
, O 0 1.0951627799071773e-10
a O 0 1.1835283864058965e-09
rare O 0 1.542356109496268e-08
clonal B-Disease 0 3.269686601470312e-07
malignancy I-Disease 0 1.4794925391470315e-06
with O 0 8.342980750697393e-10
similarities O 0 9.173048098887193e-09
to O 0 1.1003034039447357e-09
a O 0 3.247274804607514e-08
mature B-Disease 0 1.6385484968850506e-07
T I-Disease 0 7.241518233058741e-06
- I-Disease 0 5.340879852155922e-06
cell I-Disease 0 4.207946403766982e-05
leukaemia I-Disease 0 0.0002938428078778088
seen O 0 3.138237048005976e-08
in O 0 1.8439940685510692e-09
A B-Disease 1 0.9969226717948914
- I-Disease 1 0.9959631562232971
T I-Disease 1 0.9999991655349731
, O 0 3.057258446403921e-09
we O 0 1.738348076596452e-10
demonstrate O 0 7.802870016782038e-10
a O 0 6.237850791457333e-10
high O 0 2.413785171739846e-09
frequency O 0 7.95461740921155e-09
of O 0 4.4596215609260526e-11
ATM O 0 1.0657012694537116e-07
mutations O 0 1.0219936541489005e-07
in O 0 6.883438263827202e-09
T B-Disease 0 0.00013257843966130167
- I-Disease 0 0.000227490600082092
PLL I-Disease 0 0.0011951897758990526
. O 0 2.3602635224051483e-07

In O 0 1.461313416939447e-07
marked O 0 2.1547411677147466e-07
contrast O 0 1.16918883463768e-07
to O 0 1.0546474804584705e-09
the O 0 1.2167332419377175e-10
ATM O 0 3.819917182568133e-08
mutation O 0 5.496747590427731e-08
pattern O 0 9.989820881628475e-08
in O 0 1.2538071025858244e-08
A B-Disease 1 0.9999985694885254
- I-Disease 1 0.9999916553497314
T I-Disease 1 1.0
, O 0 7.1015633373860965e-09
the O 0 6.302511290634527e-11
most O 0 1.3969352063991636e-10
frequent O 0 1.6879083686305307e-09
nucleotide O 0 1.253873449513776e-09
changes O 0 7.928862011397086e-10
in O 0 1.688622436324394e-10
this O 0 4.027668865091982e-09
leukaemia B-Disease 0 9.217161277774721e-05
were O 0 4.4286466049925366e-08
missense O 0 7.775756785122212e-06
mutations O 0 1.4340840834847768e-06
. O 0 3.836755624320176e-08

These O 0 1.4650250079739635e-07
clustered O 0 3.2062618515737995e-07
in O 0 1.3404714005460505e-09
the O 0 8.5166346197596e-11
region O 0 4.0643849397170584e-10
corresponding O 0 2.660313080937726e-10
to O 0 1.3747793181639878e-10
the O 0 2.335162965771964e-11
kinase O 0 8.124358963357281e-09
domain O 0 6.865655266530268e-10
, O 0 6.181883477340833e-11
which O 0 1.5971157729666174e-10
is O 0 1.0480536577484045e-10
highly O 0 2.1759315183000894e-10
conserved O 0 5.279847115069458e-10
in O 0 7.54427006977032e-11
ATM O 0 5.999285956903577e-09
- O 0 1.3570908841131768e-08
related O 0 6.353060855168735e-10
proteins O 0 1.3516543440061923e-10
in O 0 1.0404987288437084e-10
mouse O 0 4.671047904025727e-08
, O 0 3.6904579392427195e-10
yeast O 0 2.575620605682616e-08
and O 0 3.500073342266319e-09
Drosophila O 0 2.6939703801076575e-08
. O 0 2.1923224124975604e-08

The O 0 1.1070153504988411e-07
resulting O 0 1.5837615308100794e-07
amino O 0 2.5609391940406567e-08
- O 0 1.282818686831888e-07
acid O 0 7.433042981119797e-08
substitutions O 0 7.459285633615309e-09
are O 0 4.5131046122470764e-10
predicted O 0 1.211750433327552e-08
to O 0 2.454955572162021e-09
interfere O 0 3.1141002665435735e-08
with O 0 1.465020882385204e-09
ATP O 0 8.300212073208968e-08
binding O 0 1.0685223372774999e-07
or O 0 1.1587146797609194e-09
substrate O 0 1.0350820502935676e-06
recognition O 0 3.5904928807894976e-08
. O 0 3.522242053577429e-08

Two O 0 5.87800315088316e-08
of O 0 2.472172022649488e-09
seventeen O 0 5.8446655515353996e-08
mutated O 0 9.890395631373394e-07
T B-Disease 0 7.338143859669799e-06
- I-Disease 0 1.6121467751872842e-06
PLL I-Disease 0 2.964663326565642e-05
samples O 0 2.164088641620765e-07
had O 0 1.263650428739993e-08
a O 0 2.23034790636234e-09
previously O 0 1.1127543331213019e-07
reported O 0 2.5431998551539436e-07
A B-Disease 1 0.9994156360626221
- I-Disease 1 0.9999649524688721
T I-Disease 1 0.9999997615814209
allele O 0 0.00029946895665489137
. O 0 9.10125024233821e-08

In O 0 2.0975066661321762e-07
contrast O 0 6.991012355683779e-07
, O 0 1.1375955732972898e-09
no O 0 1.5794373586786037e-09
mutations O 0 1.2491976342232647e-08
were O 0 1.5720856838541408e-09
detected O 0 1.0646850512330275e-08
in O 0 8.500973536218481e-11
the O 0 6.432041704806934e-11
p53 O 0 2.7732995899754087e-09
gene O 0 1.7685821696034054e-09
, O 0 2.7787029621695325e-11
suggesting O 0 1.2400881432839128e-09
that O 0 2.374368202051613e-10
this O 0 1.2247153291511381e-09
tumour B-Disease 1 0.9999938011169434
suppressor O 0 4.433092544786632e-05
is O 0 9.007988133191702e-09
not O 0 2.283343514264402e-09
frequently O 0 7.388768707983218e-09
altered O 0 7.177428074101044e-08
in O 0 6.79605594022803e-10
this O 0 1.239677338560341e-08
leukaemia B-Disease 0 9.416815737495199e-05
. O 0 2.8318643430225166e-08

Occasional O 0 7.891716086305678e-05
missense O 0 0.000351764407241717
mutations O 0 2.5648543669376522e-05
in O 0 1.1426847912332505e-08
ATM O 0 1.4431181227791967e-07
were O 0 8.670471629557142e-08
also O 0 2.566929957481534e-08
found O 0 1.5694320509851423e-08
in O 0 2.691226574924599e-09
tumour B-Disease 1 0.9999996423721313
DNA O 0 7.495606269003474e-07
from O 0 1.1450710379889983e-09
patients O 0 4.9765173315563516e-08
with O 0 3.661906056162678e-10
B B-Disease 0 4.559511168622521e-08
- I-Disease 0 8.281969599011063e-07
cell I-Disease 0 5.97999769524904e-06
non I-Disease 0 1.0027504515619512e-07
- I-Disease 0 0.014279080554842949
Hodgkins I-Disease 1 0.9839831590652466
lymphomas I-Disease 1 0.8912668228149414
( O 0 2.4673907361716374e-09
B B-Disease 0 1.1823178169834136e-07
- I-Disease 0 2.381372041782015e-07
NHL I-Disease 0 3.3630630724701405e-08
) O 0 1.207073330178332e-10
and O 0 2.9526392442136284e-10
a O 0 1.2781510072557012e-08
B B-Disease 0 4.803332558367401e-07
- I-Disease 0 1.7465874861954944e-06
NHL I-Disease 0 2.946488564248284e-07
cell O 0 1.1699288506861194e-06
line O 0 4.914001010547508e-07
. O 0 1.952765238399934e-08

The O 0 1.855779707682359e-08
evidence O 0 4.432007649768366e-09
of O 0 2.391853382022191e-11
a O 0 3.340307752619509e-10
significant O 0 8.450797284176303e-10
proportion O 0 2.5918223123255757e-09
of O 0 1.3668101372932284e-10
loss O 0 3.8038926675199036e-08
- O 0 3.7660359453184356e-07
of O 0 1.1701749569326125e-09
- O 0 3.4250447242811788e-06
function O 0 1.3807460064185761e-08
mutations O 0 1.2518380110293492e-08
and O 0 1.0203367317718204e-10
a O 0 3.168904028072461e-10
complete O 0 2.6703852462617306e-09
absence O 0 2.737875703928694e-09
of O 0 3.2536123101278847e-11
the O 0 9.747771340107292e-11
normal O 0 5.405921266188329e-10
copy O 0 1.61850011171083e-09
of O 0 2.0359419011795055e-11
ATM O 0 4.454482560589668e-09
in O 0 1.2706097285430928e-10
the O 0 7.461526535523788e-11
majority O 0 4.473136971938629e-09
of O 0 2.6017865639715865e-10
mutated O 0 0.0002751224674284458
tumours B-Disease 1 0.999969482421875
establishes O 0 5.415421355792205e-08
somatic O 0 1.1332501514971227e-07
inactivation O 0 2.4460720737806696e-07
of O 0 6.320616946497992e-11
this O 0 4.1556511704010646e-11
gene O 0 5.304335304323615e-10
in O 0 8.493647452034736e-11
the O 0 5.007187026118132e-11
pathogenesis O 0 8.625931080530336e-09
of O 0 1.4689373328824473e-10
sporadic B-Disease 0 3.7836791761947097e-06
T I-Disease 0 0.0005569603526964784
- I-Disease 0 1.546662133478094e-05
PLL I-Disease 0 1.7910453607328236e-05
and O 0 3.614595511791663e-09
suggests O 0 5.06240716013906e-10
that O 0 3.504652471009173e-11
ATM O 0 4.209511406116917e-09
acts O 0 1.8831989301304475e-09
as O 0 1.1814962341816226e-09
a O 0 1.7978675259655574e-07
tumour B-Disease 1 0.9999984502792358
suppressor O 0 0.004496503621339798
. O 0 1.773563127471789e-07

As O 0 7.964383286207521e-08
constitutional O 0 2.1375910819187993e-08
DNA O 0 4.784729412676825e-08
was O 0 2.6928606899900842e-08
not O 0 2.553064981647424e-10
available O 0 1.2737688681596637e-10
, O 0 2.670657445191793e-11
a O 0 1.0444023423872295e-09
putative O 0 1.300692701988737e-06
hereditary O 0 0.18574374914169312
predisposition O 0 0.015319469384849072
to O 0 8.763818755141983e-07
T B-Disease 0 0.0003570073749870062
- I-Disease 0 4.278646156308241e-05
PLL I-Disease 0 2.1009005649830215e-05
will O 0 2.711725244353147e-08
require O 0 2.766326057113133e-09
further O 0 2.3769750612245844e-09
investigation O 0 7.909351396051534e-09
. O 0 2.597573045548529e-09
. O 0 4.484677962324213e-09

Myotonic B-Disease 1 0.9999996423721313
dystrophy I-Disease 1 0.9999998807907104
protein O 0 0.00010758298594737425
kinase O 0 2.4330965970875695e-05
is O 0 9.656623944920284e-09
involved O 0 4.972840472738937e-10
in O 0 3.5290756428274506e-11
the O 0 1.6752250628360166e-11
modulation O 0 9.690111824056657e-09
of O 0 3.3780821889761725e-11
the O 0 2.7725260975941524e-10
Ca2 O 0 4.917793603453902e-07
+ O 0 7.6851002006606e-08
homeostasis O 0 1.0405692592030391e-06
in O 0 7.770111665195145e-09
skeletal O 0 8.143301238305867e-05
muscle O 0 7.040993659757078e-05
cells O 0 7.837091402507212e-07
. O 0 5.4791936321407775e-08

Myotonic B-Disease 1 0.9999997615814209
dystrophy I-Disease 1 1.0
( O 1 0.9527247548103333
DM B-Disease 1 1.0
) O 0 2.464323642925592e-07
, O 0 9.824997482255071e-10
the O 0 1.1434467261928205e-10
most O 0 1.990018372310942e-09
prevalent O 0 1.3185587022235268e-06
muscular B-Disease 1 0.9995705485343933
disorder I-Disease 1 0.9861474633216858
in O 0 6.713964495475011e-08
adults O 0 4.927835561829852e-06
, O 0 8.310470644978807e-10
is O 0 3.213722843398159e-09
caused O 0 6.109334549364576e-08
by O 0 7.551471670197429e-10
( O 0 2.4172855384030356e-10
CTG O 0 2.0662152167005843e-07
) O 0 3.459703634689504e-10
n O 0 5.06458253113351e-09
- O 0 2.9737178053323987e-08
repeat O 0 7.585341244009669e-09
expansion O 0 2.9918920119165193e-10
in O 0 3.808329693266721e-11
a O 0 8.326316025542013e-11
gene O 0 5.122295920756414e-10
encoding O 0 8.54020909546449e-10
a O 0 4.739934000852486e-10
protein O 0 3.8419766923425414e-08
kinase O 0 1.745678218867397e-06
( O 0 4.98265961823563e-09
DM B-Disease 1 0.9999984502792358
protein O 0 5.294050993143173e-07
kinase O 0 1.2818102277378784e-06
; O 0 4.105822792865865e-09
DMPK O 0 5.474794875226507e-07
) O 0 1.5151473131691517e-10
and O 0 1.444068892242356e-10
involves O 0 2.0763202268625491e-10
changes O 0 1.489568357548876e-09
in O 0 4.609681525380438e-10
cytoarchitecture O 0 6.895583055666066e-07
and O 0 6.8469581115948586e-09
ion O 0 2.4345320071006427e-06
homeostasis O 0 2.9136435841792263e-05
. O 0 6.531023188927065e-08

To O 0 1.910497502422004e-07
obtain O 0 4.623122862312812e-08
clues O 0 4.2353580198550844e-08
to O 0 2.098629492408577e-09
the O 0 2.341417060236495e-10
normal O 0 1.8418778724438312e-09
biological O 0 2.702840729007505e-10
role O 0 7.79247014137674e-11
of O 0 2.6391607649278725e-11
DMPK O 0 3.133569350666221e-07
in O 0 3.5186933922126684e-10
cellular O 0 7.927883238778577e-09
ion O 0 9.264025635502549e-08
homeostasis O 0 5.530320095203933e-07
, O 0 3.884251809083139e-10
we O 0 1.7396616092124617e-10
have O 0 3.5294611677727517e-10
compared O 0 4.787125140737203e-10
the O 0 5.346301873432324e-11
resting O 0 2.1681412221141727e-08
[ O 0 5.728837404461729e-10
Ca2 O 0 4.592369595712853e-09
+ O 0 2.056574688324986e-09
] O 0 9.723024607666275e-10
i O 0 1.488051792897238e-09
, O 0 2.2532385679507883e-11
the O 0 1.8652374783600933e-11
amplitude O 0 1.2844316721327687e-08
and O 0 7.959834458226567e-10
shape O 0 1.1904363717007982e-08
of O 0 3.3093985885024324e-10
depolarization O 0 1.4495154232463392e-07
- O 0 2.1773926164314616e-06
induced O 0 3.0752802558708936e-05
Ca2 O 0 5.440941777123953e-07
+ O 0 3.3153597200907825e-08
transients O 0 5.376819558478019e-07
, O 0 2.039405866405275e-10
and O 0 3.6595160929353554e-11
the O 0 1.228063657709999e-11
content O 0 3.5663416664277747e-10
of O 0 2.087525118044109e-11
ATP O 0 1.204588340186774e-08
- O 0 1.9379129412300244e-07
driven O 0 3.583173224797065e-07
ion O 0 7.615541619543365e-08
pumps O 0 1.0690727236806197e-07
in O 0 3.5987374191748245e-10
cultured O 0 7.109751720690838e-08
skeletal O 0 3.6237347558198962e-06
muscle O 0 3.2254942539111653e-07
cells O 0 3.439755591472249e-09
of O 0 3.887028893201361e-11
wild O 0 1.6575297800969224e-09
- O 0 4.2242729136887647e-07
type O 0 1.6029073321988108e-06
and O 0 1.3048327751619127e-08
DMPK O 0 7.587379059259547e-06
[ O 0 2.438650703595613e-08
- O 0 7.19151501016313e-07
/ O 0 3.233538734548347e-07
- O 0 8.271706064988393e-06
] O 0 3.233955112591502e-07
knockout O 0 1.551170316815842e-05
mice O 0 5.9556234191404656e-05
. O 0 1.581801711836306e-08

In O 0 2.776657481717848e-07
vitro O 0 1.2893821121906512e-06
- O 0 3.7943893858027877e-06
differentiated O 0 2.78582115242898e-06
DMPK O 0 3.3999372135440353e-06
[ O 0 4.125323727066643e-08
- O 0 3.8897869103493576e-07
/ O 0 1.4678080617613887e-07
- O 0 5.971467658127949e-07
] O 0 1.2245851443992706e-08
myotubes O 0 7.038403282422223e-08
exhibit O 0 1.0559967122958369e-08
a O 0 3.899017553266049e-09
higher O 0 3.9061709422583135e-09
resting O 0 4.8379455108715774e-08
[ O 0 1.3988689095967288e-09
Ca2 O 0 9.579520288127696e-09
+ O 0 2.3620561062642764e-09
] O 0 8.54307735664861e-10
i O 0 1.301464047642753e-09
than O 0 7.412616354063317e-11
do O 0 1.1003091493488881e-10
wild O 0 3.3572469804177274e-10
- O 0 8.326534128855201e-08
type O 0 2.2887674333560426e-07
myotubes O 0 4.874542014476901e-07
because O 0 3.8075761987776957e-10
of O 0 1.474730927653045e-11
an O 0 1.3521520014769806e-10
altered O 0 3.576126417215164e-08
open O 0 2.3818491623472937e-09
probability O 0 9.833808212178496e-10
of O 0 1.4073141263448719e-10
voltage O 0 3.992905931227142e-06
- O 0 2.3331192267050938e-07
dependent O 0 5.576295691867017e-08
l O 0 7.405504476309943e-08
- O 0 3.357833122663578e-08
type O 0 4.485707094659119e-08
Ca2 O 0 5.1059821259968885e-08
+ O 0 9.47329770184524e-09
and O 0 1.0049246990107008e-09
Na O 0 5.374138822844543e-08
+ O 0 4.987501966979835e-08
channels O 0 5.774909794808991e-08
. O 0 1.1408164191095693e-08

The O 0 4.187683444456525e-08
mutant O 0 2.4987116375996266e-07
myotubes O 0 5.803784688396263e-07
exhibit O 0 6.079820025206573e-08
smaller O 0 6.142562458677503e-09
and O 0 1.1394305499123902e-09
slower O 0 1.1891184215073736e-07
Ca2 O 0 5.079193101664714e-07
+ O 0 4.050643909181417e-08
responses O 0 7.201711227367014e-09
upon O 0 5.30820110089536e-10
triggering O 0 3.902990819426577e-09
by O 0 2.9138180757115606e-10
acetylcholine O 0 6.333829105642508e-08
or O 0 2.6141289133363443e-09
high O 0 1.3471773030460099e-08
external O 0 2.3700999918219168e-07
K O 0 4.4754477812603e-07
+ O 0 6.468689406347039e-08
. O 0 2.142763122492397e-08

In O 0 1.3724901748446428e-07
addition O 0 6.678329000919803e-09
, O 0 1.9406512508091112e-10
we O 0 8.001843632143846e-11
observed O 0 1.2946869965002605e-10
that O 0 1.2497755608187333e-10
these O 0 1.4897039157801828e-10
Ca2 O 0 8.251815586390876e-08
+ O 0 3.310216456497983e-08
transients O 0 4.843572583013156e-07
partially O 0 1.7654966200097988e-07
result O 0 1.568108753957631e-09
from O 0 2.6837655361933166e-11
an O 0 3.3876190047577026e-11
influx O 0 4.6132878073201766e-10
of O 0 4.282359536422753e-11
extracellular O 0 2.6799726882131836e-09
Ca2 O 0 3.0456313027116266e-08
+ O 0 1.3812825327974565e-09
through O 0 5.322777635319298e-11
the O 0 5.575946995795e-11
l O 0 1.578715291827848e-08
- O 0 7.172857863224635e-08
type O 0 8.244468574503117e-08
Ca2 O 0 1.9446257226718444e-07
+ O 0 4.942793552231706e-08
channel O 0 2.0209189699471608e-07
. O 0 1.896913204291195e-08

Neither O 0 2.4847017812135164e-06
the O 0 4.189359081863131e-09
content O 0 4.5920454105896624e-09
nor O 0 1.7938311946963381e-09
the O 0 1.697476013917676e-11
activity O 0 1.6985003681302402e-10
of O 0 2.3348423888736036e-11
Na O 0 1.3493683503895681e-08
+ O 0 7.484554309655778e-09
/ O 0 9.060335592891988e-09
K O 0 7.1152026492882214e-09
+ O 0 3.0294540209752086e-09
ATPase O 0 3.4680713412171826e-08
and O 0 3.039733353915608e-09
sarcoplasmic O 0 3.265725752044091e-07
reticulum O 0 1.3105116067890776e-06
Ca2 O 0 4.137057203479344e-07
+ O 0 3.0168276765607516e-08
- O 0 6.729015922246617e-08
ATPase O 0 3.169191700180818e-07
are O 0 9.424201419250267e-10
affected O 0 2.3785260427899857e-09
by O 0 7.87292397941286e-10
DMPK O 0 8.201913260563742e-06
absence O 0 1.3736791970586637e-07
. O 0 2.3743300658907174e-08

In O 0 2.052283605280536e-07
conclusion O 0 2.508605589923718e-08
, O 0 7.213874497757899e-10
our O 0 5.1964616637478755e-11
data O 0 1.4700976547210587e-10
suggest O 0 5.671973446474965e-10
that O 0 1.2631287682474124e-10
DMPK O 0 1.3163118239845062e-07
is O 0 2.1028476182571865e-10
involved O 0 4.6671402853526445e-11
in O 0 1.926503227778209e-11
modulating O 0 7.79157183217194e-09
the O 0 7.849679239946283e-11
initial O 0 8.377039617535331e-10
events O 0 6.900902072004556e-11
of O 0 1.4020434986605768e-11
excitation O 0 1.4093114231172876e-08
- O 0 2.1349503640522016e-06
contraction O 0 1.7146065829365398e-06
coupling O 0 9.98947484731616e-07
in O 0 4.331305980542766e-09
skeletal O 0 9.546250657876953e-05
muscle O 0 2.0855499315075576e-05
. O 0 4.314880452938041e-09
. O 0 1.7102212979125397e-08

Constitutional O 0 0.00010762917372630909
RB1 O 0 0.0070818886160850525
- O 0 2.3043397959554568e-05
gene O 0 2.0258967197150923e-06
mutations O 0 6.926322384970263e-06
in O 0 9.710277915075949e-09
patients O 0 2.4812443371047266e-06
with O 0 3.9054333100807526e-09
isolated O 0 2.776456085484824e-06
unilateral B-Disease 0 6.438643322326243e-05
retinoblastoma I-Disease 0 0.03978350758552551
. O 0 3.543678133155481e-07

In O 0 1.9873723999808135e-07
most O 0 3.2580633302359274e-08
patients O 0 3.1841059922044224e-07
with O 0 8.027896680751212e-10
isolated O 0 3.928712430933956e-07
unilateral B-Disease 0 1.2909871657029726e-05
retinoblastoma I-Disease 0 0.016871152445673943
, O 0 1.5509346695807835e-08
tumor B-Disease 0 2.092380100293667e-07
development O 0 1.3761146389068557e-10
is O 0 1.8248334787696052e-10
initiated O 0 6.016184772583699e-10
by O 0 1.0432271713156638e-10
somatic O 0 1.1939336630462094e-08
inactivation O 0 1.8588409034236975e-07
of O 0 4.8084446147012017e-11
both O 0 2.313953195720586e-10
alleles O 0 1.9176040755297663e-09
of O 0 6.798956536657741e-11
the O 0 4.4699555168392635e-09
RB1 O 0 1.1330841516610235e-05
gene O 0 4.102514310488914e-07
. O 0 3.6317427287713144e-08

However O 0 2.337400474061724e-06
, O 0 9.921073962360083e-10
some O 0 5.753143794695603e-11
of O 0 2.5554801330596177e-11
these O 0 1.3134916487800297e-09
patients O 0 5.701421628145908e-07
can O 0 1.5654379126317508e-08
transmit O 0 1.0710494279919658e-05
retinoblastoma B-Disease 0 4.6956909500295296e-05
predisposition O 0 0.00011121275019831955
to O 0 3.6776445000441527e-08
their O 0 7.896659326434019e-09
offspring O 0 1.0520683417780674e-06
. O 0 3.317896357657446e-08

To O 0 2.8074111924070166e-07
determine O 0 6.356605553037298e-08
the O 0 7.358471054708104e-10
frequency O 0 1.5937250452680018e-07
and O 0 1.1584252446183996e-09
nature O 0 6.939646080006412e-10
of O 0 9.414315854661126e-11
constitutional O 0 2.64705278141264e-07
RB1 O 0 3.265760824433528e-05
- O 0 2.022715790417351e-07
gene O 0 4.4081009065166654e-08
mutations O 0 7.366988086232595e-08
in O 0 8.298907117065824e-10
patients O 0 2.450141494136915e-07
with O 0 1.0714561460289929e-09
isolated O 0 4.115206309052155e-07
unilateral B-Disease 0 3.927954821847379e-06
retinoblastoma I-Disease 0 3.91979883715976e-05
, O 0 3.6206124764959213e-09
we O 0 3.6098329880829283e-10
analyzed O 0 7.272079827203015e-09
DNA O 0 1.101860203078786e-08
from O 0 5.15460896188813e-10
peripheral O 0 2.7078959874415887e-07
blood O 0 7.74290853655657e-08
and O 0 4.492760385943484e-09
from O 0 2.267026788516091e-09
tumor B-Disease 0 7.94843890616903e-06
tissue O 0 9.278308425564319e-06
. O 0 9.212626395083134e-08

The O 0 3.621249788920977e-08
analysis O 0 2.319134040362769e-08
of O 0 2.5751278887042872e-09
tumors B-Disease 1 0.9997119307518005
from O 0 3.146362503869682e-09
54 O 0 2.521274033995269e-08
( O 0 2.3175662777763506e-10
71 O 0 3.0835547448759826e-08
% O 0 9.653170623957763e-11
) O 0 1.7841625746251033e-11
of O 0 4.023572100497752e-11
76 O 0 2.1916351045092597e-07
informative O 0 8.936507356338552e-07
patients O 0 0.0011627919739112258
showed O 0 4.925307734993112e-07
loss O 0 4.610862358589429e-09
of O 0 9.134384221232139e-11
constitutional O 0 2.512049093184032e-07
heterozygosity O 0 0.0008181604207493365
( O 0 9.890513297250436e-08
LOH O 1 0.9992665648460388
) O 0 3.930137548735502e-09
at O 0 2.858066450173169e-09
intragenic O 0 1.1568756690394366e-06
loci O 0 2.1422670215542894e-07
. O 0 5.8791240320488214e-08

Three O 0 1.0260092864200487e-07
of O 0 1.5853649504293799e-09
13 O 0 3.698678341379491e-08
uninformative O 0 0.00046661606756970286
patients O 0 0.04949125275015831
had O 0 1.7256847684166132e-07
constitutional O 0 5.227206401059448e-08
deletions O 0 2.2724104837834602e-06
. O 0 1.228747805726016e-07

For O 0 1.3288999411997793e-07
39 O 0 2.2658355192106683e-07
randomly O 0 5.742682773757224e-08
selected O 0 8.95539784551147e-08
tumors B-Disease 1 0.9999445676803589
, O 0 5.492919452620981e-09
SSCP O 0 2.1869614101888146e-06
, O 0 1.348515965560182e-09
hetero O 0 3.167517661495367e-07
- O 0 2.1183772958011104e-07
duplex O 0 1.176805562863592e-05
analysis O 0 4.4738621696183145e-09
, O 0 5.732244540146425e-11
sequencing O 0 4.3017306383674736e-10
, O 0 9.89140436225e-11
and O 0 1.8853112127015237e-10
Southern O 0 7.415816294376043e-10
blot O 0 3.68000655726064e-06
analysis O 0 2.2963413393028986e-09
were O 0 3.0712724030657057e-10
used O 0 4.0569958503766657e-10
to O 0 2.7401430013895833e-09
identify O 0 2.601311166472442e-07
mutations O 0 1.0806894579218351e-06
. O 0 3.244470292429469e-08

Mutations O 0 0.0003759948303923011
were O 0 2.5424358796044544e-07
detected O 0 1.607407966730534e-07
in O 0 2.797274856192189e-09
21 O 0 1.3480023319800694e-08
( O 0 5.383068990560957e-10
91 O 0 4.641323414489307e-08
% O 0 4.0161443615183146e-10
) O 0 1.5344321646626469e-10
of O 0 1.900736901205846e-09
23 O 0 0.002914624521508813
tumors B-Disease 1 0.9999998807907104
with O 0 1.9396802599658258e-05
LOH O 1 0.9999903440475464
. O 0 7.230548249026469e-07

In O 0 8.102651349872758e-08
6 O 0 2.1528078875121537e-08
( O 0 5.484269705036127e-10
38 O 0 3.1824328061702545e-08
% O 0 2.7795682422393497e-10
) O 0 5.73648871460275e-11
of O 0 4.72408501206445e-10
16 O 0 3.457056300248951e-05
tumors B-Disease 1 1.0
without O 0 2.9184823233663337e-06
LOH O 1 0.9997095465660095
, O 0 9.177068549526268e-10
one O 0 6.334475166624998e-10
mutation O 0 5.827186733142753e-09
was O 0 1.3155808886722298e-08
detected O 0 1.0961586305313631e-08
, O 0 1.981431130282374e-10
and O 0 4.463631964046755e-10
in O 0 2.6888344328845903e-10
9 O 0 8.277613039453513e-10
( O 0 9.22675200132339e-11
56 O 0 3.203993159672791e-08
% O 0 5.031475236449978e-11
) O 0 1.0345160492142291e-11
of O 0 4.85938407568387e-11
the O 0 1.5261217356510315e-07
tumors B-Disease 1 1.0
without O 0 1.8671111092771753e-06
LOH O 1 0.9997960925102234
, O 0 8.515615435022994e-10
both O 0 5.95462901209487e-10
mutations O 0 1.713813091441807e-08
were O 0 6.6358687433876185e-09
found O 0 1.4853728025343571e-08
. O 0 2.2126672050148954e-08

Thus O 0 5.653326411447779e-07
, O 0 8.557983210977227e-10
a O 0 3.2606961575254445e-10
total O 0 1.4820292215667052e-10
of O 0 4.94978641407684e-11
45 O 0 5.180079476474475e-09
mutations O 0 4.051988611308843e-08
were O 0 7.172840987834661e-09
identified O 0 6.638555305471527e-08
in O 0 1.0273385697701087e-08
tumors B-Disease 1 0.9999967813491821
of O 0 3.6008334092230143e-09
36 O 0 1.0108760761795565e-06
patients O 0 5.14756857228349e-06
. O 0 5.306769423896185e-08

Thirty O 0 1.4337886568682734e-05
- O 0 2.195232127633062e-06
nine O 0 1.1350733686299463e-08
of O 0 6.617269926456615e-11
the O 0 3.134142390059935e-10
mutations O 0 2.30232011233511e-08
- O 0 5.667199687309221e-08
including O 0 2.032002566210167e-09
34 O 0 4.977378509352093e-09
small O 0 4.125571273494444e-10
mutations O 0 4.040782286551803e-08
, O 0 2.7690116866097014e-10
2 O 0 4.227629912811892e-10
large O 0 6.535179619682197e-10
structural O 0 3.366018859196629e-07
alterations O 0 9.201812645187601e-06
, O 0 1.791854664645598e-09
and O 0 2.770254470263467e-09
hypermethylation O 0 6.120103989815107e-06
in O 0 7.870434970413953e-09
3 O 0 5.632607553707203e-07
tumors O 1 0.9999990463256836
- O 0 0.00012226689432282
were O 0 2.4501787265762687e-07
not O 0 4.5344967780636125e-09
detected O 0 7.978747440517964e-09
in O 0 6.133191177148944e-11
the O 0 1.19127097075733e-10
corresponding O 0 4.551914400963142e-09
peripheral O 0 8.198176146834157e-07
blood O 0 1.401600968620187e-07
DNA O 0 2.6464999791642185e-07
. O 0 1.6162397642460746e-08

In O 0 7.197168088168837e-07
6 O 0 5.317022555573203e-08
( O 0 1.0806714412225915e-09
17 O 0 3.656185132427936e-09
% O 0 6.820686376807217e-11
) O 0 5.4041632280288354e-12
of O 0 7.426396303467087e-12
the O 0 1.0118602622455342e-09
36 O 0 3.0022593477951887e-07
patients O 0 3.822592873348185e-07
, O 0 7.568944776492614e-11
a O 0 1.0909767533817671e-09
mutation O 0 4.652083163136922e-08
was O 0 2.3476443899994592e-08
detected O 0 3.811211346516075e-09
in O 0 1.0927881516353821e-10
constitutional O 0 2.9804623213891546e-09
DNA O 0 1.5605786884975714e-08
, O 0 4.1613640311410904e-10
and O 0 2.3934884629817077e-10
1 O 0 4.8485337272863305e-11
of O 0 8.204857800120369e-12
these O 0 6.361933202470027e-11
mutations O 0 4.7127932667478944e-09
is O 0 4.688923138651546e-10
known O 0 7.232390797362598e-10
to O 0 1.8584850325353841e-09
be O 0 3.716028817990491e-09
associated O 0 2.032254586836757e-09
with O 0 1.4145568050238921e-09
reduced O 0 2.48583478423825e-06
expressivity O 0 0.0019483828218653798
. O 0 1.057882030863766e-07

The O 0 3.616908017534115e-08
presence O 0 6.775609406872718e-09
of O 0 4.793033678285319e-11
a O 0 1.1746271733059643e-09
constitutional O 0 4.30418083396944e-08
mutation O 0 6.676051498288871e-07
was O 0 2.09579297916207e-07
not O 0 8.305098830874158e-10
associated O 0 1.3453477221148091e-10
with O 0 4.531950162367515e-11
an O 0 5.739117514558245e-10
early O 0 2.223298523063022e-08
age O 0 1.1606928751461965e-08
at O 0 1.68152025636914e-09
treatment O 0 8.255190664385736e-07
. O 0 5.4641652980080835e-08

In O 0 2.5719785412547935e-07
1 O 0 7.315278338637654e-08
patient O 0 1.6621770555502735e-06
, O 0 1.1690751700044189e-09
somatic O 0 1.5513080597884255e-07
mosaicism O 0 9.248495189240202e-05
was O 0 2.1527068838622654e-06
demonstrated O 0 1.3925497199807069e-08
by O 0 7.474944274665773e-11
molecular O 0 6.37953134763336e-10
analysis O 0 4.2623318763368445e-10
of O 0 1.537668777029655e-11
DNA O 0 3.4297777951053376e-09
and O 0 2.3176105479194575e-10
RNA O 0 3.0053510791105964e-09
from O 0 6.169188493387878e-10
peripheral O 0 9.015534487843979e-07
blood O 0 7.419508278871945e-07
. O 0 4.410859233416886e-08

In O 0 6.768300409021322e-07
2 O 0 6.058948542886355e-07
patients O 0 2.715514256124152e-06
without O 0 7.80730646798844e-10
a O 0 5.888728171754565e-09
detectable O 0 9.192324341711355e-07
mutation O 0 1.8343207841553522e-07
in O 0 1.0404714867462417e-09
peripheral O 0 2.151459057131433e-06
blood O 0 4.422054757924343e-07
, O 0 2.0508204023883536e-09
mosaicism O 0 3.166181386404787e-06
was O 0 2.958215361559269e-07
suggested O 0 5.9884479597371865e-09
because O 0 4.2826392432360194e-10
1 O 0 6.331814933480118e-11
of O 0 3.41616179788673e-11
the O 0 6.044055922416192e-09
patients O 0 0.00018199329497292638
showed O 0 0.00010767763887997717
multifocal O 1 0.9999140501022339
tumors B-Disease 1 1.0
and O 0 2.085279859898037e-08
the O 0 2.2364382568085261e-10
other O 0 8.231006848324895e-11
later O 0 5.050980078635803e-09
developed O 0 8.231988424256542e-09
bilateral B-Disease 0 2.0404545608698754e-08
retinoblastoma I-Disease 0 0.00019021517073269933
. O 0 1.4190221975241002e-07

In O 0 1.770467150663535e-07
conclusion O 0 1.5932380748040487e-08
, O 0 1.012358308294381e-09
our O 0 1.8597356987726243e-10
results O 0 4.396819297536325e-10
emphasize O 0 1.3707190937850555e-09
that O 0 1.3826262357241603e-10
the O 0 5.985165141275672e-11
manifestation O 0 6.94431001591056e-09
and O 0 1.2652124903311801e-09
transmissibility O 0 2.8497993298515212e-08
of O 0 6.290958032284522e-11
retinoblastoma B-Disease 0 7.308096172664591e-08
depend O 0 5.365758060094095e-09
on O 0 1.4831101902146315e-09
the O 0 8.77289837997175e-11
nature O 0 2.395662279663924e-10
of O 0 7.818147171323453e-12
the O 0 5.1200172573873104e-11
first O 0 1.4125561831335176e-09
mutation O 0 5.6041322693545226e-09
, O 0 5.317886755951129e-11
its O 0 1.9074936075114124e-11
time O 0 2.3227618439758402e-10
in O 0 1.1931107490870119e-10
development O 0 4.989825913570556e-11
, O 0 1.9639390114178923e-10
and O 0 9.983026211246582e-11
the O 0 3.6690775417902444e-11
number O 0 2.8086341585797925e-10
and O 0 3.031579431933551e-10
types O 0 3.358489319982283e-10
of O 0 8.195238758446077e-12
cells O 0 6.299197830017533e-10
that O 0 4.59425941734537e-10
are O 0 4.2560927004942073e-10
affected O 0 2.772395202299549e-09
. O 0 9.027143477169375e-10
. O 0 6.697641996566972e-09

Hereditary B-Disease 1 0.9999843835830688
deficiency I-Disease 1 0.9990383386611938
of I-Disease 0 4.203390080448344e-09
the I-Disease 0 9.12399378272255e-10
fifth I-Disease 0 8.399155149163562e-09
component I-Disease 0 2.6122499718894687e-09
of I-Disease 0 2.884377459100307e-11
complement I-Disease 0 2.5601907260863754e-09
in O 0 3.0666496009246202e-09
man O 0 3.1522383778792573e-06
. O 0 2.1221055135356437e-08

I O 0 0.0001667549804551527
. O 0 1.4791763760513277e-06

Clinical O 0 0.0009290431626141071
, O 0 1.394749915561988e-07
immunochemical O 0 1.3499056876753457e-05
, O 0 5.125748270273789e-09
and O 0 1.8878165697344684e-09
family O 0 1.3800351084114482e-08
studies O 0 3.458583863746867e-09
. O 0 9.191279737308378e-09

The O 0 7.074338270740554e-08
first O 0 1.7283719344618476e-08
recognized O 0 1.3530743636636089e-08
human O 0 1.5895372795782237e-09
kindred O 0 3.2648787851030647e-07
with O 0 6.85140264522488e-08
hereditary B-Disease 1 0.9993057250976562
deficiency I-Disease 0 0.000612561299931258
of I-Disease 0 2.057695819290828e-10
the I-Disease 0 1.4210976839734712e-10
fifth I-Disease 0 4.7538706304806055e-09
component I-Disease 0 2.7305013805545286e-09
of I-Disease 0 6.834646737452488e-11
complement I-Disease 0 6.864611101775608e-09
( O 0 5.883941667228498e-10
C5 O 0 1.8164841719681135e-07
) O 0 3.4694175310434616e-10
is O 0 4.277987741829747e-09
described O 0 2.195367017066019e-07
. O 0 1.3635307105630545e-08

The O 0 1.2714502872768207e-07
proband O 0 2.0230506834195694e-06
, O 0 1.893738277303214e-09
a O 0 2.696364687082564e-09
20 O 0 1.554351314325686e-09
- O 0 2.4448223712170147e-07
year O 0 1.9453226585142147e-08
- O 0 4.989232820662437e-06
old O 0 8.807464837445877e-06
black O 0 2.487247456883779e-07
female O 0 1.2467809540339658e-07
with O 0 9.508818976655675e-08
systemic B-Disease 1 0.9999997615814209
lupus I-Disease 1 0.9999958276748657
erythematosus I-Disease 1 0.9999996423721313
since O 0 4.617690592567669e-06
age O 0 4.230812322703059e-08
11 O 0 1.2308367658420138e-09
, O 0 4.427408994978066e-10
lacked O 0 1.6056154095167585e-07
serum O 0 4.725117435100401e-07
hemolytic O 0 5.203243631513033e-07
complement O 0 2.2885275896555868e-09
activity O 0 1.2324341547298445e-09
, O 0 2.2012743017274516e-10
even O 0 2.1589419141321287e-09
during O 0 8.592138556196005e-09
remission O 0 3.007446025549143e-07
. O 0 1.3891514605290922e-08

C5 O 0 0.0014885814161971211
was O 0 5.194361619942356e-06
undetectable O 0 1.2761287280227407e-06
in O 0 3.3468079418952357e-09
her O 0 2.6761073357306486e-08
serum O 0 4.561772826150445e-08
by O 0 3.6342820419754673e-10
both O 0 7.373321397885491e-10
immunodiffusion O 0 1.8992593595612561e-06
and O 0 7.60158087587115e-08
hemolytic O 0 0.00010022099013440311
assays O 0 1.8222031940240413e-05
. O 0 1.899150987583198e-07

Other O 0 2.6468979896776546e-08
complement O 0 8.742571999675874e-09
components O 0 7.3796138089221586e-09
were O 0 1.4357917077489901e-09
normal O 0 2.4619610794474056e-09
during O 0 4.703704981068313e-09
remission O 0 7.96090446897324e-08
of O 0 3.0102145776034206e-10
lupus O 0 5.470596079248935e-06
, O 0 7.954567560197745e-10
but O 0 2.4697872635925933e-09
C1 O 0 4.672237707836757e-07
, O 0 6.148795361760051e-10
C4 O 0 1.0052552568140527e-07
, O 0 9.421869506809344e-09
C2 O 0 1.2118229051338858e-06
, O 0 2.4958421995791014e-09
and O 0 3.3842961766339386e-09
C3 O 0 8.221053349188878e-07
levels O 0 9.173957593588966e-09
fell O 0 1.6408127123668237e-07
during O 0 2.1621241685920722e-08
exacerbations O 0 0.0036145239137113094
. O 0 1.623801466621444e-07

A O 0 5.538867753784871e-06
younger O 0 6.2782582972431555e-06
half O 0 4.6582005808204485e-08
- O 0 6.705965347464371e-07
sister O 0 1.508071250100329e-06
, O 0 1.2738474719498072e-09
who O 0 2.787885833299697e-08
had O 0 6.366603599872178e-08
no O 0 5.4221573897450526e-09
underlying O 0 1.207299987981969e-06
disease O 0 2.072055394819472e-06
, O 0 1.6467744945458662e-09
was O 0 6.018331077939365e-07
also O 0 1.3339987781080254e-08
found O 0 1.9402228712550595e-09
to O 0 2.7325752771645284e-09
lack O 0 2.1387126736271966e-08
immunochemically O 0 0.00027320857043378055
detectable O 0 5.011297616874799e-06
C5 O 0 5.695423169527203e-06
. O 0 7.596261042408514e-08

By O 0 3.6581440099325846e-07
hemolytic O 0 6.660661892965436e-05
assay O 0 4.529305442702025e-06
, O 0 8.85886475288089e-09
she O 0 1.309105446267722e-08
exhibited O 0 1.601675059248464e-08
1 O 0 4.012538079578576e-10
- O 0 1.672375731232023e-07
2 O 0 1.0269604722168424e-08
% O 0 6.40388644890244e-11
of O 0 7.821667792617948e-12
the O 0 1.7949218500401543e-10
normal O 0 4.176944123912563e-09
serum O 0 1.0877800349362587e-07
C5 O 0 6.065538116217795e-08
level O 0 4.1997252897552073e-10
and O 0 2.708094026804275e-10
normal O 0 6.038268218766518e-10
concentrations O 0 2.020030809291029e-09
of O 0 1.1022368781588021e-11
other O 0 1.859844916962672e-11
complement O 0 1.5692965815716775e-09
components O 0 3.7134658015247624e-08
. O 0 1.1526402943218272e-08

C5 O 0 0.0006156854215078056
levels O 0 2.6188720880782057e-07
of O 0 1.5429135746813927e-10
other O 0 9.789358212941579e-11
family O 0 7.886209463237037e-10
members O 0 1.0883700191088863e-10
were O 0 7.570565840886445e-10
either O 0 5.945992032074798e-10
normal O 0 6.717468803429938e-10
or O 0 3.321166675007703e-10
approximately O 0 8.101175841268571e-10
half O 0 7.740379892595683e-09
- O 0 3.9634434756408154e-07
normal O 0 1.2009475192087393e-08
, O 0 1.7215333325548698e-10
consistent O 0 3.419144301020083e-09
with O 0 9.41284827860045e-10
autosomal O 0 1.6745119864935987e-05
codominant O 0 4.182358225079952e-06
inheritance O 0 1.925815418246657e-08
of O 0 6.665418217366437e-11
the O 0 2.7308438843576255e-10
gene O 0 2.0008098999824142e-07
determining O 0 5.16824729857035e-06
C5 B-Disease 1 0.9999995231628418
deficiency I-Disease 1 0.9999982118606567
. O 0 2.100689613371287e-07

Normal O 0 7.032243593130261e-05
hemolytic O 0 0.008572033606469631
titers O 0 0.0025272786151617765
were O 0 4.460219713564584e-07
restored O 0 4.8558526088982035e-08
to O 0 3.1963862667794274e-09
both O 0 2.814847377408114e-08
homozygous O 0 0.039505735039711
C5 B-Disease 1 0.9999967813491821
- I-Disease 1 0.9999825954437256
deficient I-Disease 1 1.0
( O 0 1.253367685194462e-07
C5D B-Disease 1 0.9999983310699463
) O 0 9.032762982030818e-09
sera O 0 7.286745073997736e-08
by O 0 3.213813382085817e-10
addition O 0 2.560043010912949e-10
of O 0 3.8620946718470606e-11
highly O 0 4.301076383939062e-09
purified O 0 9.787728316723587e-08
human O 0 1.7556200049284598e-08
C5 O 0 1.325199718849035e-06
. O 0 1.889135958776933e-08

In O 0 1.9315086774440715e-07
specific O 0 5.874685271578528e-08
C5 O 0 4.396380973048508e-06
titrations O 0 5.020046955905855e-05
, O 0 7.244032040887305e-09
however O 0 2.1162112062711458e-09
, O 0 1.5874762615553095e-10
it O 0 1.4506509327105732e-09
was O 0 3.3192071668963763e-07
noted O 0 3.894758737743587e-09
that O 0 2.8049296219023745e-10
when O 0 2.459176751123948e-10
limited O 0 1.5938657338399054e-10
amounts O 0 1.0201577083090996e-10
of O 0 3.6581064566387766e-11
C5 O 0 2.892645944996275e-08
were O 0 1.1709608838117447e-09
assayed O 0 1.2721289799344504e-08
in O 0 2.816111788206399e-10
the O 0 6.026115717538971e-11
presence O 0 7.229742915448867e-10
of O 0 1.3173548363276666e-10
low O 0 2.3252995973166435e-08
dilutions O 0 1.041693167280755e-06
of O 0 1.5015145793384477e-09
either O 0 2.756442540885473e-07
C5D B-Disease 1 0.9999985694885254
serum O 0 3.226569560865755e-06
, O 0 4.613464055225336e-10
curving O 0 1.7726897283409926e-08
rather O 0 1.7368243510063053e-09
than O 0 4.4330197845887653e-10
linear O 0 8.394350103912984e-09
dose O 0 8.395632562496758e-07
- O 0 3.235605561258126e-07
response O 0 9.314485538425288e-08
plots O 0 5.32471524650191e-08
were O 0 1.2076847966113746e-08
consistently O 0 1.1159999502297069e-07
obtained O 0 1.781325087435448e-09
, O 0 8.509344617824155e-11
suggesting O 0 7.765914578072852e-10
some O 0 1.6917751921585733e-10
inhibitory O 0 5.275171588436933e-08
effect O 0 1.4664928471574967e-07
. O 0 2.9295639691895303e-08

Further O 0 1.3711063502341858e-06
studies O 0 2.5187699037587663e-08
suggested O 0 1.9946858387243083e-08
that O 0 8.759226122201369e-10
low O 0 3.857138963780926e-08
dilutions O 0 5.590199180005584e-06
of O 0 9.618077001505299e-09
C5D B-Disease 1 0.9999969005584717
serum O 0 2.0129566564719426e-06
contain O 0 4.807587217214859e-09
a O 0 2.083879291348012e-09
factor O 0 2.3787167791056163e-09
( O 0 4.99323395131146e-11
or O 0 6.544381703221802e-11
factors O 0 4.3935163840380653e-10
) O 0 6.463229257347436e-11
interfering O 0 2.11322226384425e-09
at O 0 1.1536992888805386e-10
some O 0 9.419380553321588e-11
step O 0 1.5023395860680466e-09
in O 0 7.342693814083034e-11
the O 0 1.848239616908387e-10
hemolytic O 0 4.46948945409531e-07
assay O 0 6.086177961606154e-08
of O 0 5.6443244522697e-10
C5 O 0 3.49028283608277e-07
, O 0 6.328533808108716e-10
rather O 0 5.925183677035761e-10
than O 0 1.5604430247950773e-10
a O 0 1.1349299278151648e-09
true O 0 8.978860321917637e-09
C5 O 0 4.2041537540171703e-07
inhibitor O 0 1.8328711348658544e-07
or O 0 5.9874998292741566e-09
inactivator O 0 5.0190983529319055e-06
. O 0 1.0131782346434193e-07

Of O 0 6.120298223777354e-08
clinical O 0 7.812898275005864e-07
interest O 0 9.05156127828377e-09
are O 0 3.453493324645507e-10
( O 0 4.808022729951844e-11
a O 0 3.444272200781029e-09
) O 0 1.9645535198620223e-10
the O 0 1.4424750283126286e-10
documentation O 0 4.807431341902202e-09
of O 0 1.2917523717348445e-09
membranous O 1 0.9405668377876282
glomerulonephritis B-Disease 1 1.0
, O 0 6.866668263683096e-05
vasculitis B-Disease 1 0.9999997615814209
, O 0 7.533524239988765e-07
and O 0 0.00018708377319853753
arthritis B-Disease 1 1.0
in O 0 1.886597367217746e-08
an O 0 3.1608347050848806e-09
individual O 0 2.1652595272314556e-09
lacking O 0 7.362731224702657e-08
C5 O 0 4.551878021175071e-07
( O 0 2.0994732341517164e-10
and O 0 3.370187184881246e-10
its O 0 1.3645073959622778e-10
biologic O 0 1.4235325807021582e-08
functions O 0 1.8536976120753224e-10
) O 0 9.06089786534281e-11
, O 0 3.743244325615791e-10
and O 0 1.2152007178301005e-09
( O 0 8.307501908610959e-11
b O 0 1.479578348728694e-09
) O 0 1.17938983232313e-11
a O 0 2.563683154654939e-10
remarkable O 0 3.84798148900245e-09
propensity O 0 8.285610988423286e-07
to O 0 6.544390771523467e-07
bacterial B-Disease 1 0.9999994039535522
infections I-Disease 1 1.0
in O 0 5.353276488762049e-09
the O 0 4.2722289594898655e-10
proband O 0 6.50744766517164e-07
, O 0 3.1801297706302023e-10
even O 0 3.9047909350387044e-10
during O 0 2.3648816238619474e-10
periods O 0 7.966106663204187e-10
of O 0 4.916139717536794e-11
low O 0 1.520409043109794e-08
- O 0 5.96607662828319e-07
dose O 0 5.606432864624367e-07
or O 0 6.915254480155397e-10
alternate O 0 8.920923555422178e-09
- O 0 7.566832778138632e-07
day O 0 8.576832755124997e-08
corticosteroid O 0 0.016042150557041168
therapy O 0 1.1574335985642392e-05
. O 0 2.6421364651696422e-08

Other O 0 3.803675241442761e-08
observations O 0 1.9211914548122877e-07
indicate O 0 5.403617819865758e-08
that O 0 2.2747148609170154e-09
the O 0 1.947170424898559e-09
C5D B-Disease 1 0.999998927116394
state O 0 1.7797899820592988e-09
is O 0 3.668197690043229e-10
compatible O 0 1.3101838503004615e-09
with O 0 2.7175886541108696e-10
normal O 0 1.0251672843963888e-09
coagulation O 0 6.657166817802818e-09
function O 0 4.849867729639357e-10
and O 0 2.1898585722546215e-10
the O 0 2.5886480459202943e-11
capacity O 0 7.115524836009968e-10
to O 0 7.798853229878944e-10
mount O 0 8.66238920593787e-08
a O 0 2.437451485093334e-07
neutrophilic O 0 0.017755143344402313
leukocytosis O 0 0.0007791733951307833
during O 0 2.0730601590912556e-07
pyogenic B-Disease 0 0.010154237039387226
infection I-Disease 0 0.0006103630876168609
. O 0 9.47543021823094e-09
. O 0 1.4760557220938608e-08

Susceptibility O 1 0.9993651509284973
to O 0 0.37441301345825195
ankylosing B-Disease 1 1.0
spondylitis I-Disease 1 1.0
in O 0 0.0002075515512842685
twins O 0 9.484124348091427e-06
: O 0 3.768618472843599e-10
the O 0 3.820858560099616e-11
role O 0 2.5366830858075673e-10
of O 0 1.4021450667200952e-11
genes O 0 1.2186103237610268e-09
, O 0 1.117406833728296e-09
HLA O 0 5.883611038370873e-07
, O 0 2.6222641835715876e-09
and O 0 6.503049210238032e-10
the O 0 8.988211841476357e-10
environment O 0 6.732712876100777e-08
. O 0 2.5655399582547034e-08

OBJECTIVE O 0 5.6253998081956524e-06
To O 0 5.0558504938180704e-08
determine O 0 1.1249090547948981e-08
the O 0 2.8219726555533953e-10
relative O 0 6.049246437100919e-09
effects O 0 1.4682946414268372e-08
of O 0 1.477487993062354e-10
genetic O 0 2.165682033705707e-08
and O 0 1.8424048953136207e-09
environmental O 0 2.0746426798723405e-09
factors O 0 1.6866403829141063e-09
in O 0 5.50888845651798e-09
susceptibility O 1 0.9817731976509094
to O 1 0.7272824645042419
ankylosing B-Disease 1 1.0
spondylitis I-Disease 1 1.0
( O 0 1.45492213050602e-05
AS B-Disease 1 0.9999402761459351
) O 0 3.574564999553331e-08
. O 0 7.397952117571549e-08

METHODS O 0 1.1305916814308148e-05
Twins O 0 2.0374100131448358e-05
with O 0 3.921932290040786e-08
AS B-Disease 1 0.9952415227890015
were O 0 6.305706534703859e-08
identified O 0 1.0900746971742592e-08
from O 0 9.398348072009455e-11
the O 0 5.14588593958365e-10
Royal O 0 5.121144113218179e-07
National O 0 4.169971035139497e-09
Hospital O 0 1.7018816151903593e-06
for O 0 3.542488258290177e-08
Rheumatic B-Disease 1 0.8708749413490295
Diseases I-Disease 0 1.9474020518828183e-05
database O 0 1.5939151865040913e-07
. O 0 5.8172837213987805e-08

Clinical O 0 0.00038975299685262144
and O 0 2.812551258557505e-07
radiographic O 0 3.111612386419438e-05
examinations O 0 2.898473496770748e-07
were O 0 1.2088602119320058e-08
performed O 0 9.521138544243968e-09
to O 0 1.4678402937562396e-09
establish O 0 7.850169225775971e-08
diagnoses O 1 0.7817842960357666
, O 0 5.698717941982068e-09
and O 0 1.53179371409351e-07
disease O 0 7.593416285089916e-06
severity O 0 0.007429803721606731
was O 0 2.4340349682461238e-06
assessed O 0 5.212926090791825e-09
using O 0 5.201442054847405e-10
a O 0 1.3157985812028983e-09
combination O 0 1.3387704278500223e-08
of O 0 1.6011296455342716e-10
validated O 0 5.805523173307847e-08
scoring O 0 1.197779297967827e-08
systems O 0 2.219764638766719e-08
. O 0 9.774385745231484e-09

HLA O 0 0.00024939962895587087
typing O 0 6.875725375721231e-06
for O 0 3.6907852773993e-08
HLA O 0 7.246533641591668e-06
- O 0 7.0388446147262584e-06
B27 O 0 4.479868493945105e-06
, O 0 8.371868531753535e-09
HLA O 0 1.110005541704595e-06
- O 0 7.300698143808404e-07
B60 O 0 7.580613896607247e-07
, O 0 1.5726525637305144e-09
and O 0 1.928453619015613e-09
HLA O 0 6.4317341639252845e-06
- O 0 0.01768324337899685
DR1 O 1 0.9999253749847412
was O 0 5.13143504576874e-07
performed O 0 1.064457078037151e-09
by O 0 1.2862438544813948e-11
polymerase O 0 3.877732357437935e-09
chain O 0 5.0268592843849547e-08
reaction O 0 4.110210838348394e-09
with O 0 3.5717720447969725e-11
sequence O 0 3.68061636724093e-10
- O 0 7.899792819898721e-09
specific O 0 6.117374939940134e-10
primers O 0 3.828678245554329e-07
, O 0 9.368071873794293e-10
and O 0 5.37812239187474e-10
zygosity O 0 5.446491400107334e-07
was O 0 2.393112019660748e-08
assessed O 0 1.0310859721585075e-08
using O 0 8.504858151070493e-09
microsatellite O 0 3.93773279938614e-06
markers O 0 1.583328185006394e-06
. O 0 5.594597851654726e-08

Genetic O 0 5.466501534101553e-05
and O 0 3.5519533980732376e-08
environmental O 0 1.1869674132469754e-08
variance O 0 3.5290728117587378e-09
components O 0 8.382909477688827e-09
were O 0 1.0260127858430224e-08
assessed O 0 1.5215926296718862e-08
with O 0 1.348728767558427e-10
the O 0 1.7573302535378588e-10
program O 0 3.881548693573933e-10
Mx O 0 2.1535882410717022e-08
, O 0 4.441480863648373e-11
using O 0 7.967880522041781e-11
data O 0 1.664800380885012e-10
from O 0 1.1502008546993014e-11
this O 0 2.910761909280524e-11
and O 0 3.0800720307588847e-10
previous O 0 7.337084273473238e-10
studies O 0 1.534414539872131e-10
of O 0 6.531063884152033e-11
twins O 0 1.1685857259635668e-07
with O 0 2.859096959184626e-09
AS B-Disease 1 0.9806432723999023
. O 0 1.208298101573746e-07

RESULTS O 0 1.2413886906870175e-05
Six O 0 1.4200018050303242e-08
of O 0 3.9923309103073734e-10
8 O 0 1.5717239065793365e-08
monozygotic O 0 1.9853068806696683e-06
( O 0 1.4340955090119678e-08
MZ O 0 0.23424816131591797
) O 0 9.628503327974158e-09
twin O 0 0.0001416098530171439
pairs O 0 1.134558615945025e-07
were O 0 6.957146325703434e-08
disease O 0 2.0644228015953558e-07
concordant O 0 2.136200691893464e-06
, O 0 2.5446316165300686e-09
compared O 0 3.341513732380008e-09
with O 0 1.0879009498809822e-10
4 O 0 2.0114561405382148e-10
of O 0 7.757369052674434e-11
15 O 0 6.0747407104599915e-09
B27 O 0 3.090293887453299e-07
- O 0 2.6800926207215525e-06
positive O 0 1.0891170632021385e-07
dizygotic O 0 1.7810413055485697e-07
( O 0 4.757786942199971e-10
DZ O 0 7.685157470405102e-07
) O 0 1.9266226392034014e-09
twin O 0 1.184391408060037e-06
pairs O 0 6.0333786855437666e-09
( O 0 1.7618743963776495e-10
27 O 0 1.0194856514544881e-08
% O 0 1.1904942309737265e-10
) O 0 4.1602984945932064e-11
and O 0 6.253229600794441e-10
4 O 0 5.276283299160411e-10
of O 0 1.6341111797046892e-10
32 O 0 6.473132430073747e-08
DZ O 0 1.2705458175332751e-05
twin O 0 1.0693377589632291e-05
pairs O 0 6.085885573270389e-09
overall O 0 1.298288854201246e-08
( O 0 2.823760114623042e-10
12 O 0 1.6221376464287118e-09
. O 0 2.3900850742997193e-10
5 O 0 2.1639714464782855e-09
% O 0 5.141196912639145e-10
) O 0 7.559152748193299e-10
. O 0 3.109061452732931e-08

Nonsignificant O 0 0.00020370881247799844
increases O 0 2.0372831386339385e-06
in O 0 1.0409200168481902e-09
similarity O 0 4.979296974738645e-09
with O 0 2.385931174853084e-10
regard O 0 2.5516837531824876e-09
to O 0 1.978038532968185e-08
age O 0 1.0374306214089302e-07
at O 0 2.433733214957101e-09
disease O 0 6.778157626285974e-07
onset O 0 2.5588258267816855e-07
and O 0 1.2947278804631424e-08
all O 0 2.652271111069915e-11
of O 0 8.980405828695748e-12
the O 0 1.2376543123693295e-09
disease O 0 1.502616100879095e-06
severity O 0 5.753916411777027e-05
scores O 0 5.3772765795656596e-08
assessed O 0 3.301464701621626e-08
were O 0 4.778852868980721e-09
noted O 0 1.0438690800640416e-08
in O 0 5.922836443517099e-09
disease O 0 1.730696931190323e-05
- O 0 0.008582567796111107
concordant O 1 0.5769314169883728
MZ O 1 0.9977276921272278
twins O 0 4.475830792216584e-05
compared O 0 8.014227148578357e-08
with O 0 6.56809762134003e-09
concordant O 0 9.317897638538852e-05
DZ O 0 0.002506799530237913
twins O 0 2.2656575310975313e-05
. O 0 7.396061363351691e-08

HLA O 0 0.009451090358197689
- O 0 0.0004089963040314615
B27 O 0 2.5587780328351073e-05
and O 0 8.351712921239596e-08
B60 O 0 5.370951612349018e-07
were O 0 1.2156533557572402e-08
associated O 0 8.589921551838131e-10
with O 0 1.7160782517233741e-10
the O 0 1.882545452858153e-09
disease O 0 4.506365485212882e-07
in O 0 1.3883560967542508e-09
probands O 0 6.354560809995746e-06
, O 0 4.4212994376735537e-10
and O 0 9.015128921152638e-11
the O 0 5.94326809988388e-11
rate O 0 2.5775994672017077e-09
of O 0 6.926709206211967e-11
disease O 0 4.719002077990808e-08
concordance O 0 7.427416903738049e-08
was O 0 9.392680055952951e-08
significantly O 0 5.692398730161585e-08
increased O 0 1.4038036511010432e-08
among O 0 1.7067433022432965e-09
DZ O 0 5.369827704271302e-06
twin O 0 1.2028032870148309e-05
pairs O 0 2.6561415289449997e-09
in O 0 1.414448141945357e-10
which O 0 7.215869568533151e-10
the O 0 2.2553078848908115e-10
co O 0 1.4091360753809568e-06
- O 0 1.452799369872082e-05
twin O 0 0.003755788318812847
was O 0 3.8742822994208836e-07
positive O 0 1.395942361703817e-09
for O 0 1.1194414145654363e-10
both O 0 1.2844040275794555e-09
B27 O 0 6.5456515585538e-07
and O 0 6.072136926604799e-08
DR1 O 1 0.5548059344291687
. O 0 1.0618260404271496e-07

Additive O 0 9.752648111316375e-06
genetic O 0 2.342434527236037e-06
effects O 0 8.955506700658589e-07
were O 0 8.806453344334386e-09
estimated O 0 1.1893555029729441e-09
to O 0 1.5787505747155706e-09
contribute O 0 2.0968411451605107e-09
97 O 0 6.863982271454461e-09
% O 0 5.85463136304476e-11
of O 0 1.2428716042456323e-11
the O 0 1.6760536014626126e-10
population O 0 1.8241419486031418e-09
variance O 0 1.958703776949733e-08
. O 0 2.152380673692278e-08

CONCLUSION O 0 2.903394488384947e-06
Susceptibility O 0 0.0030895229429006577
to O 0 4.205533059575828e-07
AS B-Disease 1 0.999573290348053
is O 0 1.7087049997144277e-08
largely O 0 4.889027405141633e-09
genetically O 0 1.950371597558842e-08
determined O 0 7.653122793271905e-07
, O 0 3.660272085426186e-10
and O 0 1.4485378174722285e-10
the O 0 7.637247084746335e-11
environmental O 0 1.798263982166759e-09
trigger O 0 4.0240461629537094e-08
for O 0 5.376327716355433e-10
the O 0 6.091204429736763e-09
disease O 0 2.2867891402711393e-06
is O 0 7.907707377796669e-09
probably O 0 3.96293629023603e-08
ubiquitous O 0 1.8501377496704663e-07
. O 0 6.691885801046737e-08

HLA O 0 0.002872511511668563
- O 0 5.259862882667221e-05
B27 O 0 1.5130196970858378e-06
accounts O 0 1.0905779390668613e-08
for O 0 1.8717889738173454e-10
a O 0 1.3333417703265127e-09
minority O 0 4.612762616318378e-09
of O 0 1.078026990591896e-11
the O 0 7.183978412150793e-11
overall O 0 1.2191689435780972e-08
genetic O 0 4.4446196056924236e-07
susceptibility O 0 0.04199130833148956
to O 0 1.469030848966213e-06
AS B-Disease 1 0.9999821186065674
. O 0 3.9626948478144186e-07

Cell O 0 3.5428009141469374e-05
cycle O 0 1.5607593013555743e-06
- O 0 2.510885224182857e-06
dependent O 0 2.3483478628349985e-07
colocalization O 0 5.242653173809231e-07
of O 0 9.248339871703593e-10
BARD1 O 0 6.542926257679937e-06
and O 0 3.400264736441727e-09
BRCA1 O 0 2.6676071129827506e-08
proteins O 0 2.604795545924077e-10
in O 0 9.090653924070935e-11
discrete O 0 8.927971251182498e-09
nuclear O 0 3.946334459214995e-08
domains O 0 4.736441638897304e-08
. O 0 1.8449904715112098e-08

Germ O 0 0.00026525557041168213
- O 0 0.0027676629833877087
line O 0 5.286228770273738e-06
mutations O 0 9.272670098425806e-08
of O 0 3.808794599158283e-11
the O 0 1.782928527038763e-10
BRCA1 O 0 1.338020467755996e-07
gene O 0 2.4109706231456585e-08
predispose O 0 1.233565853908658e-06
women O 0 2.0461758509782157e-08
to O 0 3.782699042886861e-09
early O 0 4.4864943760103415e-08
- O 1 0.8386139273643494
onset O 1 0.6339727640151978
breast B-Disease 1 0.9999983310699463
and I-Disease 1 0.999870777130127
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999994039535522
by O 0 1.9757828706445935e-09
compromising O 0 4.288005683861229e-08
the O 0 1.2155826345505716e-10
genes O 0 3.18616022454421e-09
presumptive O 0 3.76859748030256e-06
function O 0 3.3231579710246706e-09
as O 0 7.279611358157467e-10
a O 0 1.1010156342194932e-08
tumor B-Disease 0 9.82692654361017e-06
suppressor O 0 7.315459515666589e-05
. O 0 1.7060908419352927e-07

Although O 0 6.303590680545312e-07
the O 0 1.148233508274643e-09
biochemical O 0 2.601397142143469e-08
properties O 0 3.025596662098451e-09
of O 0 8.356226127714805e-11
BRCA1 O 0 2.0425306956894929e-07
polypeptides O 0 1.0631919167281012e-07
are O 0 7.886029051995536e-10
not O 0 2.163170753632926e-09
understood O 0 1.2358809975410168e-08
, O 0 1.186108572470701e-10
their O 0 5.4425530054968974e-11
expression O 0 2.399880294490231e-09
pattern O 0 1.0681673323631458e-08
and O 0 1.015719841568341e-09
subcellular O 0 1.3579472124547465e-07
localization O 0 2.514085473137584e-08
suggest O 0 1.9161232600595213e-09
a O 0 3.92141985550154e-10
role O 0 1.0054768129208469e-09
in O 0 4.6284648336225587e-10
cell O 0 1.1058398996510732e-07
- O 0 1.0337660114601022e-06
cycle O 0 1.3744981686159008e-07
regulation O 0 8.336196088976067e-08
. O 0 2.8252928885308393e-08

When O 0 7.596332238790637e-07
resting O 0 6.262748684093822e-07
cells O 0 1.2665170245895752e-08
are O 0 4.5190221009683285e-10
induced O 0 3.997463409177726e-07
to O 0 8.5179916453626e-09
proliferate O 0 5.186349838481874e-08
, O 0 1.818599854042091e-10
the O 0 4.057357227971181e-11
steady O 0 1.4105403955966267e-08
- O 0 2.4324814162923758e-08
state O 0 4.564013611485507e-10
levels O 0 8.579127686036969e-11
of O 0 1.0940514987012318e-11
BRCA1 O 0 7.055712458736707e-09
increase O 0 9.316005744608447e-10
in O 0 1.7657297846085385e-10
late O 0 3.616926536054166e-09
G1 O 0 1.8941408086448064e-07
and O 0 7.753644948316207e-10
reach O 0 6.009498454417894e-10
a O 0 3.290612005102389e-09
maximum O 0 5.318117857200377e-08
during O 0 8.818252794640102e-09
S O 0 2.8171516532893293e-06
phase O 0 1.0076009715476175e-07
. O 0 4.460538249873025e-08

Moreover O 0 5.140621851751348e-06
, O 0 1.5380084761318358e-08
in O 0 2.7238848954169725e-09
S O 0 6.016230713612458e-07
phase O 0 3.943046777976633e-08
cells O 0 6.936529928225355e-08
, O 0 1.1642620201257614e-09
BRCA1 O 0 5.504542954781755e-08
polypeptides O 0 2.737563775667695e-08
are O 0 7.411729563422398e-10
hyperphosphorylated O 0 1.61401317200216e-07
and O 0 1.2214912414876267e-09
accumulate O 0 7.712821492589228e-09
into O 0 3.222646316469735e-10
discrete O 0 1.1769759389324008e-08
subnuclear O 0 1.1470289109638543e-06
foci O 0 8.373531272809487e-07
termed O 0 2.924763577993872e-07
" O 0 3.336586118507512e-08
BRCA1 O 0 8.122734129756282e-07
nuclear O 0 1.079016485050488e-07
dots O 0 2.3841153051762376e-06
. O 0 1.1276312505970054e-07

" O 0 2.1246808046271326e-06
BRCA1 O 0 4.116346099181101e-05
associates O 0 9.387501336277637e-07
in O 0 1.9826571495684675e-09
vivo O 0 1.8589118155887263e-07
with O 0 6.345915459782248e-10
a O 0 7.503378363082902e-09
structurally O 0 3.568237298168242e-05
related O 0 1.4444063722862666e-08
protein O 0 1.1086930840065179e-07
termed O 0 4.888395892521658e-07
BARD1 O 0 4.3526040826691315e-05
. O 0 5.2669577144115465e-08

Here O 0 3.0908981329957896e-07
we O 0 4.479053572481462e-09
show O 0 2.5549953264203396e-09
that O 0 1.2830884965620015e-10
the O 0 5.5942910026640646e-11
steady O 0 5.651914847248918e-08
- O 0 5.860628604636986e-08
state O 0 6.799063534401739e-10
levels O 0 1.3236817197892492e-10
of O 0 1.5706875036713974e-11
BARD1 O 0 5.725663640987477e-07
, O 0 5.250523349431546e-10
unlike O 0 1.6893633714154532e-10
those O 0 3.828891023682779e-11
of O 0 1.4046237263587447e-11
BRCA1 O 0 8.059017631012466e-08
, O 0 9.679910206727982e-10
remain O 0 3.7491907356468346e-09
relatively O 0 4.540416487230914e-09
constant O 0 2.0820685620037693e-08
during O 0 5.882306641780133e-09
cell O 0 1.9379794480300916e-07
cycle O 0 1.0019034846209252e-07
progression O 0 5.782437142443086e-07
. O 0 4.95938543565444e-08

However O 0 8.858198725647526e-07
, O 0 1.1757418150182275e-08
immunostaining O 0 4.386771763620345e-07
revealed O 0 6.434529353782636e-08
that O 0 2.96191959847647e-09
BARD1 O 0 3.54727285412082e-06
resides O 0 4.1275114881500485e-08
within O 0 2.3396493076255354e-10
BRCA1 O 0 3.542305648807087e-08
nuclear O 0 4.398037489750095e-09
dots O 0 9.718137050640507e-08
during O 0 7.291329762182386e-09
S O 0 1.3219302275047085e-07
phase O 0 1.0902175828775285e-09
of O 0 2.5531366951159207e-11
the O 0 6.968344651303582e-11
cell O 0 8.787878869043197e-09
cycle O 0 2.339177296306616e-09
, O 0 6.647123129699395e-11
but O 0 1.1691481116571367e-10
not O 0 1.1580092440510725e-10
during O 0 9.063680361798276e-11
the O 0 1.56096996439814e-10
G1 O 0 5.706589831788733e-07
phase O 0 7.709471105954435e-08
. O 0 3.3880048988521594e-08

Nevertheless O 0 0.00010244237637380138
, O 0 2.8383208672266846e-08
BARD1 O 0 1.0266821846016683e-06
polypeptides O 0 1.336669726015316e-07
are O 0 4.794691310650023e-10
found O 0 5.045393547398191e-10
exclusively O 0 3.5110905849400353e-10
in O 0 3.816473873041737e-11
the O 0 1.772984710435299e-11
nuclear O 0 2.100126045290196e-10
fractions O 0 1.509974645319545e-10
of O 0 8.9331693084449e-12
both O 0 1.6095440258379057e-10
G1 O 0 7.227143328236707e-08
- O 0 3.9014005892568093e-07
and O 0 1.6745406838936105e-08
S O 0 5.794455319119152e-06
- O 0 6.52568189707381e-07
phase O 0 2.1013488549215253e-07
cells O 0 3.066718932132062e-07
. O 0 4.067141645691663e-08

Therefore O 0 2.652564262461965e-06
, O 0 7.059508533302505e-09
progression O 0 4.666355124527399e-08
to O 0 8.465514511613037e-09
S O 0 2.1241073682176648e-06
phase O 0 2.8648083016946657e-08
is O 0 2.779622532145254e-09
accompanied O 0 3.91639876085037e-09
by O 0 3.310628160502205e-11
the O 0 1.1154297104021271e-11
aggregation O 0 1.0292070529160924e-09
of O 0 1.173316860336726e-10
nuclear O 0 5.149737525300679e-09
BARD1 O 0 6.91118543727498e-07
polypeptides O 0 9.591882843551502e-08
into O 0 5.0766719716932585e-09
BRCA1 O 0 1.1617822792686638e-06
nuclear O 0 8.719128885559257e-08
dots O 0 1.7617688854443259e-06
. O 0 1.6899522847779735e-07

This O 0 4.0893336716862905e-08
cell O 0 1.6341883224413323e-07
cycle O 0 3.356545974497749e-08
- O 0 3.792776226418937e-07
dependent O 0 9.623219199283994e-08
colocalization O 0 5.093254458188312e-07
of O 0 2.526142905967532e-10
BARD1 O 0 2.0737613795063226e-06
and O 0 5.696327409765445e-09
BRCA1 O 0 8.400456863455474e-08
indicates O 0 2.2004609245840356e-09
a O 0 6.151986697844336e-10
role O 0 3.3900009466236725e-09
for O 0 1.4071511733604325e-09
BARD1 O 0 5.083494670543587e-06
in O 0 7.631314247191767e-09
BRCA1 O 0 2.902029791584937e-06
- O 0 4.261407411831897e-06
mediated O 0 2.69869233306963e-05
tumor B-Disease 0 7.658171671209857e-05
suppression O 0 5.366455866351316e-07
. O 0 1.003194256554707e-07

Ethnic O 0 3.854745500575518e-06
differences O 0 4.229714818393404e-07
in O 0 1.972360053059674e-09
the O 0 1.2415743988469785e-09
HFE O 0 6.8491162892314605e-06
codon O 0 2.4347124849555257e-07
282 O 0 1.8368396581536217e-07
( O 0 1.2838780705237696e-08
Cys O 0 0.0006435278919525445
/ O 0 5.998504093440715e-06
Tyr O 0 1.5724392142146826e-05
) O 0 1.1086270568227974e-08
polymorphism O 0 8.679066922923084e-06
. O 0 9.00240877399483e-08

Recent O 0 1.321568788625882e-06
studies O 0 5.542215930631755e-08
have O 0 5.934460922674134e-09
shown O 0 8.358916403494732e-08
that O 0 4.800571332452819e-06
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
( O 0 9.979135029425379e-07
HH B-Disease 0 0.15318819880485535
) O 0 1.2103221758152927e-09
is O 0 3.379123203473e-09
likely O 0 2.2275685296335723e-08
to O 0 3.183900254555283e-09
be O 0 1.4998608577343475e-08
caused O 0 3.0767868253178676e-08
by O 0 2.5692392657816754e-10
homozygosity O 0 1.3810151244797453e-07
for O 0 1.1773204633414025e-10
a O 0 1.4024407191115529e-09
Cys282Tyr O 0 1.0354789310440538e-06
mutation O 0 8.175816645916711e-08
in O 0 1.6869453056678196e-10
the O 0 4.112074569739832e-10
HFE O 0 2.1432470020954497e-06
gene O 0 6.642760297381756e-08
located O 0 1.3466840975695504e-08
4 O 0 2.0040825887690517e-08
. O 0 1.6570627536793836e-08

5 O 0 2.6883121790888254e-06
Mb O 0 1.510523088654736e-05
telomeric O 0 0.00013755899271927774
to O 0 5.871817165825632e-07
HLA O 0 6.182303332025185e-05
- O 0 1.4321994058263954e-05
A O 0 1.589143153069017e-06
. O 0 1.655275383427579e-07

Population O 0 8.865729341778206e-07
studies O 0 3.5512199847431702e-09
of O 0 7.589284756193138e-11
this O 0 1.5758375160324078e-10
polymorphism O 0 1.3717798310608487e-06
are O 0 2.1470974997939152e-10
facilitated O 0 2.9446038940506014e-09
by O 0 2.462532677771634e-10
the O 0 5.7834216582453024e-11
fact O 0 1.9612363122423204e-10
that O 0 9.127313488344058e-11
the O 0 7.641414584425021e-11
Cys282Tyr O 0 3.7058038060422405e-07
mutation O 0 1.8843353544184538e-08
creates O 0 4.594323144146983e-09
a O 0 1.7559306231262894e-09
Rsal O 0 2.2593232529288798e-07
restriction O 0 1.0242359138601387e-07
site O 0 6.735564284099382e-08
. O 0 1.855071829481858e-08

We O 0 5.341728410712676e-07
have O 0 5.918274315064309e-09
studied O 0 2.9306299609288544e-09
the O 0 4.1816930473892455e-10
codon O 0 3.766495382251378e-08
282 O 0 8.133262952014775e-08
( O 0 5.338705477697658e-09
Cys O 0 0.0003551847185008228
/ O 0 1.3407454844127642e-06
Tyr O 0 2.857950676116161e-06
) O 0 8.331340617395711e-10
polymorphism O 0 2.3471523036278086e-07
in O 0 3.180924690315834e-10
different O 0 2.360811823809428e-10
ethnic O 0 3.161268802287509e-09
groups O 0 6.279647468687699e-09
. O 0 1.8961682002327507e-08

In O 0 1.3535834852973494e-07
agreement O 0 4.17997236823453e-09
with O 0 2.560961165354314e-10
previous O 0 6.005053121427295e-10
observations O 0 5.042615214279067e-09
the O 0 3.4186667385860403e-10
Tyr O 0 7.612925969624484e-07
allele O 0 2.2777341257551598e-07
appeared O 0 7.245859734439364e-08
to O 0 6.446316258568174e-10
be O 0 1.1188229231962055e-09
rare O 0 5.241520106835651e-09
or O 0 2.433343304630853e-09
absent O 0 4.359604588444199e-08
in O 0 3.952766114423412e-09
Asiatic O 0 2.2329198046122656e-08
( O 0 1.1648788877938188e-10
Indian O 0 3.8707470562115986e-10
, O 0 8.550180008448649e-11
Chinese O 0 9.820234209145795e-11
) O 0 4.363776284765919e-10
populations O 0 6.829949050768391e-09
. O 0 8.656654060246183e-09

The O 0 1.5192182445389335e-07
highest O 0 1.5430423161433282e-07
allele O 0 2.8061293733117054e-07
frequency O 0 1.32762551174892e-07
( O 0 6.212429459750979e-10
7 O 0 3.4312892527310623e-09
. O 0 2.2745662298095937e-10
5 O 0 1.3311107771585284e-09
% O 0 1.9798672423743113e-10
) O 0 1.219795792151146e-10
was O 0 1.0903433889097869e-07
found O 0 2.628974593577027e-09
in O 0 1.8289914027747045e-09
Swedes O 0 0.00011659513984341174
. O 0 2.819360744865662e-08

Saamis O 0 5.2602190407924354e-05
( O 0 4.233750416915427e-08
2 O 0 1.99775485043574e-08
% O 0 7.217687003624462e-10
) O 0 1.0900590152740364e-10
and O 0 1.6844896588708025e-09
Mordvinians O 0 3.2517874615223263e-07
( O 0 3.288751562746661e-11
1 O 0 8.200559675763941e-11
. O 0 4.8889288450926216e-11
8 O 0 1.79833842262056e-10
% O 0 3.2815330314184266e-11
) O 0 4.751182780537988e-11
had O 0 6.394637921403046e-07
significantly O 0 1.6852914086484816e-07
lower O 0 1.178139363844366e-08
frequencies O 0 4.582656920604222e-09
of O 0 4.7099307093345644e-11
the O 0 1.0119238780248452e-09
Tyr O 0 1.3121576557750814e-05
allele O 0 1.4424633718590485e-06
. O 0 3.705817164245673e-08

Comparisons O 0 9.662569937063381e-06
with O 0 2.1345760714552853e-08
allele O 0 7.215765549517528e-07
frequencies O 0 9.665970424066472e-08
based O 0 9.276504897570703e-09
on O 0 4.819405674538757e-08
prevalence O 0 2.1305468180798925e-06
estimates O 0 2.478774163705566e-08
of O 0 4.701980471644163e-10
HH B-Disease 1 0.753933310508728
showed O 0 1.8522085156291723e-05
some O 0 3.028782225023008e-10
disagreements O 0 1.8406707269491562e-08
with O 0 2.6408339404149217e-10
the O 0 4.93678709023726e-10
RFLP O 0 2.6937426810036413e-05
data O 0 1.4421710048395653e-08
, O 0 7.018984282680663e-10
particularly O 0 3.2578506559133302e-09
in O 0 2.181942182488683e-09
Finns O 0 5.633366527035832e-06
. O 0 3.151938443579638e-08

The O 0 1.9549047181044443e-07
newly O 0 1.885256182276862e-07
described O 0 1.8107125754340814e-07
HFE O 0 2.1667167402483756e-06
marker O 0 2.333308373181353e-07
provides O 0 2.662644327244834e-09
a O 0 8.738433310284677e-10
new O 0 5.715914963566604e-10
approach O 0 6.759216741869523e-09
to O 0 7.748470753909942e-10
the O 0 9.954809199186343e-11
screening O 0 2.5391433400301366e-09
of O 0 2.813244914801061e-10
HH B-Disease 0 0.0024062031880021095
as O 0 3.9679964203287454e-08
well O 0 3.79295084229625e-09
as O 0 4.6339415638030346e-10
studies O 0 3.1723373927761145e-11
of O 0 1.6138152012651341e-12
the O 0 9.011152934945699e-12
relationship O 0 6.70065447572199e-10
between O 0 1.746943562030978e-10
the O 0 1.2193078768873988e-09
HFE O 0 5.7690478570293635e-05
Tyr O 0 1.0373458280810155e-05
allele O 0 6.089029511713306e-07
and O 0 1.7552006514875984e-09
different O 0 2.6977535760863702e-09
disorders O 0 1.3382159522734582e-05
including O 0 1.367711774946656e-07
cancer B-Disease 0 0.0012186261592432857

Autosomal B-Disease 1 0.9999408721923828
dominant I-Disease 1 0.9997149109840393
neurohypophyseal I-Disease 1 0.9999392032623291
diabetes I-Disease 1 0.9999985694885254
insipidus I-Disease 1 0.9995895028114319
associated O 0 1.0846273426068365e-06
with O 0 1.1779229813768666e-09
a O 0 1.5669135322582406e-08
missense O 0 1.688962038315367e-05
mutation O 0 1.7470058821800194e-07
encoding O 0 4.655695562405526e-08
Gly23 O 0 2.9443917810567655e-06
- O 0 4.998005351808388e-06
- O 0 1.654694278840907e-05
> O 0 2.8214918756930274e-07
Val O 0 6.9967281888239086e-06
in O 0 6.180710609982043e-09
neurophysin O 0 2.046587496806751e-06
II O 0 1.0318579370505176e-05
. O 0 6.829444743061686e-08

Autosomal B-Disease 1 0.9999346733093262
dominant I-Disease 1 0.9988957643508911
neurohypophyseal I-Disease 1 0.9998419284820557
diabetes I-Disease 1 0.9999985694885254
insipidus I-Disease 1 0.9996069073677063
( O 0 5.320461582414282e-07
ADNDI B-Disease 0 0.00029049880686216056
) O 0 1.8941790358439903e-09
is O 0 4.722619184605037e-09
an O 0 4.121958170344442e-07
inherited B-Disease 1 1.0
disease I-Disease 1 1.0
caused O 0 0.0003719970118254423
by O 0 5.608957920344437e-08
progressive O 0 0.0027327334973961115
degeneration O 0 0.011679262854158878
of O 0 5.683171155901334e-10
the O 0 1.3047524172193903e-09
magnocellular O 0 9.332674721918011e-07
neurons O 0 8.108975180221023e-08
of O 0 6.551301168222778e-11
the O 0 1.352337686277849e-10
hypothalamus O 0 4.208116877180146e-08
leading O 0 3.630411304911263e-09
to O 0 1.9686354768566616e-09
decreased O 0 6.215659453800981e-08
ability O 0 4.338350567678617e-09
to O 0 1.0451676191181036e-09
produce O 0 6.681641906425284e-09
the O 0 1.5457539692675937e-09
hormone O 0 1.1568739921585802e-07
arginine O 0 6.479877612264318e-08
vasopressin O 0 1.6676153791195247e-07
( O 0 9.667657785428219e-10
AVP O 0 4.6809569198558165e-07
) O 0 6.894949500235725e-09
. O 0 1.540806593425259e-08

Affected O 0 2.046273584710434e-05
individuals O 0 3.832133543824057e-08
are O 0 1.154153328464247e-09
not O 0 6.4907350605381e-09
symptomatic O 0 4.430663466337137e-06
at O 0 8.344257729220317e-09
birth O 0 7.365358101196762e-08
, O 0 3.8535757918012337e-10
but O 0 4.765936534312232e-09
usually O 0 9.322038607706418e-08
develop O 0 8.767823374000727e-07
diabetes B-Disease 0 0.20878319442272186
insipidus I-Disease 0 0.00015838394756428897
at O 0 1.6707784045166818e-09
1 O 0 3.871361897722636e-09
- O 0 9.645666978030931e-06
6 O 0 1.6767531008099468e-07
yr O 0 2.466040541548864e-06
of O 0 1.1521384957191572e-09
age O 0 3.3077363070788124e-08
. O 0 1.1517876430389151e-08

The O 0 8.736859058444679e-08
genetic O 0 2.08695155379246e-07
locus O 0 1.0635893943344854e-07
of O 0 6.842019728559023e-10
the O 0 4.208837278696365e-09
disease O 0 6.517037149933458e-07
is O 0 1.9147385899032088e-09
the O 0 5.831141680623375e-10
AVP O 0 4.639125108951703e-06
- O 0 0.00012051028170390055
neurophysin O 0 0.0001850499102147296
II O 0 1.3255687917990144e-05
( O 0 6.648711581291877e-10
NPII O 0 4.326841462898301e-07
) O 0 2.505934626473305e-10
gene O 0 1.6433168159579736e-09
, O 0 2.8309754540600807e-10
and O 0 7.598195961300291e-10
mutations O 0 8.702046194741797e-09
that O 0 1.090294521333135e-09
cause O 0 1.0072509049052769e-08
ADNDI B-Disease 0 7.343289325945079e-06
have O 0 1.7255228357271335e-08
been O 0 3.6130791691846298e-09
found O 0 3.1759656016205895e-10
in O 0 3.5853275209829505e-11
both O 0 7.307555949243039e-11
the O 0 3.748350588250737e-11
signal O 0 4.013405163760808e-09
peptide O 0 2.46765774480906e-10
of O 0 4.124363611052173e-12
the O 0 3.725051864189588e-11
prepro O 0 4.862915261583112e-07
- O 0 6.298098469414981e-07
AVP O 0 3.4205302199552534e-06
- O 0 1.3778358152194414e-06
NPII O 0 7.801208994351327e-07
precursor O 0 5.4479283306818616e-09
and O 0 2.132861665060659e-09
within O 0 4.1778822068572197e-10
NPII O 0 2.344899939998868e-06
itself O 0 2.3365149104392913e-07
. O 0 3.323786756936897e-08

An O 0 8.75749435635953e-07
affected O 0 5.860404712620948e-07
girl O 0 2.4932373889896553e-06
who O 0 3.9961516762332394e-08
presented O 0 2.038166302398281e-09
at O 0 8.804479367796603e-11
9 O 0 1.4206539278305286e-09
months O 0 3.404249104832502e-09
of O 0 1.5704965106166924e-10
age O 0 3.914979895824899e-09
and O 0 1.3543337562538227e-09
her O 0 5.20003879955766e-08
similarly O 0 3.590424739741138e-07
affected O 0 3.457438069176533e-08
younger O 0 1.3361866990635463e-07
brother O 0 1.46071698736705e-07
and O 0 1.1501273267100487e-09
father O 0 2.170214052910069e-08
were O 0 7.967064230562926e-10
all O 0 1.6467131477848618e-11
found O 0 1.2344145150500196e-10
to O 0 9.065893868953623e-11
have O 0 3.592900699178614e-10
a O 0 2.008378796602983e-09
novel O 0 6.367186244915501e-08
missense O 0 1.1635574992396869e-06
mutation O 0 3.43946844338916e-08
( O 0 1.7126644547005299e-10
G1758 O 0 1.1666215016248316e-07
- O 0 1.570512381476874e-06
- O 0 1.5473140592803247e-05
> O 0 1.477845330555283e-07
T O 0 1.6074109510100243e-07
) O 0 6.265164775864918e-11
encoding O 0 4.223680294401788e-10
the O 0 3.69299105185128e-11
amino O 0 5.839567163157255e-10
acid O 0 2.3099460122466553e-09
substitution O 0 4.6330073111278125e-09
Gly23 O 0 5.431340355244174e-07
- O 0 8.289594575217052e-07
- O 0 8.187876119336579e-06
> O 0 4.382447968964698e-07
Val O 0 1.067957782652229e-05
within O 0 1.122465764780145e-08
NPII O 0 7.66023003961891e-06
. O 0 5.4377572666908236e-08

The O 0 2.0614992024547973e-07
mutation O 0 4.789198555954499e-06
was O 0 9.815415324965215e-08
confirmed O 0 1.10910507444828e-08
by O 0 2.752377492587499e-10
restriction O 0 5.937792835197797e-08
endonuclease O 0 3.5426721296971664e-05
analysis O 0 4.3548718053898483e-07
. O 0 5.0168402765393694e-08

A O 0 4.514738066063728e-06
T1 O 0 0.00010473545989952981
- O 0 2.0914394553983584e-06
weighted O 0 5.6537370340947746e-08
magnetic O 0 9.755157179824892e-07
resonance O 0 1.4046092928765574e-06
imaging O 0 1.0284970812790561e-06
of O 0 8.256704209230747e-10
the O 0 3.8151242165440635e-09
fathers O 0 1.8059235173950583e-07
pituitary O 0 8.401415243497468e-07
gland O 0 9.104060154641047e-07
demonstrates O 0 1.929317932081176e-07
an O 0 9.24271947866373e-09
attenuated O 0 2.6524186978349462e-05
posterior O 0 3.404826884434442e-06
pituitary O 0 1.4710841242049355e-05
bright O 0 3.846050276479218e-06
spot O 0 1.200006295221101e-06
. O 0 9.279234092218758e-08

This O 0 2.2966760582221468e-07
mutation O 0 2.907911266447627e-06
may O 0 5.338932496101734e-08
be O 0 5.533897229348383e-10
valuable O 0 3.0779459536667275e-10
for O 0 1.9490681291145506e-10
developing O 0 8.279444907444145e-10
models O 0 1.627108758839313e-08
of O 0 7.128075907303355e-10
dominantly B-Disease 0 0.0013473493745550513
inherited I-Disease 1 0.5736252665519714
neurodegeneration I-Disease 1 1.0
, O 0 3.57815821416807e-09
as O 0 1.9737403378350393e-10
the O 0 6.629650994849356e-11
early O 0 3.148944216491145e-09
age O 0 1.3695196088292505e-09
of O 0 2.6081251741638667e-11
onset O 0 3.596860409516012e-08
of O 0 3.330226316933249e-09
symptoms O 0 0.0004762620374094695
suggests O 0 2.513288244188061e-09
that O 0 1.0841206404821335e-10
this O 0 9.436428027864707e-11
mutation O 0 6.772224114826031e-09
may O 0 3.3031193336086062e-09
be O 0 4.893092042657088e-10
particularly O 0 1.0281554496671674e-09
deleterious O 0 2.1550329165620496e-07
to O 0 8.428023612339075e-09
the O 0 1.7333495749838335e-09
magnocellular O 0 2.217597284470685e-06
neuron O 0 2.4350033527298365e-06
. O 0 2.227907192065004e-09
. O 0 7.415254632547885e-09

Frequent O 0 7.606510916957632e-05
inactivation O 0 2.615781886561308e-05
of O 0 1.727805098994395e-08
PTEN O 0 0.00014457823999691755
/ O 0 2.6023310510936426e-06
MMAC1 O 0 2.836431667674333e-05
in O 0 9.296930869595599e-08
primary O 0 0.09179199486970901
prostate B-Disease 1 1.0
cancer I-Disease 1 0.9999996423721313
. O 0 6.359928761412448e-07

Sporadic B-Disease 1 0.998202919960022
prostate I-Disease 1 0.9999979734420776
carcinoma I-Disease 1 1.0
is O 0 5.432190164356143e-07
the O 0 3.694415884325508e-10
most O 0 8.860330247273396e-10
common O 0 4.440172673980669e-09
male B-Disease 0 1.342574705631705e-05
cancer I-Disease 0 4.523765824160364e-07
in O 0 4.1308309550736055e-10
the O 0 1.7776244365386162e-10
Western O 0 1.6718686435268637e-09
world O 0 7.582935945826819e-10
, O 0 1.3888638850101387e-10
yet O 0 6.135416619201806e-10
many O 0 1.090218627181061e-11
of O 0 8.343986309181095e-13
the O 0 4.488779140054966e-12
major O 0 3.214608787494022e-11
genetic O 0 3.073428733735284e-10
events O 0 3.704687945305096e-11
involved O 0 3.0358035529864935e-10
in O 0 7.684239355931766e-11
the O 0 7.553743741617325e-11
progression O 0 4.994782365486117e-09
of O 0 1.3789331655689185e-11
this O 0 1.371437546859866e-10
often O 0 8.746378910018393e-08
fatal O 0 0.0018627403769642115
cancer B-Disease 0 0.00019744859309867024
remain O 0 2.3050663600088228e-08
to O 0 2.3206727650659786e-09
be O 0 1.2805276838889768e-08
elucidated O 0 6.819220288889483e-06
. O 0 2.203490190311186e-08

Numerous O 0 9.882382983050775e-06
cytogenetic O 0 0.000521122885402292
and O 0 1.6617316589417896e-07
allelotype O 0 3.7998756852175575e-06
studies O 0 1.7577240996047294e-08
have O 0 3.6265561664805546e-09
reported O 0 1.8521234323998215e-08
frequent O 0 5.9127934548541816e-08
loss O 0 6.826527254588655e-08
of O 0 2.6974641964550017e-10
heterozygosity O 0 1.7516633761260891e-06
on O 0 4.938797815157159e-08
chromosomal O 0 2.0241495803929865e-05
arm O 0 6.65246125208796e-06
10q O 0 1.8424607333145104e-06
in O 0 4.413569243411075e-08
sporadic B-Disease 1 0.7715577483177185
prostate I-Disease 1 1.0
cancer I-Disease 1 0.9999994039535522
. O 0 3.3616782957324176e-07

Deletion O 0 6.645529356319457e-05
mapping O 0 1.8401603938400513e-06
studies O 0 6.523503515154516e-08
have O 0 1.6730815843857272e-08
unambiguously O 0 1.9497674657031894e-06
identified O 0 1.6666033886281184e-08
a O 0 1.7881058855806486e-09
region O 0 2.0342827422581422e-09
of O 0 1.0729320210067783e-10
chromosome O 0 1.6304832683999848e-07
10q23 O 0 4.425893607162834e-08
to O 0 1.4430232564421885e-09
be O 0 8.953751073903504e-10
the O 0 3.796582492832101e-10
minimal O 0 1.0943249151296186e-07
area O 0 1.1838812596920434e-08
of O 0 5.747816111956183e-10
loss O 0 3.2425930385215906e-07
. O 0 6.96713158276907e-08

A O 0 9.026812790580152e-07
new O 0 1.7838827304217375e-08
tumor B-Disease 0 4.499349017805798e-07
suppressor O 0 1.474044893257087e-06
gene O 0 1.604490336148956e-07
, O 0 9.88040227412057e-09
PTEN O 0 1.017667273117695e-05
/ O 0 5.908667048970528e-07
MMAC1 O 0 3.9389324228977785e-05
, O 0 4.242139084453811e-09
was O 0 5.335104802384194e-08
isolated O 0 1.6141633807364997e-08
recently O 0 7.692092296451847e-09
at O 0 6.875519598104063e-11
this O 0 3.746227980605532e-11
region O 0 3.5291716771190806e-10
of O 0 5.1959662267231366e-11
chromosome O 0 1.43543715580563e-07
10q23 O 0 1.0731443467193458e-07
and O 0 5.14286391251062e-10
found O 0 1.9801203732239259e-10
to O 0 1.6732523699936053e-10
be O 0 5.411842640690168e-10
inactivated O 0 2.6446118184253464e-08
by O 0 1.4034139128593637e-10
mutation O 0 7.231828913489835e-09
in O 0 5.739161368367718e-10
three O 0 2.37429276239709e-06
prostate B-Disease 1 1.0
cancer I-Disease 1 0.9999994039535522
cell O 0 9.988097008317709e-05
lines O 0 1.952707634700346e-06
. O 0 2.6849217960034366e-08

We O 0 1.3440610473480774e-06
screened O 0 4.5939377741888165e-05
80 O 0 4.071021521667717e-06
prostate B-Disease 1 0.9675503373146057
tumors I-Disease 1 0.999998927116394
by O 0 3.983494423209777e-09
microsatellite O 0 1.981098648684565e-06
analysis O 0 1.813790007076932e-08
and O 0 1.3987860869590918e-09
found O 0 2.2641142294332894e-09
chromosome O 0 5.595601137997619e-08
10q23 O 0 4.536160247425869e-08
to O 0 5.764724253509712e-10
be O 0 2.394209830391958e-10
deleted O 0 9.78494352210646e-09
in O 0 1.0707410513788318e-09
23 O 0 2.007265287318205e-08
cases O 0 2.196105874929799e-08
. O 0 1.8033000870332216e-08

We O 0 2.6163533561884833e-07
then O 0 8.49829095983523e-09
proceeded O 0 4.8535717667164135e-09
with O 0 4.683003637651062e-11
sequence O 0 1.497124091365265e-10
analysis O 0 1.2312212360754415e-10
of O 0 1.332275349069656e-11
the O 0 1.5279194576223176e-10
entire O 0 6.557207665736087e-09
PTEN O 0 7.078440376062645e-06
/ O 0 1.8999337214609113e-07
MMAC1 O 0 1.9822305148409214e-06
coding O 0 2.24219874667142e-07
region O 0 2.2652816511481433e-08
and O 0 6.509679462141094e-09
tested O 0 1.5747575687896642e-08
for O 0 1.3377531027369827e-10
homozygous O 0 1.85991133605512e-08
deletion O 0 8.947080409882346e-09
with O 0 2.361816020535201e-10
new O 0 8.267009299345318e-10
intragenic O 0 2.9236647947072925e-07
markers O 0 1.1196650717693046e-07
in O 0 2.9378705024285523e-10
these O 0 9.730922317929824e-11
23 O 0 1.2413660099852564e-09
cases O 0 9.622990182478475e-10
with O 0 1.1154945855906817e-09
10q23 O 0 2.0582983779604547e-06
loss O 0 7.845843441600664e-08
of O 0 1.95879246156494e-09
heterozygosity O 0 1.412229539710097e-05
. O 0 1.1176977210425321e-07

The O 0 9.068426898295456e-09
identification O 0 4.838081046898424e-09
of O 0 3.135791279418321e-11
the O 0 4.730818861653496e-11
second O 0 4.485653626318253e-09
mutational O 0 1.435216859135835e-06
event O 0 7.023488013402357e-09
in O 0 3.1006491818530435e-10
10 O 0 3.827468897377173e-10
( O 0 1.892387080371094e-10
43 O 0 2.104872720565254e-07
% O 0 1.4970563677607629e-09
) O 0 6.415507236567919e-09
tumors B-Disease 1 0.9999977350234985
establishes O 0 6.280443813011516e-06
PTEN O 0 0.00017355721502099186
/ O 0 3.924237432784139e-07
MMAC1 O 0 2.210869524787995e-06
as O 0 1.5000145570098766e-09
a O 0 8.280486851752755e-10
main O 0 3.6926282032112567e-09
inactivation O 0 7.448980454682896e-07
target O 0 1.1479188266605433e-08
of O 0 1.904648105899298e-10
10q O 0 1.7645203342908644e-07
loss O 0 3.751724975131765e-08
in O 0 1.574385066760442e-08
sporadic B-Disease 1 0.99504154920578
prostate I-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
. O 0 3.309004270590776e-08
. O 0 2.3400264836936913e-08

Risk O 0 1.5539422747679055e-05
reversals O 0 3.7917595818726113e-06
in O 0 1.0197618749430148e-08
predictive O 0 3.1038447900755273e-07
testing O 0 1.6334249153260316e-07
for O 0 1.8205457763542654e-07
Huntington B-Disease 1 0.9999945163726807
disease I-Disease 1 0.9999912977218628
. O 0 5.464654577735928e-07

The O 0 3.0303336728820796e-08
first O 0 7.96611132614089e-09
predictive O 0 8.135977935808114e-08
testing O 0 3.587604169297265e-08
for O 0 4.4532956877674224e-08
Huntington B-Disease 1 0.999994158744812
disease I-Disease 1 0.9999935626983643
( O 0 2.830491174776739e-09
HD B-Disease 0 3.92523634218378e-06
) O 0 7.992970174619529e-10
was O 0 1.6807105396310362e-07
based O 0 1.2206016197779945e-09
on O 0 8.777522597647192e-10
analysis O 0 3.192393571715968e-10
of O 0 2.7851072142981437e-11
linked O 0 8.117125638307243e-09
polymorphic O 0 6.082894543624207e-08
DNA O 0 1.3535751186566358e-08
markers O 0 1.5995777147281842e-08
to O 0 5.491638810362076e-10
estimate O 0 1.796632176365165e-09
the O 0 3.80479432682268e-11
likelihood O 0 1.0026118824058017e-09
of O 0 1.3975739836247225e-11
inheriting O 0 3.147407001691249e-09
the O 0 9.5628660545799e-10
mutation O 0 3.2056803433988534e-08
for O 0 2.57063259567758e-09
HD B-Disease 0 2.939456135209184e-05
. O 0 7.134053703339305e-08

Limits O 0 1.3600989632323035e-06
to O 0 1.3336935111851744e-08
accuracy O 0 2.2972448832092596e-08
included O 0 7.308479932355283e-10
recombination O 0 1.5268539765855849e-09
between O 0 1.6024617743859437e-10
the O 0 6.388210099794733e-11
DNA O 0 1.760012224849561e-08
markers O 0 1.329340904021592e-07
and O 0 1.0806548988995246e-09
the O 0 2.1354902568493372e-10
mutation O 0 5.3000320576757076e-08
, O 0 6.106055661092569e-10
pedigree O 0 5.7372194106619645e-08
structure O 0 3.575599816230124e-09
, O 0 7.614078118001188e-11
and O 0 7.202115986926216e-11
whether O 0 1.334109350770163e-10
DNA O 0 1.7023543685823483e-09
samples O 0 1.5165446676235206e-09
were O 0 8.547396124214401e-10
available O 0 1.4212522825296503e-10
from O 0 2.8051420561392426e-11
family O 0 6.436879917970373e-10
members O 0 2.4791690922398857e-10
. O 0 1.616266565029889e-09

With O 0 5.711387274232038e-08
direct O 0 3.008220161859754e-08
tests O 0 1.2184250053337564e-08
for O 0 1.1621890949609082e-10
the O 0 1.9820170504836199e-10
HD B-Disease 0 2.4018656858970644e-06
mutation O 0 1.0108750281290213e-08
, O 0 9.740541706548811e-11
we O 0 7.576281962906606e-11
have O 0 1.997006171539084e-10
assessed O 0 1.475934041650362e-09
the O 0 7.30722149455687e-11
accuracy O 0 9.693771119145822e-09
of O 0 5.758687970924825e-11
results O 0 2.9125415412778466e-09
obtained O 0 4.194153913061882e-10
by O 0 1.3390551167891118e-10
linkage O 0 5.050922347038522e-09
approaches O 0 3.7033986988177503e-09
when O 0 3.110167401398911e-10
requested O 0 5.7088545002415e-10
to O 0 4.6245998697180823e-10
do O 0 5.983969431078151e-10
so O 0 3.784768609627065e-10
by O 0 4.2382042320099345e-11
the O 0 1.7661574980287753e-10
test O 0 8.69368488309874e-09
individuals O 0 1.5044757661897279e-09
. O 0 7.769786591893535e-09

For O 0 7.590004713620147e-08
six O 0 4.0051082450531794e-09
such O 0 8.708147397618049e-11
individuals O 0 2.1094759272699548e-10
, O 0 1.324045317829814e-10
there O 0 3.2397545757234525e-10
was O 0 2.107861263311861e-08
significant O 0 7.50715323238893e-10
disparity O 0 1.0561537422404399e-08
between O 0 2.408940824594197e-10
the O 0 1.1304146507740143e-09
tests O 0 4.5839268381087095e-08
. O 0 2.0280463530752968e-08

Three O 0 2.598861215119541e-07
went O 0 1.1425759005589953e-08
from O 0 6.064119345561281e-11
a O 0 1.7960565257268968e-09
decreased O 0 1.4206524667770282e-07
risk O 0 3.3109788244445326e-09
to O 0 3.543255133742207e-10
an O 0 6.568169341747421e-10
increased O 0 1.5712959111624514e-07
risk O 0 2.496414985841966e-08
, O 0 2.5882840315460953e-10
while O 0 4.0122855038404737e-10
in O 0 4.086879445974745e-11
another O 0 4.5763043354796196e-10
three O 0 1.731729343257271e-10
the O 0 3.255202773999599e-10
risk O 0 5.686751958222658e-09
was O 0 1.7505918492588535e-07
decreased O 0 1.588776399330527e-07
. O 0 2.917013119940748e-08

Knowledge O 0 1.1006843436689451e-07
of O 0 4.770162598255467e-10
the O 0 2.187637709871737e-10
potential O 0 1.295448415206124e-09
reasons O 0 1.1689124113090088e-09
for O 0 4.552543758640226e-11
these O 0 4.1496552721786983e-11
changes O 0 4.3929379578422356e-10
in O 0 5.263297020441371e-10
results O 0 3.5911916995701176e-08
and O 0 6.145090547526877e-10
impact O 0 1.3874983384454254e-09
of O 0 2.3244536503930213e-11
these O 0 2.0185200733102704e-10
risk O 0 7.73255570685194e-10
reversals O 0 3.466298892362829e-08
on O 0 2.831113476986502e-08
both O 0 1.3860681491451032e-08
patients O 0 2.3736741638913372e-07
and O 0 1.0951606982390061e-10
the O 0 3.827591368854577e-11
counseling O 0 6.67812194432571e-10
team O 0 8.78225686617995e-11
can O 0 4.784192833562351e-11
assist O 0 1.0162889974019151e-10
in O 0 5.133188665795707e-11
the O 0 1.0164784812471961e-11
development O 0 3.3563019984778064e-12
of O 0 5.047717452355549e-12
strategies O 0 1.9785158233975864e-10
for O 0 5.095574309721407e-11
the O 0 1.0642615955180901e-10
prevention O 0 6.129641683116915e-09
and O 0 3.159370098870795e-09
, O 0 1.906730884293495e-10
where O 0 2.331790593945726e-10
necessary O 0 5.054919816060988e-10
, O 0 1.1411155353968638e-10
management O 0 2.9460277967130466e-11
of O 0 2.474432768059809e-12
a O 0 9.605733986006726e-10
risk O 0 2.690959677309479e-09
reversal O 0 6.17906037447824e-09
in O 0 7.222061837452998e-11
any O 0 1.7870173396605793e-10
predictive O 0 6.372821825806341e-09
testing O 0 3.4250120517498317e-09
program O 0 7.167367255256352e-10
. O 0 4.0883318952467107e-10
. O 0 4.7914299194928844e-09

A O 0 1.2817857850677683e-06
novel O 0 2.445815425744513e-07
common O 0 1.2434473006806002e-08
missense O 0 1.3270145018395851e-06
mutation O 0 1.9793374406162911e-07
G301C O 0 1.5442435596924042e-07
in O 0 9.524531163762617e-10
the O 0 6.193074386651176e-10
N O 0 6.356569883791963e-07
- O 0 4.937893208989408e-06
acetylgalactosamine O 0 5.503943975782022e-05
- O 0 4.9740870053938124e-06
6 O 0 9.999161676432777e-08
- O 0 5.0353319238638505e-06
sulfate O 0 1.5976931535988115e-05
sulfatase O 0 1.6828162188176066e-06
gene O 0 3.037219542534331e-08
in O 0 2.7093249865828284e-09
mucopolysaccharidosis B-Disease 0 4.046562480652938e-06
IVA I-Disease 0 3.894351175404154e-05
. O 0 3.246646826937649e-07

Mucopolysaccharidosis B-Disease 0 0.05903833732008934
IVA I-Disease 1 0.9744729399681091
( O 0 0.0005825834232382476
MPS B-Disease 1 0.9999995231628418
IVA I-Disease 1 0.9999939203262329
) O 0 6.884491909886492e-08
is O 0 1.636127500148632e-08
an O 0 4.133483244572744e-08
autosomal B-Disease 1 0.9974564909934998
recessive I-Disease 1 0.9997768998146057
lysosomal I-Disease 1 0.9991776347160339
storage I-Disease 1 0.9871715903282166
disorder I-Disease 1 0.9998175501823425
caused O 0 1.8988120018548216e-06
by O 0 2.404847432302404e-09
a O 0 4.596859071170911e-07
genetic B-Disease 1 0.9999983310699463
defect I-Disease 1 0.9999982118606567
in O 0 1.560233364727992e-08
N O 0 7.995749911060557e-07
- O 0 8.279305802716408e-06
acetylgalactosamine O 0 0.0002904800057876855
- O 0 4.6102806663839146e-05
6 O 0 1.473047035460695e-07
- O 0 0.00022791091760154814
sulfate O 0 0.0004226673918310553
sulfatase O 0 5.704653631255496e-06
( O 0 3.770719736451156e-09
GALNS O 0 1.3843739452568116e-06
) O 0 3.584763819119985e-09
. O 0 9.612795004443342e-09

In O 0 2.0041326820319227e-07
previous O 0 2.991227177062683e-08
studies O 0 9.591033522937664e-10
, O 0 7.856493927649311e-11
we O 0 2.0607281159268354e-10
have O 0 3.971278306202919e-10
found O 0 5.029693328495455e-10
two O 0 9.157864744313571e-11
common O 0 2.25641352824546e-10
mutations O 0 5.1069921624957715e-09
in O 0 4.4172535074160635e-10
Caucasians O 0 4.418522081550691e-08
and O 0 2.5318602769885956e-09
Japanese O 0 4.0636427556250965e-09
, O 0 6.07607020253198e-10
respectively O 0 9.292867808596839e-09
. O 0 8.01477373357784e-09

To O 0 9.387736810140268e-08
characterize O 0 5.400597729021683e-07
the O 0 3.049018371115153e-09
mutational O 0 2.5188594008795917e-05
spectrum O 0 6.152520768409886e-07
in O 0 2.2562973711615086e-10
various O 0 6.9658737111844e-11
ethnic O 0 6.457305246065914e-10
groups O 0 2.237103835511789e-10
, O 0 1.310193203929444e-10
mutations O 0 2.2075696826107105e-09
in O 0 3.92996885034691e-11
the O 0 1.0449816706392667e-10
GALNS O 0 2.88986200303043e-07
gene O 0 6.48457287866222e-09
in O 0 1.510594649367647e-09
Colombian O 0 2.5523627300572116e-06
MPS B-Disease 1 0.999996542930603
IVA I-Disease 1 0.999998927116394
patients O 1 0.9953001737594604
were O 0 3.513418889156128e-08
investigated O 0 2.8353555947546738e-08
, O 0 4.269671005641129e-10
and O 0 9.952080270991814e-10
genetic O 0 9.5320595860926e-09
backgrounds O 0 3.335146603333783e-09
were O 0 1.1840725067102653e-09
extensively O 0 2.876710647470304e-09
analyzed O 0 3.2192566390421007e-09
to O 0 3.1458571858600237e-10
identify O 0 2.9260722733681632e-09
racial O 0 2.769694473769846e-09
origin O 0 2.0005372913800556e-09
, O 0 3.304302387263647e-10
based O 0 9.898015740361643e-10
on O 0 3.0047206944772142e-09
mitochondrial O 0 1.8138857171834388e-07
DNA O 0 5.1801610112534036e-08
( O 0 4.0293340886066176e-10
mtDNA O 0 1.1100701691191261e-08
) O 0 7.191783280013908e-10
lineages O 0 2.9255435407549157e-08
. O 0 1.2349338440742486e-08

Three O 0 8.730343097340665e-07
novel O 0 8.443472552244202e-07
missense O 0 1.8053438907372765e-05
mutations O 0 3.3115916266979184e-06
never O 0 1.7330701496121037e-07
identified O 0 1.569180696492367e-08
previously O 0 5.3423927504070434e-09
in O 0 1.9235923964799895e-10
other O 0 7.626693721007882e-11
populations O 0 4.71081340602808e-10
and O 0 5.718553408584626e-10
found O 0 6.312259048790736e-10
in O 0 1.1930992305231314e-10
16 O 0 4.2635839303528655e-10
out O 0 2.1816748407843534e-10
of O 0 5.955068382856865e-11
19 O 0 7.3843589021294065e-09
Colombian O 0 4.0907156062530703e-07
MPS B-Disease 1 0.9999752044677734
IVA I-Disease 1 0.9995984435081482
unrelated O 0 5.063691901341372e-07
alleles O 0 8.568804332753643e-08
account O 0 8.711162458041599e-09
for O 0 1.6310666151042597e-09
84 O 0 8.396852280156963e-08
. O 0 1.5212009429887985e-08

2 O 0 5.327864869286714e-07
% O 0 7.10072356469027e-09
of O 0 8.040765275829642e-11
the O 0 3.895967715106252e-10
alleles O 0 1.5985376577987154e-08
in O 0 6.773202554377633e-10
this O 0 1.0310776676902833e-09
study O 0 1.0895134572308507e-08
. O 0 1.1652155684771515e-08

The O 0 2.011061610573961e-07
G301C O 0 3.0239305033319397e-06
and O 0 1.127951332335897e-08
S162F O 0 4.762322589613177e-07
mutations O 0 1.4422843719330558e-07
account O 0 1.6917576672881296e-08
for O 0 1.9657540040185495e-09
68 O 0 2.373624283791287e-07
. O 0 2.5811775827833117e-08

4 O 0 5.866225819772808e-06
% O 0 9.59459143246022e-08
and O 0 1.0880473411134517e-08
10 O 0 2.1241058689724923e-08
. O 0 2.1611141320931893e-08

5 O 0 9.094184747482359e-07
% O 0 1.0188072607775212e-08
of O 0 1.1326672239020397e-10
mutations O 0 1.023152265133831e-07
, O 0 3.1231399688635975e-09
respectively O 0 2.1313498521635665e-08
, O 0 8.855886579617334e-10
whereas O 0 1.3366852069651713e-09
the O 0 1.4464615616383014e-10
remaining O 0 3.6081553300704172e-09
F69V O 0 1.7176147366626537e-06
is O 0 2.5719371077315145e-09
limited O 0 5.369901745488903e-10
to O 0 2.0075466289348753e-10
a O 0 2.5943347470303024e-09
single O 0 2.2193735560449568e-07
allele O 0 1.4810410675636376e-06
. O 0 2.6296179456153368e-08

The O 0 1.9426572350766946e-07
skewed O 0 4.090031325176824e-06
prevalence O 0 9.051846632246452e-07
of O 0 2.76344003236062e-10
G301C O 0 9.93138158378315e-08
in O 0 5.121035262511953e-10
only O 0 1.4599773612289368e-09
Colombian O 0 9.187164806689907e-08
patients O 0 8.576227628509514e-06
and O 0 4.087039151556837e-09
haplotype O 0 4.147575054957997e-06
analysis O 0 4.895501226620524e-10
by O 0 3.351838598342205e-11
restriction O 0 5.5787290342834694e-09
fragment O 0 1.551657362597325e-07
length O 0 6.43038262637674e-08
polymorphisms O 0 8.754991398518541e-08
in O 0 3.1947813838861805e-10
the O 0 2.247299568658434e-10
GALNS O 0 7.618402264597535e-07
gene O 0 9.477057361095831e-09
suggest O 0 4.01070376909729e-09
that O 0 2.848828950519078e-10
G301C O 0 2.326071424363363e-08
originated O 0 6.343374159278881e-10
from O 0 3.520839522708208e-11
a O 0 1.0034670872016704e-09
common O 0 5.104411560097333e-09
ancestor O 0 1.0375770642667703e-07
. O 0 5.706900196855713e-08

Investigation O 0 6.976519557611027e-07
of O 0 1.1991571069458473e-09
the O 0 5.705904082553559e-10
genetic O 0 8.555343988803088e-09
background O 0 1.247224012956849e-08
by O 0 3.080823929302312e-10
means O 0 2.3235814661237697e-10
of O 0 4.462301708696437e-11
mtDNA O 0 8.82755912812172e-09
lineages O 0 1.3039364032962908e-09
indicate O 0 2.8050592959516507e-09
that O 0 2.670771104273939e-10
all O 0 6.557726583977797e-11
our O 0 2.5102206424598705e-10
patients O 0 9.275336942948798e-09
are O 0 3.759154793003816e-11
probably O 0 1.7978112332173168e-09
of O 0 8.130179862675391e-11
native O 0 2.2023547430194412e-09
American O 0 4.7252886048454457e-08
descent O 0 2.0857069102930836e-05

Low O 0 9.677484194980934e-05
frequency O 0 1.8523973039918928e-06
of O 0 1.5370076322795967e-09
BRCA1 O 0 4.2048193904520303e-07
germline O 0 2.638254557041364e-07
mutations O 0 2.8094387971577817e-07
in O 0 1.9530472794571097e-09
45 O 0 2.6319244739170244e-07
German O 1 0.9998419284820557
breast B-Disease 1 0.9999996423721313
/ I-Disease 1 0.9999997615814209
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 5.459143608277373e-07
. O 0 5.588604423678589e-08

In O 0 5.672152525448837e-08
this O 0 1.3553983491121357e-09
study O 0 1.4035431705750057e-09
we O 0 6.191987478310068e-10
investigated O 0 1.5299388422818083e-08
45 O 0 4.390680885535403e-08
German O 1 0.7087230682373047
breast B-Disease 1 0.9999988079071045
/ I-Disease 1 0.9999996423721313
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 6.428592058682625e-08
for O 0 6.849958933408118e-10
germline O 0 3.280487419488054e-07
mutations O 0 1.0622169810403648e-07
in O 0 1.9149860863709733e-10
the O 0 5.771677580312939e-10
BRCA1 O 0 9.697896530269645e-07
gene O 0 2.1871085209568264e-07
. O 0 4.286394883479261e-08

We O 0 2.60620026892866e-07
identified O 0 5.768513133830311e-08
four O 0 1.939771454573247e-09
germline O 0 9.146460655529154e-08
mutations O 0 1.0490410318197974e-07
in O 0 1.1906106101022829e-09
three O 0 1.2588276376845897e-07
breast B-Disease 1 0.9974178075790405
cancer I-Disease 0 0.015110575594007969
families O 0 4.9787272082824074e-09
and O 0 9.346047269431779e-10
in O 0 3.037739615407986e-09
one O 0 0.000458092283224687
breast B-Disease 1 0.9999912977218628
- I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
family O 0 5.044339701498757e-08
. O 0 1.0688673557357475e-10
among O 0 3.020496353034474e-11
these O 0 1.8911807883603693e-11
were O 0 4.02944150268425e-10
one O 0 2.3067936449905346e-09
frameshift O 0 3.170498530380428e-05
mutation O 0 5.1052417404662265e-08
, O 0 1.0935846672666116e-10
one O 0 5.806359282267692e-10
nonsense O 0 2.0552607793433708e-07
mutation O 0 4.23709494157265e-08
, O 0 2.4751481420004495e-10
one O 0 1.7973783572600155e-10
novel O 0 2.9397497769423353e-09
splice O 0 1.2377876146274502e-07
site O 0 3.175175322667201e-08
mutation O 0 5.066034347578352e-08
, O 0 1.412851780013824e-10
and O 0 5.976030781340569e-10
one O 0 9.94301529999575e-09
missense O 0 1.0033049875346478e-05
mutation O 0 2.142588982678717e-06
. O 0 4.9546677871603606e-08

The O 0 2.5692767735563393e-07
missense O 0 2.6441981390235014e-05
mutation O 0 1.0102368833031505e-05
was O 0 7.762501041952419e-08
also O 0 4.284537169496616e-09
found O 0 1.0357807944672004e-09
in O 0 4.5497594580723444e-10
2 O 0 3.742041698728826e-08
. O 0 5.0341132151743295e-08

8 O 0 8.646737796880188e-07
% O 0 4.851619106460703e-09
of O 0 4.221197696940848e-11
the O 0 1.3672116216945085e-10
general O 0 1.1311717118545062e-09
population O 0 1.0926094473617809e-09
, O 0 9.820270985283486e-11
suggesting O 0 2.1268575789434863e-09
that O 0 4.124894870116691e-10
it O 0 7.13392456219708e-10
is O 0 4.331256686640472e-09
not O 0 2.1789121262827393e-07
disease O 0 3.9019437281240243e-07
associated O 0 2.86320211984048e-08
. O 0 3.058846687054029e-08

The O 0 2.3839304219563928e-07
average O 0 2.879899909657979e-07
age O 0 1.9617433011376306e-08
of O 0 1.1011999090371205e-09
disease O 0 1.1859399364766432e-06
onset O 0 1.2690326229858329e-06
in O 0 2.3603234922120464e-08
those O 0 3.835143758124104e-09
families O 0 2.8827633613559556e-09
harbouring O 0 3.037979183773132e-07
causative O 0 1.097669155569747e-06
mutations O 0 8.073168942246411e-07
was O 0 4.790208052440903e-08
between O 0 1.5357856097963918e-09
32 O 0 9.389491850697596e-08
. O 0 4.409067599908667e-08

3 O 0 3.044730419787811e-06
and O 0 1.0679252682166407e-07
37 O 0 4.566290954244323e-07
. O 0 5.238324973788622e-08

4 O 0 2.084488187392708e-06
years O 0 4.927130703435978e-08
, O 0 1.255213377682196e-09
whereas O 0 1.7731826007505447e-09
the O 0 2.5996038655051734e-10
family O 0 6.9843459904461724e-09
harbouring O 0 7.07031873048436e-08
the O 0 5.160609717336229e-10
missense O 0 8.567919280721981e-07
mutation O 0 9.792564981125906e-08
had O 0 1.2429232754129771e-08
an O 0 1.0361956848115028e-09
average O 0 2.0170057624113724e-08
age O 0 2.0360915176098615e-09
of O 0 7.136643359606509e-11
onset O 0 1.0464211896987763e-07
of O 0 3.206070076089418e-09
51 O 0 2.1472242224263027e-06
. O 0 1.0513245740639832e-07

2 O 0 5.735759259550832e-06
years O 0 5.882645837118616e-07
. O 0 1.9713122867415223e-07

These O 0 1.5511513140609168e-07
findings O 0 7.272207369624084e-08
show O 0 1.6175041750443597e-08
that O 0 9.403409162445087e-10
BRCA1 O 0 8.449161725820886e-08
is O 0 2.83919665555743e-09
implicated O 0 7.54754392318091e-09
in O 0 7.342876306992707e-11
a O 0 3.012454452555602e-10
small O 0 8.64331828331899e-10
fraction O 0 1.007158711985312e-08
of O 0 9.129203171198697e-09
breast B-Disease 1 0.9999939203262329
/ I-Disease 1 0.9999995231628418
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 2.0381817478209996e-07
suggesting O 0 1.4582777652094592e-08
the O 0 1.7209392244588173e-10
involvement O 0 1.878349031869675e-09
of O 0 3.249760530121826e-11
another O 0 1.5766870475886208e-08
susceptibility O 0 0.0003228643618058413
gene O 0 3.487035371563252e-07
( O 0 3.920703761650657e-09
s O 0 1.6691104974597692e-05
) O 0 1.263407511942205e-07

Paternal O 1 0.9525155425071716
transmission O 0 0.03611871227622032
of O 0 2.620403847686248e-06
congenital B-Disease 1 0.9999991655349731
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 1.0
. O 0 0.0002583244349807501

We O 0 8.545022183170659e-07
report O 0 9.876483630932853e-09
a O 0 1.410187300265875e-09
rare O 0 3.600126197156328e-09
case O 0 4.549807641751613e-08
of O 0 9.3242586984843e-09
paternally O 0 0.2334149330854416
transmitted O 1 0.9996398687362671
congenital B-Disease 1 0.9999996423721313
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 0.0014129920164123178
DM B-Disease 1 1.0
) O 0 1.3115505907990155e-06
. O 0 1.431961464959386e-07

The O 0 8.240349558263915e-08
proband O 0 9.860709724307526e-07
is O 0 3.1854188176083653e-09
a O 0 2.720800473809959e-09
23 O 0 6.86487311440942e-09
year O 0 1.3118442998560909e-09
old O 0 1.7250872588192578e-06
, O 0 3.7753747506030777e-07
mentally B-Disease 1 1.0
retarded I-Disease 1 1.0
male O 0 0.03503115847706795
who O 0 2.658706762304064e-05
suffers O 1 0.9978803396224976
severe O 1 0.9987385869026184
muscular B-Disease 1 0.9998559951782227
weakness I-Disease 1 0.6474426984786987
. O 0 4.1525680671838927e-07

He O 0 8.900904504116625e-06
presented O 0 2.493550823601254e-07
with O 0 4.892388005828252e-08
respiratory O 1 0.7543114423751831
and O 0 6.55501594337693e-07
feeding O 0 2.6320799406676088e-06
difficulties O 0 1.974640895241464e-07
at O 0 6.323469747826493e-09
birth O 0 3.118603331131453e-07
. O 0 2.119104181019793e-08

His O 0 5.7451866268820595e-06
two O 0 3.076749237607146e-07
sibs O 0 0.003261673031374812
suffer O 0 0.0011093576904386282
from O 0 2.1939621674960108e-08
childhood O 0 1.122128469432937e-05
onset O 0 0.00469972612336278
DM B-Disease 1 0.9999998807907104
. O 0 1.0725559150159825e-05

Their O 0 2.0040887704908528e-07
late O 0 4.7844370243410594e-08
father O 0 1.1621131790207073e-07
had O 0 4.126982311447591e-09
the O 0 7.696061149475852e-11
adult O 0 1.6205705222205324e-08
type O 0 6.987866640884022e-08
of O 0 4.362713301730992e-09
DM B-Disease 1 1.0
, O 0 6.782154571283172e-08
with O 0 3.250538949117754e-09
onset O 0 2.1085675427912065e-07
around O 0 2.5266128744760863e-08
30 O 0 1.272633731730366e-08
years O 0 9.452975291424082e-09
. O 0 1.4897111100253824e-08

Only O 0 5.477369882100902e-07
six O 0 1.2527695325559307e-08
other O 0 2.547932698160338e-10
cases O 0 6.682708830751949e-10
of O 0 2.355944883625227e-10
paternal O 0 0.002182793105021119
transmission O 0 0.00023753060668241233
of O 0 3.455604868918272e-08
congenital B-Disease 1 0.9999984502792358
DM I-Disease 1 1.0
have O 0 0.013161341659724712
been O 0 1.6730709830881096e-06
reported O 0 1.1860151971632149e-07
recently O 0 1.1614373107704523e-07
. O 0 2.663011500203538e-08

We O 0 7.017572301037944e-08
review O 0 7.560728043642939e-09
the O 0 2.781880559243888e-10
sex O 0 2.8858935241515837e-09
related O 0 5.321379448197661e-10
effects O 0 5.712334782970174e-08
on O 0 2.2596466919821978e-07
transmission O 0 0.0003889201325364411
of O 0 7.688853287390884e-08
congenital B-Disease 1 0.9999979734420776
DM I-Disease 1 1.0
. O 0 3.518196172080934e-05

Decreased O 0 0.00010429763642605394
fertility O 0 1.19219930638792e-06
of O 0 7.692366743583534e-10
males O 0 2.0053596117008965e-08
with O 0 2.356602246678108e-09
adult O 0 5.388690624386072e-06
onset O 0 0.00014891244063619524
DM B-Disease 1 1.0
and O 0 2.7528380996955093e-07
contraction O 0 7.693122228147331e-08
of O 0 2.978737048686675e-11
the O 0 6.256710427532397e-11
repeat O 0 7.840918136992059e-09
upon O 0 1.7513014372028124e-09
male O 0 2.9521297406631675e-08
transmission O 0 9.711018655877979e-09
contribute O 0 5.508549727473167e-10
to O 0 5.406911585126295e-10
the O 0 3.8280822955982785e-10
almost O 0 6.0560338965842675e-09
absent O 0 1.3179292324139169e-08
occurrence O 0 3.5987324231712137e-09
of O 0 5.78376624371657e-10
paternal O 0 7.01016906532459e-05
transmission O 0 4.470652129384689e-05
of O 0 6.201307201081363e-08
congenital B-Disease 1 0.9999924898147583
DM I-Disease 1 1.0
. O 0 5.679487730958499e-05

Also O 0 2.733004862420785e-07
the O 0 1.2745570154848451e-09
fathers O 0 2.1289516816125342e-09
of O 0 6.659175814938134e-12
the O 0 1.6223161702910716e-10
reported O 0 4.888395821467384e-08
congenitally O 0 2.9446102416841313e-05
affected O 0 1.275219574381481e-07
children O 0 2.661960074590297e-08
showed O 0 6.208313152455958e-08
, O 0 8.494749348386677e-11
on O 0 2.8068898316746527e-09
average O 0 1.2934073367887322e-08
, O 0 8.629678638349958e-10
shorter O 0 2.1249310577786673e-07
CTG O 0 5.20253422564565e-07
repeat O 0 2.2812839972630172e-07
lengths O 0 9.700513601273997e-07
and O 0 8.640944626492342e-10
hence O 0 1.1985831216421161e-09
less O 0 8.818472174709768e-09
severe O 0 0.006100495345890522
clinical O 0 0.011790001764893532
symptoms O 1 0.8343794345855713
than O 0 8.276211715951831e-09
the O 0 8.329910650139993e-10
mothers O 0 2.9716654026401557e-08
of O 0 1.2344920918838653e-10
children O 0 4.114039953151405e-08
with O 0 6.094903142184194e-07
congenital B-Disease 1 0.9999979734420776
DM I-Disease 1 1.0
. O 0 0.0001592279877513647

We O 0 1.9295295317078853e-07
conclude O 0 9.612578821815987e-08
that O 0 8.18501888488754e-09
paternal O 0 8.348992196260951e-06
transmission O 0 8.744560545892455e-06
of O 0 3.249238744729155e-08
congenital B-Disease 1 0.9999995231628418
DM I-Disease 1 1.0
is O 0 0.00014420498337130994
rare O 0 1.0997442245752609e-07
and O 0 3.6747398457492864e-09
preferentially O 0 4.843762440032151e-07
occurs O 0 7.768685139630804e-10
with O 0 2.030707407785215e-10
onset O 0 4.3142904360138346e-08
of O 0 4.820377874636961e-09
DM B-Disease 1 0.9999998807907104
past O 0 1.5227647054416593e-06
30 O 0 9.391082578247278e-09
years O 0 5.798224678166264e-10
in O 0 9.528268452019262e-11
the O 0 3.169333129271479e-10
father O 0 8.934038220331786e-08
. O 0 1.1009730904731896e-09
. O 0 4.797145347623655e-09

The O 0 6.915392418704869e-07
RB1 O 0 6.765582656953484e-05
gene O 0 3.1281021506401885e-07
mutation O 0 3.3566360002623696e-07
in O 0 4.593094238281026e-10
a O 0 1.0290191809758653e-08
child O 0 1.4171966995490948e-06
with O 0 3.337108580581116e-07
ectopic B-Disease 1 0.9999641180038452
intracranial I-Disease 1 0.9999727010726929
retinoblastoma I-Disease 1 0.8030322194099426
. O 0 1.0327097470508306e-06

The O 0 4.783871645486215e-07
RB1 O 0 2.9158478355384432e-05
gene O 0 2.4591986402811017e-07
mutation O 0 2.906115526002395e-07
was O 0 1.8116326216954803e-08
investigated O 0 1.2841915975059237e-08
in O 0 2.2220837669895133e-10
a O 0 9.348941176767767e-09
child O 0 7.368167302956863e-07
with O 0 1.3271876753151446e-07
ectopic B-Disease 1 0.9998917579650879
intracranial I-Disease 1 0.9997304081916809
retinoblastoma I-Disease 0 1.2155709555372596e-05
using O 0 1.2994283871137213e-08
DNA O 0 2.989390779362111e-08
obtained O 0 1.1969107927001232e-09
from O 0 6.087040593794057e-11
both O 0 2.1428998853156855e-10
the O 0 2.1745168166109607e-10
pineal B-Disease 0 2.3149482331064064e-06
and I-Disease 0 1.4694119272462558e-06
retinal I-Disease 1 0.9932098984718323
tumours I-Disease 1 0.9999996423721313
of O 0 7.696857595718143e-10
the O 0 2.932648568432228e-09
patient O 0 2.276725172123406e-05
. O 0 5.392425705963433e-08

A O 0 2.3265920390258543e-06
nonsense O 0 5.766698450315744e-06
mutation O 0 5.406616878644854e-07
in O 0 2.7623241471985693e-09
exon O 0 2.729951802393771e-07
17 O 0 1.3612283744635079e-08
( O 0 1.9497449488259377e-10
codon O 0 5.18897902423987e-09
556 O 0 5.368194333499332e-09
) O 0 7.348789632377617e-11
of O 0 1.9573264883887553e-11
the O 0 4.668077591141184e-10
RB1 O 0 4.829030331165995e-07
gene O 0 3.2480227396547434e-09
was O 0 5.0940340834415565e-09
found O 0 3.2150518358697866e-10
to O 0 3.0635025072278665e-10
be O 0 1.3180593283479425e-09
present O 0 6.576781341749438e-10
homozygously O 0 4.742037162941415e-07
in O 0 4.674920450753461e-10
both O 0 2.414166366815351e-10
the O 0 1.5624712634831894e-10
retinal B-Disease 0 1.0887595635722391e-05
and I-Disease 0 2.7270990798911043e-08
the I-Disease 0 1.996025567052584e-08
pineal I-Disease 0 0.005109534133225679
tumours I-Disease 1 0.9999967813491821
. O 0 8.954695545071445e-07

The O 0 6.171253374986918e-08
same O 0 7.667483536977215e-09
mutation O 0 5.452422158214176e-08
was O 0 8.725746347693075e-09
present O 0 1.033994334598276e-09
heterozygously O 0 2.3371144663997256e-07
in O 0 3.305140605647239e-10
the O 0 4.9787597655726046e-11
DNA O 0 1.3170942114726358e-09
from O 0 2.8747549479790635e-11
the O 0 2.52867258382361e-11
constitutional O 0 4.616881987828947e-09
cells O 0 6.316498990521779e-10
of O 0 6.747844904370082e-12
the O 0 9.363172043252987e-11
patient O 0 1.4930412817193428e-07
, O 0 1.7117565698221426e-10
proving O 0 4.601900638334655e-09
it O 0 4.901237748988763e-10
to O 0 7.38636984909391e-10
be O 0 6.396919105533527e-10
of O 0 1.4595646913306837e-10
germline O 0 2.2452971393249754e-07
origin O 0 1.1395441035233489e-08
. O 0 2.1178314213443628e-08

The O 0 1.553065942516696e-08
initial O 0 3.871068443572767e-08
mutation O 0 6.495047699672796e-08
was O 0 2.0814370671473625e-08
shown O 0 6.507817840173402e-09
to O 0 5.81686754319577e-10
have O 0 2.280618804917367e-09
occurred O 0 7.898628973102007e-10
in O 0 7.453176964489217e-11
the O 0 4.73539818468538e-10
paternally O 0 1.3635809636980412e-06
derived O 0 1.0987147902596917e-07
RB1 O 0 1.0121637387783267e-05
allele O 0 8.110241083159053e-07
. O 0 2.0864932892550314e-08

The O 0 5.979867268024464e-08
mutation O 0 5.005815069125674e-07
is O 0 3.51338380610855e-09
in O 0 1.8476545293744095e-10
an O 0 9.837223258202243e-10
area O 0 3.9195375833855906e-09
of O 0 1.353031055251197e-11
the O 0 6.3805509487036e-11
gene O 0 1.0147360729462207e-09
that O 0 8.918277921710072e-11
encodes O 0 3.0529678785029546e-10
the O 0 1.4519060433093589e-11
protein O 0 3.69234476327307e-10
- O 0 1.0274227690842963e-08
binding O 0 6.873415170360886e-09
region O 0 1.1857720361163615e-09
known O 0 1.2645948732625811e-09
as O 0 3.6352110210913224e-10
the O 0 7.842899246712776e-11
pocket O 0 4.1760216845432296e-05
region O 0 6.789127926509764e-09
and O 0 4.478181825362526e-09
has O 0 7.360007003853752e-08
been O 0 2.967076140336644e-09
detected O 0 2.0575909864817277e-09
in O 0 2.5402646999794776e-11
other O 0 2.7497630908368542e-11
cases O 0 5.2351833979003e-10
of O 0 2.216639927166142e-10
retinoblastoma B-Disease 0 4.577196250465931e-06
. O 0 3.099674961148935e-09
. O 0 6.904951277419968e-09

Low O 0 0.0001548585860291496
levels O 0 2.525446873846704e-08
of O 0 4.4697297946205694e-11
beta O 0 2.401958076880817e-10
hexosaminidase O 0 3.769700640532392e-08
A O 0 2.9296352010987903e-09
in O 0 1.2214749212091647e-09
healthy O 0 2.0154059754418086e-08
individuals O 0 3.8190392515069504e-10
with O 0 1.3948006083452924e-09
apparent O 0 0.0018729654839262366
deficiency O 0 6.248950376175344e-05
of O 0 7.377552041498703e-11
this O 0 1.0012397577696674e-09
enzyme O 0 8.284917640821732e-08
. O 0 1.501532587155907e-08

Appreciable O 0 6.794574437662959e-05
beta O 0 3.5812703913506994e-07
hexosaminidase O 0 3.5743103126151254e-06
A O 0 5.0963201658760227e-08
( O 0 5.66421187730981e-10
hex O 0 1.866690979568375e-07
A O 0 1.79126775634586e-08
) O 0 2.473600213548366e-10
activity O 0 7.767470000530352e-10
has O 0 7.042562977233047e-09
been O 0 5.7220370663912945e-09
detected O 0 1.1747913752913064e-08
in O 0 1.1866612137367838e-09
cultured O 0 2.1936875782557763e-06
skin O 1 0.602501392364502
fibroblasts O 0 5.6574863265268505e-06
and O 0 2.2514068405143917e-06
melanoma B-Disease 0 0.16363921761512756
tissue O 0 1.7417504523109528e-06
from O 0 1.8116282918256843e-09
healthy O 0 3.4714336294427994e-08
individuals O 0 7.160384507542972e-10
previously O 0 6.976890176702e-09
reported O 0 3.07071310601259e-08
as O 0 6.1424687558542246e-09
having O 0 2.6759192905956297e-07
deficiency B-Disease 0 2.3069361532179755e-07
of I-Disease 0 3.109691323888164e-11
hex I-Disease 0 2.2987876491242787e-08
A I-Disease 0 1.3930644415793836e-09
activity O 0 5.611038855768413e-10
indistinguishable O 0 1.444234842828962e-09
from O 0 1.1563468065023397e-11
that O 0 7.765244697255369e-11
of O 0 1.3192004433282278e-10
patients O 0 2.9614029699587263e-05
with O 0 0.0008068386814557016
Tay B-Disease 1 1.0
- I-Disease 1 0.9999998807907104
Sachs I-Disease 1 1.0
disease I-Disease 0 0.32337698340415955
( O 0 6.6432392920035e-09
TSD B-Disease 0 1.4397970517165959e-05
) O 0 9.506385900692749e-09
. O 0 1.7243284133883208e-08

Identification O 0 2.144473683074466e-06
and O 0 3.618916011305373e-08
quantitation O 0 1.1237273156439187e-06
of O 0 7.394347911748866e-10
hex O 0 2.0779235399004392e-07
A O 0 3.1860341920264545e-08
, O 0 1.0511993497885896e-09
amounting O 0 8.895047365342634e-09
to O 0 4.186690993890352e-09
3 O 0 4.486306082185365e-08
. O 0 5.194131347252551e-08

5 O 0 2.5584652121324325e-06
% O 0 1.2847262098603096e-07
- O 0 2.7060241336585023e-06
6 O 0 6.33417926110269e-07
. O 0 8.725467637304973e-08

9 O 0 2.835009809132316e-06
% O 0 8.718726185463765e-09
of O 0 7.939300605830368e-11
total O 0 7.302460303115765e-10
beta O 0 7.758970688165334e-10
hexosaminidase O 0 1.355192864593846e-07
activity O 0 1.430368712362906e-09
, O 0 1.5866649660800647e-10
has O 0 1.6746452002891488e-09
been O 0 5.925545054630277e-10
obtained O 0 1.9846574383919346e-10
by O 0 1.1788978127036387e-10
cellulose O 0 2.191530654727103e-07
acetate O 0 2.4298908556374954e-06
gel O 0 2.292512363055721e-05
electrophoresis O 0 3.0257197636274213e-07
, O 0 1.2394496540224509e-09
DEAE O 0 3.0817707852293097e-07
- O 0 8.491295488965989e-08
cellulose O 0 1.5062430236412183e-07
ion O 0 1.2746480138048355e-07
- O 0 6.791189832711098e-08
exchange O 0 1.0602222433320208e-09
chromatography O 0 1.3321985292691352e-08
, O 0 4.667480846265448e-10
radial O 0 2.5758691890587215e-07
immunodiffusion O 0 1.0158431678064517e-06
, O 0 1.1973035896062356e-09
and O 0 4.123622332485866e-09
radioimmunoassay O 0 5.830524514749413e-06
. O 0 2.8777767724363912e-08

Previous O 0 2.1284388367348583e-06
family O 0 9.051806415527608e-08
studies O 0 1.5057073365909446e-09
suggested O 0 1.529628868013333e-09
that O 0 8.95210711115979e-11
these O 0 2.3074998509176048e-11
individuals O 0 4.889675123131987e-11
may O 0 8.853555111265621e-10
be O 0 5.155985638438665e-10
compound O 0 1.0395852179101439e-08
heterozygotes O 0 5.621285481538507e-08
for O 0 6.63500157593866e-11
the O 0 7.163509369023657e-11
common O 0 5.775697142773595e-10
mutant O 0 8.444843047072936e-08
TSD B-Disease 0 3.414923241962242e-07
gene O 0 9.010084234262195e-09
and O 0 6.395589613461539e-10
a O 0 3.5538083587027813e-09
rare O 0 4.434275879816596e-08
( O 0 3.215212984741811e-09
allelic O 0 4.913119937555166e-07
) O 0 2.5869033581926715e-09
mutant O 0 3.90996007126887e-07
gene O 0 1.8785475219829095e-07
. O 0 3.21900053279478e-08

Thus O 0 8.776164008850174e-07
, O 0 1.6272941882888858e-09
the O 0 8.612540541852454e-11
postulated O 0 4.3078934197637864e-08
rate O 0 9.004341161578111e-10
mutant O 0 4.332429526243686e-09
gene O 0 1.1800773691561517e-09
appears O 0 3.5744813775551165e-09
to O 0 1.384275472027241e-10
code O 0 1.708990171600533e-10
for O 0 7.617549646621313e-11
the O 0 1.164003754494658e-10
expression O 0 1.950783756754504e-09
of O 0 3.2975323860373607e-11
low O 0 8.841562149086712e-09
amounts O 0 7.880585628505798e-10
of O 0 6.049308970412781e-11
hex O 0 1.540022793733442e-07
A O 0 3.462929143438487e-08
. O 0 3.6002578696070486e-08

Heterozygotes O 0 0.0012362069683149457
for O 0 1.4596001562949823e-07
the O 0 2.6452513512964515e-09
rare O 0 1.3948757704440595e-08
mutant O 0 3.026640342795872e-07
may O 0 4.737173142643769e-08
be O 0 1.0729080957005976e-09
indistinguishable O 0 1.0294962216050862e-08
from O 0 3.2011679418353367e-10
heterozygotes O 0 1.6308052863678313e-07
for O 0 4.2380285392162875e-10
the O 0 6.700756061128743e-10
common O 0 1.0008393225291456e-08
TSD B-Disease 0 7.65058575780131e-06
mutant O 0 1.5776021200508694e-06
. O 0 3.388198877019022e-08

However O 0 1.016981173052045e-06
, O 0 2.659061193455159e-09
direct O 0 4.367566752705443e-09
visualization O 0 4.455912616663227e-08
and O 0 4.288208010905237e-09
quantitation O 0 3.1431139291271393e-07
of O 0 1.1066147997951248e-10
hex O 0 2.6362970473314817e-08
A O 0 3.0067157652524656e-09
by O 0 8.449826255363391e-11
the O 0 3.369967152555553e-11
methods O 0 2.984125391236603e-09
described O 0 1.0083199697419332e-07
may O 0 5.729528851361465e-09
prevent O 0 3.440509876995179e-09
false O 0 1.703478957892912e-08
- O 0 3.025623982466641e-06
positive O 0 3.207170209407195e-07
prenatal O 0 1.090223577193683e-05
diagnosis O 0 5.973659426672384e-06
of O 0 3.149459026907664e-10
TSD B-Disease 0 4.0357249417866115e-06
in O 0 1.2769277191182482e-08
fetuses O 0 2.8203189117448346e-07
having O 0 1.4129172276611257e-09
the O 0 8.930499395543023e-11
incomplete O 0 6.25204066295737e-09
hex B-Disease 0 5.816107204736909e-07
A I-Disease 0 2.856608034562669e-07
deficiency I-Disease 0 1.116223984354292e-06
of O 0 3.4871425191873584e-11
the O 0 1.9165900810858005e-10
type O 0 2.12388755471693e-07
described O 0 2.4235927753579745e-07
in O 0 6.820208287017238e-10
the O 0 4.1668840600195267e-10
four O 0 1.9254700944770775e-08
healthy O 0 8.87618725187167e-08
individuals O 0 2.4984633029134784e-08

The O 0 1.1459220417009419e-07
tumor B-Disease 0 1.9499943846312817e-06
suppressor O 0 2.6842360512091545e-06
gene O 0 4.496942551668326e-07
Smad4 O 0 1.971875690287561e-06
/ O 0 2.2885033956754341e-07
Dpc4 O 0 7.085668016770796e-07
is O 0 3.0216520396919577e-09
required O 0 1.2178110742055992e-09
for O 0 1.8000337331791627e-10
gastrulation O 0 4.084344951138519e-08
and O 0 9.256567956583694e-09
later O 0 6.714538702823347e-09
for O 0 2.0202302331018274e-10
anterior O 0 5.838623362564022e-09
development O 0 5.515716702819695e-11
of O 0 2.2457299908573702e-11
the O 0 2.5400431757915953e-10
mouse O 0 5.208625566410774e-07
embryo O 0 4.3733129473366716e-07
. O 0 5.161068017400794e-08

Mutations O 0 0.0005353860906325281
in O 0 9.109412957286622e-08
the O 0 7.463469842150516e-09
SMAD4 O 0 0.0007278835400938988
/ O 0 1.8573344277683645e-05
DPC4 O 0 0.00021788236335851252
tumor B-Disease 0 8.703029379830696e-06
suppressor O 0 8.949795073931455e-07
gene O 0 2.9239425103355643e-08
, O 0 1.5498212435627323e-10
a O 0 2.155081668675507e-10
key O 0 6.882726055756905e-10
signal O 0 3.335377130042616e-08
transducer O 0 1.3924509403295815e-06
in O 0 1.6650838485787745e-09
most O 0 3.896801992198107e-09
TGFbeta O 0 1.7641344811636372e-06
- O 0 3.2229021940111124e-07
related O 0 3.7057021895492426e-09
pathways O 0 1.891067302750571e-09
, O 0 4.320575494598522e-11
are O 0 1.5646116346967887e-11
involved O 0 1.349644979109499e-10
in O 0 2.4598431624944794e-10
50 O 0 1.260498816435529e-09
% O 0 1.893484674608814e-10
of O 0 4.6282000454311856e-10
pancreatic B-Disease 1 0.7535858154296875
cancers I-Disease 0 0.019690440967679024
. O 0 1.5134310160647146e-07

Homozygous O 0 0.0007869760156609118
Smad4 O 0 0.00021027648472227156
mutant O 0 4.0366776374867186e-05
mice O 0 0.00019487482495605946
die O 0 6.9846805672568735e-06
before O 0 3.0918454463346734e-09
day O 0 5.223595778147683e-09
7 O 0 2.9521972422230647e-08
. O 0 2.8053175782360995e-08

5 O 0 1.2188885420982842e-06
of O 0 4.119151597592463e-08
embryogenesis O 0 2.7717865123122465e-06
. O 0 3.447672725087614e-07

Mutant O 0 1.0119059879798442e-05
embryos O 0 1.7631656419325736e-06
have O 0 1.7699127496939582e-08
reduced O 0 1.1236524599667064e-08
size O 0 4.731563141291417e-09
, O 0 1.2542561433903643e-09
fail O 0 1.2281996930596506e-07
to O 0 9.775243725584915e-09
gastrulate O 0 8.10653727967292e-06
or O 0 1.2527259229955234e-09
express O 0 4.9907256105541364e-09
a O 0 1.3071735915914928e-09
mesodermal O 0 3.1758358431943634e-07
marker O 0 2.8633660349441925e-06
, O 0 2.3374155944111408e-09
and O 0 1.3311006741290043e-09
show O 0 3.138237048005976e-08
abnormal O 0 3.9325811940216227e-07
visceral O 0 2.786395634757355e-05
endoderm O 0 5.0064013521478046e-06
development O 0 2.3490507317092124e-08
. O 0 6.806089203337251e-08

Growth B-Disease 1 0.9999176263809204
retardation I-Disease 1 0.9999988079071045
of O 0 7.107105570725025e-09
the O 0 2.481057359560168e-09
Smad4 O 0 1.537865500722546e-05
- O 0 0.0002414944610791281
deficient O 0 1.4866553101455793e-05
embryos O 0 2.1791901616552423e-08
results O 0 1.9497867764783905e-09
from O 0 3.8241396160820784e-11
reduced O 0 2.388204300984853e-09
cell O 0 5.700631522387312e-09
proliferation O 0 5.953640358491441e-10
rather O 0 4.704294731538994e-10
than O 0 8.52149795171897e-10
increased O 0 1.4655805458119175e-08
apoptosis O 0 6.35468438758835e-07
. O 0 6.040577460453278e-08

Aggregation O 0 3.638888983914512e-06
of O 0 1.6353755682985138e-08
mutant O 0 8.992675475383294e-07
Smad4 O 0 1.3486757097780355e-06
ES O 0 3.161149919606032e-08
cells O 0 8.486579439193065e-09
with O 0 7.753260256038175e-10
wild O 0 1.939454108423888e-08
- O 0 9.221763320965692e-06
type O 0 6.980192665650975e-06
tetraploid O 0 1.2017231711070053e-05
morulae O 0 1.4322813512990251e-05
rescues O 0 2.1932648905931273e-06
the O 0 6.2781384535526286e-09
gastrulation B-Disease 0 5.1628535402414855e-06
defect I-Disease 0 1.5781237379997037e-05
. O 0 1.0649799975226415e-07

These O 0 1.5345776205322181e-07
results O 0 3.7042624967398297e-08
indicate O 0 7.118216238666264e-09
that O 0 5.63765367722624e-10
Smad4 O 0 7.392648626591836e-08
is O 0 1.0101671721329808e-09
initially O 0 1.3195843528990281e-08
required O 0 1.0422725876813033e-10
for O 0 4.778007416800234e-12
the O 0 4.147564236500756e-12
differentiation O 0 8.828998643295449e-11
of O 0 2.4086274641454963e-11
the O 0 1.703620161608299e-10
visceral O 0 2.1897246824664762e-06
endoderm O 0 4.770641339746362e-07
and O 0 1.6078754994097721e-09
that O 0 1.6527744450822723e-10
the O 0 1.0495099234120175e-10
gastrulation B-Disease 0 1.119378936209614e-07
defect I-Disease 0 2.8262854812055593e-07
in O 0 2.860857384323623e-10
the O 0 2.051457059781825e-10
epiblast O 0 4.300045191030222e-07
is O 0 3.882143051470166e-09
secondary O 0 4.450251278598216e-10
and O 0 4.745044912546348e-10
non O 0 2.0805153155833978e-09
- O 0 4.3956347326457035e-06
cell O 0 2.3309816242544912e-05
autonomous O 0 1.8599793349949323e-07
. O 0 8.429233844253758e-08

Rescued O 0 0.0001311225350946188
embryos O 0 5.576152489084052e-06
show O 0 3.3368426102242665e-06
severe O 0 0.0009341229451820254
anterior O 0 7.880659723014105e-06
truncations O 0 1.4039547750144266e-05
, O 0 6.862777901517347e-09
indicating O 0 8.061135758907767e-09
a O 0 7.586480887944447e-10
second O 0 1.4491520206050268e-09
important O 0 6.796375962014878e-11
role O 0 1.099227375789269e-09
for O 0 4.2590322935076586e-10
Smad4 O 0 4.2729018900899973e-07
in O 0 2.0673232015155918e-09
anterior O 0 2.0138656964263646e-07
patterning O 0 1.2850096027250402e-06
during O 0 3.103829726569529e-08
embryogenesis O 0 9.03229818050022e-07
. O 0 9.586012339468652e-08

Prevalence O 0 0.004879108630120754
of O 0 2.114545694098524e-08
p16 O 0 1.4462968920270214e-06
and O 0 2.4444345214647e-08
CDK4 O 0 7.327696948777884e-06
germline O 0 1.5578610828015371e-06
mutations O 0 9.731286354508484e-07
in O 0 5.899092769823255e-09
48 O 0 1.028167616823339e-06
melanoma B-Disease 1 0.6640982627868652
- O 0 0.16288922727108002
prone O 0 0.4694945216178894
families O 0 6.227715942941359e-08
in O 0 7.400291046621987e-09
France O 0 1.950271553141647e-06
. O 0 5.477918918472824e-08

The O 0 2.513668846404471e-07
French O 0 7.552020633738721e-06
Familial B-Disease 0 0.005531868897378445
Melanoma I-Disease 1 0.998502254486084
Study O 0 2.6008322606685397e-07
Group O 0 9.283252211389481e-08
. O 0 1.1676873690191769e-08

Germline O 0 0.0013610407477244735
mutations O 0 0.0011324504157528281
in O 0 3.6279278248230185e-08
the O 0 1.4586135632654873e-09
p16 O 0 8.258318473508552e-08
and O 0 2.5044544216257236e-09
CDK4 O 0 4.843919327868207e-07
genes O 0 2.6941746611441886e-09
have O 0 2.22615725853359e-09
been O 0 5.195505359267827e-09
reported O 0 2.3580724040073164e-09
in O 0 3.065851045258583e-11
a O 0 2.597195236653249e-10
subset O 0 6.753726466968146e-09
of O 0 2.43415110290357e-09
melanoma B-Disease 0 0.05264125391840935
pedigrees O 0 5.146122248333995e-07
, O 0 4.733239911125509e-10
but O 0 1.1121210619080557e-09
their O 0 4.0848396887227523e-10
prevalence O 0 3.6279693915730604e-08
is O 0 9.762345376529424e-10
not O 0 1.1143207467867455e-09
well O 0 7.669307966473582e-10
known O 0 1.3703223444849755e-08
. O 0 1.2082010059089043e-08

We O 0 2.518837618481484e-07
searched O 0 6.16707680478612e-08
for O 0 1.6346161924030156e-10
such O 0 1.0480356166242544e-10
germline O 0 3.568672113374305e-08
mutations O 0 3.720803931628325e-08
in O 0 1.0654889193162376e-09
48 O 0 9.277977852661934e-08
French O 0 1.8134280253434554e-05
melanoma B-Disease 1 0.985610842704773
- O 0 0.041057974100112915
prone O 0 0.3074008822441101
families O 0 1.3196195247644482e-08
selected O 0 6.255161943968801e-10
according O 0 9.236224979281005e-11
to O 0 8.903270481974701e-11
two O 0 1.1440662306405613e-10
major O 0 3.541457682665339e-10
criteria O 0 3.1438671665995344e-09
families O 0 2.166960638705362e-10
with O 0 1.2157634621257074e-10
at O 0 1.886322070765445e-10
least O 0 1.1340686167926606e-09
three O 0 1.9974860654414783e-10
affected O 0 9.346617924066436e-10
members O 0 7.166967019855974e-11
( O 0 2.761884124180547e-11
n O 0 7.721623340728456e-09
= O 0 8.510244953185975e-09
20 O 0 2.3760038381226423e-10
) O 0 1.4201893133725108e-11
or O 0 1.45715023380788e-10
families O 0 3.7604186431394737e-10
with O 0 1.168381363880755e-10
two O 0 7.310877458976961e-10
affected O 0 2.6556095100715993e-09
members O 0 8.84958356595078e-11
, O 0 3.9160664294657366e-11
one O 0 4.7744020542639376e-11
of O 0 4.6718137171331e-12
them O 0 6.920370526630748e-11
affected O 0 1.1483074907614466e-10
before O 0 5.046680087716915e-11
the O 0 3.028006664851368e-11
age O 0 1.6801408875277701e-10
of O 0 1.3793041361842562e-11
50 O 0 3.882688615064467e-10
( O 0 8.824520281169868e-11
n O 0 4.183388213618855e-08
= O 0 3.87437779636457e-08
28 O 0 1.2061195597823371e-08
) O 0 8.624688463410024e-11
, O 0 1.6298279392756854e-10
and O 0 1.03770624038102e-10
one O 0 1.766396751090582e-10
additional O 0 6.922671325071406e-10
minor O 0 7.253973421939008e-09
criterion O 0 2.051275913572681e-07
. O 0 4.0683133306629315e-08

Sixteen O 0 5.461150976771023e-06
different O 0 3.093357037187161e-08
p16 O 0 6.284856226557167e-07
germline O 0 8.197941951948451e-07
mutations O 0 1.1690900691974093e-06
were O 0 1.8914974475592317e-08
found O 0 3.1167133318632523e-09
in O 0 8.15357170669273e-10
21 O 0 3.0196712685892635e-08
families O 0 2.0669959077679323e-09
, O 0 1.9219018043692415e-10
while O 0 6.716379674642781e-10
one O 0 1.0350638124378975e-09
germline O 0 5.446268858122494e-08
mutation O 0 2.8618591940698934e-08
, O 0 3.2807087602115814e-10
Arg24His O 0 1.2125508419558173e-07
, O 0 4.0213798957466906e-10
was O 0 1.0370919234503617e-08
detected O 0 3.731527087325048e-09
in O 0 1.1803062693882538e-10
the O 0 3.3770081175887867e-10
CDK4 O 0 1.5877489204285666e-05
gene O 0 3.415363210024225e-07
. O 0 4.002826869964338e-08

The O 0 7.744976215917632e-08
frequency O 0 1.8562157322321582e-07
of O 0 7.129245527259798e-10
p16 O 0 8.014731633920746e-08
gene O 0 1.702608543041606e-08
mutation O 0 3.0250323135305734e-08
in O 0 1.79071590888924e-10
our O 0 1.3937148657383602e-10
sample O 0 1.0571811204229675e-09
( O 0 6.205225916433577e-11
44 O 0 1.523354442589664e-09
% O 0 1.652653881800692e-11
) O 0 9.314077287214673e-12
is O 0 4.202353465210251e-10
among O 0 8.805453588500711e-11
the O 0 6.283067816026389e-11
highest O 0 4.86276441336031e-09
rates O 0 5.625733656700049e-09
yet O 0 3.238712409370237e-09
reported O 0 4.590871682808029e-09
and O 0 1.2625699097323917e-10
the O 0 5.85376053185982e-11
CDK4 O 0 5.088839770905906e-06
mutation O 0 3.322646335846002e-08
is O 0 1.8217383157548284e-10
the O 0 3.874113183033323e-11
second O 0 4.567481948214436e-09
mutation O 0 2.3108109203917593e-08
detected O 0 7.20385440189375e-09
in O 0 4.2970047658963395e-11
this O 0 8.60674378988513e-11
gene O 0 1.8766096232525342e-08
worldwide O 0 2.6683652620818066e-08
. O 0 3.0801455608298056e-08

In O 0 2.1612156331229926e-07
summary O 0 2.169486208458693e-07
, O 0 1.5081015325435487e-09
our O 0 3.4600533549422607e-10
results O 0 1.2803658133719864e-09
show O 0 5.336323383176023e-09
frequent O 0 1.1919609299582135e-08
involvement O 0 1.8442402049956286e-09
of O 0 2.6017356671848013e-11
the O 0 4.9839667115580966e-11
p16 O 0 1.0198902167246615e-08
gene O 0 4.739502568185117e-09
in O 0 7.77928665929295e-10
familial B-Disease 0 1.7481439499533735e-05
melanoma I-Disease 1 0.9956901669502258
and O 0 4.9795271905850313e-08
confirm O 0 9.326591765557168e-08
the O 0 1.0861634508474438e-10
role O 0 7.903194765290777e-10
of O 0 1.8240077850895098e-11
the O 0 8.084870967151048e-11
CDK4 O 0 3.1649753395868174e-07
gene O 0 3.0088613822698562e-09
as O 0 7.684535785479341e-10
a O 0 3.988498775697735e-08
melanoma B-Disease 0 0.1029360219836235
- O 0 1.6274045265163295e-05
predisposing O 0 3.839124019577866e-06
gene O 0 1.2569155671826593e-07
. O 0 2.4811901422339133e-09
. O 0 1.26518182597124e-08

Progression O 0 4.2111420043511316e-05
of O 0 2.9786791699848436e-08
somatic O 0 2.5746658138814382e-06
CTG O 0 1.2543207049020566e-05
repeat O 0 1.7271679553232389e-06
length O 0 9.000466434372356e-07
heterogeneity O 0 3.2410318340225786e-07
in O 0 1.5552410470576206e-09
the O 0 1.0716399989618708e-09
blood O 0 4.347547388761086e-08
cells O 0 5.648616863140887e-08
of O 0 4.3988535480821156e-08
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
patients O 1 0.9999569654464722
. O 0 5.694298010894272e-07

The O 0 2.1841835007307964e-08
genetic O 0 1.241258331674544e-07
basis O 0 1.139455019227853e-08
of O 0 4.6767979711148655e-08
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 0.0001348286314168945
DM B-Disease 1 1.0
) O 0 9.089450081489758e-09
is O 0 1.397612803266668e-09
the O 0 1.8795763556678224e-11
expansion O 0 1.3787970765122282e-10
of O 0 1.969061719231391e-11
an O 0 6.187407253221977e-10
unstable O 0 4.0877984019971336e-07
CTG O 0 1.4433962292059732e-07
repeat O 0 1.5948799614307063e-08
in O 0 2.4620913641193454e-10
the O 0 1.56113677540759e-10
34 O 0 2.229896933769737e-09
UTR O 0 6.621937842510306e-08
of O 0 1.3964503164931585e-10
the O 0 1.4560007643993345e-09
DM B-Disease 1 0.9999995231628418
protein O 0 6.670400125585729e-07
kinase O 0 2.407295198736392e-07
gene O 0 2.1717873721627257e-08
on O 0 3.890252120442028e-09
chromosome O 0 1.956891082954826e-06
19 O 0 1.1385311182721125e-07
. O 0 3.274185544910324e-08

One O 0 1.4372930934314354e-07
of O 0 6.238743410769132e-10
the O 0 3.1897948171710766e-10
principal O 0 8.366277115534615e-10
features O 0 2.363606643740468e-09
of O 0 1.760561002539518e-10
the O 0 1.527099335874027e-08
DM B-Disease 1 1.0
mutation O 0 4.388795787235722e-05
is O 0 2.1531763039206453e-09
an O 0 5.148693693612927e-10
extraordinarily O 0 4.396312363041943e-07
high O 0 1.2193410725558351e-08
level O 0 2.217138972415711e-10
of O 0 3.071604776083703e-11
somatic O 0 8.388367689349252e-08
mosaicism O 0 7.606164217577316e-06
, O 0 4.703648581738662e-10
due O 0 8.552369923364722e-10
to O 0 2.8816145025700735e-09
an O 0 5.068486075288092e-09
extremely O 0 7.5957559602102265e-06
high O 0 2.3447711328117293e-08
degree O 0 1.7051977607707158e-09
of O 0 4.155286531526414e-11
somatic O 0 6.762778070878994e-08
instability O 0 8.016612440542303e-08
both O 0 9.179326743158356e-10
within O 0 4.8982911476924684e-11
and O 0 2.574782886899385e-10
between O 0 1.654597570066585e-10
different O 0 1.1560259416398821e-09
tissues O 0 2.4123696107380965e-07
. O 0 2.003432797437199e-08

This O 0 7.814613667278536e-08
instability O 0 2.807406076499319e-07
appears O 0 5.971706684704259e-08
to O 0 1.0597086541608292e-09
be O 0 1.2692756845567033e-09
biased O 0 3.3055350456834276e-08
towards O 0 4.082144899886231e-10
further O 0 4.6273526677076404e-10
expansion O 0 5.485901732882326e-10
and O 0 1.197467403013519e-10
continuous O 0 1.3746017657467746e-09
throughout O 0 1.9939498663301691e-10
the O 0 5.6222203975719864e-11
life O 0 1.732611554228214e-10
of O 0 8.447726893012764e-12
an O 0 1.0696137725529908e-10
individual O 0 2.353353345529996e-10
, O 0 1.4969385453422746e-10
features O 0 4.447521462225268e-09
that O 0 1.4563756867147504e-09
could O 0 7.466705653769168e-08
be O 0 3.3959870471278464e-09
associated O 0 4.500168016008388e-10
with O 0 8.793100969572976e-11
the O 0 3.9939149210077574e-10
progressive O 0 9.434494359084056e-07
nature O 0 3.3115914455095208e-09
of O 0 1.3464977743904427e-10
the O 0 8.876556378822897e-09
disease O 0 6.047516762919258e-06
. O 0 5.851101292364547e-08

Although O 0 8.158453965734225e-07
increasing O 0 2.775576568581073e-08
measured O 0 5.758646466347273e-07
allele O 0 1.2280601424663473e-07
size O 0 6.911618388727447e-09
between O 0 3.4335019272191403e-09
patients O 0 3.1852493975748075e-06
clearly O 0 3.7022282128873485e-08
correlates O 0 2.5617453047743766e-08
with O 0 1.0759322599529497e-10
an O 0 3.0087335400885706e-10
increased O 0 6.4990992143521e-08
severity O 0 3.809140616795048e-05
of O 0 2.548522282097565e-09
symptoms O 0 0.01376449316740036
and O 0 2.1684296580559703e-09
an O 0 5.46895584374596e-10
earlier O 0 6.085377179942952e-08
age O 0 1.8595700534973503e-09
of O 0 2.1800930852244882e-11
onset O 0 3.0826608821143964e-08
, O 0 3.12776443633922e-10
this O 0 6.208635688897957e-11
correlation O 0 2.440957436178337e-09
is O 0 6.734274249353689e-10
not O 0 7.440468796637845e-10
precise O 0 8.935845130508824e-08
and O 0 2.9617458707775768e-08
measured O 0 1.9508463537931675e-06
allele O 0 6.416329512148877e-08
length O 0 3.3443591007653595e-08
cannot O 0 6.379364592135062e-09
be O 0 1.449499409389432e-10
used O 0 3.250066049620415e-10
as O 0 2.1402773997536428e-10
an O 0 1.2902644230816662e-10
accurate O 0 4.7271004177673603e-07
predictor O 0 1.3681674317922443e-06
of O 0 2.3248761249483607e-10
age O 0 3.6097864697381965e-09
of O 0 5.88053106209685e-10
onset O 0 1.3199251043261029e-06
. O 0 1.6314010053974926e-07

In O 0 3.559787131734993e-08
order O 0 1.9319656985317124e-09
to O 0 1.2164691476357348e-09
further O 0 2.2773065655457003e-09
characterize O 0 6.826904552781343e-08
the O 0 1.0622666080095655e-09
dynamics O 0 7.844361959996604e-08
of O 0 4.123441588177457e-09
DM B-Disease 1 0.9999994039535522
CTG O 0 1.5707169950474054e-05
repeat O 0 3.460347954842291e-07
somatic O 0 3.468538523065945e-07
instability O 0 1.1319993831193642e-07
, O 0 6.122907736383354e-10
we O 0 5.234923605712538e-10
have O 0 3.3622321593540505e-10
studied O 0 1.2904324275808676e-09
repeat O 0 1.1775552088977292e-08
length O 0 2.4089066741339593e-08
changes O 0 5.354774956778385e-10
over O 0 2.1325514965031545e-10
time O 0 6.14052086955752e-10
in O 0 8.804483808688701e-10
111 O 0 1.0782016943267081e-05
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
patients O 1 0.999824583530426
with O 0 4.850277512957746e-09
varying O 0 2.7503057253852603e-07
clinical O 0 2.545554025346064e-06
severity O 0 0.0025483439676463604
and O 0 8.203461909772614e-09
CTG O 0 1.7027488752319186e-07
repeat O 0 1.6731775076550548e-08
size O 0 1.434811602862851e-09
over O 0 9.226597819100846e-10
time O 0 8.466123357919741e-10
intervals O 0 1.6634427169037735e-09
of O 0 5.051302778835698e-11
1 O 0 1.8732828621637054e-09
- O 0 2.51647566074098e-06
7 O 0 2.968640089306973e-08
years O 0 2.5294916383700183e-08
. O 0 2.300498280760621e-08

We O 0 2.0736217720696004e-07
have O 0 2.8046633904210694e-09
found O 0 2.010957372844402e-10
a O 0 3.9806363760774843e-10
direct O 0 5.169942252081228e-09
progression O 0 2.2423348511324548e-08
of O 0 3.749630467231313e-11
the O 0 6.596741208841905e-11
size O 0 1.14862785949299e-09
heterogeneity O 0 2.0805163813975014e-08
over O 0 1.7329594426129802e-09
time O 0 4.857885205211687e-10
related O 0 3.2443861486264325e-10
to O 0 1.4183607621731653e-09
initial O 0 6.772508331920335e-09
CTG O 0 1.4437169681968953e-07
repeat O 0 1.2894933121287977e-08
size O 0 1.2648844194274034e-09
and O 0 2.8369756543966673e-10
the O 0 4.6575271417381714e-11
time O 0 2.5393648295235494e-10
interval O 0 1.348899325570585e-09
and O 0 4.264250896834909e-10
always O 0 4.2207912720471086e-09
biased O 0 1.9455008271052066e-08
towards O 0 1.5675435394157944e-09
further O 0 2.378489849519383e-09
expansion O 0 3.220105782020255e-08
. O 0 3.059430042640088e-08

Attempts O 0 3.980765541200526e-06
to O 0 4.31868691919135e-08
mathematically O 0 6.525967819470679e-07
model O 0 6.102044380895677e-08
the O 0 5.475354059036874e-10
dynamics O 0 5.52111458773652e-08
have O 0 5.759506205293974e-09
proved O 0 7.407369650991313e-08
only O 0 2.007792598845981e-09
partially O 0 2.3814417104972563e-08
successful O 0 1.789122516804298e-09
suggesting O 0 3.1528566424299242e-09
that O 0 8.172281601437348e-11
individual O 0 2.4862469721886882e-11
specific O 0 2.1090003007873115e-11
genetic O 0 1.488449252740054e-09
and O 0 1.45518452843163e-09
/ O 0 2.9552847280456263e-08
or O 0 1.4398340297816503e-09
environmental O 0 1.3359007233759712e-08
factors O 0 3.947175919449819e-09
also O 0 3.2577638364728045e-09
play O 0 1.1493687113173223e-09
a O 0 6.668156027345162e-10
role O 0 3.3271660981881723e-09
in O 0 1.9658663585886416e-09
somatic O 0 4.012481724657846e-07
mosaicism O 0 1.8895281755249016e-05
. O 0 1.2725998033147334e-08
. O 0 1.9135784512513965e-08

Aspartylglucosaminuria B-Disease 1 0.999014139175415
among O 0 1.9656763470266014e-06
Palestinian O 0 2.698501475606463e-06
Arabs O 0 2.709078898988082e-06
. O 0 9.766189634774491e-08

Aspartylglucosaminuria B-Disease 1 0.9999963045120239
( O 0 8.66823029355146e-05
AGU B-Disease 1 0.9999963045120239
) O 0 1.0387686266710716e-08
is O 0 1.70089053952438e-09
a O 0 1.365472179770677e-08
rare O 0 5.67243978366605e-06
disorder B-Disease 0 0.08839970082044601
of I-Disease 0 5.455339513460444e-10
glycoprotein I-Disease 0 1.750641422404442e-05
metabolism I-Disease 0 1.3889814454159932e-06
caused O 0 2.5655012336756045e-07
by O 0 8.242448390483048e-10
the O 0 2.8413416064410058e-09
deficiency B-Disease 0 3.925142664229497e-06
of I-Disease 0 6.675189567761919e-11
the I-Disease 0 7.177599625762809e-10
lysosomal I-Disease 0 1.5533643136222963e-06
enzyme I-Disease 0 2.005568688900894e-07
aspartylglucosaminidase I-Disease 0 3.4704021345532965e-06
( O 0 2.8450946043534486e-09
AGA O 0 3.709629652348667e-07
) O 0 3.702395723337304e-09
. O 0 1.4660893832285637e-08

AGU B-Disease 1 0.9999927282333374
is O 0 1.0685752386052627e-05
inherited O 0 1.0386089343228377e-05
as O 0 3.997544517631013e-09
an O 0 3.1391333976671376e-09
autosomal O 0 0.03862263262271881
recessive O 1 0.627956748008728
trait O 0 0.0046230498701334
and O 0 6.512389205681757e-08
occurs O 0 1.2587353381832145e-09
with O 0 6.743448160984045e-11
a O 0 5.111397083368274e-09
high O 0 4.3729791343594115e-08
frequency O 0 1.2443852028809488e-05
in O 0 2.735568438438918e-09
Finland O 0 1.211664766742615e-05
because O 0 1.1329012172822672e-09
of O 0 1.3462814196785189e-11
a O 0 2.54400545074418e-09
founder O 0 2.0074649853540905e-07
effect O 0 1.2829288209559309e-07
. O 0 1.7171670307902787e-08

While O 0 9.012010195874609e-07
very O 0 9.091482411349716e-08
few O 0 5.610905517983156e-08
patients O 0 2.439061290715472e-06
with O 0 4.643076678689795e-08
AGU B-Disease 1 0.9999991655349731
have O 0 5.431091949503752e-07
been O 0 1.8831640247185533e-08
reported O 0 2.2889468098696852e-09
from O 0 1.9061153697097488e-11
non O 0 5.424781734930662e-10
- O 0 1.934509867851375e-07
Finnish O 0 3.141041815979406e-05
origin O 0 2.011687261216366e-09
, O 0 1.6299026017740914e-10
we O 0 1.2433423179913916e-09
diagnosed O 0 1.942279141076142e-06
the O 0 6.109573957857606e-10
disorder O 0 9.115266948356293e-06
in O 0 7.535400636804468e-10
8 O 0 1.8644293220404506e-08
patients O 0 1.3593063385997084e-07
originating O 0 4.330643066374762e-10
from O 0 6.434262150856185e-11
3 O 0 7.065323881505492e-10
unrelated O 0 9.331197148298997e-09
families O 0 1.8667662970983656e-09
, O 0 7.20610099369523e-11
all O 0 2.0357788371727636e-11
Palestinian O 0 3.516709146111907e-09
Arabs O 0 2.8450293232396007e-09
from O 0 4.165419745238985e-11
the O 0 1.0470666000905737e-10
region O 0 1.719211106809837e-09
of O 0 3.566804074317531e-10
Jerusalem O 0 5.862327725481009e-07
. O 0 3.2105877068033806e-08

The O 0 3.8117954659355746e-07
clinical O 0 9.190980563289486e-06
diagnosis O 0 0.008004985749721527
of O 0 3.919539182106746e-08
AGU B-Disease 1 0.9999992847442627
is O 0 3.0818443974567344e-07
often O 0 1.0013587292689863e-08
difficult O 0 2.072642324435492e-08
, O 0 4.884941895433315e-10
in O 0 6.173423577893189e-11
particular O 0 1.4225051692129398e-10
early O 0 6.033709643027407e-10
in O 0 9.45181155564967e-11
the O 0 7.142062635745461e-11
course O 0 1.1613165984414309e-09
of O 0 3.143875784705763e-11
the O 0 1.3906618079317923e-09
disease O 0 2.623116301947448e-07
, O 0 6.560807452871131e-10
and O 0 9.833133196579524e-10
most O 0 1.7599197099649189e-10
of O 0 1.9365533482362807e-11
the O 0 1.0722410737074028e-09
patients O 0 8.028705451579299e-06
are O 0 4.968690348050586e-09
diagnosed O 0 8.115208402159624e-06
after O 0 1.009279326780188e-09
the O 0 1.2055685616463307e-10
age O 0 9.68981117566159e-10
of O 0 4.443277343280094e-11
5 O 0 2.0707209280601546e-09
years O 0 5.243500300622372e-09
. O 0 1.1973407154641791e-08

However O 0 1.789420707609679e-06
, O 0 3.34411520697131e-09
since O 0 1.0398742977812958e-09
these O 0 8.954365582347634e-10
patients O 0 3.159082595516338e-08
excrete O 0 1.10302718070443e-08
early O 0 4.903154549040778e-10
large O 0 2.0809667877763616e-10
amounts O 0 2.338507165688952e-10
of O 0 3.942356163744165e-11
aspartylglucosamine O 0 2.9837090664841526e-07
in O 0 1.4007111026614893e-09
urine O 0 3.295230044386699e-08
, O 0 2.5368182554608154e-10
biochemical O 0 3.7656024964860535e-09
screening O 0 2.0138219980481153e-09
is O 0 8.090675907013178e-10
easy O 0 1.1039343661423118e-08
by O 0 3.6112051127190625e-09
urine O 0 1.2418952621828794e-07
chromatography O 0 1.8144337587955306e-08
. O 0 4.902714900723026e-10
. O 0 7.169353111180499e-09

Detection O 0 3.2741756967880065e-06
of O 0 9.608469575539402e-09
heterozygous O 0 1.3359106105781393e-06
carriers O 0 3.060223718875932e-08
of O 0 4.952168675131929e-10
the O 0 5.222731829235272e-07
ataxia B-Disease 1 1.0
- I-Disease 1 0.9999997615814209
telangiectasia I-Disease 1 0.9999998807907104
( O 0 4.363514349847719e-08
ATM O 0 1.210660371953054e-07
) O 0 7.211480301805295e-10
gene O 0 2.563728562776646e-09
by O 0 4.1023917596305637e-10
G2 O 0 5.026174108024861e-07
phase O 0 8.262099271405532e-08
chromosomal O 0 5.5725695347064175e-06
radiosensitivity O 0 2.215694621554576e-06
of O 0 3.2189435561491564e-09
peripheral O 0 2.5932042262866162e-05
blood O 0 5.343732937035384e-06
lymphocytes O 0 1.9808112483588047e-06
. O 0 3.545807203408913e-08

In O 0 0.0013719549169763923
ataxia B-Disease 1 1.0
- I-Disease 1 0.9999985694885254
telangiectasia I-Disease 1 1.0
( O 0 0.00020505343854893
A B-Disease 1 0.9999998807907104
- I-Disease 1 0.9999992847442627
T I-Disease 1 1.0
) O 0 4.0085953401103325e-07
patients O 0 0.0037889566738158464
, O 0 4.4232226215079606e-10
mutations O 0 4.0850598459485354e-09
in O 0 4.9788926453908644e-11
a O 0 1.1017756706976911e-09
single O 0 5.384150458809245e-09
gene O 0 4.205571002557917e-09
, O 0 1.571623386986687e-10
ATM O 0 3.831327699543863e-09
, O 0 1.2674315763572253e-10
result O 0 3.0082114577112407e-10
in O 0 6.493653947892142e-10
an O 0 3.7009747757110745e-05
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
syndrome I-Disease 1 1.0
that O 0 2.9925402600383677e-07
embraces O 0 3.039039242480612e-08
a O 0 2.6043696088606794e-09
variety O 0 5.941819813948257e-10
of O 0 1.0146310874814546e-10
clinical O 0 6.952397058057613e-08
features O 0 5.367008952816832e-07
and O 0 3.023209771413349e-08
manifests O 0 6.240200605134305e-07
extreme O 0 7.964024007378612e-06
radiosensitivity O 0 2.235787405879819e-06
and O 0 6.949712472170688e-10
a O 0 1.6789404311268186e-09
strong O 0 2.8441464294814978e-08
pre O 0 9.299659495809465e-07
- O 0 0.0006240853690542281
disposition O 0 0.00010563527030171826
to O 0 2.645788299560081e-07
malignancy B-Disease 0 1.6525464161532e-05
. O 0 5.112413958840989e-08

Heterozygotes O 0 0.00019178939692210406
for O 0 1.492179357853729e-08
the O 0 6.914107064659447e-10
ATM O 0 3.947403470760946e-08
gene O 0 2.2947485689428504e-08
have O 0 3.007392557208277e-09
no O 0 3.018242100694124e-09
clinical O 0 1.771672231143384e-08
expression O 0 1.4699366168713368e-08
of O 0 5.225167520883645e-10
A B-Disease 1 0.999993085861206
- I-Disease 1 0.9999886751174927
T I-Disease 1 1.0
but O 0 8.710693691682536e-06
may O 0 1.6375315681216307e-07
be O 0 6.628281568055172e-08
cancer B-Disease 0 5.385872441365791e-07
prone O 0 4.0892021502259013e-07
with O 0 4.4494027906516465e-10
a O 0 8.437047505083228e-09
moderate O 0 0.00026588657055981457
increase O 0 3.242638868528047e-08
in O 0 5.464410035571632e-10
in O 0 7.677957714058437e-10
vitro O 0 7.85068323239102e-07
radiosensitivity O 0 6.81901883581304e-06
. O 0 2.3405887006333614e-08

We O 0 2.7823591608466813e-07
performed O 0 4.035636891330796e-08
a O 0 4.987489976571169e-09
blind O 0 2.457815639900218e-07
chromosomal O 0 7.222650424409949e-07
analysis O 0 1.1301478863856573e-08
on O 0 1.0504441760872396e-08
G2 O 0 2.3828285975469043e-06
- O 0 9.420432434126269e-07
phase O 0 1.0634089164796023e-07
lymphocytes O 0 6.2445344894968e-08
from O 0 3.0937963302335447e-10
7 O 0 2.4058428582662827e-09
unrelated O 0 8.891353076023734e-08
A B-Disease 1 0.9999910593032837
- I-Disease 1 0.9999988079071045
T I-Disease 1 1.0
patients O 1 0.9953721165657043
, O 0 3.17348414213825e-09
13 O 0 1.6426932036850417e-09
obligate O 0 4.3664865501114036e-08
A B-Disease 1 0.9999526739120483
- I-Disease 1 0.9999728202819824
T I-Disease 1 0.9999998807907104
heterozygotes O 0 0.0008730489644221961
( O 0 1.0436137509728383e-09
parents O 0 3.491871680694203e-09
of O 0 2.700705978297968e-11
the O 0 9.119313082450731e-10
patients O 0 7.540741080447333e-07
) O 0 1.0514374093606449e-10
, O 0 5.830885774216199e-10
and O 0 1.5232876071635815e-09
14 O 0 6.005545505338716e-10
normal O 0 5.135531999655996e-10
controls O 0 1.4000926285007154e-07
following O 0 4.974538558855102e-10
X O 0 1.3517335162305244e-07
- O 0 5.515999035310415e-08
irradiation O 0 1.0347864787263461e-07
with O 0 8.891564706736688e-10
1 O 0 8.775212223532947e-10
Gy O 0 2.3651099922972207e-07
in O 0 1.0713369774650872e-10
order O 0 9.526015393168663e-11
to O 0 1.567231899812782e-10
evaluate O 0 1.6455813378613016e-09
this O 0 7.153978798246641e-11
cytogenetic O 0 6.273735664308333e-08
method O 0 3.8688372505646385e-09
as O 0 1.3733850168229367e-10
a O 0 1.0738902128659689e-10
tool O 0 2.39323383333101e-09
for O 0 1.141368041746027e-10
detection O 0 8.409922758190191e-10
of O 0 1.4500414757812052e-10
ATM O 0 5.201110298003186e-07
carriers O 0 3.1137145128923294e-07
. O 0 2.547148270082289e-08

Both O 0 4.874532351095695e-06
A B-Disease 1 0.994357168674469
- I-Disease 1 0.9996874332427979
T I-Disease 1 0.9999983310699463
homozygotes O 0 0.00043269418529234827
and O 0 1.9904824455352355e-08
heterozygotes O 0 4.5302633111532487e-07
showed O 0 9.048940796674287e-08
significantly O 0 2.4259161790496364e-08
increased O 0 6.3551728324284795e-09
levels O 0 8.664677308978241e-10
of O 0 2.793706377346439e-10
radiation O 0 0.003338797716423869
- O 0 5.8492667449172586e-05
induced O 0 0.055109865963459015
chromatid O 0 0.002474353648722172
damage O 0 4.19934758610907e-06
relative O 0 1.1518359599449468e-08
to O 0 8.595870681915585e-10
that O 0 2.943181809378359e-10
of O 0 4.3566220075952344e-11
normal O 0 5.74562664112932e-09
controls O 0 7.457847459590994e-06
. O 0 4.177439905106439e-08

These O 0 7.696072401586207e-08
results O 0 1.527116744171053e-08
show O 0 5.765650623601459e-09
that O 0 1.7889716097396757e-10
the O 0 1.077538266947009e-10
G2 O 0 4.1674135786706756e-07
- O 0 1.2760662571054127e-07
phase O 0 1.4354256450133107e-08
chromosomal O 0 3.0418263463616313e-07
radiosensitivity O 0 2.719479539337044e-07
assay O 0 2.516028096977152e-08
can O 0 6.918790540488828e-10
be O 0 9.261839212237888e-11
used O 0 5.293702143305268e-10
for O 0 3.0727122235507665e-11
the O 0 1.9076682941654433e-11
detection O 0 2.04382666346703e-09
of O 0 2.6393937035962267e-10
A B-Disease 1 0.9999866485595703
- I-Disease 1 0.999996542930603
T I-Disease 1 0.9999998807907104
heterozygotes O 0 0.003756188089028001
. O 0 1.8721804906363104e-07

In O 0 2.409339288078627e-07
combination O 0 7.706148608122021e-08
with O 0 4.680434373405262e-10
molecular O 0 6.261479779112733e-09
genetic O 0 3.2179816145117e-08
analyses O 0 2.0741135031698832e-08
, O 0 2.7116087153444823e-10
this O 0 1.7714037181537634e-10
test O 0 8.646719784621837e-09
may O 0 9.396242006687316e-09
be O 0 9.709952980552217e-11
of O 0 4.640207489081671e-12
value O 0 4.056359068083104e-11
in O 0 1.6077143089043844e-11
studies O 0 2.3759392023259274e-11
of O 0 1.5074587411678664e-11
familial B-Disease 0 1.4703291917328443e-08
and I-Disease 0 8.930576278487479e-09
sporadic I-Disease 0 3.4059439713018946e-06
cancers I-Disease 0 3.5220182326156646e-06
aimed O 0 7.771445709181535e-09
at O 0 6.100479565951389e-10
determination O 0 1.7311796440822036e-08
of O 0 1.917916693516819e-11
the O 0 4.9914253286154064e-11
potential O 0 2.9564881098842477e-10
involvement O 0 1.1117859965992238e-09
of O 0 3.659062636218735e-11
ATM O 0 7.829802228798144e-08
mutations O 0 1.542977656754374e-07
in O 0 1.0890101043159461e-09
tumor B-Disease 0 7.091886345733656e-06
risk O 0 2.445684543772586e-08
or O 0 2.1801314920022463e-10
development O 0 2.4007856813668127e-10
. O 0 2.879960714352592e-09
. O 0 1.121062176423493e-08

Ataxia B-Disease 1 1.0
- I-Disease 1 0.9999972581863403
telangiectasia I-Disease 1 0.9999990463256836
: O 0 1.5111724849248276e-07
identification O 0 3.5320240954206383e-08
and O 0 1.322718379270782e-09
detection O 0 3.2801847904551096e-09
of O 0 1.577503544458736e-10
founder O 0 8.005458340676341e-08
- O 0 8.183811246453843e-07
effect O 0 1.072865956075475e-07
mutations O 0 2.556288514199423e-08
in O 0 1.2094215906532924e-10
the O 0 3.625086342218253e-11
ATM O 0 1.0289681995345745e-08
gene O 0 7.002086466201263e-09
in O 0 5.44281564263116e-10
ethnic O 0 1.1795424192939663e-08
populations O 0 2.5189619279331055e-08
. O 0 3.4118560421347865e-08

To O 0 4.6469750714095426e-08
facilitate O 0 4.5548240734660794e-09
the O 0 4.654048813002021e-10
evaluation O 0 7.702731785741435e-10
of O 0 7.410453500833469e-11
ATM O 0 4.235333506130701e-08
heterozygotes O 0 5.670659675161005e-07
for O 0 1.463479115670907e-09
susceptibility O 0 2.8751253921655007e-05
to O 0 3.6547856296920145e-08
other O 0 6.4775762531610326e-09
diseases O 0 2.7707270078281e-07
, O 0 3.7074890379962255e-10
such O 0 3.313662122472749e-10
as O 0 2.3739780772302765e-06
breast B-Disease 1 0.9722018837928772
cancer I-Disease 0 0.00019507038814481348
, O 0 5.948782577647194e-10
we O 0 2.1615201295510644e-10
have O 0 1.1094383051135637e-10
attempted O 0 7.905792465123795e-09
to O 0 1.7984551348160238e-10
define O 0 1.9968089404187594e-09
the O 0 1.5285199495007618e-10
most O 0 4.503757367047001e-10
common O 0 4.3506370728252364e-10
mutations O 0 1.1902548280318115e-08
and O 0 5.392667423720354e-10
their O 0 2.780172481120502e-10
frequencies O 0 1.595045091562497e-07
in O 0 2.890071471028932e-07
ataxia B-Disease 1 1.0
- I-Disease 1 0.9999996423721313
telangiectasia I-Disease 1 1.0
( O 0 1.8617234900375479e-06
A B-Disease 1 0.9999994039535522
- I-Disease 1 0.999992847442627
T I-Disease 1 0.9999995231628418
) O 0 1.648972514090019e-08
homozygotes O 0 3.7382611139946675e-07
from O 0 1.3932949238792958e-10
10 O 0 4.324270941324926e-10
ethnic O 0 5.454229068391214e-09
populations O 0 1.968696672349779e-08
. O 0 2.0701849123838656e-08

Both O 0 1.1502084618086883e-07
genomic O 0 2.180015741259922e-07
mutations O 0 1.3554271163229714e-06
and O 0 2.981332070106646e-09
their O 0 3.4562741557664367e-10
effects O 0 2.6781091122529688e-08
on O 0 5.820521842281323e-09
cDNA O 0 4.740707737482808e-08
were O 0 9.94138460441718e-09
characterized O 0 7.759318521038949e-08
. O 0 3.078195476291512e-08

Protein O 0 1.1298977824480971e-06
- O 0 7.887492756708525e-07
truncation O 0 1.0254200333292829e-06
testing O 0 1.9038836285290017e-08
of O 0 3.340057397327456e-11
the O 0 3.4948800797796054e-11
entire O 0 2.5230709188583944e-10
ATM O 0 5.790127044491555e-09
cDNA O 0 1.640558622284516e-08
detected O 0 7.59957998752725e-08
92 O 0 1.1396549481901275e-08
( O 0 2.8866906087721134e-10
66 O 0 2.5960936511637556e-08
% O 0 1.782323177934586e-10
) O 0 6.351191794706779e-11
truncating O 0 2.2450995729172973e-08
mutations O 0 6.877509406422178e-08
in O 0 4.0623229780045733e-10
140 O 0 6.732133073228397e-09
mutant O 0 5.835364049744385e-07
alleles O 0 2.2166682356328238e-07
screened O 0 2.369499497945071e-06
. O 0 6.589444012661261e-08

The O 0 5.005609438057945e-08
haplotyping O 0 2.4595017293904675e-06
of O 0 3.508241031013881e-09
patients O 0 1.9939764115406433e-06
with O 0 4.6193809888350756e-10
identical O 0 3.2985258258122485e-07
mutations O 0 9.705301096119001e-08
indicates O 0 4.073389181513676e-09
that O 0 5.061142616114012e-10
almost O 0 2.039892282867939e-10
all O 0 5.1447617867295126e-12
of O 0 2.1536084547635337e-12
these O 0 1.7358026474512123e-11
represent O 0 2.5333468656185687e-10
common O 0 4.4394082854282146e-10
ancestry O 0 1.0238975889365065e-08
and O 0 5.030134642147743e-10
that O 0 5.927354163048904e-10
very O 0 1.8849024563394323e-09
few O 0 2.329888948437997e-09
spontaneously O 0 1.9025005570938447e-08
recurring O 0 8.093861936231406e-08
ATM O 0 8.501779120706487e-07
mutations O 0 8.013499268599844e-07
exist O 0 3.531862446948253e-08
. O 0 5.042858575166065e-08

Assays O 0 8.406752021983266e-05
requiring O 0 3.863224264932796e-06
minimal O 0 2.3731806209070783e-07
amounts O 0 2.030824397536435e-09
of O 0 4.105395537412626e-11
genomic O 0 3.101200629629375e-09
DNA O 0 2.3800749815450217e-08
were O 0 2.032266133156213e-09
designed O 0 1.2699906903890223e-08
to O 0 9.836172987220948e-10
allow O 0 2.868705273328942e-09
rapid O 0 3.527836156536068e-08
screening O 0 3.907819845494487e-08
for O 0 7.870671336895896e-10
common O 0 2.3364752355092833e-09
ethnic O 0 4.053210034271615e-08
mutations O 0 1.1627312233031262e-06
. O 0 4.641571393904087e-08

These O 0 4.3252732950804784e-08
rapid O 0 9.579559900885215e-08
assays O 0 3.612096293181821e-07
detected O 0 8.55684945122448e-08
mutations O 0 3.212462118540316e-08
in O 0 3.7549430231820224e-10
76 O 0 3.8188975537423175e-08
% O 0 2.0661435062852007e-10
of O 0 4.9289468340152354e-11
Costa O 0 1.9038365550727576e-08
Rican O 0 1.2566199529828737e-06
patients O 0 6.436471267079469e-06
( O 0 3.9465090917456536e-11
3 O 0 1.8420175107447534e-10
) O 0 3.0563808428585304e-11
, O 0 1.2760109635578942e-10
50 O 0 2.878772775716243e-10
% O 0 3.973791781741731e-11
of O 0 2.0311634318925798e-11
Norwegian O 0 0.0030276768375188112
patients O 0 9.144852811004966e-06
( O 0 2.8151220937688848e-11
1 O 0 1.8466468632016841e-10
) O 0 9.620049201686243e-11
, O 0 1.628147061616403e-10
25 O 0 3.2874486466383246e-10
% O 0 2.2886345596440094e-11
of O 0 5.151588877705393e-11
Polish O 0 0.021965835243463516
patients O 0 0.0005350714200176299
( O 0 8.717320615359014e-11
4 O 0 8.687282004871122e-10
) O 0 1.2102385760215384e-10
, O 0 4.747181536757239e-10
and O 0 2.9765409581550273e-10
14 O 0 4.142405585216835e-10
% O 0 1.2853316501415524e-11
of O 0 2.2246312431084547e-11
Italian O 0 5.992236765450798e-05
patients O 0 0.00012342295667622238
( O 0 1.1111282033349212e-10
1 O 0 6.892658110935201e-10
) O 0 1.3086622063784858e-10
, O 0 1.4248187352183805e-10
as O 0 1.556302586802616e-10
well O 0 1.1247363457256299e-10
as O 0 2.4510896090568224e-10
in O 0 2.0721818705382589e-10
patients O 0 2.5008567661188863e-08
of O 0 4.372205028579934e-11
Amish O 0 3.397097145807493e-07
/ O 0 4.905385253550776e-08
Mennonite O 0 1.2581111263898492e-07
and O 0 1.212467015676566e-08
Irish O 0 1.0687077178772597e-07
English O 0 3.4898029355190374e-08
backgrounds O 0 2.0376077713990526e-08
. O 0 1.3571814783119862e-08

Additional O 0 2.050264129138668e-06
mutations O 0 6.62926913719275e-06
were O 0 2.6245919215739377e-08
observed O 0 3.892434374819231e-09
in O 0 1.5198102498725774e-10
Japanese O 0 3.52530515890237e-09
, O 0 2.1236865044294007e-10
Utah O 0 5.600274910477765e-09
Mormon O 0 4.397450403814673e-09
, O 0 8.894512210089189e-11
and O 0 3.447004626178085e-10
African O 0 6.804045105113232e-10
American O 0 2.3437605634057945e-08
patients O 0 9.761885166881257e-07
. O 0 8.828030750862581e-09

These O 0 4.806278752766957e-08
assays O 0 1.1711875202990996e-07
should O 0 8.196857637088328e-10
facilitate O 0 6.153582088330722e-10
screening O 0 1.988410680553443e-08
for O 0 1.3684940292080228e-08
A B-Disease 1 0.9999923706054688
- I-Disease 1 0.9999755620956421
T I-Disease 1 0.9999997615814209
heterozygotes O 0 0.00021675929019693285
in O 0 3.577803164844795e-09
the O 0 2.9731758721673884e-10
populations O 0 1.2998639942196633e-09
studied O 0 3.257105030129992e-09
. O 0 7.26919191507136e-10
. O 0 5.082969600778142e-09

The O 0 2.180099954784964e-06
von B-Disease 1 0.9428512454032898
Hippel I-Disease 1 0.9959812164306641
- I-Disease 1 0.9290326237678528
Lindau I-Disease 1 0.9791232347488403
tumor I-Disease 0 0.0001898124028230086
suppressor O 0 4.662183528125752e-06
gene O 0 1.5559471933102031e-07
is O 0 1.1528178411879253e-09
required O 0 4.266073050374075e-10
for O 0 1.4820009108795773e-10
cell O 0 4.3748396905129994e-08
cycle O 0 1.597757304239167e-08
exit O 0 3.435849293964566e-08
upon O 0 8.481094049272997e-09
serum O 0 2.3908222601676243e-07
withdrawal O 0 1.8035345306088857e-07
. O 0 3.130095294068269e-08

The O 0 3.790696467831367e-08
inactivation O 0 9.825790812101332e-07
of O 0 7.364902021578246e-10
the O 0 4.173551282349308e-09
von B-Disease 1 0.9979845285415649
Hippel I-Disease 1 0.9995521903038025
- I-Disease 1 0.9980347752571106
Lindau I-Disease 1 0.9975074529647827
( I-Disease 0 5.852664131111851e-08
VHL I-Disease 0 5.63593539482099e-06
) I-Disease 0 3.609524901193595e-09
tumor I-Disease 0 3.3953804745578964e-07
suppressor O 0 2.4478927116433624e-06
gene O 0 2.499026265923021e-07
predisposes O 0 2.8526972528197803e-05
affected O 0 6.687470488486724e-08
individuals O 0 4.2422176882439544e-10
to O 0 7.220853914802206e-10
the O 0 3.343809007461118e-09
human O 0 2.366909257034422e-06
VHL B-Disease 1 0.99998939037323
cancer I-Disease 1 0.9999988079071045
syndrome I-Disease 1 0.9999977350234985
and O 0 7.0103447491476345e-09
is O 0 2.2218984430111277e-09
associated O 0 6.206179570256154e-09
with O 0 5.272221770269425e-09
sporadic B-Disease 0 0.4309430718421936
renal I-Disease 1 0.9999980926513672
cell I-Disease 1 0.9999935626983643
carcinomas I-Disease 1 1.0
( O 0 6.875580993437325e-07
RCC B-Disease 0 0.008943785913288593
) O 0 1.7250391337597648e-08
and O 0 5.745848952187771e-08
brain B-Disease 0 7.057840412016958e-05
hemangioblastomas I-Disease 0 3.479790029814467e-05
. O 0 7.690979941799014e-08

VHL O 0 0.003372750710695982
- O 0 0.0014604964526370168
negative O 0 2.8803777240682393e-05
786 O 0 1.0106898116646335e-05
- O 0 0.00023136810341384262
0 O 0 1.8833526382877608e-06
RCC B-Disease 0 1.3217932064435445e-05
cells O 0 7.424470283012852e-08
are O 0 8.019021002780846e-10
tumorigenic O 0 3.790397045122518e-07
in O 0 5.6038866880214755e-09
nude O 0 0.004404311068356037
mice O 0 9.291838978242595e-06
which O 0 1.9467842893305942e-09
is O 0 6.507639982444857e-10
suppressed O 0 3.907147050341564e-09
by O 0 5.74232328354185e-11
the O 0 7.11497805117034e-11
reintroduction O 0 3.133105508368317e-08
of O 0 1.0725438315262181e-09
VHL B-Disease 0 7.56445524530136e-06
. O 0 7.035450266812404e-08

Remarkably O 0 0.0013241511769592762
, O 0 2.6433058408770194e-08
this O 0 4.290488242464363e-10
occurs O 0 3.977373153052355e-10
without O 0 2.1597974797504804e-10
affecting O 0 4.851514745496388e-10
the O 0 7.642332600088508e-11
growth O 0 8.09348477126548e-10
rate O 0 1.6735658414646082e-09
and O 0 1.7487471193344817e-10
cell O 0 1.93693665551109e-08
cycle O 0 9.203577455707546e-09
profile O 0 2.72239066845259e-08
of O 0 2.779566854460569e-11
these O 0 1.0228386193578132e-10
cells O 0 6.588043444111236e-10
in O 0 3.3734418036779346e-10
culture O 0 3.8022078818755745e-09
. O 0 1.8481287611393782e-08

The O 0 7.14667862666829e-08
786 O 0 1.5813784557394683e-06
- O 0 1.7627369288675254e-06
0 O 0 9.722513283350054e-08
cell O 0 4.797752239937836e-07
line O 0 2.7677586444951885e-07
, O 0 1.6029386151750202e-10
like O 0 2.208975363737764e-10
many O 0 7.131544244032284e-10
cancer B-Disease 0 3.175332707883172e-08
cells O 0 6.543698360950145e-10
, O 0 8.70887806314613e-11
fails O 0 1.2924727066376818e-08
to O 0 6.811836095188539e-10
exit O 0 1.0429277885748434e-08
the O 0 2.0970158942645867e-10
cell O 0 3.385795821486681e-08
cycle O 0 1.1266440225199403e-08
upon O 0 2.147188649104237e-09
serum O 0 7.88388589967326e-08
withdrawal O 0 1.193656231635032e-07
. O 0 3.797571324071214e-08

Here O 0 9.950026651495136e-07
, O 0 3.826069683299238e-09
it O 0 5.805406710912564e-10
is O 0 4.4601597415372396e-10
shown O 0 2.020978939754059e-09
that O 0 1.51748127952267e-10
reintroduction O 0 2.5646089696351737e-09
of O 0 2.8345780583860503e-11
the O 0 8.453630157001513e-11
wild O 0 2.653483210934837e-09
- O 0 3.393721044631093e-06
type O 0 8.715685453353217e-07
VHL B-Disease 0 4.0198352735387743e-07
gene O 0 9.645358289844808e-09
restores O 0 1.8078115004982465e-08
the O 0 1.379970582249257e-10
ability O 0 1.3367845719258753e-09
of O 0 1.8060382356299698e-10
VHL O 0 4.3887735046155285e-06
- O 0 0.003391007659956813
negative O 0 0.00016295613022521138
RCC B-Disease 0 0.004060095641762018
cancer I-Disease 0 9.433987543161493e-06
cells O 0 3.6668141856210923e-09
to O 0 8.388007510795603e-10
exit O 0 1.499408952554404e-08
the O 0 2.839292412293304e-10
cell O 0 2.901232498686568e-08
cycle O 0 5.5424669298531626e-09
and O 0 5.48322387494693e-10
enter O 0 3.2036981956196087e-09
G0 O 0 6.84150336383027e-07
/ O 0 1.0164939112655702e-07
quiescence O 0 6.898555398038297e-07
in O 0 6.175337574632067e-09
low O 0 3.4485211131141114e-07
serum O 0 3.078365580222453e-06
. O 0 5.6061345787838945e-08

Both O 0 2.168087121390272e-06
VHL O 0 6.92044704919681e-05
- O 0 6.34902753517963e-05
positive O 0 5.763431545346975e-07
and O 0 1.3750010019464298e-08
VHL O 0 3.2737539186200593e-06
- O 0 1.607291960681323e-05
negative O 0 9.55052200879436e-07
RCC B-Disease 0 1.6460583083244273e-06
cells O 0 2.5597525876719374e-08
exit O 0 1.5995807345348112e-08
the O 0 1.3758076622405468e-10
cell O 0 2.53448035891779e-08
cycle O 0 7.839542348619943e-09
by O 0 7.069880236798554e-10
contact O 0 1.1286270584776048e-08
inhibition O 0 1.519838548347252e-07
. O 0 4.504904538293886e-08

The O 0 2.0467034289595176e-07
cyclin O 0 9.64104947343003e-06
- O 0 8.273120783997001e-07
dependent O 0 1.942827765333277e-07
kinase O 0 6.98947246746684e-07
inhibitor O 0 2.4231235329352785e-07
, O 0 7.931675871652999e-10
p27 O 0 5.170152306277487e-08
, O 0 4.963478517083786e-10
accumulates O 0 3.1935723399101335e-08
upon O 0 1.1672949273844324e-09
serum O 0 2.236739327088344e-08
withdrawal O 0 4.483874604943594e-09
, O 0 1.4488749089380804e-10
only O 0 4.4513188274253324e-11
in O 0 1.1709530046977168e-11
the O 0 2.9189789474415306e-11
presence O 0 3.745007914890408e-10
of O 0 3.4463057407840836e-11
VHL B-Disease 0 1.451670783580994e-07
, O 0 3.083022448446826e-10
as O 0 1.0959693569345674e-10
a O 0 4.151414767505912e-10
result O 0 2.916120123153121e-10
of O 0 6.0142624387637955e-12
the O 0 3.2201255550923236e-11
stabilization O 0 1.0133647254662037e-09
of O 0 3.382008215147003e-11
the O 0 1.277092043228123e-10
protein O 0 1.5451739443506085e-08
. O 0 5.002791514385763e-09

We O 0 1.458673466459004e-07
propose O 0 3.701112660792205e-08
that O 0 1.2453763575948074e-09
the O 0 2.0224508179289558e-10
loss O 0 4.6497565797665175e-09
of O 0 1.1210012085260956e-10
wild O 0 8.14459166775805e-09
- O 0 1.8048463971354067e-05
type O 0 1.2094124940631445e-05
VHL B-Disease 0 2.3064199012878817e-06
gene O 0 7.802460544326095e-08
results O 0 4.319154367493638e-09
in O 0 5.191607213572702e-11
a O 0 5.308646300328235e-10
specific O 0 4.137486186994721e-10
cellular O 0 7.913700272865754e-08
defect O 0 3.347199424297287e-07
in O 0 8.782512495031369e-10
serum O 0 7.873291707483077e-08
- O 0 1.2631183210487507e-07
dependent O 0 5.080878651142484e-08
growth O 0 1.2363283730110197e-09
control O 0 1.5170197542602182e-08
, O 0 2.7550564607459194e-10
which O 0 1.602236454623096e-09
may O 0 1.3555645494989221e-08
initiate O 0 4.6581028811942815e-08
tumor B-Disease 0 5.741659151681233e-06
formation O 0 3.11711900735645e-08
. O 0 2.041599067581501e-08

This O 0 6.537840846476684e-08
is O 0 5.981941164634463e-09
corrected O 0 1.608005106845667e-08
by O 0 7.741848134790175e-11
the O 0 4.573326786716514e-11
reintroduction O 0 5.0384909577871895e-09
of O 0 1.0661247579202282e-10
wild O 0 5.669857028323122e-09
- O 0 3.82474172511138e-05
type O 0 0.00015783307026140392
VHL B-Disease 0 5.911449625273235e-05
, O 0 9.586228699731691e-09
implicating O 0 5.893865591133363e-07
VHL B-Disease 0 9.994878382713068e-07
as O 0 3.5092446726281423e-09
the O 0 6.965222149046824e-11
first O 0 4.031893985345647e-10
tumor B-Disease 0 1.652864334289461e-08
suppressor O 0 1.5842056200199295e-07
involved O 0 1.6235552902088557e-09
in O 0 4.645638734812607e-11
the O 0 3.9086785891262465e-11
regulation O 0 9.264936040587202e-10
of O 0 5.727042798331361e-11
cell O 0 1.726368736854056e-08
cycle O 0 7.385020150962873e-09
exit O 0 1.5424854282741762e-08
, O 0 1.7708495780865974e-10
which O 0 3.2152541740160245e-10
is O 0 1.0589449317421895e-09
consistent O 0 1.0998822297381139e-08
with O 0 8.523313999031501e-11
its O 0 1.4026005357159477e-10
gatekeeper O 0 3.876166232430478e-08
function O 0 8.181362809445147e-10
in O 0 7.895099851662479e-11
the O 0 7.502830579042552e-10
kidney O 0 9.20479862998036e-07
. O 0 1.4263965564254022e-09
. O 0 8.416441765746185e-09

Piebaldism B-Disease 1 0.9999908208847046
with O 0 0.18689511716365814
deafness B-Disease 1 1.0
: O 0 8.327264566787562e-08
molecular O 0 4.686745924686875e-08
evidence O 0 1.1782988806885442e-08
for O 0 8.55884807471341e-10
an O 0 3.657790870192912e-08
expanded O 0 0.013433031737804413
syndrome O 1 0.9999512434005737
. O 0 1.0557050700299442e-07

In O 0 1.1470110905520414e-07
a O 0 1.2825564610352558e-08
South O 0 4.894457727999679e-09
African O 0 7.662815937337086e-10
girl O 0 7.638133325826857e-08
of O 0 1.5617204751627867e-10
Xhosa O 0 3.7131158592274005e-07
stock O 0 1.0037719100353115e-08
with O 0 1.9370984816191594e-09
severe O 0 0.0006384453154169023
piebaldism B-Disease 0 0.00425216369330883
and O 0 1.904977580124978e-07
profound O 0 0.00017567102622706443
congenital O 1 0.9999991655349731
sensorineural B-Disease 1 0.9999996423721313
deafness I-Disease 1 1.0
we O 0 1.575706164658186e-06
identified O 0 1.5164701494541077e-08
a O 0 9.75116098977935e-10
novel O 0 7.698755410956437e-09
missense O 0 6.392217244410858e-08
substitution O 0 1.6252904577740424e-09
at O 0 1.3522886976868875e-10
a O 0 4.1818762341883087e-10
highly O 0 9.622531660369305e-10
conserved O 0 1.6293750793039408e-09
residue O 0 7.656975498093743e-09
in O 0 3.7711906514248383e-11
the O 0 2.1460933724570808e-11
intracellular O 0 1.8174947102878036e-09
kinase O 0 1.302112906387265e-08
domain O 0 3.8135217206303196e-10
of O 0 2.1089399324103475e-11
the O 0 1.6235419952881358e-10
KIT O 0 1.3945053751740488e-06
proto O 0 3.3636930311331525e-05
- O 0 9.134724678006023e-06
oncogene O 0 6.344617759168614e-06
, O 0 9.065954209575011e-09
R796G O 0 1.3462932884067413e-06
. O 0 1.8607417828775397e-08

Though O 0 9.753885024110787e-06
auditory B-Disease 0 6.9243283178366255e-06
anomalies I-Disease 0 6.833601219113916e-05
have O 0 3.356629107997833e-08
been O 0 9.206456930144213e-09
observed O 0 5.2047295362456225e-09
in O 0 8.510354643220808e-10
mice O 0 2.859638470908976e-06
with O 0 1.3712943003341138e-09
dominant O 0 1.8600113094180415e-07
white O 0 8.2730110761986e-08
spotting O 0 8.699682894075522e-07
( O 0 5.235345490461896e-09
W O 0 0.006689802277833223
) O 0 2.867310389120803e-09
due O 0 1.6403770786155292e-08
to O 0 5.8889330745159896e-08
KIT O 0 0.15367090702056885
mutations O 0 9.19771337066777e-05
, O 0 1.6541014247195562e-07
deafness B-Disease 1 1.0
is O 0 8.320476467815752e-07
not O 0 1.71528480308325e-08
typical O 0 1.860376208639991e-08
in O 0 1.6971476446414613e-09
human O 0 5.4766315926713105e-09
piebaldism B-Disease 0 1.0213062523689587e-05
. O 0 4.162265199170179e-08

Thus O 0 1.2736617236441816e-06
, O 0 4.170686462856565e-09
the O 0 3.2651770176528316e-10
occurrence O 0 2.37833237548557e-08
of O 0 1.7491723625084887e-08
sensorineural B-Disease 1 0.9999898672103882
deafness I-Disease 1 1.0
in O 0 2.880775866742624e-07
this O 0 9.90436532788408e-09
patient O 0 1.6240541299339384e-05
extends O 0 1.4849287310880754e-07
considerably O 0 7.956866454605915e-08
the O 0 2.427584522290971e-10
phenotypic O 0 1.6683884496160317e-07
range O 0 5.6918088020552204e-09
of O 0 6.842720834399074e-11
piebaldism B-Disease 0 8.297029125969857e-07
due O 0 5.355360155334665e-09
to O 0 2.2247099717986885e-09
KIT O 0 4.377519076115277e-07
gene O 0 8.536273021775287e-09
mutation O 0 1.1301478863856573e-08
in O 0 1.3594574077568922e-10
humans O 0 3.908650625383814e-10
and O 0 4.150686461201758e-10
tightens O 0 0.0003870681975968182
the O 0 6.839045441076053e-10
clinical O 0 2.086708228432599e-08
similarity O 0 1.5262985542108254e-08
between O 0 5.382279066878937e-10
piebaldism B-Disease 0 6.508850560749124e-07
and O 0 2.2730613224997143e-10
the O 0 1.349250485643827e-11
various O 0 3.9722156119914587e-11
forms O 0 5.1511914733737285e-09
of O 0 8.629819348016099e-08
Waardenburg B-Disease 1 0.9999988079071045
syndrome I-Disease 1 0.9999871253967285
. O 0 5.428541616225857e-09
. O 0 9.112450349846313e-09

Cycloheximide O 0 5.699464600184001e-05
facilitates O 0 2.6916032425106096e-07
the O 0 7.766788878704745e-10
identification O 0 9.535964240470207e-10
of O 0 5.592327642633954e-11
aberrant O 0 3.360094424920135e-08
transcripts O 0 5.033344763205605e-08
resulting O 0 2.3164551166132696e-08
from O 0 6.089037607459602e-11
a O 0 6.454780598907917e-10
novel O 0 1.5263276864629916e-08
splice O 0 4.986180215382774e-07
- O 0 1.371828261653718e-06
site O 0 4.89765383804297e-08
mutation O 0 4.907191453185078e-08
in O 0 2.5923155289042654e-10
COL17A1 O 0 3.9505601989731076e-07
in O 0 6.945525266033314e-10
a O 0 1.4253121349838693e-08
patient O 0 4.4554940359375905e-06
with O 0 2.3643247359927955e-08
generalized O 0 0.0003540155594237149
atrophic B-Disease 1 0.9995540976524353
benign I-Disease 1 0.9935407042503357
epidermolysis I-Disease 1 0.9947584271430969
bullosa I-Disease 1 0.9160305261611938
. O 0 2.9882392027502647e-06

Patients O 1 0.9932450652122498
with O 0 6.837185537733603e-07
generalized O 0 0.00025065807858482003
atrophic B-Disease 1 0.9982503056526184
benign I-Disease 1 0.9783517718315125
epidermolysis I-Disease 1 0.9647551774978638
bullosa I-Disease 0 0.3196567893028259
often O 0 1.3270474482851569e-05
show O 0 4.3518991788005223e-07
decreased O 0 1.3800092801830033e-07
expression O 0 3.807956172607874e-09
of O 0 1.0754685336733516e-10
type O 0 3.715985315011494e-07
XVII O 0 8.704128413228318e-05
collagen O 0 1.1395220099075232e-05
, O 0 1.3611470839336448e-09
a O 0 4.777294559943357e-09
transmembrane O 0 1.7149012876416236e-07
hemidesmosomal O 0 2.1212946421655943e-07
protein O 0 5.658006063669063e-09
encoded O 0 4.308055245871856e-09
by O 0 2.3422623840474444e-09
COL17A1 O 0 3.910745817847783e-06
. O 0 6.078742131876425e-08

This O 0 3.019360974576557e-07
report O 0 1.6259486201875006e-08
documents O 0 3.634866185819874e-09
a O 0 2.1364852109684307e-09
novel O 0 3.385195057603596e-08
splice O 0 5.072957947049872e-07
- O 0 4.857353133047582e-07
site O 0 3.649331148380952e-08
mutation O 0 2.2377804498319165e-08
in O 0 3.956278915584477e-10
COL17A1 O 0 9.206633535541187e-07
in O 0 3.559667838270997e-10
a O 0 1.0931311855699732e-08
patient O 0 3.259420736867469e-06
with O 0 8.520559369173952e-09
generalized O 0 2.774270615191199e-05
atrophic B-Disease 1 0.9989809393882751
benign I-Disease 1 0.9342599511146545
epidermolysis I-Disease 1 0.7984040975570679
bullosa I-Disease 0 0.041450753808021545
, O 0 3.5424140065742904e-08
and O 0 1.2043671615558083e-09
applies O 0 5.487097443079847e-09
a O 0 6.924995576973458e-10
new O 0 2.3049145925213566e-10
methodology O 0 1.1659041510014845e-09
to O 0 3.6471844988561486e-10
define O 0 5.389307666803234e-09
and O 0 1.1843751535067781e-09
characterize O 0 2.962237211079355e-08
the O 0 2.512903496398877e-10
resulting O 0 4.109912854488584e-09
mRNA O 0 8.297344145091756e-09
splice O 0 1.00443855899357e-06
variants O 0 6.006982857797993e-07
. O 0 5.8081372600327086e-08

Mutational O 0 0.01030984241515398
analysis O 0 3.46052365784999e-06
of O 0 1.1688616297078624e-08
COL17A1 O 0 5.91572552366415e-06
identified O 0 5.4287621509274686e-08
a O 0 3.974978568521692e-09
maternally O 0 6.999952120168018e-07
inherited O 0 6.026848495821469e-07
G O 0 1.1941397133341525e-05
- O 0 4.498979819800297e-07
to O 0 5.994255758423606e-08
- O 0 1.0248889338981826e-05
T O 0 5.023484845878556e-06
transversion O 0 3.125537659798283e-07
at O 0 1.9129162143194378e-10
the O 0 4.3387599069077964e-11
- O 0 6.925355844344949e-09
1 O 0 1.4096709355371217e-09
position O 0 5.87576964861114e-09
of O 0 1.8612687779917536e-10
exon O 0 3.111452997472952e-07
32 O 0 8.676907725657657e-08
. O 0 1.974081165201369e-08

This O 0 4.5810601534412854e-08
acceptor O 0 4.250823693041639e-08
splice O 0 7.148361760300759e-07
- O 0 9.975195780498325e-07
site O 0 2.7225617316162243e-08
mutation O 0 2.631800555263908e-08
led O 0 3.9151271113979647e-10
to O 0 3.374767409969337e-10
the O 0 6.865101542796737e-11
formation O 0 2.6456234425431546e-10
of O 0 4.4507755120326564e-11
aberrant O 0 3.3488785078361616e-08
transcripts O 0 3.321467545447376e-08
present O 0 2.129195264544137e-09
at O 0 1.4849104168490612e-09
extremely O 0 2.752171326392272e-07
low O 0 2.2908777737029595e-06
levels O 0 5.960077587019441e-08
. O 0 1.999310050848635e-08

Based O 0 5.433236083263182e-07
on O 0 5.838222350007527e-09
our O 0 3.7399899843748585e-10
recent O 0 7.799150214538031e-10
finding O 0 9.356785346525953e-10
that O 0 8.678389118443874e-10
cycloheximide O 0 1.1744215271392022e-06
stabilized O 0 1.8728516124610906e-06
mutant O 0 1.8170975124576216e-07
COL17A1 O 0 5.708511139346228e-07
transcripts O 0 2.510386210019533e-08
in O 0 4.71911398847169e-10
keratinocytes O 0 1.219914906869235e-07
homozygous O 0 1.0019761020885198e-07
for O 0 1.5526378793762063e-10
a O 0 6.463334312201141e-09
frameshift O 0 0.00047119680675677955
mutation O 0 2.9110336186022323e-07
, O 0 2.0547699652873064e-10
the O 0 3.863347142196716e-11
effects O 0 8.91434126515378e-09
of O 0 2.1265916111401495e-11
the O 0 5.1663687217207155e-11
splice O 0 8.020099073746678e-08
- O 0 4.228246837101324e-07
site O 0 2.180171065901959e-08
mutation O 0 5.932491387028449e-09
on O 0 8.903915799107764e-11
splicing O 0 2.373332641525394e-09
of O 0 7.666291212959919e-11
COL17A1 O 0 2.1176985853799124e-07
transcripts O 0 1.2138831273489359e-08
were O 0 4.2200082317478405e-10
determined O 0 3.187264896453712e-10
using O 0 2.0178117510205595e-10
reverse O 0 1.3811990662304652e-08
transcriptase O 0 2.801435705634958e-08
polymerase O 0 4.176683177092855e-08
chain O 0 6.487816506250965e-08
reaction O 0 3.839755180479187e-09
of O 0 9.669492637143229e-12
total O 0 6.179549233431558e-11
RNA O 0 1.0532041905264578e-09
from O 0 2.2718650571906807e-10
keratinocytes O 0 8.44009306888438e-08
incubated O 0 9.163888137209142e-08
for O 0 7.572659721510888e-10
2 O 0 8.011075358638209e-09
. O 0 1.1908815267247519e-08

5 O 0 1.9224373772885883e-06
h O 0 1.0279715070282691e-06
in O 0 1.2899796786314255e-09
the O 0 6.612563274721595e-11
presence O 0 9.771733422425655e-10
or O 0 1.2738175791948692e-10
absence O 0 7.450963734889626e-10
of O 0 8.790317779228118e-11
10 O 0 1.3160119660682312e-09
microg O 0 9.392193192070408e-07
cycloheximide O 0 4.418679509399226e-06
per O 0 5.725325991079444e-08
ml O 0 1.4215811461326666e-06
. O 0 4.936904574037726e-08

Using O 0 4.5893681743791603e-08
this O 0 2.152018563350566e-09
approach O 0 4.460028080188749e-08
, O 0 1.5688087495746572e-09
an O 0 2.012324307187896e-09
abnormally O 0 9.418815807293868e-07
spliced O 0 0.000274209858616814
transcript O 0 7.222881777124712e-06
was O 0 1.105768205889035e-07
identified O 0 1.4914445234381901e-09
that O 0 5.867475949550283e-11
contains O 0 1.258809168014352e-10
an O 0 9.730662803297818e-11
extra O 0 3.2257290172310604e-09
264 O 0 4.700736244700465e-09
bases O 0 8.964294306856857e-10
upstream O 0 2.2295738588695713e-09
from O 0 1.8559831449493913e-10
exon O 0 2.0426274005558298e-08
32 O 0 4.487604510217125e-09
, O 0 1.1163753255161168e-10
resulting O 0 9.652623145228745e-10
in O 0 1.2688514128278428e-10
a O 0 1.0531183924911147e-08
premature O 0 7.676975428694277e-07
termination O 0 1.1012681255806456e-07
codon O 0 4.853417223671386e-08
27 O 0 1.8610185392731182e-08
bp O 0 6.79150105042936e-08
downstream O 0 5.821587656384963e-09
from O 0 7.641414584425021e-11
the O 0 2.0724703897467833e-10
cryptic O 0 8.9166405814467e-08
splice O 0 9.376263960803044e-07
site O 0 1.3703647994134371e-07
. O 0 2.1075315714824683e-08

Three O 0 7.768085197312757e-08
other O 0 5.16569176323145e-10
splice O 0 1.773172471075668e-07
variants O 0 2.5121494218183216e-07
, O 0 8.954502694891175e-10
including O 0 9.887066165781278e-11
one O 0 3.8717290484768796e-10
derived O 0 1.397289506321897e-10
from O 0 9.995443708832319e-12
the O 0 1.8135486168358028e-11
skipping O 0 1.775111391211226e-09
of O 0 5.153623361398019e-11
exon O 0 2.9133879309028998e-08
32 O 0 1.0156699481456144e-08
, O 0 2.0371472564395532e-10
were O 0 1.2803658133719864e-09
also O 0 1.4394613501167441e-08
identified O 0 4.34131592896847e-08
. O 0 7.740926122323799e-09

These O 0 1.3763477113570843e-07
results O 0 2.644980412469522e-08
indicate O 0 5.423026028239519e-09
the O 0 6.70067612507097e-11
usefulness O 0 8.084628522198045e-10
of O 0 4.109696957743658e-11
cycloheximide O 0 8.869585599313723e-07
treatment O 0 1.5405193209971912e-07
in O 0 1.2089328149667011e-10
evaluating O 0 1.140263217180859e-09
the O 0 3.6379281531662144e-11
abnormal O 0 1.0897373003970756e-09
processing O 0 1.3221829187060052e-10
of O 0 5.693797863748351e-12
mRNA O 0 2.371137175494198e-10
due O 0 4.415332821583462e-10
to O 0 4.7534420843931e-10
splice O 0 1.9121873151561886e-07
- O 0 4.155350779910805e-06
site O 0 1.3052040515049157e-07
mutations O 0 4.640748230144709e-08
, O 0 6.327061097266551e-10
because O 0 1.1931954313482152e-09
( O 0 7.622316666733298e-11
i O 0 3.373018753194401e-09
) O 0 6.696792426152953e-11
aberrant O 0 4.329381741996485e-09
splicing O 0 1.220523060396772e-08
often O 0 2.091855577646129e-09
generates O 0 5.879682074549919e-09
a O 0 4.241847761932149e-09
premature O 0 2.395359501861094e-07
termination O 0 4.233750416915427e-08
codon O 0 1.6193469676295535e-08
, O 0 5.457493346128217e-10
( O 0 1.3862597181280023e-10
ii O 0 9.846355197851153e-08
) O 0 1.2032552731966462e-10
transcripts O 0 5.540141678750388e-09
with O 0 7.744244689966706e-10
premature O 0 1.0348475854016215e-07
termination O 0 8.287268649098678e-09
codons O 0 4.233005501674825e-09
can O 0 1.1190043336384292e-09
occur O 0 4.024218736020657e-10
at O 0 1.6731439844708262e-10
low O 0 3.6811815817827664e-08
or O 0 2.92181701055938e-09
undetectable O 0 5.2330122457533434e-08
levels O 0 8.418589159120415e-10
due O 0 6.517577588738277e-10
to O 0 1.548430272890755e-09
nonsense O 0 2.0710504600174318e-07
- O 0 2.5403460668371736e-08
mediated O 0 3.604752052410731e-08
mRNA O 0 2.2293780155280274e-09
decay O 0 3.531429371150807e-09
, O 0 7.314723826645775e-11
and O 0 8.960340802666167e-11
( O 0 3.830008185601308e-11
iii O 0 3.819574700969497e-08
) O 0 7.53173218237535e-11
the O 0 1.1459794224677466e-10
levels O 0 1.1117917003700128e-10
of O 0 3.002802433788032e-12
these O 0 2.3231682202973225e-11
transcripts O 0 6.613349312623029e-10
can O 0 2.793131004263927e-10
be O 0 5.240678446760683e-10
increased O 0 1.762318957432285e-09
by O 0 9.96161375610427e-10
cycloheximide O 0 4.625518613465829e-06
. O 0 2.767087359245579e-08

A O 0 1.2040126193824108e-06
deletion O 0 5.574201168201398e-06
mutation O 0 1.9890173916792264e-06
in O 0 4.142289622421913e-09
COL17A1 O 0 4.445600097824354e-06
in O 0 1.9269754680806273e-09
five O 0 2.3337316523708296e-09
Austrian O 0 8.109490590868518e-05
families O 0 1.5296121702590426e-08
with O 0 7.61057172837809e-09
generalized O 0 0.00010388818191131577
atrophic B-Disease 1 0.999924898147583
benign I-Disease 1 0.9967231154441833
epidermolysis I-Disease 1 0.9822064638137817
bullosa I-Disease 0 0.2907956838607788
represents O 0 3.6172258432998206e-07
propagation O 0 1.4027871486632648e-07
of O 0 5.785145140713155e-10
an O 0 3.6054241814298393e-09
ancestral O 0 3.689279708396498e-07
allele O 0 7.80824302637484e-06
. O 0 6.174220601451452e-08

Patients O 1 0.9841859936714172
with O 0 9.852419680100866e-07
generalized O 0 0.00068131391890347
atrophic B-Disease 1 0.9991185069084167
benign I-Disease 1 0.9883015751838684
epidermolysis I-Disease 1 0.9873092770576477
bullosa I-Disease 1 0.8552668690681458
, O 0 5.8320154039392946e-08
a O 0 7.0301355847846025e-09
usually O 0 8.275217844300187e-09
nonlethal O 0 5.928874813321272e-08
form O 0 6.403160224266458e-09
of O 0 4.358945204785414e-09
junctional B-Disease 0 0.03657874837517738
epidermolysis I-Disease 1 0.6394852995872498
bullosa I-Disease 0 0.0116789061576128
, O 0 1.1638273456071602e-08
have O 0 2.5255610935914774e-09
generalized O 0 9.127187183821661e-08
blistering B-Disease 0 0.001697278581559658
, O 0 2.1044513687229482e-07
nail B-Disease 1 0.999936580657959
dystrophy I-Disease 1 0.999992847442627
, O 0 8.184740067918028e-07
patchy B-Disease 1 0.890282154083252
alopecia I-Disease 1 0.9999896287918091
, O 0 1.4237394907468115e-07
and O 0 4.230606407418236e-07
dental B-Disease 0 0.072032131254673
abnormalities I-Disease 1 0.9852740168571472
. O 0 1.0116604443055621e-07

Skin B-Disease 1 0.9995622038841248
fragility I-Disease 0 0.000744991353712976
in O 0 1.3983547653140249e-08
most O 0 3.5889506921904513e-09
cases O 0 5.494061650068716e-09
is O 0 2.1477948308756822e-09
due O 0 3.874789822333469e-09
to O 0 5.299402694447508e-09
mutations O 0 1.9870345369099596e-08
in O 0 1.6709944539172739e-10
the O 0 5.4089299011961245e-11
gene O 0 6.324747836572442e-09
encoding O 0 3.3811360822255665e-08
type O 0 8.401391937695735e-07
XVII O 0 6.096668585087173e-05
collagen O 0 4.444636215339415e-05
( O 0 1.960400553002728e-08
COL17A1 O 0 1.554811024107039e-05
) O 0 1.0131933514401226e-08
. O 0 1.5325557711776128e-08

Recently O 0 6.092478088248754e-06
, O 0 8.60237037159095e-09
we O 0 1.0988667753508707e-09
reported O 0 2.4691468869519895e-09
five O 0 2.2903737240120847e-10
Austrian O 0 2.447215820211568e-06
families O 0 2.8870663637547977e-09
with O 0 2.477458904692753e-09
generalized O 0 6.184043013490736e-05
atrophic B-Disease 1 0.999745786190033
benign I-Disease 1 0.9495476484298706
epidermolysis I-Disease 1 0.7735421061515808
bullosa I-Disease 0 0.17834998667240143
who O 0 1.2749396773870103e-05
share O 0 6.963342791266314e-09
the O 0 5.773736488912107e-10
same O 0 9.018818580841526e-09
COL17A1 O 0 0.00010591949103400111
mutation O 0 3.2591190120001556e-06
. O 0 3.737262588288104e-08

Affected O 0 3.245694824727252e-05
individuals O 0 9.45514244676815e-08
in O 0 2.2780104469433127e-09
three O 0 1.278847694408114e-09
families O 0 1.1947804967604725e-09
are O 0 1.8188843486921513e-10
homozygous O 0 2.4757122574214918e-08
for O 0 2.720373648568142e-10
4003delTC O 0 2.7577516448218375e-07
, O 0 1.086943313133304e-09
whereas O 0 1.2078269495674476e-09
those O 0 1.4727415120763254e-10
in O 0 7.045054817300667e-11
two O 0 6.109107664187263e-10
others O 0 3.0104398973662683e-09
are O 0 3.9659267536684695e-10
compound O 0 1.5102561690127914e-07
heterozygotes O 0 3.3933001759578474e-06
. O 0 4.312628476554892e-08

To O 0 1.7010316355481336e-07
determine O 0 2.475901439424888e-08
if O 0 5.152662740925962e-10
the O 0 4.136308309754533e-11
occurrence O 0 1.229386703549551e-09
of O 0 5.96766733251819e-11
4003delTC O 0 7.671011559295948e-08
in O 0 9.177134052684721e-11
these O 0 5.505185543541735e-11
unrelated O 0 1.700896978817923e-09
families O 0 4.5277187554759735e-10
signifies O 0 1.0572174247158728e-09
propagation O 0 3.6171610151569666e-09
of O 0 3.2820086925955394e-11
an O 0 2.883944472120703e-10
ancestral O 0 1.8374645804897227e-08
allele O 0 4.120810004337727e-08
or O 0 1.7080907521727084e-10
a O 0 2.6252315876718058e-09
mutational O 0 9.086607860808726e-06
hot O 0 2.8815227324230364e-06
spot O 0 3.3690218970150454e-07
, O 0 1.9103758575056418e-09
haplotypes O 0 5.9327888379812066e-08
were O 0 6.276845265773545e-09
determined O 0 2.6406956621372046e-08
for O 0 3.8305364435942124e-10
polymorphisms O 0 1.5467639968846925e-07
both O 0 1.0473387712650606e-09
within O 0 1.0317814658211688e-10
and O 0 6.1148113239539725e-09
flanking O 0 1.1299277502985206e-05
COL17A1 O 0 0.00042407630826346576
. O 0 8.797190531595334e-08

Five O 0 5.460601641971152e-07
intragenic O 0 5.30496936335112e-06
polymorphisms O 0 1.0393718184786849e-05
were O 0 1.1857188297881294e-07
chosen O 0 3.2373925762385625e-08
based O 0 5.573155714699851e-09
on O 0 5.079868081736549e-09
their O 0 3.7210505787754755e-09
informativeness O 0 8.65005495143123e-06
. O 0 3.2185340614887537e-08

One O 0 1.2787415926140966e-07
of O 0 3.307385754158787e-10
these O 0 1.705525443096434e-10
, O 0 1.5473222703121792e-10
not O 0 1.2326152321051609e-09
previously O 0 3.177035168278053e-08
reported O 0 1.8799198642227566e-08
, O 0 1.748600292339475e-10
was O 0 6.812489683483136e-09
2988 O 0 9.74679625898034e-09
A O 0 6.794762974493551e-09
or O 0 7.655131528672143e-10
C O 0 1.2065337173794433e-08
that O 0 3.597796782717211e-10
introduces O 0 2.505572638256126e-09
a O 0 3.8459102569277093e-10
new O 0 1.3819566324624333e-10
restriction O 0 2.4595956382711393e-09
site O 0 2.1887114343144276e-09
for O 0 2.753606509475759e-10
Eco0109 O 0 1.4076731247314456e-07
I O 0 1.4869722519961215e-07
. O 0 1.558199080875511e-08

All O 0 2.240684615628652e-08
the O 0 7.274045810135021e-10
4003delTC O 0 1.4108988466432493e-07
alleles O 0 5.999517327381909e-08
showed O 0 2.4368185691514554e-08
the O 0 3.888356303605178e-11
same O 0 1.0830464303168696e-09
haplotype O 0 9.547061381454114e-07
for O 0 2.0358188745905892e-10
these O 0 7.753670622223652e-11
five O 0 6.045332012760696e-10
polymorphic O 0 1.1648843383227359e-06
markers O 0 3.3987441838689847e-06
. O 0 1.0943394102014281e-07

Fourteen O 0 4.3658469621732365e-06
microsatellite O 0 1.4723640560987405e-05
polymorphisms O 0 1.5141084077185951e-05
were O 0 2.706192105961236e-07
selected O 0 4.04675049026082e-09
based O 0 1.9826684738433187e-09
on O 0 4.0313885563136864e-09
their O 0 9.30998389492288e-10
high O 0 2.3930160963914204e-08
heterozygosity O 0 8.277918936983042e-07
and O 0 6.83651468769142e-10
their O 0 3.041052479280104e-11
location O 0 2.0418824409063063e-09
within O 0 3.257214775675976e-10
10q23 O 0 2.9486756147889537e-07
- O 0 2.4271391794172814e-06
q25 O 0 2.3141956262406893e-06
near O 0 2.0665227395966212e-07
COL17A1 O 0 2.290401425852906e-05
. O 0 4.822826582540074e-08

Three O 0 6.817730309194303e-07
families O 0 1.162081062489051e-07
shared O 0 2.448821057043915e-08
microsatellite O 0 2.5550098143867217e-06
polymorphisms O 0 4.023435394628905e-06
covering O 0 1.3972407941764686e-07
at O 0 2.241102414757279e-09
most O 0 2.493719897245228e-09
19 O 0 1.007229766258888e-08
cM O 0 1.508547484263545e-06
, O 0 3.912516532977861e-09
whereas O 0 1.4256295033376887e-09
the O 0 1.135241067817816e-10
others O 0 2.6160393851171193e-09
shared O 0 1.6146234349534438e-10
smaller O 0 3.197055120640613e-10
regions O 0 5.564379512712492e-10
consistent O 0 5.6592281083567286e-08
with O 0 1.4491740030209144e-09
cross O 0 2.8926294248776685e-08
- O 0 1.120516913033498e-06
over O 0 1.505788560507426e-08
events O 0 5.094488164658628e-10
during O 0 2.7061938800976293e-10
passage O 0 2.772589380306556e-10
of O 0 2.8014728124109434e-12
this O 0 3.170105497551923e-11
mutation O 0 1.6497327948172824e-09
through O 0 1.1237499819571894e-10
several O 0 1.0379442860752874e-09
generations O 0 9.796428557251602e-09
. O 0 1.0642587255915714e-08

These O 0 1.5282509480130102e-07
results O 0 2.8685700925734636e-08
indicate O 0 5.0055022349226874e-09
that O 0 6.268419672217362e-10
4003delTC O 0 1.0570731490133767e-07
occurs O 0 3.570724826928995e-10
on O 0 2.483570293865256e-10
a O 0 1.726993659190157e-09
single O 0 1.7385188399998697e-08
ancestral O 0 8.653702110450467e-08
allele O 0 2.568228580912546e-07
. O 0 2.217427574890962e-09
. O 0 7.3453216842267466e-09

The O 0 5.121808044350473e-07
haptoglobin O 0 0.00010192379704676569
- O 0 4.538030680123484e-06
gene O 0 4.045417654197081e-07
deletion O 0 1.2523584018708789e-06
responsible O 0 8.612848745315205e-08
for O 0 1.0588566468072713e-08
anhaptoglobinemia B-Disease 0 1.3115745787217747e-05
. O 0 8.437759646540144e-08

We O 0 1.706434176185212e-07
have O 0 3.4887428501662043e-09
found O 0 4.366448869141948e-10
an O 0 2.1015886253472615e-10
allelic O 0 6.887196946081531e-08
deletion O 0 1.2244080949130876e-07
of O 0 3.9294012488255703e-10
the O 0 1.2804244331476866e-09
haptoglobin O 0 1.454293965252873e-06
( O 0 6.529846108271897e-10
Hp O 0 1.610187183587186e-08
) O 0 1.1756867701606666e-10
gene O 0 1.1237804020680642e-09
from O 0 6.400113078397496e-11
an O 0 2.299232609859203e-10
individual O 0 5.421906257296882e-10
with O 0 3.851108765218214e-09
anhaptoglobinemia B-Disease 0 4.606739094015211e-05
. O 0 9.345253459969172e-08

The O 0 6.542618535831934e-08
Hp O 0 2.3391635295411106e-07
gene O 0 2.9415350155659326e-08
cluster O 0 1.4039188478420783e-08
consists O 0 7.482337527342509e-10
of O 0 6.667173063634735e-11
coding O 0 2.0012329571272858e-08
regions O 0 8.74456951294178e-10
of O 0 2.489302861063969e-11
the O 0 4.457078803254966e-11
alpha O 0 6.952086128997337e-10
chain O 0 6.7780394630290175e-09
and O 0 7.292629694566344e-11
beta O 0 3.2127023263939236e-11
chain O 0 8.870204570854412e-10
of O 0 5.724549740487861e-12
the O 0 6.939933350214034e-11
haptoglobin O 0 1.353795227032606e-07
gene O 0 4.884777027314158e-09
( O 0 1.5475466741410315e-10
Hp O 0 9.229136566091256e-09
) O 0 1.6651052758831497e-10
and O 0 2.0916311738172766e-10
of O 0 8.782671638563055e-12
the O 0 8.337472379160715e-11
alpha O 0 1.240390901102728e-09
chain O 0 7.067281870831721e-09
and O 0 4.9078015956771637e-11
beta O 0 3.982746077380028e-11
chain O 0 6.92584101180671e-10
of O 0 1.0084181753522437e-11
the O 0 9.518641430616981e-11
haptoglobin O 0 3.9509029647888383e-07
- O 0 1.7255597128951194e-07
related O 0 4.858416335906668e-09
gene O 0 6.7908758616397336e-09
( O 0 6.652010053898039e-10
Hpr O 0 3.061759628053551e-07
) O 0 4.677257470220297e-10
, O 0 2.6907634453898766e-10
in O 0 1.5320193724743802e-10
tandem O 0 8.468587253673832e-08
from O 0 1.2087021661333353e-10
the O 0 2.374943575134125e-10
5 O 0 7.574151084099867e-09
side O 0 4.692287802754436e-06
. O 0 3.562564998560447e-08

Southern O 0 3.8523530747625045e-06
blot O 0 5.7428929721936584e-05
and O 0 1.7774704375028705e-08
PCR O 0 1.395088020217372e-06
analyses O 0 1.2612501620878902e-07
have O 0 5.773595823654887e-09
indicated O 0 1.0919287696253832e-08
that O 0 8.617108415709396e-11
the O 0 2.1036570055366077e-11
individual O 0 5.48993940585607e-11
with O 0 1.7948020847313728e-10
anhaptoglobinemia B-Disease 0 1.1384120170987444e-06
was O 0 5.2181114540417184e-08
homozygous O 0 1.0810141226613723e-08
for O 0 2.7599356827723298e-11
the O 0 2.2204725905194955e-11
gene O 0 1.4643001255976174e-09
deletion O 0 2.8681323982482354e-08
and O 0 9.059432648506061e-10
that O 0 1.0292576513304397e-10
the O 0 1.1777846926908087e-11
gene O 0 7.122694101191485e-10
deletion O 0 1.6962745874593566e-08
was O 0 1.7557304943238705e-08
included O 0 1.713598984931508e-10
at O 0 7.483489522508435e-11
least O 0 3.152801075767542e-10
from O 0 2.812374465255285e-11
the O 0 1.0213764556343818e-10
promoter O 0 1.6345468623057968e-07
region O 0 2.534841447854319e-09
of O 0 1.0525370158775971e-10
Hp O 0 2.026855128178795e-08
to O 0 5.378730794092235e-09
Hpr O 0 1.4652317759100697e-07
alpha O 0 1.2058865017650078e-09
but O 0 5.703216787722454e-10
not O 0 5.554496862458791e-10
to O 0 2.3762134482296915e-09
Hpr O 0 1.0085967687700759e-06
beta O 0 7.130119605847085e-09
( O 0 5.258821711429107e-10
Hpdel O 0 1.2426843909452145e-07
) O 0 2.27661178797689e-09
. O 0 6.094690974123296e-09

In O 0 8.33583015946715e-08
addition O 0 5.0594071154819176e-09
, O 0 3.1369773445533156e-10
we O 0 2.047590985654324e-10
found O 0 2.989034297851134e-10
seven O 0 1.2628467715991576e-10
individuals O 0 2.8231771087572355e-11
with O 0 1.0785704274152152e-10
hypohaptoglobinemia B-Disease 0 5.429015459412767e-07
in O 0 6.407493979843082e-10
three O 0 7.256917844422617e-10
families O 0 5.086739918169769e-10
, O 0 7.660736628389841e-11
and O 0 1.5274648212937336e-10
the O 0 1.3466673609574542e-10
genotypes O 0 5.1331571881974014e-08
of O 0 4.073571341356441e-11
six O 0 3.2142363770581994e-10
of O 0 6.2772430482749275e-12
the O 0 4.138794515440303e-11
seven O 0 3.1908048425677293e-10
individuals O 0 2.2175311933936293e-11
were O 0 1.5607555525765093e-10
found O 0 3.749346388914887e-10
to O 0 1.2320299225265785e-09
be O 0 3.026129036243219e-08
Hp2 O 0 1.6604088159510866e-05
/ O 0 9.874976285573211e-07
Hpdel O 0 5.856845746166073e-06
. O 0 4.4802007437283464e-08

The O 0 3.6781045764655573e-07
phenotypes O 0 1.6849369785632007e-05
and O 0 2.5254758284631862e-08
genotypes O 0 4.78997094432998e-07
in O 0 8.66186844472594e-10
one O 0 2.5768950862037343e-10
of O 0 6.845041027048193e-12
these O 0 7.332547763416741e-11
three O 0 2.152210215600192e-10
families O 0 4.050980106917734e-10
showed O 0 4.092500116570363e-09
the O 0 9.318169152949807e-11
father O 0 1.48439864844363e-08
to O 0 8.439843823815352e-10
be O 0 4.1104457615404044e-09
hypohaptoglobinemic B-Disease 0 3.1161030733528605e-07
( O 0 3.024648587146572e-10
Hp2 O 0 6.227454463214599e-08
) O 0 2.7922678058622807e-10
and O 0 6.690565323985709e-10
Hp2 O 0 3.2820611295392155e-07
/ O 0 1.4058374020464726e-08
Hpdel O 0 1.909643145836526e-07
, O 0 1.7361909132596054e-10
the O 0 3.3226345286241354e-11
mother O 0 9.323084526613457e-09
to O 0 2.0713521176052296e-10
be O 0 6.936046181849065e-10
Hp2 O 0 9.051289140415975e-08
- O 0 7.754805864124137e-08
1 O 0 1.7228745097241926e-09
and O 0 1.1035927727220951e-09
Hp1 O 0 2.52737038408668e-07
/ O 0 1.1362581986418263e-08
Hp2 O 0 1.2173663321846107e-07
, O 0 9.250893107104474e-11
one O 0 2.3773080726208207e-11
of O 0 2.2921718776519606e-12
the O 0 3.2722890369596414e-11
two O 0 4.241602624688312e-10
children O 0 7.970833437731528e-10
to O 0 3.3128533249993097e-10
be O 0 2.217398042958507e-09
hypohaptoglobinemic B-Disease 0 4.870285010838415e-07
( O 0 2.1590683407790578e-10
Hp2 O 0 8.780913418604541e-08
) O 0 1.5033019273857917e-10
and O 0 1.1618926931689089e-09
Hp2 O 0 3.932127299322019e-07
/ O 0 2.4690066879884398e-08
Hpdel O 0 3.587618095934886e-07
, O 0 2.753942351940708e-10
and O 0 2.7123830959041584e-11
the O 0 9.020921162838924e-12
other O 0 1.9104393414459686e-11
child O 0 1.245335945476711e-09
to O 0 6.524891182912995e-10
be O 0 3.738208853576452e-09
Hp1 O 0 9.994345191444154e-07
and O 0 6.133383578799112e-09
Hp1 O 0 8.293738460452005e-07
/ O 0 4.8057472668006085e-08
Hpdel O 0 4.99938892062346e-07
, O 0 4.304069878280359e-10
showing O 0 1.943630589806844e-09
an O 0 1.387296527655124e-10
anomalous O 0 7.143653135699424e-08
inheritance O 0 4.586865642863813e-08
of O 0 3.9617908953459846e-10
Hp O 0 1.875078794455476e-07
phenotypes O 0 5.098814312987088e-07
in O 0 3.1911884246227373e-10
the O 0 2.8256566531048577e-10
child O 0 2.9357561714959957e-08
with O 0 1.960788642563216e-09
Hp1 O 0 7.5714474405685905e-06
. O 0 3.2572184949231087e-08

The O 0 2.077241845199751e-07
Hp2 O 0 6.022256457072217e-06
/ O 0 9.346293836642872e-07
Hpdel O 0 1.9534265902620973e-06
individuals O 0 5.323666396606086e-09
had O 0 7.01299329719518e-09
an O 0 3.1855998394725304e-10
extremely O 0 2.549863609146996e-07
low O 0 4.5284403427103825e-07
level O 0 7.630960863203029e-10
of O 0 8.678102680903521e-11
Hp O 0 8.068042234299355e-09
( O 0 2.0674681411314566e-10
mean O 0 3.0308873188999996e-09
+ O 0 4.004924836209511e-09
/ O 0 8.631526604574447e-09
- O 0 1.4410167636924598e-07
SD O 0 1.4878830825182376e-06
= O 0 1.3622568850735206e-08
0 O 0 2.3352277889188144e-09
. O 0 1.825554152290465e-10
049 O 0 3.318820418485302e-08
+ O 0 4.2650176723668665e-09
/ O 0 4.719881818715521e-09
- O 0 5.1522750510457627e-08
0 O 0 1.1101337626939767e-08
. O 0 2.56092175243694e-10
043 O 0 4.957106369829489e-08
mg O 0 1.294372822258083e-07
/ O 0 5.8381557366260495e-09
ml O 0 1.8023373016262667e-08
; O 0 5.130793012675383e-10
n O 0 4.708911482964595e-09
= O 0 2.706855850576062e-09
6 O 0 4.1876632717041673e-10
) O 0 7.428085924132688e-11
, O 0 2.669762466656067e-10
compared O 0 9.911844678356374e-10
with O 0 2.6684475809557462e-11
the O 0 6.345960562592623e-11
level O 0 1.7414608644017449e-10
( O 0 1.6162864449609238e-11
1 O 0 1.1899131679982133e-10
. O 0 8.36145666593957e-11
64 O 0 7.22319537516114e-10
+ O 0 6.665091256685685e-10
/ O 0 1.889271850075147e-09
- O 0 2.418491718003679e-08
1 O 0 7.653437883448078e-10
. O 0 2.869902371305244e-10
07 O 0 5.297704941398251e-09
mg O 0 1.636597914966842e-07
/ O 0 7.070693364141789e-09
ml O 0 7.904254140100875e-09
) O 0 4.1428697278300675e-11
obtained O 0 3.1340469108798175e-10
from O 0 3.203132897811045e-11
52 O 0 7.725718731421694e-09
healthy O 0 4.397048058990549e-09
volunteers O 0 4.084981686247602e-09
having O 0 5.875892661322268e-09
phenotype O 0 3.0202016887415084e-07
Hp2 O 0 7.162235249325022e-08
, O 0 3.488834221521131e-10
whereas O 0 8.409714591373074e-10
the O 0 2.217739603072033e-10
serum O 0 4.4570004575916755e-08
Hp O 0 8.05188538066659e-09
level O 0 1.354283907240017e-10
of O 0 8.56045616337564e-12
an O 0 1.3311150792727489e-10
individual O 0 1.6992909857016514e-10
with O 0 6.767610916114108e-10
Hp1 O 0 1.6808689906611107e-06
/ O 0 7.323124151525917e-08
Hpdel O 0 7.115652920219873e-07
was O 0 2.4162284262274625e-07
0 O 0 3.82845115609598e-08
. O 0 1.552071005050948e-08

50 O 0 8.274499123217538e-06
mg O 0 2.3458760551875457e-05
/ O 0 3.3196252502420975e-07
ml O 0 6.242628955988039e-07
, O 0 9.472136408561482e-10
which O 0 4.547503762442062e-10
was O 0 1.6789060808264367e-08
approximately O 0 1.0575315623206905e-10
half O 0 1.6194903751376444e-10
the O 0 3.218345034916581e-11
level O 0 3.598701198148646e-11
of O 0 1.5065216435461437e-11
Hp O 0 5.1723092475697285e-09
in O 0 5.4377724545418e-10
control O 0 3.377385127123489e-08
sera O 0 2.7206567665416515e-08
from O 0 4.314801987925776e-11
the O 0 1.2824132034072733e-10
Hp1 O 0 1.3013775514991721e-06
phenotype O 0 1.4580908782590996e-06
( O 0 5.50340086002965e-11
1 O 0 2.925479303250711e-10
. O 0 1.633073537510299e-10
26 O 0 9.972374037658938e-10
+ O 0 7.625446940551228e-10
/ O 0 3.07100433971641e-09
- O 0 2.0266838873794768e-07
0 O 0 1.0179953768840733e-08
. O 0 3.635370338095356e-10
33 O 0 5.483498544123222e-09
mg O 0 6.82324667877765e-08
/ O 0 1.0644697567840922e-08
ml O 0 4.929066932390924e-08
; O 0 1.025384332997703e-09
n O 0 1.8358530695650188e-08
= O 0 6.049869050173129e-09
9 O 0 4.661422359220069e-10
) O 0 2.1582480594362075e-11
, O 0 3.403622175768284e-11
showing O 0 3.226073630457904e-09
a O 0 1.1623182416542477e-09
gene O 0 1.7021603682110253e-08
- O 0 2.47509024120518e-06
dosage O 0 2.6691914172261022e-05
effect O 0 2.524802198422549e-07
. O 0 2.2719627068568116e-08

The O 0 1.1016189915835639e-07
other O 0 1.0248178305971578e-08
allele O 0 2.395725005044369e-07
( O 0 1.2108117841691524e-09
Hp2 O 0 1.2498273349592637e-07
) O 0 8.327046691070095e-11
of O 0 1.4458457001098601e-11
individuals O 0 1.272190686130159e-10
with O 0 2.3904314638834023e-10
Hp2 O 0 7.678615361328411e-07
/ O 0 1.9369920778444794e-08
Hpdel O 0 2.504296503502701e-07
was O 0 6.839560029447966e-08
found O 0 6.29432173049338e-10
to O 0 6.111706696287911e-10
have O 0 4.986177248866852e-09
, O 0 9.809525414183895e-11
in O 0 5.3095961655147406e-11
all O 0 2.773275532830244e-11
exons O 0 7.3351569263024885e-09
, O 0 3.2776062419692664e-10
no O 0 8.985709398778852e-10
mutation O 0 4.311096368780909e-09
, O 0 3.298438258636516e-11
by O 0 4.665280314841702e-11
DNA O 0 5.5363389428464416e-09
sequencing O 0 4.2279562961766715e-08
. O 0 3.034440254623405e-08

On O 0 3.0174259535442616e-08
the O 0 2.638316509706584e-10
basis O 0 1.279295974709882e-10
of O 0 5.129515735780021e-12
the O 0 1.3423538669510293e-10
present O 0 3.714616947370075e-10
study O 0 2.408352961502658e-10
, O 0 1.1235563694700357e-11
the O 0 3.882255628084863e-12
mechanism O 0 7.809298346872495e-11
of O 0 2.2431272117540146e-11
anhaptoglobinemia B-Disease 0 2.8740942070726305e-07
and O 0 2.971945745056104e-10
the O 0 1.1992061857424297e-11
mechanism O 0 1.3478776428321737e-10
of O 0 2.8449125000218345e-11
anomalous O 0 5.23311172173635e-08
inheritance O 0 2.57266457026617e-08
of O 0 2.4175206281285e-10
Hp O 0 2.0808704448427306e-07
phenotypes O 0 1.8001441048909328e-06
were O 0 1.1418874734658857e-08
well O 0 6.538424024427059e-09
explained O 0 1.1955634704463591e-07
. O 0 2.3636664181481137e-08

However O 0 1.3613162082037888e-06
, O 0 5.1714117432766216e-09
the O 0 1.8077200847343988e-10
mechanism O 0 1.962790374676615e-09
of O 0 8.723878286431841e-10
hypohaptoglobinemia B-Disease 0 4.1504059481667355e-05
remains O 0 4.843346232519252e-06
unknown O 0 2.6797756618179847e-06

ATM O 0 5.6515284086344764e-05
mutations O 0 0.0006210579886101186
and O 0 5.365693596104393e-07
phenotypes O 0 0.00046597019536420703
in O 0 3.369746082171332e-06
ataxia B-Disease 1 1.0
- I-Disease 1 0.9999992847442627
telangiectasia I-Disease 1 1.0
families O 0 9.305288403993472e-05
in O 0 2.4157149614012496e-09
the O 0 1.8176160576643952e-09
British O 0 5.482755568664288e-06
Isles O 0 3.318048413802899e-08
: O 0 1.018442968847566e-10
expression O 0 4.019562183099623e-10
of O 0 7.573707286323561e-12
mutant O 0 3.8629459631067675e-09
ATM O 0 5.737577524200788e-09
and O 0 5.839232986026843e-10
the O 0 2.1649776416055033e-10
risk O 0 4.067737258139914e-09
of O 0 9.384273358392647e-10
leukemia B-Disease 0 0.26823028922080994
, O 0 2.81119628198212e-05
lymphoma B-Disease 1 1.0
, O 0 1.9516393479079852e-07
and O 0 2.3044936824589968e-05
breast B-Disease 1 0.9998401403427124
cancer I-Disease 0 0.011876722797751427
. O 0 7.972163729164095e-08

We O 0 3.737202405318385e-07
report O 0 4.7491761634432805e-09
the O 0 1.439415947546152e-10
spectrum O 0 5.830888660796063e-09
of O 0 9.450261406751537e-11
59 O 0 2.084226125020905e-08
ATM O 0 4.304041567593231e-07
mutations O 0 1.2318082553974818e-06
observed O 0 3.664285941340495e-07
in O 0 1.2228867944941157e-06
ataxia B-Disease 1 1.0
- I-Disease 1 0.9999994039535522
telangiectasia I-Disease 1 1.0
( O 0 7.378831469395664e-06
A B-Disease 1 0.9999996423721313
- I-Disease 1 0.9999966621398926
T I-Disease 1 0.9999998807907104
) O 0 5.314011275459052e-08
patients O 0 1.0408488378743641e-05
in O 0 1.728844983839295e-10
the O 0 5.487178489360645e-10
British O 0 2.1090513655508403e-06
Isles O 0 5.530800422093307e-07
. O 0 2.424824252500457e-08

Of O 0 5.098469202380329e-08
51 O 0 2.42033365793759e-07
ATM O 0 1.7508355654172192e-07
mutations O 0 2.0449591886517737e-07
identified O 0 3.918934154967246e-08
in O 0 3.000143744547046e-10
families O 0 5.819864035139233e-10
native O 0 9.752382928995829e-11
to O 0 1.1387613074731462e-09
the O 0 1.3483231198208045e-09
British O 0 1.0021116395364515e-05
Isles O 0 1.2221215683894116e-07
, O 0 6.604651270336603e-10
11 O 0 4.5046164021123047e-10
were O 0 5.754881016173385e-10
founder O 0 1.1976879044084399e-08
mutations O 0 1.3368005369329694e-08
, O 0 1.9273715956558135e-10
and O 0 3.7502190242122424e-10
2 O 0 1.3408593679820058e-10
of O 0 1.0012960079130995e-11
these O 0 4.982464787972596e-11
11 O 0 3.35384858773935e-10
conferred O 0 3.7908463035307705e-09
a O 0 1.4839032225211213e-08
milder O 1 0.7507612109184265
clinical O 0 0.0010620751418173313
phenotype O 0 0.0379285104572773
with O 0 7.627687370614922e-10
respect O 0 4.5807230231176277e-10
to O 0 2.4170010437529754e-09
both O 0 4.105213946559161e-08
cerebellar B-Disease 0 0.014877884648740292
degeneration I-Disease 1 0.9628390073776245
and O 0 4.655917607010451e-08
cellular O 0 2.219896373389929e-07
features O 0 8.16088174815377e-07
. O 0 1.2010008276774897e-07

We O 0 6.040704647602979e-07
report O 0 6.149009301736896e-09
, O 0 1.8564220993777525e-10
in O 0 9.135603384891056e-11
two O 0 3.1703868419441505e-09
A B-Disease 1 0.9999960660934448
- I-Disease 1 0.9999961853027344
T I-Disease 1 1.0
families O 0 3.02317005207442e-07
, O 0 1.192635157298838e-10
an O 0 9.551267415863762e-11
ATM O 0 6.240771455168215e-08
mutation O 0 3.1854508364403955e-08
( O 0 7.632092874354512e-11
7271T O 0 7.185536787801539e-08
- O 0 6.697030698887829e-07
- O 0 7.300165634660516e-06
> O 0 1.3906524998219538e-07
G O 0 3.961806214647368e-06
) O 0 1.5462071900618213e-10
that O 0 9.341235562843053e-10
may O 0 1.2626265366577627e-08
be O 0 5.744396625040338e-10
associated O 0 1.686613765317091e-10
with O 0 4.244012086207505e-11
an O 0 5.000823644074615e-10
increased O 0 3.052848995821478e-08
risk O 0 8.236009207962525e-09
of O 0 5.857002105535969e-10
breast B-Disease 0 0.2374083548784256
cancer I-Disease 0 5.011561370338313e-05
in O 0 2.973432833286438e-09
both O 0 7.618574215939589e-09
homozygotes O 0 1.1301552831355366e-06
and O 0 6.665400231753438e-09
heterozygotes O 0 1.8733949502802716e-07
( O 0 2.0273946410576116e-10
relative O 0 1.8959944725338573e-08
risk O 0 1.3223229622383315e-08
12 O 0 1.0325457155957452e-09
. O 0 1.5496852412422157e-10
7 O 0 1.5742461778600614e-09
; O 0 2.9284283886710227e-09
P O 0 1.0778105661302106e-06
= O 0 1.2365837243066835e-08
. O 0 3.133795722920496e-10
0025 O 0 2.6214152626380383e-08
) O 0 2.097512025178716e-10
, O 0 1.623647327697597e-10
although O 0 3.864631670236207e-10
there O 0 5.2645998671607686e-11
is O 0 2.9683526470147825e-11
a O 0 6.827080567539667e-10
less O 0 5.939582337077809e-08
severe O 1 0.7865814566612244
A B-Disease 1 0.9999998807907104
- I-Disease 1 0.9999996423721313
T I-Disease 1 1.0
phenotype O 1 0.9746266007423401
in O 0 8.227008518879586e-10
terms O 0 3.723079067263768e-10
of O 0 5.6972091974638595e-12
the O 0 3.845556165171793e-11
degree O 0 2.1101853597826903e-09
of O 0 2.025957623885688e-09
cerebellar B-Disease 0 0.06032594293355942
degeneration I-Disease 1 0.9780238270759583
. O 0 2.3449328523383883e-07

This O 0 1.0764613023184211e-07
mutation O 0 5.745388307332178e-07
( O 0 1.4440089124434508e-09
7271T O 0 2.1968519092752103e-07
- O 0 6.821274496360274e-07
- O 0 7.011817615421023e-06
> O 0 1.8083085251419106e-07
G O 0 1.5612477000104263e-06
) O 0 1.1925850584848519e-10
also O 0 3.288866123885015e-10
allows O 0 5.646844658535599e-10
expression O 0 3.720580232791093e-10
of O 0 1.126689627012345e-11
full O 0 6.005545505338716e-10
- O 0 2.970645240907288e-08
length O 0 8.642927262769717e-09
ATM O 0 3.910651358296491e-09
protein O 0 6.871602731273185e-10
at O 0 2.1458518989492248e-11
a O 0 2.353847117220198e-10
level O 0 3.0946167850487427e-10
comparable O 0 1.0170961850519689e-09
with O 0 5.803732147646734e-11
that O 0 8.114196536901375e-10
in O 0 2.6573274691799043e-09
unaffected O 0 4.200465355097549e-06
individuals O 0 2.69177080625127e-09
. O 0 7.032348481317285e-09

In O 0 1.561540869943201e-07
addition O 0 7.09660685771496e-09
, O 0 2.2020427148383703e-10
we O 0 2.214493172170151e-10
have O 0 2.5517310486833367e-10
studied O 0 3.2165685670548783e-09
18 O 0 6.7753767041267565e-09
A B-Disease 1 0.9999644756317139
- I-Disease 1 0.9999985694885254
T I-Disease 1 1.0
patients O 1 0.9977331161499023
, O 0 4.449444979126582e-10
in O 0 8.982106031174553e-11
15 O 0 9.681349055767896e-10
families O 0 6.87847390157259e-10
, O 0 5.596694774290256e-10
who O 0 3.2003353567233717e-07
developed O 0 3.4875884011853486e-06
leukemia B-Disease 1 0.8201254606246948
, O 0 3.7923634863545885e-06
lymphoma B-Disease 1 1.0
, O 0 1.9589279531828652e-08
preleukemic O 0 1.1033218470402062e-05
T O 0 5.013023383071413e-06
- O 0 4.760034073569841e-07
cell O 0 4.6079284743427706e-07
proliferation O 0 1.112170444628191e-08
, O 0 7.151271130823034e-09
or O 0 2.1321627627912676e-06
Hodgkin B-Disease 1 1.0
lymphoma I-Disease 1 1.0
, O 0 2.9504409582159496e-08
mostly O 0 7.0433689991489246e-09
in O 0 3.693811700955507e-09
childhood O 0 4.71510645638773e-07
. O 0 3.5505173912042665e-08

A O 0 1.4632394140789984e-06
wide O 0 1.0090415258900975e-07
variety O 0 5.5857451997098906e-09
of O 0 2.587060010661446e-10
ATM O 0 2.2771737917537394e-07
mutation O 0 2.9910108878539177e-07
types O 0 1.201288934993272e-08
, O 0 3.755945554573259e-10
including O 0 3.0215177582171293e-10
missense O 0 4.0340628402191214e-06
mutations O 0 3.79469014433198e-07
and O 0 1.7702055377100123e-09
in O 0 1.2808396565588964e-09
- O 0 3.189876224496402e-06
frame O 0 0.011328238993883133
deletions O 0 6.202412805578206e-07
, O 0 2.897398987400379e-09
were O 0 4.050016322310057e-09
seen O 0 8.48988257473593e-09
in O 0 4.721049662315124e-10
these O 0 3.653424451854903e-09
patients O 0 5.443505983748764e-07
. O 0 1.2561001128119642e-08

We O 0 1.3610601001801115e-07
also O 0 2.2890558337707034e-09
show O 0 1.1852293591019247e-09
that O 0 2.0821340485088768e-10
25 O 0 3.867197673201872e-10
% O 0 2.219321081076142e-11
of O 0 7.638292776057654e-12
all O 0 1.320097142709642e-09
A B-Disease 1 0.9999990463256836
- I-Disease 1 0.9999996423721313
T I-Disease 1 1.0
patients O 1 0.9645349979400635
carried O 0 6.086654735781849e-08
in O 0 1.8967305503991838e-10
- O 0 1.354489853611085e-07
frame O 0 1.216764394484926e-05
deletions O 0 1.5881084891589126e-07
or O 0 4.842346079669824e-09
missense O 0 1.5054832829264342e-06
mutations O 0 3.049168810775882e-07
, O 0 9.507795661889418e-10
many O 0 6.125264184753121e-11
of O 0 2.2373800728781035e-11
which O 0 1.8905994991769148e-08
were O 0 4.311912960019981e-08
also O 0 3.78105653453531e-08
associated O 0 1.402625349200548e-09
with O 0 6.200848862158992e-11
expression O 0 9.906835352069265e-10
of O 0 2.732765229385148e-11
mutant O 0 3.7992521129126544e-08
ATM O 0 5.106274159061286e-08
protein O 0 6.334602176139015e-08
. O 0 1.0076852241525103e-08

The O 0 1.563910672075508e-07
DMPK O 0 4.925307621306274e-06
gene O 0 2.1779295877877303e-07
of O 0 1.9726734024061443e-08
severely O 0 0.1203845664858818
affected O 0 0.02239428088068962
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
patients O 1 0.9999958276748657
is O 0 1.2462234622034885e-07
hypermethylated O 0 8.297686235891888e-07
proximal O 0 2.7958046757703414e-06
to O 0 1.7498932081139174e-08
the O 0 1.3008560895144683e-09
largely O 0 4.795217378728012e-08
expanded O 0 8.820965291533867e-08
CTG O 0 3.9178239603643306e-06
repeat O 0 1.3343953924049856e-06
. O 0 1.2673416449615615e-07

Using O 0 4.6100382178337895e-07
methylation O 0 2.4761313852650346e-06
- O 0 4.770695795741631e-06
sensitive O 0 5.597692620540329e-07
restriction O 0 1.165291649840583e-07
enzymes O 0 1.7295130660954783e-08
, O 0 3.004409776519168e-10
we O 0 1.9445416110652758e-10
characterized O 0 8.168608012226741e-10
the O 0 3.8027699045262153e-11
methylation O 0 1.5765698080372204e-08
pattern O 0 4.5247880109400285e-08
on O 0 2.121606668126219e-09
the O 0 2.181441693949182e-10
5 O 0 9.613670970409771e-10
side O 0 8.313882915444992e-09
of O 0 2.079561176038247e-11
the O 0 1.0803781480550612e-10
CTG O 0 1.1178235581610352e-07
repeat O 0 2.3565585038909376e-08
in O 0 1.9543765217289177e-10
the O 0 8.309055526956044e-11
DMPK O 0 1.2908914470699528e-07
gene O 0 1.483302591864799e-09
of O 0 3.593296493686893e-11
normal O 0 1.5631517191749822e-09
individuals O 0 7.943753294048506e-11
and O 0 1.0977559833369455e-10
of O 0 2.4189597547241704e-10
patients O 0 1.692140585873858e-06
affected O 0 3.039538043481116e-08
with O 0 1.913664618768962e-06
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
, O 0 4.2691052470900104e-08
showing O 0 1.4728749775372307e-08
expansions O 0 6.476019276391298e-09
of O 0 8.055563160969115e-11
the O 0 3.192582309630154e-10
repetitive O 0 8.50587412060122e-07
sequence O 0 8.575687360234951e-08
. O 0 2.7014518622081596e-08

The O 0 4.8600586666225354e-08
gene O 0 7.814062286115586e-08
segment O 0 6.86391956605803e-08
analyzed O 0 2.2585341596936814e-08
corresponds O 0 3.936049264297026e-09
to O 0 1.650493769433936e-10
the O 0 6.285608838974e-11
genomic O 0 1.9673940698794468e-08
SacI O 0 1.314380483563582e-06
- O 0 1.0668482985920491e-07
HindIII O 0 2.606374209790374e-07
fragment O 0 9.138405232533842e-08
carrying O 0 9.52782475138747e-09
exons O 0 6.138102293107295e-08
11 O 0 4.2910226483172664e-09
- O 0 2.856684204743942e-07
15 O 0 4.946112852621809e-08
. O 0 1.973636898355835e-08

There O 0 1.8055497719160485e-07
is O 0 1.5703175426651228e-09
constitutive O 0 3.7224274773706156e-09
methylation O 0 1.4798274605709594e-08
in O 0 5.985442141920316e-10
intron O 0 5.408550691754499e-07
12 O 0 1.6178859363336073e-09
at O 0 3.039011750582965e-11
restriction O 0 6.181119505122012e-10
sites O 0 1.5300483102720364e-10
of O 0 3.8386967216030854e-11
SacII O 0 1.4698055395001575e-07
and O 0 8.932463102517829e-10
HhaI O 0 5.3605337058115765e-08
, O 0 1.2810881522273831e-10
localized O 0 1.283814388131077e-08
1 O 0 2.1760406809789856e-09
, O 0 1.0268855765716012e-09
159 O 0 2.2163124668850287e-08
- O 0 1.3616184446618718e-07
1 O 0 1.3569763090970355e-09
, O 0 2.350921957106067e-10
232 O 0 4.578454504411411e-09
bp O 0 7.329957441015722e-08
upstream O 0 1.6653315393355683e-09
of O 0 2.923893765993668e-11
the O 0 7.410552033126905e-11
CTG O 0 1.7055945988886378e-07
repeat O 0 3.4055886999340146e-08
, O 0 6.881741843045575e-10
whereas O 0 5.551711312890006e-10
most O 0 1.7252872741568837e-10
, O 0 2.6181631515576065e-11
if O 0 1.0456735477504253e-10
not O 0 2.398249931978569e-10
all O 0 1.0339696113192964e-11
, O 0 9.010723590885394e-12
of O 0 1.8626697406709525e-12
the O 0 1.3012592739447548e-11
other O 0 1.178321763078971e-11
sites O 0 4.4246717401108526e-11
of O 0 3.5894193867180846e-11
SacII O 0 1.911357685457915e-07
, O 0 1.116980730131445e-09
HhaI O 0 1.110377638724458e-07
, O 0 5.621182408432901e-10
and O 0 1.9992546507197062e-10
HpaII O 0 2.156346035064871e-08
in O 0 6.772346572425647e-11
this O 0 5.1257820904426765e-11
region O 0 6.237255711916134e-10
are O 0 3.391757985582444e-10
unmethylated O 0 1.581340853817892e-07
, O 0 1.9748849777734279e-10
in O 0 4.319388943740954e-11
normal O 0 6.831796239836763e-10
individuals O 0 6.863346696528438e-11
and O 0 1.4029857831054926e-10
most O 0 1.2863082821112926e-10
of O 0 1.84284601467688e-11
the O 0 3.822189231783568e-09
patients O 0 2.743923687376082e-06
. O 0 2.8779304273029993e-08

In O 0 8.13743668004463e-08
a O 0 5.794192681207733e-09
number O 0 5.728728047493803e-10
of O 0 8.64542465395246e-11
young O 0 2.1929331239789462e-08
and O 0 3.265566306254186e-08
severely O 0 0.14075081050395966
affected O 0 2.9054579044895945e-06
patients O 0 6.111931725172326e-05
, O 0 1.156171602900713e-09
however O 0 2.391467912588041e-09
, O 0 6.91660964613483e-11
complete O 0 1.7831834620007925e-10
methylation O 0 1.9408707974122308e-09
of O 0 4.893778091097367e-12
these O 0 1.1331615333565193e-11
restriction O 0 3.8607711472238293e-10
sites O 0 1.6195646213024162e-10
was O 0 6.707523869664556e-09
found O 0 2.3772367407914885e-10
in O 0 4.72841904519683e-11
the O 0 4.523420249480381e-10
mutated O 0 7.4432532528589945e-06
allele O 0 1.8049607888315222e-06
. O 0 3.343517107623484e-08

In O 0 7.230314480466404e-08
most O 0 1.9903259040887633e-09
of O 0 7.92163279417224e-11
these O 0 1.0619182200244381e-09
patients O 0 3.893238442742586e-07
, O 0 1.1191766957630023e-10
the O 0 4.0641188331358435e-11
onset O 0 2.0479797413486267e-08
of O 0 1.1155047718869326e-10
the O 0 1.402494920199615e-08
disease O 0 7.2014685429167e-05
was O 0 0.0040579731576144695
congenital O 1 0.9995819926261902
. O 0 4.936542268296762e-07

Preliminary O 0 2.9535938210756285e-06
in O 0 4.922537399920657e-08
vivo O 0 2.139460775651969e-06
footprinting O 0 1.691644501988776e-05
data O 0 1.1352205397940907e-08
gave O 0 8.772488513386634e-09
evidence O 0 6.02896954582377e-10
for O 0 3.9363828169269865e-11
protein O 0 1.517603598344408e-09
- O 0 3.0493282565657864e-08
DNA O 0 2.9384226607476194e-08
contact O 0 2.264619602954099e-09
in O 0 1.6130720370544083e-10
normal O 0 4.638787409749767e-10
genes O 0 2.346155769661351e-10
at O 0 1.9471015078043052e-11
an O 0 8.267479062462613e-11
Sp1 O 0 7.613722097232767e-09
consensus O 0 2.6863020141654204e-10
binding O 0 1.0222188651098918e-09
site O 0 1.073112709804036e-09
upstream O 0 3.8224423626331827e-10
of O 0 1.6417707471294563e-11
the O 0 1.1073347100376552e-10
CTG O 0 1.056067588933729e-07
repeat O 0 2.290319223163806e-08
and O 0 3.6435132688694694e-10
for O 0 1.3980912781652588e-11
a O 0 2.1255505688877463e-10
significant O 0 5.931526936286957e-10
reduction O 0 1.2303156271542548e-09
of O 0 9.286156912868826e-12
this O 0 3.9426871489833815e-11
interaction O 0 1.2414436145746777e-10
in O 0 9.838344028345603e-11
cells O 0 7.884675690128518e-10
with O 0 1.6877980957286098e-10
a O 0 7.443084371061559e-09
hypermethylated O 0 6.5986596382572316e-06
DMPK O 0 2.38408574659843e-06
gene O 0 3.986369279118662e-08
. O 0 1.66373470555925e-09
. O 0 6.690530351960433e-09

The O 0 2.1584010028163902e-06
hemochromatosis B-Disease 1 0.9999194145202637
gene O 0 4.946594458488107e-07
product O 0 1.6343308928412625e-08
complexes O 0 6.144788677886481e-09
with O 0 3.803003745250777e-10
the O 0 4.221795690817487e-10
transferrin O 0 1.1029288060626641e-07
receptor O 0 2.368721041534627e-08
and O 0 1.6371067834697328e-09
lowers O 0 1.0076990264451524e-07
its O 0 1.0012354140220836e-10
affinity O 0 1.117573145137385e-09
for O 0 1.3168775792049559e-10
ligand O 0 4.8580293565692045e-08
binding O 0 1.3168217094516876e-07
. O 0 5.23457970302843e-08

We O 0 9.602104000805411e-07
recently O 0 1.812915542132032e-07
reported O 0 6.038916477990597e-09
the O 0 1.235507390839885e-10
positional O 0 9.502328879307242e-08
cloning O 0 7.65627383714218e-09
of O 0 1.0152350488068507e-10
a O 0 3.0585534105398438e-09
candidate O 0 6.935377427907952e-08
gene O 0 2.8282244102229015e-07
for O 0 2.0820466488657985e-06
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
called O 0 0.01479144487529993
HFE O 0 0.019033139571547508
. O 0 6.161128567327978e-07

The O 0 3.192768360804621e-08
gene O 0 4.606100389992207e-08
product O 0 9.282345558858651e-09
, O 0 2.1636978320138667e-10
a O 0 6.735661473022958e-10
member O 0 1.2331155541112082e-10
of O 0 1.015447535085423e-11
the O 0 8.809788315522482e-11
major O 0 9.534091294227665e-10
histocompatibility O 0 8.737508494505164e-08
complex O 0 2.0990510662954875e-08
class O 0 1.6031817651196434e-08
I O 0 4.5541572291085686e-08
- O 0 1.8618353081478745e-08
like O 0 6.148587416987539e-09
family O 0 2.000491550191441e-09
, O 0 5.936742070167256e-11
was O 0 2.625006212397807e-09
found O 0 2.1427118412908897e-10
to O 0 2.2705395896771563e-10
have O 0 3.7717751144583644e-10
a O 0 1.947021877057864e-09
mutation O 0 2.2338442207114895e-08
, O 0 2.335369120309849e-10
Cys O 0 2.791744293517695e-07
- O 0 2.729607899709663e-07
282 O 0 1.3559710509980505e-07
- O 0 1.7013039723678958e-06
- O 0 6.289290922723012e-06
> O 0 8.854274113900829e-08
Tyr O 0 4.091605205758242e-07
( O 0 2.0263199451697744e-10
C282Y O 0 6.28115648382277e-09
) O 0 4.0337684581448485e-11
, O 0 4.413949761250535e-11
in O 0 8.356354497252028e-11
85 O 0 4.478301729449186e-09
% O 0 1.2438232388500836e-10
of O 0 9.971189152135906e-11
patient O 0 1.682694346527569e-06
chromosomes O 0 3.333991003273695e-07
. O 0 4.565698930036888e-08

This O 0 1.2313826402987615e-07
mutation O 0 3.1076805839802546e-07
eliminates O 0 7.318195116567949e-08
the O 0 7.470872254167205e-10
ability O 0 7.51538120624673e-09
of O 0 1.3412584931593585e-10
HFE O 0 1.488279053774022e-06
to O 0 1.087184298143029e-08
associate O 0 4.34625135881106e-09
with O 0 1.639531732600119e-09
beta2 O 0 2.3438633434125222e-05
- O 0 6.289645534707233e-05
microglobulin O 0 4.9380432756152004e-05
( O 0 1.3149205058127222e-09
beta2m O 0 3.6309188544692006e-07
) O 0 4.915786111503451e-10
and O 0 8.44957215306863e-10
prevents O 0 1.406529381853261e-08
cell O 0 1.1996378361800453e-06
- O 0 1.1303308383503463e-05
surface O 0 4.3103686039103195e-05
expression O 0 7.644617312507762e-07
. O 0 4.1979198783792526e-08

A O 0 1.1593418776101316e-06
second O 0 1.050440587846424e-07
mutation O 0 1.0015042306577016e-07
that O 0 1.6762814469828413e-09
has O 0 2.542128285654144e-09
no O 0 4.5545173188443755e-10
effect O 0 2.947194266411657e-09
on O 0 1.5859587421118704e-08
beta2m O 0 1.0182099686062429e-05
association O 0 1.4058660902094289e-09
, O 0 9.518314608714107e-11
H63D O 0 2.6775455808092374e-07
, O 0 3.230517520158571e-10
was O 0 9.838204029222197e-09
found O 0 5.469164565674589e-10
in O 0 6.946342806513073e-11
eight O 0 4.4642278762552223e-10
out O 0 2.4698804113043593e-10
of O 0 3.337497639366305e-11
nine O 0 2.442719448936259e-08
patients O 0 3.1054321425472153e-07
heterozygous O 0 1.8435729387533684e-08
for O 0 5.298730204605917e-11
the O 0 7.832898218929074e-11
C282Y O 0 2.281149278360317e-07
mutant O 0 2.3676872729083698e-07
. O 0 9.10327813130607e-09

In O 0 1.1457275661541644e-07
this O 0 3.1037805658939988e-09
report O 0 2.5495576760903305e-09
, O 0 3.264814113501657e-11
we O 0 6.705636740322873e-11
demonstrate O 0 6.25489993133499e-10
in O 0 1.2288517425851353e-10
cultured O 0 4.1226336122690554e-08
293 O 0 4.4122394626811e-08
cells O 0 1.35019213587384e-08
overexpressing O 0 2.8339724167381064e-07
wild O 0 5.712800454915623e-09
- O 0 1.2854982855969865e-07
type O 0 1.5407161413349968e-07
or O 0 4.4153750100583977e-10
mutant O 0 2.612500438203824e-08
HFE O 0 1.419233370825168e-07
proteins O 0 6.354272108488601e-10
that O 0 2.1787556481189796e-10
both O 0 6.843986488647147e-11
the O 0 4.938940922905033e-11
wild O 0 5.232729805015879e-09
- O 0 7.063631528581027e-06
type O 0 9.200330168823712e-06
and O 0 1.9761529301831615e-08
H63D O 0 9.546565706841648e-06
HFE O 0 4.967304789715854e-07
proteins O 0 3.1736537842164125e-09
form O 0 6.538299679448301e-09
stable O 0 5.1406328083203334e-08
complexes O 0 2.0277011181235594e-09
with O 0 1.4003176396215622e-10
the O 0 3.0033786568850473e-10
transferrin O 0 1.0300333315171883e-06
receptor O 0 2.707374449073541e-07
( O 0 5.928747714989413e-09
TfR O 0 5.5608579714316875e-06
) O 0 4.378234663704461e-09
. O 0 1.2330226617507378e-08

The O 0 9.95867779352011e-08
C282Y O 0 3.865745384246111e-06
mutation O 0 2.4545763608330162e-06
nearly O 0 1.7723348122444804e-08
completely O 0 2.0902453101712126e-08
prevents O 0 6.409318409339448e-09
the O 0 1.766625873367289e-10
association O 0 8.834017545256145e-11
of O 0 7.96587101836721e-12
the O 0 1.1714383629790603e-10
mutant O 0 6.955527709351372e-08
HFE O 0 2.2501824048504204e-07
protein O 0 4.078753335079455e-09
with O 0 2.7578112016257705e-10
the O 0 2.139013410840107e-09
TfR O 0 5.9677273384295404e-05
. O 0 4.014142263031317e-08

Studies O 0 1.066965864993108e-06
on O 0 3.204983300975073e-08
cell O 0 1.6146904613378865e-07
- O 0 1.2514964282672736e-06
associated O 0 3.6237370437675054e-08
transferrin O 0 1.5342747872182372e-07
at O 0 5.994330032343953e-10
37 O 0 8.208439261636613e-09
degrees O 0 3.666347581088303e-08
C O 0 3.501156697893748e-08
suggest O 0 9.87625714543583e-09
that O 0 6.954791742508348e-10
the O 0 3.7270223018914805e-10
overexpressed O 0 4.0849417359822837e-07
wild O 0 7.048597261416489e-09
- O 0 5.058180363448628e-07
type O 0 3.486383945983107e-07
HFE O 0 1.0778372825370752e-06
protein O 0 1.0700189179146946e-08
decreases O 0 1.1069284155951209e-08
the O 0 5.4163427215536686e-11
affinity O 0 5.361049382202054e-10
of O 0 4.706536202436773e-11
the O 0 8.113748006799426e-10
TfR O 0 2.810110800055554e-06
for O 0 2.5509585555028025e-09
transferrin O 0 2.1686867057724157e-06
. O 0 4.1687162166681446e-08

The O 0 9.815396850854086e-08
overexpressed O 0 6.567024684045464e-06
H63D O 0 2.0283498542994494e-06
protein O 0 1.4772442824551035e-08
does O 0 1.9437713660863665e-09
not O 0 1.1878178995949895e-10
have O 0 7.625545334066786e-11
this O 0 2.7069924427025605e-11
effect O 0 5.91453908072026e-09
, O 0 2.2736336424689085e-10
providing O 0 9.38040339848456e-11
the O 0 1.3433084505853898e-11
first O 0 1.086550988071977e-10
direct O 0 4.0282965851901054e-10
evidence O 0 1.4968765116307736e-09
for O 0 7.73489675087724e-11
a O 0 1.837894836320686e-09
functional O 0 1.300199414799863e-08
consequence O 0 3.4448242036688725e-09
of O 0 2.8676028565599587e-11
the O 0 6.06049155305044e-10
H63D O 0 0.00011073191126342863
mutation O 0 1.6182960962396464e-06
. O 0 2.1816438433575058e-08

Addition O 0 1.180207860329574e-07
of O 0 1.8399888279674315e-09
soluble O 0 1.0436047404027704e-07
wild O 0 1.2524351333809136e-08
- O 0 4.389367859403137e-06
type O 0 1.0304735042154789e-05
HFE O 0 0.00015287513087969273
/ O 0 8.8959478716788e-07
beta2m O 0 2.0084657990082633e-06
heterodimers O 0 6.950718898224295e-07
to O 0 1.3537301057908735e-08
cultured O 0 1.4304150397492776e-07
cells O 0 2.490156703061075e-08
also O 0 4.114681484423954e-09
decreased O 0 3.0546472018500026e-09
the O 0 4.4670024623716387e-11
apparent O 0 1.0430570185349097e-08
affinity O 0 1.3508044682808418e-09
of O 0 2.5886480459202943e-11
the O 0 4.969957223543986e-10
TfR O 0 2.2293841084319865e-07
for O 0 3.370995843576807e-11
its O 0 6.332442903378421e-11
ligand O 0 6.413721109765902e-09
under O 0 3.4221780964571735e-09
steady O 0 1.0728353316835637e-07
- O 0 1.370443101222918e-07
state O 0 4.516500062834439e-09
conditions O 0 2.4153945332727744e-07
, O 0 2.2892904238958067e-10
both O 0 1.167323182560409e-10
in O 0 4.670123315841934e-11
293 O 0 3.3447467018277166e-09
cells O 0 5.7184474933080764e-09
and O 0 7.45032369131593e-10
in O 0 8.021070474484304e-10
HeLa O 0 1.6999271110762493e-06
cells O 0 1.3296515533056663e-07
. O 0 2.009617361409255e-08

Furthermore O 0 7.674196240259334e-06
, O 0 1.3705968804345048e-08
at O 0 4.603812331360757e-10
4 O 0 1.6248284939734958e-09
degrees O 0 2.616829988255631e-07
C O 0 1.3584514135800418e-06
, O 0 1.188498299775631e-09
the O 0 3.2737576538544033e-10
added O 0 7.721652650616306e-09
soluble O 0 5.54481438541643e-09
complex O 0 9.196834405145182e-10
of O 0 2.6445740042291277e-10
HFE O 0 7.330919288506266e-06
/ O 0 9.797011557566293e-08
beta2m O 0 2.634659210798418e-07
inhibited O 0 2.6981563649997042e-08
binding O 0 5.33559063597977e-09
of O 0 1.9931437056364132e-10
transferrin O 0 1.3429550449473027e-07
to O 0 8.874693868676786e-09
HeLa O 0 8.372445563509245e-07
cell O 0 4.270473823453358e-07
TfR O 0 7.826471346561448e-07
in O 0 4.712772394555031e-10
a O 0 3.4712595020636172e-09
concentration O 0 4.5874253373767715e-07
- O 0 5.253053245724004e-07
dependent O 0 3.394791292521404e-07
manner O 0 2.9874817641939444e-07
. O 0 2.308643409776323e-08

Scatchard O 0 5.227588917477988e-05
plots O 0 1.6384765331167728e-06
of O 0 1.1899998764164366e-09
these O 0 2.1555750240320748e-10
data O 0 4.415265375534716e-10
indicate O 0 2.0974251224714635e-09
that O 0 2.2126650511822277e-10
the O 0 1.0509441927819552e-10
added O 0 1.074546451818037e-09
heterodimer O 0 1.1554229928378845e-07
substantially O 0 3.0485841762128985e-07
reduced O 0 4.634102879208513e-09
the O 0 9.113847870834135e-11
affinity O 0 1.4483948485022324e-09
of O 0 4.712808476803332e-10
TfR O 0 2.3207439880934544e-06
for O 0 4.245206408626245e-09
transferrin O 0 3.0413382319238735e-06
. O 0 4.500996908518573e-08

These O 0 1.6028920413191372e-07
results O 0 2.256859232829811e-08
establish O 0 1.3858162395408158e-09
a O 0 1.3716736635416282e-09
molecular O 0 1.0457304355782071e-08
link O 0 1.0371675074338782e-07
between O 0 1.7073229496844533e-09
HFE O 0 5.4917823035793845e-06
and O 0 1.2358143397506183e-09
a O 0 3.0163871400645803e-10
key O 0 4.3862902199265363e-10
protein O 0 6.526658657968198e-10
involved O 0 2.7118879364351756e-10
in O 0 8.628620734585368e-11
iron O 0 5.272986982163275e-06
transport O 0 8.094322545559862e-09
, O 0 2.486186534422785e-10
the O 0 2.5614985132982326e-10
TfR O 0 2.2313652152661234e-06
, O 0 4.849128321104956e-10
and O 0 3.535707282509293e-10
raise O 0 7.384537981103279e-10
the O 0 8.555526079256914e-12
possibility O 0 9.308043225075835e-11
that O 0 8.609254975588954e-11
alterations O 0 3.104597912084728e-09
in O 0 3.1272859302156064e-11
this O 0 2.5033725092882264e-11
regulatory O 0 7.945666347097813e-10
mechanism O 0 7.976735383330436e-10
may O 0 6.630985094346897e-09
play O 0 3.469357856555888e-10
a O 0 3.8380984501706905e-10
role O 0 8.944840979019375e-10
in O 0 8.295626685583812e-11
the O 0 5.260206159540814e-10
pathogenesis O 0 2.722505598740099e-07
of O 0 4.463500147267041e-08
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
. O 0 5.948039643044467e-07
. O 0 4.140474274549888e-08

Genomic O 0 2.8523661512736e-06
organization O 0 3.828414563145088e-08
of O 0 8.994831546260684e-10
the O 0 3.4719613850597852e-09
UBE3A O 0 7.95840096543543e-05
/ O 0 1.943476036103675e-06
E6 O 0 1.3398427654465195e-05
- O 0 4.4626271119341254e-05
AP O 0 2.0542390757327667e-06
gene O 0 5.482413811819242e-08
and O 0 2.6858217871961187e-09
related O 0 1.293094076260104e-08
pseudogenes O 0 4.449939297046512e-06
. O 0 1.3820481115089933e-07

The O 0 1.5033643308015598e-07
UBE3A O 0 1.7928245142684318e-05
gene O 0 1.5204865633222653e-07
encodes O 0 1.31457568386395e-07
the O 0 1.9883110713436736e-09
E6 O 0 4.550284984361497e-07
- O 0 8.162789413290739e-07
AP O 0 2.114491906013427e-07
ubiquitin O 0 2.9194900719176076e-08
- O 0 1.1574142533277154e-08
protein O 0 1.4223322519768544e-09
ligase O 0 1.9448023191870334e-09
and O 0 5.147486326073647e-10
has O 0 1.4569508932638087e-09
recently O 0 2.463393711238382e-09
been O 0 1.7055653556141692e-09
shown O 0 2.4622978656019257e-10
to O 0 1.5119053231593682e-10
be O 0 2.374668461868623e-09
mutated O 0 2.5996769181801938e-05
in O 0 0.0007846525404602289
Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
patients O 1 0.9998395442962646
who O 0 2.4500297968188534e-06
lack O 0 8.492878400545578e-09
15q11 O 0 4.697758697602694e-07
- O 0 8.685548777975782e-07
q13 O 0 5.181792062103341e-07
deletions O 0 2.1804419247928308e-07
or O 0 1.0151315343875922e-08
chromosome O 0 3.507971268845722e-05
15 O 0 2.1938456029602094e-07
paternal O 0 3.570395347196609e-05
uniparental B-Disease 0 0.0014487489825114608
disomy I-Disease 0 0.00020615574612747878
. O 0 3.3669851973172626e-07

Previous O 0 1.907120349642355e-06
UBE3A O 0 8.76980720931897e-06
cDNA O 0 4.101254376109864e-07
analysis O 0 5.993420870709087e-08
has O 0 9.741183859546254e-09
shown O 0 2.011050659334046e-09
a O 0 1.0111657067213287e-09
coding O 0 3.54839180261024e-08
region O 0 3.675945769998634e-09
of O 0 2.1921027493210232e-10
approximately O 0 5.426989080348221e-09
2 O 0 2.166475354670183e-08
. O 0 2.8141494468059136e-08

6 O 0 7.881350938987453e-06
kb O 0 5.907443664909806e-06
and O 0 2.9205539320287244e-08
a O 0 2.510347840711802e-08
3 O 0 6.196577828632144e-08
- O 0 0.00017992896027863026
untranslated O 0 0.001314842258580029
region O 0 7.837542170818779e-08
( O 0 7.386735667580524e-10
UTR O 0 1.846976829256164e-07
) O 0 1.767549440145899e-10
of O 0 4.0461516082057614e-11
< O 0 5.662918134419215e-09
50 O 0 1.9472485845994925e-09
bp O 0 9.918830556898683e-08
, O 0 1.0929612076493456e-10
whereas O 0 6.896839765957452e-10
Northern O 0 7.398100465572099e-10
analysis O 0 3.699196504669544e-10
has O 0 2.581845848226294e-09
indicated O 0 1.368188007333515e-09
mRNA O 0 1.595033549683933e-10
sizes O 0 5.3586574066955e-10
of O 0 1.3071772830830497e-11
5 O 0 9.458704930409567e-10
- O 0 1.6301207779179094e-06
8 O 0 5.377604495038213e-08
kb O 0 4.812462066183798e-06
. O 0 4.6457873992267196e-08

We O 0 4.794787855644245e-07
have O 0 3.439453610809551e-09
analyzed O 0 4.859222357822546e-09
additional O 0 6.327531831828992e-10
cDNA O 0 9.788901245144643e-09
clones O 0 2.656487474439473e-08
and O 0 9.632354913691188e-10
provide O 0 7.287460634941567e-10
evidence O 0 9.062682271299138e-10
for O 0 1.1865317062209613e-10
an O 0 5.68351810059653e-10
additional O 0 9.58445500742755e-09
0 O 0 1.504833022636376e-07
. O 0 2.5169400785785e-08

5 O 0 7.933996357678552e-07
kb O 0 6.311241804723977e-07
of O 0 1.6671812819168963e-09
5 O 0 9.609294693291304e-09
- O 0 1.2369584965199465e-06
UTR O 0 1.528493157820776e-05
and O 0 1.688688477941014e-08
> O 0 1.2109094171819379e-08
2 O 0 2.603674387202659e-09
kb O 0 1.1736585747712525e-07
of O 0 8.577396570785822e-10
3 O 0 5.3152682255586114e-08
- O 0 0.000132253160700202
UTR O 0 0.0017825959948822856
. O 0 2.992394740886084e-07

We O 0 3.2508697245248186e-07
have O 0 3.838759088381494e-09
established O 0 2.588738112763167e-10
the O 0 3.457590810884703e-11
genomic O 0 2.6721278523211822e-09
organization O 0 1.0920401388725409e-10
of O 0 8.185947752981093e-11
UBE3A O 0 4.035761094201007e-07
and O 0 3.0832519870571673e-10
the O 0 1.6814287809308048e-11
sequence O 0 1.6503615141161276e-10
of O 0 5.3471584798847616e-11
intron O 0 2.4670662241987884e-06
- O 0 2.5794017801672453e-06
exon O 0 1.441096742382797e-06
borders O 0 1.001546223733385e-07
. O 0 4.6768960260124004e-08

We O 0 1.326346477981133e-06
have O 0 6.235703153834038e-08
also O 0 5.3197584115594054e-09
mapped O 0 1.3055377223736286e-07
two O 0 4.191418878640718e-10
highly O 0 1.2978647045969183e-09
homologous O 0 3.473199949866057e-09
processed O 0 4.065396908004004e-08
pseudogenes O 0 1.2396044724027888e-07
, O 0 1.951539152500459e-09
UBE3AP1 O 0 3.0019901942068827e-07
and O 0 1.0928721261294072e-09
UBE3AP2 O 0 2.6114176421287993e-07
, O 0 1.1334064242696229e-10
to O 0 1.3996180603381703e-10
chromosomes O 0 1.9008892238048247e-09
2 O 0 1.859591369779423e-09
and O 0 1.6249928069811403e-09
21 O 0 3.321231734076946e-09
, O 0 3.733368614255994e-10
respectively O 0 3.976934781491082e-09
, O 0 4.395854791283682e-10
and O 0 5.217946630331483e-10
determined O 0 1.1557707679799023e-08
their O 0 1.594218368428102e-10
genomic O 0 1.2030729301670817e-08
organization O 0 1.825760320706138e-09
. O 0 6.1681095786525475e-09

These O 0 3.9972385934561316e-07
results O 0 6.297413790434803e-08
will O 0 1.5641059558646475e-09
form O 0 2.5587931773429773e-10
the O 0 5.902485444853056e-11
basis O 0 2.465578297083937e-10
for O 0 1.0656997506686139e-10
studies O 0 9.909173481759126e-11
of O 0 1.8046944147420696e-11
mutation O 0 6.40842623411686e-09
and O 0 3.512041768516383e-10
imprinting O 0 1.338000004125206e-07
of O 0 2.0269006473228046e-09
UBE3A O 0 2.1982568796374835e-05
. O 0 5.146303294623067e-08

Mutation O 0 0.013515125960111618
spectrum O 0 0.00023290813260246068
and O 0 5.396283313530148e-07
genotype O 0 0.021576350554823875
- O 0 0.1444261223077774
phenotype O 1 0.8212554454803467
analyses O 0 9.533287652629951e-07
in O 0 2.7238293398568203e-08
Cowden B-Disease 1 0.8392534852027893
disease I-Disease 0 0.008176950737833977
and O 0 3.8505569932567596e-07
Bannayan B-Disease 1 0.9204142093658447
- I-Disease 1 0.9999788999557495
Zonana I-Disease 1 0.9999912977218628
syndrome I-Disease 1 0.9999985694885254
, O 0 1.0707865705228414e-08
two O 0 3.226844569326204e-08
hamartoma B-Disease 1 0.9616018533706665
syndromes I-Disease 0 0.2288164645433426
with O 0 4.904674355543648e-08
germline O 0 8.637970313429832e-05
PTEN O 0 0.007066735532134771
mutation O 0 3.743374327314086e-05
. O 0 1.3212647331783955e-07

The O 0 4.198122496745782e-06
tumour B-Disease 1 0.9999016523361206
suppressor O 0 0.00010807583021232858
gene O 0 1.942977405633428e-06
PTEN O 0 5.120322748553008e-05
, O 0 2.4561406242185058e-09
which O 0 4.782717000217929e-10
maps O 0 3.5394286612699943e-08
to O 0 2.1443044673219447e-08
10q23 O 0 5.647567377309315e-06
. O 0 9.562090497183817e-08

3 O 0 1.347839997833944e-06
and O 0 3.981443619238689e-09
encodes O 0 1.8976551885430126e-08
a O 0 4.318305713013615e-09
403 O 0 1.0519058513125401e-08
amino O 0 1.0486425061628779e-08
acid O 0 6.427782750506594e-08
dual O 0 1.9419496766204247e-07
specificity O 0 1.8911698873580463e-07
phosphatase O 0 0.00018725081463344395
( O 0 5.567745153811643e-10
protein O 0 8.131739726024989e-09
tyrosine O 0 1.9724782873709046e-07
phosphatase O 0 1.8035079847322777e-05
; O 0 3.238051382581375e-09
PTPase O 0 1.1574754665844011e-07
) O 0 3.298301631815548e-10
, O 0 2.4610583015949317e-10
was O 0 1.8644364274678082e-08
shown O 0 8.541907625669865e-09
recently O 0 3.422798267038729e-09
to O 0 3.393602343582103e-10
play O 0 1.133415583609576e-09
a O 0 1.77828329839258e-09
broad O 0 4.746459669746628e-09
role O 0 5.50592593739907e-09
in O 0 2.0451369486806925e-09
human O 0 1.1951685863209605e-08
malignancy B-Disease 0 3.5210275655117584e-06
. O 0 8.306532350843554e-08

Somatic O 0 0.0011615111725404859
PTEN O 0 0.002095008734613657
deletions O 0 7.427769742207602e-05
and O 0 2.564728447396192e-07
mutations O 0 1.0567038088993286e-06
were O 0 1.4910073176110927e-08
observed O 0 1.8426096204393616e-08
in O 0 2.484964678473034e-09
sporadic B-Disease 0 0.019851842895150185
breast I-Disease 1 0.9991849064826965
, I-Disease 0 1.183509112934189e-07
brain I-Disease 0 0.00019679077377077192
, I-Disease 0 6.77203289001227e-08
prostate I-Disease 0 0.017681388184428215
and I-Disease 0 6.588453743461287e-06
kidney I-Disease 0 0.0236187931150198
cancer I-Disease 0 8.2104277680628e-05
cell O 0 5.038166364101926e-06
lines O 0 4.5062498088555003e-07
and O 0 9.301020509333568e-10
in O 0 2.1680769679566225e-10
several O 0 2.3590260855854694e-09
primary O 0 1.0735768682934577e-06
tumours B-Disease 1 0.9999936819076538
such O 0 7.37854399801563e-09
as O 0 5.086146757093957e-06
endometrial B-Disease 1 0.9998786449432373
carcinomas I-Disease 1 1.0
, O 0 0.1491096019744873
malignant B-Disease 1 1.0
melanoma I-Disease 1 1.0
and O 1 0.9936020970344543
thyroid B-Disease 1 0.9999904632568359
tumours I-Disease 1 0.9999998807907104
. O 0 1.963529257409391e-06

In O 0 2.2807643063060823e-07
addition O 0 1.919361380942064e-08
, O 0 2.1307391406821807e-09
PTEN O 0 3.917688900401117e-06
was O 0 1.1706783453746539e-07
identified O 0 2.689522826671009e-09
as O 0 1.540067517957766e-10
the O 0 1.718757774993307e-10
susceptibility O 0 4.703941613115603e-06
gene O 0 4.294233946211534e-08
for O 0 2.8686835129576593e-09
two O 0 2.766349496141629e-07
hamartoma B-Disease 1 0.999491810798645
syndromes I-Disease 1 0.9998974800109863
Cowden B-Disease 1 0.9999270439147949
disease I-Disease 1 0.9880776405334473
( O 0 6.333753521658991e-09
CD B-Disease 0 1.1906487998203374e-05
; O 0 2.41088322638916e-08
MIM O 0 1.8325528117202339e-06
158350 O 0 2.8422763875823875e-07
) O 0 1.7274878194584176e-09
and O 0 5.890143484066357e-09
Bannayan B-Disease 0 1.0961911357298959e-05
- I-Disease 0 8.674678247189149e-05
Zonana I-Disease 0 0.00021263294911477715
( I-Disease 0 3.1225089180964005e-09
BZS I-Disease 0 3.543972297848086e-07
) I-Disease 0 9.133169776021077e-10
or I-Disease 0 4.015548782376754e-09
Ruvalcaba I-Disease 0 1.8767956134979613e-05
- I-Disease 0 2.6833511583390646e-05
Riley I-Disease 0 4.463456934900023e-05
- I-Disease 1 0.694867730140686
Smith I-Disease 1 0.8387143611907959
syndrome I-Disease 1 0.998936116695404
( O 0 1.001975746817152e-08
MIM O 0 2.6857776447286597e-06
153480 O 0 6.376149599418568e-07
) O 0 4.353785332256166e-09
. O 0 2.3251223169040713e-08

Constitutive O 0 8.798725502856541e-06
DNA O 0 8.485764624310832e-07
from O 0 5.159884075567334e-09
37 O 0 1.948977157439913e-08
CD B-Disease 0 2.641598086938757e-07
families O 0 8.132809981020728e-09
and O 0 1.2275778171755292e-09
seven O 0 2.5351267751716478e-09
BZS B-Disease 0 1.8941946109407581e-06
families O 0 1.1585208348208198e-08
was O 0 1.4121474656292321e-08
screened O 0 1.3577800928032957e-07
for O 0 6.6214176364098876e-09
germline O 0 7.761405868222937e-06
PTEN O 0 0.0006342299748212099
mutations O 0 1.1821135558420792e-05
. O 0 1.787377783557531e-07

PTEN O 0 0.0065613798797130585
mutations O 0 0.0007524222601205111
were O 0 3.600897287014959e-07
identified O 0 4.551126764340552e-08
in O 0 4.183647595024098e-10
30 O 0 1.0557705820701813e-09
of O 0 9.63451887714406e-11
37 O 0 1.696080609292494e-08
( O 0 2.4384064212235046e-10
81 O 0 9.714320015064004e-08
% O 0 1.8973890514306646e-10
) O 0 5.165215824498581e-11
CD B-Disease 0 1.1926906609005528e-06
families O 0 2.518989683508721e-09
, O 0 9.135777551128044e-11
including O 0 1.6767090493807757e-10
missense O 0 1.9549831620224722e-07
and O 0 2.478711458309135e-09
nonsense O 0 8.636948933826716e-08
point O 0 2.73653921745165e-09
mutations O 0 1.5768012673333942e-08
, O 0 1.0290534396828477e-10
deletions O 0 1.1949794043175643e-08
, O 0 6.057255252933658e-10
insertions O 0 8.75469154948405e-08
, O 0 4.622836002887709e-10
a O 0 3.975751727836041e-09
deletion O 0 6.022286811457889e-07
/ O 0 7.126600820583917e-08
insertion O 0 1.0715387332993487e-07
and O 0 5.353552268161366e-09
splice O 0 1.6201831840589875e-06
site O 0 3.458685000623518e-07
mutations O 0 8.522080179318436e-07
. O 0 3.2390477855415156e-08

These O 0 1.1846699976558739e-07
mutations O 0 6.197676611918723e-07
were O 0 1.2399894444570236e-08
scattered O 0 7.0111472183498336e-09
over O 0 7.430573045752453e-09
the O 0 9.243190102203869e-10
entire O 0 2.5580868534547108e-09
length O 0 1.7832396892458746e-08
of O 0 1.1312531467133624e-10
PTEN O 0 4.3302279664203525e-06
, O 0 3.5311448209895957e-10
with O 0 4.870380140853392e-11
the O 0 7.520736117205828e-11
exception O 0 4.494472571892061e-10
of O 0 1.180566928937754e-11
the O 0 4.7020318194590516e-11
first O 0 1.3284425781634468e-09
, O 0 3.503919099312469e-10
fourth O 0 3.648563895453094e-09
and O 0 3.2474776201496525e-09
last O 0 2.3416873773385305e-08
exons O 0 1.07590449260897e-06
. O 0 5.9268625562935995e-08

A O 0 1.0643276482369401e-06
hot O 0 1.8404605270916363e-06
spot O 0 1.709589270149081e-07
for O 0 2.1301620467539806e-09
PTEN O 0 9.497736755292863e-06
mutation O 0 1.6851130624218058e-07
in O 0 6.06814876125128e-10
CD B-Disease 0 2.3109812730126578e-07
was O 0 1.2569923057981214e-07
identified O 0 1.73843184292366e-09
in O 0 6.550301273611225e-11
exon O 0 8.760432379517624e-09
5 O 0 3.9560826836648744e-10
that O 0 8.458049538528911e-11
contains O 0 2.2299512236756414e-10
the O 0 1.1368966185143492e-10
PTPase O 0 8.527147343784236e-08
core O 0 3.14416093161185e-09
motif O 0 2.222144024344175e-09
, O 0 4.8918768341676966e-11
with O 0 3.1439420511425453e-11
13 O 0 8.475393303841727e-11
of O 0 1.2499608119387329e-11
30 O 0 5.3020488000044e-10
( O 0 7.451912004130534e-11
43 O 0 2.900358353485899e-08
% O 0 1.0692099289277834e-10
) O 0 3.712830043411941e-11
CD B-Disease 0 1.4693516732222633e-06
mutations O 0 1.5344869552791351e-07
identified O 0 6.5075442812201345e-09
in O 0 7.193028117580269e-11
this O 0 5.295964222717942e-10
exon O 0 3.0736669032194186e-07
. O 0 2.779518126772018e-08

Seven O 0 6.564243193452057e-08
of O 0 6.257143136956245e-10
30 O 0 8.702323861520256e-10
( O 0 8.327936951157966e-11
23 O 0 5.871646724386892e-09
% O 0 6.144711822697602e-11
) O 0 2.262152444532095e-11
were O 0 9.055839411686861e-10
within O 0 7.76378961120372e-12
the O 0 2.418478785293221e-11
core O 0 3.5102889484051047e-09
motif O 0 5.305086592244379e-09
, O 0 1.07913837588125e-10
the O 0 5.7525952751324994e-11
majority O 0 6.970398924721621e-09
( O 0 3.078578711401825e-11
five O 0 1.2420380002264864e-10
of O 0 8.030859831309467e-12
seven O 0 1.226173190760349e-10
) O 0 1.0493032658043244e-11
of O 0 7.687826070190695e-12
which O 0 1.6949931458398737e-09
were O 0 5.427517102418733e-09
missense O 0 2.711756792450615e-07
mutations O 0 1.4385445723519297e-08
, O 0 8.291260733539474e-11
possibly O 0 5.14045139787811e-10
pointing O 0 4.423123645125315e-09
to O 0 5.57356771846429e-10
the O 0 1.488567741292357e-10
functional O 0 2.7092215137969333e-09
significance O 0 3.313080920719358e-10
of O 0 9.28229628577304e-12
this O 0 2.2349458395076738e-10
region O 0 9.38352595625247e-09
. O 0 2.3639730173385942e-08

Germline O 0 0.003153676399961114
PTEN O 0 0.03214766085147858
mutations O 0 0.008968410082161427
were O 0 8.964727271632e-07
identified O 0 3.8266847468548804e-08
in O 0 2.330714510279108e-10
four O 0 2.849546432148742e-10
of O 0 3.340261400808231e-11
seven O 0 1.0281084872332258e-09
( O 0 2.6817562059910927e-10
57 O 0 2.2068704197408806e-07
% O 0 8.101083137646015e-10
) O 0 8.137848728217989e-10
BZS B-Disease 0 7.142956292227609e-06
families O 0 1.6552652581935945e-08
studied O 0 2.3595314146973578e-08
. O 0 1.043574471282227e-08

Interestingly O 0 9.892512753140181e-05
, O 0 3.160523220913092e-08
none O 0 3.4993192787879934e-09
of O 0 3.948647658846838e-11
these O 0 1.9575661924786658e-10
mutations O 0 9.711611959062338e-09
was O 0 3.0963676067585766e-08
observed O 0 4.707779943657897e-09
in O 0 1.4693520011821448e-10
the O 0 4.5088285882677326e-10
PTPase O 0 7.86498901561572e-07
core O 0 5.0064880241507126e-08
motif O 0 8.609859492025862e-08
. O 0 1.694958307041361e-08

It O 0 1.3822037203681248e-07
is O 0 3.719070829077964e-09
also O 0 1.049282216669667e-09
worthy O 0 8.644274740454705e-10
of O 0 1.4274401972935724e-11
note O 0 6.260282847669885e-10
that O 0 4.086146698778492e-11
a O 0 2.715754565674189e-10
single O 0 8.026462161581094e-09
nonsense O 0 2.439757906813611e-08
point O 0 2.707072788155074e-09
mutation O 0 1.2151758710388094e-08
, O 0 1.8338880414248138e-10
R233X O 0 2.09825046226797e-08
, O 0 3.095572964628701e-10
was O 0 1.1881747141728738e-08
observed O 0 8.53278447898731e-10
in O 0 2.6964853960809165e-11
the O 0 5.3943620403895665e-11
germline O 0 8.228189685155485e-09
DNA O 0 4.6800527897516986e-09
from O 0 5.182584222884756e-11
two O 0 5.239915792931704e-11
unrelated O 0 2.9761733078004227e-09
CD B-Disease 0 5.012220753997099e-07
families O 0 2.7012239112167435e-09
and O 0 8.152234443059569e-10
one O 0 5.944146952430174e-09
BZS B-Disease 0 4.991584319213871e-06
family O 0 1.598413206238547e-07
. O 0 2.0152368662706976e-08

Genotype O 1 0.9938570857048035
- O 1 0.7072679996490479
phenotype O 1 0.9965918064117432
studies O 0 7.948629843212984e-08
were O 0 2.6212152448579218e-08
not O 0 1.174468189368838e-09
performed O 0 7.712571026274873e-09
on O 0 9.837598513584567e-10
this O 0 5.517421589051885e-11
small O 0 5.486508469765283e-10
group O 0 9.201501227629194e-10
of O 0 2.2979437797054914e-10
BZS B-Disease 0 3.581564897103817e-06
families O 0 4.5930022452012054e-08
. O 0 2.043675806362444e-08

However O 0 2.6056463866552804e-06
, O 0 2.6307215961196562e-08
genotype O 0 2.577523628133349e-05
- O 0 5.659747330355458e-05
phenotype O 0 0.00032224535243585706
analysis O 0 1.0600366806556849e-08
inthe O 0 2.259465503584579e-07
group O 0 1.8194855622155615e-09
of O 0 2.0525832769568986e-11
CD B-Disease 0 7.945659064034771e-08
families O 0 1.9060226730260865e-09
revealed O 0 2.002117804877912e-09
two O 0 4.9528648543573084e-11
possible O 0 2.6843968714551636e-10
associations O 0 1.7942511365554026e-10
worthy O 0 1.4591896579929653e-09
of O 0 2.8480778499484494e-11
follow O 0 1.7729796519816432e-09
- O 0 1.5984316803496768e-07
up O 0 5.618902232384926e-09
in O 0 8.13732081716978e-10
independent O 0 1.304837748961063e-08
analyses O 0 9.927783395369261e-08
. O 0 6.505534333456353e-09

The O 0 5.688186988095367e-08
first O 0 1.073963051823057e-08
was O 0 1.2260597870294987e-08
an O 0 1.9474886980841433e-10
association O 0 5.233904976087445e-10
noted O 0 2.4023074640666664e-09
in O 0 1.274417793517557e-10
the O 0 1.70548311584362e-10
group O 0 7.877549723644961e-10
of O 0 2.4064004261470373e-11
CD B-Disease 0 1.2096868431399344e-06
families O 0 8.732905953934278e-09
with O 0 1.0108541914632951e-07
breast B-Disease 1 0.9994800686836243
disease I-Disease 0 0.0067964824847877026
. O 0 1.2319510744873696e-07

A O 0 4.581348775900551e-07
correlation O 0 6.320855163721717e-07
was O 0 9.500298858711176e-08
observed O 0 4.7250519052965956e-09
between O 0 1.9114609894899104e-10
the O 0 2.520680053574864e-10
presence O 0 1.498751345252458e-08
/ O 0 6.535010754760151e-08
absence O 0 3.443779705847305e-09
of O 0 4.236587469730324e-11
a O 0 4.377834095237176e-09
PTEN O 0 3.6590306990547106e-05
mutation O 0 9.244150334097867e-08
and O 0 1.8522344769067445e-10
the O 0 3.02282469888393e-11
type O 0 2.357129247343437e-08
of O 0 1.641340174884931e-09
breast O 0 0.05267448350787163
involvement O 0 8.798950261734717e-07
( O 0 5.429877880658296e-09
unaffected O 0 3.0207833333406597e-05
versus O 0 6.708647561026737e-06
benign O 0 0.0002343611849937588
versus O 0 9.684563337941654e-06
malignant O 0 0.00028892303816974163
) O 0 1.2116047720667211e-08
. O 0 4.440149226070389e-08

Specifically O 0 1.1325688547003665e-06
and O 0 2.004709465097676e-08
more O 0 1.6582127893016718e-09
directly O 0 3.5075584658983416e-09
, O 0 1.8706683424518644e-10
an O 0 4.0019371150279426e-10
association O 0 8.150851105170887e-10
was O 0 2.780049044304178e-07
also O 0 5.776812361801831e-09
observed O 0 7.003498891933191e-10
between O 0 1.8094645573563106e-11
the O 0 1.8249022085137234e-11
presence O 0 2.54405774224864e-10
of O 0 2.1484810458494152e-11
a O 0 1.2262773019244833e-08
PTEN O 0 0.0021429627668112516
mutation O 0 9.997166671382729e-06
and O 0 3.743173238035524e-07
malignant B-Disease 1 0.9987429976463318
breast I-Disease 1 0.9998354911804199
disease I-Disease 0 0.044355928897857666
. O 0 3.803356491971499e-07

Secondly O 0 9.22865656320937e-05
, O 0 6.371767113932947e-08
there O 0 5.908799671772158e-09
appeared O 0 2.0067740535978373e-07
to O 0 7.390681400210042e-10
be O 0 9.82792069947891e-10
an O 0 9.99831328840628e-10
interdependent O 0 3.3384549169568345e-07
association O 0 9.0742358072049e-10
between O 0 1.6693632587383433e-10
mutations O 0 7.200186669109598e-09
upstream O 0 4.0953107571795044e-09
and O 0 3.975249296406247e-10
within O 0 1.7220908726800488e-11
the O 0 6.757740200757922e-11
PTPase O 0 9.67798001738629e-08
core O 0 8.20530843270717e-09
motif O 0 4.8183554923753036e-09
, O 0 1.1987791315171137e-10
the O 0 2.800598121466269e-11
core O 0 1.7860676271297393e-09
motif O 0 1.1131057187085958e-09
containing O 0 2.792273356977404e-10
the O 0 4.08904680948563e-11
majority O 0 1.2611840460863277e-09
of O 0 3.3678598104769364e-11
missense O 0 8.852987889440556e-07
mutations O 0 4.57886741855873e-08
, O 0 1.5929145502635578e-10
and O 0 1.3121038977548238e-10
the O 0 5.706282321660261e-11
involvement O 0 2.4266597620226094e-09
of O 0 3.3658943687786547e-11
all O 0 5.930358981665051e-11
major O 0 2.957356859401017e-10
organ O 0 1.4615697807585093e-07
systems O 0 3.991695152194552e-08
( O 0 1.5582392320911964e-10
central O 0 1.9025685471518727e-09
nervous O 0 4.3112717662552313e-07
system O 0 3.8401818613920113e-08
, O 0 1.4427322447829738e-08
thyroid O 0 0.0003933178959414363
, O 0 6.987373524225404e-08
breast O 0 0.25865161418914795
, O 0 1.7549690483065206e-06
skin O 1 0.9999788999557495
and O 1 0.654150128364563
gastrointestinal O 1 0.9999948740005493
tract O 1 0.9790327548980713
) O 0 7.73119097630115e-08
. O 0 1.2866536280853325e-07

However O 0 1.8849428897738107e-06
, O 0 2.316480340880389e-09
these O 0 5.2245867354638875e-11
observations O 0 1.3708889579078232e-09
would O 0 1.384965364614743e-09
need O 0 2.7514748812684786e-10
to O 0 2.3324011610981188e-09
be O 0 2.092782658280612e-08
confirmed O 0 1.3891514605290922e-08
by O 0 1.895550556796355e-11
studying O 0 4.0693236974531644e-11
a O 0 1.188266429696938e-10
larger O 0 1.569631091768997e-10
number O 0 8.733663792170887e-11
of O 0 2.565849095692574e-11
CD B-Disease 0 6.313035783023224e-07
families O 0 1.3689039235487144e-08
. O 0 6.10146022594904e-09

Molecular O 0 0.00026151753263548017
defects O 1 0.9306312799453735
leading O 0 5.367276045831204e-08
to O 0 3.185212316125785e-09
human O 0 1.6781336320548235e-09
complement B-Disease 0 8.050135420489823e-07
component I-Disease 0 0.014561586081981659
C6 I-Disease 1 1.0
deficiency I-Disease 1 0.9999996423721313
in O 0 4.042592038899784e-09
an O 0 1.0414562545690842e-09
African O 0 1.2721914632862763e-09
- O 0 1.2780895985997631e-06
American O 0 4.99792989216985e-08
family O 0 8.051873123804398e-08
. O 0 1.127794213573452e-08

Complement B-Disease 0 0.00038809608668088913
component I-Disease 0 0.3130350410938263
C6 I-Disease 1 0.9999997615814209
deficiency I-Disease 1 0.9999998807907104
( O 0 1.0482010281975818e-07
C6D B-Disease 0 2.893347482313402e-05
) O 0 5.893222354558247e-09
was O 0 2.3097825760487467e-05
diagnosed O 0 0.0006839773268438876
in O 0 1.900706952939757e-10
a O 0 3.8620102671416134e-09
16 O 0 5.925457902122844e-09
- O 0 4.0853237237570283e-07
year O 0 1.7853635014830616e-08
- O 0 1.1282771765763755e-06
old O 0 1.178984462057997e-06
African O 0 1.017620210319592e-09
- O 0 1.0150621676530136e-07
American O 0 1.12906191063189e-08
male O 0 2.75107964853305e-07
with O 0 3.3740633398338105e-07
meningococcal B-Disease 1 0.9999992847442627
meningitis I-Disease 1 0.9999994039535522
. O 0 8.995841085379652e-07

The O 0 1.0440343203299562e-06
patients O 0 0.0003102047776337713
father O 0 9.090196044780896e-07
and O 0 5.362504662542733e-09
two O 0 4.313851942328029e-09
brothers O 0 1.047275759447075e-07
also O 0 7.447145566885638e-09
had O 0 4.112596485583708e-08
C6D B-Disease 0 2.6673915272112936e-06
, O 0 4.717718993241249e-10
but O 0 8.336935586328309e-10
gave O 0 2.2445503233825548e-09
no O 0 2.2283695721991847e-10
history O 0 3.756196187421068e-10
of O 0 8.784858396282402e-10
meningitis B-Disease 1 0.999967098236084
or O 0 2.7206032982007855e-09
other O 0 3.474903031985832e-09
neisserial B-Disease 0 0.012994447723031044
infection I-Disease 0 0.00017756488523446023
. O 0 8.476618518216128e-08

By O 0 2.7619675435630597e-08
using O 0 5.356555643487582e-09
exon O 0 4.8766061411242845e-08
- O 0 3.344831256413272e-08
specific O 0 4.612443205154193e-10
polymerase O 0 5.508092826289612e-08
chain O 0 2.1419137397060695e-07
reaction O 0 2.1706444641722555e-08
( O 0 1.3825789124677357e-10
PCR O 0 9.158559066690941e-08
) O 0 4.377731510629701e-10
/ O 0 4.661886876533572e-09
single O 0 8.058982814418414e-09
- O 0 6.346429870518477e-08
strand O 0 1.3990755576287484e-07
conformation O 0 2.632789630752086e-08
polymorphism O 0 1.5080425441738043e-07
as O 0 2.1952532847091533e-10
a O 0 7.20173157220394e-11
screening O 0 9.041066229009687e-10
step O 0 7.209596253332506e-10
and O 0 3.3586605718838314e-11
nucleotide O 0 8.719582000882298e-11
sequencing O 0 8.106024185217109e-11
of O 0 1.5394970021009868e-11
target O 0 2.148917488398183e-09
exons O 0 8.266446194227228e-09
, O 0 1.587143194647922e-10
we O 0 1.4253405400399544e-10
determined O 0 1.3963604716948907e-09
that O 0 1.3886679306462923e-10
the O 0 1.0197044597592964e-10
proband O 0 1.802387714633369e-07
was O 0 1.4135352444100135e-08
a O 0 5.779896006252727e-10
compound O 0 1.2963290885181777e-08
heterozygote O 0 4.0907661968958564e-07
for O 0 1.0151155471760376e-09
two O 0 5.375879297275787e-09
C6 O 0 1.7211292288266122e-05
gene O 0 4.395280939206714e-07
mutations O 0 1.0561285535004572e-06
. O 0 2.912987717706983e-08

The O 0 8.068229817581596e-08
first O 0 1.4226992917087955e-08
, O 0 8.877821811026365e-10
1195delC O 0 6.77857201480947e-08
located O 0 2.6425330812429593e-09
in O 0 2.7012639347567813e-10
exon O 0 4.642120288167462e-08
7 O 0 1.3245949226359244e-08
, O 0 3.3423280809685707e-10
is O 0 2.24759086342452e-10
a O 0 1.7083131576001165e-09
novel O 0 3.041788332325268e-08
mutation O 0 9.54719769907797e-09
, O 0 5.567720937071918e-11
while O 0 5.5990517777715354e-11
the O 0 1.7335129859352705e-11
second O 0 1.3138500287723787e-09
, O 0 3.7650549344903084e-10
1936delG O 0 2.896510586936074e-08
in O 0 1.7202303470575941e-10
exon O 0 2.0218125840187895e-08
12 O 0 1.568138729979296e-09
, O 0 2.323692210870476e-10
has O 0 5.767509581033892e-09
been O 0 3.2026352680958325e-09
described O 0 4.622089377903649e-09
before O 0 1.9022518282785228e-10
to O 0 7.966335369147259e-10
cause O 0 7.158162507181487e-09
C6D B-Disease 0 2.3110460460884497e-06
in O 0 4.4763864837094047e-10
an O 0 7.633377818727638e-10
unrelated O 0 1.498322532711427e-08
African O 0 1.670459659486312e-09
- O 0 4.3460136112116743e-07
American O 0 2.1947657913301555e-08
individual O 0 3.73646935614147e-09
. O 0 1.17386864673108e-08

Both O 0 6.103570058257901e-07
mutations O 0 3.503306061247713e-06
result O 0 6.223179838116266e-08
in O 0 2.017205602555805e-08
premature O 0 1.2948501534992829e-05
termination O 0 9.198138286592439e-07
codons O 0 4.587670616729156e-07
and O 0 1.2635388202397735e-07
C6 O 0 0.00012314655759837478
null O 0 5.91488387726713e-05
alleles O 0 1.5131466852835729e-06
. O 0 9.262152644851085e-08

Allele O 0 0.0002531199133954942
- O 0 2.6998709472536575e-06
specific O 0 8.812115481759975e-09
PCR O 0 3.1870483780949144e-06
indicated O 0 8.328104854626872e-07
that O 0 3.398654968567172e-10
the O 0 1.0057755323034101e-10
probands O 0 2.518165445053455e-07
two O 0 2.401464360701766e-09
brothers O 0 4.2616530748773584e-08
also O 0 2.6083017967692967e-09
inherited O 0 1.002197524968551e-08
the O 0 1.0384506449190312e-10
1195delC O 0 1.4912183132764767e-07
mutation O 0 1.4127913061656727e-08
from O 0 6.859617734944479e-11
their O 0 4.0488246089154245e-10
heterozygous O 0 2.593654357951891e-07
mother O 0 2.6306514300245e-08
and O 0 1.740457916676874e-10
the O 0 1.6441342731710051e-10
1936delG O 0 3.0109387694210454e-07
mutation O 0 2.8612040736675226e-08
from O 0 7.892524828134739e-11
their O 0 3.662031788920217e-10
homozygous O 0 7.503309973344585e-08
father O 0 5.021301419105839e-08
. O 0 6.370363681007518e-10
. O 0 4.865955638422292e-09

PAX6 O 0 0.15950000286102295
mutations O 0 0.004950868897140026
reviewed O 0 4.2305186070734635e-05
. O 0 1.5546611393801868e-06

Mutations O 0 0.0007976468768902123
in O 0 7.127022172426223e-08
PAX6 O 0 1.8085422198055312e-05
are O 0 4.245538143266003e-09
responsible O 0 6.77382638869517e-09
for O 0 5.568382421827778e-10
human O 0 6.709404587468271e-09
aniridia B-Disease 1 0.9999997615814209
and O 0 1.397072963982282e-07
have O 0 5.020436955049945e-09
also O 0 4.195292557795938e-09
been O 0 1.5481379511683713e-09
found O 0 1.1703624736014717e-09
in O 0 9.149279112108388e-10
patients O 0 1.2447308108676225e-06
with O 0 6.190635559732982e-08
Peters B-Disease 1 0.9999994039535522
anomaly I-Disease 1 0.9999997615814209
, O 0 1.34703384446766e-07
with O 0 1.0720958016463555e-05
congenital B-Disease 1 0.9999998807907104
cataracts I-Disease 1 0.9999758005142212
, O 0 1.2598432519439484e-08
with O 0 1.9289622343876545e-08
autosomal B-Disease 1 0.9586920142173767
dominant I-Disease 0 0.20524939894676208
keratitis I-Disease 1 0.9995354413986206
, O 0 1.4041870599612594e-07
and O 0 6.346087655373367e-09
with O 0 4.362016525760737e-08
isolated B-Disease 0 0.0135109294205904
foveal I-Disease 1 0.9999995231628418
hypoplasia I-Disease 1 0.9999995231628418
. O 0 2.337217438252992e-06

No O 0 8.111989018289023e-07
locus O 0 4.3269858451822074e-07
other O 0 3.3599261151096016e-09
than O 0 2.0274111278695273e-09
chromosome O 0 3.575356686269515e-07
11p13 O 0 6.01197484684235e-07
has O 0 2.5424787608585575e-08
been O 0 7.0429662102355906e-09
implicated O 0 2.7600663088378496e-08
in O 0 7.222648257254605e-09
aniridia B-Disease 1 0.9999971389770508
, O 0 6.947026065518003e-09
and O 0 2.134876497805749e-09
PAX6 O 0 1.1552978094186983e-06
is O 0 5.4503601631950005e-09
clearly O 0 5.60046720110563e-09
the O 0 1.6930203766696295e-11
major O 0 1.2832893081515806e-10
, O 0 1.7709847477398455e-10
if O 0 3.7819686271589603e-10
not O 0 5.557135307476813e-10
only O 0 4.1824907426324387e-10
, O 0 1.0234435521283558e-10
gene O 0 1.7304591093392219e-09
responsible O 0 1.0354967550085803e-08
. O 0 1.3573316692827575e-08

Twenty O 0 3.942478542739991e-06
- O 0 3.4452380077709677e-06
eight O 0 1.7366199145385508e-08
percent O 0 2.690015321604733e-09
of O 0 6.971336008465556e-11
identified O 0 4.6976019518751855e-08
PAX6 O 0 6.734525413776282e-06
mutations O 0 3.570592923551885e-07
are O 0 2.271090648875429e-09
C O 0 1.0534301253528611e-07
- O 0 3.268667933298275e-05
T O 0 4.21345976064913e-05
changes O 0 5.056474350340068e-09
at O 0 1.7603091206908061e-10
CpG O 0 6.220854231742123e-08
dinucleotides O 0 3.2339121958102623e-07
, O 0 3.475577048384082e-10
20 O 0 1.6268711378053524e-10
% O 0 1.2201487216423335e-11
are O 0 5.282672303069669e-12
splicing O 0 3.515005841947527e-09
errors O 0 1.2695934969997325e-08
, O 0 1.512176495133133e-10
and O 0 1.0568015906819994e-10
more O 0 2.6341132053353533e-10
than O 0 7.717320671396521e-10
30 O 0 1.265758053925481e-09
% O 0 3.9200122314841934e-11
are O 0 2.734887490085658e-11
deletion O 0 1.1334853944333645e-08
or O 0 3.06513925352192e-10
insertion O 0 2.1703463914946042e-08
events O 0 2.1051050680398475e-08
. O 0 3.169185447404743e-08

There O 0 1.9659579209019284e-07
is O 0 4.547367371543487e-09
a O 0 2.4959247113542915e-08
noticeably O 0 0.0002892648335546255
elevated O 0 5.9163390687899664e-05
level O 0 1.6558233673080736e-09
of O 0 4.5002258863835465e-11
mutation O 0 6.185062240149364e-09
in O 0 6.839224325760895e-11
the O 0 7.24250590056208e-11
paired O 0 7.538609736457147e-09
domain O 0 2.1820087958701606e-09
compared O 0 3.567078188382311e-09
with O 0 1.0123925309191151e-10
the O 0 1.0763099439481394e-10
rest O 0 5.238539602103742e-10
of O 0 1.1395532087399296e-11
the O 0 2.4511551122152753e-10
gene O 0 2.0556816693328983e-08
. O 0 1.756433931632273e-08

Increased O 0 4.021985205326928e-06
mutation O 0 9.078690936803469e-07
in O 0 7.354402087322853e-10
the O 0 1.4508520773670597e-10
homeodomain O 0 1.5597430547131808e-07
is O 0 2.143873967241916e-09
accounted O 0 2.1795381055511598e-09
for O 0 2.5107749213049146e-11
by O 0 6.48021428184542e-11
the O 0 5.528126845177894e-10
hypermutable O 0 1.3445405784295872e-06
CpG O 0 8.880300015334797e-07
dinucleotide O 0 3.52508919831962e-07
in O 0 2.2628967588644855e-09
codon O 0 7.879841490421313e-08
240 O 0 9.694441160945644e-08
. O 0 2.8651470529439393e-08

Very O 0 4.244514457241166e-06
nearly O 0 5.750124643100207e-08
all O 0 3.86958076692423e-10
mutations O 0 2.0699873815033243e-08
appear O 0 3.928386149709695e-08
to O 0 1.6926676948969543e-08
cause O 0 2.2913691282155924e-06
loss O 0 2.768978220046847e-07
of O 0 4.1559762575804626e-11
function O 0 1.2122300385719598e-10
of O 0 4.0552895243239906e-12
the O 0 2.821357730775631e-11
mutant O 0 2.2346412720253284e-08
allele O 0 1.4482684385086486e-08
, O 0 4.2612892381388434e-11
and O 0 1.341458055748035e-10
more O 0 1.8144630242744597e-10
than O 0 9.126552291682799e-10
80 O 0 1.2529290938090298e-09
% O 0 4.697818523080599e-11
of O 0 1.196441730411113e-11
exonic O 0 1.5520923568601575e-07
substitutions O 0 3.183489027946962e-08
result O 0 8.098275827705947e-09
in O 0 2.3101356383392613e-09
nonsense O 0 6.679452440039313e-07
codons O 0 1.841039960481794e-07
. O 0 4.494717131819925e-08

In O 0 2.7208642450204934e-08
a O 0 4.489059790557803e-09
gene O 0 3.5031724188172575e-09
with O 0 7.465270762674336e-11
such O 0 1.3025759637574907e-10
extraordinarily O 0 6.735359079357295e-07
high O 0 1.3796613629324384e-08
sequence O 0 7.322851769409056e-10
conservation O 0 1.501201662978957e-10
throughout O 0 7.018498976441023e-11
evolution O 0 1.3057525893866995e-10
, O 0 3.6452701968059387e-11
there O 0 7.769718896044608e-11
are O 0 1.8439087756672023e-10
presumed O 0 4.99393706832052e-07
undiscovered O 0 2.803451764066267e-07
missense O 0 5.103149192109413e-07
mutations O 0 6.231018545577172e-08
, O 0 1.2286946460271508e-10
these O 0 2.3056695441781017e-11
are O 0 7.200083584901762e-11
hypothesized O 0 9.581712312467516e-09
to O 0 3.7060485791329256e-09
exist O 0 7.243283195457195e-10
in O 0 2.371471630180366e-10
as O 0 2.3045023667123132e-09
- O 0 1.1090056659668335e-06
yet O 0 5.313453925737122e-07
unidentified O 0 2.1580665077181038e-07
phenotypes O 0 2.1454279419685918e-07
. O 0 1.4811031290307142e-09
. O 0 1.340344280009731e-08

Genetic O 0 0.00023867843265179545
heterogeneity O 0 0.00019867043010890484
and O 0 3.438357509821799e-07
penetrance O 0 3.143520416415413e-06
analysis O 0 2.5943398540562157e-09
of O 0 2.874129927110669e-11
the O 0 5.622384224857058e-10
BRCA1 O 0 2.0451045656955102e-06
and O 0 2.4436046075493323e-08
BRCA2 O 0 1.2565216138682445e-06
genes O 0 3.0014000174105604e-08
in O 0 9.712245230275585e-08
breast B-Disease 1 0.9990947246551514
cancer I-Disease 0 0.04966527968645096
families O 0 1.1514761411035579e-07
. O 0 2.8150406450322407e-08

The O 0 0.00010098163329530507
Breast B-Disease 1 0.9999998807907104
Cancer I-Disease 1 0.9999979734420776
Linkage O 0 9.171963756671175e-05
Consortium O 0 1.7266673921767506e-06
. O 0 5.807727276874175e-08

The O 0 6.264480845175058e-08
contribution O 0 2.1524670046346728e-08
of O 0 5.147240411673693e-10
BRCA1 O 0 1.0383357675891602e-06
and O 0 9.074486229110335e-08
BRCA2 O 0 0.00010484326776349917
to O 0 0.00027977049467153847
inherited B-Disease 1 1.0
breast I-Disease 1 1.0
cancer I-Disease 1 1.0
was O 0 0.0005746216047555208
assessed O 0 1.139567373797945e-07
by O 0 4.396877861800874e-10
linkage O 0 3.841888940314675e-08
and O 0 3.3496050377834763e-09
mutation O 0 7.72963915096625e-09
analysis O 0 4.857385049739094e-10
in O 0 9.129402789298524e-11
237 O 0 9.735239281383201e-09
families O 0 1.6639917221894507e-09
, O 0 5.981866391113755e-11
each O 0 3.440828177936339e-11
with O 0 6.058847173973092e-11
at O 0 1.172506813862384e-10
least O 0 8.824339037261097e-10
four O 0 3.020215466609244e-10
cases O 0 2.2810886513013884e-09
of O 0 1.654093528813405e-09
breast B-Disease 1 0.9802016615867615
cancer I-Disease 0 0.00036358172656036913
, O 0 2.242037666633223e-10
collected O 0 3.55567797427625e-10
by O 0 5.123068080870041e-10
the O 0 1.0394726501772311e-07
Breast B-Disease 1 1.0
Cancer I-Disease 1 0.9999980926513672
Linkage O 0 6.744061920471722e-06
Consortium O 0 2.023014928909106e-07
. O 0 2.2816250222490453e-08

Families O 0 1.7562117136549205e-05
were O 0 2.043157287801023e-08
included O 0 1.6987474760199461e-09
without O 0 4.2346828821315796e-10
regard O 0 5.258821711429107e-10
to O 0 4.917849460994717e-10
the O 0 1.608500416194758e-10
occurrence O 0 8.469552170708994e-09
of O 0 1.1412075728856053e-09
ovarian B-Disease 0 4.2487205064389855e-05
or I-Disease 0 4.143426934888339e-09
other I-Disease 0 1.3839970058882045e-08
cancers I-Disease 0 6.356309313559905e-05
. O 0 9.033386305645763e-08

Overall O 0 0.00037516915472224355
, O 0 1.8037580957752652e-06
disease O 0 1.3175493222661316e-05
was O 0 1.2794417614259146e-07
linked O 0 5.314345941087595e-08
to O 0 2.9766558107269248e-09
BRCA1 O 0 8.717881883057998e-08
in O 0 8.38804026237483e-10
an O 0 8.386520367054118e-10
estimated O 0 8.681786844988437e-09
52 O 0 1.5726532964777107e-08
% O 0 3.69111789744192e-11
of O 0 8.375849493147403e-12
families O 0 5.679789971679838e-10
, O 0 2.4654608909990827e-10
to O 0 4.281383692017471e-09
BRCA2 O 0 4.7007972625578986e-07
in O 0 5.110916689865519e-10
32 O 0 5.6735349751591e-09
% O 0 4.798961575347427e-11
of O 0 2.557386767632064e-11
families O 0 9.60652224435421e-10
, O 0 2.7510341227277024e-10
and O 0 6.001228403107461e-10
to O 0 1.0398326644178724e-09
neither O 0 3.104751788995941e-09
gene O 0 4.432259004261141e-10
in O 0 1.1392235765850245e-10
16 O 0 7.797142376197996e-10
% O 0 2.784299873992424e-11
( O 0 6.125214484925534e-12
95 O 0 1.3724509306811683e-09
% O 0 2.6302973687997167e-10
confidence O 0 2.9495561548742444e-09
interval O 0 2.189391778983918e-09
[ O 0 3.3122358189530132e-09
CI O 0 2.158555822973085e-08
] O 0 2.173933255633642e-09
6 O 0 1.166369001381895e-09
% O 0 1.8974759263823415e-10
- O 0 9.831866520926269e-08
28 O 0 4.164346592006041e-07
% O 0 9.6182325992622e-11
) O 0 2.941828031177707e-11
, O 0 1.520239212293717e-10
suggesting O 0 1.0512540171703222e-08
other O 0 7.408945124076638e-10
predisposition O 0 2.497625928299385e-06
genes O 0 8.068522561188729e-08
. O 0 3.9821742348067346e-08

The O 0 1.0343799061729442e-07
majority O 0 3.032959625670628e-07
( O 0 2.092957140931162e-09
81 O 0 1.092968915372694e-07
% O 0 2.807734322818334e-10
) O 0 3.2484157724832485e-11
of O 0 1.0452228665913665e-10
the O 0 4.889873821412039e-07
breast B-Disease 1 0.999998927116394
- I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
families O 0 3.455822650266782e-08
were O 0 4.279473220236696e-09
due O 0 1.9234172032867036e-09
to O 0 1.0174848519284296e-08
BRCA1 O 0 5.299415875015256e-07
, O 0 5.593098761913495e-10
with O 0 3.8105044120051446e-10
most O 0 2.1747708078834194e-09
others O 0 5.894245092008532e-09
( O 0 6.945495567567406e-11
14 O 0 2.0829056257554157e-09
% O 0 9.781947474252206e-11
) O 0 1.4904030787299405e-10
due O 0 1.754926870489726e-08
to O 0 9.585680800228147e-07
BRCA2 O 0 0.00043924414785578847
. O 0 1.304178880445761e-07

Conversely O 0 3.111775731667876e-05
, O 0 6.8390746399416e-09
the O 0 2.1639538771989208e-10
majority O 0 3.7105896133482474e-09
of O 0 5.3946500044865786e-11
families O 0 5.85503645567087e-10
with O 0 9.955991586707569e-10
male B-Disease 0 3.875249149132287e-06
and I-Disease 0 3.104827897004725e-07
female I-Disease 0 0.0070754000917077065
breast I-Disease 1 0.7296217083930969
cancer I-Disease 0 0.00013412898988462985
were O 0 3.339603793506285e-08
due O 0 1.507892299912328e-08
to O 0 6.122235873817772e-08
BRCA2 O 0 2.4629573090351187e-05
( O 0 1.9721608790490563e-09
76 O 0 7.596332238790637e-07
% O 0 1.2996805853759952e-09
) O 0 1.897769941194838e-09
. O 0 3.7865845570195233e-08

The O 0 3.834911765920879e-08
largest O 0 2.6963762778109412e-08
proportion O 0 1.4668446013388348e-08
( O 0 9.395091371544595e-10
67 O 0 1.1222864060300708e-07
% O 0 2.8755187120310666e-10
) O 0 3.131428102931544e-11
of O 0 8.922344113537761e-11
families O 0 3.955488825369002e-09
due O 0 2.779044772083239e-09
to O 0 1.2768978097099648e-09
other O 0 6.729545393158176e-11
genes O 0 3.34318239758602e-10
was O 0 4.128472497200164e-08
found O 0 4.170255252233801e-10
in O 0 1.0687164347933376e-10
families O 0 2.4527357922465853e-10
with O 0 4.975551221031438e-11
four O 0 2.4546079058218595e-10
or O 0 7.356754788689912e-11
five O 0 2.9613303476061503e-10
cases O 0 1.3182729352578804e-09
of O 0 6.12654094123144e-10
female O 0 0.07757799327373505
breast B-Disease 1 0.9917201995849609
cancer I-Disease 0 0.0001920508948387578
only O 0 1.9914661919528953e-08
. O 0 1.5717208867727095e-08

These O 0 3.0967873954068637e-07
estimates O 0 1.4270835890783928e-07
were O 0 6.327403045958135e-09
not O 0 2.027488399392041e-09
substantially O 0 8.182525590427758e-08
affected O 0 2.309541002887272e-09
either O 0 5.490130572383123e-10
by O 0 1.4347643906287288e-10
changing O 0 8.805173257186993e-10
the O 0 2.405277088612934e-10
assumed O 0 3.733294207108884e-08
penetrance O 0 4.1803094319448064e-08
model O 0 5.426129767727161e-09
for O 0 1.2355969025712454e-10
BRCA1 O 0 2.750386407512906e-08
or O 0 6.217997644553108e-11
by O 0 1.0368515074299367e-10
including O 0 2.6033153410764953e-10
or O 0 1.739542954126705e-09
excluding O 0 2.0483045659602794e-07
BRCA1 O 0 3.154715523123741e-05
mutation O 0 8.094231134236907e-07
data O 0 8.384800764815736e-08
. O 0 1.7352029146877612e-08

Among O 0 1.0549397302384023e-06
those O 0 8.279480212536328e-09
families O 0 2.384685782175211e-09
with O 0 5.25923526950578e-09
disease O 0 1.8818535636455636e-06
due O 0 5.19896801165487e-08
to O 0 4.367827699525151e-08
BRCA1 O 0 2.109354909407557e-06
that O 0 1.5921779450422946e-08
were O 0 9.386945443168315e-09
tested O 0 5.84997117414332e-09
by O 0 2.938597629120743e-11
one O 0 5.2172377529302594e-11
of O 0 2.2872543702784354e-12
the O 0 3.50659154491062e-11
standard O 0 3.6870966280133644e-09
screening O 0 1.5624780358436396e-09
methods O 0 1.2963629059115078e-09
, O 0 2.6189186930203334e-10
mutations O 0 4.980284185052142e-09
were O 0 1.3495425887910528e-09
detected O 0 5.014197501651552e-09
in O 0 7.926408834846299e-11
the O 0 4.9291723480671124e-11
coding O 0 1.4359888833581635e-09
sequence O 0 7.741612212397442e-11
or O 0 1.6916905376529456e-11
splice O 0 3.220558708605381e-09
sites O 0 3.5167876943908993e-10
in O 0 3.541678755825117e-11
an O 0 2.1397712768322918e-10
estimated O 0 3.135507409268712e-09
63 O 0 1.5869451530647893e-08
% O 0 7.661466600028533e-11
( O 0 3.013475927127196e-11
95 O 0 7.74122188573756e-09
% O 0 7.866364226671863e-10
CI O 0 1.8800459145040804e-07
51 O 0 6.600979531867779e-07
% O 0 7.090244502627741e-10
- O 0 4.002460798346874e-07
77 O 0 4.6866031766512606e-07
% O 0 9.250774035685083e-10
) O 0 8.915748139770585e-10
. O 0 1.5060988900472694e-08

The O 0 9.190880234655197e-08
estimated O 0 8.292569475543132e-08
sensitivity O 0 3.1766930419507844e-07
was O 0 6.317287670754013e-08
identical O 0 6.110520978097611e-09
for O 0 8.97648899655934e-11
direct O 0 6.144399433694048e-10
sequencing O 0 2.795669251653976e-09
and O 0 4.370606654369169e-10
other O 0 4.065064604374946e-11
techniques O 0 1.6609103425935245e-08
. O 0 2.334160242867256e-08

The O 0 8.033970999576923e-08
penetrance O 0 1.8968698896060232e-06
of O 0 1.901708790441603e-09
BRCA2 O 0 1.3506604545909795e-06
was O 0 1.243217724322676e-07
estimated O 0 1.4405923121074693e-09
by O 0 5.52258065666944e-11
maximizing O 0 4.1408991791058725e-09
the O 0 1.2696509399390266e-09
LOD O 0 0.00011206929775653407
score O 0 1.051294447051987e-07
in O 0 3.4088949441013483e-09
BRCA2 O 0 5.86438545724377e-06
- O 0 2.6703746698331088e-06
mutation O 0 8.026087812140759e-07
families O 0 3.476016585679531e-09
, O 0 8.37042379853159e-11
over O 0 5.681393688838909e-10
all O 0 2.263275539204912e-10
possible O 0 2.3185755537724617e-09
penetrance O 0 2.5587110030755866e-07
functions O 0 5.338461228632241e-09
. O 0 9.481685658840888e-09

The O 0 8.431500475580833e-08
estimated O 0 2.861640879814331e-08
cumulative O 0 2.1855838028272956e-08
risk O 0 1.2105630275982548e-08
of O 0 9.33197630281768e-10
breast B-Disease 0 0.20101159811019897
cancer I-Disease 0 6.620703061344102e-05
reached O 0 1.2432527896066858e-08
28 O 0 1.6765957511211127e-08
% O 0 1.9973031561981713e-10
( O 0 5.575903974652796e-11
95 O 0 1.1680615585873966e-08
% O 0 7.230169796201835e-10
CI O 0 7.609661167862214e-08
9 O 0 5.550083503891301e-09
% O 0 4.994246682876735e-10
- O 0 1.7630199522500334e-07
44 O 0 4.3882028677444396e-08
% O 0 5.7978902928690346e-11
) O 0 1.3733058093490236e-11
by O 0 1.5781656537150468e-10
age O 0 1.403248739428875e-09
50 O 0 2.7240706912401436e-10
years O 0 2.622682904185325e-10
and O 0 4.746429915769568e-10
84 O 0 6.514946804259125e-09
% O 0 5.5764146772441237e-11
( O 0 1.9107855922517736e-11
95 O 0 1.6811418923623478e-09
% O 0 2.0656390486983867e-10
CI O 0 3.867673825652673e-08
43 O 0 3.02642888527771e-08
% O 0 1.406978700213557e-10
- O 0 2.135239896006169e-08
95 O 0 1.8160159598323844e-08
% O 0 1.8971646476018122e-10
) O 0 1.9696477088215758e-11
by O 0 2.817820143885541e-10
age O 0 4.902380279503404e-09
70 O 0 3.074614784992491e-09
years O 0 5.633464361665119e-09
. O 0 1.2318942310685088e-08

The O 0 6.875410463180742e-07
corresponding O 0 0.00022972127771936357
ovarian B-Disease 1 0.9999998807907104
cancer I-Disease 1 0.9999996423721313
risks O 0 0.00015401258133351803
were O 0 5.960373172797517e-08
0 O 0 1.7185472245273559e-07
. O 0 5.6622727839794607e-08

4 O 0 1.629191501706373e-06
% O 0 2.1329766397570893e-08
( O 0 5.093875876660547e-10
95 O 0 1.7817200159697677e-08
% O 0 1.2569958407482318e-09
CI O 0 1.343149733656901e-07
0 O 0 3.068804232952971e-08
% O 0 4.175587930976832e-10
- O 0 2.7652196976646337e-08
1 O 0 4.738029080186834e-09
% O 0 9.66820651315814e-11
) O 0 1.5476463860464307e-11
by O 0 2.464214943209697e-10
age O 0 1.8541229662716319e-09
50 O 0 1.492599238650527e-10
years O 0 2.777512109197744e-10
and O 0 4.2294687196964276e-10
27 O 0 2.360304396376023e-09
% O 0 2.407947626015261e-11
( O 0 1.1880528678898106e-11
95 O 0 2.4810717924594883e-09
% O 0 3.819927985038163e-10
CI O 0 4.892649485555012e-08
0 O 0 2.102645169088646e-08
% O 0 7.371858679050547e-10
- O 0 2.787570281270746e-07
47 O 0 1.0414547659820528e-06
% O 0 1.5681349274654366e-10
) O 0 1.9977250756419984e-11
by O 0 5.710694694904817e-10
age O 0 5.42684430726581e-09
70 O 0 2.3952022587536703e-09
years O 0 1.8683727898149982e-09
. O 0 6.3538392325313e-09

The O 0 1.6417081383224286e-07
lifetime O 0 9.37826655444951e-07
risk O 0 2.393528006905399e-07
of O 0 9.17367781738676e-09
breast B-Disease 1 0.5353550314903259
cancer I-Disease 0 0.0001226619497174397
appears O 0 3.141417721508333e-07
similar O 0 1.530746751576828e-09
to O 0 9.455746186048941e-10
the O 0 4.104567519203073e-10
risk O 0 8.250316874125474e-09
in O 0 4.735091208019071e-10
BRCA1 O 0 1.9676649287703185e-07
carriers O 0 1.3707850854416392e-08
, O 0 1.6605476715891854e-10
but O 0 5.186898688336328e-10
there O 0 4.289219812658729e-10
was O 0 1.903556778870552e-08
some O 0 5.84104639655969e-11
suggestion O 0 1.066656096782026e-09
of O 0 1.3767282452947782e-11
a O 0 5.039692219099834e-09
lower O 0 8.209178758988855e-08
risk O 0 1.1009484879309639e-08
in O 0 4.98665053694225e-10
BRCA2 O 0 9.046660238709592e-07
carriers O 0 2.435554868895906e-08
< O 0 5.596174634803219e-09
50 O 0 8.156246789070565e-10
years O 0 5.205967879007289e-10
of O 0 1.3283152355825223e-10
age O 0 1.0449528353717596e-08
. O 0 8.76014905060174e-09

Eye B-Disease 1 0.998198926448822
movement I-Disease 0 0.00015909837384242564
abnormalities I-Disease 1 0.878117024898529
correlate O 0 5.401388534664875e-06
with O 0 3.9866886680783864e-08
genotype O 0 0.0016370806843042374
in O 0 6.627561077721111e-08
autosomal O 1 0.9977859258651733
dominant O 1 0.957146406173706
cerebellar B-Disease 1 0.9997374415397644
ataxia I-Disease 1 0.9999926090240479
type I-Disease 1 0.7419804930686951
I I-Disease 0 0.00024282714002765715
. O 0 9.213961504883628e-08

We O 0 1.0322351045033429e-06
compared O 0 3.840738997951121e-07
horizontal O 0 5.224698907113634e-05
eye O 0 0.19413505494594574
movements O 0 1.2563154996314552e-06
( O 0 4.354516303095579e-09
visually O 0 1.0552596449997509e-06
guided O 0 6.858089705019665e-07
saccades O 0 1.9068265828536823e-05
, O 0 2.5661208713501082e-09
antisaccades O 0 1.303169341326793e-07
, O 0 3.726261521563856e-10
and O 0 2.4041810209318726e-10
smooth O 0 4.0749920771077086e-08
pursuit O 0 1.6959932125359956e-08
) O 0 2.2718736614191215e-10
in O 0 2.642597529689539e-10
control O 0 1.3040644830653036e-07
subjects O 0 2.3091761391924592e-08
( O 0 2.333419013567095e-10
n O 0 4.409160325735684e-08
= O 0 1.9261239714296607e-08
14 O 0 1.4078599397393532e-09
) O 0 1.5990726798253974e-10
and O 0 3.3676332833465494e-08
patients O 0 1.4989907413109904e-06
with O 0 8.137021612064643e-11
three O 0 1.1821582601712066e-10
forms O 0 1.493476314839981e-10
of O 0 1.4494330735637106e-10
autosomal O 0 0.0018926006741821766
dominant O 0 2.333321208425332e-05
cerebellar B-Disease 0 4.6802448196103796e-05
ataxias I-Disease 0 5.357025293051265e-05
type I-Disease 0 4.830034413316753e-06
I I-Disease 0 2.153404921045876e-06
spinocerebellar B-Disease 0 0.00010791250679176301
ataxias I-Disease 0 2.069318497888162e-06
1 I-Disease 0 3.110091961744388e-09
and I-Disease 0 2.6589295210044384e-09
2 I-Disease 0 2.361583373300391e-09
( O 0 4.1013434315395614e-10
SCA1 B-Disease 0 6.2849794630892575e-06
, O 0 8.334296031087263e-10
n O 0 1.3135024623522895e-08
= O 0 7.120524614379065e-09
11 O 0 4.4406869847968267e-10
; O 0 1.9264599637747182e-10
SCA2 B-Disease 0 8.97360564522387e-07
, O 0 6.415822317862308e-10
n O 0 5.897585086955814e-09
= O 0 7.3418475743380895e-09
10 O 0 5.425485616328274e-10
) O 0 1.4443662932350776e-10
and O 0 1.1021964674284845e-08
SCA3 B-Disease 1 0.9999992847442627
/ O 0 1.1230351901758695e-06
Machado B-Disease 0 4.1992893784481566e-07
- I-Disease 0 2.1489191567525268e-05
Joseph I-Disease 0 6.829119229223579e-05
disease I-Disease 0 5.29440194441122e-06
( O 0 4.850314372362163e-09
MJD B-Disease 1 0.9999914169311523
) O 0 5.2580220177844694e-09
( O 0 1.1306345859551925e-09
n O 0 1.2847090147261042e-07
= O 0 5.526561608348857e-08
16 O 0 6.826224918654589e-09
) O 0 1.989289843962183e-09
. O 0 1.1265989030562196e-08

In O 0 3.361890037467674e-07
SCA1 B-Disease 0 3.3184394396812422e-06
, O 0 2.45017472977338e-09
saccade O 0 2.0161024849585374e-07
amplitude O 0 3.413467766222311e-07
was O 0 2.174552804490304e-07
significantly O 0 8.526676253950427e-08
increased O 0 8.925638006473946e-09
, O 0 3.645668211760267e-10
resulting O 0 4.335422243428866e-09
in O 0 3.400342452053451e-09
hypermetria B-Disease 0 2.8008886147290468e-05
. O 0 7.120744527355782e-08

The O 0 7.079656683117719e-08
smooth O 0 6.349541195049824e-07
pursuit O 0 4.7165633532131324e-07
gain O 0 1.4515740076603834e-06
was O 0 2.1001776531193173e-06
decreased O 0 5.413396593212383e-07
. O 0 4.265117325985557e-08

In O 0 7.002936399658211e-07
SCA2 B-Disease 0 1.5257245649991091e-05
, O 0 7.079342889682039e-09
saccade O 0 6.144996973489469e-07
velocity O 0 4.895706524621346e-07
was O 0 6.025825882716163e-07
markedly O 0 1.3757490705756936e-05
decreased O 0 7.226929028547602e-07
. O 0 2.3305032570419826e-08

The O 0 2.747146155002156e-08
percentage O 0 3.329497388904201e-08
of O 0 1.1391887433376269e-10
errors O 0 5.060961427716393e-09
in O 0 9.271830525570124e-10
antisaccades O 0 3.354426098667318e-06
was O 0 4.016999639588903e-07
greatly O 0 3.130429604425444e-08
increased O 0 1.0031154573653112e-08
and O 0 2.3056896392148474e-09
was O 0 2.165308643498065e-07
significantly O 0 3.6099400801958836e-08
correlated O 0 2.2507419927819683e-08
with O 0 1.311959318961442e-09
age O 0 9.92849980008259e-09
at O 0 3.420272731702312e-09
disease O 0 2.0675747691711877e-06
onset O 0 4.517339220910799e-06
. O 0 3.3017295208992437e-07

In O 0 1.0017583207400094e-07
addition O 0 2.3740209798006617e-09
, O 0 2.738866633489323e-10
a O 0 3.5617803151311023e-10
correlation O 0 6.146430031606087e-09
between O 0 3.796481184981104e-10
smooth O 0 3.886179058554262e-07
pursuit O 0 7.817924085884442e-08
gain O 0 2.17351612263883e-07
and O 0 5.585188422863041e-10
the O 0 2.185567872514671e-11
number O 0 1.602021709734558e-10
of O 0 1.0803266614622942e-10
trinucleotide O 0 3.7420917919916974e-07
repeats O 0 7.517362377029713e-08
was O 0 3.947998550302145e-08
found O 0 6.944389507879123e-09
. O 0 8.704867937581184e-09

In O 0 4.8587057790427934e-06
SCA3 B-Disease 1 0.9999189376831055
, O 0 1.6202096730921767e-07
gaze B-Disease 0 2.9756050935247913e-05
- I-Disease 0 7.516478945035487e-05
evoked I-Disease 0 0.0002691595000214875
nystagmus I-Disease 0 0.00048817164497449994
was O 0 4.2575751990625577e-07
often O 0 4.0630383502104905e-09
present O 0 4.6421158583775934e-10
as O 0 4.5780940149953153e-10
was O 0 1.7854144829243523e-08
saccade O 0 1.5473511894015246e-07
hypometria O 0 3.0240522619351395e-07
and O 0 7.091313092288942e-10
smooth O 0 4.8486523240853785e-08
pursuit O 0 4.790975793866892e-08
gain O 0 1.494752268627053e-07
was O 0 8.317421702486172e-07
markedly O 0 2.0610976207535714e-05
decreased O 0 7.875767664700106e-07
. O 0 2.762473272355237e-08

Three O 0 1.3439390045277833e-07
major O 0 4.123040575620962e-09
criteria O 0 4.367992190168479e-09
, O 0 3.653157776284388e-10
saccade O 0 1.2612959210400732e-07
amplitude O 0 6.98149875688614e-08
, O 0 3.414183380456848e-10
saccade O 0 4.810112130826383e-08
velocity O 0 5.3294193946840096e-08
, O 0 2.9913041488249803e-10
and O 0 1.4685563876071228e-10
presence O 0 3.753052590926842e-10
of O 0 8.540889523400708e-11
gaze B-Disease 0 1.710074138827622e-05
- I-Disease 0 1.60859854076989e-05
evoked I-Disease 0 5.5635322496527806e-05
nystagmus I-Disease 0 7.495516456401674e-06
, O 0 3.0782512649984994e-10
permitted O 0 1.6104037547925998e-10
the O 0 1.5666960784255224e-11
correct O 0 1.5334380432108219e-09
assignment O 0 5.397617353075645e-10
of O 0 1.141193216314118e-11
90 O 0 2.2716137304534811e-10
% O 0 2.0706320338903517e-11
of O 0 5.4225625725767834e-12
the O 0 1.257311754709889e-10
SCA1 B-Disease 0 4.022982466267422e-06
, O 0 3.10392128666237e-10
90 O 0 8.588577626866822e-10
% O 0 3.604856690930802e-11
of O 0 3.673599185266552e-12
the O 0 2.411800481549875e-10
SCA2 B-Disease 0 6.632627446379047e-06
, O 0 6.78526623776321e-10
and O 0 2.6559679455750995e-10
93 O 0 2.420825540028204e-09
% O 0 2.2110565114918934e-11
of O 0 6.741027007428624e-12
the O 0 1.7208350300279562e-09
patients O 0 1.449276169296354e-05
with O 0 5.8159717042371994e-09
SCA3 B-Disease 1 0.9999994039535522
to O 0 3.5369048134725745e-08
their O 0 4.723751945157062e-10
genetically O 0 3.956192173859563e-08
confirmed O 0 6.291248837442254e-07
patient O 0 7.69941891576309e-07
group O 0 2.4148305577398332e-09
and O 0 4.0893613495462944e-10
, O 0 2.409170640760294e-10
therefore O 0 1.2508111213449524e-09
, O 0 2.160023965247504e-10
may O 0 7.260617884696785e-09
help O 0 2.7764222032544694e-09
orient O 0 9.754738812262076e-07
diagnoses O 0 4.9230537115363404e-05
of O 0 3.854649377466046e-10
SCA1 B-Disease 0 8.869172233971767e-06
, O 0 2.5472295384076915e-09
SCA2 B-Disease 0 2.514604375392082e-06
, O 0 6.058525903185341e-10
and O 0 1.3274497057125245e-09
SCA3 B-Disease 1 0.999990701675415
at O 0 7.429407644643504e-10
early O 0 3.132554216023209e-09
clinical O 0 1.8440371007955036e-08
stages O 0 3.490260302996262e-09
of O 0 6.098079680105783e-11
the O 0 1.5343508685816687e-09
diseases O 0 1.900272650345869e-07
. O 0 2.7311941597218947e-09
. O 0 1.751656242277022e-08

Genetic O 0 1.6891264749574475e-05
basis O 0 6.031159927033514e-08
and O 0 1.0223534241404764e-09
molecular O 0 1.7880761760125097e-08
mechanism O 0 1.1508745245691898e-07
for O 0 1.6295939531119075e-06
idiopathic B-Disease 1 1.0
ventricular I-Disease 1 0.9999996423721313
fibrillation I-Disease 1 1.0
. O 0 7.397402077913284e-05

Ventricular B-Disease 1 0.9990172386169434
fibrillation I-Disease 1 0.9998252987861633
causes O 0 0.00014834821922704577
more O 0 2.5796026648094994e-08
than O 0 8.165746301358467e-09
300 O 0 1.7535543017643818e-09
, O 0 6.7134725556528e-10
000 O 0 2.923656650111184e-09
sudden O 0 2.0793387989215262e-07
deaths O 0 8.498244596921722e-07
each O 0 2.6129712282774165e-10
year O 0 2.362771367447891e-10
in O 0 1.5167289646456084e-10
the O 0 1.332091215111575e-09
USA O 0 2.3745616317683016e-07
alone O 0 1.1373145980542176e-07
. O 0 1.6440480976598337e-08

In O 0 1.7785427530725428e-07
approximately O 0 1.1950227474244457e-08
5 O 0 3.892671962546501e-09
- O 0 2.0300593916999787e-07
12 O 0 1.4474620613214029e-08
% O 0 6.892891118992495e-11
of O 0 4.3636721840101256e-12
these O 0 1.2176618047199383e-10
cases O 0 2.2211610328781717e-09
, O 0 4.426446431615716e-10
there O 0 3.39662020731879e-10
are O 0 6.120242507234863e-11
no O 0 1.863774246047001e-09
demonstrable O 0 1.5885849279584363e-05
cardiac O 0 0.0029163346625864506
or O 0 3.679509141818471e-09
non O 0 1.4980255258478792e-08
- O 0 0.011640303768217564
cardiac O 1 0.9974263310432434
causes O 0 1.3596425105788512e-06
to O 0 4.172612033670475e-09
account O 0 1.9941903683928786e-09
for O 0 6.472716113092858e-11
the O 0 4.598491379348424e-11
episode O 0 1.4907541867614782e-08
, O 0 1.0540798095481918e-10
which O 0 3.493668687681861e-10
is O 0 8.396203177163386e-10
therefore O 0 4.232149741767444e-09
classified O 0 3.5797707909068777e-08
as O 0 2.1333871700335294e-06
idiopathic B-Disease 1 1.0
ventricular I-Disease 1 0.9999997615814209
fibrillation I-Disease 1 1.0
( O 0 1.329418591922149e-05
IVF B-Disease 1 0.999998927116394
) O 0 8.817028884777756e-08
. O 0 5.877262765352498e-08

A O 0 8.638462531962432e-07
distinct O 0 1.1716779368953212e-07
group O 0 6.52211014084969e-08
of O 0 3.472670151438706e-09
IVF B-Disease 1 0.9999997615814209
patients O 1 0.9939194917678833
has O 0 1.746229685295475e-07
been O 0 4.837601430551786e-09
found O 0 8.250186089853173e-10
to O 0 5.532599378632597e-10
present O 0 2.6861071700245986e-10
with O 0 1.585001296877664e-10
a O 0 5.84825299299041e-09
characteristic O 0 2.412213007119135e-07
electrocardiographic O 0 4.147185245528817e-05
pattern O 0 4.405232175486162e-06
. O 0 4.1270553197136906e-08

Because O 0 6.017693863213935e-07
of O 0 2.4920354668722666e-10
the O 0 6.604673058463462e-11
small O 0 8.645787558103635e-11
size O 0 8.474719259687902e-10
of O 0 5.297497510103888e-11
most O 0 1.0105949410643689e-09
pedigrees O 0 5.938245806191844e-08
and O 0 1.386746939502359e-09
the O 0 2.170667257050951e-10
high O 0 2.0957465096671513e-08
incidence O 0 2.5346625989186577e-06
of O 0 3.215487320851196e-10
sudden B-Disease 0 3.4606819099280983e-06
death I-Disease 0 0.0003993455902673304
, O 0 5.021717486286548e-10
however O 0 1.1173068026337774e-09
, O 0 4.9672731206040766e-11
molecular O 0 7.855013861579607e-10
genetic O 0 2.882939442727661e-09
studies O 0 1.904560814613987e-10
of O 0 1.95062646590749e-10
IVF B-Disease 1 0.9999794960021973
have O 0 9.037884041163124e-08
not O 0 1.276515448900284e-09
yet O 0 2.16875650771442e-09
been O 0 2.983926217225985e-09
done O 0 1.0878584255635815e-08
. O 0 7.656859146720763e-09

Because O 0 6.553383718710393e-05
IVF B-Disease 1 0.9999220371246338
causes O 0 0.0006928096408955753
cardiac O 1 0.5351904630661011
rhythm O 0 0.0019385205814614892
disturbance O 0 1.672836151556112e-05
, O 0 2.5084321286783506e-09
we O 0 5.45638034754603e-10
investigated O 0 1.0343794265565975e-08
whether O 0 1.3333163462192488e-09
malfunction O 0 2.9246297117424547e-07
of O 0 1.733302390505287e-10
ion O 0 1.486422149810096e-07
channels O 0 5.3879126937772526e-08
could O 0 7.306827853881259e-08
cause O 0 4.701590583522375e-08
the O 0 2.7431759086482543e-09
disorder O 0 2.9814738809363917e-05
by O 0 2.739242721538915e-10
studying O 0 9.477884033159967e-10
mutations O 0 1.4188321628694212e-08
in O 0 2.3244105251674085e-10
the O 0 1.1271464872564252e-09
cardiac O 0 0.0001366716023767367
sodium O 0 0.00011545512825250626
channel O 0 1.8909584014181746e-06
gene O 0 2.0508868203705788e-07
SCN5A O 0 9.57171869231388e-06
. O 0 5.2590877430702676e-08

We O 0 9.09066386611812e-07
have O 0 2.272977006612109e-08
now O 0 2.546117094937017e-09
identified O 0 3.511950064094549e-09
a O 0 3.9291783160422256e-09
missense O 0 5.300889370118966e-06
mutation O 0 1.1076996742076517e-07
, O 0 1.9790667715735566e-10
a O 0 7.873764418242502e-10
splice O 0 1.043987481352815e-06
- O 0 4.510266535362462e-06
donor O 0 5.989295459585264e-08
mutation O 0 7.181049568316666e-07
, O 0 2.865603032642383e-10
and O 0 3.592160735532701e-10
a O 0 1.5098926553491765e-08
frameshift O 0 0.0004741211305372417
mutation O 0 1.2972373042430263e-07
in O 0 1.8857106154346326e-10
the O 0 7.835976312264847e-11
coding O 0 1.8501744136756315e-08
region O 0 2.7357562881746844e-09
of O 0 9.763904268433876e-11
SCN5A O 0 2.416510369585012e-06
in O 0 1.7817939346187472e-09
three O 0 1.0050861476429418e-08
IVF B-Disease 1 0.9998983144760132
families O 0 6.506702732167469e-08
. O 0 1.645365621527617e-08

We O 0 1.4397556924450328e-07
show O 0 1.9386479976901683e-08
that O 0 3.6456124230532794e-10
sodium O 0 1.5812526399372473e-08
channels O 0 8.375378723890492e-10
with O 0 4.355873994832393e-11
the O 0 1.1779538455769512e-10
missense O 0 3.3563031820449396e-07
mutation O 0 2.2638865004864783e-08
recover O 0 2.1901241709088026e-08
from O 0 1.478562133838679e-10
inactivation O 0 2.498466358247242e-07
more O 0 5.686706106011741e-10
rapidly O 0 1.0687435381129262e-09
than O 0 5.572610706217063e-10
normal O 0 4.803964448463205e-10
and O 0 2.985501845742533e-10
that O 0 2.383156727514546e-10
the O 0 3.7703296040803025e-10
frameshift O 0 3.9331967855105177e-05
mutation O 0 2.8671806262536847e-08
causes O 0 2.3969068951856798e-09
the O 0 9.152137381285286e-11
sodium O 0 2.280742421589821e-07
channel O 0 4.0162714043390224e-08
to O 0 7.838820703653937e-10
be O 0 1.6276201497689158e-09
non O 0 2.6224040716726904e-09
- O 0 1.0873937981159543e-06
functional O 0 1.498540427746775e-06
. O 0 6.98701398960111e-08

Our O 0 4.6454064772660786e-07
results O 0 3.580877105946456e-08
indicate O 0 5.3275566180843725e-09
that O 0 4.229565586655326e-10
mutations O 0 1.1573546565557535e-08
in O 0 6.90592250052191e-10
cardiac O 0 1.8433289596941904e-06
ion O 0 7.747464678686811e-07
- O 0 9.456148859499081e-07
channel O 0 8.294910713857462e-08
genes O 0 6.233129012933603e-10
contribute O 0 3.2224251045320784e-10
to O 0 2.538183274669592e-10
the O 0 3.745315169112473e-10
risk O 0 7.245690714086095e-09
of O 0 3.2082583811821053e-10
developing O 0 1.6116221246420537e-08
IVF B-Disease 1 0.9998025298118591
. O 0 1.0608417255753011e-08
. O 0 7.541715696390838e-09

Molecular O 0 9.682033123681322e-06
heterogeneity O 0 1.3912383110437077e-05
in O 0 2.7058764118237377e-08
mucopolysaccharidosis B-Disease 0 4.74358375868178e-06
IVA I-Disease 0 2.7924050300498493e-05
in O 0 3.8138892932693125e-08
Australia O 0 3.964561656744081e-08
and O 0 5.088538035380452e-09
Northern O 0 3.856800745438704e-08
Ireland O 0 3.4511653979052426e-08
: O 0 2.0129528599532875e-10
nine O 0 9.126864819464231e-10
novel O 0 3.2106228786688007e-09
mutations O 0 5.73730396524752e-09
including O 0 6.728262391675344e-11
T312S O 0 1.4219478039478872e-08
, O 0 6.063471252870656e-11
a O 0 2.4921401053923375e-10
common O 0 7.147707981047802e-10
allele O 0 3.899309675148288e-08
that O 0 1.4054398755902753e-09
confers O 0 1.9815830398783874e-07
a O 0 5.492481705005048e-07
mild O 1 0.9917540550231934
phenotype O 1 0.998818576335907
. O 0 3.2773667157925956e-07

Mucopolysaccharidosis B-Disease 0 0.014163227751851082
IVA I-Disease 1 0.9443817734718323
( O 0 0.0006643092492595315
MPS B-Disease 1 0.9999997615814209
IVA I-Disease 1 0.9999959468841553
) O 0 1.2968509821575935e-08
is O 0 1.398947002684281e-08
an O 0 3.8959640846769616e-08
autosomal B-Disease 1 0.9997079968452454
recessive I-Disease 1 0.9998898506164551
lysosomal I-Disease 1 0.999601423740387
storage I-Disease 1 0.9964460730552673
disorder I-Disease 1 0.9996104836463928
caused O 0 2.495473381713964e-06
by O 0 3.893726230330685e-09
a O 0 1.4322239394459757e-06
genetic B-Disease 1 0.9999971389770508
defect I-Disease 1 0.9999985694885254
in O 0 2.073385729772781e-08
N O 0 1.6799186823845957e-06
- O 0 1.2493555004766677e-05
acetylgalactosamine O 0 0.00030585675267502666
- O 0 0.00010749061038950458
6 O 0 1.6321853024692246e-07
- O 0 0.0009675213368609548
sulfate O 0 0.002012896118685603
sulfatase O 0 1.9476918168948032e-05
( O 0 5.423709037444269e-09
GALNS O 0 2.396886429778533e-06
) O 0 7.3987385107443515e-09
. O 0 1.5144323128879478e-08

Previous O 0 4.269569728876377e-07
studies O 0 6.327403045958135e-09
of O 0 4.5709658280657095e-10
patients O 0 8.690886943441001e-08
from O 0 1.0127054056452423e-10
a O 0 6.134717622785502e-09
British O 0 6.710419256705791e-06
- O 0 5.325880010786932e-06
Irish O 0 9.343111742055044e-07
population O 0 6.778656524986104e-10
showed O 0 5.1913744414378016e-09
that O 0 4.662896457841015e-11
the O 0 2.5076402759838246e-11
I113F O 0 6.22308533593241e-08
mutation O 0 1.4745813459171586e-08
is O 0 1.2500329937825683e-10
the O 0 1.1910908891132888e-11
most O 0 7.18880302508218e-11
common O 0 7.526045758821098e-11
single O 0 1.27849224540455e-08
mutation O 0 3.8238542288127064e-07
among O 0 8.449773503116376e-08
MPS B-Disease 1 0.9999995231628418
IVA I-Disease 1 1.0
patients O 1 0.9998677968978882
and O 0 1.89588593713097e-08
produces O 0 7.441909133376612e-08
a O 0 2.425611285161722e-07
severe O 1 0.9846345782279968
clinical O 0 0.11950645595788956
phenotype O 1 0.9346877932548523
. O 0 1.9012115615169023e-07

We O 0 2.4427851030850434e-07
studied O 0 5.583809326026312e-08
mutations O 0 1.0187649479576066e-07
in O 0 6.034491795148256e-10
the O 0 2.9985589011793934e-10
GALNS O 0 6.862020995868079e-07
gene O 0 1.8028735837560816e-08
from O 0 6.147564124425742e-10
23 O 0 1.4859424801727528e-08
additional O 0 1.5602579139795125e-07
MPS B-Disease 1 0.9999988079071045
IVA I-Disease 1 0.9999996423721313
patients O 1 0.9955371618270874
( O 0 4.941166920069406e-10
15 O 0 7.927954959185968e-10
from O 0 2.748055394352633e-10
Australia O 0 2.623069317309046e-09
, O 0 1.2800892290609767e-10
8 O 0 5.106969847012977e-10
from O 0 2.2895350892948585e-10
Northern O 0 1.1097673890958504e-08
Ireland O 0 1.0784377835193482e-08
) O 0 3.1248885423718065e-11
, O 0 2.7125175369735466e-11
with O 0 1.8754615915828055e-11
various O 0 1.2930828630075553e-10
clinical O 0 2.0441481751731772e-07
phenotypes O 0 2.6591189907776425e-06
( O 0 5.563488003623718e-10
severe O 0 0.019194351509213448
, O 0 2.630831907879383e-08
16 O 0 7.717500416504208e-09
cases O 0 2.4050549995990878e-08
; O 0 1.056427278989247e-09
intermediate O 0 1.5401278474769242e-08
, O 0 1.8395562850770375e-10
4 O 0 1.2004317540004195e-09
cases O 0 3.3939489441081605e-08
; O 0 4.375398532374675e-08
mild O 1 0.923319935798645
, O 0 5.4590504561247144e-08
3 O 0 1.3132769538515277e-08
cases O 0 7.858948691819023e-08
) O 0 1.0424464846892079e-08
. O 0 4.5829999351099104e-08

We O 0 3.4473276855351287e-07
found O 0 8.473365120664766e-09
two O 0 2.027556872397085e-10
common O 0 2.1108283176918263e-10
mutations O 0 3.336431797507089e-09
that O 0 1.7795515061536094e-10
together O 0 2.168424328985452e-10
accounted O 0 1.1895483487123215e-09
for O 0 9.788442972835654e-11
32 O 0 1.6367509569903405e-09
% O 0 2.3807612131721e-11
of O 0 3.661511198405076e-12
the O 0 1.1542495431671185e-10
44 O 0 5.972683236876719e-09
unrelated O 0 5.142336778618528e-09
alleles O 0 1.458725673586514e-08
in O 0 1.287998041554772e-09
these O 0 6.423000353805719e-09
patients O 0 3.2796908726595575e-06
. O 0 2.7120664825019958e-08

One O 0 4.0933929312814143e-07
is O 0 3.782691937459504e-09
the O 0 4.774295403464635e-10
T312S O 0 3.126730234725983e-07
mutation O 0 7.141268554278213e-08
, O 0 2.1285934126424877e-10
a O 0 1.939249871796278e-09
novel O 0 4.1724870669668235e-08
mutation O 0 4.812681808630259e-08
found O 0 9.491198937894296e-10
exclusively O 0 3.275883120323897e-09
in O 0 4.246105245186982e-09
milder O 1 0.8537133932113647
patients O 0 0.2288503795862198
. O 0 1.2578028929510765e-07

The O 0 3.6943561099178623e-08
other O 0 6.616162617767429e-10
is O 0 2.411542909808162e-10
the O 0 9.080464852262438e-11
previously O 0 1.8868457019038942e-08
described O 0 1.5284980392493708e-08
I113F O 0 3.360344535963122e-08
that O 0 3.4870908938167133e-10
produces O 0 7.987639882856001e-09
a O 0 5.976719563705046e-08
severe O 1 0.9317090511322021
phenotype O 1 0.9739079475402832
. O 0 1.8715591920681618e-07

The O 0 4.856028112953936e-08
I113F O 0 6.673034249615739e-07
and O 0 2.862168946293764e-09
T312S O 0 1.1289331780517387e-07
mutations O 0 5.86002464331159e-08
accounted O 0 4.159699251715665e-09
for O 0 2.3201891796720275e-10
8 O 0 1.221029943820895e-09
( O 0 1.505023328185473e-10
18 O 0 3.9460164025229005e-09
% O 0 7.838458354614275e-11
) O 0 4.83634174375247e-11
and O 0 3.4620026845288976e-09
6 O 0 2.5863606811782347e-09
( O 0 1.462167192878283e-10
14 O 0 1.1471215088931785e-09
% O 0 3.650251975684249e-11
) O 0 1.3429626334604539e-11
of O 0 2.0044540680053125e-11
44 O 0 2.3806321358676996e-09
unrelated O 0 5.386409984708962e-09
alleles O 0 1.9166943587833885e-08
, O 0 1.557473261470932e-09
respectively O 0 3.147960825344853e-08
. O 0 2.1297083208082768e-08

The O 0 1.9313041832447198e-07
relatively O 0 2.481147021171637e-07
high O 0 1.3512226004763761e-08
residual O 0 2.5753558929864084e-07
GALNS O 0 2.1199689399509225e-06
activity O 0 1.0472033906694378e-08
seen O 0 1.185813403026259e-08
when O 0 2.5204974218873133e-10
the O 0 3.128013473241431e-11
T312S O 0 1.4823247518336302e-08
mutant O 0 4.128029029715208e-09
cDNA O 0 4.678722742568198e-09
is O 0 4.999498037783212e-10
overexpressed O 0 4.457799462898038e-08
in O 0 1.1453894777080365e-10
mutant O 0 1.469891763861142e-08
cells O 0 2.8742808133586095e-09
provides O 0 6.023935239518607e-10
an O 0 1.1660658549850211e-10
explanation O 0 4.020346278110765e-09
for O 0 4.439247303089644e-10
the O 0 3.93396248909994e-09
mild O 1 0.9986885190010071
phenotype O 1 0.9997727274894714
in O 0 6.476615510564443e-08
patients O 0 7.424989689752692e-06
with O 0 1.425384116293671e-10
this O 0 9.4058127952934e-10
mutation O 0 5.220521188675775e-07
. O 0 2.167500134930833e-08

The O 0 1.4672474790700107e-08
distribution O 0 1.7254923045939563e-09
and O 0 2.826573142211686e-10
relative O 0 2.010321908940682e-09
frequencies O 0 3.018011618394212e-09
of O 0 3.0954596524912503e-11
the O 0 9.361564301535452e-11
I113F O 0 4.477526971413681e-08
and O 0 8.102999382586518e-10
T312S O 0 3.225460076805575e-08
mutations O 0 6.819119491296988e-09
in O 0 2.3190344089485393e-10
Australia O 0 7.412478408852508e-10
corresponded O 0 6.395861174013362e-09
to O 0 4.1963144070678027e-10
those O 0 8.782474053559142e-11
observed O 0 8.42937053491255e-10
in O 0 2.6400784336466643e-10
Northern O 0 2.1707604602738684e-08
Ireland O 0 4.3905131974497635e-08
and O 0 4.300910461108032e-10
are O 0 3.109406829238104e-11
unique O 0 6.356633275306223e-11
to O 0 5.168894756657494e-10
these O 0 4.3909754304793935e-11
two O 0 1.0894832258578901e-10
populations O 0 1.2027137619163852e-10
, O 0 7.685587583017295e-11
suggesting O 0 8.54297910191093e-10
that O 0 9.795951549929072e-11
both O 0 9.540925688389379e-11
mutations O 0 1.7498122950598827e-09
were O 0 7.764596743342622e-10
probably O 0 8.726507849665666e-10
introduced O 0 1.515856329348253e-09
to O 0 1.2201011312384935e-09
Australia O 0 1.4722423280488783e-09
by O 0 2.07265621332553e-10
Irish O 0 2.5473509968065855e-09
migrants O 0 5.60773261160108e-10
during O 0 1.400194821199463e-10
the O 0 5.5647271512970775e-11
19th O 0 6.2425553615241824e-09
century O 0 2.1229272562095503e-08
. O 0 4.305954348637897e-08

Haplotype O 0 0.17523418366909027
analysis O 0 9.447153388464358e-07
using O 0 6.901162663552896e-08
6 O 0 2.8104803817541324e-08
RFLPs O 0 3.1231064667736064e-07
provides O 0 3.160051331718705e-09
additional O 0 3.0419125551794934e-10
data O 0 2.535473497822238e-10
that O 0 4.585494137177015e-11
the O 0 7.150649516951546e-11
I113F O 0 1.7289893605720863e-07
mutation O 0 1.3211558069770035e-08
originated O 0 8.203614454416197e-10
from O 0 3.234196591095362e-11
a O 0 1.3288227185270785e-09
common O 0 2.4752389027327126e-09
ancestor O 0 5.569981098574317e-08
. O 0 3.1279583367904706e-08

The O 0 5.534008806762358e-08
other O 0 2.1935426808283864e-09
9 O 0 5.542276859671347e-09
novel O 0 1.079691269723071e-08
mutations O 0 2.9275138757611785e-08
identified O 0 4.945808651513062e-09
in O 0 5.1485243152127325e-11
these O 0 1.932067977827856e-10
23 O 0 2.7305290473123023e-08
patients O 0 2.3500685131239152e-07
were O 0 8.983139232476844e-10
each O 0 6.801356006169712e-11
limited O 0 2.5397234315605033e-10
to O 0 6.737151947433517e-10
a O 0 8.96270879735539e-09
single O 0 8.930835804221715e-08
family O 0 6.316528811112221e-08
. O 0 1.641053160028605e-08

These O 0 2.3431125484307813e-08
data O 0 3.0437190545740123e-09
provide O 0 7.8568124228795e-10
further O 0 5.815114501039886e-10
evidence O 0 1.5957586363413157e-09
for O 0 2.2313083325453675e-10
extensive O 0 1.6899580401741332e-08
allelic O 0 1.1242933624089346e-06
heterogeneity O 0 5.538925961445784e-06
in O 0 2.2730101534307323e-07
MPS B-Disease 1 0.9999890327453613
IVA I-Disease 1 0.9999322891235352
in O 0 6.662408509328088e-07
British O 0 0.00014052580809220672
- O 0 0.000365532876458019
Irish O 0 1.5204489500320051e-05
patients O 0 1.4146583453111816e-05
and O 0 1.9313385613006773e-10
provide O 0 2.015642236452564e-10
evidence O 0 3.9369330018246274e-10
for O 0 7.889439795905062e-11
their O 0 1.3893143580023803e-10
transmission O 0 1.334461874336057e-08
to O 0 1.912738190057439e-09
Australia O 0 1.9572388154642795e-09
by O 0 7.678382374365356e-10
British O 0 5.171863790565112e-07
- O 0 6.809386263739725e-07
Irish O 0 5.6920725910458714e-08
migrants O 0 6.737271185386362e-09
. O 0 8.901780423897776e-10
. O 0 2.438528490245062e-09

Identification O 0 8.532090873814013e-07
of O 0 4.772276351872051e-09
constitutional O 0 1.2984206421151612e-07
WT1 O 0 0.0003286948776803911
mutations O 0 6.5576814449741505e-06
, O 0 1.7735207746838455e-09
in O 0 2.3158928108557575e-09
patients O 0 1.2633825008379063e-06
with O 0 9.674359091604856e-09
isolated O 0 0.0008578524575568736
diffuse B-Disease 1 0.9999430179595947
mesangial I-Disease 1 1.0
sclerosis I-Disease 1 1.0
, O 0 3.045828833592168e-08
and O 0 9.619797181059653e-10
analysis O 0 9.284519264518565e-10
of O 0 4.114930340914924e-10
genotype O 0 0.0016145671252161264
/ O 0 8.534739208698738e-06
phenotype O 0 0.0001478741323808208
correlations O 0 7.222030973252913e-08
by O 0 2.9266292167484664e-10
use O 0 7.204400409577261e-10
of O 0 3.5991817165514917e-11
a O 0 4.866197222952451e-09
computerized O 0 5.071437044534832e-06
mutation O 0 1.3110217196299345e-06
database O 0 7.431610526964505e-08
. O 0 2.76393326004154e-08

Constitutional O 0 1.0673876204236876e-05
mutations O 0 2.072395000141114e-05
of O 0 2.7753739306746184e-09
the O 0 7.393698986390973e-10
WT1 O 0 1.080333845493442e-06
gene O 0 2.6769956917860327e-08
, O 0 3.556166194851329e-10
encoding O 0 2.007034760609372e-09
a O 0 1.3415872857081013e-08
zinc O 0 6.001777364872396e-06
- O 0 1.3360363482206594e-07
finger O 0 2.226256725634812e-07
transcription O 0 7.285907877019326e-09
factor O 0 3.9299425935723775e-09
involved O 0 2.6165185573745475e-09
in O 0 2.004146404388507e-09
renal O 0 0.047344595193862915
and O 0 6.313324973916679e-08
gonadal O 0 3.1789329568709945e-07
development O 0 6.189083134877649e-10
, O 0 1.7497713000746984e-10
are O 0 5.733491459380957e-11
found O 0 6.61900256826442e-10
in O 0 2.584450986553577e-10
most O 0 4.504601580634926e-09
patients O 0 3.7348470982578874e-07
with O 0 1.5338601500047844e-08
Denys B-Disease 1 0.9996933937072754
- I-Disease 1 0.9999954700469971
Drash I-Disease 1 0.9999960660934448
syndrome I-Disease 1 0.9999996423721313
( O 0 6.596436463723876e-08
DDS B-Disease 1 0.9999994039535522
) O 0 1.9502079950939333e-08
, O 0 7.927535961016474e-09
or O 0 8.195536338462261e-08
diffuse B-Disease 1 0.9999116659164429
mesangial I-Disease 1 1.0
sclerosis I-Disease 1 1.0
( O 0 2.824216380759026e-07
DMS B-Disease 0 0.0070046475157141685
) O 0 3.240782531221953e-09
associated O 0 7.979584992767741e-09
with O 0 1.0582185794305587e-08
pseudohermaphroditism B-Disease 1 0.9999996423721313
and O 0 1.1168906439706916e-06
/ O 0 2.579790361778578e-06
or O 0 7.846307426007115e-08
Wilms B-Disease 0 0.10331983864307404
tumor I-Disease 0 0.005000637844204903
( O 0 5.826033699918298e-08
WT B-Disease 1 0.9998760223388672
) O 0 2.5283098281647653e-08
. O 0 2.8870788426615945e-08

Most O 0 3.0636747396783903e-06
mutations O 0 3.445993934292346e-05
in O 0 1.3979298785216088e-07
DDS B-Disease 1 1.0
patients O 1 0.9998955726623535
lie O 0 2.1258319975459017e-06
in O 0 7.272214497255902e-10
exon O 0 4.1876994316680793e-08
8 O 0 1.853062259193905e-09
or O 0 3.827468897377173e-10
exon O 0 6.294278875884629e-08
9 O 0 9.467536088436646e-09
, O 0 3.86747800451559e-10
encoding O 0 1.344520494939161e-08
zinc O 0 1.0168192829951295e-06
finger O 0 2.535356316002435e-06
2 O 0 5.98589044997766e-09
or O 0 2.505075702430304e-09
zinc O 0 3.8119367218314437e-06
finger O 0 1.2437621990102343e-05
3 O 0 8.29069968233398e-09
, O 0 5.524100621379091e-10
respectively O 0 1.324035991956407e-09
, O 0 3.971730930252271e-11
with O 0 5.274892328488434e-11
a O 0 4.024412358916152e-09
hot O 0 1.2084509762644302e-05
spot O 0 4.807361051462067e-07
( O 0 2.4152302380286983e-10
R394W O 0 3.649136459671354e-08
) O 0 6.547153097447023e-11
in O 0 3.558934813518988e-10
exon O 0 1.5099824679509766e-07
9 O 0 3.8987963080217014e-08
. O 0 1.2939255000787853e-08

We O 0 1.0106247572139182e-07
analyzed O 0 2.8055154643880087e-08
a O 0 9.776580656151168e-10
series O 0 1.7996467649439296e-09
of O 0 3.450135177551772e-10
24 O 0 2.768965146060509e-07
patients O 0 2.4664425382070476e-06
, O 0 2.4750962390740483e-10
10 O 0 4.168712319785328e-10
with O 0 3.2962466089969666e-09
isolated B-Disease 0 0.00011424998956499621
DMS I-Disease 1 0.7840283513069153
( O 0 5.3735211835714836e-09
IDMS B-Disease 0 8.240400347858667e-06
) O 0 9.51654088865439e-10
, O 0 7.598036644296258e-10
10 O 0 5.28485477602203e-10
with O 0 8.35947044919294e-09
DDS B-Disease 1 0.9999998807907104
, O 0 4.3530814508585536e-08
and O 0 4.367075590039349e-09
4 O 0 4.0232461806510855e-09
with O 0 1.7182285816375042e-08
urogenital B-Disease 0 0.2920346260070801
abnormalities I-Disease 1 0.99996018409729
and O 0 5.303457783156773e-06
/ O 0 0.00016277348913718015
or O 0 6.914271580171771e-06
WT B-Disease 1 0.9999974966049194
. O 0 9.321165066467074e-07

We O 0 6.486925485660322e-07
report O 0 1.3486560135334003e-07
WT1 O 0 1.246076135430485e-05
heterozygous O 0 3.688016931846505e-06
mutations O 0 4.128697241867485e-07
in O 0 4.8956714238101995e-09
16 O 0 1.0378937531640986e-07
patients O 0 2.350630529690534e-05
, O 0 9.909878473379763e-10
4 O 0 1.8420746039637947e-09
of O 0 1.822906131598856e-10
whom O 0 2.623671662149718e-07
presented O 0 2.1047798171025534e-08
with O 0 9.22850329487801e-09
IDMS B-Disease 0 0.0013589010341092944
. O 0 2.2808730193446536e-07

One O 0 8.894658662939037e-07
male O 0 9.050284575096157e-07
and O 0 4.623543770065908e-09
two O 0 7.120877665300895e-09
female O 0 9.27683140616864e-05
IDMS B-Disease 1 0.9364220499992371
patients O 0 0.0421358160674572
with O 0 6.782477868227943e-08
WT1 O 0 0.07212135195732117
mutations O 0 0.00012826488818973303
underwent O 0 0.00014336548338178545
normal O 0 4.0549969071435044e-07
puberty O 0 3.8261742929535103e-07
. O 0 4.029591593734949e-08

Two O 0 7.211858132905036e-07
mutations O 0 5.705910098185996e-06
associated O 0 1.2438759711130842e-07
with O 0 8.478377111487134e-09
IDMS B-Disease 0 0.00013790490629617125
are O 0 3.347293109356997e-09
different O 0 1.0029021363378021e-10
from O 0 1.1395798887869901e-10
those O 0 3.9156350384317307e-10
described O 0 1.1024450685681586e-07
in O 0 7.979252814038773e-08
DDS B-Disease 1 1.0
patients O 1 0.9726966619491577
. O 0 8.704224541133954e-08

No O 0 5.112714461574797e-06
WT1 O 0 0.00011543906293809414
mutations O 0 3.740408646990545e-05
were O 0 6.264253471499615e-08
detected O 0 3.9203019497335845e-08
in O 0 2.1538364147755118e-10
the O 0 1.583653624903647e-10
six O 0 2.7773969790700903e-09
other O 0 2.301322243880577e-09
IDMS B-Disease 1 0.5788527131080627
patients O 0 0.017831675708293915
, O 0 5.14655318362145e-10
suggesting O 0 6.8981327316919305e-09
genetic O 0 1.7696596188443436e-08
heterogeneity O 0 8.336259327279549e-08
of O 0 6.096059768090356e-10
this O 0 2.6625951221603827e-08
disease O 0 1.6029003745643422e-05
. O 0 6.631999838191405e-08

We O 0 2.967998398162308e-07
analyzed O 0 1.298271058658429e-06
genotype O 0 0.00016278061957564205
/ O 0 6.283750735747162e-06
phenotype O 0 0.0004932465963065624
correlations O 0 1.957167114596814e-06
, O 0 1.3837297974106377e-09
on O 0 2.1270845085297196e-09
the O 0 1.1578083630725544e-10
basis O 0 1.1750367345797486e-10
of O 0 9.004573128801319e-12
the O 0 1.3405014598344422e-10
constitution O 0 1.5209128401139083e-09
of O 0 2.9122832617689554e-11
a O 0 3.4525333703072647e-09
WT1 O 0 2.7971113922831137e-06
mutation O 0 2.3397317860940348e-08
database O 0 5.415622394977504e-10
of O 0 5.50218343109421e-11
84 O 0 5.852571316466992e-09
germ O 0 1.398371267669063e-07
- O 0 7.568408818769967e-06
line O 0 1.6484602838318096e-06
mutations O 0 1.6609483566298877e-08
, O 0 6.936043406291503e-11
to O 0 1.8223568487574227e-10
compare O 0 1.332477461701842e-09
the O 0 3.452543112514306e-11
distribution O 0 1.433074214851615e-10
and O 0 1.6472731512173766e-10
type O 0 3.984193419626081e-09
of O 0 5.428463928369709e-11
mutations O 0 2.492076056626047e-08
, O 0 9.089024671782298e-11
according O 0 8.050709404683332e-11
to O 0 2.2253325571153226e-10
the O 0 2.639997942477379e-10
different O 0 9.766427666590971e-09
symptoms O 0 2.3643446183996275e-05
. O 0 5.448201534363761e-08

This O 0 1.735240005018568e-07
demonstrated O 0 1.8417529190628557e-07
( O 0 4.3695896900786124e-10
1 O 0 9.42303346462836e-10
) O 0 8.508694443465359e-11
the O 0 2.2161157631206407e-10
association O 0 3.337690124283199e-10
between O 0 1.1940599897730664e-10
mutations O 0 9.18588227705186e-09
in O 0 4.855810753490175e-10
exons O 0 2.666030241016415e-08
8 O 0 3.870808562567163e-09
and O 0 1.5824225263472158e-09
9 O 0 4.716354418121682e-09
and O 0 7.377361832539009e-09
DMS B-Disease 0 0.009134816937148571
; O 0 3.905828105388309e-09
( O 0 1.5921308715860505e-10
2 O 0 3.615533428202866e-09
) O 0 6.915492067882667e-10
among O 0 5.4371946944797855e-09
patients O 0 7.193723376985872e-07
with O 0 1.888021960994024e-09
DMS B-Disease 0 0.00028412192477844656
, O 0 7.898507958792322e-10
a O 0 7.730048823262337e-10
higher O 0 6.624243931163676e-10
frequency O 0 1.1784584863505643e-08
of O 0 3.3564959839305075e-11
exon O 0 1.3310302193758616e-08
8 O 0 3.421682048809771e-09
mutations O 0 3.485870792019341e-08
among O 0 8.612758284343158e-10
46 O 0 1.2377210367731095e-08
, O 0 1.9791095429155803e-09
XY O 0 0.00015773648920003325
patients O 0 5.812961535411887e-05
with O 0 2.1887947010412745e-09
female O 0 9.053754865817609e-07
phenotype O 0 1.1944541256525554e-05
than O 0 3.292344841199224e-09
among O 0 8.946836604906139e-10
46 O 0 3.670818671253073e-08
, O 0 3.508990431555503e-09
XY O 0 0.0016914632869884372
patients O 0 4.5896984374849126e-05
with O 0 5.511660572388166e-10
sexual O 0 3.9678127450315515e-09
ambiguity O 0 2.4133399278980505e-08
or O 0 1.4151672722562125e-08
male O 0 2.712630885071121e-05
phenotype O 0 0.0009703508112579584
; O 0 5.305289096924071e-09
and O 0 7.585529537834645e-09
( O 0 1.5155317278914282e-10
3 O 0 1.032163798875274e-09
) O 0 5.929567253870616e-11
statistically O 0 2.076340877010807e-09
significant O 0 2.203244392484649e-10
evidence O 0 6.639220284654357e-10
that O 0 2.800396303737074e-10
mutations O 0 2.174588509262776e-09
in O 0 5.217397000545354e-11
exons O 0 1.4970201078767786e-08
8 O 0 1.0305861719572817e-09
and O 0 6.22166651531586e-10
9 O 0 1.2205177979396353e-09
preferentially O 0 2.391791440459201e-07
affect O 0 1.148041484100304e-08
amino O 0 1.5163045263832942e-09
acids O 0 3.003573223470113e-10
with O 0 8.830948125537752e-12
different O 0 6.911502186540686e-12
functions O 0 5.04850952709468e-11
. O 0 2.4648261209847533e-10
. O 0 3.2977873765105414e-09

The O 0 3.822435985512129e-07
185delAG O 0 1.5575235011056066e-05
BRCA1 O 0 1.1619104043347761e-05
mutation O 0 5.212516498431796e-07
originated O 0 3.2427736051943157e-09
before O 0 1.9847710974740806e-10
the O 0 3.7174145706142525e-11
dispersion O 0 2.945481725191712e-08
of O 0 9.845289861143414e-11
Jews O 0 2.2623185547132607e-09
in O 0 5.497735600101805e-11
the O 0 6.697775667419137e-11
diaspora O 0 2.922915021130734e-09
and O 0 9.682217250173153e-10
is O 0 3.7001701702621403e-10
not O 0 8.52956316688136e-10
limited O 0 1.4481241761288288e-09
to O 0 8.35508728869172e-09
Ashkenazim O 0 1.325943003394059e-06
. O 0 4.9051703143732084e-08

The O 0 1.4035579454230174e-07
185delAG O 0 2.386792857578257e-06
mutation O 0 5.205428124099853e-07
in O 0 9.714460347254317e-10
BRCA1 O 0 2.3977042928891024e-07
is O 0 5.380177192648716e-09
detected O 0 1.9945108675756273e-08
in O 0 9.25331533618845e-10
Ashkenazi O 0 1.194485435007664e-07
Jews O 0 3.084882793658039e-09
both O 0 2.835298662517971e-10
in O 0 8.152234443059569e-10
familial B-Disease 0 0.004329139832407236
breast I-Disease 1 0.9999901056289673
and I-Disease 1 0.999840259552002
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
and O 0 1.9039164911305306e-08
in O 0 4.2812345335541124e-10
the O 0 1.2702801310826572e-10
general O 0 3.950354265924716e-09
population O 0 2.3193762466178214e-09
. O 0 9.851310878161712e-09

All O 0 1.2988367359412223e-07
tested O 0 3.668936585654592e-07
Ashkenazi O 0 4.1543503925822733e-07
mutation O 0 5.87458437451005e-08
carriers O 0 4.8874140290422474e-09
share O 0 5.345274778356668e-10
the O 0 2.9798625372778886e-11
same O 0 4.3506287461525517e-10
allelic O 0 8.272696305766658e-08
pattern O 0 2.675832604381867e-07
at O 0 7.815441072089868e-10
the O 0 1.126982951404898e-09
BRCA1 O 0 1.1558091728147701e-06
locus O 0 6.89732530645415e-07
. O 0 6.913995065360723e-08

Our O 0 2.442321829221328e-07
previous O 0 2.0742835005194138e-08
study O 0 1.867357379836676e-09
showed O 0 7.630616138953883e-09
that O 0 5.7543945303217825e-11
this O 0 1.1537520938631474e-10
Ashkenazi O 0 1.7228499871180247e-07
mutation O 0 2.4849279967043003e-08
also O 0 3.4056779618651944e-09
occurs O 0 1.6020583470943706e-10
in O 0 6.463081458907283e-11
Iraqi O 0 4.064712566531625e-09
Jews O 0 9.436773584781122e-10
with O 0 6.424342308131159e-11
a O 0 2.3905237789279e-09
similar O 0 1.654188963584602e-08
allelic O 0 3.3977751172642456e-06
pattern O 0 3.207725285392371e-06
. O 0 8.78320776109831e-08

We O 0 5.602151986749959e-07
extended O 0 4.022281530069449e-08
our O 0 4.645773765687977e-10
analysis O 0 2.30850463744936e-10
to O 0 8.615398672251473e-11
other O 0 2.6369165531670014e-11
non O 0 1.626802859089338e-10
- O 0 4.4522849407258036e-08
Ashkenazi O 0 3.5325090408377946e-08
subsets O 0 2.20244711357509e-09
354 O 0 5.020054150151054e-09
of O 0 9.456680577502041e-11
Moroccan O 0 1.5011838172540592e-07
origin O 0 2.4088595562687942e-09
, O 0 2.5145768800527435e-10
200 O 0 7.178133643037654e-10
Yemenites O 0 5.676103143059663e-08
and O 0 3.580805096881079e-10
150 O 0 6.565915033895919e-10
Iranian O 0 2.1707688091510136e-08
Jews O 0 5.228143606927915e-08
. O 0 1.9380490101639225e-08

Heteroduplex O 0 0.00017198215937241912
analysis O 0 3.827736065886711e-07
complemented O 0 1.2770524904226477e-07
by O 0 3.543694226948446e-10
direct O 0 3.0306659959400406e-10
DNA O 0 2.4509132501293607e-09
sequencing O 0 1.4846469609253177e-09
of O 0 1.9442376875122847e-10
abnormally O 0 4.829325206401336e-08
migrating O 0 4.628325722677573e-09
bands O 0 9.042760318322962e-09
were O 0 3.6698790673028725e-09
employed O 0 1.5102244788067765e-07
. O 0 2.4051741931430115e-08

Four O 0 1.9194662570498622e-07
of O 0 9.79524683586419e-10
Moroccan O 0 1.8210702990018035e-07
origin O 0 4.116957885713646e-09
( O 0 1.0326752647449311e-10
1 O 0 9.166642445102013e-10
. O 0 1.8065896001395743e-10
1 O 0 5.514215750679341e-10
% O 0 8.069680340616614e-11
) O 0 4.5364472595066374e-11
and O 0 2.555897271605545e-09
none O 0 1.1502414576369802e-09
of O 0 9.125603050996745e-12
the O 0 2.2917852338100175e-10
Yemenites O 0 2.3028690065984847e-08
or O 0 1.3631287765214495e-10
Iranians O 0 1.8053125661054992e-09
was O 0 3.4961169514957646e-09
a O 0 8.619085445360497e-10
carrier O 0 1.1825068035875574e-08
of O 0 1.5932144492580846e-11
the O 0 4.6251114049766784e-10
185delAG O 0 1.9892318050551694e-06
mutation O 0 9.987321618609712e-07
. O 0 2.7045969019923177e-08

BRCA1 O 0 0.0012657594634220004
allelic O 0 0.0001902285875985399
patterns O 0 5.922700802329928e-05
were O 0 5.341468636288482e-07
determined O 0 2.7158100124324847e-07
for O 0 5.015093895721634e-10
four O 0 2.934213705341193e-10
of O 0 1.6176405701062713e-11
these O 0 1.350955874945825e-10
individuals O 0 3.391297312416164e-11
and O 0 1.2072183530609237e-10
for O 0 6.004649555357844e-11
12 O 0 2.5405616499440953e-10
additional O 0 7.041136007579496e-10
non O 0 2.107377827798018e-09
- O 0 1.4276023421189166e-06
Ashkenazi O 0 1.1615252333285753e-06
185delAG O 0 3.3265465049225895e-07
mutation O 0 2.499074014394864e-07
carriers O 0 2.829078482591285e-08
who O 0 3.167910449519695e-07
had O 0 0.0003953263512812555
breast B-Disease 1 0.9999289512634277
/ I-Disease 1 0.9999971389770508
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
. O 0 9.391942512593232e-07

Six O 0 3.1291872346628224e-06
non O 0 3.379280144599761e-07
- O 0 1.875646921689622e-05
Ashkenazi O 0 2.243308517790865e-05
individuals O 0 3.1139797407320202e-09
shared O 0 5.941094283201664e-10
the O 0 8.886880814573672e-11
common O 0 1.894316481454439e-09
Ashkenazi O 0 3.0169599085638765e-06
haplotype O 0 0.0002201048337155953
, O 0 1.804427718354873e-09
four O 0 3.7855987788937284e-10
had O 0 3.785773916575863e-09
a O 0 2.2595315896101198e-10
closely O 0 3.4723983688422777e-09
related O 0 6.117852890952236e-10
pattern O 0 1.1481186135142707e-07
, O 0 1.0624247037682721e-09
and O 0 1.4574010887002942e-09
the O 0 4.062075398270082e-10
rest O 0 1.6694341464784657e-09
( O 0 5.2725789012608715e-11
n O 0 1.266529192633925e-08
= O 0 1.3862453407398334e-08
6 O 0 1.072437472160459e-09
) O 0 6.041053074445912e-11
displayed O 0 5.4219295719803995e-09
a O 0 2.903545182064704e-09
distinct O 0 2.1460555998942255e-08
BRCA1 O 0 3.902609023498371e-06
allelic O 0 2.441435071887099e-06
pattern O 0 3.0053095088078408e-06
. O 0 1.1889562046007995e-07

We O 0 1.5253068852416618e-07
conclude O 0 2.8036701849032397e-08
that O 0 7.336342644492788e-10
the O 0 2.546703681272078e-10
185delAG O 0 8.693470476828224e-07
BRCA1 O 0 1.6247848861894454e-06
mutation O 0 9.38918773840669e-08
occurs O 0 3.899208733670889e-10
in O 0 7.610317237505271e-11
some O 0 1.9474441503852802e-10
non O 0 1.1243249664616428e-09
- O 0 9.465893526794389e-07
Ashkenazi O 0 3.0382973363884958e-06
populations O 0 4.439165035563519e-09
at O 0 1.849992520286392e-10
rates O 0 1.8243020427632928e-09
comparable O 0 4.427510302829063e-10
with O 0 2.917621005904536e-11
that O 0 2.076161881303662e-10
of O 0 2.768076878822967e-10
Ashkenazim O 0 4.985966484127857e-07
. O 0 2.280385125175144e-08

The O 0 1.045631066176611e-07
majority O 0 6.3763501145786e-08
of O 0 3.54489770870714e-10
Jewish O 0 5.509645184531564e-09
185delAG O 0 3.820078120497783e-07
mutation O 0 1.4372342604929145e-07
carriers O 0 4.238394080147145e-09
have O 0 3.521029579012236e-10
a O 0 1.144490280324817e-09
common O 0 1.877560995566796e-09
allelic O 0 5.766378876614908e-07
pattern O 0 5.824228082929039e-06
, O 0 1.4994139263535544e-09
supporting O 0 1.9141617180196135e-09
the O 0 2.0353489726954166e-10
founder O 0 5.214596754399281e-09
effect O 0 2.4802861986472635e-09
notion O 0 1.1200015359591475e-09
, O 0 4.1847709325582017e-11
but O 0 6.384433953732227e-11
dating O 0 6.7589260577261e-11
the O 0 2.638083848593986e-11
mutations O 0 6.796341267545358e-10
origin O 0 3.5387009295062555e-11
to O 0 1.225700929641249e-10
an O 0 3.164627448981605e-10
earlier O 0 8.334809287191547e-09
date O 0 6.172734767773136e-09
than O 0 3.026150663387739e-09
currently O 0 1.4208362486556325e-08
estimated O 0 1.615367573037929e-08
. O 0 1.7311434064026798e-08

However O 0 9.31821432459401e-07
, O 0 7.040034666339068e-10
the O 0 4.6782543117185327e-11
different O 0 9.007669610205937e-11
allelic O 0 5.367971667169513e-08
pattern O 0 2.827978846653423e-07
at O 0 4.6514217477700015e-10
the O 0 1.8233511922538526e-10
BRCA1 O 0 1.0927250571057812e-07
locus O 0 1.2434164808894366e-08
even O 0 7.240769095417932e-10
in O 0 5.16518633419949e-11
some O 0 7.399832135934759e-11
Jewish O 0 7.813965585690141e-10
mutation O 0 7.2648429494392985e-09
carriers O 0 1.066045918207692e-09
, O 0 5.006919531758136e-11
might O 0 1.2870599030989638e-09
suggest O 0 1.07792119674599e-09
that O 0 1.2078034405949012e-10
the O 0 1.2342284139155169e-10
mutation O 0 1.8489995312620522e-08
arose O 0 1.926431458798561e-09
independently O 0 5.658923107887404e-09
. O 0 7.899909615360912e-10
. O 0 7.401858237443548e-09

Crystal O 0 0.00021344199194572866
structure O 0 1.9131923068016476e-07
of O 0 6.888491443923783e-10
the O 0 1.728273169021577e-08
hemochromatosis B-Disease 1 0.9999994039535522
protein O 0 2.0800757738470566e-06
HFE O 0 1.719749161566142e-05
and O 0 2.0855623006355017e-08
characterization O 0 5.0074334012606414e-08
of O 0 2.5290873562067162e-11
its O 0 7.466979118353478e-11
interaction O 0 6.091898652194061e-10
with O 0 1.1985556991334079e-09
transferrin O 0 1.2953116765856976e-06
receptor O 0 5.205189381740638e-07
. O 0 2.8491472292557773e-08

HFE O 0 0.00837001483887434
is O 0 1.484590598010982e-06
an O 0 3.513385493647547e-08
MHC O 0 3.393054157641018e-06
- O 0 8.007074256966007e-07
related O 0 1.0386180804289324e-08
protein O 0 4.062123526438199e-09
that O 0 4.135435049956726e-10
is O 0 2.2728187387688337e-10
mutated O 0 2.2843378744141773e-08
in O 0 2.3000878979217987e-10
the O 0 1.370705993153365e-09
iron B-Disease 1 0.9863472580909729
- I-Disease 1 0.9999111890792847
overload I-Disease 1 0.9999339580535889
disease I-Disease 1 0.9999358654022217
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
. O 0 2.474824032105971e-05

HFE O 0 0.00024825826403684914
binds O 0 6.2381932366406545e-06
to O 0 2.1204066058544413e-07
transferrin O 0 1.6889048310986254e-06
receptor O 0 2.7355864062883484e-07
( O 0 3.2797344839963216e-09
TfR O 0 7.271846698131412e-07
) O 0 2.847840296915649e-10
and O 0 2.719445224563799e-10
reduces O 0 4.347544990679353e-09
its O 0 1.6882327480427506e-10
affinity O 0 2.4780260066137316e-09
for O 0 9.630370945146183e-10
iron O 0 2.7296669941279106e-05
- O 0 1.0855452501346008e-06
loaded O 0 2.2763963158922706e-07
transferrin O 0 1.0512168273635325e-06
, O 0 1.8770383025668025e-09
implicating O 0 2.807427392781392e-07
HFE O 0 3.973915227106772e-06
in O 0 1.434248808607208e-08
iron O 0 8.72247401275672e-05
metabolism O 0 2.6437000997248106e-06
. O 0 2.7720002293563084e-08

The O 0 1.808884633192065e-07
2 O 0 4.0866214590096206e-07
. O 0 8.052303002159533e-08

6 O 0 1.1799855883509736e-06
A O 0 2.340640889997303e-07
crystal O 0 8.51179356686771e-06
structure O 0 3.748177235252115e-08
of O 0 2.390919406902725e-10
HFE O 0 3.087046934524551e-06
reveals O 0 4.901747274743684e-08
the O 0 1.0229635194480835e-10
locations O 0 1.0798966165737056e-09
of O 0 1.1480847383893433e-09
hemochromatosis B-Disease 1 1.0
mutations O 0 6.175698945298791e-05
and O 0 2.9521509681273983e-09
a O 0 5.594637642047928e-09
patch O 0 2.798830064421054e-05
of O 0 2.709003021905687e-10
histidines O 0 5.691670139640337e-07
that O 0 1.5303759370866032e-09
could O 0 3.551179572625074e-09
be O 0 2.4144333754527736e-10
involved O 0 5.17864418014824e-10
in O 0 9.517920895874e-10
pH O 0 9.426100405107718e-06
- O 0 4.5291717469808646e-06
dependent O 0 4.0510698795515054e-07
interactions O 0 4.90986913348479e-08
. O 0 1.824431627994727e-08

We O 0 8.45414035666181e-07
also O 0 1.4234673884061522e-08
demonstrate O 0 2.3901421286609548e-08
that O 0 7.033702953407328e-09
soluble O 0 4.3439459318506124e-07
TfR O 0 3.52614551957231e-06
and O 0 1.4796178726683706e-09
HFE O 0 2.10653752219514e-07
bind O 0 3.347103216810865e-08
tightly O 0 1.4355890698425355e-07
at O 0 5.265827218714492e-10
the O 0 5.426238625094726e-11
basic O 0 9.54617385140466e-10
pH O 0 1.1648444875334008e-08
of O 0 1.6003778163797833e-11
the O 0 4.251400620436385e-11
cell O 0 3.6567310957025256e-08
surface O 0 1.0910376886386075e-06
, O 0 2.3475343891021794e-10
but O 0 5.941434566558712e-10
not O 0 3.6752006993268083e-10
at O 0 6.753590742203386e-11
the O 0 2.7889784925960726e-10
acidic O 0 6.633519205934135e-06
pH O 0 6.344505436572945e-07
of O 0 2.541283572465858e-10
intracellular O 0 6.177766209702895e-08
vesicles O 0 4.5522600089498155e-07
. O 0 2.255318598542999e-08

TfR O 0 0.10977759957313538
HFE O 0 0.0013044456718489528
stoichiometry O 0 3.752477277885191e-05
( O 0 7.422954695357475e-08
2 O 0 1.8150117853110714e-08
1 O 0 3.868889209002191e-09
) O 0 1.0200258415693497e-09
differs O 0 4.201131886816256e-08
from O 0 1.894793433265818e-09
TfR O 0 7.25284166946949e-07
transferrin O 0 1.1291356116771567e-07
stoichiometry O 0 4.304435208268842e-08
( O 0 1.5958855070774547e-10
2 O 0 4.334146652684723e-10
2 O 0 5.043718775965544e-10
) O 0 7.776241456314281e-11
, O 0 5.834832617068741e-11
implying O 0 6.257692142241922e-10
a O 0 2.0770013486881567e-10
different O 0 2.3608151891729712e-11
mode O 0 2.340184712679161e-10
of O 0 1.1692279089370317e-11
binding O 0 1.195452958846488e-09
for O 0 4.3253517434393984e-10
HFE O 0 1.3504866274161031e-06
and O 0 4.811540943450154e-09
transferrin O 0 3.3556057132955175e-07
to O 0 4.775857931349492e-08
TfR O 0 1.1460654604888987e-05
, O 0 1.2105854096944313e-09
consistent O 0 1.0493268476352569e-08
with O 0 3.5518143981505546e-10
our O 0 3.1144950507489e-10
demonstration O 0 2.223076833729465e-09
that O 0 7.5197936766358e-10
HFE O 0 3.6074692388865515e-07
, O 0 2.215123862114865e-09
transferrin O 0 1.2176913344319473e-07
, O 0 1.4912170387404444e-09
and O 0 6.659223839022843e-09
TfR O 0 2.8529318569781026e-06
form O 0 1.1831514656890363e-09
a O 0 2.949308797184358e-09
ternary O 0 1.500207673643672e-07
complex O 0 1.8839872950593417e-07
. O 0 6.481496939159115e-08

Identification O 0 9.978982689062832e-07
of O 0 2.5675945813929957e-09
three O 0 9.154865754368302e-10
novel O 0 1.2700536622389791e-08
mutations O 0 2.558610390224203e-08
and O 0 5.308322670316556e-10
a O 0 5.930161250944366e-09
high O 0 4.2172285219521655e-08
frequency O 0 1.9298147435620194e-07
of O 0 4.7085654819589706e-11
the O 0 2.2950354117146077e-10
Arg778Leu O 0 1.0284599056831212e-06
mutation O 0 5.003996150776402e-08
in O 0 3.2123487203605805e-10
Korean O 0 3.551655325395586e-08
patients O 0 9.612136864234344e-07
with O 0 8.067273071787895e-09
Wilson B-Disease 0 4.805380740435794e-06
disease I-Disease 0 4.767975497088628e-06
. O 0 6.515569594967019e-08

Four O 0 9.373992497785366e-07
mutations O 0 2.1755556645075558e-06
- O 0 1.8619756474436144e-06
- O 0 3.146972858303343e-06
R778L O 0 1.1402091786294477e-06
, O 0 1.4249552648948338e-09
A874V O 0 2.55895695744357e-08
, O 0 2.3724897046939475e-10
L1083F O 0 1.6192634788581017e-08
, O 0 1.5666551389514893e-10
and O 0 3.506513135409506e-10
2304delC O 0 7.377759203563983e-08
- O 0 6.131591590019525e-07
- O 0 1.3899912119086366e-06
in O 0 2.03522176889237e-09
the O 0 3.4680214255899955e-10
copper O 0 1.298771756808037e-08
- O 0 5.694599902739128e-09
transporting O 0 5.477258202546409e-09
enzyme O 0 2.1773149949666504e-09
, O 0 2.1620559509383241e-10
P O 0 3.67440549098319e-08
- O 0 1.1328114624120644e-07
type O 0 3.1815045531402575e-07
ATPase O 0 3.29404940657696e-07
( O 0 4.354763216696256e-10
ATP7B O 0 2.4340971549463575e-07
) O 0 1.4518486413095388e-10
, O 0 1.1637418806387245e-10
were O 0 3.8029746018963806e-10
identified O 0 1.998493148747116e-09
in O 0 1.9485812963182525e-10
Korean O 0 8.147702601490892e-08
Patients O 0 2.419044449197827e-06
with O 0 8.787795380271746e-09
Wilson B-Disease 0 4.1344360397488344e-06
disease I-Disease 0 2.6745569812192116e-06
. O 0 3.4243281987755836e-08

Arg778Leu O 0 0.00011064524733228609
, O 0 1.1175012026853892e-08
the O 0 1.5541312681222053e-10
most O 0 4.194802005752507e-10
frequently O 0 3.540495541187738e-08
reported O 0 1.092376678002438e-08
mutation O 0 1.4630605615906234e-09
of O 0 7.922958296380234e-12
this O 0 2.5953716606408328e-11
enzyme O 0 6.513339867453283e-10
, O 0 1.918942088563469e-10
was O 0 1.0278697004650894e-08
found O 0 7.235301802133165e-10
in O 0 5.885779363890009e-11
six O 0 1.7356975579030376e-10
of O 0 2.554296010814916e-11
eight O 0 2.0743737838557763e-09
unrelated O 0 9.909281573072803e-08
patients O 0 2.4274402221635683e-06
studied O 0 3.9477252578024036e-09
, O 0 8.024433201248016e-11
an O 0 9.502858916432544e-11
allele O 0 4.0309444671038364e-08
frequency O 0 2.356329353858655e-08
of O 0 2.1579937836690988e-10
37 O 0 5.987822504494034e-08
. O 0 1.7185397993557672e-08

5 O 0 1.4391464446816826e-06
% O 0 3.0138483708697095e-08
, O 0 3.39172578911473e-10
which O 0 1.2571637064695551e-09
is O 0 2.7699798010871746e-09
considerably O 0 3.4332819609517173e-07
higher O 0 2.6643767192524592e-09
than O 0 5.343307463157032e-10
those O 0 4.823132171427602e-11
in O 0 2.15903857292421e-11
other O 0 4.227901709286108e-11
Asian O 0 2.1732107780003673e-10
populations O 0 5.995785645751539e-09
. O 0 7.571984816934219e-09

The O 0 3.6229490518735474e-08
novel O 0 2.435638357667358e-08
single O 0 2.03246752761288e-09
nucleotide O 0 3.494490252720084e-09
deletion O 0 3.0585546539896313e-08
, O 0 8.479262292304668e-10
2304delC O 0 1.0182617415921413e-07
, O 0 1.2478038602381503e-09
was O 0 1.6787140566520975e-08
found O 0 8.561835684872676e-10
in O 0 2.8994262546433447e-10
one O 0 9.866843342365428e-09
patient O 0 1.4938445929146837e-06
. O 0 2.8437776578016383e-08

Since O 0 3.6501253930509847e-07
a O 0 2.6424993748719316e-08
mutation O 0 8.638926374260336e-08
at O 0 8.315242938650158e-10
cDNA O 0 9.33264132640943e-08
nucleotide O 0 1.7070786384465464e-07
2302 O 0 4.4351432393341383e-07
( O 0 1.4124430514073083e-09
2302insC O 0 1.236553401895435e-07
) O 0 7.504147303549757e-10
had O 0 9.162525316241954e-08
been O 0 6.560585408266206e-09
previously O 0 7.418309522222444e-09
described O 0 1.2349880229578503e-08
, O 0 6.044626604806425e-11
this O 0 2.2808166813548247e-11
region O 0 1.6655181400704322e-10
of O 0 2.8135225052516866e-11
the O 0 2.8944199814695537e-10
ATP7B O 0 1.8701922499531065e-06
gene O 0 1.4907911349837377e-08
may O 0 1.986431819034351e-08
be O 0 3.934405246042161e-09
susceptible O 0 7.159284223234863e-07
to O 0 8.004721330223674e-09
gene O 0 3.8207340935514367e-07
rearrangements O 0 0.00024802450207062066
causing O 0 2.742985998338554e-05
Wilson B-Disease 0 3.728169031091966e-05
disease I-Disease 0 4.605978756444529e-05
. O 0 9.58080264013006e-08

Disruption O 0 8.393502503167838e-05
of O 0 1.3301622914241307e-08
splicing O 0 2.683089519450732e-07
regulated O 0 7.613754604562928e-08
by O 0 5.933100122312851e-10
a O 0 3.417299110353156e-09
CUG O 0 4.250242000125581e-06
- O 0 2.990737186792103e-07
binding O 0 1.4976718887282914e-07
protein O 0 1.8001476576046116e-07
in O 0 1.2915072034047625e-07
myotonic B-Disease 1 0.9999998807907104
dystrophy I-Disease 1 1.0
. O 0 1.7728658576743328e-06

Myotonic B-Disease 1 0.9999998807907104
dystrophy I-Disease 1 1.0
( O 1 0.9833952188491821
DM B-Disease 1 1.0
) O 0 7.817624236849952e-07
is O 0 1.248969425660107e-07
caused O 0 1.333804675596184e-07
by O 0 2.1626211932357364e-10
a O 0 2.3893114153850092e-09
CTG O 0 1.4875396914248995e-07
expansion O 0 2.0804598044321665e-09
in O 0 2.144109889634649e-10
the O 0 1.7660127527019398e-10
3 O 0 2.6903952399237596e-09
untranslated O 0 1.4447211924561998e-06
region O 0 1.3550217836666434e-08
of O 0 4.3681230854630826e-10
the O 0 1.576822405979783e-08
DM B-Disease 1 0.9999996423721313
gene O 0 7.815693606971763e-06
. O 0 8.296999709500597e-08

One O 0 3.8144500535963743e-07
model O 0 2.5887169385896414e-07
of O 0 8.13620726347608e-09
DM B-Disease 1 0.9999998807907104
pathogenesis O 0 8.301476191263646e-05
suggests O 0 3.415118143834661e-08
that O 0 2.280761274287002e-10
RNAs O 0 2.4392681208240674e-09
from O 0 1.819810101222341e-11
the O 0 3.5244257599181816e-12
expanded O 0 4.138228093530927e-10
allele O 0 4.191941016529199e-09
create O 0 3.0918143045788327e-10
a O 0 1.280805461689738e-09
gain O 0 3.3131474452829934e-08
- O 0 2.1174179209992872e-07
of O 0 4.96667929006378e-10
- O 0 4.5841019868930744e-07
function O 0 3.62720653512838e-09
mutation O 0 2.9279874080856416e-09
by O 0 1.576335763309178e-11
the O 0 2.192938018674706e-11
inappropriate O 0 3.340213883262777e-09
binding O 0 8.960635566879205e-10
of O 0 8.153889889672694e-12
proteins O 0 7.634815696322406e-11
to O 0 3.40096367734688e-10
the O 0 7.554813996613063e-10
CUG O 0 2.5412980903638527e-05
repeats O 0 9.133959224527644e-07
. O 0 3.7341770564580656e-08

Data O 0 4.899419536741334e-07
presented O 0 4.0818370905526535e-08
here O 0 1.3326248993195122e-09
indicate O 0 2.6750652803997355e-09
that O 0 1.0388350596413076e-10
the O 0 7.945268748477119e-11
conserved O 0 5.461964214248383e-09
heterogeneous O 0 2.9356328923313413e-08
nuclear O 0 2.051983472028951e-08
ribonucleoprotein O 0 8.26373650397727e-07
, O 0 1.7174149880005984e-09
CUG O 0 3.746598338238982e-07
- O 0 5.988016482660896e-08
binding O 0 1.0952765805427589e-08
protein O 0 4.517163088024745e-09
( O 0 1.1803062693882538e-10
CUG O 0 8.334843641932821e-07
- O 0 1.5099119536898797e-06
BP O 0 4.266608357283985e-06
) O 0 2.2441126734662475e-10
, O 0 1.5354274796042233e-10
may O 0 1.7111045913509315e-09
mediate O 0 7.804782597986559e-08
the O 0 1.0328057298281124e-09
trans O 0 2.615586858212282e-08
- O 0 1.3221889503256534e-06
dominant O 0 9.910472442697937e-08
effect O 0 5.456008089765874e-09
of O 0 3.544672541599958e-11
the O 0 4.1402412054303284e-10
RNA O 0 6.492867044016748e-08
. O 0 1.8422371184101394e-08

CUG O 0 0.002295237500220537
- O 0 0.0010320540750399232
BP O 0 0.00015711835294496268
was O 0 5.54473231773045e-08
found O 0 5.61982127500471e-10
to O 0 1.1434162644485824e-10
bind O 0 3.326290576310953e-09
to O 0 1.6097289057270814e-09
the O 0 4.2220857365826703e-10
human O 0 6.429141219399526e-09
cardiac O 0 0.0007260462734848261
troponin O 0 7.33748747734353e-05
T O 0 2.70137525149039e-06
( O 0 5.455891294303683e-10
cTNT O 0 3.993720909534204e-08
) O 0 1.4257865721400975e-10
pre O 0 1.533073401560614e-08
- O 0 5.1884278207126044e-08
messenger O 0 3.5601317449618364e-09
RNA O 0 3.583169039256262e-10
and O 0 3.942544207768961e-11
regulate O 0 5.082317899862687e-10
its O 0 1.8897935993855697e-10
alternative O 0 3.4339604493283105e-09
splicing O 0 1.7151123188341444e-07
. O 0 2.801980691913286e-08

Splicing O 0 7.869649380154442e-06
of O 0 2.2486565498525124e-08
cTNT O 0 2.694690465432359e-06
was O 0 6.37174252915429e-07
disrupted O 0 1.1634588190645445e-06
in O 0 7.305810356683651e-08
DM B-Disease 1 0.9999998807907104
striated O 0 0.2429640144109726
muscle O 0 0.07663379609584808
and O 0 1.5971417965943147e-08
in O 0 5.526925028753737e-10
normal O 0 5.8881215458939096e-09
cells O 0 7.558045744815445e-09
expressing O 0 8.715932864333809e-09
transcripts O 0 7.999531703717366e-09
that O 0 2.1997350607705357e-09
contain O 0 5.258305435518196e-08
CUG O 0 3.325974466861226e-05
repeats O 0 2.4877699615899473e-06
. O 0 9.773308562444072e-08

Altered O 0 3.100555113633163e-05
expression O 0 1.745773516859117e-07
of O 0 4.5833101203207605e-10
genes O 0 3.411028126620863e-09
regulated O 0 1.096499424591002e-08
posttranscriptionally O 0 4.010671830201318e-07
by O 0 2.0301893499663493e-09
CUG O 0 2.587221160865738e-06
- O 0 3.2591128729109187e-06
BP O 0 8.527230420440901e-06
therefore O 0 7.50359330226047e-09
may O 0 5.8536993030600115e-09
contribute O 0 3.635372447519103e-09
to O 0 1.0027466146311781e-07
DM B-Disease 1 1.0
pathogenesis O 0 0.00016247236635535955
. O 0 8.739271528668269e-09
. O 0 1.6477839537287764e-08

Identification O 0 1.2014102139801253e-06
of O 0 2.7636153365762084e-09
a O 0 9.735165562574366e-09
novel O 0 8.894728154018594e-08
nonsense O 0 7.473643108824035e-07
mutation O 0 3.8978296146297e-08
and O 0 3.220483324462009e-10
a O 0 5.400170866032283e-10
missense O 0 6.433142374362433e-08
substitution O 0 1.5310065437645903e-09
in O 0 4.355394378485755e-10
the O 0 3.565532313842823e-10
vasopressin O 0 3.419994527575909e-07
- O 0 7.548684379798942e-07
neurophysin O 0 2.3388786303257803e-06
II O 0 2.1767354496660118e-07
gene O 0 3.6382996615458296e-09
in O 0 1.1836429059108866e-10
two O 0 2.9378033339355625e-10
Spanish O 0 6.798315244083142e-09
kindreds O 0 2.7114285217066936e-07
with O 0 7.67220864617002e-09
familial B-Disease 0 0.00043272587936371565
neurohypophyseal I-Disease 1 0.9952605366706848
diabetes I-Disease 1 0.9999021291732788
insipidus I-Disease 1 0.9345974326133728
. O 0 6.026406254022731e-07

Familial B-Disease 1 0.9993119239807129
neurohypophyseal I-Disease 1 0.9998781681060791
diabetes I-Disease 1 0.9999992847442627
insipidus I-Disease 1 0.9999716281890869
( O 0 0.00010390354145783931
FNDI B-Disease 1 0.9999997615814209
) O 0 1.3486710415122616e-08
is O 0 2.8749882474699007e-09
an O 0 1.1206132022323345e-08
autosomal B-Disease 1 0.9973118305206299
dominant I-Disease 1 0.9995601773262024
disease I-Disease 1 0.9145938158035278
caused O 0 9.552097617415711e-05
by O 0 2.602316158117901e-07
deficiency O 0 0.0005254428251646459
in O 0 1.3366724394003882e-09
the O 0 2.1844908104640126e-09
antidiuretic O 0 4.7945595724741e-06
hormone O 0 5.290372087074502e-07
arginine O 0 1.7109675809479086e-07
vasopressin O 0 2.33095533985761e-07
( O 0 5.575683248437713e-10
AVP O 0 3.7055272628094826e-08
) O 0 4.295529903997064e-11
encoded O 0 7.561387627141869e-10
by O 0 7.953714770136955e-11
the O 0 1.765386170582417e-10
AVP O 0 1.2758779348587268e-06
- O 0 2.8752283469657414e-06
neurophysin O 0 1.4373069461726118e-05
II O 0 2.3781587970006512e-06
( O 0 4.83089568348305e-10
AVP O 0 6.007304023114557e-07
- O 0 1.640484015297261e-06
NPII O 0 3.7948889257677365e-06
) O 0 3.044582641553717e-10
gene O 0 4.011981413754029e-09
on O 0 7.641422605786374e-09
chromosome O 0 2.6612246983859222e-06
20p13 O 0 4.6146574277372565e-06
. O 0 7.231666643292556e-08

In O 0 9.141857049144164e-08
this O 0 1.480905287287726e-09
study O 0 5.244087941669306e-10
, O 0 9.452712917967787e-11
we O 0 8.326125899849046e-11
analyzed O 0 1.7337992153088067e-09
two O 0 3.4318636821240034e-10
families O 0 2.8161548093486033e-10
with O 0 5.31779786872022e-10
FNDI B-Disease 1 0.9999408721923828
using O 0 2.7537021551893304e-09
direct O 0 1.681193073643783e-09
automated O 0 1.7988273981472958e-08
fluorescent O 0 1.060508409977956e-07
, O 0 4.2854172987993877e-10
solid O 0 6.9313021988648416e-09
phase O 0 3.850081142786621e-09
, O 0 3.3766345275410004e-10
single O 0 4.420458665777005e-09
- O 0 1.1885152417789868e-07
stranded O 0 1.775437397100177e-08
DNA O 0 1.2004088834061122e-09
sequencing O 0 7.434000082184866e-10
of O 0 5.051842277836727e-11
PCR O 0 7.699536013205943e-07
- O 0 1.4704322666148073e-06
amplified O 0 5.867854270036332e-06
AVP O 0 4.138230906391982e-06
- O 0 2.146040969819296e-06
NPII O 0 1.3926784959039651e-05
DNA O 0 6.995694548095344e-07
. O 0 2.0875599915370913e-08

In O 0 9.788718102754501e-08
one O 0 4.049792057259083e-09
of O 0 5.993949780958019e-11
the O 0 3.2915895009644203e-10
families O 0 2.0300345848767165e-09
, O 0 9.130416978031519e-10
affected O 0 2.727014392078786e-09
individuals O 0 8.186838013068964e-11
presented O 0 4.151224919368701e-10
a O 0 1.7951385933301367e-09
novel O 0 1.7683873920759652e-08
nonsense O 0 3.827618755281037e-08
mutation O 0 3.79656306392917e-09
in O 0 5.6944310378170826e-11
exon O 0 5.471650688093632e-09
3 O 0 1.9934022488232728e-10
of O 0 8.034383922050914e-12
the O 0 2.7150228246175523e-11
gene O 0 1.6252904577740424e-09
, O 0 1.1617015682752196e-10
consisting O 0 2.1136969952095797e-10
in O 0 4.782276658010787e-11
a O 0 4.763873295843268e-09
G O 0 0.0001632660860195756
to O 0 3.246773161436067e-08
T O 0 7.484555908376933e-07
transition O 0 1.7265260332521848e-09
at O 0 1.355640738553987e-10
nucleotide O 0 1.3288709022063472e-09
2101 O 0 2.5003700443448906e-08
, O 0 2.397115839158914e-10
which O 0 2.38414787911978e-10
produces O 0 6.338766178615174e-10
a O 0 4.6185527624587053e-10
stop O 0 5.062438024339144e-09
signal O 0 4.4846466096259974e-08
in O 0 5.733100105764777e-10
codon O 0 2.4721733993260386e-08
82 O 0 4.7077197251610414e-08
( O 0 7.998429696343123e-10
Glu O 0 8.330271157319658e-06
) O 0 7.55127016471846e-10
of O 0 6.857384104996811e-10
NPII O 0 5.400402733357623e-05
. O 0 6.264695429081257e-08

The O 0 1.5820918974895903e-07
premature O 0 2.5719639324961463e-06
termination O 0 1.2724387943308102e-07
eliminates O 0 3.752784394350783e-08
part O 0 3.119347669056083e-09
of O 0 1.1065535987508923e-10
the O 0 4.6043566181985796e-10
C O 0 7.54028164351439e-08
- O 0 2.498163894415484e-06
terminal O 0 3.4366166801191866e-07
domain O 0 6.360092452695199e-10
of O 0 6.310570815903915e-11
NPII O 0 2.134328269676189e-07
, O 0 3.366838405294281e-11
including O 0 3.2404747288272695e-12
a O 0 2.0713984347220382e-11
cysteine O 0 8.555759573036781e-11
residue O 0 1.928681658824871e-09
in O 0 7.079214298100212e-11
position O 0 2.0198775985136308e-08
85 O 0 2.4005943899396698e-09
, O 0 1.2144354966103776e-10
which O 0 3.4912039925671934e-10
could O 0 4.7209440801054825e-09
be O 0 4.732192415701775e-10
involved O 0 2.838512758174261e-10
in O 0 5.983932099828948e-11
the O 0 8.023422898295607e-11
correct O 0 2.0864613148319222e-08
folding O 0 3.687435778942927e-08
of O 0 1.747243322247627e-10
the O 0 3.0623124036566196e-09
prohormone O 0 1.7121952623710968e-05
. O 0 6.584657796793181e-08

In O 0 6.148449216425433e-08
the O 0 5.911874323416555e-10
second O 0 3.993292363446699e-09
family O 0 3.222629496590912e-09
, O 0 7.321786232861172e-11
a O 0 3.537103387962759e-10
G279A O 0 8.018229635808893e-09
substitution O 0 8.462346379189967e-10
at O 0 2.7087446174967056e-10
position O 0 1.071362643045859e-08
- O 0 3.134241310931429e-08
1 O 0 6.95204616096845e-10
of O 0 1.4901748238149715e-11
the O 0 3.214026267350789e-11
signal O 0 1.897470625067399e-08
peptide O 0 1.7608304814231701e-09
was O 0 1.9382773164267064e-09
observed O 0 2.834963375164534e-10
in O 0 3.4149891248169695e-11
all O 0 6.997540047404271e-11
affected O 0 3.13979220400995e-09
individuals O 0 1.5964162214388011e-09
. O 0 9.910184672889955e-09

This O 0 4.5349747779255267e-07
missense O 0 7.385575008811429e-05
mutation O 0 9.367376151203644e-06
, O 0 6.083610504248327e-09
which O 0 6.127327090155177e-09
replaces O 0 4.827547854802106e-07
Ala O 0 3.583528780382039e-07
with O 0 3.398319625702584e-09
Thr O 0 1.3852047686668811e-06
, O 0 1.404110938629799e-09
is O 0 1.0146993245641056e-09
frequent O 0 2.269221965889301e-07
among O 0 1.7511128191927128e-07
FNDI B-Disease 1 1.0
patients O 1 0.9950022101402283
and O 0 2.9739317675137045e-09
is O 0 7.246406252825466e-10
thought O 0 7.898252052385146e-10
to O 0 1.1225074342258168e-10
reduce O 0 1.7706275334816723e-09
the O 0 5.722456883350269e-11
efficiency O 0 1.61124324993267e-09
of O 0 2.1032398045406353e-11
cleavage O 0 1.5155507071540342e-08
by O 0 5.449962148240672e-10
signal O 0 2.514954076104914e-07
peptidases O 0 5.006746164326614e-07
. O 0 4.6837049794135055e-09
. O 0 1.7546859965023032e-08

Genetic O 0 0.0002037208469118923
heterogeneity O 0 0.00012028136552544311
of O 0 5.721542493120069e-07
Saethre B-Disease 1 0.5591564178466797
- I-Disease 1 0.9998466968536377
Chotzen I-Disease 1 0.9999116659164429
syndrome I-Disease 1 0.9999982118606567
, O 0 7.788986344792193e-09
due O 0 3.422609085035333e-09
to O 0 4.684526988540938e-09
TWIST O 0 6.458259304054081e-05
and O 0 9.370456410806582e-08
FGFR O 0 0.0008276239968836308
mutations O 0 2.3278305434359936e-06
. O 0 1.4783887003488871e-08

Thirty O 0 1.2180345038359519e-05
- O 0 7.397616172966082e-06
two O 0 2.3745112542883362e-08
unrelated O 0 1.8796872325310687e-07
patients O 0 5.268794666335452e-06
with O 0 4.1904676950643704e-10
features O 0 2.3446013130978827e-08
of O 0 1.2765568602191024e-09
Saethre B-Disease 0 0.3713361620903015
- I-Disease 1 0.9995793700218201
Chotzen I-Disease 1 0.9999382495880127
syndrome I-Disease 1 0.9999889135360718
, O 0 3.342104926140621e-10
a O 0 2.1362245306022487e-09
common O 0 2.4178829605148167e-08
autosomal B-Disease 1 0.8212493658065796
dominant I-Disease 1 0.7548795342445374
condition I-Disease 0 0.0015863353619351983
of O 0 2.292551481986038e-09
craniosynostosis B-Disease 0 0.11700448393821716
and O 0 1.5888612097114674e-06
limb B-Disease 0 0.06838391721248627
anomalies I-Disease 0 0.0005934278015047312
, O 0 3.6591780716577205e-09
were O 0 4.159421695959509e-09
screened O 0 7.802386647881576e-08
for O 0 9.476401885422092e-10
mutations O 0 2.528136278101556e-08
in O 0 1.0321322685413747e-09
TWIST O 0 1.1363802514097188e-05
, O 0 9.812005430376303e-09
FGFR2 O 0 3.3799485663621454e-06
, O 0 1.2434205887146277e-09
and O 0 2.4563138190103473e-09
FGFR3 O 0 1.7958838725462556e-05
. O 0 5.374672440439099e-08

Nine O 0 5.09610026711016e-06
novel O 0 6.061895874154288e-07
and O 0 3.829384365161559e-09
three O 0 8.389735572933432e-10
recurrent O 0 2.865464807655371e-07
TWIST O 0 4.7028199332999066e-05
mutations O 0 2.6653801796783227e-06
were O 0 8.786487981637947e-09
found O 0 1.0190011057176207e-09
in O 0 3.404662940464931e-10
12 O 0 7.964242598745841e-09
families O 0 8.637225157315243e-09
. O 0 1.4252170110751194e-08

Seven O 0 8.932008768169908e-07
families O 0 6.008381348010516e-08
were O 0 2.8691486964049773e-09
found O 0 8.106369464577767e-10
to O 0 1.7161019272293743e-09
have O 0 8.662071060427934e-09
the O 0 6.006175556905191e-10
FGFR3 O 0 1.5935267583699897e-05
P250R O 0 2.5586035690139397e-07
mutation O 0 2.611085569981242e-08
, O 0 9.916830551182088e-11
and O 0 1.461247095546625e-10
one O 0 3.3932787135704245e-10
individual O 0 6.715056982686818e-11
was O 0 9.366074138483782e-09
found O 0 2.1533434757525782e-10
to O 0 3.3436542423714855e-10
have O 0 1.8111480093452315e-09
an O 0 5.047847695394125e-10
FGFR2 O 0 8.704274478077423e-06
VV269 O 0 7.108883437467739e-07
- O 0 6.967210879338381e-07
270 O 0 3.371207242253149e-07
deletion O 0 4.780127710546367e-06
. O 0 6.389291229424998e-08

To O 0 5.4576702268605e-07
date O 0 5.5686641076135857e-08
, O 0 6.198203061913432e-10
our O 0 9.7508397189916e-11
detection O 0 1.907754176855292e-09
rate O 0 1.031459251343847e-09
for O 0 3.9166041937432894e-11
TWIST O 0 3.3959440770559013e-07
or O 0 4.306774048501438e-09
FGFR O 0 1.680091372691095e-05
mutations O 0 2.0119959742714855e-07
is O 0 3.449301511082581e-09
68 O 0 4.15222665139936e-08
% O 0 7.56359072595636e-11
in O 0 1.508834585051133e-10
our O 0 4.413213350318301e-09
Saethre B-Disease 0 0.00045456673251464963
- I-Disease 1 0.9960975050926208
Chotzen I-Disease 1 0.999930739402771
syndrome I-Disease 1 0.9999992847442627
patients O 0 0.005995020270347595
, O 0 4.747380821790159e-10
including O 0 5.246516415757796e-11
our O 0 2.2295215673651114e-10
five O 0 2.6903337335681954e-09
patients O 0 2.3491497813665774e-07
elsewhere O 0 5.892705434717982e-09
reported O 0 3.3570626278844884e-09
with O 0 6.23926632581373e-10
TWIST O 0 6.784591096220538e-05
mutations O 0 1.0627428309817333e-05
. O 0 3.126526948449282e-08

More O 0 4.362981940175814e-07
than O 0 1.5898566019245663e-08
35 O 0 3.5442231371973776e-09
different O 0 7.919336714179437e-11
TWIST O 0 2.714307925089088e-07
mutations O 0 2.5610719944779703e-07
are O 0 7.824136893930245e-10
now O 0 3.003116422206631e-09
known O 0 1.156550855085925e-09
in O 0 8.094884484943776e-11
the O 0 2.1730366117633793e-10
literature O 0 2.5830821925865166e-09
. O 0 7.436527837967333e-09

The O 0 4.008770915220339e-08
most O 0 4.229115724285748e-09
common O 0 5.846365613848548e-10
phenotypic O 0 1.9812486584669387e-07
features O 0 2.4242976337518485e-07
, O 0 7.739844876120117e-10
present O 0 3.638346290912864e-10
in O 0 9.280637369712963e-11
more O 0 2.907306340116378e-10
than O 0 2.4119201080807784e-10
a O 0 5.812696990403765e-10
third O 0 2.399248577589219e-09
of O 0 5.2161733266054e-11
our O 0 1.6278125514190833e-09
patients O 0 3.700633044445567e-08
with O 0 2.9922456179498624e-10
TWIST O 0 1.2574767424666788e-05
mutations O 0 5.703014949176577e-07
, O 0 4.3635928204110996e-10
are O 0 1.482439171418548e-10
coronal B-Disease 0 8.465266319035436e-07
synostosis I-Disease 0 7.980530426721089e-06
, O 0 2.6822382093172337e-09
brachycephaly B-Disease 0 2.5241406547138467e-06
, O 0 1.212994416022184e-08
low B-Disease 0 1.643380892346613e-05
frontal I-Disease 1 0.9999816417694092
hairline I-Disease 1 0.9999808073043823
, O 0 7.977858444974117e-07
facial B-Disease 1 0.9231926202774048
asymmetry I-Disease 0 0.0005713875871151686
, O 0 1.8379306965243813e-08
ptosis B-Disease 0 0.00045667137601412833
, O 0 5.630331045836101e-08
hypertelorism B-Disease 0 0.00032103381818160415
, O 0 9.534277367606592e-09
broad B-Disease 0 1.3215242233854951e-07
great I-Disease 0 4.5654809355255566e-07
toes I-Disease 0 8.028779848245904e-05
, O 0 4.213833282307178e-09
and O 0 3.7838030486625485e-09
clinodactyly B-Disease 0 6.3570032580173574e-06
. O 0 4.522165397702338e-08

Significant O 0 7.592421411573014e-07
intra O 0 3.3330181281598925e-07
- O 0 1.054439417202957e-05
and O 0 2.200835602650386e-08
interfamilial O 0 4.499959231907269e-06
phenotypic O 0 2.2420765162678435e-05
variability O 0 3.226720309612574e-06
is O 0 4.123009045287063e-09
present O 0 6.464243029746797e-10
for O 0 2.3688045969194604e-10
either O 0 1.3856293001879294e-08
TWIST O 0 6.686613050987944e-05
mutations O 0 4.21375762016396e-06
or O 0 1.3092603445841178e-08
FGFR O 0 0.00027411108021624386
mutations O 0 3.5245718663645675e-06
. O 0 5.396520919020986e-08

The O 0 1.3779445851014316e-07
overlap O 0 1.6340854358531942e-07
in O 0 3.984132579404331e-09
clinical O 0 5.994964880073894e-08
features O 0 9.620906382679095e-08
and O 0 2.0722619176183343e-09
the O 0 1.713174185846711e-10
presence O 0 3.8006855440642084e-09
, O 0 2.599569171035654e-10
in O 0 4.238964040892412e-11
the O 0 2.3569909912701803e-11
same O 0 1.1460231374993413e-10
genes O 0 1.2425688256101353e-10
, O 0 1.2750591381338605e-11
of O 0 2.6769493739753347e-12
mutations O 0 1.1309106984214168e-09
for O 0 9.879733142703628e-11
more O 0 3.3010835731595023e-10
than O 0 5.012052994857186e-10
one O 0 7.896083231706541e-10
craniosynostotic B-Disease 0 4.507252015173435e-06
condition I-Disease 0 1.3739071391682955e-07
- O 0 1.111930725272714e-08
such O 0 2.2753257611363154e-10
as O 0 3.35079364255364e-09
Saethre B-Disease 0 5.661754016728082e-07
- I-Disease 0 2.823446152433462e-07
Chotzen I-Disease 0 7.004032340773847e-07
, I-Disease 0 8.521660044280566e-10
Crouzon I-Disease 0 6.31904768511049e-08
, I-Disease 0 6.578375066901287e-10
and I-Disease 0 2.325378112288945e-09
Pfeiffer I-Disease 0 3.812031309280428e-06
syndromes I-Disease 0 2.117834083037451e-05
- O 0 5.646547833748627e-07
support O 0 1.021147610913431e-08
the O 0 1.9016206664890234e-10
hypothesis O 0 7.103757582171966e-09
that O 0 1.6209306119563394e-10
TWIST O 0 8.485903890687041e-08
and O 0 2.247553476664166e-09
FGFRs O 0 4.779219864303741e-08
are O 0 5.768130417749262e-11
components O 0 1.9378622317933747e-10
of O 0 3.504650779653784e-12
the O 0 3.4540183213582765e-11
same O 0 1.293556511905436e-10
molecular O 0 4.004426235049152e-10
pathway O 0 4.987563695380004e-10
involved O 0 2.539907451026835e-10
in O 0 4.217962090713456e-11
the O 0 4.9732364060250944e-11
modulation O 0 5.759063697041711e-07
of O 0 1.8309076477152075e-09
craniofacial O 1 0.9850821495056152
and O 0 3.6147633863947704e-07
limb O 0 0.00017213950923178345
development O 0 4.208064730004679e-10
in O 0 1.7307330013593969e-09
humans O 0 5.333229857740207e-09
. O 0 1.1322185411444252e-09
. O 0 1.3405539789346221e-08

Mutation O 0 0.00021533913968596607
analysis O 0 7.943974651425378e-07
of O 0 5.207840558796306e-08
UBE3A O 1 0.5511161088943481
in O 0 0.09759144484996796
Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
patients O 1 0.9997555613517761
. O 0 2.1796311955313286e-07

Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 0.008560107089579105
AS B-Disease 1 0.9999938011169434
) O 0 3.1394808974738453e-09
is O 0 7.835087245666728e-09
caused O 0 5.7261448915824076e-08
by O 0 7.808363955419395e-10
chromosome O 0 1.293147875003342e-06
15q11 O 0 8.017527193260321e-07
- O 0 2.116137949315089e-07
q13 O 0 2.334953421723185e-07
deletions O 0 5.265561853207146e-08
of O 0 5.669085756387915e-10
maternal O 0 3.6333054254100716e-07
origin O 0 1.7528052342896672e-09
, O 0 3.7157435461843136e-10
by O 0 1.176099995170432e-09
paternal O 0 1.2234981113579124e-05
uniparental B-Disease 0 0.00013868372479919344
disomy I-Disease 0 7.555040065199137e-05
( O 0 1.832218643471606e-08
UPD B-Disease 1 0.9999918937683105
) O 0 5.00454744312151e-09
15 O 0 2.005236199309479e-09
, O 0 8.520615463192271e-11
by O 0 2.5516433410643913e-10
imprinting O 0 0.0003200442879460752
defects O 1 0.9588262438774109
, O 0 6.058364365735258e-10
and O 0 2.8210847546894513e-10
by O 0 2.1847229580984617e-10
mutations O 0 1.2001484250845351e-08
in O 0 1.529102955366568e-10
the O 0 1.5020988897163079e-09
UBE3A O 0 1.272660847462248e-05
gene O 0 5.89362969094509e-07
. O 0 3.2537599281567964e-08

UBE3A O 0 0.0009181923815049231
encodes O 0 6.718487838952569e-06
a O 0 1.9484238578115765e-07
ubiquitin O 0 4.610574535490741e-07
- O 0 1.6731237906242313e-07
protein O 0 1.2946562932825145e-08
ligase O 0 1.5307913159290365e-08
and O 0 2.4196069592363756e-09
shows O 0 4.705242062641446e-08
brain O 0 1.7776419554138556e-06
- O 0 2.310075615241658e-07
specific O 0 9.066940087620878e-09
imprinting O 0 2.6169298052991508e-06
. O 0 7.350131170369423e-08

Here O 0 2.837390695731301e-07
we O 0 1.4045348883939823e-08
describe O 0 1.3491397510279057e-07
UBE3A O 0 4.52070526080206e-06
coding O 0 6.471676101682533e-07
- O 0 5.669307938660495e-07
region O 0 1.30977486634265e-08
mutations O 0 6.676981456621434e-08
detected O 0 1.9357290881316658e-08
by O 0 2.832541978747827e-10
SSCP O 0 3.73885626459014e-07
analysis O 0 2.1827080143310695e-09
in O 0 1.4192204356167082e-10
13 O 0 1.7010041153397992e-09
AS B-Disease 1 0.9660177230834961
individuals O 0 6.175145395026505e-10
or O 0 4.966783651028095e-10
families O 0 6.003063379722562e-09
. O 0 1.3869699166946248e-08

Two O 0 2.0326571359419177e-07
identical O 0 1.830284190873499e-07
de O 0 3.0400073569580854e-08
novo O 0 1.3792961794933944e-07
5 O 0 5.302284389330225e-09
- O 0 1.0366235869696538e-07
bp O 0 4.413068666053732e-07
duplications O 0 1.7803543528316368e-08
in O 0 1.1514245112920207e-09
exon O 0 1.0574563447107721e-07
16 O 0 1.0158055729903026e-08
were O 0 4.75113326459109e-09
found O 0 1.391017967478092e-08
. O 0 1.7403801066961933e-08

Among O 0 4.0461623029841576e-07
the O 0 1.1479796002689113e-09
other O 0 1.508063535160531e-10
11 O 0 3.3039179725413703e-10
unique O 0 6.827992060642885e-10
mutations O 0 2.2044654102160166e-08
, O 0 3.6089173316433687e-10
8 O 0 6.270045593836926e-10
were O 0 5.449661277800999e-10
small O 0 8.646661164846137e-11
deletions O 0 1.4400435510708576e-08
or O 0 4.87861084863539e-10
insertions O 0 2.728418735387095e-07
predicted O 0 1.900119855235971e-06
to O 0 1.3145551314153181e-08
cause O 0 4.2719281623249117e-07
frameshifts O 0 1.2192338544991799e-05
, O 0 7.873824925397344e-10
1 O 0 5.090282639841348e-10
was O 0 2.5419454985353696e-08
a O 0 1.3106937757356718e-09
mutation O 0 4.501011563462498e-09
to O 0 2.1417065343420916e-10
a O 0 7.880796015768965e-10
stop O 0 7.2605068623943225e-09
codon O 0 4.072953974088023e-09
, O 0 7.530554652079857e-11
1 O 0 1.1957282386454438e-10
was O 0 4.941640874278619e-09
a O 0 1.767364810056904e-09
missense O 0 1.2637800637094188e-06
mutation O 0 3.7283840015334135e-08
, O 0 2.3702823037652365e-10
and O 0 3.0060146039012636e-10
1 O 0 6.452011702684501e-10
was O 0 4.421198696036299e-07
predicted O 0 5.702765903947693e-08
to O 0 9.201097661559743e-10
cause O 0 4.7453823093235314e-09
insertion O 0 5.975657746404295e-09
of O 0 9.945168299996254e-11
an O 0 9.6374275226907e-10
isoleucine O 0 6.435833256546175e-06
in O 0 1.0619425339086774e-09
the O 0 2.0223737962066224e-10
hect O 0 3.569925155488818e-08
domain O 0 4.5757983513361467e-10
of O 0 2.7775741776037144e-11
the O 0 1.3252431096955064e-10
UBE3A O 0 1.4504917089652736e-07
protein O 0 2.1261110649817283e-09
, O 0 4.5796377107221176e-11
which O 0 2.732926905613109e-11
functions O 0 1.1962660029229966e-11
in O 0 4.663198299725835e-11
E2 O 0 4.184362012438214e-08
binding O 0 5.186722606964622e-09
and O 0 7.696329129558421e-10
ubiquitin O 0 3.9217976421923595e-08
transfer O 0 1.8818068880932515e-08
. O 0 1.1419788670252728e-08

Eight O 0 1.6661257973282773e-07
of O 0 2.724600545178646e-10
the O 0 2.1207437195247536e-10
cases O 0 3.3667391097225163e-09
were O 0 1.6624952081656375e-08
familial O 0 8.780961024967837e-07
, O 0 1.0246672843550186e-08
and O 0 1.9862262945480325e-09
five O 0 1.0946245021514756e-09
were O 0 4.756881999412599e-09
sporadic O 0 7.078400017235253e-07
. O 0 6.715489320185952e-08

In O 0 2.81435433180377e-07
two O 0 1.2695063666967599e-08
familial O 0 1.1182686421307153e-06
cases O 0 2.2504593744088197e-07
and O 0 4.462969993568322e-09
one O 0 2.202178217558526e-09
sporadic O 0 4.997472160539473e-07
case O 0 9.876210924630868e-07
, O 0 4.023461119828653e-09
mosaicism O 0 1.1769308230213937e-06
for O 0 2.2136117383553255e-09
UBE3A O 0 5.599771611741744e-06
mutations O 0 1.5981969170297816e-07
was O 0 1.201197363798201e-08
detected O 0 9.183166227444417e-09
in O 0 1.0215225887399981e-10
the O 0 9.712917276027966e-11
mother O 0 2.5638570377850556e-08
of O 0 2.173806620819896e-11
three O 0 7.692561254657448e-09
AS B-Disease 1 0.9999872446060181
sons O 0 4.281614849332982e-07
, O 0 7.584060462972886e-11
in O 0 2.4558148917219746e-11
the O 0 3.223150357722915e-10
maternal O 0 2.442980928663019e-07
grandfather O 0 3.3710392699504155e-08
of O 0 6.911427680167392e-11
two O 0 2.562594358934689e-09
AS B-Disease 1 0.9821352958679199
first O 0 1.6237356348369758e-08
cousins O 0 8.71460699158888e-08
, O 0 7.305887006481271e-10
and O 0 7.251604872138273e-10
in O 0 2.8925106754229546e-10
the O 0 3.2480643175070156e-10
mother O 0 7.492312903423226e-08
of O 0 3.325665437481362e-11
an O 0 8.94218388225454e-09
AS B-Disease 1 0.9999774694442749
daughter O 0 0.0008373293094336987
. O 0 9.15836650960955e-08

The O 0 4.091690186669439e-08
frequencies O 0 8.555787900377254e-08
with O 0 3.288376793086911e-10
which O 0 8.333819745409698e-10
we O 0 4.493383998216416e-10
detected O 0 8.933915829345551e-09
mutations O 0 7.951280522888737e-09
were O 0 1.0200764677392726e-09
5 O 0 1.5479777182303422e-10
( O 0 4.2568049779534434e-11
14 O 0 1.4919681046166033e-09
% O 0 3.49458656456747e-11
) O 0 7.876670669870744e-12
of O 0 1.0114712886699628e-11
35 O 0 1.0648957271541803e-09
in O 0 1.0026496299886389e-10
sporadic O 0 2.6995107305083366e-07
cases O 0 1.4163722994453565e-07
and O 0 5.13030640192369e-09
8 O 0 1.2636834911816663e-09
( O 0 1.2886117173316336e-10
80 O 0 4.569433720291727e-09
% O 0 6.659496565308842e-11
) O 0 1.5437900957593342e-11
of O 0 2.5003757744834765e-11
10 O 0 2.0844545534082215e-10
in O 0 4.3534842397718876e-10
familial O 0 6.793598572585324e-07
cases O 0 1.9789600003150554e-07
. O 0 9.007231405178118e-09
. O 0 2.2932960419552728e-08

The O 0 3.211744569853181e-06
hemochromatosis B-Disease 1 0.9999682903289795
845 O 0 8.96808851393871e-05
G O 0 0.0026951159816235304
- O 0 1.4411831216420978e-05
- O 0 9.884315659292042e-06
> O 0 3.4968454798445237e-08
A O 0 1.6545298464620828e-08
and O 0 9.812787249430244e-10
187 O 0 5.158565574703289e-09
C O 0 6.958831022529921e-08
- O 0 4.552009613689734e-06
- O 0 0.00011163849558215588
> O 0 3.8342213315445406e-07
G O 0 3.479209408396855e-05
mutations O 0 1.6278514181067294e-07
: O 0 1.3793133302186789e-09
prevalence O 0 5.930752422500518e-08
in O 0 5.274894410156605e-10
non O 0 1.3151217892470868e-08
- O 0 1.5228115444188006e-05
Caucasian O 0 1.4421331798075698e-05
populations O 0 7.626472608990298e-08
. O 0 2.346650340712131e-08

Hemochromatosis B-Disease 1 0.9960848093032837
, O 0 1.5370192159025464e-06
the O 0 2.7454237283564e-07
inherited B-Disease 1 0.9999998807907104
disorder I-Disease 1 0.9999998807907104
of I-Disease 0 4.805964959331277e-09
iron I-Disease 0 0.1418127715587616
metabolism I-Disease 0 3.548484073689906e-06
, O 0 1.410822236813658e-09
leads O 0 5.789740686878986e-09
, O 0 6.996662138547549e-10
if O 0 1.0654895632455919e-08
untreated O 0 2.6314140995964408e-05
, O 0 3.897008271636082e-10
to O 0 4.6285557608882755e-09
progressive O 0 0.0011228893417865038
iron B-Disease 1 0.9967430233955383
overload I-Disease 0 0.03327590599656105
and O 0 1.0998322608202216e-07
premature B-Disease 0 6.001857400406152e-06
death I-Disease 0 2.2028316379874013e-05
. O 0 3.9821593134092836e-08

The O 0 1.4460526926995954e-06
hemochromatosis B-Disease 1 0.9999886751174927
gene O 0 3.5680845940078143e-06
, O 0 1.8099230558732415e-08
HFE O 0 6.7053533712169155e-06
, O 0 9.650676702221972e-09
recently O 0 4.1953903462399467e-08
has O 0 2.2452150361118584e-08
been O 0 3.68967123520747e-09
identified O 0 3.534690762307946e-09
, O 0 9.655307109390776e-11
and O 0 2.1492198298833642e-10
characterization O 0 5.755772747306764e-09
of O 0 2.1417178794336245e-11
this O 0 1.1897542673278139e-10
gene O 0 3.288441075000037e-09
has O 0 2.0571878422970258e-08
shown O 0 2.6489472837454286e-09
that O 0 3.176599955301285e-11
it O 0 6.20517873195503e-11
contains O 0 7.008425784160721e-11
two O 0 6.869292634714697e-11
mutations O 0 7.684887726178147e-10
that O 0 1.858019710310188e-10
result O 0 3.91720350600977e-10
in O 0 7.74022443361666e-11
amino O 0 6.631639126730704e-10
acid O 0 1.242735359063829e-09
substitutions O 0 1.4681931226334655e-09
- O 0 2.0966810510003597e-09
cDNA O 0 9.126000399817258e-09
nucleotides O 0 6.772017613343451e-09
845 O 0 7.307287575031296e-08
G O 0 9.776736078492831e-07
- O 0 3.443305729433632e-07
- O 0 6.593322723347228e-07
> O 0 1.7059305079669684e-08
A O 0 9.737578743340691e-09
( O 0 2.448155567158494e-10
C282Y O 0 2.1462724930643162e-08
) O 0 7.447138045124646e-11
and O 0 1.9849301369223582e-10
187 O 0 3.4338032417480235e-09
C O 0 6.194757418143126e-08
- O 0 1.2160880032752175e-05
- O 0 0.010969216004014015
> O 0 2.0621591829694808e-06
G O 0 0.00016082559886854142
( O 0 1.911731661863314e-09
H63D O 0 3.3958513085963205e-06
) O 0 3.5481599880426984e-09
. O 0 8.029340747839342e-09

Although O 0 0.0002488156023900956
hemochromatosis B-Disease 1 0.9999924898147583
is O 0 1.5407073306050734e-07
common O 0 9.362805641899286e-09
in O 0 2.609272131692819e-09
Caucasians O 0 1.136833063242193e-07
, O 0 5.394714674977763e-10
affecting O 0 1.3788293840022448e-09
> O 0 4.192668434654934e-09
= O 0 3.1575146941520416e-09
1 O 0 7.746165375799308e-10
/ O 0 8.238648874225873e-09
300 O 0 1.08611852844831e-09
individuals O 0 5.994955920574085e-11
of O 0 7.22361493538104e-12
northern O 0 2.696611378638636e-09
European O 0 8.626880876327903e-10
origin O 0 7.120710687757992e-10
, O 0 1.2204659505243853e-10
it O 0 4.0638420406580167e-10
has O 0 2.6114925777420694e-09
not O 0 2.084979411343113e-10
been O 0 4.120601082568953e-10
recognized O 0 1.4861592512183108e-10
in O 0 5.2453753146552984e-11
other O 0 1.2386740244618721e-10
populations O 0 2.635712537113477e-09
. O 0 9.624445240774548e-09

The O 0 3.352201360939944e-08
present O 0 1.5965927468997165e-09
study O 0 3.2787070280981823e-10
used O 0 5.785829593207836e-10
PCR O 0 1.7814387831549539e-07
and O 0 1.3321724834369775e-09
restriction O 0 3.5018630217820146e-09
- O 0 6.57642118540025e-09
enzyme O 0 1.219966128118699e-09
digestion O 0 1.1808518607381302e-09
to O 0 1.0468229061366685e-10
analyze O 0 2.759142359032296e-10
the O 0 4.0945257601121554e-11
frequency O 0 3.6058227514956798e-09
of O 0 9.665749103882071e-12
the O 0 1.0211466394682844e-10
845 O 0 2.1905458780224762e-08
G O 0 4.7595617616025265e-06
- O 0 3.134809674065764e-07
- O 0 7.494677447539289e-07
> O 0 7.100154242323242e-09
A O 0 1.5287304755418063e-09
and O 0 3.7767211580330695e-10
187 O 0 2.1219344059630885e-09
C O 0 1.3358498307525224e-08
- O 0 3.848974756692769e-07
- O 0 1.6061150745372288e-05
> O 0 8.878422619318371e-08
G O 0 5.108756340632681e-06
mutations O 0 2.7554586168321293e-08
in O 0 2.4695695488574643e-10
HLA O 0 9.356382690839382e-08
- O 0 5.829079441355134e-08
typed O 0 5.374231193400192e-08
samples O 0 4.280893861619006e-09
from O 0 1.0533161842740668e-10
non O 0 6.311428601968316e-10
- O 0 1.8463904893906147e-07
Caucasian O 0 8.527966315341473e-07
populations O 0 4.312280754703579e-09
, O 0 1.649584219221012e-10
comprising O 0 4.718295198991029e-10
Australian O 0 6.879015135297095e-09
Aboriginal O 0 3.858814601187532e-09
, O 0 1.2544038030526394e-10
Chinese O 0 1.2845186025955968e-10
, O 0 4.1417028140422474e-10
and O 0 9.346832197110189e-10
Pacific O 0 1.3606772375496234e-09
Islanders O 0 1.79285763124426e-07
. O 0 8.123987704777846e-09

Results O 0 1.2050467375956941e-05
showed O 0 1.0028919916749146e-07
that O 0 6.980983152660158e-11
the O 0 3.6731107738718904e-11
845 O 0 6.586541445585681e-08
G O 0 6.270553421927616e-05
- O 0 6.092292551329592e-06
- O 0 5.132710157340625e-06
> O 0 2.825670186723528e-08
A O 0 7.312777938750514e-09
mutation O 0 3.4831593609396805e-08
was O 0 1.210281386221368e-08
present O 0 2.8410584995697263e-10
in O 0 2.704654729346334e-11
these O 0 3.994415562202924e-11
populations O 0 1.328360754726532e-10
( O 0 2.4189308542310606e-11
allele O 0 6.774859784286491e-09
frequency O 0 1.3486221028813361e-08
0 O 0 2.307070756657481e-09
. O 0 1.5005717501903604e-10
32 O 0 2.189826320275756e-09
% O 0 3.632173728451704e-11
) O 0 1.629765072896916e-11
, O 0 1.553097095374767e-10
and O 0 6.95026980412905e-10
, O 0 2.2002207000770824e-10
furthermore O 0 5.372124967095715e-10
, O 0 4.440058390398072e-11
it O 0 2.8761604209393e-10
was O 0 1.0011066642334754e-08
always O 0 5.394367619260265e-09
seen O 0 1.7228876103558832e-09
in O 0 2.683422581362116e-11
conjunction O 0 4.0379893873065953e-10
with O 0 5.493230870179389e-10
HLA O 0 7.70338431266282e-07
haplotypes O 0 3.4719968766694365e-07
common O 0 2.4949855514933006e-09
in O 0 1.0387443127868323e-09
Caucasians O 0 6.023550014333523e-08
, O 0 2.5023091931863917e-10
suggesting O 0 1.675386496202691e-09
that O 0 3.595738984341068e-10
845 O 0 3.899941702911747e-08
G O 0 3.117924279649742e-05
- O 0 6.9468424044316635e-06
- O 0 9.67546111496631e-06
> O 0 1.7203010571620325e-08
A O 0 4.4595005022074474e-08
may O 0 1.4308666607121268e-07
have O 0 2.702640999885375e-09
been O 0 1.176261532620515e-09
introduced O 0 6.508459327037031e-10
into O 0 6.248779271800231e-11
these O 0 5.642814687734088e-11
populations O 0 2.612497718157414e-10
by O 0 3.031828399446823e-10
Caucasian O 0 2.3461474540908966e-07
admixture O 0 1.3549540653912118e-06
. O 0 7.39183008136024e-08

187 O 0 1.1373583220120054e-05
C O 0 4.0690651985642035e-06
- O 0 7.147862561396323e-06
- O 0 3.687632852233946e-05
> O 0 3.5032482514907315e-07
G O 0 1.4131440366327297e-05
was O 0 2.900020845686413e-08
present O 0 8.033530091156038e-11
at O 0 2.2244742506338788e-11
an O 0 1.4517019530924102e-10
allele O 0 2.6104583383812496e-08
frequency O 0 1.5338191161617942e-08
of O 0 1.3559510458893698e-10
2 O 0 2.8155829667753096e-08
. O 0 4.432990508007606e-08

68 O 0 0.0003355525550432503
% O 0 4.4868109227991226e-08
in O 0 2.384802633148553e-10
the O 0 1.1635931801423638e-10
two O 0 1.1327500049063133e-09
populations O 0 1.7410565211761764e-09
analyzed O 0 1.7820905640064666e-08
( O 0 2.852711400436192e-10
Australian O 0 3.654757563253952e-08
Aboriginal O 0 8.722052413645542e-09
and O 0 3.831851780322637e-10
Chinese O 0 3.3600142113066056e-10
) O 0 4.773857975592932e-10
. O 0 6.294253118710458e-09

In O 0 1.6632729682442005e-07
the O 0 4.341040416022679e-09
Australian O 0 2.70098841070876e-08
Aboriginal O 0 5.619020360114746e-09
samples O 0 1.8700985204844756e-09
, O 0 3.074542842540495e-10
187 O 0 3.606717147164318e-09
C O 0 2.2855843440083845e-08
- O 0 6.685021958219295e-07
- O 0 2.3557018721476197e-05
> O 0 1.1150297041240265e-07
G O 0 8.342418368556537e-06
was O 0 4.267053910211871e-08
found O 0 3.527092506949714e-10
to O 0 2.2444893166273516e-10
be O 0 1.2304893770576086e-09
associated O 0 6.368237603915361e-10
with O 0 3.0675020856740787e-10
HLA O 0 1.838434286582924e-06
haplotypes O 0 7.517405151702405e-07
common O 0 2.8763482706750665e-09
in O 0 9.29268662019922e-10
Caucasians O 0 5.292203653084471e-08
, O 0 4.531848785127579e-10
suggesting O 0 2.833980827787741e-09
that O 0 2.3140503402352408e-10
it O 0 3.5995542657651924e-10
was O 0 5.154080717773013e-09
introduced O 0 4.803726305624423e-10
by O 0 8.212659025064184e-11
recent O 0 1.721130460374809e-09
admixture O 0 4.071294767982181e-07
. O 0 3.496805334179953e-08

In O 0 9.41274862498176e-08
the O 0 1.644231556463538e-10
Chinese O 0 7.995740874955359e-11
samples O 0 5.231589605969589e-10
analyzed O 0 1.4335150844146938e-09
, O 0 9.399531847309461e-11
187 O 0 2.735568438438918e-09
C O 0 1.6324740670370375e-08
- O 0 5.157894520380069e-07
- O 0 2.4104794647428207e-05
> O 0 1.7545310981859075e-07
G O 0 8.572907972848043e-06
was O 0 6.291183041184922e-08
present O 0 1.3529155573621665e-10
in O 0 9.80902026270769e-11
association O 0 1.0147201134902417e-10
with O 0 3.593838074356093e-11
a O 0 1.5039278711270754e-09
wide O 0 1.5622521942759704e-08
variety O 0 1.5704613165468118e-09
of O 0 2.727408299207923e-10
HLA O 0 1.85946998954023e-06
haplotypes O 0 5.200738542043837e-07
, O 0 7.804686341650324e-10
showing O 0 3.868173337195913e-09
this O 0 1.322853909746513e-10
mutation O 0 4.350547921916359e-09
to O 0 3.7893049809056834e-10
be O 0 1.15435139225184e-09
widespread O 0 6.8126455587957935e-09
and O 0 1.0717039700125497e-08
likely O 0 3.265049386413921e-08
to O 0 1.7699859355957415e-09
predate O 0 1.393174109409756e-08
the O 0 1.0329904986949856e-10
more O 0 1.8755555442062644e-10
genetically O 0 4.970092781775293e-09
restricted O 0 4.4280366040538865e-09
845 O 0 6.703497490434529e-08
G O 0 6.0750906413886696e-05
- O 0 1.4138220649329014e-05
- O 0 5.3115581977181137e-05
> O 0 1.3015410615935252e-07
A O 0 7.961724435290307e-08
mutation O 0 9.279514188165194e-07
. O 0 2.5153802596378227e-08

Genotype O 1 0.9977340698242188
- O 1 0.9917904138565063
phenotype O 1 0.9928218722343445
correlations O 0 0.0003351129707880318
in O 0 4.551444817479933e-06
attenuated B-Disease 1 0.9990457892417908
adenomatous I-Disease 1 0.9999972581863403
polyposis I-Disease 1 0.999882698059082
coli I-Disease 1 0.9999749660491943
. O 0 1.3944966667622793e-05

Germ O 0 0.00012609224359039217
- O 0 0.0007705740281380713
line O 0 8.189243089873344e-06
mutations O 0 1.3046155800111592e-07
of O 0 1.007194258551003e-10
the O 0 6.317462108995642e-10
tumor B-Disease 0 8.700835678610019e-07
suppressor O 0 9.359143405163195e-06
APC O 0 3.9126979345383006e-07
are O 0 4.1316998711238284e-09
implicated O 0 2.5708698103699135e-07
in O 0 1.3508353902125236e-07
attenuated B-Disease 1 0.9996494054794312
adenomatous I-Disease 1 0.9999995231628418
polyposis I-Disease 1 0.9999854564666748
coli I-Disease 1 0.9999990463256836
( O 0 7.126843229343649e-06
AAPC B-Disease 1 0.9999957084655762
) O 0 1.3619191108205086e-08
, O 0 5.787904600040861e-10
a O 0 3.5044556145891193e-09
variant O 0 4.255029489286244e-05
of O 0 7.359235354442717e-08
familial B-Disease 1 0.9999997615814209
adenomatous I-Disease 1 0.9999901056289673
polyposis I-Disease 1 0.9999996423721313
( O 0 1.958078200914315e-06
FAP B-Disease 0 3.7741250707767904e-05
) O 0 1.1486574180707976e-07
. O 0 7.875980401195193e-08

AAPC B-Disease 1 0.9999645948410034
is O 0 3.3624555726419203e-06
recognized O 0 1.9021667796437214e-08
by O 0 2.465267989748554e-10
the O 0 1.1055092952183543e-10
occurrence O 0 4.3590615561583945e-09
of O 0 3.4970820683710713e-10
< O 0 6.793780471525679e-08
100 O 0 5.896550359096864e-09
colonic B-Disease 0 2.3421127934852848e-06
adenomas I-Disease 0 4.411904683365719e-06
and O 0 1.6072132513755832e-09
a O 0 1.9678771945308426e-09
later O 0 5.615059350816409e-08
onset O 0 9.382703183291596e-07
of O 0 8.490811524097808e-06
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
( O 0 1.1042397218830047e-08
age O 0 2.065578108556565e-08
> O 0 2.063428183873839e-08
40 O 0 7.122697986972071e-09
years O 0 2.651489916516425e-09
) O 0 1.4831017525196444e-09
. O 0 2.2711395430974335e-08

The O 0 5.7575764600414914e-08
aim O 0 1.1186698678500306e-08
of O 0 5.919769535678299e-11
this O 0 4.800398620274926e-11
study O 0 2.145365829431256e-10
was O 0 2.925290898403432e-09
to O 0 5.7888982496479e-10
assess O 0 1.8317227841180284e-06
genotype O 0 0.18259035050868988
- O 0 0.008729125373065472
phenotype O 0 0.0579768642783165
correlations O 0 1.8878230321206502e-06
in O 0 8.428381192970846e-08
AAPC B-Disease 1 0.9999874830245972
families O 0 1.053990331456589e-06
. O 0 4.6577476098264015e-08

By O 0 6.295371690612228e-08
protein O 0 3.964055039773484e-08
- O 0 1.4367984135787992e-07
truncation O 0 4.1288669194727845e-07
test O 0 1.4139106951915892e-07
( O 0 4.245649665168827e-10
PTT O 0 5.9213707714889097e-08
) O 0 1.1743331307378924e-10
assay O 0 8.337575962968913e-09
, O 0 8.456985112204052e-11
the O 0 2.7949734540677618e-11
entire O 0 4.274103571066945e-10
coding O 0 6.064587942944399e-09
region O 0 4.1273659490137504e-10
of O 0 1.5010376622215382e-11
the O 0 6.325634460679908e-11
APC B-Disease 0 6.75261890847878e-09
gene O 0 2.731069148609322e-09
was O 0 9.451748717026476e-09
screened O 0 3.74608326580983e-08
in O 0 5.149862758457857e-10
affected O 0 6.462471446866402e-09
individuals O 0 2.9095309495019706e-10
from O 0 5.375384581896014e-10
11 O 0 5.3843375980022756e-08
AAPC B-Disease 1 0.9999905824661255
kindreds O 0 7.881742931203917e-05
, O 0 3.6430425343070283e-09
and O 0 4.749011184301821e-10
their O 0 4.111415929930473e-10
phenotypic O 0 6.268975312195835e-07
differences O 0 1.0537717543002145e-07
were O 0 5.622410981231951e-08
examined O 0 1.2248407301740372e-06
. O 0 3.917670809983065e-08

Five O 0 3.9823649444770126e-07
novel O 0 2.7847775641021144e-07
germ O 0 1.1099452876806026e-06
- O 0 1.5006188732513692e-05
line O 0 1.72825218669459e-06
APC B-Disease 0 4.095305996543175e-07
mutations O 0 1.918867695849258e-07
were O 0 5.447096995681022e-09
identified O 0 6.214257552983327e-09
in O 0 2.1959360718692977e-10
seven O 0 9.005925782901159e-09
kindreds O 0 3.214027401554631e-06
. O 0 4.532354580533138e-08

Mutations O 0 0.0005505630979314446
were O 0 4.992908770873328e-07
located O 0 6.527459017746651e-09
in O 0 5.7719418133928e-10
three O 0 4.827984678712482e-10
different O 0 1.0497862301672711e-10
regions O 0 1.8646764687879624e-10
of O 0 1.2602546610451792e-11
the O 0 9.306445891699155e-11
APC B-Disease 0 7.448921479635828e-09
gene O 0 1.3342831284290924e-09
( O 0 1.7286626990964393e-11
1 O 0 1.181977848929705e-10
) O 0 3.857868885459581e-11
at O 0 4.808801967737253e-11
the O 0 4.046097484833311e-11
5 O 0 4.806787190503314e-10
end O 0 7.924659262137368e-10
spanning O 0 7.461705031630572e-09
exons O 0 3.7718727696756105e-08
4 O 0 1.2482705979977027e-09
and O 0 1.215163636381078e-09
5 O 0 9.421901037143243e-10
, O 0 1.9399258588403967e-10
( O 0 3.38884025008479e-11
2 O 0 4.1266023931285645e-10
) O 0 7.394710538344285e-11
within O 0 1.313699010685454e-10
exon O 0 1.608597166580239e-08
9 O 0 3.0533540140709192e-09
, O 0 4.866733127606437e-10
and O 0 5.95273275116881e-10
( O 0 3.4446237529017765e-11
3 O 0 2.5380186841061914e-10
) O 0 3.354166597246966e-11
at O 0 4.688687979537143e-11
the O 0 6.496797544386368e-11
3 O 0 1.2037539853793078e-09
distal O 0 2.5160409222735325e-07
end O 0 1.3690075739702934e-09
of O 0 3.216154079166422e-11
the O 0 3.542869608796906e-10
gene O 0 5.5257711295553236e-08
. O 0 3.3341557070798444e-08

Variability O 0 0.00020618288544937968
in O 0 1.4070096199247928e-08
the O 0 5.13435682858443e-10
number O 0 3.431394057784587e-09
of O 0 1.1211759698426249e-07
colorectal B-Disease 1 1.0
adenomas I-Disease 1 0.9999998807907104
was O 0 0.0017638357821851969
most O 0 2.046877334294095e-09
apparent O 0 3.316738528269525e-08
in O 0 2.7265553703692547e-10
individuals O 0 3.384867039435413e-11
with O 0 6.247289491279062e-11
mutations O 0 7.665845735971288e-09
in O 0 3.825980088301151e-10
region O 0 3.5940745934937013e-09
1 O 0 1.229621915399548e-08
, O 0 4.534998598870743e-09
and O 0 5.8479212583506524e-08
upper O 0 0.00018145027570426464
- O 1 0.9994294047355652
gastrointestinal O 1 0.9999281167984009
manifestations O 0 3.1392362416227115e-06
were O 0 4.183962687420717e-08
more O 0 4.433876377163415e-09
severe O 0 0.00015013686788734049
in O 0 5.614221088023896e-09
them O 0 1.0704230390956582e-08
. O 0 2.421021072507301e-08

In O 0 2.549990369971056e-07
individuals O 0 1.1069240635208644e-08
with O 0 9.92355309037407e-10
mutations O 0 5.475954978351183e-08
in O 0 7.703819249194055e-10
either O 0 8.553157293533786e-09
region O 0 5.969153171747621e-09
2 O 0 7.811674862523432e-09
or O 0 8.439876020283066e-10
region O 0 2.9765534481640543e-09
3 O 0 1.8560194492422966e-09
, O 0 2.503774965134653e-10
the O 0 9.545185475356988e-11
average O 0 1.324576559547097e-09
number O 0 9.88985837668821e-11
of O 0 4.019238414310067e-11
adenomas B-Disease 0 1.759764529651875e-07
tended O 0 6.259623205551179e-06
to O 0 6.900764848438712e-09
be O 0 7.55977591637702e-09
lower O 0 1.948493988379596e-08
than O 0 1.8509499488672532e-09
those O 0 1.0944276734869973e-10
in O 0 7.194537327004369e-11
individuals O 0 2.963515891019064e-11
with O 0 4.492370364594933e-11
mutations O 0 4.1715777499007345e-09
in O 0 2.434530632644538e-10
region O 0 1.1777118169575829e-09
1 O 0 3.7442884348593e-09
, O 0 1.4358656486024302e-09
although O 0 1.110209968402387e-08
age O 0 3.7199721081293546e-09
at O 0 7.94983523455528e-10
diagnosis O 0 8.89812042714766e-07
was O 0 1.1259226795345967e-07
similar O 0 1.5635222894161416e-08
. O 0 2.4010535781826547e-08

In O 0 6.354690640364424e-07
all O 0 1.135569647203738e-07
AAPC B-Disease 1 0.9998307228088379
kindreds O 0 4.330697993282229e-05
, O 0 4.635517303341885e-09
a O 0 1.1598577653870734e-09
predominance O 0 2.2273141553341702e-07
of O 0 2.5438744444272743e-09
right O 0 0.10601257532835007
- O 1 0.9999932050704956
sided O 1 1.0
colorectal B-Disease 1 1.0
adenomas I-Disease 1 0.9999998807907104
and O 0 4.320014704717323e-05
rectal B-Disease 1 0.9886399507522583
polyp I-Disease 0 0.012149023823440075
sparing O 0 2.255608478662907e-06
was O 0 2.407370800483477e-07
observed O 0 4.69707330807978e-08
. O 0 1.1704591074135351e-08

No O 0 2.169284562114626e-05
desmoid B-Disease 0 0.10896629095077515
tumors I-Disease 1 0.999998927116394
were O 0 1.1936130306366977e-07
found O 0 2.9510700549906232e-09
in O 0 6.161897658785165e-10
these O 0 3.091491729279028e-09
kindreds O 0 2.8842555366281886e-06
. O 0 2.2728512405478796e-08

Our O 0 1.3647697016949678e-07
data O 0 4.754432847420276e-09
suggest O 0 3.892894451240636e-09
that O 0 6.81797174273413e-10
, O 0 8.566899967199504e-10
in O 0 1.0745837997205854e-08
AAPC B-Disease 1 0.9999994039535522
families O 0 1.3536764242871868e-07
, O 0 1.1863846016701984e-10
the O 0 3.4607844368039764e-11
location O 0 2.216598904425382e-09
of O 0 2.4702465767356685e-11
the O 0 6.327205981371264e-10
APC B-Disease 0 1.2889506706414977e-06
mutation O 0 6.836194756942859e-07
may O 0 4.0289922509373355e-08
partially O 0 1.1511731656810298e-07
predict O 0 5.0236963033967186e-08
specific O 0 2.9389706224236534e-09
phenotypic O 0 5.019576747145038e-06
expression O 0 1.0848373221961083e-06
. O 0 5.308409001258951e-08

This O 0 4.5004473037124626e-08
should O 0 4.801328667980442e-09
help O 0 6.708851252312797e-10
in O 0 7.586230255096638e-11
the O 0 8.94210677726548e-11
design O 0 8.868129341976783e-09
of O 0 1.7404780394691954e-10
tailored O 0 7.076719157339539e-06
clinical O 0 8.523210226485389e-07
- O 0 1.5790290035511134e-06
management O 0 2.0471739858862747e-09
protocols O 0 1.4018469718379833e-09
in O 0 5.884747550366498e-11
this O 0 5.304190767163597e-11
subset O 0 1.4434966555398887e-09
of O 0 3.3967365031806196e-10
FAP B-Disease 0 1.8421707864035852e-05
patients O 0 0.013705272227525711
. O 0 2.5075137521923807e-09
. O 0 7.170570359704698e-09

Wilms B-Disease 0 0.009937028400599957
' I-Disease 0 2.2083257135818712e-05
tumor I-Disease 0 5.1370589062571526e-06
1 O 0 1.5348492254929624e-08
and O 0 7.156796932861198e-09
Dax O 0 4.227791941957548e-05
- O 0 2.407552983640926e-06
1 O 0 1.512515446222551e-08
modulate O 0 4.806402671420074e-07
the O 0 1.337743693596849e-09
orphan O 0 2.542030870245071e-07
nuclear O 0 1.0541412187592414e-08
receptor O 0 2.4688656452553914e-08
SF O 0 3.953680788981728e-05
- O 0 1.629845911566008e-07
1 O 0 2.7242488265244447e-09
in O 0 4.018657906446066e-10
sex O 0 1.3208635074590802e-08
- O 0 4.63020022323235e-08
specific O 0 1.7854475675704862e-09
gene O 0 3.125990488683783e-08
expression O 0 6.654769180158837e-08
. O 0 1.859173615059717e-08

Products O 0 7.017424081823265e-07
of O 0 6.220305603932275e-09
steroidogenic O 0 2.0656077595049283e-06
factor O 0 6.135609709190248e-08
1 O 0 9.826277569402464e-09
( O 0 3.330175690763326e-09
SF O 1 0.7732312679290771
- O 0 0.00010465329251019284
1 O 0 1.9501149139955487e-08
) O 0 1.0372516179302238e-09
and O 0 1.755054235275111e-08
Wilms B-Disease 0 1.5069534128997475e-05
tumor I-Disease 0 6.548548867613135e-07
1 O 0 1.6536204627826123e-09
( O 0 2.80180684208986e-10
WT1 O 0 3.1740916028866195e-07
) O 0 6.587411865988102e-11
genes O 0 1.704735103080779e-10
are O 0 3.39647580893665e-11
essential O 0 7.343577135277002e-11
for O 0 5.8005114600412355e-11
mammalian O 0 3.2772018432325467e-09
gonadogenesis O 0 1.717803286283015e-07
prior O 0 9.262409172983155e-10
to O 0 1.1292251578254309e-09
sexual O 0 5.457236440520319e-09
differentiation O 0 2.0740975159583286e-08
. O 0 3.4792552838780466e-08

In O 0 1.1380559499230003e-06
males O 0 1.1117462008769508e-06
, O 0 1.610678879160332e-08
SF O 0 0.012039069086313248
- O 0 3.4555798720248276e-06
1 O 0 1.0233255132163777e-08
participates O 0 3.4019256300865663e-09
in O 0 3.751120247752482e-10
sexual O 0 1.08372633089715e-09
development O 0 3.094048628415891e-11
by O 0 7.458254153158705e-11
regulating O 0 4.483626359075288e-09
expression O 0 4.519653984402794e-09
of O 0 7.535037177541781e-11
the O 0 5.873536657041711e-10
polypeptide O 0 1.3205759614720591e-06
hormone O 0 3.0897987812750216e-07
Mullerian O 0 1.0642108918546e-06
inhibiting O 0 2.7073357955487154e-07
substance O 0 4.1437778008912574e-07
( O 0 8.706544818437578e-09
MIS O 0 1.3663316167367157e-06
) O 0 9.615693130626823e-09
. O 0 2.6817177811722104e-08

Here O 0 4.3443603203741077e-07
, O 0 2.958226996696567e-09
we O 0 4.3496992119251843e-10
show O 0 5.572124539554579e-09
that O 0 1.4037413453849013e-09
WT1 O 0 5.982399216009071e-06
- O 0 3.1604677133145742e-06
KTS O 0 1.3413206033874303e-05
isoforms O 0 1.6475050301778538e-07
associate O 0 1.635958923884573e-08
and O 0 2.3759052503180556e-09
synergize O 0 6.019243414812081e-07
with O 0 1.539716620868603e-08
SF O 0 0.11417604982852936
- O 0 3.3861492738651577e-06
1 O 0 8.250631289286048e-09
to O 0 3.235187229222447e-09
promote O 0 3.3849303804345254e-08
MIS O 0 6.106951332185417e-06
expression O 0 2.837855959114677e-07
. O 0 1.3980134383473342e-08

In O 0 1.4422172398553812e-06
contrast O 0 2.947611619674717e-06
, O 0 2.476170379850373e-08
WT1 O 0 2.1991440007695928e-05
missense O 0 1.473316388000967e-05
mutations O 0 1.2135495808252017e-06
, O 0 1.2804195481663783e-09
associated O 0 3.1138016609588703e-09
with O 0 6.060679513808509e-09
male B-Disease 0 0.00019467461970634758
pseudohermaphroditism I-Disease 1 0.9999980926513672
in O 0 6.091997306612029e-07
Denys B-Disease 1 0.9980081915855408
- I-Disease 1 0.9998505115509033
Drash I-Disease 1 0.9999288320541382
syndrome I-Disease 1 0.9999911785125732
, O 0 1.2365971580052815e-09
fail O 0 1.6817969239468766e-08
to O 0 3.791504443739768e-09
synergize O 0 1.0120616025233176e-06
with O 0 5.058040031258315e-08
SF O 1 0.982099175453186
- O 0 5.7628185459179804e-05
1 O 0 8.110908567005026e-08
. O 0 2.9060563733196432e-08

Additionally O 0 5.3424437282956205e-06
, O 0 5.405975667116536e-09
the O 0 2.346084160276263e-10
X O 0 2.3570279154228047e-05
- O 0 0.00014509339234791696
linked O 0 0.00017109840700868517
, O 0 1.282582706707558e-09
candidate O 0 9.144085488799192e-09
dosage O 0 1.1804543476046092e-07
- O 0 4.095016237215532e-08
sensitive O 0 1.6389135382155473e-08
sex O 0 7.2220829316904656e-09
- O 0 2.0275821910331615e-08
reversal O 0 3.852235153090078e-08
gene O 0 5.110012413211962e-09
, O 0 4.4170511692698256e-10
Dax O 0 1.1064090585932718e-06
- O 0 1.559781708238006e-07
1 O 0 4.5176027363424964e-09
, O 0 4.360015404270001e-10
antagonizes O 0 1.318601050570578e-07
synergy O 0 7.222730857847637e-09
between O 0 1.0908395298159235e-09
SF O 0 0.00937650352716446
- O 0 2.8368867788231e-06
1 O 0 5.169064731802564e-09
and O 0 1.1974451430418753e-09
WT1 O 0 4.4834064283350017e-07
, O 0 5.338335884452761e-10
most O 0 1.6651337253481557e-10
likely O 0 1.0473028000390627e-09
through O 0 1.867437454672327e-11
a O 0 2.385994735121244e-10
direct O 0 5.005814651681817e-10
interaction O 0 6.327061097266551e-10
with O 0 2.8207900459875646e-09
SF O 1 0.9931467175483704
- O 0 0.0001401683548465371
1 O 0 1.315057147621701e-07
. O 0 3.24045643651516e-08

We O 0 1.8640137966485781e-07
propose O 0 3.44138527452742e-07
that O 0 9.385298760378191e-09
WT1 O 0 6.897733783262083e-06
and O 0 4.491246130555737e-08
Dax O 0 4.1576313378755e-05
- O 0 1.760860186550417e-06
1 O 0 8.288612463047684e-09
functionally O 0 4.932998720619253e-08
oppose O 0 4.944997300526666e-09
each O 0 1.5942548670100365e-10
other O 0 3.887251631695676e-11
in O 0 1.0572089037541588e-10
testis O 0 5.312521622613531e-08
development O 0 7.815825764367901e-11
by O 0 3.8646907896122684e-10
modulating O 0 5.966742833152239e-07
SF O 0 0.10016529262065887
- O 0 4.717418505606474e-06
1 O 0 1.7283127817790955e-08
- O 0 4.807241680282459e-07
mediated O 0 3.1356366889667697e-06
transactivation O 0 6.472807854152052e-06
. O 0 6.3853540233083095e-09
. O 0 9.733810202305904e-09

A O 0 1.828635163292347e-06
mouse O 0 1.3110968211549334e-05
model O 0 8.194618203560822e-06
for O 0 1.0448341072333278e-06
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 0.9999998807907104
imprinting O 0 0.002680218080058694
- O 0 0.004399485886096954
centre O 0 8.72345390234841e-06
mutations O 0 5.608718765870435e-06
. O 0 7.50260866766439e-08

Imprinting O 0 3.480367377051152e-05
in O 0 1.1131555766041856e-07
the O 0 6.544937924957139e-09
15q11 O 0 6.928363518454717e-07
- O 0 6.253867468331009e-07
q13 O 0 3.477093173387402e-07
region O 0 2.265708509696651e-09
involves O 0 3.9609598934120527e-10
an O 0 2.486385541899949e-10
imprinting O 0 1.0272899686469827e-07
centre O 0 3.37565886354696e-08
( O 0 2.8858210265880757e-10
IC O 0 4.651532847788076e-08
) O 0 1.854252723587635e-10
, O 0 9.607653561616303e-11
mapping O 0 1.6631825916491039e-09
in O 0 1.5710298340021467e-10
part O 0 1.4437162576541596e-10
to O 0 2.019721750956549e-10
the O 0 9.212121343527002e-11
promoter O 0 8.78672707926853e-08
and O 0 7.217246245083686e-10
first O 0 1.8406486335109662e-09
exon O 0 2.041723767831627e-08
of O 0 4.716693147166495e-10
SNRPN O 0 3.4903056075563654e-05
. O 0 9.284969593181813e-08

Deletion O 0 3.16792938974686e-05
of O 0 8.037829957174836e-09
this O 0 3.1679083800639773e-09
IC O 0 1.3513820249499986e-06
abolishes O 0 9.22646086110035e-06
local O 0 1.50538657095467e-08
paternally O 0 3.921648783489218e-07
derived O 0 4.109176110489443e-09
gene O 0 6.093784143956782e-09
expression O 0 1.1318456394349141e-08
and O 0 1.5295764654865707e-09
results O 0 2.489140449313254e-08
in O 0 2.0139973457844462e-06
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 8.036006420297781e-07
PWS B-Disease 1 0.9999771118164062
) O 0 1.3667103360148758e-07
. O 0 8.29793265211265e-08

We O 0 2.2094037888109597e-07
have O 0 3.813349191972293e-09
created O 0 9.569398606856794e-10
two O 0 3.777174684138629e-10
deletion O 0 1.5755753679513873e-07
mutations O 0 1.5294232014184672e-07
in O 0 1.0228098368258998e-09
mice O 0 7.783695764373988e-06
to O 0 3.430041317642463e-08
understand O 0 2.702676283661276e-06
PWS B-Disease 1 0.999997615814209
and O 0 5.915858913851935e-09
the O 0 4.461612676531779e-11
mechanism O 0 4.093715644248874e-10
of O 0 4.468706654714438e-11
this O 0 4.925472252281793e-10
IC O 0 4.1352527659910265e-06
. O 0 5.568005789768904e-08

Mice O 0 0.005968243815004826
harbouring O 0 1.9229293684475124e-05
an O 0 2.99086231336787e-08
intragenic O 0 1.191808451039833e-06
deletion O 0 6.378643320203992e-07
in O 0 4.769310280039463e-09
Snrpn O 0 3.233599045415758e-06
are O 0 5.026300708976805e-09
phenotypically O 0 4.284451733838068e-06
normal O 0 8.796263273325167e-09
, O 0 1.609562344517812e-10
suggesting O 0 2.1027926067063163e-09
that O 0 3.663261083364233e-10
mutations O 0 2.8702105137057288e-09
of O 0 5.982916245761416e-11
SNRPN O 0 2.012814775298466e-06
are O 0 4.435557199311546e-10
not O 0 7.295276605034928e-10
sufficient O 0 2.9407647428314476e-09
to O 0 8.041939558722788e-09
induce O 0 6.951687100809067e-05
PWS B-Disease 1 0.9999904632568359
. O 0 7.105372787918895e-07

Mice O 0 0.0013501793146133423
with O 0 1.4417337546035469e-08
a O 0 4.667821684734008e-09
larger O 0 7.218818875998068e-09
deletion O 0 7.007059110719638e-08
involving O 0 5.0489963321354026e-09
both O 0 3.297800033053022e-09
Snrpn O 0 4.967499194208358e-07
and O 0 1.2545049443701828e-09
the O 0 3.2046132414365047e-10
putative O 0 3.3730252653185744e-06
PWS O 1 0.9999903440475464
- O 0 0.0009657259797677398
IC O 0 2.589996438473463e-05
lack O 0 9.173384540872576e-08
expression O 0 6.9863714813322986e-09
of O 0 3.4265115050891026e-11
the O 0 6.932471957599162e-11
imprinted O 0 1.1327163917940197e-07
genes O 0 6.818390740903624e-09
Zfp127 O 0 6.532268770342853e-08
( O 0 9.294773284374003e-11
mouse O 0 9.16381459603599e-09
homologue O 0 1.2034956853312906e-07
of O 0 8.512790472536835e-10
ZNF127 O 0 1.6502189055245253e-06
) O 0 1.0332392719192285e-09
, O 0 8.240279014692931e-10
Ndn O 0 1.6024397098135523e-07
and O 0 1.4389555103022644e-09
Ipw O 0 1.4802557757320756e-07
, O 0 8.134186102459751e-10
and O 0 4.2406322897647897e-10
manifest O 0 3.49027509116695e-08
several O 0 9.651426324808199e-10
phenotypes O 0 1.7006651376050286e-07
common O 0 5.984474249487448e-09
to O 0 3.993906830146443e-06
PWS B-Disease 1 1.0
infants O 1 0.999629020690918
. O 0 2.841460684521735e-07

These O 0 2.6671695962932063e-08
data O 0 4.2876520112145045e-09
demonstrate O 0 3.959980343637426e-09
that O 0 1.9336901524447114e-10
both O 0 9.5933705424045e-11
the O 0 5.765050936634708e-11
position O 0 1.606693089684086e-08
of O 0 3.90642032610522e-11
the O 0 1.1772845198709803e-10
IC O 0 1.246734484539047e-07
and O 0 1.4681090787505013e-09
its O 0 6.472555824643678e-11
role O 0 3.5535016595922286e-10
in O 0 6.372900124285152e-11
the O 0 3.034916068456184e-11
coordinate O 0 1.787219483517788e-09
expression O 0 1.3114840324846e-09
of O 0 5.142230825178062e-12
genes O 0 1.700283108752032e-10
is O 0 6.206551939058613e-11
conserved O 0 3.3727273751615883e-10
between O 0 7.289682052435964e-11
mouse O 0 5.5163145162850924e-08
and O 0 2.255605702217167e-09
human O 0 2.0006202250399951e-10
, O 0 1.4038155360385218e-10
and O 0 2.5300825323704146e-10
indicate O 0 1.510810920812844e-09
that O 0 1.5658724317191286e-10
the O 0 2.5909102988053156e-11
mouse O 0 1.1433388458215177e-08
is O 0 2.3766202894570654e-10
a O 0 5.26641008580242e-10
suitable O 0 5.575866879325986e-09
model O 0 2.264849818800485e-08
system O 0 2.292803863435111e-10
in O 0 3.7534156338558944e-11
which O 0 2.36737268677345e-10
to O 0 1.9071781653945408e-10
investigate O 0 9.220018637456917e-10
the O 0 2.1230172134178993e-11
molecular O 0 2.089198952726079e-10
mechanisms O 0 5.917455414561346e-11
of O 0 6.139367226404291e-12
imprinting O 0 2.2294345924933623e-08
in O 0 2.4700924639020627e-10
this O 0 9.478819812391848e-11
region O 0 3.805136761236838e-10
of O 0 1.8603237006420414e-11
the O 0 1.241758501580037e-10
genome O 0 1.4121251945553581e-09
. O 0 9.406045942128571e-10
. O 0 5.896752863776555e-09

Mutations O 0 0.0001535720657557249
of O 0 6.710735966919401e-09
the O 0 4.953349397318618e-10
ATM O 0 4.8782059280938483e-08
gene O 0 2.7265684821031755e-08
detected O 0 9.895003216797704e-08
in O 0 3.9811851593185565e-09
Japanese O 0 3.568135070963763e-05
ataxia B-Disease 1 1.0
- I-Disease 1 0.9999998807907104
telangiectasia I-Disease 1 1.0
patients O 1 0.9999935626983643
: O 0 1.5843130141135475e-09
possible O 0 2.3485655642474512e-09
preponderance O 0 6.097809546190547e-08
of O 0 2.733729735637791e-11
the O 0 5.3778835551465676e-11
two O 0 5.44597200669017e-10
founder O 0 1.0050213461454405e-07
mutations O 0 6.307547550932213e-08
4612del165 O 0 1.1668507227113878e-07
and O 0 5.63621593840935e-09
7883del5 O 0 1.245702151209116e-06
. O 0 7.629818554732992e-08

The O 0 5.3619139350757905e-08
ATM O 0 4.856296982325148e-07
( O 0 2.5818177817882315e-08
A O 1 0.9999738931655884
- O 1 0.9999887943267822
T O 1 1.0
, O 0 2.5818275517508482e-08
mutated O 0 1.0622797219639324e-07
) O 0 1.671721094886891e-10
gene O 0 1.9444610366292636e-09
on O 0 1.3758214567616278e-09
human O 0 1.9490133951194366e-09
chromosome O 0 3.429107209740323e-06
11q22 O 0 4.004524726042291e-06
. O 0 3.4441491436609795e-08

3 O 0 3.0094711291894782e-06
has O 0 1.2135029692217358e-07
recently O 0 1.9156674468945312e-08
been O 0 4.760648764090547e-09
identified O 0 1.6865052687720095e-09
as O 0 6.2072388895551e-11
the O 0 2.0958674032400815e-11
gene O 0 3.48749695788797e-10
responsible O 0 3.422999106383884e-10
for O 0 3.806789952709444e-11
the O 0 6.337690372504312e-10
human O 0 1.3357279726733395e-07
recessive B-Disease 1 0.999897837638855
disease I-Disease 1 0.9999879598617554
ataxia B-Disease 1 1.0
- I-Disease 1 0.9999998807907104
telangiectasia I-Disease 1 1.0
( O 0 5.3696578106610104e-05
A B-Disease 1 0.9999998807907104
- I-Disease 1 0.9999985694885254
T I-Disease 1 0.9999997615814209
) O 0 1.5605166936438764e-07
. O 0 4.276864373764511e-08

In O 0 4.7870109654013504e-08
order O 0 3.0681941431964788e-09
to O 0 5.737213482071013e-10
define O 0 5.933068703001254e-09
the O 0 5.889769227884756e-10
types O 0 5.118206303222905e-09
of O 0 6.528239615555265e-10
disease O 0 2.111999947373988e-06
- O 0 1.2876341315859463e-05
causing O 0 1.1878069727799812e-07
ATM O 0 7.080521413627139e-08
mutations O 0 6.604216196137713e-08
in O 0 4.880993387246235e-10
Japanese O 0 6.546213171532145e-08
A B-Disease 1 0.9999963045120239
- I-Disease 1 0.9999990463256836
T I-Disease 1 1.0
patients O 1 0.9769443869590759
as O 0 1.0748579803987468e-09
well O 0 1.1145306899607021e-10
as O 0 1.0052423476958339e-10
to O 0 1.3991484359987538e-10
look O 0 5.778101996867235e-09
for O 0 1.3114534458402716e-10
possible O 0 1.994517662140538e-09
mutational O 0 2.6220061499770964e-06
hotspots O 0 4.0522832023270894e-07
, O 0 1.6143040237892592e-09
reverse O 0 8.019517849788826e-08
- O 0 1.8395165568563243e-07
transcribed O 0 3.827005556900076e-08
RNA O 0 2.202749538326998e-09
derived O 0 1.88807497414345e-10
from O 0 3.561588177158903e-11
ten O 0 4.060603520095185e-10
patients O 0 4.554676191759199e-09
belonging O 0 1.6552036130601522e-10
to O 0 1.342983779739626e-10
eight O 0 4.800135844362785e-10
unrelated O 0 6.1016698360560895e-09
Japanese O 0 4.3730207011094535e-08
A B-Disease 1 0.9999183416366577
- I-Disease 1 0.999896764755249
T I-Disease 1 0.9999998807907104
families O 0 5.950173331825681e-08
was O 0 1.4072323750724536e-08
analyzed O 0 4.158478006388577e-09
for O 0 5.47835977970923e-11
mutations O 0 1.5613340620390659e-09
by O 0 3.001784931733198e-11
the O 0 6.912416472548699e-11
restriction O 0 2.2829093282439317e-08
endonuclease O 0 1.2625249610209721e-06
fingerprinting O 0 3.0936021744309983e-07
method O 0 1.307313226561746e-07
. O 0 2.954799960264154e-08

As O 0 5.381724008657329e-07
has O 0 5.0685471819633676e-08
been O 0 4.876659076558099e-09
reported O 0 2.3835944329420045e-09
by O 0 2.5310428752867153e-10
others O 0 2.2199835303382542e-09
, O 0 5.878240949552804e-11
mutations O 0 1.0487299917372184e-09
that O 0 1.4396850378517456e-10
lead O 0 1.6969210481221353e-09
to O 0 8.541578000453853e-10
exon O 0 3.4820963890069834e-08
skipping O 0 2.2084636341901387e-08
or O 0 4.696172895002348e-10
premature O 0 1.709767794011441e-08
protein O 0 1.5885007753624336e-09
truncation O 0 5.943753222936721e-08
were O 0 4.1211553281073066e-08
also O 0 7.894475295699976e-09
predominant O 0 5.536521641147374e-08
in O 0 7.482965913574446e-10
our O 0 1.1247154318994035e-09
mutants O 0 1.0849868914419858e-07
. O 0 1.4480114884918294e-08

Six O 0 1.4256430347359128e-07
different O 0 1.955365647177132e-09
mutations O 0 1.769794444328454e-08
were O 0 2.8300106702516814e-09
identified O 0 6.7912520052004766e-09
on O 0 2.7766764443271086e-09
12 O 0 5.606535236069021e-10
of O 0 1.514349236286794e-11
the O 0 5.12564823917927e-10
16 O 0 8.222510672339922e-09
alleles O 0 5.0893454783818015e-08
examined O 0 1.0411062021375983e-06
. O 0 4.565568190173508e-08

Four O 0 4.6565483557969856e-07
were O 0 9.667607159258296e-09
deletions O 0 2.660736875270686e-08
involving O 0 3.3909515195773565e-09
a O 0 1.8021104608578753e-08
loss O 0 6.492805937341473e-08
of O 0 5.805569913697184e-11
a O 0 4.779053597303573e-09
single O 0 3.378016444344212e-08
exon O 0 8.074372459532242e-08
exon O 0 7.388926803741924e-08
7 O 0 9.658594812833599e-09
, O 0 3.884926269570599e-10
exon O 0 2.825492551039588e-08
16 O 0 3.406301685160429e-09
, O 0 2.161103657138952e-10
exon O 0 4.4675033450403134e-08
33 O 0 1.9028925990483003e-08
or O 0 1.1706571267922072e-09
exon O 0 1.804763058999015e-07
35 O 0 9.812439571987852e-08
. O 0 2.1654342319266107e-08

The O 0 1.2125067883062002e-07
others O 0 4.5433818485207667e-08
were O 0 1.1467540250720276e-09
minute O 0 3.0174822640560706e-09
deletions O 0 4.375407058887504e-08
, O 0 1.0422530616338577e-09
4649delA O 0 5.3879126937772526e-08
in O 0 1.226204249249463e-09
exon O 0 1.1674273281414571e-07
33 O 0 2.2858896997490774e-08
and O 0 5.939326808146461e-10
7883del5 O 0 3.9223813530497864e-08
in O 0 8.85801487715554e-10
exon O 0 6.421227567443566e-07
55 O 0 1.435554821682672e-07
. O 0 1.677459238180745e-08

The O 0 1.313497932642349e-07
mutations O 0 1.8577063656266546e-06
4612del165 O 0 1.2542528793346719e-06
and O 0 1.3343855798098048e-08
7883del5 O 0 2.5768864020392357e-07
were O 0 1.0072066736199758e-08
found O 0 5.795151025722589e-10
in O 0 4.908195030961515e-11
more O 0 2.6542257280937065e-10
than O 0 4.060494995794528e-10
two O 0 1.4015308358317213e-10
unrelated O 0 5.078628184662648e-09
families O 0 8.506460535961935e-10
; O 0 6.732527313424441e-10
44 O 0 8.552047958687581e-09
% O 0 7.431558146642203e-11
( O 0 2.7977576852467045e-11
7 O 0 8.715928534464013e-10
of O 0 7.543420749156482e-11
16 O 0 8.010918595147132e-10
) O 0 2.1180624962258143e-11
of O 0 7.052458877304657e-12
the O 0 4.864855740471796e-11
mutant O 0 5.3429253910053376e-08
alleles O 0 8.927561800931016e-09
had O 0 7.028258863783776e-09
one O 0 5.5128561438078094e-11
of O 0 8.199757713100997e-12
the O 0 1.0457911620020965e-10
two O 0 2.164314061303685e-09
mutations O 0 1.0846144249399003e-07
. O 0 1.6146559644880654e-08

The O 0 7.738995577710739e-08
4612del165 O 0 1.3856076748197665e-06
mutations O 0 2.5940005343727535e-07
in O 0 8.495402159525156e-10
three O 0 3.1845606707214813e-10
different O 0 1.3362995432419922e-10
families O 0 3.8263156532103437e-10
were O 0 6.596392321256417e-10
all O 0 2.5600611908149773e-11
ascribed O 0 1.7057150136778887e-09
to O 0 4.562064337410021e-10
the O 0 1.0820713769454926e-10
same O 0 2.4155768496569863e-09
T O 0 4.3710198838198266e-07
- O 0 1.9762120473387768e-07
- O 0 2.1892225277042598e-07
> O 0 2.6233895056293477e-09
A O 0 9.25331533618845e-10
substitution O 0 6.644882977191457e-10
at O 0 3.451015861966056e-11
the O 0 1.4772532155871154e-11
splice O 0 1.1850221248721482e-08
donor O 0 8.488923453064956e-10
site O 0 2.420040834394399e-09
in O 0 3.4887409627870625e-10
intron O 0 1.6775600670371205e-05
33 O 0 1.454669700251543e-07
. O 0 1.2783069713862005e-08

Microsatellite O 0 0.0008449562592431903
genotyping O 0 0.00012764654820784926
around O 0 2.596524950604362e-07
the O 0 1.7183914291507563e-09
ATM O 0 5.5886893335355126e-08
locus O 0 7.945401847564426e-08
also O 0 2.9262636758176086e-08
indicated O 0 2.0683614820882212e-08
that O 0 1.3555115363494963e-10
a O 0 2.4842823354020993e-09
common O 0 9.632286968042081e-09
haplotype O 0 0.000510031299199909
was O 0 8.573411491852312e-07
shared O 0 3.382558400044644e-10
by O 0 4.0361002734412565e-11
the O 0 2.608816634941391e-11
mutant O 0 1.967926976931267e-08
alleles O 0 4.558621924388717e-09
in O 0 3.888172839250359e-10
both O 0 3.7139598063617996e-09
mutations O 0 2.2776384867029265e-07
. O 0 2.9580705884768577e-08

This O 0 1.411391252759131e-07
suggests O 0 6.488707526841608e-08
that O 0 7.544662672387403e-10
these O 0 3.933568401559562e-11
two O 0 1.0879777634364984e-10
founder O 0 3.3590886516776663e-08
mutations O 0 4.750510385065354e-08
may O 0 1.360369239478132e-08
be O 0 3.008769677848022e-09
predominant O 0 8.701419318413173e-08
among O 0 1.0860023991199341e-09
Japanese O 0 4.043393619923563e-09
ATM O 0 1.0810991568632744e-07
mutant O 0 6.89215085003525e-07
alleles O 0 3.5603309811449435e-07
. O 0 5.752143295012502e-08

W474C O 0 5.1713723223656416e-05
amino O 0 8.475929575979535e-07
acid O 0 7.614844577119584e-08
substitution O 0 5.938469271882241e-09
affects O 0 9.423559710342033e-09
early O 0 2.5423113614309045e-10
processing O 0 9.695629021866381e-11
of O 0 9.305980465390551e-12
the O 0 1.6243310516084186e-11
alpha O 0 8.74498182201755e-11
- O 0 4.0059541794867926e-10
subunit O 0 4.911157036602276e-10
of O 0 2.1500714403321908e-11
beta O 0 3.822114291729406e-10
- O 0 2.9219076935760313e-08
hexosaminidase O 0 1.8760786701932375e-07
A O 0 1.776612812420808e-08
and O 0 1.2590162246084446e-09
is O 0 1.919675307604507e-09
associated O 0 3.6511744738731977e-09
with O 0 7.061757401061186e-09
subacute O 1 0.6044275164604187
G B-Disease 0 0.38347840309143066
( I-Disease 0 5.2765480873517845e-09
M2 I-Disease 0 4.619280105089274e-07
) I-Disease 0 6.673974262128013e-09
gangliosidosis I-Disease 0 6.159915756143164e-06
. O 0 4.047878832125207e-08

Mutations O 0 0.00042618572479113936
in O 0 4.3774690539066796e-08
the O 0 1.7127698148655668e-09
HEXA O 0 2.498683215890196e-06
gene O 0 2.468940785149698e-08
, O 0 1.3989241709477795e-10
encoding O 0 4.740340897591011e-10
the O 0 3.818527438692598e-11
alpha O 0 1.5336712455571444e-10
- O 0 2.633002982310728e-10
subunit O 0 3.7088046522804063e-10
of O 0 9.426636554676904e-12
beta O 0 1.2612796917998992e-10
- O 0 8.498194148387483e-09
hexosaminidase O 0 1.3865393100331858e-07
A O 0 7.800345258601737e-09
( O 0 1.397086890619903e-10
Hex O 0 2.5431724282043433e-08
A O 0 4.7465045227568226e-09
) O 0 8.014765934261092e-11
, O 0 2.940840626575181e-11
that O 0 1.0995119398282682e-10
abolish O 0 6.103392458101098e-09
Hex O 0 1.9840161513684507e-08
A O 0 1.9812169682609237e-09
enzyme O 0 6.708918753872695e-09
activity O 0 1.573025443235565e-08
cause O 0 0.00034643884282559156
Tay B-Disease 1 1.0
- I-Disease 1 0.999998927116394
Sachs I-Disease 1 0.9999997615814209
disease I-Disease 0 0.05307453125715256
( O 0 1.0400666994314633e-09
TSD B-Disease 0 1.7693678273644764e-06
) O 0 1.086263523575326e-09
, O 0 2.898563611353211e-10
the O 0 4.993845892364845e-10
fatal O 0 0.00012533464177977294
infantile B-Disease 0 5.798511847387999e-05
form I-Disease 0 1.999775278704874e-08
of I-Disease 0 6.74237110587228e-10
G I-Disease 0 6.5888452809304e-05
( I-Disease 0 4.149008636655793e-10
M2 I-Disease 0 4.1346581269863236e-08
) I-Disease 0 9.165697645308057e-10
gangliosidosis I-Disease 0 3.236151826513378e-07
, I-Disease 0 6.320427514694416e-10
Type I-Disease 0 1.665094195857364e-08
1 I-Disease 0 1.62235487266571e-08
. O 0 2.6408969233671087e-08

Less O 0 0.00019154085021000355
severe O 1 0.6496034860610962
, O 0 2.732113273395953e-07
subacute O 0 0.32657164335250854
( O 0 6.136264829592619e-08
juvenile O 0 0.06025407835841179
- O 0 0.04844893887639046
onset O 0 0.00013323655002750456
) O 0 8.747543134290936e-09
and O 0 6.043978260095173e-07
chronic O 0 0.18883413076400757
( O 0 3.7810039543728635e-09
adult O 0 3.748468225239776e-05
- O 0 0.00020028409198857844
onset O 0 1.5401799373648828e-06
) O 0 7.87415521674717e-10
variants O 0 1.4986026641850003e-08
are O 0 3.146625182637308e-10
characterized O 0 4.9951061065200975e-09
by O 0 2.27199509206244e-10
a O 0 6.52183418381469e-09
broad O 0 5.2999109101392605e-08
spectrum O 0 1.5017049292964657e-07
of O 0 1.829297546773745e-10
clinical O 0 3.679166837855519e-08
manifestations O 0 6.480185987811637e-08
and O 0 3.379161617189652e-09
are O 0 3.358329170310981e-10
associated O 0 1.2533999393937734e-09
with O 0 7.696784320998518e-10
residual O 0 9.490448064752854e-06
levels O 0 1.4211118948281865e-09
of O 0 1.5513080403595225e-11
Hex O 0 2.9346644225825003e-08
A O 0 2.3576720575846366e-09
enzyme O 0 1.170121954885417e-08
activity O 0 6.445065814375539e-09
. O 0 5.188108165299354e-09

We O 0 4.946414833284507e-07
identified O 0 5.8710558192842655e-08
a O 0 1.3820159239230634e-08
1422 O 0 1.774068437043752e-06
G O 0 0.00011438407091191038
- O 0 2.3017219064058736e-05
- O 0 0.00010209266474703327
> O 0 2.8462474688240036e-07
C O 0 4.694905797464344e-08
( O 0 1.1836519264729617e-10
amino O 0 1.3125701636695908e-09
acid O 0 3.992211006220714e-09
W474C O 0 1.7206152058690805e-09
) O 0 6.3710378118975175e-12
substitution O 0 5.878857817220862e-11
in O 0 2.4195354053624385e-11
the O 0 1.8421221145703548e-11
first O 0 3.1927285815136486e-10
position O 0 1.1185883330711022e-09
of O 0 1.9648224020007987e-11
exon O 0 8.786068761423849e-09
13 O 0 5.917593637327911e-10
of O 0 2.152279049427719e-11
HEXA O 0 6.551290994138981e-07
of O 0 1.4014346627622132e-10
a O 0 4.568005085303639e-09
non O 0 3.75178021982947e-09
- O 0 5.304583510223893e-07
Jewish O 0 4.288937915930546e-08
proband O 0 3.078688223467907e-06
who O 0 4.9168132676413734e-08
manifested O 0 2.0197775896235726e-08
a O 0 1.0727837285173791e-08
subacute O 0 0.00019620284729171544
variant O 0 3.1428815418621525e-05
of O 0 5.286540982751831e-09
G B-Disease 0 0.002575263613834977
( I-Disease 0 5.42728928465408e-09
M2 I-Disease 0 6.37128096059314e-07
) I-Disease 0 9.695620306615638e-09
gangliosidosis I-Disease 0 2.0331437553977594e-05
. O 0 1.3688313060811197e-07

On O 0 6.180712830428092e-08
the O 0 1.439389163415683e-09
second O 0 1.9246623850222022e-08
maternally O 0 2.255918161608861e-06
inherited O 0 1.6589940514677437e-06
allele O 0 5.213863687458797e-07
, O 0 5.542379888368032e-10
we O 0 2.0274797118968735e-10
identified O 0 1.1802754329437448e-09
the O 0 1.5967868693955722e-10
common O 0 3.5628502814688545e-08
infantile O 1 0.7569078207015991
disease O 0 0.03368715941905975
- O 0 8.042919944273308e-05
causing O 0 2.65991798187315e-06
4 O 0 1.7607071356451343e-08
- O 0 1.5385724054794991e-06
bp O 0 4.3742825255321804e-06
insertion O 0 8.184007782574554e-08
, O 0 2.4721908964409067e-09
+ O 0 5.280071491142735e-09
TATC O 0 5.735244030802278e-07
1278 O 0 5.396901201493165e-07
, O 0 5.591690444006758e-10
in O 0 3.326365016764754e-10
exon O 0 1.9211896074011747e-07
11 O 0 2.9353307340329593e-08
. O 0 1.611831201842051e-08

Pulse O 0 0.00021165677753742784
- O 0 1.3582774045062251e-05
chase O 0 2.734383883762348e-07
analysis O 0 3.793862557444072e-09
using O 0 1.0963921992512837e-09
proband O 0 6.582849465530671e-08
fibroblasts O 0 1.9898978464993888e-08
revealed O 0 1.2730683174311253e-08
that O 0 1.1847949010768133e-10
the O 0 4.5806164417072637e-11
W474C O 0 1.1788114484545531e-08
- O 0 3.6482021847916712e-09
containing O 0 1.9900667225236646e-10
alpha O 0 2.992684988711858e-10
- O 0 5.359638843849268e-10
subunit O 0 6.000266949968136e-10
precursor O 0 7.751781994080886e-10
was O 0 5.015938331354164e-09
normally O 0 1.3403742560313958e-09
synthesized O 0 6.116292805558032e-09
, O 0 1.1120419862731268e-10
but O 0 2.374110352754144e-10
not O 0 9.601644479495519e-11
phosphorylated O 0 1.0847892584209262e-09
or O 0 8.17377832085242e-11
secreted O 0 2.6457962487569375e-09
, O 0 1.5552491239301247e-10
and O 0 2.8708549426603724e-10
the O 0 9.758430868922474e-11
mature O 0 3.90144272444104e-09
lysosomal O 0 4.859299096438008e-08
alpha O 0 3.2636222613291466e-09
- O 0 4.3993630960414976e-09
subunit O 0 7.412793490146896e-09
was O 0 2.0013931845141997e-08
not O 0 1.6608019404174001e-09
detected O 0 7.675651403360462e-08
. O 0 1.2837361396123015e-08

When O 0 3.2747044542702497e-07
the O 0 2.5803099656940276e-09
W474C O 0 1.0044809073406213e-07
- O 0 1.9885092683580297e-08
containing O 0 4.1173349174528084e-09
alpha O 0 2.1006119066413476e-09
- O 0 2.9807465384834586e-09
subunit O 0 2.709738433637199e-09
was O 0 2.456136982686985e-08
transiently O 0 2.6866308644457604e-07
co O 0 4.7935440505852966e-08
- O 0 9.223966657145866e-08
expressed O 0 5.049718421190619e-09
with O 0 2.5879571055598127e-11
the O 0 1.5446619677783602e-11
beta O 0 5.051986953774623e-11
- O 0 3.1942026801345946e-10
subunit O 0 3.8726005735512103e-10
to O 0 2.1113437387310086e-10
produce O 0 4.509465023616599e-10
Hex O 0 9.886547580606475e-09
A O 0 3.943458448674164e-09
( O 0 1.442851949029489e-10
alphabeta O 0 1.1928585763598676e-07
) O 0 1.4888461297157818e-10
in O 0 3.49012541089877e-10
COS O 0 4.106146320737025e-07
- O 0 4.2808554212570016e-07
7 O 0 3.934727654808512e-09
cells O 0 1.4658482205831547e-09
, O 0 3.722707905828848e-11
the O 0 1.4093361026812357e-11
mature O 0 3.0667182682186933e-10
alpha O 0 1.3130802001271036e-10
- O 0 7.603792040455915e-10
subunit O 0 8.865113643174993e-10
was O 0 7.471588681084995e-09
present O 0 1.8797960410488201e-10
, O 0 8.671633550116908e-11
but O 0 3.2163707808230413e-10
its O 0 6.221319293064909e-11
level O 0 2.1391877158549732e-10
was O 0 1.2190341180939868e-08
much O 0 8.08029698706747e-10
lower O 0 6.474982328086298e-09
than O 0 7.254703504600002e-10
that O 0 2.5494201194575794e-10
from O 0 2.5480190873894415e-11
normal O 0 1.0197919592114246e-10
alpha O 0 1.2128012483181294e-10
- O 0 5.339272912685544e-10
subunit O 0 8.765559944556855e-10
transfections O 0 3.644698409743796e-08
, O 0 1.0063358479861506e-10
although O 0 1.7090749648840386e-10
higher O 0 1.1498044183433365e-10
than O 0 1.9833483466680235e-10
in O 0 7.047285671690773e-11
those O 0 2.7659660672973985e-10
cells O 0 8.055567324305457e-10
transfected O 0 4.131197428591804e-08
with O 0 1.360193901955853e-10
an O 0 1.342438382678779e-10
alpha O 0 2.2292081514052597e-09
- O 0 2.1963739271768645e-08
subunit O 0 1.5445285939108544e-08
associated O 0 1.4351956068026084e-08
with O 0 7.63017915517139e-09
infantile O 0 9.578365279594436e-05
TSD B-Disease 0 0.00020004951511509717
. O 0 2.571323705069517e-07

Furthermore O 0 3.287463414380909e-06
, O 0 3.6319001139872853e-09
the O 0 9.193269756568867e-11
precursor O 0 1.3643884910763404e-09
level O 0 1.5340516357209566e-10
of O 0 1.3644782352606466e-11
the O 0 3.7438132455269724e-11
W474C O 0 5.508594025371849e-09
alpha O 0 2.9714694593785396e-10
- O 0 7.738693019732068e-10
subunit O 0 6.954088416222248e-10
was O 0 5.237223543730352e-09
found O 0 2.9920002586614203e-10
to O 0 3.738035714295762e-10
accumulate O 0 5.720018680932526e-09
in O 0 5.1273076062674505e-11
comparison O 0 6.297252164166878e-10
to O 0 3.122209435435508e-10
the O 0 3.236813247986525e-11
normal O 0 2.869283977080528e-10
alpha O 0 6.677179364977803e-10
- O 0 2.3908797164295947e-09
subunit O 0 5.396137314761518e-09
precursor O 0 1.2998721210522035e-08
levels O 0 5.489473764441755e-09
. O 0 3.807411275147388e-09

We O 0 1.5160803457092697e-07
conclude O 0 2.7594030171940176e-08
that O 0 5.625580001833441e-10
the O 0 5.90393012256385e-10
1422 O 0 6.793676448069164e-07
G O 0 0.00044079028884880245
- O 0 1.2158306162746157e-05
- O 0 7.460551569238305e-05
> O 0 2.3918713054627005e-07
C O 0 7.964580106545327e-08
mutation O 0 2.5949896453880683e-08
is O 0 5.689917426110469e-10
the O 0 5.8075634579157764e-11
cause O 0 3.573990658978232e-09
of O 0 8.66632529628042e-11
Hex B-Disease 0 1.5610899026796687e-06
A I-Disease 0 4.35023321188055e-06
enzyme I-Disease 1 0.9999798536300659
deficiency I-Disease 1 0.9999943971633911
in O 0 9.513764220869803e-10
the O 0 5.375763723058924e-10
proband O 0 8.509390681865625e-06
. O 0 3.296720052503588e-08

The O 0 7.981034144677324e-08
resulting O 0 5.342701570043573e-08
W474C O 0 8.922135208422333e-08
substitution O 0 9.6647490011037e-09
clearly O 0 1.8344669783232348e-08
interferes O 0 3.7830975685437807e-08
with O 0 1.847587638437176e-10
alpha O 0 9.4436525266417e-10
- O 0 9.558471791848433e-10
subunit O 0 8.940030937765187e-10
processing O 0 1.1060836691001441e-09
, O 0 1.008616801190243e-10
but O 0 1.0976156789022085e-10
because O 0 2.8500667104136568e-11
the O 0 6.706605323175685e-12
base O 0 3.09336556369999e-10
substitution O 0 9.039169968083627e-10
falls O 0 5.176822526209435e-08
at O 0 1.9190362840482145e-11
the O 0 2.3542412810884095e-11
first O 0 5.343857578665734e-10
position O 0 3.5997758107697564e-09
of O 0 3.382105359661658e-11
exon O 0 1.9671350770522622e-08
13 O 0 9.102179010511691e-10
, O 0 8.614708946197425e-11
aberrant O 0 5.123627300207545e-09
splicing O 0 5.501562228005241e-08
may O 0 4.129385544615616e-08
also O 0 2.7581386063957325e-09
contribute O 0 6.655005435618477e-10
to O 0 1.5468215597280732e-09
Hex B-Disease 0 2.5257513698306866e-06
A I-Disease 0 5.595169568550773e-06
deficiency I-Disease 0 1.1373148481652606e-05
in O 0 1.8219710462563654e-10
this O 0 3.3527611242867295e-10
proband O 0 1.5534266140093678e-06
. O 0 3.0738993572754225e-09
. O 0 7.312861871611176e-09

Two O 0 4.853889663536393e-07
frequent O 0 5.373009116738103e-06
missense O 0 0.0005252883420325816
mutations O 0 0.0021161576732993126
in O 0 1.5908499335637316e-05
Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 3.109541466983501e-06

Pendred B-Disease 1 0.9999998807907104
syndrome I-Disease 1 1.0
is O 0 3.2936000934569165e-05
an O 0 0.0001788433437468484
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
disorder I-Disease 1 1.0
characterized O 1 0.9844725728034973
by O 0 5.426664984042873e-07
early O 0 2.285559276060667e-05
childhood O 1 0.950168788433075
deafness B-Disease 1 1.0
and O 1 0.9771728515625
goiter B-Disease 1 1.0
. O 0 5.579025128099602e-06

A O 0 3.1163676794676576e-07
century O 0 7.0505192795167204e-09
after O 0 9.535727762965962e-10
its O 0 9.04051000727435e-11
recognition O 0 3.7401465258213307e-10
as O 0 3.4831444395422295e-09
a O 0 1.0807072612806223e-05
syndrome O 1 0.9999240636825562
by O 0 5.181897577699601e-09
Vaughan O 0 3.6883438951917924e-06
Pendred O 0 8.651142024973524e-07
, O 0 8.890344016521112e-10
the O 0 1.1057249560408877e-09
disease O 0 2.80781819128606e-07
gene O 0 1.4252550251114826e-08
( O 0 6.814552255818285e-10
PDS O 0 5.6843859965738375e-06
) O 0 6.493691140363467e-10
was O 0 6.605639413237441e-08
mapped O 0 3.223028102183889e-07
to O 0 8.064334089397107e-09
chromosome O 0 3.3940348203032045e-06
7q22 O 0 1.1496210845507449e-06
- O 0 2.499770062058815e-06
q31 O 0 8.767122380959336e-06
. O 0 6.962721954550943e-08

1 O 0 1.6824326394271338e-06
and O 0 4.307810996806438e-08
, O 0 2.1368684599565313e-09
recently O 0 8.860284061995571e-09
, O 0 1.0038685160917993e-10
found O 0 1.1603286387273926e-10
to O 0 6.393732071563463e-11
encode O 0 5.539634528872739e-09
a O 0 2.5513200441196204e-08
putative O 0 2.785717470032978e-06
sulfate O 0 1.7601147192181088e-05
transporter O 0 2.0087485609110445e-05
. O 0 8.509957183377992e-08

We O 0 6.464989041887748e-07
performed O 0 1.620948353320273e-07
mutation O 0 6.348003722678186e-08
analysis O 0 9.78185976663326e-10
of O 0 4.507794137964538e-11
the O 0 2.113567931782967e-10
PDS B-Disease 0 3.6533749607770005e-06
gene O 0 6.267886476507556e-08
in O 0 6.641921679317875e-09
patients O 0 5.486043050950684e-07
from O 0 2.745341454168937e-10
14 O 0 1.2089563794503988e-09
Pendred B-Disease 0 1.3747131788477418e-07
families O 0 6.760089155122273e-10
originating O 0 9.944446655030248e-11
from O 0 4.375467349548856e-11
seven O 0 1.4936814285437805e-10
countries O 0 1.884404438046161e-11
and O 0 6.209041614191335e-10
identified O 0 5.7653095630882945e-09
all O 0 2.684069078107143e-10
mutations O 0 5.4805735061336236e-08
. O 0 9.407145284967555e-09

The O 0 1.4293364358763938e-07
mutations O 0 7.87122473866475e-07
include O 0 2.2697179691277825e-09
three O 0 1.1017797785228822e-09
single O 0 1.7108639838170348e-08
base O 0 1.546173322708455e-08
deletions O 0 4.5727929887107166e-08
, O 0 6.929038454117631e-10
one O 0 4.2918138487557655e-10
splice O 0 1.5076027182203688e-07
site O 0 4.457816515923696e-08
mutation O 0 8.996967437724379e-08
and O 0 1.0835320418678407e-09
10 O 0 3.60758423134655e-09
missense O 0 1.1985893252131063e-05
mutations O 0 3.909358838427579e-06
. O 0 5.2308767095610165e-08

One O 0 1.1082127002737252e-06
missense O 0 6.181920616654679e-05
mutation O 0 2.5109043235715944e-06
( O 0 2.277767086056315e-09
L236P O 0 2.6959398269355006e-07
) O 0 4.4618783667793593e-10
was O 0 9.896399433273473e-08
found O 0 1.7748675862350183e-09
in O 0 7.828865333792123e-11
a O 0 1.3317202895990476e-09
homozygous O 0 1.6211950892852656e-08
state O 0 1.195062521164303e-10
in O 0 8.926599737169028e-11
two O 0 5.659891444409482e-10
consanguineous O 0 2.6020060772680154e-07
families O 0 4.67169636308995e-09
and O 0 3.782632540527686e-10
in O 0 6.153156456578657e-11
a O 0 1.8517761768421792e-09
heterozygous O 0 4.765393413208585e-08
state O 0 2.6699139427099894e-11
in O 0 1.3589381356315933e-11
five O 0 7.70516705994595e-11
additional O 0 2.5515461965497366e-10
non O 0 2.136860244306149e-09
- O 0 3.4955232877109665e-06
consanguineous O 0 5.83568362344522e-05
families O 0 7.378927335821572e-08
. O 0 3.994879094193493e-08

Another O 0 2.8487124836829025e-06
missense O 0 0.00010018821922130883
mutation O 0 5.304742444423027e-06
( O 0 4.092062688698661e-09
T416P O 0 3.328279092329467e-07
) O 0 1.003545468947209e-09
was O 0 7.462633533350527e-08
found O 0 1.1903177332683867e-09
in O 0 6.363001792131229e-11
a O 0 1.0655620830135604e-09
homozygous O 0 2.8430996223960392e-08
state O 0 1.3226572614932763e-10
in O 0 7.370392490768651e-11
one O 0 5.802627822681927e-10
family O 0 6.265765684076996e-10
and O 0 1.4474550724674629e-10
in O 0 3.95762034255398e-11
a O 0 1.6683328052380375e-09
heterozygous O 0 5.671871505796844e-08
state O 0 1.2434009377670918e-10
in O 0 1.0190336768856056e-10
four O 0 1.8591763684128182e-09
families O 0 4.065642933426261e-09
. O 0 5.111270073854257e-09

Pendred B-Disease 0 0.016356907784938812
patients O 0 0.49884992837905884
in O 0 7.698139015133165e-09
three O 0 1.3141332466659605e-09
non O 0 2.620903938321817e-09
- O 0 9.095581390283769e-07
consanguineous O 0 7.540952083218144e-06
families O 0 2.0250970678148406e-08
were O 0 1.7382958406031435e-09
shown O 0 1.8748913532817824e-09
to O 0 4.909340156622477e-10
be O 0 1.9819992314040746e-09
compound O 0 2.0243362541805254e-08
heterozygotes O 0 7.864151996272994e-08
for O 0 7.994891415563643e-10
L236P O 0 2.0205044393151184e-07
and O 0 1.0081889101343222e-08
T416P O 0 7.147264113882557e-07
. O 0 2.2002481614435965e-08

In O 0 1.3436493873086874e-07
total O 0 4.559674415816062e-09
, O 0 4.012438714617872e-10
one O 0 5.084867527038739e-10
or O 0 1.4791994018548138e-10
both O 0 2.837863000149099e-10
of O 0 1.0763791767620656e-11
these O 0 7.330366175173353e-11
mutations O 0 3.6668841296716437e-09
were O 0 1.0528868887860199e-09
found O 0 4.189564806189594e-10
in O 0 3.7046102296933725e-11
nine O 0 2.617550620698239e-10
of O 0 8.406226235935232e-12
the O 0 3.0702240749747034e-10
14 O 0 4.818557997054995e-09
families O 0 1.4730681119345945e-09
analyzed O 0 4.472089898399645e-08
. O 0 1.9375981707980827e-08

The O 0 1.8647352106881954e-08
identification O 0 1.0163947017360897e-08
of O 0 1.149267209177296e-10
two O 0 1.236413194050101e-09
frequent O 0 5.00228850341955e-07
PDS B-Disease 0 0.007701999507844448
mutations O 0 7.152050329750637e-07
will O 0 1.6618570963800039e-09
facilitate O 0 7.243296518133491e-10
the O 0 6.648382400165076e-10
molecular O 0 8.029563787204097e-07
diagnosis O 0 0.01767827570438385
of O 0 4.2400785105201066e-07
Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 1.6882574982446386e-06

Insertional O 0 0.00011004727275576442
mutation O 0 2.3796199457137845e-05
by O 0 1.8073288643449814e-08
transposable O 0 1.868953063421941e-06
element O 0 1.0232673730570241e-07
, O 0 3.577598439719054e-09
L1 O 0 2.91274972141764e-07
, O 0 8.520717464932659e-10
in O 0 2.930114206822765e-10
the O 0 8.401397799673305e-09
DMD B-Disease 1 0.9999998807907104
gene O 0 5.5112841437221505e-06
results O 0 5.573934558356086e-08
in O 0 9.595063410472449e-09
X B-Disease 1 0.9993694424629211
- I-Disease 1 0.9999257326126099
linked I-Disease 1 0.9998453855514526
dilated I-Disease 1 0.9992372989654541
cardiomyopathy I-Disease 1 0.9999996423721313
. O 0 3.817634024017025e-06

X B-Disease 1 0.9992917776107788
- I-Disease 1 0.9998476505279541
linked I-Disease 1 0.9998618364334106
dilated I-Disease 1 0.9999548196792603
cardiomyopathy I-Disease 1 1.0
( O 0 1.9231620740356448e-07
XLDCM B-Disease 0 7.605901919305325e-05
) O 0 1.18744236665691e-09
is O 0 9.173796167161186e-10
a O 0 1.0555999629957569e-08
clinical O 0 1.8269095107825706e-06
phenotype O 0 6.816795939812437e-05
of O 0 3.3662173049009425e-10
dystrophinopathy B-Disease 0 1.825544131861534e-06
which O 0 3.7103204952870783e-09
is O 0 6.77826905715051e-10
characterized O 0 2.761161610465024e-08
by O 0 4.290490185354656e-09
preferential O 0 5.979366051178658e-07
myocardial B-Disease 1 0.5145533680915833
involvement I-Disease 0 6.224949089528309e-08
without O 0 1.7844603572569895e-09
any O 0 4.936061559490668e-10
overt O 0 7.500648280256428e-08
clinical O 0 6.013362394696742e-07
signs O 0 1.197393089569232e-06
of O 0 6.908326355414829e-08
skeletal B-Disease 1 1.0
myopathy I-Disease 1 1.0
. O 0 3.1780720746610314e-05

To O 0 5.417471129476326e-07
date O 0 4.444182621909931e-08
, O 0 4.336445369457209e-10
several O 0 2.2866196436321928e-10
mutations O 0 1.1591219539752728e-08
in O 0 7.030802606777797e-10
the O 0 4.117297791594865e-08
Duchenne B-Disease 1 0.9998942613601685
muscular I-Disease 1 0.999972939491272
dystrophy I-Disease 1 0.9999693632125854
gene O 0 1.3432919331535231e-05
, O 0 1.78426120100994e-07
DMD O 1 0.9999998807907104
, O 0 3.273324011843215e-08
have O 0 8.273670637493069e-09
been O 0 1.6355253151800753e-08
identified O 0 2.528136278101556e-08
in O 0 1.2993582876319465e-09
patients O 0 4.5382023472484434e-07
with O 0 4.122314711807462e-10
XLDCM B-Disease 0 1.790044734661933e-05
, O 0 3.6292671645732355e-10
but O 0 1.7532757190519277e-10
a O 0 3.8746766906072594e-10
pathogenic O 0 5.123363511216894e-09
correlation O 0 1.2666903081992587e-09
of O 0 3.775163168184825e-11
these O 0 1.5969452149544594e-10
cardiospecific O 0 1.6345668427675264e-06
mutations O 0 1.9906691761661932e-07
in O 0 3.7251619566802674e-09
DMD O 1 0.9999998807907104
with O 0 1.819882200493339e-08
the O 0 4.533666775330403e-09
XLDCM B-Disease 0 0.4829571545124054
phenotype O 0 0.463344544172287
has O 0 4.3897765067413275e-07
remained O 0 6.133819141496133e-08
to O 0 1.3100990292613801e-09
be O 0 2.1244582981694293e-08
elucidated O 0 6.019128250045469e-06
. O 0 6.086352044576415e-08

We O 0 2.678549151369225e-07
report O 0 8.101859627629437e-09
here O 0 1.4999165798279535e-10
the O 0 1.2940420436591271e-11
identification O 0 1.0200098404800073e-10
of O 0 8.100549744871621e-12
a O 0 5.599236074793623e-10
unique O 0 9.10947373089499e-10
de O 0 1.2995193809928196e-09
novo O 0 1.778928648832334e-08
L1 O 0 2.9700334636117987e-08
insertion O 0 6.537900443248645e-09
in O 0 2.723748449007246e-10
the O 0 1.9224591363276033e-10
muscle O 0 1.365032602507199e-07
exon O 0 1.8502456100577547e-07
1 O 0 7.702721127600398e-09
in O 0 6.729629298263262e-09
DMD O 1 1.0
in O 0 7.820429459570732e-08
three O 0 1.7305755051211236e-08
XLDCM B-Disease 0 0.0033182271290570498
patients O 0 9.949572813638952e-06
from O 0 5.4200526011793926e-11
two O 0 6.011122849480799e-11
unrelated O 0 2.2221355866491876e-09
Japanese O 0 1.987299924621766e-08
families O 0 9.509505183302736e-09
. O 0 9.33133925684615e-09

The O 0 9.682318591330841e-08
insertion O 0 4.99043323998194e-07
was O 0 5.615370213263304e-08
a O 0 2.8880413616150236e-09
5 O 0 3.097086365144719e-09
- O 0 1.6206824682285514e-07
truncated O 0 1.5402372355310945e-07
form O 0 2.4017943189846847e-09
of O 0 3.932833225750443e-11
human O 0 1.0947075190781419e-10
L1 O 0 2.4543012955291488e-08
inversely O 0 1.588393132578858e-07
integrated O 0 2.8024512488400433e-08
in O 0 7.468906049190593e-10
the O 0 3.4051045316729756e-10
5 O 0 2.7634257104836024e-09
- O 0 9.014588044919947e-07
untranslated O 0 1.0177953299717046e-05
region O 0 1.0316544951649576e-08
in O 0 1.8062448758904281e-10
the O 0 1.319799408650013e-10
muscle O 0 3.679089743968689e-08
exon O 0 2.2069267302526896e-08
1 O 0 1.7895388504385323e-09
, O 0 1.8635565313118718e-10
which O 0 7.211439223553384e-10
affected O 0 2.7504254429544517e-10
the O 0 8.508820384389715e-12
transcription O 0 7.178859728895759e-10
or O 0 8.474035362304733e-11
the O 0 7.421189357481595e-11
stability O 0 4.973456646517604e-10
of O 0 1.6194401722402496e-11
the O 0 1.2570096352693128e-10
muscle O 0 1.5541422726528253e-07
form O 0 7.761516984672312e-10
of O 0 6.15678411031162e-11
dystrophin O 0 2.201923763323066e-07
transcripts O 0 1.6485069309624123e-08
but O 0 9.565382930176725e-10
not O 0 1.393135468097384e-10
that O 0 2.771847855409515e-11
of O 0 1.1557403471751382e-11
the O 0 1.635670210387019e-10
brain O 0 1.597651362317265e-07
or O 0 4.447578416666431e-10
Purkinje O 0 2.0478026385717385e-07
cell O 0 2.4660846520419e-07
form O 0 5.413198334025537e-09
, O 0 6.051320000644012e-10
probably O 0 1.1757598450401474e-08
due O 0 1.2501957247224027e-09
to O 0 1.0315812648542533e-09
its O 0 2.874635529614977e-10
unique O 0 6.100293603594764e-10
site O 0 6.694407250762424e-10
of O 0 4.470181516613714e-11
integration O 0 2.2282813372243027e-09
. O 0 9.643390086466752e-09

We O 0 2.140037196340927e-07
speculate O 0 1.7248883921183733e-07
that O 0 3.6383257517869083e-10
this O 0 2.477182348137319e-11
insertion O 0 2.4626938266436582e-09
of O 0 4.788337087946459e-11
an O 0 2.733094861540053e-10
L1 O 0 1.2055231479735085e-07
sequence O 0 4.496189198732736e-09
in O 0 3.859499386749121e-09
DMD O 1 0.9999997615814209
is O 0 6.956920373113462e-08
responsible O 0 4.053671620596333e-09
for O 0 5.476364500767161e-11
some O 0 4.400180914077012e-11
of O 0 3.147714510917665e-12
the O 0 7.644038874099479e-11
population O 0 1.6970753968781338e-10
of O 0 3.0890720537080085e-11
Japanese O 0 2.988489811173167e-08
patients O 0 1.4493454614239454e-07
with O 0 3.6924363566726015e-10
XLDCM B-Disease 0 5.9240642258373555e-06
. O 0 3.311667384764405e-09
. O 0 1.0467361200028336e-08

Severe O 1 0.9808323383331299
early O 0 1.548763975733891e-05
- O 1 0.9614851474761963
onset O 1 0.9897918701171875
obesity B-Disease 1 1.0
, O 0 0.0033566963393241167
adrenal B-Disease 1 0.9999994039535522
insufficiency I-Disease 1 0.9999998807907104
and O 0 5.911354946874781e-06
red O 0 3.412539081182331e-05
hair O 1 0.9331286549568176
pigmentation O 1 0.8226124048233032
caused O 0 1.3839218809152953e-05
by O 0 1.72171255030662e-08
POMC O 0 0.0005331152933649719
mutations O 0 1.8841683413484134e-06
in O 0 2.6039423950408036e-09
humans O 0 3.229011724670272e-08
. O 0 2.0400653610863628e-08

Sequential O 0 5.486688678502105e-06
cleavage O 0 4.9419918468629476e-06
of O 0 4.112955309665267e-09
the O 0 3.232976941713872e-10
precursor O 0 2.2699215840304987e-09
protein O 0 3.730089570552764e-09
pre O 0 5.014199899733285e-08
- O 0 4.100881596968975e-06
pro O 0 7.922285476524848e-06
- O 0 2.8378170100040734e-05
opiomelanocortin O 0 1.5112405890249647e-05
( O 0 1.4050056673653444e-09
POMC O 0 6.520480724248046e-07
) O 0 5.021775217883828e-10
generates O 0 9.582297622046099e-09
the O 0 4.677292997357085e-10
melanocortin O 0 4.962754474036046e-07
peptides O 0 1.7674204855211428e-07
adrenocorticotrophin O 0 1.0952097682093154e-06
( O 0 1.0824867668901561e-09
ACTH O 0 6.584054403901973e-07
) O 0 1.1157521573323947e-09
, O 0 8.488825753438789e-10
melanocyte O 0 8.544255933884415e-07
- O 0 2.9256441393954447e-06
stimulating O 0 3.163767985370214e-07
hormones O 0 1.421387025857257e-07
( O 0 5.454288687367637e-10
MSH O 0 3.2044491149463283e-07
) O 0 1.2994964826429367e-10
alpha O 0 2.748925531648183e-10
, O 0 1.495516557814547e-11
beta O 0 2.078102100122603e-11
and O 0 1.1446179941365653e-11
gamma O 0 2.7295524174242303e-10
as O 0 1.251282966130418e-10
well O 0 1.137228367031895e-10
as O 0 7.369464760653699e-11
the O 0 5.294103350150792e-11
opioid O 0 6.155571696808693e-08
- O 0 6.272347974345394e-08
receptor O 0 5.5670181353661974e-08
ligand O 0 7.008475932934743e-08
beta O 0 2.1768801872212862e-08
- O 0 1.0625608410919085e-06
endorphin O 0 5.5226453696377575e-05
. O 0 1.4699035943976924e-07

While O 0 2.136588790335736e-07
a O 0 5.723314266958823e-09
few O 0 2.1364121582934104e-09
cases O 0 2.704172441525543e-09
of O 0 4.4928802900301434e-09
isolated O 0 0.032308414578437805
ACTH B-Disease 1 0.9995625615119934
deficiency I-Disease 0 0.0705794245004654
have O 0 1.5458548219271506e-08
been O 0 3.229578027230673e-08
reported O 0 4.5224155087453255e-08
( O 0 7.354317710372982e-10
OMIM O 0 5.272212092677364e-06
201400 O 0 2.423812190954777e-07
) O 0 8.829137421173527e-10
, O 0 5.782013201560687e-10
an O 0 4.297714628620497e-09
inherited O 0 2.1489006030606106e-05
POMC O 0 0.0008123163133859634
defect O 0 5.156568659003824e-05
has O 0 4.1362909541931003e-08
not O 0 1.4130951964119731e-09
been O 0 3.585556962448777e-09
described O 0 1.9480925317338915e-08
so O 0 3.0719651267219206e-09
far O 0 1.1746165817783094e-08
. O 0 8.106187721068636e-09

Recent O 0 1.2938436384501983e-06
studies O 0 9.342648432664191e-09
in O 0 4.172077128217211e-10
animal O 0 3.8410372660280245e-09
models O 0 4.078849258348782e-08
elucidated O 0 2.2753633288630226e-07
a O 0 2.1878432399091707e-09
central O 0 5.177436951386838e-11
role O 0 2.07505720939416e-10
of O 0 4.850772214459731e-11
alpha O 0 2.4127035924692564e-09
- O 0 2.0963007330010441e-07
MSH O 0 3.5330658647581004e-06
in O 0 4.2324949101057996e-10
the O 0 2.091303172302439e-11
regulation O 0 3.9294159592806466e-10
of O 0 3.2488310652833974e-11
food O 0 9.71912994529589e-10
intake O 0 5.144664783074404e-08
by O 0 7.017415121213233e-11
activation O 0 3.1247177068038923e-10
of O 0 1.723355833038731e-11
the O 0 9.087568891841258e-11
brain O 0 1.3606448590053333e-07
melanocortin O 0 2.1535392136229348e-07
- O 0 2.1431110042158252e-07
4 O 0 6.149220688200785e-09
- O 0 9.694811353710975e-08
receptor O 0 5.728406193838964e-08
( O 0 7.694714865280616e-10
MC4 O 0 3.937421297450783e-06
- O 0 2.0086420136067318e-06
R O 0 3.600843001549947e-06
; O 0 1.4735964670720136e-09
refs O 0 5.291578020205634e-08
3 O 0 3.021444427986353e-09
- O 0 6.368680516288805e-08
5 O 0 1.7762392667819427e-09
) O 0 5.0431010062412795e-11
and O 0 8.264577910921389e-11
the O 0 2.0247463428102463e-11
linkage O 0 1.621522827122135e-08
of O 0 1.0529004057513447e-10
human O 0 3.2010840644858263e-09
obesity B-Disease 1 0.9999189376831055
to O 0 5.016359327925102e-09
chromosome O 0 9.909641107697098e-08
2 O 0 1.650755754312172e-09
in O 0 3.143721671872157e-10
close O 0 1.6319254836361097e-09
proximity O 0 9.517362897781823e-09
to O 0 8.87328965859524e-09
the O 0 6.798635543425746e-10
POMC O 0 2.4217497411882505e-06
locus O 0 7.26515096971525e-08
, O 0 2.9417845937018683e-10
led O 0 4.3659240112070563e-10
to O 0 5.675804826132946e-10
the O 0 1.0358038732283248e-10
proposal O 0 1.0903304037412909e-08
of O 0 6.109093092510065e-11
an O 0 1.0512213322044772e-09
association O 0 7.945454294500109e-10
of O 0 1.1458330118063742e-10
POMC O 0 8.565692041884176e-06
with O 0 9.360198838237466e-09
human O 0 9.555454028031818e-08
obesity B-Disease 1 0.999968409538269
. O 0 2.572464268268959e-07

The O 0 3.3114794462107966e-08
dual O 0 7.49694422097491e-08
role O 0 1.895892332015592e-09
of O 0 6.848387829050395e-11
alpha O 0 7.211594432732227e-09
- O 0 1.0994459671564982e-06
MSH O 0 1.1249014278291725e-05
in O 0 1.1280927303403132e-09
regulating O 0 1.3378055108148601e-08
food O 0 9.59828572177912e-09
intake O 0 3.17609050171086e-07
and O 0 1.9766270842325184e-09
influencing O 0 5.495773081065636e-08
hair O 0 0.00014187759370543063
pigmentation O 0 0.00022831675596535206
predicts O 0 1.848144734140078e-06
that O 0 3.1214844042892764e-09
the O 0 5.754046128458867e-10
phenotype O 0 4.787263605976477e-05
associated O 0 1.0955601981166296e-09
with O 0 1.1263034949138273e-10
a O 0 1.908242630577206e-08
defect O 0 2.1212967112660408e-05
in O 0 2.354872297161137e-09
POMC O 0 5.555913048738148e-06
function O 0 7.661957290849841e-09
would O 0 6.894081749919678e-09
include O 0 1.150301365271389e-08
obesity B-Disease 1 0.9999985694885254
, O 0 1.222072132378571e-08
alteration O 0 4.719614139503392e-07
in O 0 8.615182167659441e-08
pigmentation O 1 0.9822986125946045
and O 0 0.05538991093635559
ACTH B-Disease 1 0.9995321035385132
deficiency I-Disease 0 0.11589337885379791
. O 0 9.912136533785088e-08

The O 0 9.844983850371136e-08
observation O 0 2.810175772083312e-07
of O 0 2.4845892010461057e-10
these O 0 1.750146028101085e-09
symptoms O 0 2.767805881376262e-06
in O 0 1.4084124144719823e-10
two O 0 1.1100865782154301e-09
probands O 0 3.73783336726774e-07
prompted O 0 1.5687048104950918e-08
us O 0 4.621143190330912e-10
to O 0 2.586418579308969e-10
search O 0 1.0642297043617077e-09
for O 0 4.01919414416696e-10
mutations O 0 1.535265070629066e-08
within O 0 1.236573066165647e-10
their O 0 5.648632672716758e-10
POMC O 0 6.2514027376892045e-06
genes O 0 8.094556847026979e-08
. O 0 1.5474538983539787e-08

Patient O 0 0.2783587574958801
1 O 0 3.121254508187121e-07
was O 0 1.1701759916604715e-07
found O 0 8.662347505961066e-10
to O 0 2.463886039638652e-10
be O 0 2.0080673235334245e-10
a O 0 6.938640217946102e-10
compound O 0 1.6224509735707215e-08
heterozygote O 0 9.897193109509317e-08
for O 0 2.1304900899021817e-10
two O 0 3.379147239801483e-10
mutations O 0 7.628113252167168e-09
in O 0 5.161653326979376e-10
exon O 0 4.7855504448079955e-08
3 O 0 1.7088737092052497e-09
( O 0 2.1772020297738948e-10
G7013T O 0 2.575694679762819e-07
, O 0 7.442086391584724e-10
C7133delta O 0 4.726532409904394e-08
) O 0 5.40606275023503e-11
which O 0 1.83165774214622e-10
interfere O 0 1.1102474495316983e-09
with O 0 9.01172469980338e-11
appropriate O 0 5.179424666934551e-10
synthesis O 0 1.7223487080997302e-09
of O 0 5.257818624926358e-10
ACTH O 0 2.5669967271824135e-06
and O 0 7.09536207565975e-09
alpha O 0 6.26455260999137e-08
- O 0 6.202795702847652e-06
MSH O 0 0.00029686480411328375
. O 0 1.1887998141446587e-07

Patient O 0 0.14749684929847717
2 O 0 1.542718734981463e-07
was O 0 3.753199706579835e-08
homozygous O 0 3.852183638741735e-08
for O 0 1.647895431222679e-10
a O 0 5.193781404955189e-09
mutation O 0 6.406266095382307e-08
in O 0 8.937746098780508e-10
exon O 0 9.196141093070764e-08
2 O 0 1.3967393464042743e-08
( O 0 4.0488634667212864e-10
C3804A O 0 1.404556826400949e-07
) O 0 6.297840582369929e-10
which O 0 8.472976986695357e-09
abolishes O 0 0.00011188147618668154
POMC O 0 0.00013173425395507365
translation O 0 6.392168643287732e-07
. O 0 5.607653008610214e-08

These O 0 7.165186133306634e-08
findings O 0 1.6250989887112155e-08
represent O 0 2.363591822263089e-10
the O 0 2.4201122009182008e-11
first O 0 3.2003863448260006e-10
examples O 0 5.960026361329085e-10
of O 0 9.979617826560983e-11
a O 0 2.8924594630552747e-07
genetic B-Disease 1 0.9999948740005493
defect I-Disease 1 0.9999915361404419
within O 0 6.558530385447625e-10
the O 0 5.798843627502492e-10
POMC O 0 2.0496268007264007e-06
gene O 0 1.6679326364510416e-08
and O 0 4.483863558224499e-10
define O 0 2.8949960206858805e-09
a O 0 6.779771855036643e-09
new O 0 2.9278659496867476e-08
monogenic B-Disease 0 0.03069489262998104
endocrine I-Disease 0 0.0324658527970314
disorder I-Disease 0 0.007187551818788052
resulting O 0 2.4391484387820128e-08
in O 0 1.893326606605683e-09
early O 0 2.942195180821727e-07
- O 1 0.9983752965927124
onset O 1 0.9981279969215393
obesity B-Disease 1 1.0
, O 0 0.0009546470828354359
adrenal B-Disease 1 0.9999990463256836
insufficiency I-Disease 1 0.9999997615814209
and O 0 1.266155550183612e-06
red O 0 2.7504891022545053e-06
hair O 0 0.00429869769141078
pigmentation O 0 0.0009522306500002742
. O 0 1.6565127936019053e-08
. O 0 2.0763538444157348e-08

A O 0 1.9697761217685184e-06
European O 0 1.9508297555148602e-07
multicenter O 0 8.459328091703355e-05
study O 0 9.865868833003333e-08
of O 0 1.665662630045972e-08
phenylalanine B-Disease 1 0.9999998807907104
hydroxylase I-Disease 1 0.9999986886978149
deficiency I-Disease 1 1.0
: O 0 5.588217444341126e-09
classification O 0 7.586353767408127e-09
of O 0 3.3216842471039953e-11
105 O 0 3.917743907067006e-09
mutations O 0 3.020581473833772e-08
and O 0 2.704769463957035e-10
a O 0 9.03968677690159e-10
general O 0 6.530070928434384e-10
system O 0 1.2755979605927337e-09
for O 0 9.837636261167404e-10
genotype O 0 1.3533006494981237e-05
- O 0 8.207689461414702e-07
based O 0 3.864333208980497e-08
prediction O 0 1.0230488101115043e-07
of O 0 1.2898049295273495e-09
metabolic O 0 0.0015447917394340038
phenotype O 0 0.0007262832950800657
. O 0 7.30509981394789e-08

Phenylketonuria B-Disease 1 0.9942247271537781
( O 0 1.7815789760788903e-05
PKU B-Disease 0 0.012130632996559143
) O 0 2.915300854056113e-07
and O 0 9.766106813913211e-06
mild B-Disease 1 0.9999905824661255
hyperphenylalaninemia I-Disease 1 1.0
( O 0 7.379183080047369e-05
MHP B-Disease 1 1.0
) O 0 2.7375740785373637e-08
are O 0 8.487765512654732e-08
allelic B-Disease 0 0.18042516708374023
disorders I-Disease 1 0.9696903824806213
caused O 0 9.84250277724641e-07
by O 0 1.4231789080554336e-09
mutations O 0 9.042280879612008e-08
in O 0 2.4576202184434237e-10
the O 0 3.1931973731857966e-10
gene O 0 6.514090955533902e-08
encoding O 0 6.598405093427573e-07
phenylalanine O 0 8.677781443111598e-05
hydroxylase O 0 0.0009539820021018386
( O 0 3.2954499573634166e-08
PAH O 0 9.9308217613725e-06
) O 0 1.2739111987514207e-08
. O 0 2.0200857875352085e-08

Previous O 0 9.622629022487672e-07
studies O 0 9.19683884603728e-09
have O 0 1.7621575310045046e-09
suggested O 0 1.6929705415336116e-09
that O 0 8.846934296258269e-11
the O 0 7.244218419577564e-11
highly O 0 1.8680601954201848e-08
variable O 0 8.356543730769772e-06
metabolic O 0 0.03448529541492462
phenotypes O 0 7.33862179913558e-05
of O 0 3.945657311987816e-08
PAH B-Disease 1 0.9996696710586548
deficiency I-Disease 1 0.8905569911003113
correlate O 0 2.938783472927753e-05
with O 0 3.3459932069490605e-07
PAH O 0 0.04553676024079323
genotypes O 0 0.0001661322166910395
. O 0 1.705599430579241e-07

We O 0 4.4030929302607547e-07
identified O 0 7.361663989513545e-08
both O 0 8.053908095995155e-10
causative O 0 5.644610112653936e-08
mutations O 0 1.7935964535809035e-07
in O 0 3.7799079422029536e-09
686 O 0 2.178175600420218e-05
patients O 0 0.13894250988960266
from O 0 1.542249439268062e-09
seven O 0 1.99805105793871e-09
European O 0 2.716911362554697e-09
centers O 0 1.4151672722562125e-08
. O 0 1.7403202434707055e-08

On O 0 3.908796131213421e-08
the O 0 3.5430183786822056e-10
basis O 0 9.732073480428483e-11
of O 0 5.097904303558165e-12
the O 0 1.1606362398941528e-10
phenotypic O 0 6.224224762263475e-07
characteristics O 0 1.8518194977446e-08
of O 0 1.6440464267741817e-10
297 O 0 1.201475043899336e-07
functionally O 0 2.3207926460599992e-06
hemizygous O 0 0.0002143603633157909
patients O 0 4.1654140659375116e-05
, O 0 1.6664682134237552e-10
105 O 0 3.377677859628392e-10
of O 0 3.889355851272036e-12
the O 0 4.592548910609118e-11
mutations O 0 1.089237144924482e-08
were O 0 1.5188083013484288e-09
assigned O 0 7.012989633459199e-10
to O 0 2.5689159133257533e-10
one O 0 2.1148421902594805e-10
of O 0 1.4370779739814044e-11
four O 0 3.075217303027955e-10
arbitrary O 0 1.72587903080057e-07
phenotype O 0 0.0006282185786403716
categories O 0 2.1107419811983164e-08
. O 0 2.293147360887815e-08

We O 0 5.568026040236873e-07
proposed O 0 2.7831360327468246e-08
and O 0 2.8816640185169717e-09
tested O 0 9.579994575403816e-09
a O 0 1.1932319576857253e-09
simple O 0 2.41082687146843e-09
model O 0 1.3181654878735571e-08
for O 0 1.3309882362921854e-10
correlation O 0 5.8317786155726026e-09
between O 0 1.3030015955095564e-09
genotype O 0 1.2122149200877175e-05
and O 0 8.49020675985912e-09
phenotypic O 0 2.6300704121240415e-06
outcome O 0 6.532275165227475e-07
. O 0 9.782857546269952e-08

The O 0 2.2221033191272e-07
observed O 0 9.312465749644616e-07
phenotype O 0 3.9506958273705095e-05
matched O 0 2.5452936824876815e-07
the O 0 5.343979703198443e-10
predicted O 0 5.215146643422486e-07
phenotype O 0 3.1047267839312553e-05
in O 0 1.2663569082249637e-09
79 O 0 4.9855810146937074e-08
% O 0 9.575783915805047e-11
of O 0 4.1438475914534756e-12
the O 0 1.5465434488604046e-10
cases O 0 1.3473623106108334e-08
, O 0 4.73127204081436e-10
and O 0 5.734631658427247e-10
in O 0 1.5236094330628447e-10
only O 0 4.069977965759364e-10
5 O 0 6.817096886990726e-11
of O 0 1.2151692846407158e-11
184 O 0 2.5301428507873425e-08
patients O 0 3.383560397196561e-06
was O 0 1.2259499193589818e-08
the O 0 1.1535936789153212e-10
observed O 0 1.1711268399494656e-08
phenotype O 0 3.705987410285161e-07
more O 0 3.776173540526173e-10
than O 0 2.4964078026989966e-10
one O 0 3.6275230042015494e-10
category O 0 5.347365328312037e-10
away O 0 1.0864540378463516e-09
from O 0 9.732704225884348e-11
that O 0 1.282142503278294e-09
expected O 0 4.215555549080818e-08
. O 0 2.4729137848567007e-08

Among O 0 4.0879348262023996e-07
the O 0 1.6068271158076186e-09
seven O 0 6.681510900108378e-10
contributing O 0 6.346593250938781e-10
centers O 0 4.05278061110792e-10
, O 0 6.439382360667878e-11
the O 0 3.49750749195632e-11
proportion O 0 2.36145258902809e-09
of O 0 1.8975011839561517e-10
patients O 0 4.827487600778113e-07
for O 0 3.3898761575557046e-10
whom O 0 8.571579002136787e-09
the O 0 1.683589379020134e-10
observed O 0 1.2734739485154023e-08
phenotype O 0 1.0876914302571095e-06
did O 0 1.603936428118402e-09
not O 0 1.2193421272677085e-10
match O 0 6.66652788527955e-10
the O 0 2.873210558362871e-10
predicted O 0 4.327951330651558e-07
phenotype O 0 6.418254088202957e-06
was O 0 1.68537095390775e-08
4 O 0 5.335262232009086e-10
% O 0 2.213555588825855e-10
- O 0 2.1875507627555635e-07
23 O 0 4.768057522142044e-07
% O 0 5.769454358706128e-10
( O 0 1.6879815600834291e-10
P O 0 4.4858740011477494e-07
< O 0 6.589051970706805e-09
. O 0 4.396676633877661e-10
0001 O 0 2.474672466945549e-09
) O 0 1.203592642218254e-10
, O 0 1.0599628813556805e-10
suggesting O 0 1.5774502815091296e-09
that O 0 1.798695220545099e-10
differences O 0 4.69841276995453e-10
in O 0 1.5905122704995556e-11
methods O 0 1.6789300505415383e-10
used O 0 9.9778907358683e-10
for O 0 1.3842199608760097e-10
mutation O 0 9.53271417358792e-09
detection O 0 4.097654660029093e-09
or O 0 4.69266492331144e-09
phenotype O 0 0.05935834348201752
classification O 0 1.2677854783760267e-06
may O 0 6.343252607621253e-07
account O 0 1.1750328487991624e-09
for O 0 3.8275545927168864e-11
a O 0 9.6491992174208e-10
considerable O 0 1.8110901223167275e-08
proportion O 0 9.473840378859677e-09
of O 0 8.740266843609845e-10
genotype O 0 0.01227567344903946
- O 0 0.19942812621593475
phenotype O 0 0.3335525393486023
inconsistencies O 0 2.884987225115765e-06
. O 0 7.584982597563794e-08

Our O 0 1.8911175914126943e-07
data O 0 1.5870540437390446e-08
indicate O 0 1.3424806155626356e-08
that O 0 6.02657868054024e-10
the O 0 2.635692331054429e-09
PAH O 0 3.910107261617668e-05
- O 0 4.854832513956353e-05
mutation O 0 6.898655101394979e-06
genotype O 0 2.659966185092344e-06
is O 0 7.34232008525737e-10
the O 0 3.5513789825580844e-11
main O 0 9.875537054782058e-10
determinant O 0 2.541736954242424e-08
of O 0 8.017430053186558e-10
metabolic O 0 0.006879882887005806
phenotype O 0 0.015108020044863224
in O 0 4.226043515132005e-09
most O 0 1.6792944279586663e-07
patients O 0 0.0065634530037641525
with O 0 7.639656359970104e-06
PAH B-Disease 1 0.9997714161872864
deficiency I-Disease 1 0.7913820147514343
. O 0 5.151331805564041e-08

In O 0 3.987646834957559e-08
the O 0 5.610428788216382e-10
present O 0 1.082193668011655e-09
study O 0 8.274803064978187e-10
, O 0 1.3560390310640713e-10
the O 0 1.192212162326456e-10
classification O 0 8.581426236276002e-09
of O 0 1.8607114460333918e-10
105 O 0 1.0308112052825891e-07
PAH O 0 0.00011119217379018664
mutations O 0 9.142979138232477e-07
may O 0 1.63745426107198e-08
allow O 0 1.372511104769103e-09
the O 0 1.6784114376111603e-10
prediction O 0 1.8975248039510006e-08
of O 0 1.024786939335387e-11
the O 0 1.1272147104612884e-10
biochemical O 0 1.3995853009873827e-07
phenotype O 0 5.910475920245517e-06
in O 0 3.135715020974317e-10
> O 0 6.625776372004566e-09
10 O 0 8.902425463475083e-10
, O 0 3.533880132966516e-10
000 O 0 1.6921762879817948e-09
genotypes O 0 8.565650233549604e-08
, O 0 4.818316301502534e-10
which O 0 2.7037601046941973e-09
may O 0 1.578745312258434e-08
be O 0 4.946089648960594e-10
useful O 0 3.15988069043982e-10
for O 0 8.93356638664855e-11
the O 0 8.942175472315128e-11
management O 0 3.305771212325226e-10
of O 0 1.188479592517666e-10
hyperphenylalaninemia B-Disease 1 0.9999915361404419
in O 0 9.554651825283145e-08
newborns O 0 2.0030307496199384e-05
. O 0 3.382813673624696e-08

Somatic O 0 0.00020739804313052446
instability O 0 1.5824987713131122e-05
of O 0 1.1551537504317366e-08
the O 0 3.257496494768475e-09
CTG O 0 1.4884664096825873e-06
repeat O 0 1.8639728693869984e-07
in O 0 1.086760903490358e-09
mice O 0 1.0886414969490943e-07
transgenic O 0 3.8225849152695446e-08
for O 0 2.477317240234811e-09
the O 0 4.190392033365242e-08
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
region O 0 6.363286956911907e-06
is O 0 6.891152537491507e-08
age O 0 4.386610630291443e-09
dependent O 0 1.0591064691922725e-09
but O 0 5.498178579088631e-10
not O 0 3.013943261631624e-10
correlated O 0 5.690786175627238e-10
to O 0 1.7440003607926968e-10
the O 0 6.544381703221802e-11
relative O 0 4.51463089135018e-09
intertissue O 0 1.519113936865324e-07
transcription O 0 2.826155309776368e-08
levels O 0 6.761589066428542e-09
and O 0 8.375510063274305e-09
proliferative O 0 0.001993530197069049
capacities O 0 3.0763021641178057e-06
. O 0 6.198327184847585e-08

A O 0 5.458224677568069e-06
( O 0 6.25850944402373e-08
CTG O 0 1.1555733863133355e-06
) O 0 3.0612496981774484e-09
nexpansion O 0 1.561874682920461e-07
in O 0 5.821517712334412e-10
the O 0 3.323206987371208e-10
3 O 0 1.123185366935786e-08
- O 0 2.398925971647259e-05
untranslated O 0 0.00036724680103361607
region O 0 1.0598672872674797e-07
( O 0 1.1133944877173008e-09
UTR O 0 3.0134637540868425e-07
) O 0 2.570945123459012e-10
of O 0 7.906869603502287e-11
the O 0 2.8870994484009316e-09
DM O 1 0.9999998807907104
protein O 0 2.1088360426801955e-06
kinase O 0 5.767665811617917e-07
gene O 0 2.9390111677685127e-08
( O 0 4.138157316813107e-10
DMPK O 0 3.498654166378401e-07
) O 0 2.0429213876127506e-10
is O 0 3.491883171502508e-10
responsible O 0 6.835944699190577e-09
for O 0 1.011447725574044e-08
causing O 0 0.006953900214284658
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 0.00043860485311597586
DM B-Disease 1 1.0
) O 0 9.832033356360625e-07
. O 0 2.4098633844005235e-07

Major O 0 1.2227760635141749e-06
instability O 0 2.1423193174996413e-06
, O 0 5.353879117819815e-09
with O 0 3.592462161083887e-10
very O 0 1.0736819211487614e-09
large O 0 2.008488930727026e-10
expansions O 0 3.2636098268312708e-09
between O 0 3.6300559780322317e-10
generations O 0 1.4381982271771676e-09
and O 0 7.192181294968236e-10
high O 0 1.6737766728169845e-09
levels O 0 3.0628133362853305e-10
of O 0 4.464617564536866e-11
somatic O 0 6.21129743194615e-08
mosaicism O 0 6.133180249889847e-06
, O 0 3.557875938309252e-10
is O 0 4.671622533258812e-10
observed O 0 4.8250319295561894e-09
in O 0 2.9721967109708203e-09
patients O 0 2.0624818262149347e-06
. O 0 2.76130887044701e-08

There O 0 1.3463686343584413e-07
is O 0 2.6750652803997355e-09
a O 0 1.7676918817599585e-09
good O 0 6.539097707758401e-09
correlation O 0 3.4702136719744203e-09
between O 0 2.0180120074986263e-10
repeat O 0 9.537151512972741e-09
size O 0 4.843103695861828e-09
( O 0 1.0657363880284265e-10
at O 0 2.6579494161182993e-10
least O 0 1.107880343020895e-09
in O 0 2.0303743408778274e-10
leucocytes O 0 2.424226011044084e-07
) O 0 2.792528985828824e-10
, O 0 6.924784079487267e-10
clinical O 0 7.092144471698703e-08
severity O 0 0.00030579176382161677
and O 0 3.1595345006962816e-08
age O 0 4.119864449592114e-09
of O 0 4.308989831613985e-10
onset O 0 3.991254118318466e-07
. O 0 1.628797150488026e-07

The O 0 1.3150194888567057e-07
trinucleotide O 0 2.052625859505497e-05
repeat O 0 1.4724698758072918e-06
instability O 0 1.8757083353193593e-07
mechanisms O 0 1.2623712741799409e-08
involved O 0 1.242506098009244e-08
in O 0 2.4266425313612672e-08
DM B-Disease 1 1.0
and O 0 7.171660172389238e-07
other O 0 1.1485709050518267e-09
human O 0 2.2463717996856758e-08
genetic B-Disease 1 0.9999954700469971
diseases I-Disease 1 0.9999843835830688
are O 0 1.3870466553100869e-08
unknown O 0 1.0582513709778141e-07
. O 0 1.410752847874619e-08

We O 0 3.1636415087632486e-07
studied O 0 3.11078771630946e-08
somatic O 0 1.8002215540491306e-07
instability O 0 9.396245559400995e-08
by O 0 5.946604320072879e-10
measuring O 0 4.7068844821751554e-08
the O 0 3.6194092167818326e-10
CTG O 0 2.8183509925838734e-07
repeat O 0 8.082446356638684e-08
length O 0 1.0705582553782733e-07
at O 0 2.425386280702213e-10
several O 0 3.316646957074454e-10
ages O 0 8.414768326581168e-10
in O 0 3.5654285079900205e-11
various O 0 4.406849538063362e-11
tissues O 0 2.3681416827514568e-09
of O 0 3.269911771908163e-11
transgenic O 0 5.266937819214945e-08
mice O 0 4.1021465335688845e-07
carrying O 0 1.1371573682694702e-09
a O 0 1.0679834794302678e-09
( O 0 2.2957183376526302e-10
CTG O 0 3.5403814990786486e-07
) O 0 9.867628936177653e-10
55expansion O 0 2.356428723260251e-07
surrounded O 0 3.998309239250375e-08
by O 0 6.028831878168717e-10
45 O 0 1.2697817242113274e-09
kb O 0 3.1853474524723424e-08
of O 0 6.560766513397098e-11
the O 0 3.4034033924434937e-10
human O 0 3.768420953065288e-08
DM B-Disease 1 1.0
region O 0 4.897373742096534e-07
, O 0 6.935186869228005e-10
using O 0 1.4396582814768522e-09
small O 0 1.968012419695242e-09
- O 0 1.6218837117776275e-06
pool O 0 1.0861137980100466e-06
PCR O 0 8.603047717770096e-06
. O 0 1.1514740094753506e-07

These O 0 3.3980498415076e-07
mice O 0 2.963407041534083e-06
have O 0 7.294876702701458e-09
been O 0 2.2807145061420897e-09
shown O 0 5.087606336218187e-09
to O 0 1.877217270518372e-09
reproduce O 0 1.8289929926140758e-07
the O 0 2.0573741321694428e-10
intergenerational O 0 1.561882889689059e-08
and O 0 1.3678853605370023e-09
somatic O 0 2.5179820895004923e-08
instability O 0 4.69275462933183e-09
of O 0 4.424857355522782e-11
the O 0 3.143206250832975e-10
55 O 0 7.1864669770604905e-09
CTG O 0 1.697820977142328e-07
repeat O 0 4.2644014541792785e-08
suggesting O 0 1.4695442196455133e-08
that O 0 4.317364799000245e-10
surrounding O 0 4.4697831547146905e-10
sequences O 0 2.0628760921681533e-09
and O 0 4.663752162237245e-10
the O 0 4.169871392623037e-11
chromatin O 0 5.787642809451654e-09
environment O 0 2.05136441167042e-09
are O 0 6.027495169647068e-11
involved O 0 4.835016276238946e-10
in O 0 5.828806881602588e-10
instability O 0 6.098763094541937e-08
mechanisms O 0 4.686817334231819e-08
. O 0 1.9517448990313824e-08

As O 0 2.3667662674142775e-07
observed O 0 3.7475768266403975e-08
in O 0 1.83864770630926e-10
some O 0 8.452969574301861e-11
of O 0 1.113482570036517e-11
the O 0 2.3336771404203205e-10
tissues O 0 1.2374074742638186e-07
of O 0 9.753527763223246e-09
DM B-Disease 1 1.0
patients O 1 0.9999759197235107
, O 0 9.562410863139803e-10
there O 0 1.1839997038354255e-10
is O 0 9.58477394674695e-11
a O 0 4.684203025462352e-10
tendency O 0 1.7720406475518757e-08
for O 0 3.1374680631302e-10
repeat O 0 3.4583745645022645e-08
length O 0 1.0930376959095156e-07
and O 0 7.0351624525955e-10
somatic O 0 1.4124788449976222e-08
mosaicism O 0 3.1545999945592484e-07
to O 0 2.766104456597418e-09
increase O 0 4.371642603473447e-09
with O 0 5.446824102861569e-10
the O 0 9.154341729100679e-10
age O 0 1.5906563843870458e-09
of O 0 2.1304281255796198e-11
the O 0 2.2124961585046066e-10
mouse O 0 8.175955485967279e-07
. O 0 4.107281625920223e-08

Furthermore O 0 1.2041737136314623e-05
, O 0 2.390005526820005e-08
we O 0 1.1362316643115378e-09
observed O 0 1.6187748919094247e-09
no O 0 3.9523870287716534e-10
correlation O 0 1.5300782862937012e-09
between O 0 8.024999414990575e-11
the O 0 1.8012014102453122e-10
somatic O 0 5.346764169189555e-07
mutation O 0 1.3343941418497707e-06
rate O 0 1.81716632852158e-08
and O 0 2.0001786893431017e-09
tissue O 0 9.869515906757442e-07
proliferation O 0 1.426406015525572e-07
capacity O 0 1.7580367739356006e-07
. O 0 3.39152244066554e-08

The O 0 6.587497125565278e-08
somatic O 0 2.6050076940009603e-06
mutation O 0 1.0017914974014275e-05
rates O 0 9.213785290285159e-08
in O 0 4.926120067416662e-10
different O 0 2.5634144806829795e-10
tissues O 0 2.6621277626759365e-08
were O 0 6.94282720203887e-09
also O 0 2.362249951204376e-09
not O 0 1.0149722173835585e-09
correlated O 0 3.3909255403585803e-09
to O 0 5.770774968993919e-10
the O 0 7.835035398251478e-11
relative O 0 2.38454012091438e-09
inter O 0 3.522959257651337e-09
- O 0 3.3678857107588556e-06
tissue O 0 9.47765443015669e-07
difference O 0 3.901874379153014e-09
in O 0 4.597491831681566e-11
transcriptional O 0 3.1317060056323953e-09
levels O 0 3.0534630379719374e-10
of O 0 4.066481960190993e-12
the O 0 1.0908009738519464e-11
three O 0 9.357048469382789e-11
genes O 0 3.8044839500983585e-10
( O 0 1.3987107305712954e-10
DMAHP O 0 1.144465613833745e-06
, O 0 1.3986847235969435e-09
DMPK O 0 1.98130646822392e-06
and O 0 6.1172844567636275e-09
59 O 0 7.542752200606628e-09
) O 0 8.114594413077825e-11
surrounding O 0 1.3076050242588622e-09
the O 0 5.876382713765338e-10
repeat O 0 1.390533128642346e-07
. O 0 5.262075220002771e-09
. O 0 7.142342273169788e-09

A O 0 3.3186831842613174e-06
novel O 0 1.9215428892493946e-06
missense O 0 2.6255685952492058e-05
mutation O 0 4.196217105345568e-06
in O 0 1.1470325134155246e-08
patients O 0 7.39108259040222e-07
from O 0 2.1422499885126456e-10
a O 0 2.4765247630398335e-08
retinoblastoma B-Disease 0 0.00019341794541105628
pedigree O 0 1.9230265024816617e-05
showing O 0 1.1293882380414288e-06
only O 0 1.2690366979484224e-08
mild O 0 0.00012456686818040907
expression O 0 2.7827963933191313e-08
of O 0 1.903678326087288e-10
the O 0 5.510433442879048e-09
tumor B-Disease 0 0.0005159148713573813
phenotype O 0 0.000476138578960672
. O 0 3.319649977129302e-08

We O 0 3.415385947391769e-07
have O 0 3.6991840701716683e-09
used O 0 1.184497055994882e-09
single O 0 5.47266321149209e-09
strand O 0 3.750465893403998e-08
conformation O 0 3.3632169049724325e-08
polymorphism O 0 8.39207871194958e-07
analysis O 0 1.5643745188143043e-09
to O 0 8.472650359081513e-10
study O 0 7.597529272374004e-10
the O 0 1.7680348851634164e-10
27 O 0 2.6396065333500474e-09
exons O 0 4.305730438858291e-09
of O 0 2.9569603710033476e-11
the O 0 1.4431546235815773e-10
RB1 O 0 1.351674256966362e-07
gene O 0 1.1922900444716333e-09
in O 0 1.3907407170332675e-10
individuals O 0 3.0474164858240727e-11
from O 0 1.4799860989511693e-11
a O 0 2.6056217183878516e-09
family O 0 2.527085030123999e-08
showing O 0 4.5494863343265024e-07
mild O 0 0.0015083631733432412
expression O 0 4.809616882539558e-08
of O 0 1.703698154775779e-10
the O 0 2.4910580265213866e-09
retinoblastoma B-Disease 0 0.00031747124739922583
phenotype O 0 0.002948785899206996
. O 0 7.463544449137771e-08

In O 0 4.903729688976455e-08
this O 0 8.127331585505715e-10
family O 0 5.960916205083322e-09
affected O 0 3.6116323265389383e-09
individuals O 0 4.875801429271576e-10
developed O 0 3.147078686538407e-08
unilateral B-Disease 0 0.011528991162776947
tumors I-Disease 1 1.0
and O 0 8.551837709092069e-07
, O 0 3.5760683303465157e-10
as O 0 1.8850344896126359e-10
a O 0 6.369343386047888e-10
result O 0 9.88850445970968e-10
of O 0 6.54489379359191e-11
linkage O 0 2.2308452685138036e-07
analysis O 0 9.612007190185068e-09
, O 0 1.0172941378172595e-09
unaffected O 0 2.9982678029227827e-07
mutation O 0 7.063066931323192e-08
carriers O 0 7.016284442329379e-09
were O 0 4.373035267235537e-09
also O 0 6.189180723481513e-09
identified O 0 4.173846157584649e-09
within O 0 7.034420268503538e-11
the O 0 4.166438860586652e-10
pedigree O 0 7.258605592141976e-07
. O 0 2.4179568569593357e-08

A O 0 1.0235303307126742e-06
single O 0 8.509973525860914e-08
band O 0 3.4694078721031474e-08
shift O 0 1.9272263784841925e-08
using O 0 4.7601673713870696e-09
SSCP O 0 2.2282838472165167e-06
was O 0 4.6221881433439194e-08
identified O 0 3.143663329652213e-09
in O 0 8.265145512442729e-11
exon O 0 2.2866178284175476e-08
21 O 0 2.439663582265439e-09
which O 0 2.0823524848889718e-10
resulted O 0 6.925880424724085e-10
in O 0 1.2765707935180615e-10
a O 0 4.593604607805446e-09
missense O 0 1.2942126659254427e-06
mutation O 0 1.4938311920786873e-08
converting O 0 1.8934385170865653e-09
a O 0 3.730786790612228e-09
cys O 0 1.4482441656582523e-05
- O 0 2.109000888594892e-06
- O 0 7.472887659787375e-07
> O 0 3.576774432190177e-08
arg O 0 1.7270208374497997e-08
at O 0 6.533630581007088e-11
nucleotide O 0 8.119150907148764e-10
position O 0 7.756696618343994e-09
28 O 0 2.0883952345229773e-09
in O 0 8.749937580043721e-11
the O 0 9.357998820291868e-10
exon O 0 8.560192554796231e-07
. O 0 7.163464488257887e-08

The O 0 1.724733778019072e-07
mutation O 0 1.4426793768507196e-06
destroyed O 0 6.055874735011457e-08
an O 0 2.3969526363742943e-09
NdeI O 0 8.450883797195274e-07
restriction O 0 6.062646917825987e-08
enzyme O 0 2.424338951811933e-08
site O 0 4.3879097688659385e-08
. O 0 1.8473462759516224e-08

Analysis O 0 5.5263399190153e-07
of O 0 2.278657929011274e-09
all O 0 3.839606688149644e-10
family O 0 1.6322025953030561e-09
members O 0 1.822645367965947e-10
demonstrated O 0 1.5435384081996517e-09
that O 0 1.3299046586201513e-10
the O 0 1.0148904633355826e-10
missense O 0 8.557205433135096e-07
mutation O 0 1.328218246499091e-07
co O 0 1.0349996415470741e-07
- O 0 1.1421224144214648e-06
segregated O 0 1.21057723845297e-07
with O 0 3.4422448891291424e-08
patients O 0 0.00016608803707640618
with O 0 2.734957718075748e-07
tumors B-Disease 1 0.9999998807907104
or O 0 1.3155910139062144e-08
who O 0 9.359976047562668e-07
, O 0 1.1387390336237146e-10
as O 0 8.937128120889426e-11
a O 0 1.4207054421788712e-09
result O 0 2.1883355127982895e-09
of O 0 6.708349153949911e-11
linkage O 0 1.1495188090293595e-07
analysis O 0 9.152111068999602e-09
had O 0 1.9967643538620905e-08
been O 0 1.7447532307812708e-09
predicted O 0 3.6704739247994667e-09
to O 0 2.55108378865998e-10
carry O 0 1.6767865984590458e-09
the O 0 6.848600020425977e-10
predisposing O 0 1.8444156921759713e-06
mutation O 0 8.409094789385563e-07
. O 0 3.27233777852598e-08

These O 0 2.4191653125171797e-08
observations O 0 2.8458233103378916e-08
point O 0 3.165033568564013e-09
to O 0 2.2343502603661136e-09
another O 0 8.370144577440897e-09
region O 0 2.537903887045445e-09
of O 0 8.697606523888624e-11
the O 0 1.0823547613725282e-09
RB1 O 0 4.517742695497873e-07
gene O 0 1.92815186039752e-09
where O 0 5.81080183970073e-10
mutations O 0 3.043957086390492e-09
only O 0 1.4786326330007427e-10
modify O 0 4.219752991474479e-09
the O 0 5.047373283217915e-11
function O 0 3.949430713023894e-11
of O 0 1.5371841169745104e-12
the O 0 9.435181802519566e-12
gene O 0 4.371065176478339e-10
and O 0 2.669808263355833e-10
raise O 0 8.423391983924944e-10
important O 0 2.9066450635273355e-11
questions O 0 1.7610411739976684e-10
for O 0 5.355170473730908e-11
genetic O 0 3.47649398158012e-09
counseling O 0 4.4589878456235965e-09
in O 0 1.877123179117035e-10
families O 0 4.94859930810776e-10
with O 0 2.1530026372840183e-10
these O 0 1.2252433512216498e-09
distinctive O 0 1.0324212098566932e-06
phenotypes O 0 3.4537054034444736e-06
. O 0 2.277923627502787e-09
. O 0 1.4944353310397673e-08

Maternal B-Disease 0 0.40183722972869873
disomy I-Disease 0 0.1426459401845932
and O 0 0.05623609572649002
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
consistent O 0 2.496268507456989e-06
with O 0 6.690412113208311e-10
gamete O 0 6.753007397719557e-08
complementation O 0 6.490329269581707e-07
in O 0 9.966403258232504e-10
a O 0 1.3757873729147718e-09
case O 0 2.0806394829264718e-08
of O 0 8.41906683257676e-11
familial O 0 1.2457064713089494e-07
translocation O 0 6.021081162543851e-07
( O 0 5.859057683466062e-10
3 O 0 3.039895668521808e-09
; O 0 1.7063722657084668e-09
15 O 0 2.8090962889137927e-09
) O 0 2.8607319291218403e-10
( O 0 2.935932330583313e-10
p25 O 0 7.497945375689596e-08
; O 0 1.3217775762797146e-09
q11 O 0 3.1900597718959034e-08
. O 0 2.0994331273449518e-10
2 O 0 8.283646546480838e-10
) O 0 1.8649726207797812e-09
. O 0 1.5996599600498485e-08

Maternal B-Disease 1 0.6602975726127625
uniparental I-Disease 0 0.4147464334964752
disomy I-Disease 0 0.054977383464574814
( I-Disease 0 2.840443812601734e-06
UPD I-Disease 1 0.9999860525131226
) I-Disease 0 1.365730017965916e-08
for I-Disease 0 1.0356463464589183e-09
chromosome I-Disease 0 5.51163395812182e-07
15 I-Disease 0 2.9141531410203925e-09
is O 0 1.666411036937987e-10
responsible O 0 5.538744463073897e-10
for O 0 2.2009163588854186e-11
an O 0 2.3725801878704544e-10
estimated O 0 2.1966493068958926e-09
30 O 0 7.585178041225049e-10
% O 0 2.8102135202212608e-11
of O 0 1.0344450122878879e-11
cases O 0 1.835096874458486e-08
of O 0 1.54008876052103e-06
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 9.93139906313445e-07
PWS B-Disease 1 0.9999890327453613
) O 0 8.239862125947184e-08
. O 0 4.382882679010436e-08

We O 0 6.341014682220703e-07
report O 0 1.1502727659262746e-08
on O 0 5.703825745051461e-10
an O 0 1.76217693215186e-10
unusual O 0 6.015304254702869e-09
case O 0 4.662040353764496e-08
of O 0 3.4336183896144234e-10
maternal B-Disease 0 4.5735995968243515e-07
disomy I-Disease 0 2.4770217805780703e-06
15 I-Disease 0 8.700784093207403e-09
in O 0 3.2933495930365098e-09
PWS B-Disease 1 0.9999949932098389
that O 0 3.3902999518886645e-08
is O 0 1.8939585455512997e-09
most O 0 6.444324518461997e-10
consistent O 0 1.1926636567238802e-08
with O 0 3.9676745222649856e-10
adjacent O 0 4.382938900704403e-09
- O 0 1.6539530633963295e-07
1 O 0 3.888063648815887e-09
segregation O 0 6.051276812968354e-09
of O 0 7.532278273325588e-11
a O 0 1.1573414226973e-08
paternal O 0 2.6021300527645508e-06
t O 0 1.2120582937313884e-07
( O 0 1.1445137892973634e-10
3 O 0 6.248317974133499e-10
; O 0 7.34761529397332e-10
15 O 0 9.583115412326038e-10
) O 0 1.5179155155031765e-10
( O 0 2.2465708460206457e-10
p25 O 0 9.327035854767018e-08
; O 0 1.4207108822716918e-09
q11 O 0 3.585121177707151e-08
. O 0 1.3005652110820165e-10
2 O 0 9.391323135821139e-11
) O 0 2.1493334889655102e-11
with O 0 7.815765395990937e-11
simultaneous O 0 2.4270406129289768e-08
maternal O 0 1.3627719397391047e-07
meiotic O 0 2.3784893699030363e-07
nondisjunction O 0 7.394283443318272e-07
for O 0 1.4238142886924265e-09
chromosome O 0 1.1813480114142294e-06
15 O 0 3.573576279336521e-08
. O 0 3.46467317058341e-08

The O 0 3.0252581950662716e-07
patient O 0 1.1516860467963852e-05
( O 0 3.4261360415399622e-09
J O 0 2.815180596371647e-05
. O 0 3.6269298675506434e-09
B O 0 2.6018241783276608e-08
. O 0 8.185822852890823e-11
) O 0 1.7006260982777022e-11
, O 0 3.94541031789597e-11
a O 0 1.3514900309985478e-09
17 O 0 2.83818946122949e-09
- O 0 1.8746710850336967e-07
year O 0 4.949734400128136e-09
- O 0 2.224275476692128e-06
old O 0 5.547351520363009e-06
white O 0 7.806450241787388e-08
male O 0 4.6018550392545876e-07
with O 0 1.6661964252762118e-08
PWS B-Disease 1 0.9999980926513672
, O 0 1.1009737121980834e-08
was O 0 2.596900827711579e-08
found O 0 4.1513040227592057e-10
to O 0 4.231953953937051e-10
have O 0 3.849919494314236e-09
47 O 0 5.926621859941861e-09
chromosomes O 0 1.2623200262851242e-09
with O 0 1.266506066688322e-10
a O 0 3.949088611676643e-09
supernumerary O 0 1.3505317610906786e-06
, O 0 1.6283903114810983e-09
paternal O 0 6.518205282191047e-07
der O 0 6.143670361780096e-06
( O 0 1.794319554049295e-10
15 O 0 4.321475954860432e-10
) O 0 2.8054097239715858e-11
consisting O 0 1.450367881350445e-10
of O 0 1.1491635767968411e-11
the O 0 2.0399466837961455e-10
short O 0 3.783112134669864e-08
arm O 0 4.00718136006617e-07
and O 0 5.863082241930329e-10
the O 0 1.0225655738826944e-10
proximal O 0 8.041135401981592e-07
long O 0 3.303455571312952e-07
arm O 0 6.228683560038917e-07
of O 0 1.7384142736442953e-10
chromosome O 0 3.7592755575133197e-07
15 O 0 3.034137829871497e-09
, O 0 3.5473124437856995e-10
and O 0 3.151515937105387e-09
distal O 0 0.0003359039546921849
chromosome O 0 0.3070065677165985
arm O 0 0.00020142931316513568
3p O 0 2.5789595383685082e-05
. O 0 1.2315904029946978e-07

The O 0 6.120204432136234e-08
t O 0 4.987949751011911e-07
( O 0 7.601326790229734e-10
3 O 0 2.147499733595737e-09
; O 0 8.299271270217901e-10
15 O 0 6.45753950312411e-10
) O 0 6.06143607528864e-11
was O 0 4.103382167386371e-08
present O 0 2.4416083044265235e-10
in O 0 6.090896537136459e-11
the O 0 8.091828596068495e-11
balanced O 0 2.2753008366294125e-09
state O 0 1.0498663050029222e-10
in O 0 9.607121348453873e-11
the O 0 8.154317776565279e-10
patients O 0 1.588150780662545e-06
father O 0 3.738310283551982e-08
and O 0 5.650744872021107e-10
a O 0 8.615654856214405e-09
sister O 0 8.112855311992462e-07
. O 0 1.3657587061288723e-08

Fluorescent O 0 1.4084741451370064e-05
in O 0 1.8395125422898673e-08
situ O 0 2.263746807784628e-07
hybridization O 0 2.1070814426593643e-08
analysis O 0 1.5969286337735866e-08
demonstrated O 0 2.107837282494529e-08
that O 0 7.840884053145203e-10
the O 0 1.6162757798809935e-09
PWS B-Disease 1 0.9999934434890747
critical O 0 1.2906776873933268e-06
region O 0 1.1531768429051681e-08
resided O 0 3.274410431686192e-08
on O 0 6.933030816114183e-10
the O 0 3.653156249727729e-11
derivative O 0 4.644075346504906e-09
chromosome O 0 3.433673967379036e-08
3 O 0 6.224313842118079e-10
and O 0 3.519404490059941e-10
that O 0 6.702366994737474e-10
there O 0 5.755166343490714e-10
was O 0 2.2968505319909127e-08
no O 0 2.4800581033268543e-10
deletion O 0 2.0451604854088146e-09
of O 0 5.935450742011739e-11
the O 0 1.7412491448709488e-09
PWS B-Disease 1 0.9999967813491821
region O 0 3.293413897154096e-08
on O 0 7.696758785868951e-09
the O 0 2.1380905379508874e-10
normal O 0 1.1181701120577259e-09
pair O 0 3.6362532984668405e-09
of O 0 6.72818536995301e-11
15s O 0 1.792915327314404e-08
present O 0 1.7688217557321195e-09
in O 0 3.2524862803029464e-09
J O 0 0.0002711915585678071
. O 0 1.3265092491110408e-07

B O 0 0.0013342483434826136
. O 0 2.768692866084166e-06

Methylation O 0 8.740775228943676e-06
analysis O 0 3.2717139220039826e-07
at O 0 1.7092877113711324e-09
exon O 0 1.8155276393372333e-08
alpha O 0 2.6675244235718765e-09
of O 0 4.2885143353155186e-11
the O 0 1.2384046566005225e-10
small O 0 1.5593756286236271e-09
nuclear O 0 4.171094403204734e-08
ribonucleoprotein O 0 1.4898112112859963e-06
- O 0 7.123080081328226e-07
associated O 0 5.428440985610905e-08
polypeptide O 0 2.707002693114191e-07
N O 0 1.132673119741412e-07
( O 0 3.236993728616966e-10
SNRPN O 0 1.7547554875818605e-07
) O 0 8.744797941329097e-11
gene O 0 9.790259714037575e-10
showed O 0 6.726575296767123e-09
a O 0 2.062576220929202e-10
pattern O 0 5.650276335700255e-08
characteristic O 0 1.0858497212495877e-08
of O 0 9.835323527829232e-11
only O 0 9.057549710256296e-10
the O 0 2.442642477173962e-10
maternal O 0 2.0598270111804595e-07
chromosome O 0 3.030715731711098e-07
15 O 0 3.0162450315174283e-09
in O 0 1.8154193703878718e-09
J O 0 0.0006840507849119604
. O 0 6.682421371806413e-08

B O 0 0.0006633425946347415
. O 0 2.5616097900638124e-06

Maternal B-Disease 0 0.036946795880794525
disomy I-Disease 0 0.00019084502127952874
was O 0 1.3323988241609186e-06
confirmed O 0 7.786163713774386e-09
by O 0 4.289357063980148e-11
polymerase O 0 2.6140307696209675e-08
chain O 0 1.4204114506810583e-07
reaction O 0 1.5032231459599643e-08
analysis O 0 7.344869157321909e-10
of O 0 4.559782412760782e-11
microsatellite O 0 1.4704559703204723e-07
repeats O 0 2.2093527007882585e-08
at O 0 7.459634299156193e-11
the O 0 8.678202600975737e-11
gamma O 0 1.6080266007634236e-08
- O 0 1.71482113842103e-07
aminobutyric O 0 1.9828980839520227e-06
acid O 0 1.0147272888616499e-07
receptor O 0 2.828776324292903e-08
beta3 O 0 9.00805972037233e-08
subunit O 0 1.6045767381456244e-08
( O 0 7.52762852052058e-10
GABRB3 O 0 7.301547384486184e-07
) O 0 2.2633110940972756e-09
locus O 0 3.0143144158500945e-07
. O 0 4.0897628394986896e-08

A O 0 5.573669568548212e-06
niece O 0 2.704195139813237e-05
( O 0 1.739232047270889e-08
B O 0 8.226200520766724e-08
. O 0 9.348437579603797e-10
B O 0 7.47041983828467e-09
. O 0 2.7844592950798663e-11
) O 0 9.391534425140513e-12
with O 0 1.0509000614167263e-10
45 O 0 7.460676521020559e-10
chromosomes O 0 5.016184689843328e-10
and O 0 1.093659815487591e-10
the O 0 3.7940470209996136e-11
derivative O 0 2.6008351028394827e-09
3 O 0 4.753596405393523e-10
but O 0 3.161785833150077e-10
without O 0 5.441577743958703e-11
the O 0 4.48345909009884e-11
der O 0 5.083006726636086e-07
( O 0 7.9405114428166e-11
15 O 0 1.486868128619534e-10
) O 0 4.825322086343675e-11
demonstrated O 0 9.091564834307064e-09
a O 0 2.0756171892344355e-08
phenotype O 0 0.0006643168744631112
consistent O 0 6.150161624418615e-08
with O 0 3.786645996761706e-10
that O 0 3.2038387498545262e-09
reported O 0 6.4883338701804405e-09
for O 0 1.4424446359573295e-10
haploinsufficiency O 0 1.400359650460814e-07
of O 0 1.7639524563239917e-10
distal O 0 1.5238865671562962e-05
3 O 0 5.897160235690535e-07
p O 0 7.1810413828643505e-06
. O 0 3.59289060725132e-08

Uniparental B-Disease 1 0.9998903274536133
disomy I-Disease 1 0.9997897744178772
associated O 0 1.9995990442112088e-05
with O 0 1.5004674835950027e-08
unbalanced O 0 1.192596187138406e-06
segregation O 0 6.420552978170235e-08
of O 0 4.6542972254037807e-10
non O 0 5.625572452316874e-09
- O 0 8.188861784219625e-07
Robertsonian O 0 5.752543984272052e-06
translocations O 0 2.9867005650885403e-06
has O 0 2.9476183271981427e-07
been O 0 1.0755107027193844e-08
reported O 0 4.604042480593762e-09
previously O 0 2.902614815170068e-09
but O 0 9.390075383919338e-10
has O 0 6.447279154997432e-09
not O 0 6.498461213588769e-10
, O 0 8.882831276091352e-11
to O 0 3.6651554014e-10
our O 0 1.4094765632410855e-10
knowledge O 0 5.516727005772104e-11
, O 0 4.621070540111738e-11
been O 0 4.1318395926914775e-10
observed O 0 5.625473420423077e-10
in O 0 2.8729789380843584e-11
a O 0 1.82633164147461e-09
case O 0 1.1935128441109555e-07
of O 0 2.38918520523157e-08
PWS B-Disease 1 0.9999901056289673
. O 0 1.2210002751089633e-06

Furthermore O 0 2.0278923329897225e-05
, O 0 1.4575797457894168e-08
our O 0 9.834427716626237e-10
findings O 0 1.2726427689457864e-09
are O 0 4.769796363435219e-11
best O 0 7.061525253426737e-10
interpreted O 0 5.8337366048988315e-09
as O 0 3.03070069040956e-10
true O 0 9.483779317420726e-10
gamete O 0 4.593098523741901e-08
complementation O 0 3.349760788751155e-07
resulting O 0 6.149269893285236e-08
in O 0 2.3952901884172206e-08
maternal B-Disease 0 0.0691046491265297
UPD I-Disease 1 0.9999988079071045
15 I-Disease 0 1.8420566902932478e-06
and O 0 1.4844462157270755e-06
PWS B-Disease 1 0.9999661445617676

Schwartz B-Disease 0 0.21283763647079468
- I-Disease 1 0.9985005855560303
Jampel I-Disease 1 0.9985567927360535
syndrome I-Disease 1 0.9999837875366211
type I-Disease 0 2.0081843103980646e-06
2 I-Disease 0 6.220379589194636e-08
and O 0 6.569039356918438e-08
Stuve B-Disease 0 0.4298747479915619
- I-Disease 1 0.9999560117721558
Wiedemann I-Disease 1 0.9999988079071045
syndrome I-Disease 1 0.9999959468841553
: O 0 7.121444545177269e-10
a O 0 2.3985073926979794e-09
case O 0 1.8800884404868157e-08
for O 0 2.4839019729938627e-10
" O 0 2.5332851372183995e-09
lumping O 0 1.0238901637649178e-07
" O 0 2.227504758423038e-08
. O 0 7.360917209098261e-09

Recent O 0 1.2911048088426469e-06
studies O 0 6.031045529653056e-08
demonstrated O 0 4.570639333678628e-08
the O 0 2.0013492252335396e-10
existence O 0 1.713295061378517e-10
of O 0 1.4565603931315785e-11
a O 0 1.8293646597555835e-09
genetically O 0 3.4481651312034955e-08
distinct O 0 3.984725438499481e-09
, O 0 8.181862409806229e-10
usually O 0 2.7990414430689725e-09
lethal O 0 9.280999968552806e-09
form O 0 1.5234380423834182e-10
of O 0 2.3415408501037405e-11
the O 0 1.338779975768034e-09
Schwartz B-Disease 0 0.0011040347162634134
- I-Disease 1 0.9962289929389954
Jampel I-Disease 1 0.9998974800109863
syndrome I-Disease 1 0.9999927282333374
( O 0 9.325076710808844e-09
SJS B-Disease 0 2.127250627381727e-05
) O 0 1.3518973718262828e-09
of O 0 1.0180589704589238e-09
myotonia B-Disease 1 0.7424529194831848
and O 0 1.1477741281851195e-06
skeletal B-Disease 1 0.7647708058357239
dysplasia I-Disease 1 0.9999545812606812
, O 0 9.452975291424082e-09
which O 0 2.388085951210428e-09
we O 0 6.111730010971428e-10
called O 0 1.2530779081032506e-08
SJS B-Disease 0 2.927343302872032e-05
type I-Disease 0 4.4668601617559034e-07
2 I-Disease 0 6.283196540834979e-08
. O 0 2.2860813686520487e-08

This O 0 7.331704523494409e-07
disorder O 0 0.011675763875246048
is O 0 5.366351807367664e-09
reminiscent O 0 4.077759996334862e-08
of O 0 1.9494361680472139e-10
another O 0 1.3589661840285316e-08
rare O 0 8.4519179210929e-08
condition O 0 2.783216132229427e-06
, O 0 5.389613755291123e-10
the O 0 1.864499443726686e-09
Stuve B-Disease 0 0.3495538532733917
- I-Disease 1 0.9999904632568359
Wiedemann I-Disease 1 0.9999996423721313
syndrome I-Disease 1 0.9999992847442627
( O 0 6.5631762247164716e-09
SWS B-Disease 0 7.634561916347593e-05
) O 0 6.915782391203606e-10
, O 0 4.189340818694376e-10
which O 0 1.0680384354699868e-09
comprises O 0 1.009747174762765e-09
campomelia B-Disease 0 3.7800475638505304e-07
at O 0 6.200828184255158e-10
birth O 0 1.36915980775143e-08
with O 0 5.095044386393965e-09
skeletal B-Disease 1 0.9382668733596802
dysplasia I-Disease 1 0.9999830722808838
, O 0 2.808554597777402e-07
contractures B-Disease 0 0.009609419852495193
, O 0 6.250490347525783e-09
and O 0 1.5167181954822695e-09
early B-Disease 0 9.023360725279872e-09
death I-Disease 0 6.398172445187811e-06
. O 0 2.5383503299281074e-08

To O 0 3.8145373082443257e-07
test O 0 3.601192233304573e-08
for O 0 1.2979035901583558e-10
possible O 0 1.2501051305235933e-09
nosologic O 0 9.786577948034392e-07
identity O 0 7.536481660963545e-09
between O 0 1.1258572962802305e-09
these O 0 4.17748591274858e-09
disorders O 0 3.1664956168242497e-06
, O 0 6.615317182934177e-10
we O 0 7.977191129882044e-10
reviewed O 0 1.3758634231919586e-09
the O 0 3.31954359833464e-11
literature O 0 9.236841153059672e-11
and O 0 6.749881903411747e-11
obtained O 0 1.041618666319799e-10
a O 0 1.5164222655350557e-10
follow O 0 7.492333975456233e-10
- O 0 4.606961567787948e-08
up O 0 1.3688040700898796e-09
of O 0 2.199829207683024e-11
the O 0 8.975906823360802e-11
only O 0 4.857255708756725e-10
two O 0 3.459743047606878e-10
surviving O 0 7.440183935614186e-07
patients O 0 2.465080797264818e-07
, O 0 4.634116007595779e-11
one O 0 1.330825727396956e-10
with O 0 1.4588076580057674e-10
SJS B-Disease 0 2.8591066438821144e-06
type I-Disease 0 3.0436689257840044e-07
2 I-Disease 0 1.5454945101467388e-09
at O 0 2.8965077558673613e-10
age O 0 1.3620873318131999e-09
10 O 0 1.4961193395279793e-10
years O 0 1.2688175510255917e-10
and O 0 6.64528501670425e-11
another O 0 8.096665005119519e-10
with O 0 1.3769055895451743e-09
SWS B-Disease 0 8.036418148549274e-05
at O 0 3.2932616633729594e-09
age O 0 5.060401431222772e-09
7 O 0 4.57813120746664e-09
years O 0 7.63017915517139e-09
. O 0 1.539992666721446e-08

Patients O 1 0.9989927411079407
reported O 0 2.005215947065153e-06
as O 0 3.6340412901125774e-09
having O 0 1.2374755442579044e-08
either O 0 7.831251025436359e-08
neonatal O 1 0.99992835521698
SJS B-Disease 1 0.9618772268295288
or O 0 3.6878938658446714e-07
SWS B-Disease 0 0.0010939008789137006
presented O 0 1.806622407229952e-08
a O 0 1.1938237065578505e-09
combination O 0 5.56566659426494e-09
of O 0 5.550353232575134e-11
a O 0 4.6659099695034456e-08
severe O 0 0.22895832359790802
, O 0 2.1197233479597344e-07
prenatal O 0 0.12789373099803925
- O 1 0.9958869814872742
onset O 1 0.9762077927589417
neuromuscular B-Disease 1 0.9999856948852539
disorder I-Disease 1 0.9999793767929077
( O 0 9.593087213488616e-09
with O 0 7.70071224565072e-08
congenital B-Disease 1 0.9999697208404541
joint I-Disease 0 0.05036972835659981
contractures I-Disease 1 0.9999840259552002
, O 0 6.274184124777094e-05
respiratory O 1 0.993685781955719
and O 0 3.010439115769259e-07
feeding O 0 3.7631923532899236e-07
difficulties O 0 2.6006283349033765e-08
, O 0 1.609482547237917e-10
tendency O 0 2.061040582646001e-08
to O 0 7.038349281174305e-08
hyperthermia B-Disease 1 0.9996142387390137
, O 0 6.008722408523681e-09
and O 0 4.920141183362148e-09
frequent O 0 1.8664130720935646e-06
death O 0 0.0077394586987793446
in O 0 7.305333671325798e-09
infancy O 0 5.359930455028916e-08
) O 0 3.3592628678746905e-11
with O 0 3.524064373650049e-11
a O 0 3.552216076840864e-09
distinct O 0 3.6962660487915855e-08
campomelic B-Disease 0 0.00027635833248496056
- I-Disease 0 0.029548270627856255
metaphyseal I-Disease 0 0.4386816620826721
skeletal I-Disease 1 0.8931590914726257
dysplasia I-Disease 1 0.9996465444564819
. O 0 5.311022164278256e-07

The O 0 2.0343225770602658e-08
similarity O 0 3.151349403651693e-08
of O 0 1.614309241837475e-10
the O 0 6.28718299644504e-10
clinical O 0 6.069820557286221e-08
and O 0 1.3053878866742252e-08
radiographic O 0 0.0019507347606122494
findings O 0 2.4906609041863703e-07
is O 0 9.373111176103066e-10
so O 0 4.5988973740307415e-10
extensive O 0 2.2094062135380454e-09
that O 0 2.5896282895843115e-09
these O 0 1.194115251124117e-09
disorders O 0 9.567414736011415e-07
appear O 0 7.208115437862261e-09
to O 0 6.831796239836763e-10
be O 0 1.128075632905734e-09
a O 0 2.6454027857170104e-09
single O 0 3.5082962313026655e-08
entity O 0 1.240689044834653e-07
. O 0 1.6405303782107694e-08

The O 0 2.743313309849782e-08
follow O 0 3.9841498988835156e-08
- O 0 2.9527276979024464e-07
up O 0 7.0807613106183e-09
observation O 0 4.617764659542445e-08
of O 0 4.275357151639625e-11
an O 0 4.0942468859661574e-10
identical O 0 7.229307641409832e-08
and O 0 6.969810839585477e-10
unique O 0 1.0742082778847362e-09
pattern O 0 4.1937024519711485e-08
of O 0 3.4459393671859573e-10
progressive O 0 0.0001895649911602959
bone B-Disease 0 0.3932490646839142
dysplasia I-Disease 1 0.9999862909317017
in O 0 2.7084428921853032e-08
the O 0 2.1210966316687063e-09
two O 0 7.45807966495704e-08
patients O 0 8.271952083305223e-07
( O 0 3.911437840287135e-11
one O 0 8.521757743906733e-10
with O 0 1.4079994947735486e-09
SJS B-Disease 0 0.00013025743828620762
type I-Disease 0 2.0083659819647437e-06
2 I-Disease 0 2.383376163095363e-09
, O 0 2.861223202810237e-10
one O 0 1.0199830979829017e-09
with O 0 2.525618825188758e-09
SWS B-Disease 0 3.062429459532723e-05
) O 0 4.511607198942613e-10
surviving O 0 2.8883622604780612e-08
beyond O 0 4.847576562383438e-09
infancy O 0 1.98310043941774e-08
adds O 0 2.3504926893735956e-09
to O 0 2.2575931402091243e-10
the O 0 1.9523898123208205e-11
evidence O 0 5.836649497048541e-10
in O 0 5.851170936654881e-11
favor O 0 5.567490357627491e-10
of O 0 1.5065799996438756e-10
identity O 0 2.808979893131891e-08
. O 0 1.6393698842875892e-08

The O 0 8.417762131784912e-08
hypothesis O 0 5.052004325989401e-07
that O 0 6.655338502525865e-09
SWS B-Disease 0 2.1358961021178402e-05
and O 0 2.732076076483736e-08
SJS B-Disease 0 1.1659852134471294e-05
type I-Disease 0 4.06438942945897e-07
2 I-Disease 0 2.706556534448623e-09
are O 0 1.422044010324086e-10
the O 0 1.4358156330551708e-10
same O 0 3.701924455867811e-08
disorder O 0 3.153581565129571e-05
should O 0 4.565626987584892e-09
be O 0 1.2522004544379683e-09
testable O 0 5.330768715339218e-09
by O 0 5.557514171083966e-11
molecular O 0 8.680308694053451e-10
methods O 0 3.3413225519751677e-09
. O 0 1.5248603491002655e-09
. O 0 8.99837093726319e-09

A O 0 1.2555417470139218e-06
mouse O 0 3.5035932341997977e-06
model O 0 3.6219202570464404e-07
of O 0 1.4312591112286555e-08
severe O 1 0.9989618062973022
von B-Disease 1 1.0
Willebrand I-Disease 1 1.0
disease I-Disease 1 1.0
: O 0 8.060593972913921e-05
defects O 1 0.9952341914176941
in O 0 3.777445201080809e-08
hemostasis O 0 0.00137869524769485
and O 0 2.550929593780893e-06
thrombosis B-Disease 0 0.02015877515077591
. O 0 3.151313592297811e-07

von B-Disease 1 0.9888725876808167
Willebrand I-Disease 1 0.9940823912620544
factor I-Disease 0 0.00030128774233162403
( I-Disease 0 1.1722618182830047e-06
vWf I-Disease 0 0.0013206405565142632
) I-Disease 0 9.019721801450942e-06
deficiency I-Disease 1 0.965410590171814
causes O 0 0.0014836539048701525
severe O 1 0.9999808073043823
von B-Disease 1 1.0
Willebrand I-Disease 1 1.0
disease I-Disease 1 1.0
in O 0 1.0743111715783016e-06
humans O 0 2.693020633159904e-07
. O 0 6.434676436128939e-08

We O 0 1.7256024875678122e-07
generated O 0 1.9242328619384352e-08
a O 0 3.5881089210931805e-09
mouse O 0 5.6172233087181667e-08
model O 0 7.422048753369381e-08
for O 0 2.430067813641301e-10
this O 0 9.177873461219122e-10
disease O 0 2.592822667679684e-08
by O 0 4.215613969016374e-11
using O 0 1.8184274086507912e-09
gene O 0 1.3921753527768033e-08
targeting O 0 5.1230923503453596e-08
. O 0 2.459756487382947e-08

vWf B-Disease 0 0.03286151960492134
- I-Disease 1 0.9968451261520386
deficient I-Disease 1 0.9792436957359314
mice O 0 0.004298975691199303
appeared O 0 5.4630158956570085e-06
normal O 0 1.6298358218591602e-08
at O 0 7.846748806272785e-10
birth O 0 1.0241612891093155e-08
; O 0 9.490763730468643e-10
they O 0 1.6420008686068854e-09
were O 0 3.2353104639781805e-09
viable O 0 1.392966808566598e-08
and O 0 6.401365215680244e-09
fertile O 0 2.293130592079251e-07
. O 0 5.8140226855130095e-08

Neither O 0 9.088243677979335e-05
vWf O 0 0.0007544366526417434
nor O 0 4.147557046962902e-05
vWf O 0 6.331288022920489e-05
propolypeptide O 0 3.62377759302035e-05
( O 0 9.741316375766473e-08
von B-Disease 0 0.004201511852443218
Willebrand I-Disease 0 0.18221409618854523
antigen O 0 9.376511297887191e-05
II O 0 1.1477717634988949e-05
) O 0 2.0347947771170993e-09
were O 0 7.367349841302939e-09
detectable O 0 1.6400642621761108e-08
in O 0 2.2126987742066007e-10
plasma O 0 1.116223486974377e-07
, O 0 3.672019632805501e-10
platelets O 0 1.9122978756058728e-08
, O 0 5.378235634623252e-10
or O 0 2.4353480343464184e-10
endothelial O 0 4.3327457177610995e-08
cells O 0 3.99240107640253e-09
of O 0 3.663287381772129e-11
the O 0 4.353600258077961e-10
homozygous O 0 6.006284252180194e-07
mutant O 0 1.2136549685237696e-06
mice O 0 3.474988943708013e-06
. O 0 3.270989878956243e-08

The O 0 3.6578896356331825e-07
mutant O 0 1.973333564819768e-05
mice O 0 0.006153041496872902
exhibited O 0 0.0003668230783659965
defects O 0 0.2656509280204773
in O 0 7.533162538209126e-09
hemostasis O 0 5.139856966707157e-06
with O 0 3.2575770969600626e-09
a O 0 1.500147028821175e-08
highly O 0 1.570355152580305e-07
prolonged O 0 0.0022674393840134144
bleeding O 0 0.4284608066082001
time O 0 6.5937544313499075e-09
and O 0 1.2084238054654861e-09
spontaneous O 0 1.7465454860143836e-08
bleeding O 0 1.4042332622921094e-05
events O 0 8.671273699079052e-10
in O 0 1.617360551042779e-10
approximately O 0 4.6519629814945063e-10
10 O 0 3.843050322416275e-10
% O 0 9.663339572973939e-11
of O 0 1.8841250781775898e-10
neonates O 0 0.00039691009442321956
. O 0 5.777939549034272e-08

As O 0 6.66746160504772e-08
in O 0 5.056491891863857e-10
the O 0 1.586356324079219e-10
human O 0 2.796522791115308e-09
disease O 0 1.548535095707848e-07
, O 0 1.6595154417320401e-10
the O 0 1.1302070390684094e-10
factor O 0 3.782078650260701e-09
VIII O 0 4.574911145027727e-05
level O 0 1.6057272178571225e-09
in O 0 1.9289271568911914e-10
these O 0 3.374233115138736e-10
mice O 0 2.905511564676999e-07
was O 0 2.2122874199226317e-08
reduced O 0 3.767606671090107e-09
strongly O 0 3.812461901731012e-09
as O 0 1.654114761828751e-10
a O 0 7.017150749355494e-10
result O 0 1.1515366438175079e-09
of O 0 2.872699300660031e-11
the O 0 1.3877887727886673e-10
lack O 0 8.783853089333604e-10
of O 0 5.495806587596519e-11
protection O 0 8.666301454240966e-09
provided O 0 5.169695782569761e-09
by O 0 3.3370555208023234e-09
vWf O 0 4.494987933867378e-06
. O 0 7.273262525586688e-08

Defective O 0 0.10443703830242157
thrombosis B-Disease 1 0.8274397850036621
in O 0 5.3089863172317564e-08
mutant O 0 1.5835441899980651e-06
mice O 0 2.777701593004167e-05
was O 0 1.1203315608554476e-07
also O 0 2.5184851981663314e-09
evident O 0 5.814995152064739e-09
in O 0 6.613622843820721e-11
an O 0 4.0965431047368384e-10
in O 0 1.1255480991678724e-09
vivo O 0 4.6011660970179946e-07
model O 0 4.7328835961479854e-08
of O 0 9.513527743365557e-10
vascular B-Disease 0 0.3757380545139313
injury I-Disease 0 0.15757806599140167
. O 0 2.348780157035435e-07

In O 0 2.959831491011755e-08
this O 0 6.951197395466124e-10
model O 0 1.6194858787343946e-08
, O 0 1.3458353875783757e-10
the O 0 9.397183031722989e-11
exteriorized O 0 6.496298965430469e-07
mesentery O 0 1.4119449360805447e-06
was O 0 1.1647360764754922e-07
superfused O 0 1.311737776177324e-07
with O 0 5.014175741280269e-10
ferric O 0 2.0739440742545412e-07
chloride O 0 2.2196772988536395e-06
and O 0 2.149368460990786e-09
the O 0 8.554878333510985e-11
accumulation O 0 1.584524622622041e-09
of O 0 9.48590928029347e-11
fluorescently O 0 2.5930012270691805e-06
labeled O 0 4.114338878480339e-07
platelets O 0 2.099351803508398e-07
was O 0 1.495940971096843e-08
observed O 0 3.6236662559474553e-09
by O 0 7.489148190487072e-10
intravital O 0 2.188125563407084e-06
microscopy O 0 9.18206410460698e-07
. O 0 3.5787465435532795e-08

We O 0 1.9873610312970413e-07
conclude O 0 9.312176274534067e-08
that O 0 1.9181454202765735e-09
these O 0 3.584406382817207e-10
mice O 0 7.444251082233677e-08
very O 0 1.5394456820416735e-09
closely O 0 2.6831093791201965e-08
mimic O 0 1.113343023462221e-05
severe O 0 0.01492209080606699
human O 0 1.62731248565251e-06
von B-Disease 1 1.0
Willebrand I-Disease 1 0.9999997615814209
disease I-Disease 1 1.0
and O 0 3.223869043722516e-06
will O 0 2.94471789175077e-08
be O 0 4.220750859929012e-09
very O 0 4.533941000417485e-10
useful O 0 2.71774963644944e-10
for O 0 3.3430151008539966e-11
investigating O 0 4.933915498384067e-10
the O 0 6.365599020119461e-11
role O 0 2.8317370670549735e-10
of O 0 2.586644093360846e-11
vWf O 0 9.841585324465996e-08
in O 0 1.9341483969981255e-09
normal O 0 1.9460909328472553e-08
physiology O 0 2.2671706290111615e-08
and O 0 2.3146431438192394e-09
in O 0 3.2381688441773804e-09
disease O 0 8.189369964384241e-07
models O 0 1.640111975120817e-07
. O 0 2.141160582169732e-09
. O 0 1.173684971433886e-08

Oral O 0 0.0006641522631980479
contraceptives O 0 0.14446154236793518
and O 0 2.403019117025451e-08
the O 0 2.6478812475971836e-09
risk O 0 6.2444271975437e-08
of O 0 3.7448188550115447e-08
hereditary B-Disease 1 0.9999997615814209
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
. O 0 1.0149436775463982e-06

Hereditary B-Disease 1 0.9999953508377075
Ovarian I-Disease 1 0.9999958276748657
Cancer I-Disease 1 0.9995185136795044
Clinical O 0 0.00021216817549429834
Study O 0 3.1965407742973184e-07
Group O 0 2.6290695132047404e-07
. O 0 2.9233014231522247e-08

BACKGROUND O 0 0.003900643438100815
Women O 0 7.7633876571781e-07
with O 0 9.914566945212755e-10
mutations O 0 3.6610856568586314e-08
in O 0 4.761999683466911e-10
either O 0 1.7965566811994904e-09
the O 0 6.918500217167889e-10
BRCA1 O 0 3.147196139252628e-07
or O 0 2.3910837199103696e-10
the O 0 2.0330637173771038e-10
BRCA2 O 0 1.647041614205591e-07
gene O 0 5.444064310466956e-09
have O 0 1.5724936908156906e-09
a O 0 3.1470708261593927e-09
high O 0 5.435818550836302e-08
lifetime O 0 1.576738810626921e-07
risk O 0 1.9848191357141332e-07
of O 0 1.1013878520316212e-07
ovarian B-Disease 1 1.0
cancer I-Disease 1 0.999998927116394
. O 0 4.396848964915989e-07

Oral O 0 0.00048623589100316167
contraceptives O 1 0.5766125917434692
protect O 0 0.00012288731522858143
against O 0 0.17103156447410583
ovarian B-Disease 1 1.0
cancer I-Disease 1 0.9999991655349731
in O 0 9.240886278405469e-09
general O 0 4.6960497712689175e-09
, O 0 9.140453394174131e-10
but O 0 1.709447472464376e-09
it O 0 6.069595381852366e-10
is O 0 2.502152096628407e-10
not O 0 1.7128801155230633e-10
known O 0 2.2937399202227482e-10
whether O 0 5.696976224101036e-10
they O 0 3.7269157204811165e-10
also O 0 1.1402697674967044e-09
protect O 0 1.739665633770926e-09
against O 0 1.5708996770058548e-08
hereditary B-Disease 0 0.001341329189017415
forms I-Disease 0 1.310870061388414e-07
of I-Disease 0 3.7551869809249183e-06
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999995231628418
. O 0 2.8575726673807367e-07

METHODS O 0 2.312697461093194e-06
We O 0 2.488589601057356e-08
enrolled O 0 1.0039251208127098e-08
207 O 0 1.8337148688374327e-08
women O 0 7.182153183293849e-08
with O 0 2.859407288724469e-07
hereditary B-Disease 1 0.9999997615814209
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 8.618551561312415e-08
161 O 0 4.8087180459788215e-08
of O 0 1.980543368196308e-10
their O 0 7.689447412140282e-10
sisters O 0 1.5647394491224986e-08
as O 0 4.1157938168723263e-10
controls O 0 6.135820029840033e-08
in O 0 1.1760613316535995e-10
a O 0 2.8496565107616334e-09
case O 0 2.467427862029581e-07
- O 0 5.903585588384885e-06
control O 0 6.9893185354885645e-06
study O 0 3.100386081200668e-08
. O 0 1.64892206555578e-08

All O 0 7.356358366905624e-08
the O 0 3.1982037018707388e-09
patients O 0 1.867971519686762e-07
carried O 0 1.070302069194895e-09
a O 0 1.1807662625429316e-09
pathogenic O 0 5.025018623427968e-08
mutation O 0 8.500872894501299e-08
in O 0 4.491901295367029e-10
either O 0 6.635742177962811e-09
BRCA1 O 0 1.3444362423342682e-07
( O 0 2.6427890431612866e-10
179 O 0 5.672769276543477e-08
women O 0 1.8514592525775697e-08
) O 0 4.524075836176422e-10
or O 0 4.965355238084612e-09
BRCA2 O 0 7.038187050056877e-06
( O 0 1.942774385810253e-09
28 O 0 1.1660108611977194e-07
women O 0 7.583995653703823e-09
) O 0 1.4198874298543274e-09
. O 0 1.8901955556316352e-08

The O 0 1.2545037009203952e-07
control O 0 5.481283551489469e-07
women O 0 6.39376551703208e-08
were O 0 3.972916662320358e-09
enrolled O 0 6.523783735445932e-10
regardless O 0 1.5512584272681096e-10
of O 0 6.887446342418446e-12
whether O 0 4.810620790607345e-10
or O 0 1.9406290463486187e-10
not O 0 1.9874353274218493e-09
they O 0 1.2675531735339973e-09
had O 0 2.150206057649484e-08
either O 0 7.480999819620138e-09
mutation O 0 1.1965329349550302e-07
. O 0 1.5490929428096933e-08

Lifetime O 0 1.3894986295781564e-05
histories O 0 7.369776540144812e-07
of O 0 3.0208855417157565e-09
oral O 0 1.829668150321595e-07
- O 0 2.8574738735187566e-06
contraceptive O 0 0.00012107513612136245
use O 0 4.1014025953245437e-08
were O 0 5.001798975001748e-09
obtained O 0 6.098059834869218e-10
by O 0 1.1617237033467731e-10
interview O 0 3.073701648759197e-08
or O 0 7.218233649686212e-11
by O 0 1.1348535305932828e-10
written O 0 2.803497434200608e-09
questionnaire O 0 2.149119637806507e-08
and O 0 3.48443163211698e-10
were O 0 1.8169574733661875e-09
compared O 0 4.022632449363073e-09
between O 0 1.2775970281708737e-09
patients O 0 3.481942030703067e-06
and O 0 4.651814489164963e-09
control O 0 9.024919336297899e-07
women O 0 2.6687624554710965e-08
, O 0 9.054815924836035e-11
after O 0 2.268985277442681e-10
adjustment O 0 5.732556651594223e-09
for O 0 2.2422003143063307e-10
year O 0 2.045838082276319e-10
of O 0 4.4403206805876394e-11
birth O 0 1.7183038991674948e-08
and O 0 3.147220928312322e-09
parity O 0 1.0276387740759674e-07
. O 0 2.407841037666003e-08

RESULTS O 0 4.808387984667206e-06
The O 0 3.987120411608203e-09
adjusted O 0 2.723326133491355e-07
odds O 0 1.8179656535721733e-06
ratio O 0 3.6051933420822024e-06
for O 0 1.376088857796276e-05
ovarian B-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
associated O 0 7.247642486163386e-08
with O 0 1.8919106559156518e-10
any O 0 2.9261712497508086e-10
past O 0 5.101868372214824e-10
use O 0 1.4877112874955856e-09
of O 0 1.999430204735475e-10
oral O 0 5.28030625446263e-07
contraceptives O 0 0.007340605370700359
was O 0 5.206966875448416e-07
0 O 0 3.173486007312931e-08
. O 0 1.5508341277836735e-08

5 O 0 7.392816883111664e-07
( O 0 2.8211342151251984e-09
95 O 0 1.0699903185695803e-08
percent O 0 8.542461849003757e-09
confidence O 0 3.700863837607926e-09
interval O 0 1.9148189700501916e-09
, O 0 1.5197058889082626e-10
0 O 0 7.960866965639468e-10
. O 0 3.4340093268969696e-11
3 O 0 8.005232587926514e-11
to O 0 4.795304153759616e-10
0 O 0 9.022294022997812e-09
. O 0 4.836934741625498e-10
8 O 0 1.5153330812367471e-09
) O 0 1.161480578382168e-09
. O 0 1.2412246341853006e-08

The O 0 7.607904706219415e-08
risk O 0 2.309124056409928e-07
decreased O 0 4.191503322203971e-08
with O 0 6.337690372504312e-10
increasing O 0 2.4578323820634296e-09
duration O 0 1.2727235265685977e-08
of O 0 5.021925930659421e-11
use O 0 1.8197319207047258e-09
( O 0 5.481153309006004e-10
P O 0 6.767642446448008e-08
for O 0 2.4650612107102177e-10
trend O 0 5.0809338958401895e-09
, O 0 3.0411007045927363e-10
< O 0 9.390183075552727e-10
0 O 0 1.3923339148291802e-09
. O 0 1.2695680617902383e-10
001 O 0 2.1783370662831203e-09
) O 0 2.4560301709053434e-11
; O 0 4.329550606918531e-11
use O 0 2.448799774068533e-10
for O 0 1.3889962791058252e-10
six O 0 3.1912064657468875e-10
or O 0 5.016325896334273e-11
more O 0 4.30414343055574e-10
years O 0 2.004264976207537e-09
was O 0 3.264625902943408e-08
associated O 0 1.866918425408315e-10
with O 0 5.2357999880126016e-11
a O 0 1.8606840512802592e-09
60 O 0 5.016148829639633e-09
percent O 0 3.3357190343252796e-09
reduction O 0 5.489107390843628e-09
in O 0 8.915105986773142e-09
risk O 0 1.7161265475351684e-07
. O 0 2.9499853226866435e-08

Oral O 0 0.00015183526556938887
- O 0 7.496321632061154e-05
contraceptive O 0 0.00019221760157961398
use O 0 1.1230957852603751e-07
protected O 0 1.284145128011005e-05
against O 0 0.026679018512368202
ovarian B-Disease 1 1.0
cancer I-Disease 1 0.9999997615814209
both O 0 1.7655589212850487e-09
for O 0 1.1299053359614675e-10
carriers O 0 7.616245412123135e-10
of O 0 1.1236078040210984e-11
the O 0 1.869209509397507e-10
BRCA1 O 0 4.5510100221690664e-07
mutation O 0 6.566321530954156e-08
( O 0 2.110429747625986e-10
odds O 0 4.4503667595563456e-07
ratio O 0 4.7010704662397984e-08
, O 0 2.253506131699723e-10
0 O 0 9.821867763548653e-10
. O 0 4.4864362225283116e-11
5 O 0 5.3302549873901484e-11
; O 0 5.489771831568291e-11
95 O 0 8.64918969778472e-10
percent O 0 4.428281297208514e-09
confidence O 0 1.8954728897568884e-09
interval O 0 6.517055783916703e-10
, O 0 7.290487658018208e-11
0 O 0 2.43437742186714e-10
. O 0 1.0077490057713856e-11
3 O 0 4.824696198113543e-11
to O 0 4.055703550776002e-10
0 O 0 4.150134458313914e-09
. O 0 2.2719517933644795e-10
9 O 0 4.134701470093205e-10
) O 0 1.7440760641251885e-11
and O 0 2.379287322717971e-10
for O 0 1.6467453789470454e-10
carriers O 0 7.949577662813567e-10
of O 0 1.3673570956052039e-11
the O 0 4.477214710085775e-10
BRCA2 O 0 6.838156991761934e-07
mutation O 0 1.9541884554996614e-08
( O 0 2.0043786075341075e-10
odds O 0 4.699887199421937e-07
ratio O 0 4.827777999594218e-08
, O 0 2.0221886665172661e-10
0 O 0 1.1818432898991205e-09
. O 0 6.277401515264458e-11
4 O 0 1.5670076347618078e-10
; O 0 6.12902714691721e-11
95 O 0 1.1121210619080557e-09
percent O 0 3.86311560518493e-09
confidence O 0 3.127587078211036e-09
interval O 0 8.663834094591039e-10
, O 0 7.319943262640294e-11
0 O 0 2.7194138607633533e-10
. O 0 1.3977953343402572e-11
2 O 0 8.569151638271322e-11
to O 0 6.303356170356267e-10
1 O 0 1.1942701272360523e-09
. O 0 1.3928484754455184e-10
1 O 0 1.0880945033875378e-09
) O 0 7.938849577726614e-10
. O 0 6.927244999843651e-09

CONCLUSIONS O 0 9.434126695850864e-05
Oral O 0 1.1542280844878405e-05
- O 0 2.3965387299540453e-05
contraceptive O 0 0.0001432994904462248
use O 0 3.041062868192057e-08
may O 0 2.7297843985252257e-08
reduce O 0 7.086706332870563e-09
the O 0 1.1402675470506551e-09
risk O 0 7.641717303386031e-08
of O 0 6.439759658860567e-08
ovarian B-Disease 1 1.0
cancer I-Disease 1 0.9999996423721313
in O 0 1.0160613683751762e-08
women O 0 7.399148405085043e-09
with O 0 4.459683178303919e-10
pathogenic O 0 7.961588011085041e-08
mutations O 0 1.10820472798423e-07
in O 0 1.6441593919669373e-10
the O 0 8.061316059126966e-10
BRCA1 O 0 2.991620931425132e-06
or O 0 2.682444133483841e-08
BRCA2 O 0 2.4447095711366273e-05
gene O 0 1.1627273124759085e-05

A O 0 3.3045657801267225e-06
Japanese O 0 5.924545121160918e-07
family O 0 1.4706468220992974e-07
with O 0 3.1982782644490726e-08
adrenoleukodystrophy B-Disease 1 0.999991774559021
with O 0 9.004139656099142e-09
a O 0 7.6542594484863e-09
codon O 0 7.405758850609345e-08
291 O 0 1.730186127701927e-08
deletion O 0 1.0310549924952284e-07
: O 0 3.195701758773595e-10
a O 0 4.095967121031663e-09
clinical O 0 8.642700777272694e-08
, O 0 5.950064885240636e-10
biochemical O 0 3.9973180321339896e-08
, O 0 3.9499753468064114e-10
pathological O 0 1.5976421252617e-07
, O 0 1.4109190482614054e-09
and O 0 3.736448039859397e-09
genetic O 0 1.5503259476190578e-07
report O 0 2.526391185142529e-08
. O 0 1.889370082608366e-08

We O 0 1.0170835906819775e-07
report O 0 2.371061347261616e-09
a O 0 7.737040452759913e-10
Japanese O 0 1.3419455768826083e-08
family O 0 2.592090631026167e-08
with O 0 1.7030963306297053e-07
adrenoleukodystrophy B-Disease 1 1.0
( O 0 4.648199137591291e-06
ALD B-Disease 1 0.9999998807907104
) O 0 5.031019600920672e-09
with O 0 7.410188573864218e-10
a O 0 4.4240264784889405e-09
three O 0 1.0202788613966618e-09
base O 0 2.7701394955670366e-08
pair O 0 5.995536156433445e-08
deletion O 0 9.567326486603633e-08
( O 0 6.185684187087759e-10
delGAG O 0 1.6166195848654752e-07
291 O 0 1.531311077940245e-08
) O 0 2.44452513786797e-10
in O 0 9.837298753367918e-10
the O 0 4.553592702905007e-08
ALD B-Disease 1 0.9999982118606567
gene O 0 4.9091104301624e-06
. O 0 4.706094713924358e-08

A O 0 8.813109388938756e-07
variety O 0 4.271760900564914e-08
of O 0 2.2396495769072544e-09
phenotypes O 0 2.5830918275460135e-06
were O 0 1.4502145262440536e-08
observed O 0 5.043894635292645e-09
within O 0 1.3483121563684364e-10
this O 0 1.63858138169104e-09
family O 0 3.3704733226613826e-08
. O 0 2.0149910184841247e-08

While O 0 6.2460588878821e-07
the O 0 5.362586819046555e-09
proband O 0 1.022665855998639e-06
( O 0 3.203783682792505e-09
patient O 0 1.1460940640972694e-06
1 O 0 1.4589529584441152e-09
) O 0 3.5746364202005054e-10
was O 0 5.270013048175315e-07
classified O 0 1.57413204693313e-09
as O 0 1.4182924279459996e-10
having O 0 2.488226569230534e-10
a O 0 4.017692012414642e-10
rare O 0 2.4511002116867076e-09
intermediate O 0 1.9164897224754895e-08
type O 0 2.9721302752250267e-08
of O 0 2.151258060578698e-10
adult O 0 1.0809494597197045e-05
cerebral O 0 0.0015019744168967009
and O 0 6.451143974572915e-08
cerebello O 0 0.0006383424624800682
- O 0 0.0012231569271534681
brain O 0 0.00014319759793579578
stem O 0 6.454281731294031e-08
forms O 0 2.3391606873701676e-08
, O 0 3.598636055812676e-09
his O 0 5.429632210507407e-08
younger O 0 2.427849494779366e-07
brother O 0 7.843988214517594e-08
( O 0 1.732489152139749e-10
patient O 0 6.510104526569194e-07
2 O 0 2.450272873488757e-09
) O 0 3.2287494899918556e-10
and O 0 2.2085352213707665e-08
nephew O 0 4.778151196660474e-05
( O 0 9.184826232910837e-10
patient O 0 1.200758561026305e-05
3 O 0 2.3771200563516004e-09
) O 0 4.564353062175286e-10
had O 0 2.796818137085211e-07
a O 0 2.1526913940306258e-07
childhood O 0 5.495636287378147e-05
ALD B-Disease 1 0.9999990463256836
type O 0 0.0005893719498999417
. O 0 1.340562221230357e-07

Another O 0 3.033274197150604e-06
nephew O 0 3.5666253097588196e-05
( O 0 4.913072970680332e-08
patient O 0 8.251079634646885e-06
4 O 0 6.927535878276103e-09
) O 0 1.5395712482657586e-10
of O 0 2.164618484457037e-10
patient O 0 1.2568352758535184e-05
1 O 0 5.804966729527905e-09
was O 0 4.021104587081936e-07
classified O 0 5.009647363607428e-09
as O 0 8.329370526638513e-10
having O 0 1.3625783834569916e-09
an O 0 7.889263686777781e-10
adolescent O 0 3.8079619457676017e-07
form O 0 4.76956714123844e-08
. O 0 5.592784191321698e-08

The O 0 3.9941934204534846e-08
tau O 0 1.3853043157041611e-08
level O 0 2.0662904720580855e-09
in O 0 2.9389130018486753e-10
the O 0 1.778351244041687e-09
cerebrospinal O 0 6.425922038033605e-05
fluid O 0 2.8748785553034395e-05
( O 0 4.227051153549155e-09
CSF O 0 0.0021925733890384436
) O 0 7.58629215003026e-10
in O 0 8.876365753529569e-10
patient O 0 2.6656493901100475e-06
1 O 0 1.6546173320364232e-09
was O 0 4.0763299580248713e-07
as O 0 1.7062876667139903e-09
high O 0 2.6455035939676463e-09
as O 0 2.8858701539569154e-10
that O 0 2.0298863978585047e-10
of O 0 3.7166508759511885e-10
patients O 0 8.639173756819218e-06
with O 0 7.574486176054052e-07
Alzheimers B-Disease 1 0.999745786190033
disease I-Disease 0 0.0021701916120946407
( O 0 8.740551060704149e-10
AD B-Disease 0 1.3595050631920458e-06
) O 0 1.466506116543087e-08
. O 0 2.719894176550497e-08

His O 0 2.443755192871322e-06
brain O 0 1.1186079063918442e-05
magnetic O 0 1.145556234405376e-05
resonance O 0 1.9550852812244557e-05
image O 0 3.215613105567172e-05
( O 0 6.1440506016197105e-09
MRI O 0 0.00012381911801639944
) O 0 6.993730927717934e-09
showed O 0 0.0002659613674040884
abnormalities B-Disease 0 0.0005790829891338944
in I-Disease 0 2.534071563697893e-10
the I-Disease 0 5.781825018758013e-10
bilateral I-Disease 0 5.089646748501764e-08
cerebellar I-Disease 0 0.19653697311878204
hemispheres I-Disease 0 0.06501307338476181
and O 0 2.7049889439467734e-08
brain O 0 3.7636482375091873e-07
stem O 0 1.6108048228602456e-08
, O 0 8.728505695998479e-10
but O 0 7.299228999002594e-10
not O 0 8.037028265128754e-10
in O 0 2.775711327451802e-10
the O 0 1.5741681291814302e-09
cerebral O 0 0.00015658378833904862
white O 0 3.505286017002618e-08
matter O 0 6.857099332790995e-09
, O 0 1.6619418341523584e-10
where O 0 1.4243269064184716e-10
marked O 0 1.4873482445665331e-09
reductions O 0 7.593795814386795e-09
of O 0 7.128548445978211e-11
the O 0 1.051185249956177e-09
cerebral O 0 0.00013654811482410878
blood O 0 1.515305569910197e-07
flow O 0 1.7275546326800395e-08
and O 0 6.1651923566330424e-09
oxygen O 0 1.6448824524673e-08
metabolism O 0 3.3633564822110884e-09
were O 0 8.784656890803433e-10
clearly O 0 9.695176217405788e-09
demonstrated O 0 2.8705606780476955e-09
by O 0 2.701897594548086e-10
positron O 0 5.345188469618734e-07
emission O 0 1.5662001828786742e-07
tomography O 0 2.084728748741327e-06
( O 0 3.861185149389712e-09
PET O 0 7.718901429143443e-07
) O 0 4.936233199970275e-09
. O 0 2.010905753024872e-08

In O 0 1.638287358218804e-06
patients O 0 4.713129237643443e-05
2 O 0 1.0755926815875227e-08
and O 0 2.4454218650049597e-09
3 O 0 3.4837224216488494e-09
, O 0 6.456676859833976e-10
the O 0 5.247599577096196e-10
autopsy O 0 0.18913200497627258
findings O 0 7.874703555899032e-08
showed O 0 1.4269161852098478e-07
massive O 0 1.4819408988842042e-07
demyelination B-Disease 1 0.9999898672103882
of I-Disease 0 1.4156066319159777e-09
the I-Disease 0 3.971447171124964e-09
cerebral I-Disease 0 0.0006659593200311065
white I-Disease 0 3.589369867995629e-08
matter I-Disease 0 1.5207851644660764e-09
with O 0 1.3957313083068357e-10
sparing O 0 7.57559615038872e-09
of O 0 1.2598275200836895e-10
the O 0 3.043462148966114e-10
U O 0 9.941719326889142e-06
- O 0 0.0008664836059324443
fibers O 0 8.641900058137253e-05
, O 0 4.717718993241249e-10
compatible O 0 5.25827992259309e-10
with O 0 4.565517755517057e-11
the O 0 9.616159257763712e-11
findings O 0 6.393019447159531e-09
of O 0 6.488082848754573e-10
childhood O 0 6.727053460053867e-06
ALD B-Disease 1 0.9999929666519165
. O 0 4.896107839158503e-07

Oleic O 1 0.7027523517608643
and O 0 6.21732260697172e-06
erucic O 0 0.0009416089160367846
acids O 0 3.0956002206039557e-07
( O 0 1.036859931247136e-09
Lorenzos O 0 1.1329799320947131e-07
Oil O 0 8.08458633372311e-09
) O 0 5.697244759295117e-11
were O 0 1.0731495692084536e-09
administered O 0 2.2718271708299653e-09
to O 0 3.5292342381865183e-09
patients O 0 1.2610482258423872e-07
1 O 0 4.5812911797504796e-10
and O 0 2.6146225184930927e-09
4 O 0 7.552249381426179e-10
, O 0 2.0379010978732737e-10
but O 0 5.259844781946299e-10
sufficient O 0 2.308294444475223e-09
effectiveness O 0 4.751495641386327e-09
was O 0 1.5987145829399196e-08
not O 0 8.048103850022414e-10
obtained O 0 6.772443938984907e-09
. O 0 9.602496575666919e-09

The O 0 5.8321372620184775e-08
findings O 0 3.497398992635681e-08
in O 0 1.4218107247110368e-10
this O 0 1.422176959531285e-10
family O 0 1.5221666149756174e-09
suggest O 0 9.015511670540377e-10
that O 0 6.196796409341232e-10
delGAG291 O 0 8.803014850400359e-08
is O 0 8.325843903200791e-10
part O 0 1.9040377607915104e-10
of O 0 1.3293106199130378e-11
the O 0 9.040268533766493e-11
cause O 0 5.0840940346574826e-09
of O 0 2.0915195964033018e-10
Japanese O 0 2.4739906621107366e-06
ALD B-Disease 1 0.9999986886978149
with O 0 5.696102078900367e-08
phenotypic O 0 1.4846802514512092e-05
variations O 0 2.647343080752762e-06
. O 0 8.838143372713603e-08

Moreover O 0 3.7960614918119973e-06
, O 0 8.482873958826076e-09
although O 0 6.163801691272397e-10
the O 0 3.0034572051640396e-11
scale O 0 1.2945025051891434e-09
of O 0 5.1034232395608115e-11
the O 0 1.4304006590304397e-10
study O 0 1.1845378011798857e-09
is O 0 1.1548006995099058e-09
limited O 0 1.894233214727592e-09
, O 0 1.4828294148117038e-10
there O 0 2.2951973654983249e-10
is O 0 1.0159711960611162e-10
a O 0 3.0776173276514385e-10
possibility O 0 5.967556448993605e-10
that O 0 3.7066688607367837e-10
PET O 0 2.5548748894266282e-08
can O 0 7.303853077900158e-10
detect O 0 3.400603532099922e-08
an O 0 1.6456535023579022e-09
insidious B-Disease 0 2.568395939306356e-05
lesion I-Disease 0 0.21641959249973297
which O 0 1.2556910178318503e-07
is O 0 3.812403726044522e-09
undetectable O 0 1.3997797587705918e-08
by O 0 2.442427926574453e-10
computed O 0 1.7991775180803415e-08
tomogram O 0 3.4955257888213964e-07
( O 0 3.343411936196361e-10
CT O 0 1.380800881634059e-06
) O 0 1.88085755303824e-10
or O 0 1.89170137887551e-10
MRI O 0 2.585282572908909e-06
analysis O 0 1.4872942877275364e-09
, O 0 5.0098522552666225e-11
and O 0 5.967894928238238e-11
that O 0 1.0713042952747998e-10
the O 0 2.982802199680279e-11
higher O 0 3.127102465860787e-10
level O 0 5.7448865109499536e-11
of O 0 1.1563115048796035e-11
tau O 0 4.13849648994713e-10
reflects O 0 7.530817081047303e-10
the O 0 1.1538835859026264e-11
process O 0 4.2995301763326665e-11
of O 0 2.8428148723946833e-10
neuronal B-Disease 0 5.794256139779463e-06
degeneration I-Disease 0 0.29252684116363525
in O 0 1.069310769707954e-06
ALD B-Disease 1 0.9999977350234985
. O 0 1.5754702644699137e-06

Lorenzos O 0 4.780115341418423e-05
Oil O 0 4.99080897498061e-07
should O 0 9.771254028123622e-09
be O 0 3.1148456036689254e-10
given O 0 2.437959834011849e-10
in O 0 5.518989779074168e-11
the O 0 7.61821786210426e-11
early O 0 2.8523483575071396e-09
stage O 0 1.046105850832646e-07
. O 0 2.331204562722178e-09
. O 0 9.432191028224679e-09

Nonsense O 0 0.00011012505274266005
mutation O 0 1.564690683153458e-05
in O 0 7.993430806152446e-09
exon O 0 1.5806593012257508e-07
4 O 0 4.968311095865374e-09
of O 0 7.025838244523186e-11
human O 0 7.628079834454127e-10
complement O 0 8.966230424789501e-09
C9 O 0 6.278727937569784e-07
gene O 0 2.3030709783711245e-08
is O 0 7.317462191736013e-10
the O 0 4.9416359892973105e-11
major O 0 5.257909108102865e-10
cause O 0 1.4083065380532389e-08
of O 0 2.3411983463006436e-10
Japanese O 0 1.3760273986918037e-07
complement B-Disease 0 1.964098601092701e-06
C9 I-Disease 0 0.06962759792804718
deficiency I-Disease 0 0.03699394315481186
. O 0 1.457647158531472e-07

Deficiency B-Disease 1 0.9933302998542786
of I-Disease 0 7.171855997967214e-09
the I-Disease 0 6.735584312522747e-10
ninth I-Disease 0 8.326133560387916e-09
component I-Disease 0 3.2579623443496075e-09
of I-Disease 0 7.663367163068813e-11
human I-Disease 0 3.4185690389598733e-10
complement I-Disease 0 7.202370699843641e-09
( O 0 8.654469363378325e-10
C9 O 0 3.928288947463443e-07
) O 0 2.871402560167269e-10
is O 0 1.8424813064132906e-10
the O 0 4.9108168920231066e-11
most O 0 1.7984217448585582e-09
common O 0 2.4468322479265225e-08
complement B-Disease 1 0.9999760389328003
deficiency I-Disease 1 0.9999973773956299
in O 0 1.6300651939360478e-09
Japan O 0 2.8738478263790057e-09
but O 0 1.5307146661314164e-09
is O 0 2.3095088341751335e-10
rare O 0 2.478194871535777e-10
in O 0 8.577196591863512e-11
other O 0 5.7501819278327204e-11
countries O 0 1.802865079447713e-10
. O 0 5.924655432920645e-09

We O 0 2.8925862238793343e-07
studied O 0 1.1331567684180754e-08
the O 0 7.02532962360003e-11
molecular O 0 1.4559229377653082e-09
basis O 0 3.5424710387310654e-10
of O 0 5.796909063882083e-10
C9 B-Disease 0 0.13634218275547028
deficiency I-Disease 0 0.0023513485211879015
in O 0 1.1319378767638e-09
four O 0 2.172441115888546e-09
Japanese O 0 3.878599841300456e-08
C9 B-Disease 0 8.286528463941067e-05
- I-Disease 0 0.10291162878274918
deficient I-Disease 0 0.4895324409008026
patients O 0 0.1152256429195404
who O 0 4.055557383253472e-07
had O 0 1.083903498511063e-06
suffered O 0 0.01582329161465168
from O 0 5.226857524576189e-07
meningococcal B-Disease 1 0.9999998807907104
meningitis I-Disease 1 0.9999998807907104
. O 0 1.4362781257659663e-06

Direct O 0 1.1556514891708503e-06
sequencing O 0 1.4012628923865122e-07
of O 0 5.038587325145727e-09
amplified O 0 5.622109711111989e-07
C9 O 0 1.8950762523672893e-06
cDNA O 0 1.2447196695575258e-07
and O 0 2.55287635475554e-09
DNA O 0 1.915185166012634e-08
revealed O 0 1.455973741570915e-08
a O 0 2.068581528291702e-09
nonsense O 0 2.1778353342938317e-08
substitution O 0 3.881210020040271e-09
( O 0 3.126464365177384e-10
CGA O 0 3.364738176969695e-07
- O 0 1.8582892380436533e-06
- O 0 3.4539064017735654e-06
> O 0 6.238689564952438e-08
TGA O 0 6.840759851911571e-07
) O 0 3.186328978443953e-10
at O 0 7.560115033999892e-11
codon O 0 1.1121210619080557e-09
95 O 0 4.687796262281552e-10
in O 0 9.013684937331234e-11
exon O 0 1.4599336850551481e-08
4 O 0 2.4886452898442712e-09
in O 0 2.0339906148247877e-10
the O 0 3.720913854809993e-10
four O 0 2.4922901076251947e-08
C9 B-Disease 0 0.00011539966362761334
- I-Disease 0 0.017808260396122932
deficient I-Disease 0 0.001824351493269205
individuals O 0 1.7744117286611072e-08
. O 0 6.699468979576295e-09

An O 0 9.66250510714417e-08
allele O 0 1.3666311815541121e-06
- O 0 7.629018483612526e-08
specific O 0 1.0117714444035641e-09
polymerase O 0 4.6041328971568873e-08
chain O 0 2.4862845293682767e-07
reaction O 0 1.2861133491526289e-08
system O 0 3.3730168658152593e-10
designed O 0 1.6076096898132164e-08
to O 0 8.189762201737949e-10
detect O 0 6.802662966265416e-08
exclusively O 0 7.724893613669792e-09
only O 0 7.536665180829516e-10
one O 0 6.634849614162164e-11
of O 0 2.430278417744902e-12
the O 0 3.08565638318381e-11
normal O 0 4.943373488330849e-10
and O 0 2.958699674149301e-10
mutant O 0 7.1840000614997734e-09
alleles O 0 1.7338388502707858e-09
indicated O 0 9.250761046075695e-09
that O 0 8.857942851436817e-11
all O 0 9.694422348216492e-12
the O 0 3.694230685247213e-11
four O 0 1.6482735176737151e-09
patients O 0 2.6891960658304015e-08
were O 0 4.239661677285511e-10
homozygous O 0 3.602557585580257e-09
for O 0 3.107960069859139e-11
the O 0 8.076455476624389e-11
mutation O 0 3.21505333467087e-09
in O 0 1.7234652593955957e-10
exon O 0 1.4982083129666535e-08
4 O 0 1.7085478587475222e-09
and O 0 5.26733434647042e-10
that O 0 3.7911698780312975e-10
the O 0 2.421743638958418e-10
parents O 0 1.089548229415982e-09
of O 0 3.9523623956982945e-11
patient O 0 1.3508314111732034e-07
2 O 0 4.0761949371415085e-09
were O 0 2.871027682260774e-08
heterozygous O 0 1.0907141358984518e-06
. O 0 1.329092125246234e-08

The O 0 8.353099190117064e-08
common O 0 3.0615606050332644e-08
mutation O 0 5.047342455100079e-08
at O 0 5.011250303610382e-10
codon O 0 6.7384400281866874e-09
95 O 0 1.878019517675966e-09
in O 0 2.6736507452440605e-10
exon O 0 2.40001867268802e-08
4 O 0 2.7934998758638585e-09
might O 0 3.8419822878665855e-09
be O 0 2.43656539389292e-10
responsible O 0 5.425941362879882e-10
for O 0 1.2833920037813584e-10
most O 0 2.5192778974059138e-09
Japanese O 0 7.724483452875575e-07
C9 B-Disease 0 0.029711928218603134
deficiency I-Disease 0 0.00041517443605698645
. O 0 2.9356315156547907e-09
. O 0 7.610267971358553e-09

BRCA1 O 0 0.0005194778786972165
required O 0 1.9780317472850584e-07
for O 0 2.0278132506490465e-09
transcription O 0 9.987230242813894e-08
- O 0 1.3085623322695028e-05
coupled O 0 9.491760465607513e-06
repair O 0 1.8147437685911427e-06
of O 0 1.5694492372375635e-09
oxidative O 0 2.364989632042125e-05
DNA O 0 8.087563401204534e-06
damage O 0 1.5134732166188769e-05
. O 0 4.854009461041642e-08

The O 0 4.22315542891738e-06
breast B-Disease 1 0.9997721314430237
and I-Disease 1 0.9630867838859558
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
susceptibility O 1 0.9985736608505249
gene O 0 8.229484592447989e-06
BRCA1 O 0 5.33500497112982e-06
encodes O 0 1.5556963717244798e-07
a O 0 2.001216330427269e-07
zinc O 0 4.252879080013372e-05
finger O 0 4.727307896246202e-06
protein O 0 3.5627554240136305e-08
of O 0 1.5494960869943952e-10
unknown O 0 6.908270844263598e-09
function O 0 4.660686503399347e-09
. O 0 4.966207889367524e-09

Association O 0 5.032212584410445e-07
of O 0 8.798641815133124e-10
the O 0 4.4387560294012474e-10
BRCA1 O 0 5.8532222624307906e-08
protein O 0 1.6007519754168698e-09
with O 0 8.071866092196345e-11
the O 0 2.242204477642673e-10
DNA O 0 2.4999314618412427e-08
repair O 0 3.610531962294772e-08
protein O 0 5.567280414453535e-09
Rad51 O 0 7.336993235185219e-08
and O 0 1.3413967159259244e-10
changes O 0 1.1651056508465985e-10
in O 0 1.8181343583445475e-11
the O 0 7.52615678112356e-12
phosphorylation O 0 5.751105702778148e-10
and O 0 3.7326924884339974e-10
cellular O 0 2.2595758597532267e-09
localization O 0 3.2744840172682643e-09
of O 0 8.605244988801886e-12
the O 0 8.322469449706382e-12
protein O 0 5.7471361003536e-10
after O 0 9.822468394204975e-10
exposure O 0 1.1443991532189557e-08
to O 0 2.823124511941444e-10
DNA O 0 1.021363882358628e-08
- O 0 1.0673571892994005e-07
damaging O 0 4.759316851732365e-08
agents O 0 1.02092123643871e-09
are O 0 5.7790657675971246e-11
consistent O 0 1.6799238666820315e-09
with O 0 3.5791099251003544e-11
a O 0 3.3792244003016947e-10
role O 0 8.74995853550331e-10
for O 0 4.077297111049205e-10
BRCA1 O 0 1.0489849699979459e-07
in O 0 7.197492046806531e-10
DNA O 0 9.470266348898804e-08
repair O 0 1.8658311091712676e-06
. O 0 7.846487193319263e-08

Here O 0 5.88892135056085e-07
, O 0 3.484799115938131e-09
it O 0 4.937022457518481e-10
is O 0 3.5854799684820193e-10
shown O 0 2.1817008200031296e-09
that O 0 6.213187742076798e-10
mouse O 0 1.1960584345160896e-07
embryonic O 0 1.122590376212429e-07
stem O 0 1.3831267153818771e-07
cells O 0 1.9361192471478716e-07
deficient B-Disease 0 1.3299207921591005e-06
in I-Disease 0 1.1552633294442671e-09
BRCA1 I-Disease 0 1.3544537580401084e-07
are O 0 7.115958933212596e-10
defective O 0 1.5213610993214388e-07
in O 0 6.804486418765521e-10
the O 0 1.5122889052143762e-10
ability O 0 2.0088537500129178e-09
to O 0 3.8605724173024214e-10
carry O 0 1.5254537633069276e-09
out O 0 5.221172383329531e-10
transcription O 0 5.288194770969312e-09
- O 0 7.973849847076053e-07
coupled O 0 2.903198605963553e-07
repair O 0 1.960397355560417e-07
of O 0 1.361673551691922e-10
oxidative O 0 1.6670301192789339e-06
DNA O 0 4.1761578017940337e-07
damage O 0 1.8985693941431236e-06
, O 0 3.198165066109482e-10
and O 0 9.503516862352512e-10
are O 0 1.6609792430344328e-09
hypersensitive O 0 0.004997108597308397
to O 0 4.046123649459332e-07
ionizing O 0 0.015255982987582684
radiation O 0 0.10367342829704285
and O 0 1.9955496810553086e-08
hydrogen O 0 1.7389574225035176e-07
peroxide O 0 9.468283678870648e-06
. O 0 2.650439334672683e-08

These O 0 7.719904004943601e-08
results O 0 2.4633809658780592e-08
suggest O 0 8.415286245622156e-09
that O 0 2.872910576101617e-09
BRCA1 O 0 1.9132288286982657e-07
participates O 0 7.244502331360536e-09
, O 0 6.182452327863075e-10
directly O 0 8.148410279851248e-10
or O 0 3.73474307036048e-10
indirectly O 0 5.386104362514743e-08
, O 0 2.2114371445169922e-10
in O 0 1.0374449910255379e-10
transcription O 0 1.1989838455406243e-08
- O 0 3.1336189749708865e-06
coupled O 0 6.784126753700548e-07
repair O 0 2.937014471626753e-07
of O 0 4.3095324531172707e-10
oxidative O 0 3.1769491215527523e-06
DNA O 0 1.5736022760393098e-06
damage O 0 1.1736042324628215e-06
. O 0 5.337341235644999e-09
. O 0 1.1507116148834484e-08

Truncation O 0 0.00012414093362167478
mutations O 0 0.0004573340411297977
in O 0 3.1943155676117385e-08
the O 0 2.282777522566448e-09
transactivation O 0 1.3663914160133572e-06
region O 0 1.4451172702933945e-08
of O 0 6.435628141510108e-10
PAX6 O 0 5.5020677791617345e-06
result O 0 4.356287774953671e-08
in O 0 8.641142246190725e-10
dominant O 0 1.3639187557146215e-07
- O 0 5.844252882525325e-06
negative O 0 1.3951213304608245e-06
mutants O 0 1.0075142427012906e-06
. O 0 3.4273401894324707e-08

PAX6 O 0 0.0025161171797662973
is O 0 1.868178287622868e-07
a O 0 6.903397409274703e-09
transcription O 0 5.044336948145656e-09
factor O 0 2.754505956659159e-09
with O 0 7.719613143164494e-11
two O 0 1.9619995905717502e-10
DNA O 0 5.349816589728107e-09
- O 0 6.474749625340337e-08
binding O 0 1.6298669081038497e-08
domains O 0 1.156400863955298e-09
( O 0 1.2868432708312838e-10
paired O 0 1.1258706855699074e-08
box O 0 8.13492277984551e-08
and O 0 2.346801197816717e-09
homeobox O 0 9.93966366991117e-08
) O 0 1.3741500992647815e-10
and O 0 1.465811083622981e-10
a O 0 1.407381988727252e-09
proline O 0 5.034852961216529e-07
- O 0 8.021751796150056e-08
serine O 0 5.441990680310482e-08
- O 0 4.0194942130256095e-07
threonine O 0 1.9350467539425154e-07
( O 0 3.469311782300366e-10
PST O 0 3.2062831678558723e-07
) O 0 1.8613514063403613e-09
- O 0 2.481561125478038e-07
rich O 0 2.4646688245866244e-08
transactivation O 0 1.486766791458649e-06
domain O 0 4.6046597645954535e-08
. O 0 2.908745955210179e-08

PAX6 O 0 0.008994282223284245
regulates O 0 9.13080875761807e-05
eye O 0 0.000673476723022759
development O 0 6.5044667429958736e-09
in O 0 1.25146970564316e-09
animals O 0 1.1710458158731285e-09
ranging O 0 2.59530485990922e-09
from O 0 3.0631402969660826e-10
jellyfish O 0 1.9146446206264045e-08
to O 0 1.2221204048756817e-09
Drosophila O 0 2.664895193404959e-09
to O 0 1.405627503281437e-09
humans O 0 5.008978565257394e-09
. O 0 8.984222255037366e-09

Heterozygous O 0 0.008895236067473888
mutations O 0 7.617616938659921e-05
in O 0 5.2740927181105235e-09
the O 0 4.5012152338763656e-10
human O 0 7.432185422651116e-10
PAX6 O 0 1.2217573157613515e-06
gene O 0 3.555118865961049e-08
result O 0 3.4797711379042084e-09
in O 0 2.5198723663244493e-10
various O 0 3.2056282628367683e-10
phenotypes O 0 6.996755246291286e-07
, O 0 1.4079833965396915e-09
including O 0 5.5111692986997696e-09
aniridia B-Disease 1 0.9999998807907104
, O 0 8.851595225678466e-07
Peters B-Disease 1 0.999995231628418
anomaly I-Disease 1 0.9999961853027344
, O 0 8.410427909666396e-08
autosomal B-Disease 0 0.038828711956739426
dominant I-Disease 0 0.002484766533598304
keratitis I-Disease 1 0.9957774877548218
, O 0 8.609218582478206e-08
and O 0 8.434251697053696e-08
familial B-Disease 0 0.004889152944087982
foveal I-Disease 1 0.9934379458427429
dysplasia I-Disease 1 0.9999779462814331
. O 0 1.942152948686271e-06

It O 0 1.306865584638217e-07
is O 0 8.28077517667225e-09
believed O 0 1.2373056357262158e-08
that O 0 3.4444411212142256e-10
the O 0 2.408770960471429e-10
mutated O 0 2.288522864546394e-07
allele O 0 8.786776817260034e-08
of O 0 3.112790580850344e-10
PAX6 O 0 2.052030367849511e-06
produces O 0 5.0323272660079965e-08
an O 0 5.413453574298899e-10
inactive O 0 1.1420834056252716e-08
protein O 0 6.394409890475572e-09
and O 0 1.2332860066521789e-08
aniridia B-Disease 1 0.9999982118606567
is O 0 2.0169080983123422e-07
caused O 0 2.74458841431624e-07
due O 0 1.2579414843116865e-08
to O 0 1.8573235394114818e-08
genetic O 0 8.196800536097726e-07
haploinsufficiency O 0 5.7072309573413804e-05
. O 0 8.118956884572981e-08

However O 0 7.153462320275139e-07
, O 0 1.078361178130649e-09
several O 0 1.1828191204266147e-10
truncation O 0 2.4407075471799544e-08
mutations O 0 6.962893905892997e-08
have O 0 2.9988347360898615e-09
been O 0 5.736713326598419e-09
found O 0 1.3544344534821562e-09
to O 0 1.8151423697432278e-09
occur O 0 1.061590038098359e-09
in O 0 3.3980454561266527e-10
the O 0 3.8203143426507324e-10
C O 0 1.6700248295364872e-07
- O 0 8.603236892668065e-06
terminal O 0 1.510881361355132e-06
half O 0 2.713596902736981e-09
of O 0 8.502076126459812e-11
PAX6 O 0 1.0064070465887198e-06
in O 0 4.3763144219610695e-09
patients O 0 5.476319984154543e-07
with O 0 1.7818279074433008e-09
Aniridia B-Disease 1 0.9999921321868896
resulting O 0 7.557675019143062e-08
in O 0 1.23069998636538e-10
mutant O 0 2.4359159134235142e-09
proteins O 0 5.980201056576817e-11
that O 0 1.2351210332273155e-10
retain O 0 3.873652065777833e-09
the O 0 4.501951589297448e-11
DNA O 0 4.524596253219215e-09
- O 0 8.519129401918235e-09
binding O 0 4.053053004327012e-09
domains O 0 7.960259118533486e-10
but O 0 2.2756914130894756e-09
have O 0 1.2493852619144263e-09
lost O 0 4.569198353010506e-09
most O 0 9.052070204518259e-11
of O 0 1.1119269567594348e-11
the O 0 3.5317912483456837e-10
transactivation O 0 1.1464898079793784e-06
domain O 0 5.114949530593549e-08
. O 0 2.72247362431699e-08

It O 0 9.943854450966683e-08
is O 0 2.655027309117486e-09
not O 0 6.893104975702613e-10
clear O 0 2.851668456926859e-09
whether O 0 3.6106731493568134e-10
such O 0 4.0255600936012215e-11
mutants O 0 2.987578184843187e-08
really O 0 1.7288732223619263e-08
behave O 0 9.434907966010542e-09
as O 0 3.5475694604159003e-10
loss O 0 2.697588818989516e-09
- O 0 1.4464685449411263e-08
of O 0 1.747676725560865e-10
- O 0 1.1242488540119666e-07
function O 0 2.1622839074808553e-09
mutants O 0 1.1562360846539832e-08
as O 0 2.7345131714540116e-10
predicted O 0 7.62120500041874e-09
by O 0 1.3553363986673617e-09
haploinsufficiency O 0 2.514374045858858e-06
. O 0 3.5104111617556555e-08

Contrary O 0 6.510354069177993e-06
to O 0 4.855241186874082e-08
this O 0 1.0826375351769002e-09
theory O 0 2.6219537652139024e-09
, O 0 6.809338509716767e-11
our O 0 2.1357865129245646e-11
data O 0 1.7863664714123928e-10
showed O 0 2.727846615258045e-09
that O 0 3.546640758855801e-11
these O 0 9.85949169529654e-12
mutants O 0 1.2445665609206458e-09
are O 0 3.334061846049785e-11
dominant O 0 2.3316315544974486e-09
- O 0 6.001806696076528e-08
negative O 0 3.9806934637454106e-08
in O 0 3.1102803665916667e-10
transient O 0 6.880186020907786e-08
transfection O 0 2.9422261604850064e-07
assays O 0 1.3844093871284713e-07
when O 0 1.706414565205705e-09
they O 0 2.434711598997552e-10
are O 0 4.387308918940569e-11
coexpressed O 0 2.0622557883598347e-08
with O 0 3.628159717106172e-10
wild O 0 6.297615318118233e-09
- O 0 2.0962015696568415e-05
type O 0 0.0001260361314052716
PAX6 O 0 0.00042906810995191336
. O 0 1.0342615297531665e-07

We O 0 1.8798861844970816e-07
found O 0 5.630005794898807e-09
that O 0 1.2964167239726265e-10
the O 0 9.617334012501644e-11
dominant O 0 3.161680339758277e-08
- O 0 6.585316896234872e-07
negative O 0 6.200419875312946e-07
effects O 0 4.278230960608198e-07
result O 0 4.352739058077759e-09
from O 0 5.8013191472916503e-11
the O 0 3.41213099441795e-11
enhanced O 0 3.287538019591807e-09
DNA O 0 1.0702148500740805e-08
binding O 0 3.1619804552462938e-09
ability O 0 1.333077315202047e-09
of O 0 1.6545714451310367e-11
these O 0 1.5085639681888807e-10
mutants O 0 6.063756785579244e-08
. O 0 9.341027507048238e-09

Kinetic O 0 4.966972028341843e-06
studies O 0 4.4981817381994915e-08
of O 0 4.663698871532063e-10
binding O 0 2.980964097787364e-08
and O 0 3.7437173361354326e-09
dissociation O 0 1.0702029129561197e-07
revealed O 0 5.896921617676298e-09
that O 0 5.0784293437189376e-11
various O 0 1.1336241841075623e-11
truncation O 0 8.589140065851097e-09
mutants O 0 4.457697500015456e-08
have O 0 1.5270927855581817e-09
3 O 0 7.246627187207366e-10
- O 0 1.263328073264347e-07
5 O 0 4.581756751775856e-09
- O 0 3.7621444448632246e-07
fold O 0 7.855184094296419e-07
higher O 0 1.493192236523555e-09
affinity O 0 2.2841002700335622e-10
to O 0 7.741966789875931e-11
various O 0 8.459303570129695e-12
DNA O 0 9.640516163145207e-10
- O 0 2.4230615291997992e-09
binding O 0 1.7142798292013595e-09
sites O 0 1.9157751773857257e-10
when O 0 5.061113195203859e-10
compared O 0 4.0831885095293785e-10
with O 0 3.940086104603502e-11
the O 0 1.5520221219311736e-10
wild O 0 5.303589123428765e-09
- O 0 1.2523545592557639e-05
type O 0 1.2996414625376929e-05
PAX6 O 0 0.00010437732271384448
. O 0 8.856165578663422e-08

These O 0 1.1837122571023428e-07
results O 0 1.902979640533431e-08
provide O 0 1.28422028566888e-09
a O 0 1.8102604970593461e-09
new O 0 1.8871615381499396e-09
insight O 0 2.517923203271266e-09
into O 0 4.997235611425843e-11
the O 0 6.166653125638799e-12
role O 0 1.379725778072327e-10
of O 0 3.809448589908726e-11
mutant O 0 8.452240507494935e-08
PAX6 O 0 2.8709978323604446e-06
in O 0 6.899895765855035e-09
causing O 0 7.367029297711269e-07
aniridia B-Disease 1 0.9999649524688721
. O 0 2.9366075793291202e-08
. O 0 1.8299450843528575e-08

Reversal O 0 0.00010871181439142674
of O 0 2.9525418199227715e-07
severe O 1 0.9903247356414795
hypertrophic B-Disease 1 0.9998884201049805
cardiomyopathy I-Disease 1 1.0
and O 0 2.9306984288268723e-06
excellent O 0 4.119042387173977e-07
neuropsychologic O 0 3.7072918530611787e-06
outcome O 0 6.858201118120633e-08
in O 0 1.8576628013633467e-09
very B-Disease 0 4.0561022984775263e-08
- I-Disease 0 1.73578937392449e-05
long I-Disease 0 1.5488084272874403e-06
- I-Disease 0 1.180745766760083e-05
chain I-Disease 0 3.68378482562548e-06
acyl I-Disease 0 1.5434087572430144e-06
- I-Disease 0 3.6198619568494905e-07
coenzyme I-Disease 0 2.803579945975798e-07
A I-Disease 0 5.177356001695443e-07
dehydrogenase I-Disease 0 0.0001958275679498911
deficiency I-Disease 0 0.0003693080216180533
. O 0 4.003376474770448e-08

Very B-Disease 0 5.878125739400275e-05
- I-Disease 0 0.00013013018178753555
long I-Disease 0 3.0752139537071344e-06
- I-Disease 0 6.249394118640339e-06
chain I-Disease 0 5.513644737220602e-06
acyl I-Disease 0 2.047907400992699e-06
- I-Disease 0 2.9195132356107933e-07
coenzyme I-Disease 0 7.042216054742312e-08
A I-Disease 0 3.90959407070568e-08
dehydrogenase I-Disease 0 6.256217375266715e-07
( I-Disease 0 5.66559732462224e-09
VLCAD I-Disease 0 0.00024512395611964166
) I-Disease 0 5.3832899027383974e-08
deficiency I-Disease 0 6.229898281162605e-05
is O 0 4.4040815438961545e-09
a O 0 2.517896291465149e-07
disorder O 0 0.01066817156970501
of O 0 2.8189167666781145e-10
fatty O 0 1.388492449905243e-07
acid O 0 1.679094907558465e-08
beta O 0 2.6907068240156207e-10
oxidation O 0 1.846669039906601e-09
that O 0 4.675098641548914e-10
reportedly O 0 1.0513766568465144e-07
has O 0 1.411552297270191e-08
high O 0 9.651081711581355e-09
rates O 0 9.275797019370202e-09
of O 0 5.905259059524326e-10
morbidity O 0 0.018468668684363365
and O 0 4.3959349227407074e-07
mortality O 0 4.143344995100051e-06
. O 0 3.326977449091828e-08

We O 0 1.0508814085596896e-07
describe O 0 1.713084429866285e-08
the O 0 1.6565553095926333e-10
outcome O 0 8.371369708548571e-10
of O 0 2.4291580899560294e-11
a O 0 1.264761406716275e-09
5 O 0 2.224056494526394e-09
- O 0 5.926556809754402e-07
year O 0 1.2537832105863345e-08
- O 0 6.731853773089824e-06
old O 0 1.6410147509304807e-05
girl O 0 1.7762147763278335e-05
with O 0 7.125771617211285e-08
VLCAD B-Disease 1 1.0
deficiency I-Disease 1 0.9999997615814209
who O 0 8.102881565719144e-07
was O 0 7.428263337772023e-09
first O 0 2.312986885355528e-10
seen O 0 5.769500877050859e-09
at O 0 9.320870464346598e-11
5 O 0 5.338876007954241e-10
months O 0 2.6547033460389002e-09
of O 0 9.539034145911174e-11
age O 0 1.2598720289247467e-08
with O 0 3.8632425258811054e-08
severe O 1 0.9987093210220337
hypertrophic B-Disease 1 0.999988317489624
cardiomyopathy I-Disease 1 1.0
, O 0 0.15320570766925812
hepatomegaly B-Disease 1 0.9999998807907104
, O 0 3.6179761082166806e-05
encephalopathy B-Disease 0 0.0011761282803490758
, O 0 2.385787922776217e-08
and O 0 6.71049562583903e-08
hypotonia B-Disease 0 0.42332908511161804
. O 0 4.721495940884779e-07

Biochemical O 0 0.00019819026056211442
studies O 0 5.6489948292437475e-06
indicated O 1 0.926287829875946
VLCAD B-Disease 1 1.0
deficiency I-Disease 1 1.0
caused O 0 3.520711743476568e-06
by O 0 1.0221994362069609e-09
a O 0 4.031067390997123e-08
stable O 0 1.4318565035864594e-06
yet O 0 3.513439139624097e-08
inactive O 0 1.2700347440386395e-07
enzyme O 0 8.268215623274955e-08
. O 0 1.1781819964085116e-08

Molecular O 0 1.0199455573456362e-05
genetic O 0 3.000970764333033e-06
analysis O 0 5.48125278498901e-08
of O 0 1.1068771454958437e-09
her O 0 7.7057229930233e-08
VLCAD O 0 1.008915114653064e-05
gene O 0 7.593393291926986e-08
revealed O 0 3.152383243332224e-08
a O 0 5.861240826021685e-09
T1372C O 0 3.838296720459766e-07
( O 0 4.118338170489011e-10
F458L O 0 1.4355028099544143e-07
) O 0 1.4332963704788426e-09
missense O 0 1.5483328752452508e-06
mutation O 0 2.1417869788820099e-07
and O 0 1.7133415797232487e-09
a O 0 5.135252933996526e-08
1668 O 0 0.00014592170191463083
ACAG O 0 0.00011416483175707981
1669 O 0 2.7447374577604933e-06
splice O 0 4.133368292968953e-06
site O 0 5.062393029220402e-07
mutation O 0 9.705520369607257e-07
. O 0 1.7627501236461285e-08

After O 0 1.1063996225857409e-06
initial O 0 4.867592338086979e-07
treatment O 0 1.184314669444575e-06
with O 0 6.535731067458528e-09
intravenous O 0 3.0491182769765146e-06
glucose O 0 4.3754480429925025e-05
and O 0 2.2342149463838723e-08
carnitine O 0 1.1270856248302152e-06
, O 0 5.939825298284518e-10
the O 0 1.415819267380769e-10
patient O 0 7.046232894936111e-07
has O 0 1.4573546813778648e-08
thrived O 0 2.5140661108480344e-08
on O 0 2.8430331422413246e-09
a O 0 8.348619573439464e-09
low O 0 2.637092393342755e-07
- O 0 2.804766836561612e-06
fat O 0 0.00016964432143140584
diet O 0 2.2859751425130526e-07
supplemented O 0 6.367330218637335e-09
with O 0 1.786690240201949e-10
medium O 0 2.571124291250726e-08
- O 0 1.0694178627090878e-06
chain O 0 3.473103788564913e-06
triglyceride O 0 8.218670473070233e-07
oil O 0 2.4271981757806316e-08
and O 0 1.102658520046873e-09
carnitine O 0 2.1897486135458166e-07
and O 0 1.951364181351778e-09
avoidance O 0 7.0647381278377e-08
of O 0 2.991282999076361e-09
fasting O 0 1.316710267929011e-06
. O 0 9.87100747806835e-08

Her O 0 1.0783497600641567e-05
ventricular O 0 0.0012212756555527449
hypertrophy O 0 0.0010893583530560136
resolved O 0 3.976508651248878e-06
significantly O 0 8.277389724753448e-07
over O 0 7.95829002697701e-09
1 O 0 3.9324246081662295e-09
year O 0 2.879246618903153e-09
, O 0 1.7480776826062083e-09
and O 0 3.204345899732175e-09
cognitively O 0 9.571493819748866e-07
, O 0 3.6830041794111423e-10
she O 0 3.021473293784993e-09
is O 0 1.318531395178013e-10
in O 0 6.648480377346999e-11
the O 0 1.2541549743172453e-10
superior O 0 1.6601788388470595e-08
range O 0 3.40299610712691e-09
for O 0 1.08641473595128e-09
age O 0 1.624324141857869e-08
. O 0 5.638366218363444e-09

Clinical O 0 0.0002588881179690361
recognition O 0 1.4290149010776076e-06
of O 0 2.3131795501285524e-07
VLCAD B-Disease 1 1.0
deficiency I-Disease 1 0.9999998807907104
is O 0 1.4296547945491511e-08
important O 0 2.448108660235704e-10
because O 0 8.019448993756839e-10
it O 0 3.084263400232601e-10
is O 0 4.979598400289831e-10
one O 0 1.2153786310697967e-10
of O 0 7.2043382544351164e-12
the O 0 1.2617849820539817e-10
few O 0 8.130220052748882e-09
directly O 0 4.3239620595159067e-07
treatable O 0 0.00012388102186378092
causes O 0 6.393253215719596e-08
of O 0 4.4318722025593615e-09
cardiomyopathy B-Disease 1 0.9999998807907104
in O 0 5.718252964470594e-07
children O 0 3.4370492585367174e-07
. O 0 1.861688803117545e-09
. O 0 1.4668417591678917e-08

Cloning O 0 1.696673280093819e-06
of O 0 4.8440553790385366e-09
a O 0 6.434575983149671e-09
novel O 0 2.3292946238484546e-08
member O 0 4.76238104507587e-10
of O 0 5.0148621366652435e-11
the O 0 2.4775664853038393e-10
low O 0 1.6761500774009619e-06
- O 0 0.0055155400186777115
density O 0 0.00016856803267728537
lipoprotein O 0 7.055592868709937e-05
receptor O 0 1.5366924799309345e-06
family O 0 1.8454151984315104e-07
. O 0 1.7638599913993858e-08

A O 0 5.748029821006639e-07
gene O 0 1.48050006032463e-07
encoding O 0 5.381339818200104e-08
a O 0 1.2314337993757363e-08
novel O 0 4.106929196723286e-08
transmembrane O 0 3.405751058949136e-08
protein O 0 8.145492280675626e-09
was O 0 1.1121449539075456e-08
identified O 0 6.38311015155324e-10
by O 0 2.102585813790192e-11
DNA O 0 4.0450656713098e-10
sequence O 0 1.6182152839938624e-10
analysis O 0 1.2425023510065358e-10
within O 0 9.803385533913023e-12
the O 0 1.1806081112730737e-10
insulin B-Disease 0 0.0070843156427145
- I-Disease 1 0.984199047088623
dependent I-Disease 1 0.9982290863990784
diabetes I-Disease 1 1.0
mellitus I-Disease 1 1.0
( O 0 1.8226057107995075e-08
IDDM B-Disease 0 1.193315620184876e-05
) O 0 1.1398457733236e-09
locus O 0 1.732861960590526e-07
IDDM4 O 0 3.4255479022249347e-06
on O 0 5.5766673057178195e-08
chromosome O 0 8.175914445018861e-06
11q13 O 0 6.210389528860105e-06
. O 0 8.844113352779459e-08

Based O 0 2.80750782621908e-07
on O 0 4.929120667185316e-09
its O 0 3.5382372032266574e-10
chromosomal O 0 4.6736857939322363e-07
position O 0 5.203184514357417e-07
, O 0 3.0007615836602497e-10
this O 0 2.918255220807353e-11
gene O 0 5.728160168416707e-10
is O 0 2.2315083114676781e-10
a O 0 7.890181286107634e-10
candidate O 0 5.028295557707452e-09
for O 0 3.3279959343879284e-10
conferring O 0 2.2525635756664997e-07
susceptibility O 0 0.245221346616745
to O 0 1.308141781919403e-05
diabetes B-Disease 1 0.9956068396568298
. O 0 9.376281582262891e-07

The O 0 2.62598920386381e-08
gene O 0 3.958350802690802e-08
, O 0 1.8693708803141362e-09
termed O 0 6.556759757359032e-08
low O 0 6.269979735407105e-07
- O 0 2.4108565412461758e-05
density O 0 4.2148508327954914e-06
lipoprotein O 0 2.3141515157476533e-06
receptor O 0 5.119595769542684e-08
related O 0 9.260806344002503e-09
protein O 0 1.7737686874852443e-08
5 O 0 2.861541004151036e-09
( O 0 8.572800802575387e-10
LRP5 O 0 8.760888704273384e-06
) O 0 2.4771459883332625e-10
, O 0 5.360586627367603e-11
encodes O 0 1.1661399623719149e-09
a O 0 7.513456523611239e-10
protein O 0 1.739098420827645e-09
of O 0 8.295911874123263e-11
1615 O 0 5.557925675248043e-08
amino O 0 2.97748470323711e-09
acids O 0 9.113158006002209e-10
that O 0 3.294696807043529e-11
contains O 0 2.8855823980267203e-11
conserved O 0 2.0925650101588644e-10
modules O 0 7.374685306871243e-10
which O 0 1.4049834906604275e-10
are O 0 1.7251975889531757e-11
characteristic O 0 6.286067222305292e-10
of O 0 2.8464919657467114e-11
the O 0 6.400580621068741e-10
low O 0 3.1958322779246373e-06
- O 0 0.05706580728292465
density O 0 0.005506191868335009
lipoprotein O 0 0.0004596481448970735
( O 0 1.1872029581638799e-08
LDL O 0 4.511965926212724e-06
) O 0 4.13625755868452e-09
receptor O 0 2.180431692977436e-07
family O 0 1.1195155735777007e-07
. O 0 9.371828646465019e-09

These O 0 9.42573805673419e-08
modules O 0 7.538498891790368e-08
include O 0 9.263451672403278e-10
a O 0 3.6427785232717724e-09
putative O 0 8.430311027041171e-08
signal O 0 1.101900508615472e-07
peptide O 0 4.633219141680911e-09
for O 0 2.795495952778726e-11
protein O 0 1.7027365628585756e-10
export O 0 1.1181865849918537e-10
, O 0 4.406412734692111e-11
four O 0 9.329835515270446e-11
epidermal O 0 9.658005062362918e-09
growth O 0 1.8839103610446273e-09
factor O 0 4.55073401184336e-09
( O 0 2.5832730399244497e-10
EGF O 0 9.324012495426359e-08
) O 0 6.708173461156264e-10
repeats O 0 1.4201561704396681e-08
with O 0 6.042900069225254e-10
associated O 0 1.7249263128960024e-09
spacer O 0 5.1600444805899315e-08
domains O 0 5.2536410777292986e-09
, O 0 3.240582802099823e-10
three O 0 2.488829142777149e-10
LDL O 0 1.412754073726319e-07
- O 0 1.5509885997744277e-07
receptor O 0 8.978710042129023e-08
( O 0 7.645384325627447e-10
LDLR O 0 1.2868123349107918e-06
) O 0 3.9946007612812195e-10
repeats O 0 9.98368321347698e-09
, O 0 1.4747542076420928e-10
a O 0 4.3780909453339234e-10
single O 0 1.1801229327090823e-08
transmembrane O 0 1.9917321125717535e-08
spanning O 0 2.984279046103211e-09
domain O 0 2.037754409656145e-09
, O 0 2.162666573601868e-10
and O 0 2.122317876995794e-10
a O 0 2.8380811034622866e-09
cytoplasmic O 0 3.830299988294428e-07
domain O 0 1.2030045581923332e-07
. O 0 4.10996179311951e-08

The O 0 9.3274596935089e-09
encoded O 0 1.1454124759779916e-08
protein O 0 7.098638121760814e-09
has O 0 7.474036389787386e-10
a O 0 1.9697425635012422e-10
unique O 0 4.151414767505912e-10
organization O 0 5.978034040010627e-11
of O 0 6.230772148230201e-11
EGF O 0 9.523576238734677e-08
and O 0 1.4637478784607083e-08
LDLR O 0 6.885587936267257e-06
repeats O 0 5.800453806159567e-08
; O 0 3.85422305182459e-10
therefore O 0 8.030607845377347e-10
, O 0 1.7890908199369449e-10
LRP5 O 0 3.6186608554089617e-07
likely O 0 2.9363498299517232e-08
represents O 0 5.008727321786921e-10
a O 0 3.024752670555131e-10
new O 0 2.7468446961442794e-10
category O 0 1.3008114585488784e-09
of O 0 8.128629713777258e-11
the O 0 1.8564868531356638e-09
LDLR O 0 0.00010797209688462317
family O 0 1.5012925302926305e-07
. O 0 1.5435920985851226e-08

Both O 0 6.21681465418078e-07
human O 0 1.330309462588275e-08
and O 0 6.367244953509044e-09
mouse O 0 4.856241844208853e-07
LRP5 O 0 1.1682926924549975e-05
cDNAs O 0 5.670540303981397e-07
have O 0 1.3728416625724549e-08
been O 0 6.0335740847961006e-09
isolated O 0 3.2303052677207234e-08
and O 0 4.2792508425648634e-10
the O 0 1.5193341376673608e-11
encoded O 0 9.171609582914186e-10
mature O 0 1.2977006969006055e-10
proteins O 0 1.954364448053525e-11
are O 0 2.6171148581610737e-11
95 O 0 2.998701842393814e-10
% O 0 8.36695990269476e-11
identical O 0 1.8635537557543103e-09
, O 0 1.3870002368854273e-10
indicating O 0 3.004176241105938e-09
a O 0 2.5946813586585904e-09
high O 0 7.754492159506299e-09
degree O 0 1.3369324536327554e-09
of O 0 9.444404980296639e-11
evolutionary O 0 3.5782807827899887e-09
conservation O 0 1.7013739306293019e-09
. O 0 6.215534753550855e-10
. O 0 8.484362545857493e-09

The O 0 1.9988949873095407e-07
APC B-Disease 0 7.165056103985989e-07
variants O 0 1.7021935150296486e-07
I1307K O 0 3.6778203593712533e-07
and O 0 2.3569617368934814e-09
E1317Q O 0 1.0719536902570326e-07
are O 0 1.1692334878077304e-09
associated O 0 1.1199811211781707e-07
with O 1 0.8174476027488708
colorectal B-Disease 1 1.0
tumors I-Disease 1 1.0
, O 0 8.185208457689441e-07
but O 0 1.5800587505054864e-08
not O 0 2.527869691348883e-09
always O 0 3.7387506424124695e-09
with O 0 6.38008812448021e-11
a O 0 1.3528930198347666e-09
family O 0 1.2121804005005288e-08
history O 0 7.575798655068411e-09
. O 0 1.548661465733403e-08

Classical O 0 0.00408409396186471
familial B-Disease 1 0.9999978542327881
adenomatous I-Disease 1 0.999974250793457
polyposis I-Disease 1 0.9999997615814209
( O 0 6.91246023052372e-05
FAP B-Disease 0 0.00010928419214906171
) O 0 1.7002264485199703e-08
is O 0 7.957909886613379e-09
a O 0 1.4187510721797025e-08
high O 0 1.125799713008746e-06
- O 1 0.891908586025238
penetrance O 1 0.7421906590461731
autosomal B-Disease 1 0.9982365369796753
dominant I-Disease 0 0.05056416243314743
disease I-Disease 0 5.104219962959178e-05
that O 0 1.8704480186926276e-09
predisposes O 0 1.0690926046663662e-06
to O 0 4.207568959913033e-09
hundreds O 0 1.849079778182272e-09
or O 0 5.855728679726724e-10
thousands O 0 5.073613085215811e-09
of O 0 2.0978507109248312e-07
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and I-Disease 1 0.9997528195381165
carcinoma I-Disease 1 1.0
and O 0 6.101765848143259e-07
that O 0 3.801729597796566e-09
results O 0 1.9169750231640137e-09
from O 0 7.002626950525226e-11
truncating O 0 5.0207077606501116e-08
mutations O 0 4.0196738382292097e-08
in O 0 1.3279402577559551e-10
the O 0 3.6485273136044327e-10
APC B-Disease 0 1.7720297762480186e-07
gene O 0 9.904407249905489e-08
. O 0 1.8264998402628407e-08

A O 0 4.581358098221244e-06
variant O 0 1.8254175301990472e-05
of O 0 1.4048242569231206e-08
FAP B-Disease 0 3.393411680008285e-05
is O 0 1.6029660400818102e-05
attenuated B-Disease 1 0.9787396192550659
adenomatous I-Disease 1 0.9999896287918091
polyposis I-Disease 1 0.9996205568313599
coli I-Disease 1 0.9999938011169434
, O 0 2.5502697553747566e-07
which O 0 1.3805827592250353e-08
results O 0 3.5309311030573554e-09
from O 0 1.1511473024805596e-10
germ O 0 4.504758521761687e-08
- O 0 2.881082991734729e-06
line O 0 9.41655230235483e-07
mutations O 0 1.4745587861852982e-08
in O 0 1.3248335761772978e-10
the O 0 1.5913748097062808e-10
5 O 0 7.140895097457189e-10
and O 0 1.4112151447420729e-09
3 O 0 1.3291522327207872e-09
regions O 0 2.8994096012979753e-10
of O 0 6.074016289936424e-11
the O 0 8.06042399492668e-10
APC B-Disease 0 4.365953714113857e-07
gene O 0 1.0199566702340235e-07
. O 0 2.055226744346328e-08

Attenuated B-Disease 1 0.9995875954627991
adenomatous I-Disease 1 0.9999942779541016
polyposis I-Disease 1 0.9999877214431763
coli I-Disease 1 0.9999996423721313
patients O 1 0.9999940395355225
have O 0 3.3044133829207567e-07
" O 0 2.7611088526668937e-08
multiple O 0 3.9981574673220166e-07
" O 0 0.021962884813547134
colorectal B-Disease 1 1.0
adenomas I-Disease 1 0.9999974966049194
( O 0 7.771505217135655e-09
typically O 0 3.311163609964751e-08
fewer O 0 4.502883399482016e-09
than O 0 6.313764511212128e-10
100 O 0 1.1786685516490536e-10
) O 0 3.952188923350697e-11
without O 0 2.7640673083695333e-10
the O 0 5.06371056196997e-10
florid O 0 0.00035066166310571134
phenotype O 0 0.00017669223598204553
of O 0 3.0964472652605934e-10
classical O 0 5.546710468706806e-08
FAP B-Disease 0 4.144767899560975e-06
. O 0 8.436005316525552e-08

Another O 0 8.35432388157642e-07
group O 0 7.061316154022279e-08
of O 0 1.5883704351793426e-09
patients O 0 3.1285399018088356e-06
with O 0 1.8814756419516243e-09
multiple O 0 1.3396777376328828e-07
adenomas B-Disease 0 8.371923286176752e-06
has O 0 4.0580761151431943e-07
no O 0 1.0547440698616128e-09
mutations O 0 3.5561682487639246e-09
in O 0 8.08496325443997e-11
the O 0 1.4889312005550437e-10
APC B-Disease 0 2.0734963968038755e-08
gene O 0 7.958168346533512e-09
, O 0 1.9509203974532596e-10
and O 0 4.4163939172392475e-10
their O 0 4.976920542354435e-10
phenotype O 0 9.95858044916531e-06
probably O 0 5.447099837851965e-08
results O 0 9.741755180314726e-10
from O 0 2.8698352722011933e-11
variation O 0 5.088401699993028e-09
at O 0 1.7469034552242135e-10
a O 0 2.018836875450347e-09
locus O 0 2.4231738393609703e-08
, O 0 3.430122852421391e-10
or O 0 1.8210297159093614e-10
loci O 0 2.9541167290147996e-09
, O 0 5.240817779750273e-10
elsewhere O 0 2.204321614129867e-09
in O 0 1.2678402772081654e-10
the O 0 2.771035345627837e-10
genome O 0 1.145325079221493e-08
. O 0 6.838500876682474e-09

Recently O 0 5.660011993313674e-06
, O 0 7.48825179641699e-09
however O 0 7.211081731739455e-10
, O 0 8.763800102284947e-11
a O 0 2.082158889749053e-09
missense O 0 2.40749341173796e-06
variant O 0 1.276383045478724e-06
of O 0 3.518666191748565e-10
APC B-Disease 0 1.1912727160279246e-07
( O 0 3.7946135122979285e-10
I1307K O 0 7.055096062913435e-08
) O 0 2.506570506710659e-10
was O 0 2.693107248319393e-08
described O 0 6.2266205524963425e-09
that O 0 1.547900974063765e-10
confers O 0 4.153491772740381e-09
an O 0 2.385685538008886e-10
increased O 0 3.637059720063007e-08
risk O 0 1.814396171084809e-07
of O 0 7.639430805284064e-06
colorectal B-Disease 1 1.0
tumors I-Disease 1 1.0
, O 0 6.045268463594766e-08
including O 0 1.3708969515136005e-09
multiple O 0 8.239123161501993e-08
adenomas B-Disease 0 3.3726134915923467e-06
, O 0 9.356968533325016e-09
in O 0 3.534448067554763e-09
Ashkenazim O 0 2.7945623060077196e-06
. O 0 5.6028529371587865e-08

We O 0 2.2536465849043452e-07
have O 0 5.570807370958164e-09
studied O 0 1.285043627063942e-09
a O 0 4.287723232021534e-10
set O 0 2.3717534602951673e-09
of O 0 2.216707511992766e-10
164 O 0 1.1454871895466567e-07
patients O 0 3.1699037208454683e-06
with O 0 5.537397740340566e-08
multiple O 1 0.9177536368370056
colorectal B-Disease 1 1.0
adenomas I-Disease 1 0.9999998807907104
and I-Disease 0 0.0013195115607231855
/ I-Disease 0 0.0009991808328777552
or I-Disease 0 6.625028618145734e-05
carcinoma I-Disease 1 1.0
and O 0 5.296490712680679e-07
analyzed O 0 1.978529695634279e-07
codons O 0 5.813656756004093e-08
1263 O 0 8.44026772028883e-07
- O 0 6.216589554242091e-07
1377 O 0 1.2339340855760383e-06
( O 0 1.400078053492848e-09
exon O 0 3.829984862591118e-08
15G O 0 1.1811322053745243e-07
) O 0 6.444800249028049e-11
of O 0 6.988359543824707e-12
the O 0 3.697995382134778e-11
APC B-Disease 0 1.0267763528304386e-08
gene O 0 2.1130368565991375e-09
for O 0 2.259876452637144e-10
germ O 0 1.32831459609406e-07
- O 0 5.227184374234639e-06
line O 0 2.381263357165153e-06
variants O 0 2.338773157362084e-07
. O 0 1.7291963416710132e-08

Three O 0 4.552777681965381e-06
patients O 0 8.18156149762217e-06
with O 0 2.914351815430649e-10
the O 0 3.0479760382284837e-10
I1307K O 0 3.5458688785183767e-07
allele O 0 3.709948259711382e-07
were O 0 4.289966604176243e-09
detected O 0 1.3733288284356604e-08
, O 0 1.606718924573869e-10
each O 0 8.534652151670485e-11
of O 0 1.9103127413266918e-10
Ashkenazi O 0 1.230952193509438e-06
descent O 0 4.2518636291788425e-06
. O 0 5.67613547275414e-08

Four O 0 4.9964323807216715e-06
patients O 0 5.843040344188921e-05
had O 0 1.5034009592795883e-08
a O 0 4.573025957910204e-09
germ O 0 4.970551117366995e-07
- O 0 6.0222664615139365e-05
line O 0 4.348702532297466e-06
E1317Q O 0 2.247949595357568e-07
missense O 0 2.5204934672728996e-07
variant O 0 3.019625083311439e-08
of O 0 4.6367153172521824e-11
APC O 0 1.8855326189282096e-08
that O 0 1.1035022895455882e-09
was O 0 1.7005246988333056e-08
not O 0 5.787750279040438e-10
present O 0 2.0945775669467537e-10
in O 0 1.3669612664024555e-10
controls O 0 7.323700629058294e-06
; O 0 5.178891204771219e-10
one O 0 1.1287292628336942e-10
of O 0 6.07404794863986e-12
these O 0 5.549771059376596e-11
individuals O 0 6.027058019331122e-11
had O 0 3.314232888129709e-09
an O 0 1.3931991671434218e-10
unusually O 0 2.5472849074503756e-07
large O 0 1.4253033198130538e-09
number O 0 5.819442150389875e-10
of O 0 1.2505146917973775e-10
metaplastic B-Disease 0 3.3491646718175616e-06
polyps I-Disease 0 1.2828468243242241e-07
of I-Disease 0 1.066527421933472e-10
the I-Disease 0 9.024561098414097e-10
colorectum I-Disease 0 9.214889360009693e-06
. O 0 4.4880522409584955e-08

There O 0 2.4872002768461243e-07
is O 0 3.4180294150587542e-09
increasing O 0 8.73521754929385e-10
evidence O 0 1.861081511123075e-09
that O 0 3.6983430207193635e-10
there O 0 4.4591558223672223e-10
exist O 0 4.802351849519937e-10
germ O 0 2.1308458997282287e-08
- O 0 8.866235816640256e-07
line O 0 1.282131449897861e-07
variants O 0 1.6887294895795435e-09
of O 0 9.636865958007057e-12
the O 0 2.784916047771091e-11
APC B-Disease 0 2.681378896696174e-09
gene O 0 4.6076598092525956e-10
that O 0 1.1305607144906915e-10
predispose O 0 9.496925912344523e-09
to O 0 6.960007015166525e-10
the O 0 5.000382399811265e-11
development O 0 1.3307749346935793e-10
of O 0 2.377881891391098e-09
multiple O 1 0.7103109359741211
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and I-Disease 1 0.9996106028556824
carcinoma I-Disease 1 1.0
, O 0 1.641066234014943e-07
but O 0 1.4489647703896935e-08
without O 0 5.019247240056757e-10
the O 0 5.685664716814642e-10
florid O 0 0.00016900143236853182
phenotype O 0 9.378299728268757e-05
of O 0 3.258321112920015e-10
classical O 0 1.9254041916383358e-08
FAP B-Disease 0 9.72011889643909e-07
, O 0 1.8644568111625404e-09
and O 0 1.9390157535159602e-10
possibly O 0 3.965616723888843e-10
with O 0 1.4009909898859974e-10
importance O 0 6.9333254693049184e-09
for O 0 0.005832125898450613
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
risk O 0 1.4705570947626256e-06
in O 0 2.035380058940106e-10
the O 0 6.615919617702914e-11
general O 0 8.622110803102601e-10
population O 0 7.26355087188324e-10
. O 0 3.7036440581061925e-10
. O 0 4.9821848868703e-09

Genomic O 0 8.268140845757443e-06
structure O 0 3.1856822602094326e-07
of O 0 1.3686369815246735e-09
the O 0 4.043386070406996e-09
human O 0 1.2097883654860198e-06
congenital B-Disease 1 0.9999992847442627
chloride I-Disease 1 0.9999997615814209
diarrhea I-Disease 1 1.0
( O 0 7.73523970565293e-06
CLD B-Disease 0 0.03318715840578079
) O 0 2.4235159656882388e-08
gene O 0 2.9233916620796663e-07
. O 0 5.336590902516036e-08

Congenital B-Disease 1 0.9999996423721313
chloride I-Disease 1 0.9999991655349731
diarrhea I-Disease 1 1.0
( O 0 0.00011089971667388454
CLD B-Disease 1 0.6877083778381348
) O 0 6.277039688029618e-08
is O 0 8.444779098226718e-08
caused O 0 2.313868066039504e-07
by O 0 1.8264639800591453e-09
mutations O 0 1.0179878984217794e-07
in O 0 2.68273847581213e-10
a O 0 3.228431078028393e-09
gene O 0 5.554933846241283e-09
which O 0 6.305424515851143e-10
encodes O 0 2.0527039623630117e-08
an O 0 2.5975547046641623e-08
intestinal O 0 0.0032377324532717466
anion O 0 1.8341266695642844e-05
transporter O 0 2.3876511477283202e-05
. O 0 4.6691063460002624e-08

We O 0 2.8070820690118126e-07
report O 0 9.97351978782035e-09
here O 0 3.7838304711712567e-10
the O 0 3.9442216853702305e-11
complete O 0 4.431836009288759e-10
genomic O 0 7.401925183891933e-10
organization O 0 5.1369984654936474e-11
of O 0 9.011789578461382e-12
the O 0 8.477252927407974e-11
human O 0 9.36614119595447e-10
CLD B-Disease 0 1.3938750953457202e-06
gene O 0 4.101950068502447e-08
which O 0 6.862045154321095e-09
spans O 0 4.735935732469443e-08
approximately O 0 2.7182018857985213e-09
39kb O 0 2.593184262877912e-07
, O 0 7.310222427392432e-10
and O 0 6.763442583768153e-10
comprises O 0 8.706989018669731e-10
21 O 0 6.29092822279631e-09
exons O 0 2.4874799464669195e-07
. O 0 2.8868422319305864e-08

All O 0 9.435073167196606e-08
exon O 0 1.2327026297498378e-06
/ O 0 5.809476988360984e-07
intron O 0 4.500981049204711e-06
boundaries O 0 3.4889172439989125e-08
conform O 0 2.3186476738601414e-08
to O 0 1.2247012293187254e-09
the O 0 1.6548098447088933e-09
GT O 0 1.444893428015348e-06
/ O 0 7.221243322419468e-06
AG O 0 0.08260948956012726
rule O 0 5.571903898271557e-07
. O 0 8.357242364809281e-08

An O 0 4.0148616875512744e-08
analysis O 0 6.139751373979152e-09
of O 0 1.2453924003175132e-10
the O 0 1.6088655407919816e-10
putative O 0 4.9189424089490785e-08
promoter O 0 2.1166245289805374e-07
region O 0 2.356651762625006e-09
sequence O 0 1.1376519726269407e-09
shows O 0 1.9393942007894793e-09
a O 0 2.507790863859327e-09
putative O 0 1.189211360497211e-07
TATA O 0 4.453389408354269e-07
box O 0 5.84027475269977e-08
and O 0 9.54617385140466e-10
predicts O 0 1.3122553710331886e-08
multiple O 0 1.548894013048141e-09
transcription O 0 7.169900229087034e-09
factor O 0 4.099867556561776e-09
binding O 0 1.724499476551955e-08
sites O 0 2.403170284992484e-08
. O 0 2.8896074866224808e-08

The O 0 4.610635784274564e-08
genomic O 0 1.1919591003106689e-07
structure O 0 6.433793231508389e-08
was O 0 2.123526599007164e-08
determined O 0 4.229341765693562e-09
using O 0 7.022157855196554e-10
DNA O 0 3.4342093613304314e-09
from O 0 4.7672678304966354e-11
several O 0 4.690199617574109e-11
sources O 0 4.2548728429459004e-11
including O 0 4.2633705593653204e-11
multiple O 0 1.2055071385574934e-09
large O 0 2.0937678257837433e-09
- O 0 1.0402120551589178e-06
insert O 0 2.170747620766633e-06
libaries O 0 1.562178567837691e-06
and O 0 4.2760117668905195e-10
genomic O 0 6.3326184296386145e-09
DNA O 0 3.218601563048651e-08
from O 0 1.5708178091600189e-09
Finnish O 0 0.0002376882912358269
CLD B-Disease 0 0.2644599974155426
patients O 0 0.006665940396487713
and O 0 8.7852640717756e-09
controls O 0 1.5841158528928645e-05
. O 0 1.1657384391128289e-07

Exon O 0 4.935670585837215e-05
- O 0 6.6366260398353916e-06
specific O 0 2.6925015106371575e-08
primers O 0 1.4223188600226422e-06
developed O 0 4.9116298583840035e-08
in O 0 1.9043029653165178e-10
this O 0 6.119238449286968e-11
study O 0 2.1693674634448712e-10
will O 0 1.3511285146261542e-10
facilitate O 0 5.091331245488107e-10
mutation O 0 1.9251139349307778e-08
screening O 0 7.988523620383603e-09
studies O 0 3.401612325149017e-10
of O 0 9.870598088879134e-11
patients O 0 1.2498045975917194e-07
with O 0 6.467659185993568e-10
the O 0 1.814423278290178e-08
disease O 0 5.7360762184544e-06
. O 0 5.1335682371700386e-08

Genomic O 0 1.77197182438249e-06
sequencing O 0 1.2278518113362225e-07
of O 0 1.5942952513725572e-09
a O 0 3.639738466176823e-08
BAC O 0 1.233261082234094e-05
clone O 0 6.936363661225187e-06
H O 1 0.9999521970748901
_ O 0 7.62846230628611e-09
RG364P16 O 0 6.09111410199148e-08
revealed O 0 5.30419619337863e-09
the O 0 3.2100561792036686e-11
presence O 0 2.283098432531716e-10
of O 0 1.4840821280226457e-11
another O 0 9.046137172674662e-10
, O 0 1.6000153979511822e-10
highly O 0 1.486601536315746e-10
homologous O 0 1.9974022436031191e-10
gene O 0 1.060003862463077e-09
3 O 0 1.875727351219325e-10
of O 0 1.6827185478351936e-11
the O 0 4.300663991596565e-10
CLD B-Disease 0 3.6537026062433142e-06
gene O 0 1.4329690323222621e-08
, O 0 1.4620583910218699e-10
with O 0 4.379700421774935e-11
a O 0 1.466670451755192e-09
similar O 0 2.2329698090572947e-09
genomic O 0 8.110610849598743e-09
structure O 0 1.1504680763607666e-08
, O 0 2.0712492831975737e-10
recently O 0 2.2282431455522556e-09
identified O 0 2.358517825484796e-09
as O 0 6.180306821867987e-10
the O 0 7.889225628332497e-08
Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
gene O 0 3.427449655646342e-06
( O 0 8.871072765259669e-09
PDS B-Disease 0 4.671369424613658e-06
) O 0 4.864768143875153e-09
. O 0 2.7305639971331175e-09
. O 0 7.182889838475148e-09

The O 0 2.0941189404766192e-07
APCI1307K O 0 4.348546644905582e-05
allele O 0 4.4158106902614236e-05
and O 0 1.941547935757626e-07
cancer B-Disease 0 5.673337909684051e-06
risk O 0 1.2653025294184772e-08
in O 0 2.6637655969885543e-10
a O 0 6.945648056699838e-09
community O 0 1.962636941854612e-09
- O 0 2.2158479850986623e-07
based O 0 1.3399634291033635e-08
study O 0 7.677883884227299e-10
of O 0 1.5949422338401575e-10
Ashkenazi O 0 4.2431406654941384e-07
Jews O 0 6.914495997989434e-08
. O 0 3.0415620244639285e-08

Mutations O 0 0.0019883078057318926
in O 0 5.669297209465185e-08
APC O 0 1.971584197235643e-06
are O 0 4.007119613902432e-08
classically O 0 0.2149934023618698
associated O 0 9.094262622966198e-07
with O 0 1.410547724844946e-06
familial B-Disease 1 0.9999998807907104
adenomatous I-Disease 1 0.9999940395355225
polyposis I-Disease 1 0.9999998807907104
( O 0 7.682431260036537e-07
FAP B-Disease 0 1.5662551959394477e-05
) O 0 5.5633422313405845e-09
, O 0 6.823513420961547e-10
a O 0 1.7289226050820616e-08
highly O 0 1.2530043932201806e-05
penetrant O 1 0.9995618462562561
autosomal B-Disease 1 1.0
dominant I-Disease 1 0.9999992847442627
disorder I-Disease 1 1.0
characterized O 0 0.000603495049290359
by O 0 5.562729654684517e-08
multiple O 0 3.933150310331257e-06
intestinal O 0 0.14116057753562927
polyps B-Disease 0 2.616802157717757e-05
and O 0 1.5015096721526788e-08
, O 0 4.5132164672168074e-10
without O 0 1.0714642506570726e-09
surgical O 0 1.753313512153909e-07
intervention O 0 1.673911675936779e-08
, O 0 2.397838316792189e-10
the O 0 8.437650578230205e-11
development O 0 5.817444304057062e-10
of O 0 9.445961040910333e-06
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
( O 0 5.362077359905015e-08
CRC B-Disease 0 4.254151463101152e-06
) O 0 7.034642202086161e-09
. O 0 1.3647430741059452e-08

APC B-Disease 0 3.331043626531027e-05
is O 0 1.8810501956068038e-07
a O 0 4.87401166537893e-07
tumour O 1 0.9999971389770508
- O 0 4.8175177653320134e-05
suppressor O 0 2.932316783699207e-05
gene O 0 3.7811292941114516e-07
, O 0 1.8144882263371187e-09
and O 0 1.4929246727746204e-09
somatic O 0 3.599242575091921e-07
loss O 0 3.7641618177985947e-07
occurs O 0 1.75733188001459e-08
in O 0 4.015949173208355e-08
tumours B-Disease 1 0.9999979734420776
. O 0 2.866730426376307e-07

The O 0 3.297717512396048e-07
germline O 0 5.499591679836158e-06
T O 0 7.067108526825905e-06
- O 0 7.959065442264546e-07
to O 0 1.7688462250475823e-08
- O 0 6.548548867613135e-07
A O 0 2.676965777936857e-07
transversion O 0 1.0881385605898686e-06
responsible O 0 5.258182778078435e-09
for O 0 3.835140191532638e-11
the O 0 4.73289463176485e-11
APC O 0 2.9421578062738263e-08
I1307K O 0 2.6003059261370254e-08
allele O 0 8.1625692871512e-09
converts O 0 4.054947932985442e-09
the O 0 6.072869290774108e-11
wild O 0 7.5197936766358e-10
- O 0 3.823073058129012e-08
type O 0 2.129379161885936e-08
sequence O 0 4.5341314036662084e-10
to O 0 7.588173422945488e-10
a O 0 4.2664598964847755e-08
homopolymer O 0 0.02415628917515278
tract O 0 0.012186668813228607
( O 0 1.2126052384431318e-09
A8 O 0 4.0233817344415e-06
) O 0 5.70474001371224e-10
that O 0 9.051384641800553e-10
is O 0 2.244635810555451e-09
genetically O 0 1.3527704822990927e-07
unstable O 0 7.668988109799102e-05
and O 0 5.179252582365734e-08
prone O 0 7.869590262998827e-06
to O 0 2.415776201303288e-08
somatic O 0 7.087126505211927e-06
mutation O 0 5.848172349942615e-06
. O 0 6.275914188336174e-08

The O 0 5.093395216704266e-08
I1307K O 0 3.6213023122400045e-06
allele O 0 1.952476850419771e-06
was O 0 4.06070022052063e-08
found O 0 2.4745876459064675e-09
in O 0 8.675889451303931e-10
6 O 0 3.762703926213362e-08
. O 0 6.466863311516136e-08

1 O 0 3.4231013046337466e-07
% O 0 6.217375503325684e-09
of O 0 4.339208714565501e-10
unselected O 0 9.03137606655946e-06
Ashkenazi O 0 6.139546712802257e-06
Jews O 0 6.246225581207909e-08
and O 0 3.9842538157586205e-09
higher O 0 6.35490593481336e-09
proportions O 0 4.7569571393069054e-08
of O 0 8.026610487377184e-10
Ashkenazim O 0 2.572493826846767e-07
with O 0 1.2079744982074203e-09
family O 0 2.105497554083513e-09
or O 0 9.109260568074262e-11
personal O 0 8.449189792258949e-09
histories O 0 5.19291942779887e-09
of O 0 3.159832673294005e-10
CRC B-Disease 0 9.613420388632221e-07
( O 0 2.2247481634707356e-09
ref O 0 1.9458461792964954e-06
. O 0 7.001976221054917e-10
2 O 0 1.2094591994582515e-09
) O 0 1.2147487460367756e-09
. O 0 2.3367883628111485e-08

To O 0 3.811162798683654e-07
evaluate O 0 1.906642381754864e-07
the O 0 4.004441500615741e-10
role O 0 4.5320303065921053e-10
of O 0 1.0409672429601002e-10
I1307K O 0 2.8815287578254356e-07
in O 0 6.745049851986096e-09
cancer B-Disease 0 5.523294248632737e-07
, O 0 2.510306962300035e-10
we O 0 5.063247043857189e-10
genotyped O 0 7.564337778376284e-08
5 O 0 1.0581292508859974e-09
, O 0 5.324059526579106e-10
081 O 0 2.8052434686287597e-07
Ashkenazi O 0 1.2725104170385748e-07
volunteers O 0 2.6248359041858293e-09
in O 0 3.575575599490399e-11
a O 0 7.752580244435592e-10
community O 0 2.873387305868391e-09
survey O 0 5.522873536278894e-08
. O 0 9.355826335877282e-09

Risk O 0 3.944250784115866e-05
of O 0 1.6273880021344667e-08
developing O 0 1.5852816659389646e-06
colorectal B-Disease 1 1.0
, I-Disease 0 1.5565094145131297e-05
breast I-Disease 0 0.45967763662338257
and I-Disease 0 9.651858334791541e-08
other I-Disease 0 2.2812018940499e-09
cancers I-Disease 0 1.3314132047526073e-05
were O 0 2.4722394798004643e-08
compared O 0 8.042123411655666e-09
between O 0 2.1649404491341784e-10
genotyped O 0 9.138733503277763e-07
I1307K O 0 1.447076272143022e-07
carriers O 0 9.404579337513042e-09
and O 0 1.3633868478635236e-09
non O 0 1.4431856820706912e-09
- O 0 1.640058684415635e-07
carriers O 0 2.964339884670153e-08
and O 0 8.029918396879054e-10
their O 0 1.0832194863308331e-10
first O 0 1.0198040190090296e-09
- O 0 1.252590919875729e-07
degree O 0 4.418151178242624e-08
relatives O 0 9.94984930002829e-08
. O 0 1.9587373500939975e-08

Sperm O 0 5.422048616310349e-06
DNA O 0 5.999631866870914e-07
analysis O 0 3.3278407585157765e-08
in O 0 1.3404970466979194e-09
a O 0 1.0958684271145103e-07
Friedreich B-Disease 1 0.998136043548584
ataxia I-Disease 1 0.9998836517333984
premutation O 0 0.0033093541860580444
carrier O 0 5.186569978832267e-06
suggests O 0 7.3762080887718184e-09
both O 0 2.4048094071638104e-10
meiotic O 0 2.7712337313801072e-08
and O 0 3.918571023220352e-10
mitotic O 0 1.4142310433840066e-08
expansion O 0 5.2980184683804055e-09
in O 0 6.435849075892008e-10
the O 0 1.0643433911994293e-09
FRDA B-Disease 0 8.59038937051082e-06
gene O 0 2.676046904070972e-07
. O 0 5.169876260424644e-08

Friedreich B-Disease 1 0.9998189806938171
ataxia I-Disease 1 0.9999804496765137
is O 0 0.0015958171570673585
usually O 0 1.795373646018561e-05
caused O 0 2.737345425884996e-07
by O 0 2.3058072118331552e-10
an O 0 1.7507427452212454e-10
expansion O 0 8.330593437300138e-10
of O 0 1.2077065736360026e-10
a O 0 7.763533815818846e-09
GAA O 0 8.24678068056528e-08
trinucleotide O 0 3.4178492569481023e-07
repeat O 0 8.359442205119194e-08
in O 0 4.952130927549092e-10
intron O 0 5.12044550760038e-07
1 O 0 1.0934266825302075e-09
of O 0 4.473943090999022e-11
the O 0 4.968773170688223e-10
FRDA B-Disease 0 5.455226983031025e-06
gene O 0 2.1229196534022776e-07
. O 0 1.7178876987600233e-08

Occasionally O 0 1.715256439638324e-05
, O 0 6.6575727153406206e-09
a O 0 4.790077223759681e-09
fully O 0 1.0288307983330469e-08
expanded O 0 4.980056367287489e-09
allele O 0 9.955107316272915e-08
has O 0 5.01103292194216e-09
been O 0 6.319246237396214e-10
found O 0 3.381823154846586e-10
to O 0 6.468485747035402e-10
arise O 0 6.820494724557591e-10
from O 0 5.717089301970901e-11
a O 0 1.5645684747767064e-09
premutation O 0 1.741197621640822e-07
of O 0 7.668645579661515e-11
100 O 0 6.038245459194513e-10
or O 0 5.518729362385955e-10
less O 0 5.2545356510336205e-08
triplet O 0 0.00018227603868581355
repeats O 0 9.074709055312269e-07
. O 0 2.2639254027012612e-08

We O 0 3.380975783784379e-07
have O 0 4.799021624535271e-09
examined O 0 1.3213523608612832e-08
the O 0 1.2649248315454997e-10
sperm O 0 2.798673071069402e-09
DNA O 0 1.7336404534162853e-09
of O 0 3.964449948878901e-11
a O 0 6.1539728868353905e-09
premutation O 0 2.0194356693536974e-05
carrier O 0 1.4272553926275577e-05
. O 0 4.925439611724869e-08

This O 0 1.0660530591621864e-07
mans O 0 3.5860900879924884e-06
leucocyte O 0 4.666311269829748e-06
DNA O 0 6.611701905967493e-07
showed O 0 1.837447598518338e-07
one O 0 8.70619187853805e-10
normal O 0 2.98903590767452e-09
allele O 0 4.247419482794612e-08
and O 0 4.094434236101563e-10
one O 0 7.884043418115994e-10
allele O 0 1.3173813151468039e-08
of O 0 6.550775893954253e-11
approximately O 0 1.3574448232134273e-09
100 O 0 1.4835006556523922e-09
repeats O 0 8.982940613577739e-08
. O 0 2.0208025475199065e-08

His O 0 9.200147701449168e-07
sperm O 0 3.0099855052867497e-07
showed O 0 6.70723281359642e-08
an O 0 1.7964597864850163e-10
expanded O 0 2.9945481649917838e-09
allele O 0 4.829288613450444e-08
in O 0 3.7438865896355367e-10
a O 0 5.777098799342184e-09
tight O 0 5.325364895725215e-07
range O 0 1.1344824635273199e-08
centering O 0 1.4023933125884014e-08
on O 0 2.358432116267295e-09
a O 0 1.1827904211614282e-09
size O 0 3.204633225450948e-09
of O 0 2.1556159635061078e-10
approximately O 0 2.5878161835635183e-09
320 O 0 8.801605133612611e-08
trinucleotide O 0 9.518974366073962e-06
repeats O 0 2.211116225225851e-06
. O 0 7.851561889538061e-08

His O 0 9.3887965704198e-06
affected O 0 1.1769824368457193e-06
son O 0 2.644133701323881e-06
has O 0 1.0965747421209926e-08
repeat O 0 1.0813730355607731e-08
sizes O 0 6.913490668836175e-09
of O 0 1.7981155453483666e-10
1040 O 0 1.1735242821941938e-07
and O 0 6.6208878379825364e-09
540 O 0 1.6556322179894778e-07
. O 0 2.0240273457261537e-08

These O 0 2.721674086103576e-08
data O 0 3.6771379274824767e-09
suggest O 0 2.2623272144528528e-09
that O 0 7.002293189728448e-11
expansion O 0 6.060375534744367e-10
occurs O 0 2.356569384076579e-10
in O 0 5.447267983904602e-11
two O 0 2.494127959717929e-10
stages O 0 3.2689175810673987e-09
, O 0 9.938132955467083e-11
the O 0 8.144067017989975e-12
first O 0 6.452094414299836e-11
during O 0 8.097293668907213e-11
meiosis O 0 8.085260239099057e-10
followed O 0 2.678423038915412e-10
by O 0 1.4633103756489518e-11
a O 0 2.0001394984703325e-10
second O 0 9.950181789619705e-10
mitotic O 0 7.193257545168308e-08
expansion O 0 8.305327270363705e-08
. O 0 3.143149385209654e-08

We O 0 4.3077045575046213e-07
also O 0 1.0330585276108195e-08
show O 0 5.13261610990412e-09
that O 0 4.0647724075526526e-10
in O 0 6.898284027334611e-11
all O 0 5.561119620356436e-11
informative O 0 6.966650811790487e-09
carrier O 0 3.974237472448294e-08
father O 0 7.569096460713354e-09
to O 0 4.618218030216781e-10
affected O 0 3.6037122175258673e-09
child O 0 6.657905515794482e-08
transmissions O 0 1.4399341807802557e-07
, O 0 9.468249101418635e-11
with O 0 4.1710961073970765e-11
the O 0 4.497437144923566e-11
notable O 0 1.370483726503835e-09
exception O 0 8.298178810761669e-10
of O 0 1.7503045887656832e-11
the O 0 2.2960598700105805e-10
premutation O 0 1.280259766645031e-06
carrier O 0 1.126530619899313e-07
, O 0 2.1168185260211914e-11
the O 0 3.087621304465049e-12
expansion O 0 1.2829759477028801e-10
size O 0 2.445729618827386e-09
decreases O 0 1.1234686070338284e-07
. O 0 1.2595109399882176e-09
. O 0 6.046247058577592e-09

The O 0 6.507001160116488e-08
R496H O 0 1.2116692005292862e-06
mutation O 0 1.8414824864976254e-07
of O 0 2.7410929082094526e-10
arylsulfatase O 0 6.670978791589732e-07
A O 0 8.317375232991253e-08
does O 0 1.0183219956161338e-07
not O 0 1.2761368850533472e-07
cause O 0 2.8804684916394763e-05
metachromatic B-Disease 1 0.9999988079071045
leukodystrophy I-Disease 1 0.9999984502792358
. O 0 9.867427479548496e-07

Deficiency B-Disease 1 0.9961723685264587
of I-Disease 0 5.153493631837591e-08
arylsulfatase I-Disease 0 2.4011578716454096e-05
A I-Disease 0 4.8184267598117e-07
( O 0 8.292786901620275e-09
ARSA O 0 5.7577861298341304e-05
) O 0 1.7403659624548595e-09
enzyme O 0 1.9538379802952477e-08
activity O 0 4.844621770416779e-08
causes O 0 7.965930308273528e-06
metachromatic B-Disease 1 0.9999996423721313
leukodystrophy I-Disease 1 0.9999998807907104
( O 0 4.692045877163764e-06
MLD B-Disease 1 0.9999703168869019
) O 0 8.687241148663816e-08
. O 0 3.4861503905858626e-08

A O 0 5.171316388441483e-07
number O 0 1.107392932908624e-08
of O 0 9.562592939715842e-10
ARSA O 0 0.0001062410810845904
gene O 0 5.755391043749114e-07
mutations O 0 4.601639602697105e-07
responsible O 0 1.2148657901889237e-07
for O 0 4.6980229484461233e-08
MLD B-Disease 1 0.9999977350234985
have O 0 2.862274186554714e-06
been O 0 2.060206014675714e-07
identified O 0 2.0717912718737352e-07
. O 0 2.660417131039594e-08

Recently O 0 3.755015541173634e-06
, O 0 8.19586087885682e-09
the O 0 5.84726878027908e-10
R496H O 0 1.2313473973790678e-07
mutation O 0 2.4478683968709447e-08
of O 0 2.363758633272539e-10
ARSA O 0 1.0077668775920756e-05
was O 0 6.996895507427325e-08
proposed O 0 8.087635561260242e-10
to O 0 4.047396306994244e-10
be O 0 9.81454584270125e-10
a O 0 1.6784769130140376e-08
cause O 0 1.3843397255186574e-06
of O 0 9.084769381217939e-09
MLD B-Disease 1 0.9999946355819702
( O 0 7.585254202524538e-09
Draghia O 0 2.8178396860312205e-06
et O 0 5.318462470427221e-08
al O 0 1.168090975056657e-07
. O 0 9.620311214320054e-10
, O 0 2.605729798599299e-10
1997 O 0 1.3214020988527864e-09
) O 0 1.2972781737730088e-09
. O 0 1.4398018777228572e-08

We O 0 5.070094744041853e-07
have O 0 4.996954849900703e-09
investigated O 0 1.3409912291706405e-08
the O 0 2.328714721056002e-10
R496H O 0 2.0862073313310248e-07
mutation O 0 3.878725252093318e-08
and O 0 2.4282514887730144e-10
found O 0 2.7569960203699395e-10
this O 0 4.213379298234621e-11
mutation O 0 5.103252931348834e-09
at O 0 4.305816467264911e-11
a O 0 6.209918135269277e-10
relatively O 0 8.416297880842194e-09
high O 0 4.039131695776632e-09
frequency O 0 5.381052048392121e-08
in O 0 1.5707121714392258e-10
an O 0 1.1109036607281908e-10
African O 0 8.93567927984229e-11
American O 0 3.8827038806310554e-10
population O 0 9.525415178845975e-11
( O 0 2.6773999683982197e-11
f O 0 2.562101997227728e-08
= O 0 1.3223129258221888e-08
0 O 0 5.746876308165838e-09
. O 0 3.455390418238835e-10
09 O 0 1.8574360938217183e-09
, O 0 4.3636264046575945e-10
n O 0 1.8322291239769584e-08
= O 0 8.266418660696218e-08
61 O 0 5.529967239681355e-08
subjects O 0 9.837360259723482e-09
) O 0 1.8050404504421635e-09
. O 0 9.973006420693764e-09

The O 0 7.896873910340219e-08
ARSA O 0 1.1413675565563608e-05
enzyme O 0 6.09434493981098e-08
activity O 0 4.9016510850208306e-09
in O 0 6.512942407610467e-10
subjects O 0 6.36550856469853e-09
with O 0 8.279918417564147e-10
and O 0 8.364618442335825e-10
without O 0 1.285886397361935e-10
the O 0 3.004614612667211e-11
R496H O 0 3.715860685815642e-08
mutation O 0 6.836622823414018e-09
was O 0 4.231649253227943e-09
determined O 0 6.287941278770859e-09
and O 0 2.8181426636741946e-10
found O 0 3.56063234452364e-10
to O 0 8.462184841739884e-10
be O 0 7.79900588554483e-09
normal O 0 2.3700678752902604e-08
. O 0 2.2060975268800576e-08

It O 0 1.3062127379726007e-07
is O 0 6.0279496949533495e-09
therefore O 0 2.369207718899702e-09
concluded O 0 1.6293502103081892e-09
that O 0 1.0771991632019251e-10
the O 0 4.0556936281577194e-11
R496H O 0 5.013683690435755e-08
mutation O 0 7.718928607403086e-09
of O 0 8.048529204218724e-11
ARSA O 0 1.5659746850360534e-06
does O 0 7.754151987171554e-09
not O 0 5.55806844992901e-10
negatively O 0 2.9437505766338745e-09
influence O 0 3.5278055476872794e-10
the O 0 5.3191343690750514e-11
activity O 0 2.567769608052828e-10
of O 0 7.267372120756121e-11
ARSA O 0 5.423094626166858e-05
and O 0 3.9339322910336705e-09
is O 0 6.369950678042358e-10
not O 0 8.398830519951161e-10
a O 0 7.39421057716072e-09
cause O 0 2.865615158498258e-07
of O 0 3.68504551317983e-08
MLD B-Disease 1 0.9999891519546509

Down O 0 2.704256758079282e-06
- O 0 4.02840498736623e-07
regulation O 0 1.8565089021649328e-08
of O 0 3.277531301915104e-10
transmembrane O 0 1.6706430017165985e-07
carbonic O 0 9.474645139562199e-07
anhydrases O 0 8.073723165580304e-07
in O 0 1.2186434972250026e-08
renal B-Disease 1 0.9973483085632324
cell I-Disease 1 0.9998874664306641
carcinoma I-Disease 1 1.0
cell O 0 0.01971801370382309
lines O 0 7.847187930565269e-07
by O 0 6.222414805634457e-10
wild O 0 9.487963303911329e-09
- O 0 3.3230226108571514e-05
type O 0 0.002817972796037793
von B-Disease 1 0.9954490065574646
Hippel I-Disease 1 0.9740095138549805
- I-Disease 0 0.045517031103372574
Lindau I-Disease 0 0.05058273300528526
transgenes O 0 0.00014869761071167886
. O 0 3.2357135637539614e-07

To O 0 2.685905826638191e-07
discover O 0 1.1339593442016849e-07
genes O 0 3.1421901525163776e-08
involved O 0 1.2054754527923706e-08
in O 0 1.8906716192645945e-08
von B-Disease 1 0.9946505427360535
Hippel I-Disease 1 0.9995802044868469
- I-Disease 1 0.9956583976745605
Lindau I-Disease 1 0.9785774946212769
( O 0 3.265834180865568e-08
VHL B-Disease 0 2.0523887087620096e-06
) O 0 2.509733754152421e-09
- O 0 4.684717112013459e-07
mediated O 0 4.1226362554880325e-06
carcinogenesis O 0 2.9619141059811227e-05
, O 0 1.574960939443315e-09
we O 0 3.358418820820219e-10
used O 0 2.0025164815251628e-07
renal B-Disease 1 0.9933237433433533
cell I-Disease 1 0.9999252557754517
carcinoma I-Disease 1 1.0
cell O 0 0.44092485308647156
lines O 0 5.429649718280416e-06
stably O 0 1.9184519715054194e-06
transfected O 0 4.7620410441595595e-06
with O 0 4.585026136538772e-09
wild O 0 2.0530249500438913e-08
- O 0 2.929993934230879e-05
type O 0 0.0001686119067016989
VHL O 0 0.00018009151972364634
- O 0 8.199920557672158e-05
expressing O 0 1.0566553783064592e-06
transgenes O 0 1.594344576005824e-05
. O 0 1.275195273819918e-07

Large O 0 1.0232610065941117e-06
- O 0 1.616796680536936e-06
scale O 0 8.070292523143507e-08
RNA O 0 5.1168818515634484e-08
differential O 0 6.626277695431781e-07
display O 0 1.737424959458167e-08
technology O 0 9.305562986838822e-10
applied O 0 4.392186170321111e-09
to O 0 7.105528943007755e-10
these O 0 1.1536949173773792e-10
cell O 0 2.1182358977966942e-07
lines O 0 8.003014784208062e-08
identified O 0 3.6235969780307187e-09
several O 0 2.22918156156382e-10
differentially O 0 1.7089242021484097e-07
expressed O 0 5.956346971203175e-09
genes O 0 2.1072974476510353e-09
, O 0 8.968752823745874e-11
including O 0 5.668618352494548e-11
an O 0 6.473842573129218e-10
alpha O 0 4.727524682834883e-08
carbonic O 0 7.818525773473084e-07
anhydrase O 0 9.955940640793415e-07
gene O 0 4.7085723764439535e-08
, O 0 2.4443678192653806e-09
termed O 0 1.7867745327748707e-07
CA12 O 0 2.6771627744892612e-05
. O 0 1.07470519594699e-07

The O 0 5.658213453330063e-08
deduced O 0 1.0375434555953689e-07
protein O 0 5.101111977268147e-09
sequence O 0 8.519124850003834e-10
was O 0 2.6489472837454286e-09
classified O 0 6.486672310401786e-10
as O 0 3.619802790844062e-10
a O 0 1.8695562875592486e-09
one O 0 9.50344958283722e-09
- O 0 4.694181370723527e-06
pass O 0 5.934361411163991e-07
transmembrane O 0 1.1569292013291488e-07
CA O 0 3.448145591278262e-08
possessing O 0 2.525748943327244e-09
an O 0 3.1701069547196425e-10
apparently O 0 2.3938834914360996e-08
intact O 0 1.0944699591064477e-09
catalytic O 0 1.0746878942313742e-09
domain O 0 2.5519353297198677e-10
in O 0 5.678422315691378e-11
the O 0 4.700695735437854e-11
extracellular O 0 1.624590595383779e-08
CA O 0 1.063263425749028e-06
module O 0 1.0972484005833394e-06
. O 0 2.89806898479128e-08

Reintroduced O 0 3.1510473490925506e-05
wild O 0 2.212683511970681e-06
- O 0 3.7680907553294674e-05
type O 0 5.949196292931447e-06
VHL B-Disease 0 9.858051271294244e-06
strongly O 0 8.213343107854598e-07
inhibited O 0 1.1076679840016368e-07
the O 0 3.360892397719084e-10
overexpression O 0 3.118260849532817e-08
of O 0 2.817539604405006e-11
the O 0 9.587370480845792e-11
CA12 O 0 2.9895196007601044e-07
gene O 0 7.68237029546981e-09
in O 0 3.8674929925264223e-10
the O 0 1.654093528813405e-09
parental O 0 0.07734070718288422
renal B-Disease 1 0.9999477863311768
cell I-Disease 1 0.999975323677063
carcinoma I-Disease 1 1.0
cell O 1 0.7823020219802856
lines O 0 7.5756739533972e-05
. O 0 1.967038230077378e-07

Similar O 0 3.1136601137404796e-06
results O 0 4.4187075332047243e-07
were O 0 8.581000798812966e-09
obtained O 0 2.135385424040237e-09
with O 0 1.6106627143130936e-09
CA9 O 0 3.107111115241423e-05
, O 0 1.1757501638953727e-09
encoding O 0 5.472465147704497e-09
another O 0 1.0646322934348973e-08
transmembrane O 0 1.0827045571204508e-07
CA O 0 8.795831263341825e-08
with O 0 3.8488748299592146e-10
an O 0 1.1274711164688256e-09
intact O 0 5.685475557015707e-08
catalytic O 0 6.371512029090809e-08
domain O 0 7.806271895560712e-08
. O 0 1.9072601276093337e-08

Although O 0 7.264305281751149e-07
both O 0 1.648304936985312e-09
domains O 0 9.255433641719435e-10
of O 0 6.08924646816611e-11
the O 0 9.583275145663706e-11
VHL B-Disease 0 1.496403996270601e-07
protein O 0 4.8800834484552524e-09
contribute O 0 2.742944482658771e-10
to O 0 1.565502172340416e-10
regulation O 0 2.300892143480837e-09
of O 0 2.3228990952972595e-10
CA12 O 0 1.5998200979083776e-05
expression O 0 1.3719620994834258e-08
, O 0 6.330124618925126e-11
the O 0 3.326782252455196e-11
elongin O 0 4.870192071848578e-08
binding O 0 2.6783528728202555e-09
domain O 0 2.1792927462627176e-09
alone O 0 6.163122900915141e-09
could O 0 2.5428850136677283e-09
effectively O 0 3.3385148867637326e-08
regulate O 0 3.716024536970508e-07
CA9 O 0 0.0001318494905717671
expression O 0 1.3123338931109174e-06
. O 0 1.0437003084007301e-07

We O 0 1.4970121355872834e-06
mapped O 0 1.3408820450422354e-05
CA12 O 0 3.06241781800054e-05
and O 0 4.348343551896505e-08
CA9 O 0 7.977988389029633e-06
loci O 0 9.11306159423475e-08
to O 0 2.2062868865191376e-08
chromosome O 0 2.4614798803668236e-06
bands O 0 1.6492593601924455e-07
15q22 O 0 8.875102253114164e-07
and O 0 1.7750039660313632e-08
17q21 O 0 1.6961166693363339e-06
. O 0 6.805751695537765e-08

2 O 0 1.5100774817256024e-06
respectively O 0 2.2536077892709727e-07
, O 0 2.659801934257189e-09
regions O 0 5.05427610875131e-09
prone O 0 6.294072591117583e-06
to O 0 2.3735148957371166e-08
amplification O 0 9.949534387487802e-07
in O 0 4.179571688744943e-10
some O 0 7.048593375635903e-10
human O 0 1.3835562029385073e-08
cancers B-Disease 0 1.5083119251357857e-05
. O 0 8.03625397338692e-08

Additional O 0 2.4365706963180855e-07
experiments O 0 3.8426218651466115e-08
are O 0 3.856517327704978e-10
needed O 0 2.0548220902583125e-09
to O 0 5.718466256077193e-10
define O 0 5.638904010396573e-09
the O 0 8.299266829325802e-11
role O 0 7.927501433080408e-10
of O 0 1.3668230436358897e-10
CA O 0 1.1613459491854883e-06
IX O 0 5.470705218613148e-05
and O 0 3.985943308748574e-08
CA O 0 2.481201306636649e-07
XII O 0 8.92758919235348e-07
enzymes O 0 1.9960322283907317e-09
in O 0 1.0552506091165981e-10
the O 0 4.252958055173117e-11
regulation O 0 8.482982649660187e-10
of O 0 2.0564873415285234e-10
pH O 0 2.5057227048819186e-07
in O 0 1.364496987621422e-10
the O 0 4.9730840973039037e-11
extracellular O 0 1.8871615381499396e-09
microenvironment O 0 3.925285625427932e-07
and O 0 3.1379826515021136e-10
its O 0 8.689730185418298e-11
potential O 0 7.763397147364515e-10
impact O 0 8.760850711553303e-09
on O 0 8.996881462053352e-08
cancer B-Disease 0 3.6507699405774474e-06
cell O 0 4.99748182392068e-07
growth O 0 4.5746425314519e-08
. O 0 2.8292079790048774e-08

A O 0 7.137251145650225e-07
gene O 0 1.1280625500376118e-07
encoding O 0 3.9167591836530846e-08
a O 0 5.565603089507931e-09
transmembrane O 0 4.12869276544825e-08
protein O 0 2.295789336415055e-09
is O 0 2.076969846109833e-10
mutated O 0 9.263513334190066e-08
in O 0 8.582425436998165e-09
patients O 0 0.002091769129037857
with O 0 0.0006301287794485688
diabetes B-Disease 1 1.0
mellitus I-Disease 1 1.0
and O 1 0.970770001411438
optic B-Disease 1 0.9999998807907104
atrophy I-Disease 1 0.9999929666519165
( O 0 0.0009920350275933743
Wolfram B-Disease 1 1.0
syndrome I-Disease 1 1.0
) O 0 4.603606029718321e-08
. O 0 4.108041551376118e-08

Wolfram B-Disease 1 0.9999995231628418
syndrome I-Disease 1 1.0
( O 0 8.769946725806221e-05
WFS B-Disease 0 0.017430409789085388
; O 0 1.7831789591582492e-06
OMIM O 0 0.00025427949731238186
222300 O 0 1.5838053286643117e-06
) O 0 1.5047771917409136e-09
is O 0 2.2304669222705797e-09
an O 0 1.9049261723580457e-08
autosomal B-Disease 1 0.9995808005332947
recessive I-Disease 1 0.9999899864196777
neurodegenerative I-Disease 1 0.9999985694885254
disorder I-Disease 1 0.999970555305481
defined O 0 4.788225851370953e-07
by O 0 6.211342551409871e-09
young O 0 3.7833501664863434e-08
- O 0 2.6362654352851678e-06
onset O 0 2.599577555884025e-06
non O 0 1.7612654801268945e-07
- O 0 0.04047521576285362
immune O 0 0.005582015961408615
insulin B-Disease 1 0.9965662360191345
- I-Disease 0 0.42913731932640076
dependent I-Disease 1 0.9154009819030762
diabetes I-Disease 1 1.0
mellitus I-Disease 1 1.0
and O 0 0.00021058869606349617
progressive O 1 0.9337031841278076
optic B-Disease 1 0.9999986886978149
atrophy I-Disease 1 0.9975531697273254
. O 0 9.89013187790988e-07

Linkage O 0 4.525065014604479e-05
to O 0 3.0928029559618153e-07
markers O 0 1.2432122957761749e-06
on O 0 7.447943772831422e-08
chromosome O 0 0.00010438160097692162
4p O 0 0.0002036806254182011
was O 0 5.052987148701504e-07
confirmed O 0 4.3456651610540575e-08
in O 0 3.0784039206643854e-10
five O 0 2.643919749800716e-09
families O 0 4.731987246486824e-09
. O 0 1.6481800813039627e-08

On O 0 4.9761947451543165e-08
the O 0 8.775212223532947e-10
basis O 0 3.664707981521076e-10
of O 0 7.46408837515311e-11
meiotic O 0 4.6362274019884353e-07
recombinants O 0 0.00032257637940347195
and O 0 1.2572143077704823e-06
disease O 0 1.2646985851461068e-05
- O 0 5.922598938923329e-05
associated O 0 1.137486378866015e-06
haplotypes O 0 2.8734082206938183e-06
, O 0 1.0021836693852038e-09
the O 0 1.2700621110361965e-10
WFS B-Disease 0 1.3573827573054587e-07
gene O 0 3.014140048662739e-09
was O 0 2.722565728419113e-09
localized O 0 8.467920586952005e-09
to O 0 4.132503672593657e-09
a O 0 7.25688238389921e-08
BAC O 0 3.189938433934003e-05
/ O 0 1.684704784565838e-07
P1 O 0 2.3666127901833534e-07
contig O 0 1.5305553802136274e-07
of O 0 5.79645290099684e-11
less O 0 1.4187124808273666e-09
than O 0 1.5010562792738824e-09
250 O 0 6.766827098658723e-09
kb O 0 4.029648152936716e-06
. O 0 4.291237587494834e-08

Mutations O 0 0.00044237799011170864
in O 0 1.861558196480928e-08
a O 0 2.028007628496198e-08
novel O 0 7.443583882604798e-08
gene O 0 2.0735281935913008e-08
( O 0 5.633655209003052e-10
WFS1 O 0 7.97278516984079e-07
) O 0 9.942949241725785e-11
encoding O 0 1.5223785565510184e-09
a O 0 1.3664146480962813e-09
putative O 0 2.8140849650526434e-08
transmembrane O 0 1.3357453809703657e-08
protein O 0 1.949474359719261e-09
were O 0 7.566956505833389e-10
found O 0 4.614766346833221e-10
in O 0 5.182189052876929e-11
all O 0 7.786720573887962e-11
affected O 0 1.2737745302970893e-09
individuals O 0 1.7248859285334817e-10
in O 0 4.040516254910642e-10
six O 0 1.6187076568030534e-08
WFS B-Disease 0 2.8159965950180776e-06
families O 0 7.486695707825675e-09
, O 0 1.8994529560334428e-10
and O 0 3.130928016847889e-10
these O 0 1.029485455217305e-10
mutations O 0 5.607478925639953e-09
were O 0 7.207286434329774e-10
associated O 0 4.941487774523523e-10
with O 0 8.416694563528893e-10
the O 0 1.5393649732686754e-07
disease O 0 0.027239328250288963
phenotype O 0 0.042792096734046936
. O 0 1.1433414925932084e-07

WFS1 O 0 0.0005062062991783023
appears O 0 3.1873946682026144e-06
to O 0 1.2099350854555269e-08
function O 0 1.8771957321916943e-09
in O 0 5.666437874474184e-10
survival O 0 4.0537354806247095e-08
of O 0 1.4496598366164903e-10
islet O 0 1.2192593885629321e-06
beta O 0 8.403914009136315e-09
- O 0 2.568382626577659e-07
cells O 0 3.120997860150965e-08
and O 0 2.429364487355201e-09
neurons O 0 1.4968200900966622e-08
. O 0 5.544176784333388e-10
. O 0 5.1515649523992124e-09

Stable O 0 4.7462937800446525e-05
interaction O 0 7.091765752420542e-08
between O 0 2.1624613211201904e-09
the O 0 2.154374734164577e-10
products O 0 9.963780911448339e-10
of O 0 2.799049360346917e-11
the O 0 5.156683968721154e-10
BRCA1 O 0 1.7714227169562946e-06
and O 0 2.155996448038877e-08
BRCA2 O 0 2.240551566501381e-06
tumor B-Disease 0 4.0269259216074715e-07
suppressor O 0 4.0147781987798226e-07
genes O 0 1.0719063858743993e-08
in O 0 2.663557430171437e-10
mitotic O 0 1.1077566597350597e-07
and O 0 1.3825273370571267e-08
meiotic O 0 2.769353159237653e-06
cells O 0 1.8292073491465999e-06
. O 0 7.289845171953857e-08

BRCA1 O 0 0.009737594053149223
and O 0 8.089053267212876e-07
BRCA2 O 0 3.495699957056786e-06
account O 0 1.4951964999454503e-08
for O 0 2.41238501397234e-10
most O 0 6.920176098823561e-10
cases O 0 1.2476277788664447e-09
of O 0 6.81984052564033e-11
familial O 0 9.641845508667757e-07
, O 0 4.138025033739723e-09
early O 0 1.9490403957433955e-08
onset O 0 1.195050026581157e-05
breast B-Disease 1 0.9905833005905151
and I-Disease 0 2.485315599187743e-05
/ I-Disease 0 0.1250675767660141
or I-Disease 0 0.05275703966617584
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
and O 0 3.5318334923317707e-09
encode O 0 5.792369250912088e-09
products O 0 4.456683910802894e-09
that O 0 4.565232636366545e-10
each O 0 9.282973695290409e-11
interact O 0 3.523945579786414e-10
with O 0 8.616323765586742e-10
hRAD51 O 0 2.4711985133762937e-06
. O 0 3.383897606568098e-08

Results O 0 2.2039541818230646e-06
presented O 0 1.9689444741288753e-08
here O 0 8.190168543364962e-10
show O 0 6.055202117494218e-09
that O 0 1.5785066587170604e-09
BRCA1 O 0 2.1051819487638568e-07
and O 0 1.424477780176403e-08
BRCA2 O 0 7.716833465565287e-07
coexist O 0 4.8075712300033047e-08
in O 0 1.726222220721496e-10
a O 0 1.7057474321902077e-09
biochemical O 0 2.9027436454498456e-08
complex O 0 2.9073798923917593e-09
and O 0 3.620287847283521e-09
colocalize O 0 5.745333169215883e-07
in O 0 1.3174812352190202e-09
subnuclear O 0 4.1735498257367e-07
foci O 0 1.1463232141295521e-07
in O 0 4.257619257153067e-10
somatic O 0 4.59329143609466e-08
cells O 0 2.2911974539852054e-08
and O 0 6.738591351584944e-10
on O 0 1.1775052044527001e-09
the O 0 1.5835568967226266e-10
axial O 0 1.4894673938670167e-07
elements O 0 4.294764543999463e-09
of O 0 1.552596523568539e-10
developing O 0 7.534211476922792e-09
synaptonemal O 0 1.0391024716227548e-06
complexes O 0 1.6510156797266973e-07
. O 0 3.0726642563649875e-08

Like O 0 1.0771241250040475e-06
BRCA1 O 0 2.3273745682672597e-05
and O 0 1.8740205121048348e-07
RAD51 O 0 7.97479588072747e-05
, O 0 3.164244688491635e-08
BRCA2 O 0 8.220426366278843e-07
relocates O 0 5.274256409393274e-07
to O 0 5.647539680353475e-08
PCNA O 0 4.65360562884598e-06
+ O 0 6.889507186969013e-09
replication O 0 1.5626478999664073e-09
sites O 0 9.901187647542997e-10
following O 0 5.491292975889905e-10
exposure O 0 8.942422802249439e-09
of O 0 5.627337484881423e-11
S O 0 2.1909350778059888e-07
phase O 0 8.480269819699515e-09
cells O 0 1.5932380748040487e-08
to O 0 5.648742806840801e-09
hydroxyurea O 0 1.486160635977285e-05
or O 0 2.2194344140302746e-08
UV O 0 0.00019829421944450587
irradiation O 0 1.206189608637942e-05
. O 0 1.037181291962952e-07

Thus O 0 4.619263108907035e-06
, O 0 4.411809939597333e-08
BRCA1 O 0 6.358758355418104e-07
and O 0 6.474599523187408e-09
BRCA2 O 0 1.7425648479729716e-07
participate O 0 1.322370324352562e-09
, O 0 3.6988295759599055e-10
together O 0 4.675883569227324e-10
, O 0 2.0041529547043524e-10
in O 0 1.0872952538321101e-10
a O 0 5.6676725534998695e-09
pathway O 0 8.351613622892273e-09
( O 0 3.2112829062569404e-10
s O 0 2.364295994539134e-07
) O 0 1.4940831905008167e-10
associated O 0 7.572703020208849e-10
with O 0 2.521198180782669e-11
the O 0 8.191535123824867e-12
activation O 0 1.691181639174033e-10
of O 0 2.1003934702612526e-11
double O 0 2.3610034816101688e-08
- O 0 2.0834845599893015e-06
strand O 0 1.297305630032497e-06
break O 0 7.352122821657758e-08
repair O 0 1.1013748917321209e-06
and O 0 7.187604733616126e-09
/ O 0 1.7213972469676264e-08
or O 0 4.799934338883816e-10
homologous O 0 1.3299796819410403e-08
recombination O 0 9.78140164420438e-08
. O 0 8.775538162808516e-08

Dysfunction O 0 0.0015930329682305455
of O 0 6.0783453825763445e-09
this O 0 1.0329358479665984e-09
pathway O 0 8.216521685255884e-09
may O 0 2.4999410541681755e-08
be O 0 8.448315935716266e-10
a O 0 1.2934608939474401e-09
general O 0 1.399925841916172e-09
phenomenon O 0 8.709517551608315e-09
in O 0 3.374664159228047e-10
the O 0 1.2003029126184117e-10
majority O 0 2.1255839310896363e-09
of O 0 2.5817448873199922e-11
cases O 0 1.3894475570097597e-09
of O 0 1.2629317591716926e-09
hereditary B-Disease 1 0.9984288811683655
breast I-Disease 1 0.9994692206382751
and I-Disease 0 0.0007369827944785357
/ I-Disease 1 0.9425609707832336
or I-Disease 1 0.505029559135437
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
. O 0 4.7135866765302126e-08
. O 0 1.8290238656959446e-08

A O 0 2.1392506823758595e-06
novel O 0 8.173928449650703e-07
Arg362Ser O 0 2.8476588340708986e-06
mutation O 0 3.2304967589880107e-07
in O 0 3.632306955214659e-10
the O 0 2.685077715725015e-10
sterol O 0 1.6366557247238234e-05
27 O 0 2.8437216315069236e-07
- O 0 3.983003011853725e-07
hydroxylase O 0 3.160304913762957e-06
gene O 0 2.3238364121880295e-08
( O 0 2.0749424400889893e-10
CYP27 O 0 2.594732961824775e-07
) O 0 9.519929983214936e-11
: O 0 1.5450626889013108e-11
its O 0 5.649103754223894e-11
effects O 0 8.081302738105478e-09
on O 0 2.0930770450178215e-09
pre O 0 2.6148983423013306e-08
- O 0 3.621608613002536e-08
mRNA O 0 1.6380500289514544e-09
splicing O 0 8.597252687536638e-09
and O 0 1.9557973296446818e-10
enzyme O 0 2.652385200363483e-09
activity O 0 4.054785396334637e-09
. O 0 4.231455630332448e-09

A O 0 3.55560132447863e-06
novel O 0 8.772389605837816e-07
C O 0 7.080953423610481e-08
to O 0 1.3856946701196193e-09
A O 0 1.574138863702501e-08
mutation O 0 8.646014038049543e-08
in O 0 4.66647553931665e-10
the O 0 1.0012283224725138e-09
sterol O 0 9.840895654633641e-05
27 O 0 4.232539652093692e-07
- O 0 4.902514092464116e-07
hydroxylase O 0 7.5566317718767095e-06
gene O 0 4.480029858200396e-08
( O 0 5.949111758773995e-10
CYP27 O 0 3.9994998246584146e-07
) O 0 2.2890284112619952e-10
was O 0 8.716830812716125e-09
identified O 0 1.1619569750820347e-09
by O 0 3.235085116459757e-11
sequencing O 0 3.571980045080636e-09
amplified O 0 2.664190787982079e-07
CYP27 O 0 5.385040253713669e-07
gene O 0 1.1552351963928231e-08
products O 0 2.236772100872031e-09
from O 0 6.364664351110605e-11
a O 0 1.0852575726971736e-08
patient O 0 4.6068969822954386e-05
with O 0 3.388839218132489e-07
cerebrotendinous B-Disease 1 0.9999978542327881
xanthomatosis I-Disease 1 0.9999896287918091
( O 0 6.305189970134961e-08
CTX B-Disease 0 0.0003027363563887775
) O 0 4.19494234904505e-08
. O 0 5.572552552735033e-08

The O 0 4.43253398429988e-08
mutation O 0 6.660102371824905e-07
changed O 0 1.203963595486357e-08
the O 0 1.7334741975183476e-10
adrenodoxin O 0 1.4320488617158844e-07
cofactor O 0 1.1350347506322578e-07
binding O 0 2.1078571776911303e-08
residue O 0 6.883178826910807e-08
362Arg O 0 2.004702253088908e-07
to O 0 1.0040534625943565e-08
362Ser O 0 3.5636057305055147e-07
( O 0 9.971878878189955e-10
CGT O 0 2.7421504000813e-07
362Arg O 0 2.6326097213313915e-07
to O 0 5.0815249785785e-09
AGT O 0 6.927576805537683e-07
362Ser O 0 4.190172546714166e-07
) O 0 7.675600155465645e-10
, O 0 5.102374633914053e-10
and O 0 8.186638589258166e-10
was O 0 4.1059969646539685e-08
responsible O 0 5.720804274744751e-09
for O 0 1.6118089085637166e-09
deficiency O 0 1.915386604878222e-07
in O 0 1.390968867864828e-10
the O 0 4.044147794424191e-10
sterol O 0 5.614926521957386e-06
27 O 0 3.104137746845481e-08
- O 0 4.1509277792783905e-08
hydroxylase O 0 1.7093937287882e-07
activity O 0 7.594168072166951e-10
, O 0 4.671967673841593e-11
as O 0 1.659126169784031e-10
confirmed O 0 1.7282194564316455e-09
by O 0 2.943096114038646e-11
expression O 0 1.1823318712966824e-10
of O 0 3.912779388687282e-12
mutant O 0 1.0961475060966563e-09
cDNA O 0 1.6076148190435902e-09
into O 0 3.808171833430407e-10
COS O 0 2.1109960357534874e-07
- O 0 2.1203945266279334e-07
1 O 0 1.0443629960832368e-08
cells O 0 6.605513647173211e-08
. O 0 1.8661655332152804e-08

Quantitative O 0 1.2398567150739837e-06
analysis O 0 2.3030321472106152e-07
showed O 0 1.0223485702454127e-07
that O 0 2.3220088352093882e-10
the O 0 3.56302175263945e-11
expression O 0 9.416349922020117e-10
of O 0 1.9526356226373665e-11
CYP27 O 0 1.0345831213953716e-07
gene O 0 1.0299062713770013e-09
mRNA O 0 5.04416175495237e-10
in O 0 7.416222497225178e-11
the O 0 1.462440446520219e-10
patient O 0 2.8758159942299244e-07
represented O 0 1.7989577827393077e-08
52 O 0 1.838248664398634e-07
. O 0 1.4233914491512678e-08

5 O 0 1.7956655256057275e-06
% O 0 1.0122853666416631e-08
of O 0 1.4025630656888666e-10
the O 0 3.3945216082464924e-10
normal O 0 1.4552463234451807e-08
level O 0 8.317498689791591e-09
. O 0 3.1284418611221554e-08

As O 0 1.6520677093012637e-07
the O 0 1.5487641169542599e-09
mutation O 0 3.8396983370603266e-08
occurred O 0 2.020770883959244e-09
at O 0 5.30893766448326e-11
the O 0 3.5073808440921894e-11
penultimate O 0 8.06450373147527e-09
nucleotide O 0 1.964816753741161e-09
of O 0 1.1620960443936568e-10
exon O 0 1.1886370998581697e-08
6 O 0 1.5831048694181504e-09
( O 0 7.708578220189111e-11
- O 0 6.266476049177072e-08
2 O 0 3.905932466352624e-09
position O 0 9.326357464090052e-09
of O 0 4.012314092083358e-11
exon O 0 1.1284117640286695e-08
6 O 0 3.5363092454332445e-09
- O 0 3.40519896724345e-08
intron O 0 7.867885187806678e-07
6 O 0 3.528103365013635e-09
splice O 0 3.7400361918571434e-08
site O 0 3.3435409996229737e-09
) O 0 2.8847297814382777e-11
of O 0 6.539761353979712e-12
the O 0 6.4864835724876e-11
gene O 0 1.5693953914208691e-09
, O 0 1.314308106792339e-10
we O 0 1.27259355831022e-10
hypothesized O 0 2.3295556594860045e-09
that O 0 9.550502749755552e-11
the O 0 1.364127560909978e-10
mutation O 0 5.3211209660730674e-08
may O 0 2.0259120603327574e-08
partially O 0 8.932880035672497e-08
affect O 0 1.2422637363229683e-09
the O 0 5.0715761451547436e-11
normal O 0 5.120283641524281e-10
splicing O 0 6.157013565655234e-09
efficiency O 0 1.384722447816955e-09
in O 0 1.0444536208131794e-10
exon O 0 1.7400349605622978e-08
6 O 0 2.657722708576671e-09
and O 0 5.021411064731751e-10
cause O 0 2.897023065884241e-09
alternative O 0 1.2788038405986413e-09
splicing O 0 1.0189899590784535e-08
elsewhere O 0 7.971005189233438e-09
, O 0 1.380249525784194e-10
which O 0 2.1110538317437033e-10
resulted O 0 1.7775644289841352e-09
in O 0 6.736740609802894e-10
decreased O 0 8.738508228134378e-08
transcript O 0 3.079810539929895e-08
in O 0 2.1999940758021808e-10
the O 0 6.987380674061683e-10
patient O 0 3.0191010864655254e-06
. O 0 1.6412409209465295e-08

Transfection O 0 0.00013251737982500345
of O 0 8.302254883574278e-08
constructed O 0 5.22336961239489e-07
minigenes O 0 7.632170309079811e-06
, O 0 1.3877736737555324e-09
with O 0 9.825217722747581e-11
or O 0 1.197435345323683e-10
without O 0 2.784248109843901e-10
the O 0 7.666963591779208e-11
mutation O 0 1.0954354756620432e-08
, O 0 1.2823447859133807e-10
into O 0 3.507369117361492e-10
COS O 0 2.2701505031363922e-07
- O 0 2.6260173058290093e-07
1 O 0 1.7680390484997588e-09
cells O 0 2.2346058337063823e-09
confirmed O 0 1.938432747650154e-09
that O 0 1.863072196517379e-11
the O 0 1.5388100516045e-11
mutant O 0 9.126313038620992e-09
minigene O 0 4.113836027386242e-08
was O 0 8.509514870524981e-09
responsible O 0 7.154992154312367e-10
for O 0 2.998500059359088e-11
a O 0 2.6935514929604665e-10
mRNA O 0 1.0654482851535363e-09
species O 0 9.492859276427623e-11
alternatively O 0 2.7001421099015488e-09
spliced O 0 3.867261284540291e-07
at O 0 2.2331390903129744e-10
an O 0 4.706089962169813e-10
activated O 0 7.857839534608502e-08
cryptic O 0 3.905986289964858e-08
5 O 0 3.9740818968958536e-10
splice O 0 1.937893756576159e-08
site O 0 8.048276711747349e-09
88 O 0 1.5889288107473476e-08
bp O 0 8.686909325206216e-08
upstream O 0 2.1066746125342206e-09
from O 0 6.102966743082305e-11
the O 0 3.494999775699448e-11
3 O 0 2.666764864489579e-10
end O 0 2.6964763755188415e-10
of O 0 1.6757818743773356e-10
exon O 0 1.8142750946026354e-07
6 O 0 4.824915222911841e-08
. O 0 9.992827898486212e-09

Our O 0 1.1395120225188293e-07
data O 0 7.536280932640693e-09
suggest O 0 3.132171855213528e-09
that O 0 6.518842410319081e-11
the O 0 3.317670096980585e-11
C O 0 2.598752546489891e-09
to O 0 6.188374812587938e-10
A O 0 3.3360002760218777e-08
mutation O 0 3.5629454941954464e-08
at O 0 6.046586842334278e-11
the O 0 2.2660519294337433e-11
penultimate O 0 4.827121813377744e-09
nucleotide O 0 2.2026656054663363e-09
of O 0 3.8521335427033065e-11
exon O 0 1.311359554279079e-08
6 O 0 4.0992945149476157e-10
of O 0 1.3552419603213295e-11
the O 0 8.600360007493535e-11
CYP27 O 0 4.5123346126274555e-07
gene O 0 6.5314198494093034e-09
not O 0 1.8833463677481177e-09
only O 0 5.746555453711721e-10
causes O 0 3.5206420001543393e-09
the O 0 2.298356838181803e-09
deficiency B-Disease 0 1.7573825061845127e-06
in I-Disease 0 1.231676843849172e-10
the I-Disease 0 4.308661205598696e-10
sterol I-Disease 0 1.0108006790687796e-05
27 I-Disease 0 5.8779356493232626e-08
- I-Disease 0 4.2035924963101934e-08
hydroxylase I-Disease 0 3.3160719681291084e-07
activity I-Disease 0 2.4564263956250443e-09
, O 0 1.82840104168136e-10
but O 0 6.458869550307611e-10
also O 0 3.931892145203619e-09
partially O 0 8.817449526077326e-08
leads O 0 2.7885118658588226e-09
to O 0 2.5437565942532103e-10
alternative O 0 6.424932808002382e-10
pre O 0 6.492889781384292e-09
- O 0 1.55256838496598e-08
mRNA O 0 6.352915415952509e-10
splicing O 0 3.413729299239776e-09
of O 0 2.2943338201519836e-11
the O 0 6.88498077994204e-11
gene O 0 1.8391826728247906e-08
. O 0 6.164569743560833e-09

To O 0 2.1650362214131746e-07
our O 0 2.360803996737104e-09
knowledge O 0 1.3202879067808482e-10
, O 0 2.295839733601479e-11
this O 0 1.5139015041576442e-11
is O 0 9.446872450968868e-11
the O 0 1.3262285367132698e-11
first O 0 3.818937110988685e-10
report O 0 1.326570658877202e-10
regarding O 0 7.798194728847463e-11
effects O 0 9.839437042913346e-10
on O 0 8.392568862092276e-10
pre O 0 7.4102630698291705e-09
- O 0 4.9433093174400256e-09
mRNA O 0 1.9203333367912023e-10
splicing O 0 1.1199802196770747e-09
of O 0 8.771856505052078e-12
a O 0 1.2722345399396318e-10
mutation O 0 1.015192929720854e-09
at O 0 1.109698097301326e-11
the O 0 4.850818358104192e-11
- O 0 1.8388780631539703e-07
2 O 0 4.697357613991926e-09
position O 0 8.339324786277302e-09
of O 0 3.13136842844397e-11
a O 0 2.9380513577592637e-09
5 O 0 1.8952088787216326e-09
splice O 0 4.464773439849523e-07
site O 0 2.0040695858369872e-07
. O 0 1.947761951726079e-08

ATM O 0 6.698995275655761e-05
germline O 0 0.000336568511556834
mutations O 0 0.0006490214145742357
in O 0 4.042247780944308e-07
classical O 0 0.08372253179550171
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
patients O 1 0.9999969005584717
in O 0 4.839225464792207e-09
the O 0 1.7574450783541806e-09
Dutch O 0 0.0001067749981302768
population O 0 2.5668613901075332e-08
. O 0 1.4453984675810716e-08

Germline O 0 0.001058900379575789
mutations O 0 0.0016813063994050026
in O 0 1.3489051653436945e-08
the O 0 4.2358544449783153e-10
ATM O 0 2.388397035701928e-08
gene O 0 7.450441597001145e-09
are O 0 1.0555243484811072e-10
responsible O 0 1.0103599068500557e-09
for O 0 1.287136064398453e-09
the O 0 7.211952834040858e-06
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
disorder I-Disease 1 1.0
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 0 0.00032224933966062963
A B-Disease 1 0.9999997615814209
- I-Disease 1 0.9999980926513672
T I-Disease 1 0.9999997615814209
) O 0 1.3523627728773135e-07
. O 0 6.289934617598192e-08

In O 0 2.5863380415103165e-07
our O 0 6.714781619621135e-09
study O 0 4.943024323189604e-10
, O 0 4.12530148929946e-11
we O 0 9.14767012138995e-11
have O 0 2.0202610417907607e-10
determined O 0 2.173808688610279e-09
the O 0 4.733661726485927e-11
ATM O 0 1.77849113214279e-08
mutation O 0 4.003078402092797e-08
spectrum O 0 1.1021881185513394e-08
in O 0 2.2125257181926372e-10
19 O 0 3.246140023449584e-09
classical O 0 5.8272231484579606e-08
A B-Disease 1 0.9999992847442627
- I-Disease 1 0.9999997615814209
T I-Disease 1 1.0
patients O 1 0.9854766726493835
, O 0 1.295472618068061e-10
including O 0 1.5478797063539496e-11
some O 0 1.1814527134390573e-10
immigrant O 0 4.165712041981351e-08
populations O 0 1.3115690755682863e-09
, O 0 7.517279854152292e-11
as O 0 3.7416308940052545e-10
well O 0 6.580169742420594e-10
as O 0 5.712688655457043e-10
12 O 0 1.4570446238426626e-10
of O 0 2.1224948881792827e-11
Dutch O 0 2.030792529694736e-06
ethnic O 0 6.987477707554035e-09
origin O 0 1.5100653172339662e-08
. O 0 8.90640361461692e-09

Both O 0 1.3325980319223163e-07
the O 0 1.5676482334470165e-09
protein O 0 7.175920302415761e-09
truncation O 0 1.2802522064703226e-07
test O 0 6.279470454728653e-08
( O 0 4.393373997935157e-10
PTT O 0 7.911723542974869e-08
) O 0 1.0358355839734656e-10
and O 0 9.17603146244339e-11
the O 0 2.7741751604248854e-11
restriction O 0 8.459219102974203e-09
endonuclease O 0 8.976489880296867e-07
fingerprinting O 0 1.1720233317191742e-07
( O 0 3.222849209727485e-10
REF O 0 2.083294816657144e-07
) O 0 8.917614563452858e-11
method O 0 2.532188458914675e-09
were O 0 1.715797504076022e-09
used O 0 3.135166348755547e-09
and O 0 8.243674631813747e-10
compared O 0 2.8058833034805275e-09
for O 0 6.536347851859858e-11
their O 0 5.6550004262634346e-11
detection O 0 1.0866862965031032e-09
efficiency O 0 1.0290893692754821e-09
, O 0 3.6963595378969316e-11
identifying O 0 3.123662717374742e-10
76 O 0 4.5316088659319576e-09
% O 0 7.714284766535684e-11
and O 0 4.945768794506478e-10
60 O 0 2.5671538228522195e-09
% O 0 3.941423923348175e-11
of O 0 4.39318460082605e-12
the O 0 4.738985315277944e-10
mutations O 0 1.825615782991008e-07
, O 0 2.936678900056222e-09
respectively O 0 2.8183876565890387e-08
. O 0 2.6815541787073016e-08

Most O 0 1.5138053640839644e-05
patients O 0 0.00024640970514155924
were O 0 4.5260288850101915e-09
found O 0 7.994296336022444e-10
to O 0 7.979306659855467e-10
be O 0 7.231856002931636e-09
compound O 0 4.1233028014175943e-07
heterozygote O 0 1.320853152719792e-05
. O 0 6.93007535801371e-08

Seventeen O 0 1.0272531653754413e-05
mutations O 0 6.124354968051193e-06
were O 0 2.265895382436156e-08
distinct O 0 3.47662654220926e-09
, O 0 3.562289629943649e-10
of O 0 3.189282171689456e-11
which O 0 1.2760463796723798e-08
10 O 0 1.108098057756024e-09
were O 0 2.7780220346329543e-09
not O 0 7.821350678227645e-09
reported O 0 4.1697504116200435e-08
previously O 0 2.7664858848197582e-08
. O 0 2.4593434844177864e-08

Mutations O 0 0.0006676306365989149
are O 0 1.4675833881483413e-08
small O 0 1.900077206684614e-09
deletions O 0 2.190224819287323e-07
or O 0 4.60028592996764e-09
point O 0 4.911180084832267e-08
mutations O 0 1.3154074167687213e-06
frequently O 0 1.53635838273658e-07
affecting O 0 3.003118109745628e-08
splice O 0 2.8805557121813763e-06
sites O 0 7.479804509102905e-08
. O 0 3.748070298570383e-08

Moreover O 0 1.0234747605863959e-05
, O 0 3.0445743703921835e-08
a O 0 2.1186636445236218e-08
16 O 0 5.1608910922595896e-08
. O 0 4.365812245055167e-08

7 O 0 4.050910320074763e-06
- O 0 3.1737331482872833e-06
kb O 0 1.1142999483126914e-06
genomic O 0 4.75626755758185e-08
deletion O 0 6.350619230488519e-08
of O 0 1.0475459388814556e-10
the O 0 5.6525853442401797e-11
3 O 0 4.256157648541148e-10
end O 0 3.062112508001036e-10
of O 0 1.6587108422894126e-11
the O 0 3.604086820652164e-11
gene O 0 5.771633171391954e-10
, O 0 6.172422295502855e-11
most O 0 4.432814532107088e-11
likely O 0 1.7197916424294135e-09
a O 0 6.165083443754327e-10
result O 0 5.724293261621938e-10
of O 0 9.652226934386832e-12
recombination O 0 3.5271058296260094e-10
between O 0 2.046392361121363e-10
two O 0 1.6475694142314978e-09
LINE O 0 8.495878773828736e-07
elements O 0 7.26318027943762e-09
, O 0 9.769609565779547e-10
was O 0 1.7300811805398553e-07
identified O 0 4.064311198703763e-08
. O 0 3.7190210910864607e-09

The O 0 6.084843562348397e-08
most O 0 1.552340478383485e-08
frequently O 0 9.00752681332051e-08
found O 0 7.619446407147734e-09
mutation O 0 2.94690902791217e-08
, O 0 1.1360316160002881e-10
identified O 0 1.4200878251102722e-09
in O 0 4.363973765686424e-11
three O 0 1.0149679013915502e-10
unrelated O 0 4.345008353112689e-09
Turkish O 0 5.22557911608601e-06
A B-Disease 1 0.9999885559082031
- I-Disease 1 0.9998795986175537
T I-Disease 1 0.9999997615814209
individuals O 0 1.6988195739031653e-08
, O 0 1.5257177465866079e-10
was O 0 3.5455030911180074e-08
previously O 0 3.160461004014792e-09
described O 0 1.6334513741611545e-09
to O 0 2.737122195561881e-10
be O 0 3.538385695556201e-10
a O 0 3.6363223543389722e-09
Turkish O 0 3.332727283122949e-05
A B-Disease 1 0.999995231628418
- I-Disease 1 0.9999779462814331
T I-Disease 1 0.9999997615814209
founder O 0 2.9612732760142535e-05
mutation O 0 8.727795375307323e-07
. O 0 1.3978053381435984e-08

The O 0 2.3409057803291944e-08
presence O 0 8.09260924938826e-09
of O 0 6.198318247552237e-11
a O 0 2.6446560497106475e-09
founder O 0 8.754824420975638e-08
mutation O 0 3.9916344007906446e-08
among O 0 4.600300973489624e-10
relatively O 0 1.2498905244129332e-09
small O 0 4.308159939903078e-10
ethnic O 0 2.908810969870501e-09
population O 0 9.90931114941418e-10
groups O 0 1.0676488859662214e-10
in O 0 1.1423872264826329e-10
Western O 0 9.277739132507179e-10
Europe O 0 9.073128359737836e-10
could O 0 3.161461981093794e-09
indicate O 0 8.565266274018768e-10
a O 0 9.734937300720503e-10
high O 0 1.0981591636038956e-08
carrier O 0 6.831032806076109e-07
frequency O 0 6.85488004137369e-08
in O 0 2.2625375184492924e-10
such O 0 2.0920462584506083e-10
communities O 0 5.867224484035205e-09
. O 0 9.687597390950486e-09

In O 0 1.3809166148348595e-06
patients O 0 2.0485074855969287e-05
of O 0 2.3809076932224116e-10
Dutch O 0 2.305476755282143e-06
ethnic O 0 1.6644433387114077e-08
origin O 0 4.813413667648092e-09
, O 0 6.079652337120933e-10
however O 0 1.3164210832528056e-09
, O 0 7.85659870494726e-11
no O 0 1.520018971801207e-10
significant O 0 2.1309901065968972e-10
founder O 0 2.789384279111573e-09
effect O 0 4.1624850233290545e-09
could O 0 1.7262040685750435e-08
be O 0 4.668613939884381e-09
identified O 0 6.162020582678451e-08
. O 0 6.940377161868128e-09

The O 0 4.860021718400276e-08
observed O 0 3.544995763604675e-08
genetic O 0 1.5957198229443748e-08
heterogeneity O 0 4.563426614367927e-08
including O 0 6.162308996415788e-10
the O 0 3.6611799703045733e-10
relative O 0 2.206644644786593e-08
high O 0 9.12377196016223e-09
percentage O 0 2.3378037283805497e-09
of O 0 4.237234174642168e-11
splice O 0 3.3524131026752e-07
- O 0 5.225130735198036e-06
site O 0 2.872992297398014e-07
mutations O 0 9.245402310398276e-08
had O 0 2.0150832114040895e-08
no O 0 7.547641955873985e-10
reflection O 0 5.2073212408743075e-09
on O 0 3.769260015218379e-09
the O 0 7.010304781118748e-09
phenotype O 0 0.00041941512608900666
. O 0 4.4326100123726064e-08

All O 0 7.04568208220735e-07
patients O 0 3.053340333281085e-05
manifested O 0 4.062769392021437e-07
classical O 0 1.842800116946819e-07
A B-Disease 1 0.9999618530273438
- I-Disease 1 0.9999140501022339
T I-Disease 1 0.9999995231628418
and O 0 2.1043449294211314e-07
increased O 0 2.369453255823828e-08
cellular O 0 6.130134977411217e-08
radioresistant O 0 3.3063835758184723e-07
DNA O 0 6.151498865847316e-08
synthesis O 0 1.0667609018355506e-07
. O 0 2.2795370924200142e-08

Determination O 0 1.3896643395128194e-05
of O 0 3.821357896782729e-09
the O 0 2.8905802751388876e-10
genomic O 0 4.291128785638421e-09
structure O 0 2.8855691169837883e-09
of O 0 1.7344722880174857e-11
the O 0 1.1472216926433632e-10
COL4A4 O 0 2.315431856914074e-06
gene O 0 7.74817898729907e-09
and O 0 1.4733989028847816e-10
of O 0 5.8190504498289997e-11
novel O 0 2.654132913448848e-07
mutations O 0 1.9310004063299857e-05
causing O 0 1.2565344150061719e-05
autosomal B-Disease 1 0.9999610185623169
recessive I-Disease 1 0.9999992847442627
Alport I-Disease 1 1.0
syndrome I-Disease 1 0.9999998807907104
. O 0 2.6219186111120507e-06

Autosomal B-Disease 1 0.9999974966049194
recessive I-Disease 1 0.9999998807907104
Alport I-Disease 1 1.0
syndrome I-Disease 1 1.0
is O 0 7.915820788184647e-06
a O 0 2.669684363354463e-06
progressive O 1 0.5244967937469482
hematuric B-Disease 1 0.999482274055481
glomerulonephritis I-Disease 1 0.9999998807907104
characterized O 0 0.05117029324173927
by O 0 1.2615413425010047e-07
glomerular B-Disease 0 0.001689100987277925
basement I-Disease 0 0.00109683140181005
membrane I-Disease 0 0.0018838400719687343
abnormalities I-Disease 1 0.9950827360153198
and O 0 4.63378491133426e-09
associated O 0 4.451509827418931e-09
with O 0 5.226244437217531e-10
mutations O 0 7.240430477395421e-08
in O 0 2.998604697879159e-10
either O 0 1.437641450330318e-09
the O 0 3.122143932277055e-10
COL4A3 O 0 6.694107923976844e-06
or O 0 4.104802608928537e-10
the O 0 1.8539381141380318e-10
COL4A4 O 0 6.424344860533893e-07
gene O 0 6.344756720011446e-09
, O 0 5.163718411194118e-11
which O 0 1.4045059386347258e-11
encode O 0 2.1820244222592322e-10
the O 0 1.2554761397165493e-10
alpha3 O 0 2.90871895458622e-07
and O 0 2.256793418808911e-09
alpha4 O 0 5.265903837425867e-07
type O 0 5.553167170546658e-07
IV O 0 0.0012995764845982194
collagen O 0 1.833009264373686e-05
chains O 0 2.3997567950573284e-06
, O 0 1.3956068523057752e-09
respectively O 0 7.979934935065103e-09
. O 0 7.089004494531537e-09

To O 0 9.099930764477904e-08
date O 0 1.0401405958759824e-08
, O 0 6.012181308356901e-10
mutation O 0 5.158801386073719e-09
screening O 0 3.110062429811933e-09
in O 0 1.224457757409425e-10
the O 0 5.4105601943188475e-11
two O 0 2.1427484786507023e-10
genes O 0 1.3091296935385799e-09
has O 0 5.0616105085055096e-08
been O 0 1.0959996465942368e-08
hampered O 0 2.229766806749467e-07
by O 0 8.846415266994256e-10
the O 0 1.9493692771099802e-10
lack O 0 7.670712398599733e-10
of O 0 1.8401063658912697e-11
genomic O 0 8.94162077713645e-09
structure O 0 1.4219532218362474e-08
information O 0 2.079820982103797e-09
. O 0 5.3403961253195575e-09

We O 0 3.4355846878497687e-07
report O 0 4.424288047033542e-09
here O 0 1.767744839398233e-10
the O 0 2.6484595766484986e-11
complete O 0 5.761756072253377e-10
characterization O 0 3.216091570834578e-08
of O 0 5.6552703492362966e-11
the O 0 1.4909376511162975e-10
48 O 0 2.98530378195494e-09
exons O 0 3.040295792899883e-09
of O 0 3.6834448685629795e-11
the O 0 7.791281508851e-11
COL4A4 O 0 9.41885161864775e-07
gene O 0 7.657793510418287e-09
, O 0 1.5047046941774056e-10
a O 0 2.408472310477805e-10
comprehensive O 0 1.1177052616773153e-09
gene O 0 8.900138404044355e-09
screen O 0 4.889356546300405e-07
, O 0 5.860756879805251e-10
and O 0 1.455869591548975e-10
the O 0 3.0365085446071305e-11
subsequent O 0 5.186968077275367e-10
detection O 0 1.2834662221905546e-09
of O 0 3.247003360629108e-11
10 O 0 1.8149960701041579e-10
novel O 0 3.2113702808089784e-09
mutations O 0 1.1894512930155088e-08
in O 0 2.9422894676223166e-10
eight O 0 1.0574825637377216e-07
patients O 0 0.0009584337240085006
diagnosed O 0 0.0018393726786598563
with O 0 3.692398138355202e-07
autosomal B-Disease 1 0.9999926090240479
recessive I-Disease 1 0.9999997615814209
Alport I-Disease 1 1.0
syndrome I-Disease 1 0.9999998807907104
. O 0 7.758466153973131e-07

Furthermore O 0 3.250384452258004e-06
, O 0 5.1702477854576046e-09
we O 0 2.951575095444525e-10
identified O 0 3.1526264931969195e-10
a O 0 1.5958002974603147e-10
glycine O 0 4.526011565531007e-09
to O 0 9.939787881663165e-10
alanine O 0 1.53869486041458e-08
substitution O 0 1.489011469679724e-09
in O 0 1.5330746394592865e-10
the O 0 2.4096577511123485e-10
collagenous O 0 5.875648412256851e-07
domain O 0 2.7544901914922093e-09
that O 0 3.783887925212781e-10
is O 0 4.385604102097318e-10
apparently O 0 2.1018232487790556e-08
silent O 0 2.2036163116467833e-08
in O 0 9.145995072401547e-11
the O 0 1.630319212964082e-10
heterozygous O 0 6.426948573334812e-08
carriers O 0 1.3853829194943046e-09
, O 0 1.0225675167729875e-10
in O 0 2.0483292839656997e-10
11 O 0 8.340152568564463e-09
. O 0 1.1750781681030276e-08

5 O 0 2.880879719668883e-06
% O 0 2.1870974364901485e-08
of O 0 1.4537578085782599e-10
all O 0 2.4726615199810453e-10
control O 0 4.196710889914357e-08
individuals O 0 8.264266493362982e-10
, O 0 2.321495079504743e-10
and O 0 2.3103854940309532e-10
in O 0 6.305349298241225e-11
one O 0 5.467725161523163e-10
control O 0 7.301127258330098e-09
individual O 0 1.656176307207602e-10
homozygous O 0 3.0417923735370778e-09
for O 0 1.433264791572686e-11
this O 0 3.5627500949431123e-11
glycine O 0 8.235600645889463e-09
substitution O 0 2.4665498088438653e-08
. O 0 1.934348681231768e-08

There O 0 1.5134223758650478e-06
has O 0 4.109898910087395e-08
been O 0 1.6051912021808334e-09
no O 0 2.6843557932032525e-10
previous O 0 2.2376246688882162e-10
finding O 0 1.583955605566345e-10
of O 0 5.598589734173709e-12
a O 0 9.82383063785619e-11
glycine O 0 1.4602281606101997e-09
substitution O 0 1.273716132565994e-09
that O 0 7.916652333683771e-10
is O 0 3.8914077515883605e-10
not O 0 6.366914218070008e-10
associated O 0 2.542805965788375e-10
with O 0 4.7481837905927193e-11
any O 0 7.878001029304471e-10
obvious O 0 2.0594340810475842e-07
phenotype O 0 7.418008317472413e-05
in O 0 4.331281111547014e-09
homozygous O 0 1.3218663070801995e-06
individuals O 0 9.114240917540428e-09
. O 0 1.4830203731719394e-08

Founder O 0 9.024639439303428e-05
BRCA1 O 0 0.0005575138493441045
and O 0 1.839109557977281e-07
BRCA2 O 0 3.867935902235331e-06
mutations O 0 3.332910125664057e-07
in O 0 7.515525091150721e-09
French O 0 4.994576011085883e-05
Canadian O 0 0.02205384522676468
breast B-Disease 1 0.9999538660049438
and I-Disease 1 0.9987707734107971
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
families O 0 3.550843246102886e-07
. O 0 3.6130533231926165e-08

We O 0 3.772301226945274e-07
have O 0 7.467157558949111e-09
identified O 0 5.558749460732315e-09
four O 0 2.019082262494365e-10
mutations O 0 1.791653048144326e-09
in O 0 5.70139734035191e-11
each O 0 6.395049767515815e-11
of O 0 3.575153020851651e-11
the O 0 1.3579505520056045e-08
breast B-Disease 1 0.9997648596763611
cancer I-Disease 0 0.3144514858722687
- O 0 0.02438421919941902
susceptibility O 1 0.8092339634895325
genes O 0 1.9070589019065665e-07
, O 0 2.260774456530612e-09
BRCA1 O 0 2.1348698453493853e-07
and O 0 9.40384481395995e-09
BRCA2 O 0 3.9727868283989665e-07
, O 0 3.186389485598795e-10
in O 0 2.8025978759949055e-10
French O 0 2.2313759018288692e-06
Canadian O 0 5.1047118176938966e-05
breast B-Disease 1 0.9916533827781677
cancer I-Disease 0 0.042297229170799255
and O 0 0.0003150600241497159
breast B-Disease 1 0.9999985694885254
/ I-Disease 1 0.9999994039535522
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 4.0830568082128593e-07
from O 0 1.360223933488669e-08
Quebec O 0 4.94325013278285e-06
. O 0 4.782530282909647e-08

To O 0 7.152160037549038e-07
identify O 0 6.918703547853511e-07
founder O 0 5.26165138126089e-07
effects O 0 1.3288482705320348e-06
, O 0 2.5807429526736314e-09
we O 0 8.855345901004341e-10
examined O 0 2.4612205606899806e-08
independently O 0 1.8514946020786738e-08
ascertained O 0 5.9378152172939735e-08
French O 0 6.334722968404094e-08
Canadian O 0 2.2931654086733033e-07
cancer B-Disease 0 4.1118207150248054e-07
families O 0 5.774429823190985e-10
for O 0 2.5234016265418546e-11
the O 0 3.078965901681663e-11
distribution O 0 6.104480115842748e-11
of O 0 1.3179222470294238e-11
these O 0 7.052153305764364e-11
eight O 0 1.9906183368334496e-09
mutations O 0 4.2129514099542575e-08
. O 0 8.8132257047846e-09

Mutations O 0 0.0009035570546984673
were O 0 4.934240678267088e-07
found O 0 9.602496575666919e-09
in O 0 4.200254311026441e-10
41 O 0 6.24259133275018e-09
of O 0 2.714744540277536e-10
97 O 0 6.340210489952369e-08
families O 0 2.1528652638380663e-08
. O 0 2.568751789056023e-08

Six O 0 3.8022864146114443e-07
of O 0 1.0095738689486211e-09
eight O 0 3.3814893107830812e-09
mutations O 0 2.612998706297276e-08
were O 0 1.6890322473983588e-09
observed O 0 5.553673076974519e-09
at O 0 5.415498605110258e-10
least O 0 7.483426323062758e-09
twice O 0 9.050356197803922e-08
. O 0 1.7503404947660783e-08

The O 0 1.388654027323355e-07
BRCA1 O 0 6.59019451632048e-06
C4446T O 0 1.4115934163783095e-06
mutation O 0 4.945141540702025e-07
was O 0 1.3170045498611671e-08
the O 0 6.787230499849528e-11
most O 0 1.2018613881892293e-09
common O 0 2.1632369229251935e-09
mutation O 0 1.2534655979834497e-07
found O 0 7.865962992070763e-09
, O 0 1.3834756951158766e-10
followed O 0 2.816122335325133e-10
by O 0 1.8651673261427248e-10
the O 0 1.8425596604032535e-09
BRCA2 O 0 4.4010539568262175e-06
8765delAG O 0 1.3557657894125441e-06
mutation O 0 9.757101224749931e-07
. O 0 3.6803672998075854e-08

Together O 0 3.160670871693583e-07
, O 0 1.7467377544377882e-09
these O 0 2.56328736014666e-10
mutations O 0 7.50157624906933e-09
were O 0 1.3457973624397823e-09
found O 0 1.0620944124184462e-09
in O 0 1.8015931801951268e-10
28 O 0 2.5794930635925084e-09
of O 0 5.850969708731668e-11
41 O 0 1.6862616192270252e-08
families O 0 2.804319554350343e-10
identified O 0 7.6413020355659e-10
to O 0 3.440383533614977e-10
have O 0 2.413113264765343e-09
a O 0 1.5612751980143003e-08
mutation O 0 8.586126796217286e-07
. O 0 1.965447538054832e-08

The O 0 6.881498393340735e-08
odds O 0 5.351161007638439e-07
of O 0 4.681246501547776e-10
detection O 0 2.8559139497730257e-09
of O 0 2.7010511882696875e-11
any O 0 1.1121374654532445e-10
of O 0 2.912083421624523e-11
the O 0 3.547785676349946e-10
four O 0 9.46450295913337e-09
BRCA1 O 0 1.0635980061124428e-06
mutations O 0 3.384175784049148e-07
was O 0 1.380304297526891e-07
18 O 0 1.4216412935752487e-08
. O 0 1.2260388260187938e-08

7x O 0 0.0008135386742651463
greater O 0 1.000814563667518e-06
if O 0 7.894175091394118e-09
one O 0 3.1246935594531067e-10
or O 0 6.030542037960274e-11
more O 0 6.246720918312576e-10
cases O 0 5.507105171886906e-08
of O 0 7.377424481092021e-06
ovarian B-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
were O 0 7.066919920362125e-07
also O 0 2.0844883152904004e-08
present O 0 6.659906515160685e-10
in O 0 1.678238520375075e-10
the O 0 7.837654414366568e-10
family O 0 4.477791293311384e-08
. O 0 1.643552849373009e-08

The O 0 8.919123928308181e-08
odds O 0 4.3727959564421326e-07
of O 0 5.836504612943827e-10
detection O 0 4.269070430495958e-09
of O 0 6.894797927037288e-11
any O 0 1.190498810643703e-10
of O 0 1.9385451577313972e-11
the O 0 2.7564966975646144e-10
four O 0 7.534842971779199e-09
BRCA2 O 0 1.7409149677405367e-06
mutations O 0 1.801049194227744e-07
was O 0 7.974034588187351e-08
5 O 0 1.1702113056344388e-08
. O 0 1.7778500449594503e-08

3x O 0 6.11762297921814e-05
greater O 0 5.103377702653233e-07
if O 0 1.3904026374689238e-08
there O 0 1.0923636439841289e-09
were O 0 1.0905440994690707e-09
at O 0 1.2200981891474783e-10
least O 0 1.2268616123023435e-09
five O 0 6.621262982342557e-10
cases O 0 3.1764697538960718e-09
of O 0 3.7126426377653843e-09
breast B-Disease 1 0.969141960144043
cancer I-Disease 0 3.353926877025515e-05
in O 0 7.519621592066983e-10
the O 0 1.214966571794207e-09
family O 0 4.897280447835328e-08
. O 0 9.656734079044327e-09

Interestingly O 0 4.3279313103994355e-05
, O 0 9.851028437424247e-09
the O 0 1.2409606675589657e-10
presence O 0 3.957018324118877e-10
of O 0 9.321101529513598e-11
a O 0 1.916230729648305e-07
breast B-Disease 1 0.9157825112342834
cancer I-Disease 0 1.4619820831285324e-05
case O 0 1.1198530103229132e-07
< O 0 2.72399027778647e-08
36 O 0 1.0523172555565452e-08
years O 0 6.747220560043843e-10
of O 0 9.063697709033036e-11
age O 0 1.6014237713690704e-09
was O 0 6.329961443896082e-09
strongly O 0 1.9172894383245875e-09
predictive O 0 8.551847563431636e-10
of O 0 1.5324892396750833e-11
the O 0 3.429610762051283e-11
presence O 0 1.7298081023131573e-10
of O 0 5.211884309547221e-12
any O 0 2.1819815052004365e-11
of O 0 5.986463495061267e-12
the O 0 9.105716874957537e-11
eight O 0 2.5981676810005183e-09
mutations O 0 4.3374672742402254e-08
screened O 0 4.824864845431875e-07
. O 0 2.660523712449958e-08

Carriers O 0 3.152698354824679e-06
of O 0 1.0197924726895735e-09
the O 0 3.491004152422761e-10
same O 0 1.4859076191697795e-09
mutation O 0 6.406947417048059e-09
, O 0 5.339046565966399e-11
from O 0 2.4365407261250915e-11
different O 0 1.0621688945056107e-10
families O 0 4.514887075313112e-10
, O 0 1.8724459482921674e-10
shared O 0 4.91121310286502e-10
similar O 0 1.5562736654928244e-09
haplotypes O 0 1.711992609898516e-07
, O 0 3.5355857130880963e-10
indicating O 0 1.8337105167631762e-09
that O 0 1.918334657791121e-10
the O 0 3.72074870913508e-11
mutant O 0 9.328599226421375e-09
alleles O 0 3.182436980608827e-09
were O 0 1.5892948068696455e-09
likely O 0 7.870675666765692e-09
to O 0 3.0938747119790833e-09
be O 0 3.599063447268236e-08
identical O 0 1.6883285525182146e-07
by O 0 8.229660841685416e-10
descent O 0 7.193435891394984e-08
for O 0 1.6205099762078845e-10
a O 0 2.9300990522784787e-09
mutation O 0 2.6247272799651e-08
in O 0 1.9425620834123691e-10
the O 0 5.893309729110285e-10
founder O 0 3.30820995486647e-07
population O 0 1.3624751993290829e-08
. O 0 1.4374749390810848e-08

The O 0 1.6316212381184414e-08
identification O 0 1.3448769209389866e-08
of O 0 1.1685462319999118e-10
common O 0 5.965989036127439e-09
BRCA1 O 0 5.301652890921105e-06
and O 0 7.432107196336801e-08
BRCA2 O 0 1.9719564079423435e-06
mutations O 0 3.089477118578543e-08
will O 0 5.842608619133216e-10
facilitate O 0 1.5795819097164099e-09
carrier O 0 1.9726664390873339e-07
detection O 0 1.5789952456657375e-08
in O 0 2.6155653198856044e-09
French O 0 3.2790810564620188e-06
Canadian O 0 4.255524618201889e-05
breast B-Disease 1 0.9965174198150635
cancer I-Disease 0 0.07928453385829926
and O 0 0.0015388443134725094
breast B-Disease 1 0.9999979734420776
/ I-Disease 1 0.9999994039535522
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 4.090278764579125e-07
. O 0 5.978692740882252e-08

Are O 0 1.4377993693415192e-06
Dp71 O 0 2.1777830625069328e-05
and O 0 9.342758744423918e-08
Dp140 O 0 1.1102798453066498e-05
brain O 0 2.6107947633136064e-05
dystrophin O 0 6.747214683855418e-06
isoforms O 0 1.3095655049255583e-07
related O 0 6.6810810217532435e-09
to O 0 2.5386167834540174e-08
cognitive B-Disease 0 0.0001417167077306658
impairment I-Disease 0 0.00026385244564153254
in O 0 2.644032690568565e-07
Duchenne B-Disease 1 0.9999254941940308
muscular I-Disease 1 0.9999879598617554
dystrophy I-Disease 1 0.9999862909317017
? O 0 5.249104287941009e-05

Molecular O 0 3.129026026726933e-06
study O 0 8.838632226115806e-08
and O 0 5.144338288687322e-09
neuropsychological O 0 2.246682981876802e-07
analysis O 0 2.7425273163572683e-09
were O 0 1.8785926148012777e-09
performed O 0 6.135454810873853e-09
concurrently O 0 8.47889491950582e-09
on O 0 2.252996900153903e-08
49 O 0 1.2322783504714607e-06
patients O 0 6.166688990560942e-07
with O 0 1.3794252140542085e-07
Duchenne B-Disease 1 0.9999237060546875
muscular I-Disease 1 0.9999983310699463
dystrophy I-Disease 1 0.9999986886978149
( O 0 5.526750896933663e-07
DMD B-Disease 1 0.9999998807907104
) O 0 5.780670164767798e-09
in O 0 6.039662103773935e-10
order O 0 2.3081524191947977e-10
to O 0 5.119932255936988e-10
find O 0 1.2485253941818542e-09
a O 0 9.71101421498588e-10
molecular O 0 3.4251101954652086e-09
explanation O 0 3.2697031748796235e-09
for O 0 6.930779561375999e-11
the O 0 2.6838231637071885e-10
cognitive B-Disease 0 2.892629709094763e-06
impairment I-Disease 0 9.454579981138522e-07
observed O 0 5.079693998766288e-09
in O 0 7.763411580263835e-10
most O 0 5.355133225748432e-07
DMD B-Disease 1 1.0
patients O 1 0.999626636505127
. O 0 8.695231201727438e-08

Complete O 0 4.031483626931731e-07
analysis O 0 2.8959252773574917e-08
of O 0 1.6654799761539607e-10
the O 0 2.7800242663467145e-10
dystrophin O 0 1.753606113652495e-07
gene O 0 1.4787270963267929e-08
was O 0 3.371836498899938e-08
performed O 0 1.8218401232061865e-09
to O 0 8.212549390540502e-11
define O 0 1.2129568460750306e-09
the O 0 4.870314915250695e-11
localization O 0 2.507279495134185e-09
of O 0 2.9379700061671343e-11
deletions O 0 1.0821858964504827e-08
and O 0 1.188652398731449e-09
duplications O 0 8.218810521043451e-09
in O 0 5.995210994313993e-10
relation O 0 1.729630771940549e-09
to O 0 1.683593486845325e-09
the O 0 1.7452258527228537e-09
different O 0 2.145846877965596e-08
DMD B-Disease 1 0.9999982118606567
promoters O 0 5.602867531706579e-05
. O 0 1.340270614491601e-07

Qualitative O 0 4.4157013689982705e-06
analysis O 0 1.0475893930106395e-07
of O 0 8.257428629754315e-10
the O 0 6.559706111630703e-10
Dp71 O 0 5.324836820363998e-07
transcript O 0 1.9018335706277867e-07
and O 0 7.76770703314611e-10
testing O 0 1.981223379798891e-10
for O 0 7.972650317711327e-12
the O 0 4.535640526354134e-12
specific O 0 1.7300414573151457e-11
first O 0 1.6326157092905191e-10
exon O 0 4.367208816802304e-09
of O 0 9.835867537111298e-11
Dp140 O 0 1.0692154717162339e-07
were O 0 1.5480797088684994e-08
also O 0 6.09414474439518e-09
carried O 0 2.0864455052560515e-08
out O 0 8.659279515654816e-09
. O 0 1.5724134883043916e-08

Neuropsychological O 0 0.0008025618153624237
analysis O 0 1.086891984414251e-06
assessed O 0 1.481909976064344e-06
verbal O 0 1.3336651818462997e-06
and O 0 6.168746580215156e-08
visuospatial O 0 4.646390607376816e-06
intelligence O 0 1.9419639230022767e-08
, O 0 1.507385549714968e-09
verbal O 0 5.397560798314771e-08
memory O 0 1.983398050242613e-07
, O 0 1.4057078834284198e-09
and O 0 3.526589686941861e-09
reading O 0 3.7180654999247054e-08
skills O 0 3.2963804130758945e-08
. O 0 1.6773377353729302e-08

Comparison O 0 2.0934949134243652e-06
of O 0 1.4908103640465242e-09
molecular O 0 1.2775903890371865e-08
and O 0 2.2973050128882733e-09
psychometric O 0 2.2124694964986702e-07
findings O 0 3.542130144751354e-08
demonstrated O 0 7.388373468586451e-09
that O 0 1.9236474912975865e-10
deletions O 0 9.181205129493719e-09
and O 0 1.2998639942196633e-09
duplications O 0 5.0936548312563446e-09
that O 0 1.0474785483438609e-09
were O 0 1.245335945476711e-09
localized O 0 2.4699676970385553e-08
in O 0 6.448382383617002e-10
the O 0 3.490524813631879e-10
distal O 0 1.3107265885992092e-06
part O 0 4.057214564312517e-09
of O 0 2.6085729062930163e-11
the O 0 5.496037305818824e-11
gene O 0 1.3538740128993254e-09
seemed O 0 1.3687158961772639e-08
to O 0 3.775237067404902e-10
be O 0 2.0440995562864828e-09
preferentially O 0 2.548815700720297e-07
associated O 0 6.940390484544423e-09
with O 0 2.8201123658533334e-09
cognitive B-Disease 0 2.2429212549468502e-05
impairment I-Disease 0 1.3036908967478666e-05
. O 0 2.6830889510165434e-08

Two O 0 4.661218042656401e-07
altered O 0 1.8398269503450138e-06
Dp71 O 0 1.2474403092710418e-06
transcripts O 0 8.424910191706658e-08
and O 0 7.917860811446076e-10
two O 0 1.6583320827656678e-10
deleted O 0 7.89745779883333e-09
Dp140 O 0 1.500158397504947e-08
DNA O 0 2.7040798489252893e-09
sequences O 0 6.859019463512084e-10
were O 0 3.3120889364468553e-10
found O 0 2.792598374767863e-10
in O 0 1.0577957954005512e-10
four O 0 5.30534949305661e-09
patients O 0 6.507875696115661e-07
with O 0 2.5788056134956605e-08
severe O 1 0.9965761303901672
cerebral B-Disease 1 0.9999167919158936
dysfunction I-Disease 0 0.30795732140541077
. O 0 3.1063117944540863e-07

These O 0 7.470936225217883e-08
findings O 0 4.506133421955383e-08
suggest O 0 9.66167146287944e-09
that O 0 2.1037944997193136e-10
some O 0 8.178066557285035e-11
sequences O 0 1.0502333447348633e-09
located O 0 8.365192982751068e-10
in O 0 1.0427914781674374e-10
the O 0 6.280443526351931e-11
distal O 0 1.5959791710429272e-07
part O 0 1.4828669403499362e-09
of O 0 1.7061817236818655e-11
the O 0 2.5778379431073972e-11
gene O 0 1.0652125848054084e-09
and O 0 5.248320111839178e-10
, O 0 1.0955931301070976e-10
in O 0 6.997833562616407e-11
particular O 0 8.016665664634104e-10
, O 0 2.7139887559535225e-10
some O 0 2.2378816577628413e-09
DMD B-Disease 1 0.9999994039535522
isoforms O 0 4.6468196046589583e-07
expressed O 0 2.1455113241586332e-08
in O 0 2.1558092810902707e-10
the O 0 2.360167894455145e-10
brain O 0 8.047809956224228e-07
may O 0 9.03627839221599e-09
be O 0 3.034796025591646e-10
related O 0 1.8332410589572135e-10
to O 0 1.4406938975142225e-09
the O 0 4.4418242417521014e-09
cognitive B-Disease 0 0.0005738550098612905
impairment I-Disease 0 4.1607647290220484e-05
associated O 0 2.3997715814516596e-08
with O 0 5.4127983872831464e-08
DMD B-Disease 1 0.9999998807907104
. O 0 2.2557644285825518e-07
. O 0 4.352765969883876e-08

I1307K O 0 9.065600170288235e-05
APC O 0 8.577732842240948e-06
and O 0 2.4747210503051065e-08
hMLH1 O 0 2.3579437424814387e-07
mutations O 0 5.4010520500469283e-08
in O 0 1.1262174526294189e-10
a O 0 2.157682255088389e-09
non O 0 3.3929570264490394e-09
- O 0 4.586423756336444e-07
Jewish O 0 9.39258715249025e-09
family O 0 3.804130344065015e-09
with O 0 2.6939384056845483e-09
hereditary B-Disease 0 0.2544356882572174
non I-Disease 0 5.601184966508299e-05
- I-Disease 1 0.9999967813491821
polyposis I-Disease 1 0.9999995231628418
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 3.084954414589447e-06

We O 0 1.5332115310684458e-07
describe O 0 6.699714560909342e-08
a O 0 1.9193979738929556e-08
French O 0 3.175654228471103e-07
Canadian O 0 7.310354135370289e-07
hereditary B-Disease 0 0.06425895541906357
non I-Disease 0 8.685422653798014e-05
- I-Disease 1 0.9999991655349731
polyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
( O 0 1.2475853736759746e-06
HNPCC B-Disease 0 0.009487003087997437
) O 0 1.005642324969358e-08
kindred O 0 2.660711970747798e-07
which O 0 2.441721269619279e-09
carries O 0 7.816429281604087e-09
a O 0 1.6809430514186374e-09
novel O 0 2.376967245254491e-08
truncating O 0 2.488243922016409e-07
mutation O 0 3.652695284017682e-07
in O 0 3.78690812041782e-09
hMLH1 O 0 5.601032171398401e-06
. O 0 6.634200389044054e-08

Interestingly O 0 3.0184219212969765e-05
, O 0 1.4793420710645933e-08
the O 0 5.303677497181525e-10
I1307K O 0 1.4694465733100515e-07
APC O 0 2.153976907948163e-07
polymorphism O 0 8.780493772064801e-06
, O 0 8.974644361003925e-10
associated O 0 6.756570858357236e-10
with O 0 8.030006520831634e-11
an O 0 8.512530680349073e-10
increased O 0 1.5222812521642481e-07
risk O 0 1.5348192050623766e-07
of O 0 6.985214326959976e-07
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, O 0 1.807042870893838e-08
is O 0 1.5113180706904927e-09
also O 0 3.3167371071840535e-09
present O 0 1.779368180576668e-10
in O 0 7.336353052833644e-11
this O 0 3.197225817430649e-10
family O 0 2.1209441314340438e-08
. O 0 1.0296199448589505e-08

The O 0 9.843951431776077e-08
I1307K O 0 1.2807203120246413e-06
polymorphism O 0 5.620206502499059e-05
has O 0 9.674768364220654e-08
previously O 0 7.557844128314173e-09
only O 0 3.5208280735332664e-10
been O 0 1.0446593590174302e-09
identified O 0 1.611037525606207e-09
in O 0 4.2031531033437375e-11
individuals O 0 2.5930460903489383e-11
of O 0 3.351410121643639e-11
self O 0 2.193277623518952e-06
- O 0 0.00019999172945972532
reported O 0 1.5130601696000667e-06
Ashkenazi O 0 1.3408076426912885e-07
Jewish O 0 4.408434950420315e-09
origins O 0 1.4806603942929542e-08
. O 0 1.3861686021243713e-08

In O 0 1.9116565397325758e-07
addition O 0 6.6432392920035e-09
, O 0 2.3145270422464392e-10
in O 0 5.1241302867488514e-11
this O 0 1.6966936189355408e-10
family O 0 1.7689970599477078e-09
, O 0 8.83649542426923e-11
there O 0 3.4709465857041266e-10
appears O 0 1.0444626497019271e-08
to O 0 3.183704411213739e-10
be O 0 5.812431091989367e-10
no O 0 1.8406970392348398e-10
relationship O 0 2.1094358204631902e-10
between O 0 3.407916310260717e-11
the O 0 1.3069935411724742e-10
I1307K O 0 7.669504498153401e-08
polymorphism O 0 6.222111892384419e-07
and O 0 4.025501043614099e-10
the O 0 4.041392914766462e-11
presence O 0 8.300981013675823e-10
or O 0 3.0380567506149703e-10
absence O 0 5.727725849169474e-09
of O 0 1.3972663026606824e-09
cancer B-Disease 0 1.287233317270875e-06
. O 0 2.303179647000775e-09
. O 0 2.0331354377844946e-08

Identification O 0 8.547597190045053e-07
of O 0 2.9226419062666764e-09
a O 0 7.566180570961478e-09
novel O 0 7.887600617095814e-08
mutation O 0 1.5800408093014084e-08
of O 0 2.1803425384603337e-11
the O 0 8.101201653953893e-11
CPO O 0 2.4957941491265956e-07
gene O 0 6.90666368541315e-09
in O 0 1.3648875085703338e-10
a O 0 8.514336791165533e-09
Japanese O 0 1.387282821951885e-07
hereditary B-Disease 0 0.0005702960770577192
coproporphyria I-Disease 0 5.865018465556204e-05
family O 0 1.7238129146335268e-07
. O 0 2.5703105421825967e-08

Hereditary B-Disease 1 0.9997785687446594
coproporphyria I-Disease 0 0.43164360523223877
( O 0 1.241790300809953e-06
HCP B-Disease 0 0.0002246790681965649
) O 0 7.279934877146843e-09
is O 0 8.20945622592717e-09
an O 0 2.4751741989348375e-08
autosomal B-Disease 1 0.993756890296936
dominant I-Disease 1 0.9983739852905273
disease I-Disease 0 0.3292156159877777
characterized O 0 3.7032637010270264e-06
by O 0 2.984536706662766e-08
a O 0 2.4310265871463344e-06
deficiency B-Disease 0 8.59641659189947e-05
of I-Disease 0 5.440635719722309e-10
coproporphyrinogen I-Disease 0 8.898748092178721e-06
oxidase I-Disease 0 4.649342315588001e-07
( O 0 2.6229041161229816e-09
CPO O 0 4.169689418631606e-06
) O 0 1.604781085795537e-09
caused O 0 3.877113030625878e-08
by O 0 1.5416309895321945e-10
a O 0 5.718512774421924e-09
mutation O 0 3.5574451828779274e-08
in O 0 1.6262320656768026e-10
the O 0 8.316353161674783e-10
CPO O 0 7.454561455233488e-06
gene O 0 3.841702778117906e-07
. O 0 2.4909260432082192e-08

Only O 0 5.573455723606457e-07
11 O 0 2.4258188346948373e-08
mutations O 0 2.7296904292484214e-08
of O 0 4.1239955894667446e-11
the O 0 1.0656388271801376e-10
gene O 0 7.470164042899796e-09
have O 0 8.017954300498786e-09
been O 0 2.3595537967935343e-08
reported O 0 1.89846254272652e-08
in O 0 2.1076109746331895e-09
HCP B-Disease 1 0.6025580167770386
patients O 0 0.010493416339159012
. O 0 5.390070967337124e-08

We O 0 2.7157892645846005e-07
report O 0 1.1770162622326552e-08
another O 0 1.7613713820807675e-09
mutation O 0 5.645845568835739e-09
in O 0 1.9791007721536857e-10
a O 0 4.142352239000502e-09
Japanese O 0 5.512738354696012e-08
family O 0 3.079546218032192e-08
. O 0 9.609093076790032e-09

Polymerase O 0 3.541787009453401e-05
chain O 0 1.6015052096918225e-05
reaction O 0 1.7920660866366234e-06
- O 0 3.8196665741452307e-07
single O 0 4.173744727609119e-08
strand O 0 5.458936058744257e-08
conformational O 0 3.788469982168863e-08
polymorphism O 0 1.3771002613793826e-06
and O 0 4.641770301461179e-10
direct O 0 8.45008840677508e-10
sequence O 0 3.1007865164411896e-09
analyses O 0 7.094942411356442e-09
demonstrated O 0 3.679684557056362e-09
a O 0 1.0482100742947864e-09
C O 0 3.1407383360715357e-09
to O 0 6.663794516192922e-10
T O 0 3.1426697688630156e-08
substitution O 0 2.1042128039994168e-09
in O 0 2.68650712786922e-10
exon O 0 4.607460191152768e-09
1 O 0 1.4965959027612996e-10
of O 0 1.4929031968979878e-11
the O 0 8.066772250181486e-11
CPO O 0 4.3910993952067656e-08
gene O 0 7.050368067140766e-10
at O 0 2.1634326274888593e-11
nucleotide O 0 2.813062560669266e-10
position O 0 3.022199601687703e-09
85 O 0 1.1690618473281233e-09
, O 0 6.477272884719554e-11
which O 0 5.591946350413934e-10
lies O 0 4.3631458446213855e-09
in O 0 9.7937470633358e-11
the O 0 7.563374232466558e-11
putative O 0 8.894419423199906e-09
presequence O 0 5.9453174827694966e-08
for O 0 1.6036634520322224e-10
targeting O 0 6.244674999322797e-09
to O 0 6.51671072660065e-09
mitochondria O 0 3.787647244735126e-07
. O 0 3.3367260954264566e-08

This O 0 6.772149419020934e-08
mutation O 0 1.2482335876029538e-07
changes O 0 1.2655866354904788e-09
the O 0 5.910326394964471e-11
codon O 0 2.7902358201714605e-09
for O 0 8.603001644402752e-11
glutamine O 0 9.528641875533594e-09
to O 0 5.50487322392712e-10
a O 0 1.3024350487000902e-09
termination O 0 2.6323528246052774e-08
codon O 0 5.951895420963638e-09
at O 0 2.744043048341638e-10
amino O 0 2.153923928105428e-09
acid O 0 1.3809145826826352e-08
position O 0 3.1014270263085564e-08
29 O 0 2.9107884103041215e-08
. O 0 1.1226841678535493e-08

MaeI O 0 7.454279693774879e-05
restriction O 0 6.360608040267834e-07
analysis O 0 3.7150172715882945e-08
showed O 0 3.736471398951835e-08
two O 0 2.500815943218271e-10
other O 0 4.028694045032921e-11
carriers O 0 1.2864119769417925e-09
in O 0 1.599704119170653e-10
the O 0 7.842917981726316e-10
family O 0 6.056243506691317e-08
. O 0 1.8953871361304664e-08

The O 0 2.553082936174178e-07
C O 0 5.098409474157961e-06
- O 0 0.0002770627324935049
T O 0 0.0006747709703631699
mutation O 0 4.1515068005537614e-07
is O 0 8.450313782049079e-10
located O 0 1.8180727756611503e-10
within O 0 5.48295957247813e-11
a O 0 1.1569876168238125e-09
recently O 0 2.6231058214420955e-08
proposed O 0 2.5265582959121957e-09
putative O 0 9.551659907458543e-09
alternative O 0 6.193593971026701e-10
translation O 0 4.56978010987541e-10
initiation O 0 4.8567000421329e-10
codon O 0 6.52971277048664e-09
( O 0 2.2032023427875913e-10
TIC O 0 9.494556252320763e-08
- O 0 6.769966631736679e-08
1 O 0 2.638881557714967e-09
) O 0 1.3670707621482592e-10
, O 0 1.0363612051866866e-10
supporting O 0 6.953213005367331e-10
that O 0 4.1442074771858017e-10
TIC O 0 2.8729724377285493e-08
- O 0 3.247336621825525e-08
1 O 0 6.125057128159028e-10
is O 0 1.159341997403196e-10
the O 0 4.050081450768239e-11
real O 0 8.987817712302615e-10
TIC O 0 2.619425920613594e-08
rather O 0 1.7436054822184133e-09
than O 0 5.793824864319674e-10
TIC O 0 7.164749149524141e-08
- O 0 1.336235158078125e-07
2 O 0 4.36624247868167e-09
. O 0 1.1994566451178912e-09
. O 0 9.696951686066768e-09

Human B-Disease 0 9.203894819620473e-07
complement I-Disease 0 4.342386546341004e-06
factor I-Disease 0 7.303053280338645e-05
H I-Disease 1 1.0
deficiency I-Disease 1 0.998826801776886
associated O 0 1.758560983944335e-06
with O 0 1.920180511660874e-05
hemolytic B-Disease 1 0.9999984502792358
uremic I-Disease 1 1.0
syndrome I-Disease 1 0.9999998807907104
. O 0 5.236414381215582e-06

This O 0 1.154282003312801e-07
study O 0 1.6409591907518006e-08
reports O 0 3.219821742561635e-09
on O 0 7.605909790875387e-10
six O 0 1.7060468593399492e-09
cases O 0 6.555957110521149e-09
of O 0 1.0501872704793414e-09
deficiency B-Disease 0 1.6028008758439682e-05
in I-Disease 0 1.2042562780312238e-10
the I-Disease 0 9.127591737989604e-11
human I-Disease 0 7.272848989714475e-11
complement I-Disease 0 3.4856015296291787e-10
regulatory I-Disease 0 1.5005239273335746e-09
protein I-Disease 0 5.106563616408266e-09
Factor I-Disease 0 1.2087403078453463e-08
H I-Disease 1 0.9998531341552734
( O 0 2.0972972247790267e-09
FH O 0 2.2969331894273637e-06
) O 0 1.149613598760979e-10
in O 0 2.804794417554657e-11
the O 0 1.3949003410673733e-11
context O 0 2.2466824234346205e-10
of O 0 2.537708931882321e-10
an O 0 4.477697643778811e-07
acute B-Disease 1 0.9999855756759644
renal I-Disease 1 1.0
disease I-Disease 1 1.0
. O 0 2.396628360656905e-06

Five O 0 1.3155839440059935e-07
of O 0 2.6242391593100933e-10
the O 0 4.507401119013821e-10
cases O 0 7.837224202944526e-09
were O 0 1.13461231521228e-08
observed O 0 9.971161674116047e-09
in O 0 4.211846704738065e-10
children O 0 1.2511505609325013e-08
presenting O 0 2.3272962224041294e-08
with O 0 3.0647499897895614e-06
idiopathic O 1 0.9999979734420776
hemolytic B-Disease 1 1.0
uremic I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 1.071608221536735e-05
HUS B-Disease 1 0.9999386072158813
) O 0 3.57272881501558e-07
. O 0 2.443796347506577e-07

Two O 0 6.962615373140579e-08
of O 0 2.8037419608217817e-10
the O 0 5.545763848147089e-10
children O 0 1.6118743673132485e-08
exhibited O 0 4.1710478626555414e-07
a O 0 7.492747613468964e-07
homozygous O 0 0.20213431119918823
deficiency O 0 0.00028456191648729146
characterized O 0 4.7957662729913864e-08
by O 0 6.17319029228014e-10
the O 0 1.1794960841360336e-10
absence O 0 1.4596822639489915e-09
of O 0 1.5372670150726186e-11
the O 0 1.10272950493151e-10
150 O 0 4.774823869624356e-10
- O 0 1.1360262952564426e-08
kD O 0 4.444708068263026e-08
form O 0 7.327281004165798e-10
of O 0 3.937141584975379e-11
Factor O 0 3.7692813315004514e-09
H O 1 0.9995182752609253
and O 0 1.215499700890632e-09
the O 0 6.756734755031246e-11
presence O 0 1.1169380975672993e-09
, O 0 6.9330541307977e-11
upon O 0 1.586356324079219e-10
immunoblotting O 0 2.4949773802518393e-08
, O 0 4.340531406521464e-11
of O 0 1.825096063862164e-12
the O 0 2.6393168900407105e-11
42 O 0 1.7452391753991492e-09
- O 0 1.3507742480101115e-08
kD O 0 3.583200509638118e-07
Factor O 0 2.5463613440024346e-08
H O 1 0.947910726070404
- O 0 1.039617458786779e-07
like O 0 1.619222644855256e-09
protein O 0 2.330137860440118e-09
1 O 0 4.0239656051710426e-10
( O 0 2.1034976538381045e-10
FHL O 0 1.419707160721373e-07
- O 0 1.7641501415255334e-07
1 O 0 2.172068080952272e-09
) O 0 1.2373327362702469e-10
and O 0 9.025559744024747e-10
other O 0 8.105534576863249e-10
FH O 0 1.4507225387205835e-05
- O 0 2.84683096651861e-07
related O 0 1.3233146134439266e-08
protein O 0 6.53261578165143e-09
( O 0 1.8869805717969257e-10
FHR O 0 4.063734309056599e-07
) O 0 6.007412900466136e-10
bands O 0 2.1838211239355587e-08
. O 0 1.001599336802883e-08

Southern O 0 5.403696832217975e-06
blot O 0 3.610710336943157e-05
and O 0 9.346069695936876e-09
PCR O 0 2.4818831434458843e-07
analysis O 0 4.183003277091757e-09
of O 0 2.854690962783568e-11
DNA O 0 1.14245979343508e-09
of O 0 2.6353681389923445e-11
one O 0 1.7156144282992614e-09
patient O 0 6.945100494704093e-07
with O 0 4.0050545102587876e-09
homozygous O 0 8.449081360595301e-05
deficiency O 0 5.9390322348917834e-06
ruled O 0 7.73976296386536e-08
out O 0 1.5703326416982577e-09
the O 0 5.342183639900355e-11
presence O 0 1.7520287998173956e-10
of O 0 6.067656359992624e-12
a O 0 3.648492341579157e-10
large O 0 7.303211924103437e-10
deletion O 0 3.50481812461112e-08
of O 0 1.6088257115409732e-10
the O 0 9.568303926954513e-10
FH O 0 4.416358478920301e-06
gene O 0 7.850645467044615e-09
as O 0 6.30506369336814e-10
the O 0 1.0516800624804645e-10
underlying O 0 3.504758083749948e-08
defect O 0 1.9285545249658753e-07
for O 0 1.4168681783388593e-09
the O 0 6.189183210381088e-08
deficiency O 0 0.0002546988253016025
. O 0 6.526838802756174e-08

The O 0 4.9062272466926515e-08
other O 0 1.997708221068706e-09
four O 0 1.3554397604309543e-09
children O 0 1.8385154509914514e-09
presented O 0 4.048340329632083e-09
with O 0 7.297914095261149e-08
heterozygous O 0 0.28347042202949524
deficiency O 0 2.7505955586093478e-05
and O 0 1.6366074051532564e-09
exhibited O 0 2.702957715428056e-07
a O 0 6.264394780686189e-09
normal O 0 1.1296737767452214e-08
immunoblotting O 0 5.605539854514063e-07
pattern O 0 1.3517226449266673e-08
of O 0 1.9397509640195487e-11
proteins O 0 1.8206129659414927e-10
of O 0 1.0224153468296748e-10
the O 0 4.837896749876336e-09
FH O 0 0.004109861329197884
family O 0 1.459377472201595e-07
. O 0 1.617402212161778e-08

Factor B-Disease 0 0.13809296488761902
H I-Disease 1 0.9999998807907104
deficiency I-Disease 1 0.9981111288070679
is O 0 1.8380077904112113e-08
the O 0 1.338943400597259e-09
only O 0 5.891139949198987e-07
complement B-Disease 1 0.9999977350234985
deficiency I-Disease 1 0.9999997615814209
associated O 0 4.517630713962717e-07
with O 0 4.743873205370619e-08
HUS B-Disease 1 0.9994920492172241
. O 0 7.360750942098093e-07

These O 0 1.1903335916940705e-07
observations O 0 6.982057954019183e-08
suggest O 0 5.06410913203581e-09
a O 0 7.213640240699704e-10
role O 0 4.281163423769385e-09
for O 0 3.6405696235419782e-09
FH O 0 9.700313239591196e-05
and O 0 1.4620130173170764e-07
/ O 0 2.2690834100558277e-07
or O 0 6.462570034670989e-09
FH O 0 2.6629599233274348e-05
receptors O 0 4.25719335339636e-08
in O 0 3.914708834873437e-10
the O 0 7.360126952349333e-10
pathogenesis O 0 1.353338205944965e-07
of O 0 4.754877380719336e-09
idiopathic O 0 0.405828595161438
HUS B-Disease 1 0.9999338388442993
. O 0 1.4250298363549518e-07
. O 0 4.631436567592573e-08

Further O 0 3.990614914073376e-07
evidence O 0 2.7229514643067887e-08
for O 0 1.2799403203977988e-10
a O 0 7.466000595535149e-10
major O 0 9.416420976293693e-10
ancient O 0 6.0760498854506295e-09
mutation O 0 1.8797885786625557e-05
underlying O 0 5.501986379385926e-05
myotonic B-Disease 1 0.9999998807907104
dystrophy I-Disease 1 1.0
from O 0 8.656855499111771e-08
linkage O 0 1.8770231235976098e-06
disequilibrium O 0 8.146200343617238e-06
studies O 0 4.796788299898935e-09
in O 0 1.1185449788619906e-10
the O 0 1.0171850167717267e-10
Japanese O 0 1.6658660229040834e-08
population O 0 6.660926032964198e-09
. O 0 7.651282274423465e-09

The O 0 7.645519508514553e-05
myotonic B-Disease 1 0.9999998807907104
dystrophy I-Disease 1 1.0
( O 0 0.024943046271800995
DM B-Disease 1 1.0
) O 0 1.8764741582799616e-07
mutation O 0 1.872592520157923e-06
is O 0 7.71136487998092e-09
an O 0 2.6387707574571095e-09
unstable O 0 1.5680514479754493e-05
( O 0 1.3110639240920818e-09
CTG O 0 2.312041544882959e-07
) O 0 2.5582611029584257e-10
n O 0 7.318163852687576e-09
repeat O 0 2.683099076250528e-08
, O 0 3.717969543348687e-10
present O 0 1.2480128042113847e-10
at O 0 1.4904705941676255e-11
a O 0 1.866954091322981e-10
copy O 0 1.9059935851828413e-09
number O 0 1.2042379593513175e-10
of O 0 1.2631714250976867e-11
5 O 0 3.762269384921524e-10
- O 0 5.390527917370491e-07
37 O 0 4.453210422639131e-08
repeats O 0 4.5821764160791645e-09
on O 0 7.973570692598742e-10
normal O 0 4.812548137778094e-10
chromosomes O 0 8.706490528531674e-10
but O 0 3.936106995894306e-10
amplified O 0 1.0867427846505961e-08
to O 0 4.907074191429217e-10
50 O 0 1.0233308644913564e-09
- O 0 4.3914848646409155e-08
3000 O 0 1.2873994315043547e-08
copies O 0 1.6396139557173228e-08
on O 0 1.0707276487664785e-07
DM B-Disease 1 0.9999972581863403
chromosomes O 0 3.278171561760246e-06
. O 0 7.307037463988308e-08

Previous O 0 1.1150100363011006e-06
findings O 0 2.9743199547738186e-07
in O 0 2.051192105056998e-09
Caucasian O 0 1.7472025604092778e-07
populations O 0 3.698323425282979e-09
of O 0 1.1889239592832723e-10
a O 0 1.233850525750313e-06
DM B-Disease 1 1.0
founder O 0 8.621314009360503e-06
chromosome O 0 1.0278569106958457e-06
raise O 0 1.867390331256047e-08
a O 0 9.92641191466248e-10
question O 0 7.266224844038049e-10
about O 0 9.456283672770738e-11
the O 0 3.333057094212499e-11
molecular O 0 6.181014033934673e-10
events O 0 1.5532598818257526e-10
involved O 0 2.8346389124855875e-10
in O 0 3.967029135742983e-11
the O 0 1.8351792308024528e-10
expansion O 0 2.503863427705255e-08
mutation O 0 4.626355689651973e-07
. O 0 2.117072028795519e-08

To O 0 2.736277622261696e-07
investigate O 0 1.3025032785662916e-07
whether O 0 3.32047314088868e-08
a O 0 6.372335548121555e-09
founder O 0 2.7370361976863933e-08
chromosome O 0 1.9030636622119346e-07
for O 0 9.574838699677457e-10
the O 0 6.011611208833756e-09
DM B-Disease 1 1.0
mutation O 0 2.337468322366476e-05
exists O 0 3.57059071198762e-09
in O 0 5.6310095475353705e-11
the O 0 5.433581015679145e-11
Japanese O 0 6.224697202128482e-09
population O 0 3.722752384138772e-10
, O 0 1.8449922145613584e-10
we O 0 2.539481125385379e-10
genotyped O 0 9.908790588042393e-08
families O 0 3.5503244788515076e-10
using O 0 5.371797451303451e-10
polymorphic O 0 1.86388945166982e-07
markers O 0 2.0151989588157448e-07
near O 0 2.008965971356247e-08
the O 0 1.2240753965997442e-09
( O 0 8.949499474830702e-10
CTG O 0 3.3334950444441347e-07
) O 0 5.874298270036604e-10
n O 0 8.898660475153974e-09
repeat O 0 2.894997308544589e-08
region O 0 1.1949452094484059e-08
and O 0 4.3206287436703406e-09
constructed O 0 1.092455818252347e-06
haplotypes O 0 2.996700686708209e-06
. O 0 3.395535230765745e-08

Six O 0 3.2314764553120767e-07
different O 0 7.1271828439023466e-09
haplotypes O 0 5.874074417988595e-07
were O 0 7.356723585871805e-08
found O 0 3.127266623437208e-08
and O 0 1.1952066358844604e-07
DM B-Disease 1 1.0
alleles O 0 8.086337402346544e-06
were O 0 1.0589842958097506e-07
always O 0 7.727283701797205e-08
haplotype O 0 3.6943886243534507e-06
A O 0 1.5068005154716957e-07
. O 0 5.192823593347384e-08

To O 0 2.517819552849687e-07
find O 0 2.8564983267642674e-08
an O 0 5.224589649799327e-10
origin O 0 2.7388039058884317e-10
of O 0 2.59298676280606e-11
the O 0 3.5113587038004823e-10
( O 0 4.2375916664560975e-10
CTG O 0 2.2277349387422873e-07
) O 0 2.7893884424479154e-10
n O 0 6.1739000578597825e-09
repeat O 0 2.5330304964654715e-08
mutation O 0 1.7817709974110585e-08
and O 0 1.848260711145855e-10
to O 0 3.0441182907736675e-10
investigate O 0 1.3079467509058418e-09
the O 0 2.7026434909482866e-11
mechanism O 0 1.4957483862598764e-10
of O 0 1.5995111485311853e-11
the O 0 2.313810948395556e-11
expansion O 0 7.827167247675959e-10
mutation O 0 2.1268087291304028e-09
in O 0 2.65714204111811e-11
the O 0 2.86314305597557e-11
Japanese O 0 1.9931065686762395e-09
population O 0 1.2244531777394485e-10
we O 0 1.1267933808234432e-10
have O 0 3.0871061262871535e-10
studied O 0 9.085666108354928e-10
90 O 0 1.8132531032222232e-09
Japanese O 0 6.597530699536946e-08
DM B-Disease 1 0.9999997615814209
families O 0 3.021612826614728e-08
comprising O 0 1.2945566840727452e-09
190 O 0 1.0916851422848595e-08
affected O 0 9.952958457404293e-09
and O 0 5.4172470953517404e-09
130 O 0 3.464871412006687e-08
unaffected O 0 2.821641828631982e-06
members O 0 4.097826966642515e-09
. O 0 1.1382320863617679e-08

The O 0 3.784396795936118e-08
results O 0 3.9836404397419756e-08
suggest O 0 4.808109910214853e-09
that O 0 2.266619392177205e-10
a O 0 1.0327545485466771e-09
few O 0 9.627139085921499e-10
common O 0 1.7941244323527172e-10
ancestral O 0 3.57093110636697e-09
mutations O 0 2.8595346535098543e-08
in O 0 3.6071143294513774e-10
both O 0 1.1989558235114828e-09
Caucasian O 0 4.465892899929713e-08
and O 0 1.113543146580298e-09
Japanese O 0 1.9530472794571097e-09
populations O 0 3.229962963757771e-10
have O 0 1.4020334893061204e-10
originated O 0 8.482105295914977e-11
by O 0 1.0118707954864803e-11
expansion O 0 6.270281516229659e-11
of O 0 9.923467429728827e-12
an O 0 2.0118320898099284e-10
ancestral O 0 3.3910938501691135e-09
n O 0 1.3150314615018033e-08
= O 0 3.957337568749608e-09
5 O 0 4.2979744763194105e-10
repeat O 0 1.1883628303621663e-08
to O 0 6.795799922798551e-09
n O 0 6.652928874473218e-08
= O 0 5.756818666213803e-08
19 O 0 7.559257220179916e-09
- O 0 1.5635706063221733e-07
37 O 0 3.586947272538055e-08
copies O 0 2.111273467164665e-08
. O 0 1.3795377284964161e-08

These O 0 1.5213437620786863e-07
data O 0 2.8058419587750905e-08
support O 0 4.45684511518607e-09
multistep O 0 2.592551311408897e-07
models O 0 5.5852151348290136e-08
of O 0 4.537444864283202e-10
triplet O 0 7.436934765792103e-07
repeat O 0 1.1701934532482028e-08
expansion O 0 1.6482608611312344e-09
that O 0 3.2220931478477155e-10
have O 0 9.509772969096275e-10
been O 0 8.90093165839545e-10
proposed O 0 1.345158540111413e-09
for O 0 1.6358302490360188e-09
both O 0 3.559135848263395e-07
DM B-Disease 1 1.0
and O 0 2.3771048290655017e-05
Friedreichs B-Disease 0 0.0025924129877239466
ataxia I-Disease 1 0.9649104475975037
. O 0 5.4757251177761646e-08
. O 0 3.266612935703961e-08

The O 0 3.32582246187485e-08
molecular O 0 2.4332702963647534e-08
basis O 0 7.726249862116674e-09
of O 0 1.5574059375467186e-08
C6 B-Disease 1 1.0
deficiency I-Disease 1 0.9999998807907104
in O 0 1.3425983880210879e-08
the O 0 1.3757033290318077e-09
western O 0 2.562224210578279e-08
Cape O 0 6.827529119846076e-08
, O 0 4.1860439559116e-09
South O 0 7.34134353308491e-09
Africa O 0 6.271771102461798e-09
. O 0 1.9906609693975952e-08

Deficiency B-Disease 1 0.9892473816871643
of I-Disease 0 6.068846314377652e-09
the I-Disease 0 9.38638611280851e-10
sixth I-Disease 0 1.2716850683602843e-08
component I-Disease 0 3.5172591505983064e-09
of I-Disease 0 9.100577236242913e-11
human I-Disease 0 4.507615947169086e-10
complement I-Disease 0 3.5151535016098023e-09
( O 0 3.700021955488353e-10
C6 O 0 6.224948947419762e-07
) O 0 5.22089371735035e-10
has O 0 3.181498087201362e-08
been O 0 1.6072446484827196e-08
reported O 0 1.0500390557055539e-09
in O 0 1.1536326581518264e-11
a O 0 2.0999739447358223e-10
number O 0 1.924888026749727e-10
of O 0 3.375499532665138e-11
families O 0 7.192921813725661e-10
from O 0 5.1701445208385266e-11
the O 0 3.084963673405383e-10
western O 0 1.177748387704014e-08
Cape O 0 2.8528612361355954e-08
, O 0 1.7262559159902935e-09
South O 0 1.4821147642507526e-09
Africa O 0 3.357664812853045e-09
. O 0 1.62538729142625e-08

Meningococcal B-Disease 1 0.999448835849762
disease I-Disease 1 0.9919998645782471
is O 0 1.974236027990628e-07
endemic O 0 4.5632177148036135e-08
in O 0 1.9554851071745816e-09
the O 0 5.143550585451351e-10
Cape O 0 2.7105771849278426e-08
and O 0 3.5933276354427335e-09
almost O 0 3.0956320840047624e-10
all O 0 2.3072092847353787e-11
pedigrees O 0 4.57827997735194e-09
of O 0 2.902303397611661e-10
total O 0 2.562162080721464e-06
C6 B-Disease 1 1.0
deficiency I-Disease 1 1.0
( O 0 2.551007183271281e-09
C6Q0 O 0 6.058189683244564e-06
) O 0 3.867728637363399e-10
have O 0 1.3130884157774858e-09
been O 0 6.365872717850607e-09
ascertained O 0 3.451771135587478e-08
because O 0 4.0181671878691816e-10
of O 0 2.909075758061874e-10
recurrent O 0 0.002459575654938817
disease O 0 0.007952656596899033
. O 0 1.6738452757181221e-07

We O 0 1.8308340088424302e-07
have O 0 3.6558365223982037e-09
sequenced O 0 7.57799512030033e-09
the O 0 2.1976706565673965e-10
expressed O 0 2.428067524817834e-09
exons O 0 1.8684023217474532e-08
of O 0 9.855848775996989e-11
the O 0 4.672077169587396e-10
C6 O 0 2.7279088499199133e-07
gene O 0 1.8595524009512587e-09
from O 0 9.639518350201826e-11
selected O 0 8.530018358321456e-10
cases O 0 1.2213841049657503e-09
and O 0 7.073077123997962e-10
have O 0 2.7479938324859177e-09
found O 0 9.957586977193955e-10
three O 0 2.8253224759744455e-10
molecular O 0 1.8187959582860458e-08
defects O 0 6.623670924454927e-05
leading O 0 2.4187487568383403e-09
to O 0 9.00135788128864e-09
total O 0 1.0314916920606265e-07
deficiency O 0 5.910897016292438e-05
879delG O 0 6.862937311780115e-07
, O 0 5.919625900574488e-10
which O 0 6.251786865973941e-10
is O 0 2.2941512578533718e-10
the O 0 3.9380273347822126e-11
common O 0 8.775530302429502e-10
defect O 0 2.392692692865239e-07
in O 0 3.340218657221783e-10
the O 0 4.381407181508479e-10
Cape O 0 2.081651651053562e-08
and O 0 2.979075430786793e-09
hitherto O 0 7.372877774969311e-08
unreported O 0 2.140781951709414e-08
, O 0 2.8857108369528817e-10
and O 0 3.740924514605837e-10
1195delC O 0 8.946144447463666e-08
and O 0 2.2483124251237996e-09
1936delG O 0 4.8752202275181844e-08
, O 0 1.205462674125357e-10
which O 0 2.2382305731039054e-10
have O 0 3.876288456883259e-10
been O 0 3.820454619329894e-09
previously O 0 6.159409871031585e-09
reported O 0 1.5492545024642368e-09
in O 0 9.973814829589145e-11
African O 0 1.9299023490404466e-10
- O 0 1.1249561566728516e-06
Americans O 0 1.1371540864502094e-07
. O 0 8.927561800931016e-09

We O 0 2.3557433337373368e-07
also O 0 9.652995736075809e-09
show O 0 4.745590587162951e-09
that O 0 3.148684646347988e-10
the O 0 1.8802119583494203e-10
879delG O 0 7.543323476966179e-07
and O 0 2.284913058758775e-08
1195delC O 0 4.333692413638346e-05
defects O 0 0.014777116477489471
are O 0 6.655690443224671e-10
associated O 0 2.100459584042369e-09
with O 0 1.3830542267001533e-09
characteristic O 0 3.959967216360383e-05
C6 O 1 0.6300023794174194
/ O 0 1.713227538857609e-05
C7 O 0 9.425461939827073e-06
region O 0 1.7394707896301043e-08
DNA O 0 6.718961031992876e-08
marker O 0 5.695937943528406e-07
haplotypes O 0 6.390065436789882e-07
, O 0 4.6282705445932493e-10
although O 0 2.927890707660197e-10
small O 0 3.225001377060721e-10
variations O 0 5.529851421215426e-08
were O 0 3.6835483996355833e-08
observed O 0 6.051994461131471e-08
. O 0 2.0963382141303555e-08

The O 0 1.6448235840016423e-07
1936delG O 0 3.472441449048347e-06
defect O 0 6.8024623942619655e-06
was O 0 6.862885726377499e-08
observed O 0 3.726881914190017e-09
only O 0 8.441260468394773e-10
once O 0 1.3541063825783795e-09
in O 0 1.5967624444890305e-10
the O 0 2.816788746695664e-10
Cape O 0 1.041317787553453e-08
, O 0 2.4565705025736406e-10
but O 0 2.700027701418861e-10
its O 0 5.836438554673862e-10
associated O 0 1.713208597209359e-08
haplotype O 0 3.069406830036314e-06
could O 0 7.01912483691558e-08
be O 0 2.444932034606495e-09
deduced O 0 2.048683569455534e-07
. O 0 1.216711176255103e-08

The O 0 1.2114314884570376e-08
data O 0 5.061685293128448e-09
from O 0 2.7145362346825408e-11
the O 0 3.408962695461426e-11
haplotypes O 0 6.825133880283829e-08
indicate O 0 2.3790807546220094e-08
that O 0 6.343591762991707e-10
these O 0 5.11794773228047e-11
three O 0 9.492787111931023e-11
molecular O 0 1.2842651386790749e-08
defects O 0 4.443322177394293e-05
account O 0 3.2511588976547046e-09
for O 0 1.826351569977902e-10
the O 0 8.104112381168704e-10
defects O 0 0.0008851205348037183
in O 0 2.0021356794686085e-10
all O 0 3.342033247366594e-11
the O 0 5.998718882738174e-11
38 O 0 3.0724223165634612e-09
unrelated O 0 4.038260836836116e-09
C6Q0 O 0 2.0707675503217615e-06
individuals O 0 4.760437599671263e-10
we O 0 1.7832754717339583e-10
have O 0 4.747869319920994e-10
studied O 0 9.654096411182422e-10
from O 0 6.554325138186101e-11
the O 0 3.735227682710729e-10
Cape O 0 7.329957441015722e-08
. O 0 1.836557217416157e-08

We O 0 5.281046355776198e-07
have O 0 2.229983131485369e-08
also O 0 4.00812671941253e-09
observed O 0 2.528684595048958e-09
the O 0 1.325999032797398e-10
879delG O 0 1.718406252848581e-07
defect O 0 2.305691424453471e-07
in O 0 4.368681527644469e-10
two O 0 1.3092403605696745e-08
Dutch O 1 0.9995965361595154
C6 B-Disease 1 1.0
- I-Disease 1 0.999994158744812
deficient I-Disease 1 0.9999998807907104
kindreds O 0 5.167555718799122e-05
, O 0 5.645293676970198e-10
but O 0 2.368004958785974e-10
the O 0 7.167089838278073e-11
879delG O 0 1.5019914201275242e-07
defect O 0 1.5732031499737786e-07
in O 0 3.8465336471560363e-10
the O 0 3.6363206890044353e-10
Cape O 0 8.20225665165708e-09
probably O 0 1.6913576317278967e-08
did O 0 2.1249029202863312e-09
not O 0 1.6659375268179843e-10
come O 0 1.3749155980402605e-10
from O 0 6.753484490390482e-12
The O 0 4.170022313565447e-11
Netherlands O 0 1.0718842702317488e-07
. O 0 2.6698048216644565e-09
. O 0 3.936529324732874e-09

Complement B-Disease 1 0.9904450178146362
C7 I-Disease 1 0.9999997615814209
deficiency I-Disease 1 1.0
: O 0 2.3062807485985104e-07
seven O 0 1.2692061623909012e-08
further O 0 5.078201859021192e-09
molecular O 0 7.487054745070054e-07
defects O 0 0.28253763914108276
and O 0 1.985309916463507e-09
their O 0 8.644802651502914e-10
associated O 0 1.520832348944623e-08
marker O 0 3.0911803605704335e-06
haplotypes O 0 1.821096520870924e-05
. O 0 7.413885327878234e-08

Seven O 0 8.139716101140948e-07
further O 0 8.978521748304047e-08
molecular O 0 5.849527795476206e-08
bases O 0 1.3183520763959677e-07
of O 0 2.7964046012129984e-07
C7 B-Disease 1 1.0
deficiency I-Disease 1 1.0
are O 0 1.1950368161706137e-07
described O 0 3.2559441933699418e-06
. O 0 5.974737149472276e-08

All O 0 2.9230838194393982e-08
these O 0 1.155567419530712e-09
new O 0 5.014902937361398e-10
molecular O 0 2.996058157123116e-08
defects O 0 1.3042007594776805e-05
involve O 0 1.8345955865584074e-09
single O 0 2.1626604507218872e-08
- O 0 5.3257206644730104e-08
nucleotide O 0 7.632799281509506e-09
events O 0 9.550326085516758e-10
, O 0 9.508099169108775e-11
deletions O 0 5.545533809936387e-09
and O 0 1.1947713929316706e-09
substitutions O 0 1.0303311981374463e-08
, O 0 2.3319596254012254e-10
some O 0 2.2863570411923995e-11
of O 0 4.2211958754811985e-12
which O 0 1.6904432020847793e-10
alter O 0 1.3770480755681547e-08
splice O 0 3.871378950748294e-08
sites O 0 3.2773204150515767e-09
, O 0 3.5841807299874517e-10
and O 0 9.867026085075281e-10
others O 0 4.023599231572916e-09
codons O 0 3.608342780125895e-08
. O 0 1.6656532153547232e-08

They O 0 7.838773399271304e-07
are O 0 1.483647760203155e-09
distributed O 0 1.2005416660798574e-09
along O 0 9.065672657015966e-10
the O 0 3.969476136678196e-10
C7 O 0 4.6747646820222144e-07
gene O 0 6.948417397012463e-09
, O 0 2.1346063805438575e-10
but O 0 2.466890580699044e-10
predominantly O 0 4.813016096782974e-10
towards O 0 2.2431370649833582e-10
the O 0 1.8876178398130605e-10
3 O 0 3.0108302517817265e-09
end O 0 1.0727653432240913e-08
. O 0 2.7911685407389086e-08

All O 0 1.2706721008726163e-07
were O 0 1.031440088894442e-08
found O 0 2.3022705963882117e-09
in O 0 3.707375795247714e-10
compound O 0 2.6124936880478344e-07
heterozygous O 0 5.765692094428232e-06
individuals O 0 6.320189704922541e-09
. O 0 1.0021421026351618e-08

The O 0 3.6207154607836856e-06
C6 O 0 0.019481303170323372
/ O 0 0.00044581256224773824
C7 O 0 0.00047573272604495287
marker O 0 0.00013132448657415807
haplotypes O 0 0.00014482384722214192
associated O 0 4.454689417343616e-07
with O 0 7.298703863511946e-09
most O 0 2.2678696609546023e-07
C7 B-Disease 1 0.923319399356842
defects I-Disease 1 0.975145697593689
are O 0 1.3003011112289187e-08
tabulated O 0 3.6025392091687536e-07
. O 0 5.813664660792028e-09
. O 0 1.2251412329078448e-08

A O 0 8.291840458696242e-07
genome O 0 7.059592377345325e-08
- O 0 4.960809860676818e-07
wide O 0 1.7272878238827616e-08
search O 0 9.763611030777497e-10
for O 0 1.0786897763903625e-10
chromosomal O 0 1.155339290903612e-07
loci O 0 2.0248691612323455e-08
linked O 0 1.678877652011579e-06
to O 0 2.2361766127687588e-07
mental O 1 0.5184277296066284
health O 0 3.173879861151363e-07
wellness O 0 2.24687369154708e-07
in O 0 1.4411968285443777e-09
relatives O 0 2.573140811534813e-08
at O 0 4.002105036260417e-10
high O 0 2.5364871092392605e-08
risk O 0 5.857722840119095e-08
for O 0 1.8436503879115662e-08
bipolar B-Disease 1 0.9999936819076538
affective I-Disease 1 0.9999443292617798
disorder I-Disease 1 0.9987921118736267
among O 0 4.954778365373613e-09
the O 0 5.436361916189014e-10
Old O 0 5.917554446455142e-08
Order O 0 9.566519132420126e-09
Amish O 0 1.2884529496659525e-06
. O 0 3.75366475680039e-08

Bipolar B-Disease 1 0.9999923706054688
affective I-Disease 1 0.9999797344207764
disorder I-Disease 1 0.9999980926513672
( O 0 0.00016164501721505076
BPAD B-Disease 1 0.9999995231628418
; O 0 0.0011773293372243643
manic B-Disease 1 0.9999715089797974
- I-Disease 1 0.9999974966049194
depressive I-Disease 1 0.9999998807907104
illness I-Disease 1 0.9994588494300842
) O 0 1.917406677875988e-09
is O 0 2.8042033139996647e-09
characterized O 0 3.996944641926348e-08
by O 0 9.380300980410539e-10
episodes O 0 1.0811832318324832e-08
of O 0 1.4346221433036987e-10
mania B-Disease 0 1.6096273611765355e-06
and O 0 1.832333929030483e-08
/ O 0 1.658249004776735e-07
or O 0 1.060202503566643e-08
hypomania B-Disease 0 0.0002100630517816171
interspersed O 0 3.473268748166447e-07
with O 0 1.1709563318973437e-09
periods O 0 1.11746922826228e-08
of O 0 6.572718480590822e-10
depression B-Disease 0 1.8921381297332118e-06
. O 0 4.551821319864757e-08

Compelling O 0 3.82283833459951e-05
evidence O 0 2.5790623681132274e-07
supports O 0 1.4904728118381172e-08
a O 0 1.0897872604331837e-09
significant O 0 1.6944726732859294e-09
genetic O 0 5.67868863043941e-09
component O 0 2.3274016047736268e-09
in O 0 2.445373903370296e-10
the O 0 1.1066870753140279e-09
susceptibility O 0 0.0004764136974699795
to O 0 1.687364346025788e-07
develop O 0 3.129247033939464e-06
BPAD B-Disease 1 0.9999992847442627
. O 0 6.477399665527628e-07

To O 0 2.1327370802737278e-07
date O 0 9.134274847610868e-08
, O 0 3.121091607383164e-09
however O 0 2.8568944987483746e-09
, O 0 1.5255198493324684e-10
linkage O 0 2.0383540189072846e-08
studies O 0 5.489607102227012e-10
have O 0 4.572535128311017e-10
attempted O 0 1.3744136495574821e-08
only O 0 2.073075322517326e-10
to O 0 9.079027113445548e-11
identify O 0 1.0776272096890693e-09
chromosomal O 0 3.026082850965395e-08
loci O 0 3.8046747974362916e-09
that O 0 2.0095705099976158e-09
cause O 0 1.6980486350348656e-08
or O 0 3.3944438926347686e-10
increase O 0 5.679728243279669e-09
the O 0 7.915595401364328e-10
risk O 0 1.666755977680623e-08
of O 0 4.679149290254259e-10
developing O 0 1.1717327197402483e-07
BPAD B-Disease 1 0.9999912977218628
. O 0 3.4682540217545466e-07

To O 0 2.870880564387335e-07
determine O 0 6.402112973091789e-08
whether O 0 1.7139210939376426e-08
there O 0 2.187492853522599e-09
could O 0 3.342216459145675e-08
be O 0 6.255213236272539e-09
protective O 0 2.912757963713375e-07
alleles O 0 9.796054634136908e-09
that O 0 4.467157754817208e-10
prevent O 0 1.2869323384734344e-09
or O 0 5.391916912955708e-10
reduce O 0 2.212848926319566e-08
the O 0 1.4389005542625455e-09
risk O 0 4.723069935153035e-09
of O 0 5.472845440723795e-11
developing O 0 6.304189614780853e-09
BPAD B-Disease 1 0.999998927116394
, O 0 9.198255490616702e-10
similar O 0 3.299836792702848e-10
to O 0 3.0594618505297433e-10
what O 0 1.7349693903767616e-10
is O 0 2.6435653666112557e-10
observed O 0 7.06244063231054e-10
in O 0 1.0506816250366313e-10
other O 0 1.5854918489210945e-09
genetic B-Disease 1 0.9999938011169434
disorders I-Disease 1 0.9999998807907104
, O 0 1.7172839816836927e-09
we O 0 8.99394003717191e-10
used O 0 1.2652911891564145e-06
mental O 0 0.43506744503974915
health O 0 3.3561144618943217e-07
wellness O 0 5.341066184882948e-07
( O 0 2.095524587186759e-10
absence O 0 3.0711098109037493e-09
of O 0 6.991296430669536e-11
any O 0 5.074002729088534e-08
psychiatric B-Disease 1 0.9951974749565125
disorder I-Disease 0 0.00040658842772245407
) O 0 2.682292998823499e-10
as O 0 1.5324439495145725e-09
the O 0 1.5405617892483292e-09
phenotype O 0 0.0003791967174038291
in O 0 3.723093222607332e-10
our O 0 1.5823914401025263e-10
genome O 0 4.125461361415006e-10
- O 0 2.915789210078401e-08
wide O 0 2.1905334435246004e-08
linkage O 0 1.7038567534655158e-07
scan O 0 1.2706808547591208e-06
of O 0 5.181388304520418e-11
several O 0 1.0311912435057025e-10
large O 0 2.5419139015880887e-10
multigeneration O 0 1.2641017121950426e-07
Old O 0 1.7806362606620496e-08
Order O 0 3.398978876134606e-10
Amish O 0 4.410371445828787e-08
pedigrees O 0 4.1505163750343854e-08
exhibiting O 0 8.930355122060973e-09
an O 0 6.609994773754124e-10
extremely O 0 7.036389320091985e-07
high O 0 1.1421485623941408e-06
incidence O 0 0.0009382885764352977
of O 0 2.859425585199915e-08
BPAD B-Disease 1 0.9999988079071045
. O 0 3.639461283455603e-07

We O 0 3.3378341868228745e-07
have O 0 4.443764911599146e-09
found O 0 1.0522565041526377e-09
strong O 0 3.5600637993127293e-09
evidence O 0 2.8461581980110395e-09
for O 0 9.304226833428686e-11
a O 0 8.711407706307739e-10
locus O 0 2.8847450650459905e-08
on O 0 2.1366657776411557e-08
chromosome O 0 1.6170928347492008e-06
4p O 0 3.884755187755218e-06
at O 0 9.42894762268054e-10
D4S2949 O 0 7.873997276419686e-08
( O 0 8.048164912288769e-10
maximum O 0 6.259296725374952e-08
GENEHUNTER O 0 3.875452421198133e-06
- O 0 2.380886030550755e-07
PLUS O 0 3.3271422950065244e-08
nonparametric O 0 1.8788682609738316e-07
linkage O 0 8.970032183697185e-08
score O 0 9.630487518563768e-09
= O 0 6.623830373087003e-09
4 O 0 8.780536853159049e-10
. O 0 1.4082995880571048e-10
05 O 0 5.556799020922654e-09
, O 0 2.2481567996113228e-10
P O 0 1.916687075720347e-08
= O 0 2.2634536467336375e-09
5 O 0 2.4728219472081037e-10
. O 0 5.2866568761578137e-11
22 O 0 2.902325324516397e-10
x O 0 9.007661283533253e-09
10 O 0 4.838014433516946e-10
( O 0 7.799920431761365e-11
- O 0 1.7100198590469518e-07
4 O 0 2.762176709580899e-09
) O 0 1.763148516076285e-10
; O 0 3.262151659910728e-10
SIBPAL O 0 1.654981787169163e-07
Pempirical O 0 2.0840351666606693e-08
value O 0 2.477764937669491e-10
< O 0 1.0644367609558003e-09
3 O 0 3.4585359576233543e-10
x O 0 3.293313710628354e-08
10 O 0 1.0599068289707247e-09
( O 0 6.768807736534654e-11
- O 0 9.09562771767014e-08
5 O 0 1.3910332885558319e-09
) O 0 4.2949074852138835e-11
) O 0 2.6333381655807564e-11
and O 0 3.14823389579999e-10
suggestive O 0 7.499333065652536e-08
evidence O 0 6.962529441878473e-10
for O 0 3.1001628347793186e-11
a O 0 8.673275431192451e-10
locus O 0 2.3562842343949342e-08
on O 0 2.1268951044817186e-08
chromosome O 0 2.9384696972556412e-05
4q O 0 0.26741504669189453
at O 0 1.8505050825012859e-09
D4S397 O 0 6.478047964719735e-08
( O 0 3.0228378133934086e-10
maximum O 0 4.96761209944907e-08
GENEHUNTER O 0 2.5594461021682946e-06
- O 0 2.7981360517514986e-07
PLUS O 0 2.189764813920192e-08
nonparametric O 0 1.0821037932373656e-07
linkage O 0 6.39061994434087e-08
score O 0 1.646875880112475e-08
= O 0 2.3092368017785248e-09
3 O 0 5.261440172432685e-10
. O 0 1.9245208204843323e-10
29 O 0 1.6434139604726283e-09
, O 0 1.0499463798385733e-10
P O 0 1.5092618710355055e-08
= O 0 1.350155431900646e-09
2 O 0 7.350839381636831e-10
. O 0 1.6998680241187003e-10
57 O 0 3.027541994882199e-09
x O 0 2.126813924974158e-08
10 O 0 5.242447587150423e-10
( O 0 7.489044107078513e-11
- O 0 8.372415294388702e-08
3 O 0 1.614319566911604e-09
) O 0 1.1899040086582602e-10
; O 0 3.0839397702209226e-10
SIBPAL O 0 2.3924781089590397e-07
Pempirical O 0 7.400563362125467e-08
value O 0 4.847297008225837e-10
< O 0 1.296157736696557e-09
1 O 0 2.5760499289262384e-10
x O 0 1.9636338777218043e-08
10 O 0 5.581610174054674e-10
( O 0 1.2505003976759355e-10
- O 0 2.0284259960590134e-07
3 O 0 2.912875052274444e-09
) O 0 4.7085831761384256e-11
) O 0 1.8241052765488597e-11
that O 0 1.2211505417969448e-10
are O 0 1.1228329377388491e-10
linked O 0 7.61956613359871e-08
to O 0 9.437070502826828e-08
mental O 0 0.08104410767555237
health O 0 6.845340863037563e-07
wellness O 0 4.103639639652101e-06
. O 0 6.593832324597315e-08

These O 0 1.471555890475429e-07
findings O 0 6.695191956396229e-08
are O 0 7.331013573974587e-10
consistent O 0 1.750741063233363e-08
with O 0 1.743212102445213e-10
the O 0 1.7453581635518134e-10
hypothesis O 0 1.3604860349403225e-08
that O 0 7.845068344947137e-11
certain O 0 7.274181257344026e-11
alleles O 0 1.6424959170535658e-09
could O 0 4.549709942125446e-09
prevent O 0 2.6257573892962682e-09
or O 0 2.924017972194548e-10
modify O 0 2.1337335454063577e-08
the O 0 9.001456247048623e-10
clinical O 0 1.1242124742238957e-07
manifestations O 0 3.772117196376712e-08
of O 0 1.2822060080353026e-09
BPAD B-Disease 1 0.9999996423721313
and O 0 1.504571400801069e-08
perhaps O 0 1.6935227664660601e-09
other O 0 3.621183908286696e-10
related O 0 6.344626513055118e-08
affective B-Disease 1 0.9988219141960144
disorders I-Disease 1 0.9905329942703247
. O 0 3.4587444019962277e-07

Segregation O 0 0.0005491760675795376
distortion O 0 0.003142469795420766
in O 0 1.9556411643861793e-05
myotonic B-Disease 1 0.9999996423721313
dystrophy I-Disease 1 1.0
. O 0 1.683467417024076e-05

Myotonic B-Disease 1 0.9999998807907104
dystrophy I-Disease 1 1.0
( O 1 0.974212646484375
DM B-Disease 1 1.0
) O 0 8.804374829196604e-08
is O 0 7.684832326049218e-09
an O 0 3.6770257949569896e-09
autosomal B-Disease 1 0.9115241169929504
dominant I-Disease 1 0.9833024144172668
disease I-Disease 0 0.15389376878738403
which O 0 3.93581096602702e-08
, O 0 2.4263441256167084e-10
in O 0 7.455466799477506e-11
the O 0 7.126441797788985e-11
typical O 0 1.661563153732004e-08
pedigree O 0 2.0833006431075773e-07
, O 0 1.6705928307381157e-10
shows O 0 4.978838452629475e-10
a O 0 4.258204067131288e-10
three O 0 3.869388975896726e-10
generation O 0 6.549183417803306e-09
anticipation O 0 1.4547246074414488e-08
cascade O 0 2.2408988797906204e-07
. O 0 3.6806902414809883e-08

This O 0 6.073550196106225e-08
results O 0 5.647560996635548e-08
in O 0 1.8080251962260263e-08
infertility B-Disease 0 0.19710925221443176
and O 0 0.002717262599617243
congenital B-Disease 1 0.9999998807907104
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 3.000727701873984e-07
CDM B-Disease 0 1.7776961840354488e-06
) O 0 1.6732913943329208e-09
with O 0 3.328357867093956e-10
the O 0 2.6896448956925667e-10
disappearance O 0 3.1302981540193286e-08
of O 0 2.2047081937870416e-09
DM B-Disease 1 1.0
in O 0 3.733400788519248e-08
that O 0 2.2789501841202764e-08
pedigree O 0 1.955321977220592e-06
. O 0 4.787303353737116e-08

The O 0 1.5041525358583385e-08
concept O 0 6.240412186997446e-09
of O 0 5.44733314011836e-10
segregation O 0 2.7486082743166662e-08
distortion O 0 3.65510345545772e-06
, O 0 6.853304590492826e-10
where O 0 7.943151691947037e-10
there O 0 2.858637215830129e-10
is O 0 4.009286791450961e-10
preferential O 0 1.2053743780882087e-08
transmission O 0 2.838548063266444e-08
of O 0 2.932416462431142e-11
the O 0 1.0504952463463724e-10
larger O 0 1.0546232775965336e-09
allele O 0 5.103450462229375e-08
at O 0 2.2917721886894782e-10
the O 0 2.6375630568509223e-09
DM B-Disease 1 0.9999998807907104
locus O 0 8.94328513822984e-06
, O 0 7.405049018416321e-09
has O 0 6.236200444931228e-09
been O 0 1.1717518066944876e-09
put O 0 2.8405451324431397e-09
forward O 0 1.8450846406281585e-09
to O 0 1.6644043920877039e-09
explain O 0 1.3908004525831075e-08
partially O 0 8.426115272186507e-08
the O 0 3.4428054851431966e-10
maintenance O 0 1.755027412286836e-08
of O 0 1.1688210399540822e-09
DM B-Disease 1 0.9999996423721313
in O 0 1.2329026688462363e-08
the O 0 1.844102981429785e-09
population O 0 9.82069359167781e-09
. O 0 9.112953947010283e-09

In O 0 3.817702776132137e-08
a O 0 1.342053135289234e-08
survey O 0 1.742818334093954e-08
of O 0 4.920570617628073e-10
DM B-Disease 1 0.9999997615814209
in O 0 3.860900790186861e-07
Northern O 0 3.557022125733056e-07
Ireland O 0 6.11715833542803e-08
, O 0 8.743468171701352e-10
59 O 0 1.1702290692028328e-08
pedigrees O 0 2.7037303951260583e-08
were O 0 8.26069346260283e-09
ascertained O 0 2.0698993807855004e-07
. O 0 1.4838012596385397e-08

Sibships O 0 3.988471144111827e-05
where O 0 7.310772787150199e-08
the O 0 5.707417316536123e-10
status O 0 4.1335265765773954e-10
of O 0 1.927855791672428e-11
all O 0 2.760735910711798e-11
the O 0 2.6377216383322022e-11
members O 0 9.648017107455331e-11
had O 0 6.2133098666095066e-09
been O 0 1.1758130025185665e-09
identified O 0 1.2770804413975156e-09
were O 0 2.6975774392035134e-10
examined O 0 1.3018340849768606e-09
to O 0 2.0969520564406707e-10
determine O 0 2.1640622627217e-09
the O 0 1.055037307517992e-10
transmission O 0 1.3737690096604638e-08
of O 0 4.386497415298507e-11
the O 0 2.5435544781515773e-09
DM B-Disease 1 0.9999991655349731
expansion O 0 3.1168692515848306e-08
from O 0 9.46040024096817e-10
affected O 0 6.362109949975547e-09
parents O 0 1.984711728297839e-09
to O 0 5.644066325416475e-10
their O 0 1.704823837656022e-09
offspring O 0 1.467083023953819e-07
. O 0 1.4088491262498337e-08

Where O 0 1.4585609733330784e-06
the O 0 1.4060089981171586e-08
transmitting O 0 3.383852913430019e-07
parent O 0 6.249860717844058e-08
was O 0 2.349857375349984e-08
male O 0 7.124099710154042e-08
, O 0 4.411462750653072e-09
58 O 0 2.445768814141047e-07
. O 0 3.56714124905011e-08

3 O 0 1.0265921446261927e-06
% O 0 4.035358269760536e-09
of O 0 8.567876269571784e-11
the O 0 5.131791658286033e-10
offspring O 0 1.1959808432493446e-07
were O 0 2.5153275018396926e-08
affected O 0 4.73250150179183e-09
, O 0 5.509169231920907e-10
and O 0 7.283958436410387e-10
in O 0 1.0242168918539463e-10
the O 0 4.7915255096953047e-11
case O 0 3.6687171078853e-09
of O 0 9.318626599530422e-12
a O 0 1.0789336535310667e-08
female O 0 9.690777460491518e-07
transmitting O 0 1.787882411008468e-07
parent O 0 3.363345157936237e-08
, O 0 1.3941675591766511e-09
68 O 0 1.263928055550423e-07
. O 0 1.8799843459760268e-08

7 O 0 6.7281957853992935e-06
% O 0 1.463960757064342e-07
were O 0 2.2174541314257112e-08
affected O 0 1.4989892349603906e-07
. O 0 1.126322146660641e-07

Studies O 0 4.4151946099191264e-07
on O 0 1.7199596413774998e-08
meiotic O 0 4.1255211158386373e-07
drive O 0 2.799828564548079e-07
in O 0 1.4070069553895337e-08
DM B-Disease 1 0.9999997615814209
have O 0 1.143340614362387e-05
shown O 0 1.11439831584903e-07
increased O 0 5.776305656013392e-09
transmission O 0 3.683434224299731e-09
of O 0 8.602635964694016e-12
the O 0 3.100890030860448e-11
larger O 0 2.2071486860397727e-09
allele O 0 5.428927707384901e-08
at O 0 2.938722321044196e-10
the O 0 1.0176919307269827e-09
DM B-Disease 1 0.9999986886978149
locus O 0 1.0841445146070328e-06
in O 0 7.83575959673044e-09
non O 0 7.140207003430987e-08
- O 0 0.09468832612037659
DM O 1 0.9999998807907104
heterozygotes O 0 0.000455334346042946
for O 0 3.919614144365369e-08
CTGn O 0 4.9134382607007865e-06
. O 0 5.3311786984977516e-08

This O 0 4.942586073752864e-08
study O 0 3.1985694093350503e-09
provides O 0 1.617836420386709e-09
further O 0 2.892940886844997e-10
evidence O 0 1.7318723122272672e-09
that O 0 8.231450521201111e-10
the O 0 1.2551607531108289e-09
DM B-Disease 1 0.9999988079071045
expansion O 0 7.266633872404782e-08
tends O 0 2.9362891496020893e-07
to O 0 3.7192058321977584e-09
be O 0 7.184588923792035e-09
transmitted O 0 1.755935699065958e-07
preferentially O 0 6.533577447953576e-07
. O 0 3.2054845888751515e-08

Diagnosis O 1 0.9976305961608887
of O 0 9.50188587012235e-06
hemochromatosis B-Disease 1 0.9999957084655762
. O 0 7.335674126807135e-06

If O 0 3.170519630657509e-05
untreated O 0 0.017908552661538124
, O 0 3.1511572728959436e-07
hemochromatosis B-Disease 1 0.9999996423721313
can O 0 6.000987468723906e-06
cause O 0 5.546886313823052e-06
serious O 0 0.007086416706442833
illness O 1 0.8343527913093567
and O 0 5.9132556629037936e-08
early B-Disease 0 1.0087104840295069e-07
death I-Disease 0 0.000274522986728698
, O 0 1.2017307149392309e-09
but O 0 2.3691490991240016e-09
the O 0 8.108874682832834e-10
disease O 0 2.551846307596861e-07
is O 0 2.012205513324261e-09
still O 0 6.780860672961353e-08
substantially O 0 1.9751155377889518e-07
under O 0 2.29187122613439e-07
- O 1 0.959775447845459
diagnosed O 1 0.9929186701774597
. O 0 9.413412982439695e-08

The O 0 3.5605136616823074e-08
cornerstone O 0 1.4430355577133014e-07
of O 0 3.409276749799517e-10
screening O 0 7.813686586644053e-09
and O 0 1.0832345020972411e-09
case O 0 6.043133549127333e-09
detection O 0 4.642790596420809e-09
is O 0 5.527368007740563e-10
the O 0 3.7835248822837286e-11
measurement O 0 7.389923784018038e-09
of O 0 5.162339999920107e-11
serum O 0 2.5500842326664497e-08
transferrin O 0 5.268505276490032e-08
saturation O 0 2.8996835155226108e-08
and O 0 4.72673511442423e-10
the O 0 1.6352647014272748e-10
serum O 0 2.722819658629305e-07
ferritin O 0 3.963786639360478e-06
level O 0 1.80970207708242e-08
. O 0 1.1673354727292917e-08

Once O 0 3.1369677344628144e-06
the O 0 1.529329196614526e-08
diagnosis O 0 8.53883375384612e-06
is O 0 4.867162228805455e-09
suspected O 0 5.215634146793491e-08
, O 0 2.61491184261331e-09
physicians O 0 1.1195044891110228e-08
must O 0 1.8211000485379714e-09
use O 0 3.788511726554589e-09
serum O 0 6.057850328033965e-07
ferritin O 0 5.062588388682343e-05
levels O 0 1.4014040594645394e-08
and O 0 3.039768214918581e-09
hepatic O 0 1.3696334235646646e-06
iron O 0 0.0012335388455539942
stores O 0 7.191378159632222e-08
on O 0 1.061505638944027e-08
liver O 0 1.169485926766356e-06
biopsy O 0 0.00016561437223572284
specimens O 0 1.358476442447909e-08
to O 0 3.4559197725769764e-09
assess O 0 1.377068656438496e-06
patients O 0 9.550836693961173e-06
for O 0 1.3815823485252565e-10
the O 0 1.2584105979485116e-10
presence O 0 1.5041459189291118e-09
of O 0 3.304938822612513e-10
iron B-Disease 0 0.0038641784340143204
overload I-Disease 0 0.00013749943173024803
. O 0 4.8006349118168146e-08

Liver O 1 0.8494754433631897
biopsy O 1 0.8371268510818481
is O 0 1.571523569054989e-07
also O 0 4.099030892490418e-09
used O 0 8.920102434473165e-10
to O 0 5.103941713713311e-10
establish O 0 1.4024300609705165e-09
the O 0 1.7450318967604517e-10
presence O 0 1.7435323185210905e-09
or O 0 4.699479139169682e-10
absence O 0 4.393962527160511e-09
of O 0 5.063440222663473e-10
cirrhosis B-Disease 0 4.648614412872121e-05
, O 0 1.6247014844594787e-09
which O 0 3.9176986099676014e-09
can O 0 9.606383599702895e-08
affect O 0 1.0332338433727273e-06
prognosis O 0 0.1451350897550583
and O 0 1.615925171449817e-08
management O 0 1.3468175907860314e-08
. O 0 5.271558300989909e-09

A O 0 1.1091304941146518e-06
DNA O 0 6.212399625837861e-07
- O 0 1.5755348385937396e-06
based O 0 5.8293238680562354e-08
test O 0 6.6435692502864185e-09
for O 0 1.1521951448489887e-10
the O 0 1.2014413075522867e-10
HFE O 0 3.0199370826267113e-07
gene O 0 7.549632030645625e-09
is O 0 3.540978343874457e-10
commercially O 0 3.3418834366472083e-09
available O 0 6.338004565620281e-10
, O 0 7.574403604326818e-11
but O 0 1.230613111413703e-10
its O 0 2.998277320864773e-11
place O 0 5.648007617153894e-10
in O 0 2.681019573014254e-10
the O 0 9.822168633988326e-10
diagnosis O 0 9.517004400549922e-06
of O 0 2.5926529811926002e-09
hemochromatosis B-Disease 1 1.0
is O 0 2.069538282967187e-07
still O 0 4.934579678206319e-08
being O 0 2.3758067513313108e-08
evaluated O 0 9.503615672201704e-08
. O 0 1.0493107716058603e-08

Currently O 0 1.4110106576481485e-06
, O 0 1.5859999979994654e-09
the O 0 3.529890268971769e-11
most O 0 8.225231606928674e-11
useful O 0 2.1955338935786273e-10
role O 0 3.3604949378762683e-10
for O 0 6.361096371865216e-11
this O 0 1.9139526075129254e-10
test O 0 4.224085525805776e-09
is O 0 2.59102045374604e-10
in O 0 1.8796518161390274e-11
the O 0 3.3152664641322716e-11
detection O 0 3.850293861518139e-09
of O 0 1.925402948188548e-09
hemochromatosis B-Disease 1 0.9999998807907104
in O 0 8.768942016956771e-09
the O 0 2.86480533739919e-10
family O 0 1.29539412530022e-09
members O 0 3.970852119339341e-11
of O 0 5.4970646090612973e-11
patients O 0 6.80481733184024e-08
with O 0 8.940418544378659e-11
a O 0 9.612722173812926e-09
proven O 0 1.1274586313447799e-06
case O 0 1.645786262827187e-08
of O 0 1.7889237313717388e-10
the O 0 4.230357841805699e-09
disease O 0 1.577018679199682e-06
. O 0 2.9425281766748412e-08

It O 0 7.957321912499538e-08
is O 0 2.2477377736862536e-09
crucial O 0 5.136651104464818e-09
to O 0 3.803356491971499e-07
diagnose O 1 0.9999876022338867
hemochromatosis B-Disease 1 1.0
before O 0 0.00014722428750246763
hepatic B-Disease 1 0.9687232971191406
cirrhosis I-Disease 1 0.8037516474723816
develops O 0 3.120920518995263e-05
because O 0 6.094181514981756e-08
phlebotomy O 0 1.3264566405268852e-05
therapy O 0 7.611309229105245e-06
can O 0 2.1406062700179973e-08
avert O 0 5.361609964893432e-06
serious O 1 0.9532079100608826
chronic O 1 0.9999972581863403
disease O 1 0.952184796333313
and O 0 2.545933952546875e-08
can O 0 1.0239014969215532e-08
even O 0 1.629835044703043e-09
lead O 0 5.436613825793302e-09
to O 0 4.367492145718188e-09
normal O 0 1.6265687463601353e-08
life O 0 2.476298099907126e-08
expectancy O 0 4.83162878595067e-08
. O 0 1.8455202643874458e-10
. O 0 2.2177786274113487e-09

Prevalence O 0 0.005879451986402273
of O 0 1.3912940133309348e-08
the O 0 1.4697172368016709e-09
I1307K O 0 2.3001568649760884e-07
APC B-Disease 0 6.72480737762271e-08
gene O 0 1.2560570361586088e-08
variant O 0 6.484501113845909e-08
in O 0 8.902425463475083e-10
Israeli O 0 8.316582267298145e-08
Jews O 0 2.3414896688223052e-09
of O 0 5.4152682338326485e-11
differing O 0 7.4349113532434785e-09
ethnic O 0 3.6185066054628123e-09
origin O 0 5.097669397713389e-09
and O 0 1.5127145758242477e-08
risk O 0 2.3758890677072486e-07
for O 0 1.5077369425853249e-05
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 7.769046419525694e-07

BACKGROUND O 0 5.8885616454062983e-05
& O 0 6.338166826935776e-07
AIMS O 0 1.3815817112572404e-07
Israeli O 0 8.384657235183113e-08
Jews O 0 2.2731274640364063e-09
of O 0 3.584452526461668e-11
European O 0 2.7792621537514606e-09
birth O 0 2.9191671302442046e-08
, O 0 4.830361111096693e-10
i O 0 2.202438675880103e-09
. O 0 3.267779796756187e-11
e O 0 1.7955383013745774e-10
. O 0 4.117236759859644e-11
, O 0 9.059739763950247e-11
Ashkenazim O 0 9.182466342849693e-09
, O 0 1.5586731905159468e-10
have O 0 6.309803235460265e-10
the O 0 3.449064589489126e-09
highest O 0 0.1400492787361145
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
incidence O 0 0.0006446464103646576
of O 0 7.949543801011316e-11
any O 0 5.981413142563952e-10
Israeli O 0 3.5561708955356153e-07
ethnic O 0 1.608937871822036e-08
group O 0 8.248495220186669e-08
. O 0 1.235711355462854e-08

The O 0 2.435945702927711e-07
I1307K O 0 4.908220944344066e-06
APC B-Disease 0 5.228806685408927e-07
gene O 0 1.2633883272883395e-07
variant O 0 4.275382252671989e-06
was O 0 5.622067078547843e-07
found O 0 5.2531703431668575e-09
in O 0 1.070496025157297e-09
6 O 0 2.5571271322633038e-08
. O 0 2.6881087578090046e-08

1 O 0 8.1816028796311e-07
% O 0 1.2441542907026815e-08
of O 0 4.882871537659206e-11
American O 0 1.4694425676253786e-09
Jews O 0 5.247352330428612e-09
, O 0 6.272402042206693e-10
28 O 0 2.6449080703372374e-09
% O 0 2.519938598066762e-11
of O 0 1.754766991435286e-11
their O 0 3.520885272223495e-08
familial O 1 0.9999595880508423
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
cases O 0 0.00019309253548271954
, O 0 3.283301852619047e-09
but O 0 1.9380850257988413e-09
not O 0 4.720329682683655e-10
in O 0 9.116525589991653e-11
non O 0 2.639415130900602e-09
- O 0 1.6340338788722875e-06
Jews O 0 1.3088937578231707e-07
. O 0 1.5422619625837797e-08

We O 0 2.5532995096000377e-07
assessed O 0 9.647495602393974e-08
the O 0 1.4293651817709474e-09
I1307K O 0 5.639013807012816e-07
prevalence O 0 1.91834814700087e-07
in O 0 6.211505199082978e-10
Israeli O 0 5.320481832882251e-08
Jews O 0 1.6611313435888064e-09
of O 0 5.101116751227153e-11
differing O 0 4.343235104897758e-09
ethnic O 0 2.318858660643741e-09
origin O 0 5.019939131045703e-09
and O 0 1.963030982210512e-08
risk O 0 3.3973435620282544e-07
for O 0 3.2174379157368094e-05
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 1.4229252656150493e-06

METHODS O 0 1.5420112049469026e-06
DNA O 0 3.71517018038503e-07
samples O 0 1.0131314454042695e-08
from O 0 1.0159208196913738e-10
500 O 0 2.161553019908169e-10
unrelated O 0 1.8753205655031024e-09
Jews O 0 1.3110238450408929e-09
of O 0 3.4774322310582306e-11
European O 0 6.705589417066449e-10
or O 0 5.292490889985402e-10
non O 0 2.4343276283644855e-09
- O 0 1.031571855492075e-06
European O 0 1.6916866130145536e-08
origin O 0 2.150582378845911e-09
, O 0 1.182437897595534e-10
with O 0 1.3688658540012e-10
or O 0 1.3197339054915602e-10
without O 0 1.0423202578824231e-10
a O 0 8.560464004325752e-10
personal O 0 2.0941042677691257e-08
and O 0 1.3834453582717288e-08
/ O 0 4.01242736813856e-08
or O 0 6.203904057144882e-10
family O 0 1.684737016560689e-09
history O 0 3.5069810944143853e-10
of O 0 1.0810130568472687e-10
neoplasia B-Disease 0 3.714199863225076e-07
, O 0 8.152296060437436e-10
were O 0 1.1392632393025792e-09
examined O 0 6.941370589430562e-09
for O 0 5.720535850572972e-11
the O 0 2.0038587456028267e-10
I1307K O 0 7.328097950676238e-08
variant O 0 4.1795122029952836e-08
by O 0 9.2612029156669e-11
the O 0 9.383731985890265e-11
allele O 0 4.06447426826162e-08
- O 0 3.375427226615102e-08
specific O 0 3.4658742542603704e-09
oligonucleotide O 0 2.000738504648325e-06
( O 0 3.836344131258329e-09
ASO O 0 8.823167263471987e-07
) O 0 5.25545218454937e-10
method O 0 4.211963045008815e-08
. O 0 2.5962867411521984e-08

RESULTS O 0 7.47620561014628e-06
In O 0 2.3912627433730904e-09
persons O 0 1.7880922298374458e-09
at O 0 2.440639912393294e-10
average O 0 2.5369759626414634e-08
risk O 0 1.8724929873314977e-07
for O 0 0.00025895595899783075
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, O 0 4.219264226890118e-08
I1307K O 0 3.033691484688461e-07
was O 0 8.126006179054457e-08
found O 0 1.3395053954923242e-09
in O 0 3.390192848673479e-10
5 O 0 5.7890781057778895e-09
. O 0 1.978864894169874e-08

0 O 0 9.280777703679632e-06
% O 0 1.7110663108610424e-08
of O 0 1.933192217418167e-10
120 O 0 4.648745388635689e-09
European O 0 3.264518655399229e-09
and O 0 9.340261009072037e-09
1 O 0 4.046937007728957e-08
. O 0 2.2955717327022285e-08

6 O 0 9.130770877163741e-07
% O 0 4.879133985724593e-09
of O 0 6.567790061806633e-11
188 O 0 9.487619578862905e-09
non O 0 7.85039055983816e-09
- O 0 8.499476393808436e-07
European O 0 1.5920988971629413e-08
Jews O 0 3.228260325727206e-08
( O 0 7.195432583095851e-10
P O 0 2.5244989387829264e-07
= O 0 2.7579877937000674e-08
0 O 0 7.495025933224042e-09
. O 0 5.985977824529698e-10
08 O 0 4.291145216939185e-09
) O 0 1.204794597420289e-09
. O 0 8.27671708947264e-09

It O 0 3.737729628028319e-07
occurred O 0 1.52523412566552e-07
in O 0 5.807259118029151e-09
15 O 0 4.523959518110132e-08
. O 0 2.8070303415006492e-08

4 O 0 1.870111987045675e-06
% O 0 2.161810819245602e-08
of O 0 5.701411565084413e-10
52 O 0 1.935434283950599e-07
Ashkenazi O 0 5.592543175225728e-07
Israelis O 0 1.9627132985533535e-07
with O 0 7.839960680655622e-09
familial O 0 0.000358079734724015
cancer B-Disease 0 0.009379399940371513
( O 0 5.181265194664775e-09
P O 0 1.2199037655591383e-06
= O 0 2.2857063797232513e-08
0 O 0 1.3349762184589054e-08
. O 0 2.7242835765051154e-10
02 O 0 1.060153409504494e-09
) O 0 2.444621761965582e-11
and O 0 1.4509046741828513e-10
was O 0 1.082999467882928e-08
not O 0 2.4028379286278323e-10
detected O 0 1.6407517566818797e-09
in O 0 8.147566649130411e-11
51 O 0 7.027320503283363e-09
non O 0 3.6965869254501627e-10
- O 0 4.468244441113711e-08
European O 0 2.048248237684902e-09
Jews O 0 5.250966328418372e-09
at O 0 5.01291341770127e-10
increased O 0 2.415244750864076e-07
cancer B-Disease 0 8.387594789383002e-06
risk O 0 1.2855939246492198e-07
. O 0 2.0925352117728835e-08

Colorectal B-Disease 1 0.9975513815879822
neoplasia I-Disease 0 0.024134712293744087
occurred O 0 9.471145858697128e-06
personally O 0 1.6442414789707982e-06
or O 0 2.458047765330207e-09
in O 0 2.991829006759872e-10
the O 0 3.6290734306554384e-10
families O 0 4.956666743716198e-10
of O 0 2.699119747151535e-11
13 O 0 4.789125207516065e-10
of O 0 6.602682983691821e-11
20 O 0 3.402379711303638e-09
Ashkenazi O 0 5.12989792866847e-08
I1307K O 0 1.1478657313546137e-07
carriers O 0 9.37955402235957e-09
, O 0 1.3652988462009574e-10
8 O 0 1.0198366456881658e-10
of O 0 7.626621556511282e-11
whom O 0 8.265914175353828e-08
also O 0 1.6640559152847345e-08
had O 0 1.4081829036172167e-08
a O 0 6.789409034979599e-10
personal O 0 1.8292086068072422e-08
or O 0 1.4821656124652804e-09
family O 0 2.6025124277850864e-09
history O 0 3.7624992010876213e-10
of O 0 9.510697784875788e-10
noncolonic O 0 4.279188942746259e-05
neoplasia B-Disease 0 5.055911242379807e-05
. O 0 1.1452250703314348e-07

CONCLUSIONS O 0 1.9630553651950322e-05
The O 0 2.1933260541118216e-08
I1307K O 0 9.105327762881643e-07
APC O 0 5.352421794668771e-07
variant O 0 2.6016462015832076e-06
may O 0 3.171840035065543e-08
represent O 0 4.529014663301467e-10
a O 0 6.560873178074189e-09
susceptibility O 0 0.001729445531964302
gene O 0 4.88206922000245e-07
for O 0 4.840040332965145e-07
colorectal B-Disease 1 1.0
, I-Disease 0 1.6261532564953995e-08
or I-Disease 0 5.248250722900138e-10
other I-Disease 0 5.192956620270195e-10
, I-Disease 0 4.053965607653254e-09
cancers I-Disease 0 3.788874892052263e-06
in O 0 3.6292551186534183e-09
Ashkenazi O 0 7.488061442018079e-07
Jews O 0 2.182238922898705e-08
, O 0 7.244637112435726e-10
and O 0 8.322826872131373e-10
partially O 0 4.467119651963003e-08
explains O 0 3.53556739440819e-09
the O 0 6.978506661425854e-11
higher O 0 2.544728650022421e-09
incidence O 0 2.9565069780801423e-05
of O 0 2.026064748861245e-06
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
in O 0 8.149377173083394e-09
European O 0 1.2150552564094141e-08
Israelis O 0 4.747073205635388e-07
. O 0 1.821114814504199e-08

Systematic O 0 6.692933766316855e-06
analysis O 0 5.962339741927281e-07
of O 0 5.260730517875345e-09
coproporphyrinogen O 0 5.69998201171984e-06
oxidase O 0 4.958022600476397e-06
gene O 0 5.6718613450357225e-06
defects O 0 0.09098578989505768
in O 0 1.1760737272936694e-08
hereditary B-Disease 0 0.13663144409656525
coproporphyria I-Disease 0 0.001900966977700591
and O 0 1.0787798032652063e-07
mutation O 0 5.042983843850379e-07
update O 0 3.265302268573578e-07
. O 0 1.072951931746502e-07

Hereditary B-Disease 1 0.9988322854042053
coproporphyria I-Disease 0 0.03051663003861904
( O 0 2.453897650411818e-06
HC B-Disease 0 0.0572989322245121
) O 0 3.4889172439989125e-08
is O 0 3.2683644235476095e-08
an O 0 3.1543297041025653e-07
acute O 1 0.9999141693115234
hepatic B-Disease 1 0.9999585151672363
porphyria I-Disease 1 0.9999902248382568
with O 0 3.508354438963579e-06
autosomal O 1 0.9897735714912415
dominant O 0 0.006341258529573679
inheritance O 0 4.067494592163712e-05
caused O 0 8.284859177365433e-06
by O 0 5.315234918867873e-09
deficient B-Disease 0 7.181535579547926e-07
activity I-Disease 0 6.778346217650721e-10
of I-Disease 0 9.76863590018695e-11
coproporphyrinogen I-Disease 0 2.8692325031443033e-06
III I-Disease 0 5.216374120209366e-05
oxidase I-Disease 0 4.1107506376647507e-07
( O 0 3.6132721259463096e-09
CPO O 0 3.1092210974748014e-06
) O 0 4.997355418367988e-09
. O 0 3.1714527892745537e-08

Clinical O 0 0.0007724167080596089
manifestations O 0 7.87673798186006e-06
of O 0 4.33757252338296e-09
the O 0 1.3116547847857873e-08
disease O 0 7.0263836278172676e-06
are O 0 4.830031929969891e-09
characterized O 0 6.92994262863067e-07
by O 0 4.501820782820687e-08
acute O 0 0.008617894724011421
attacks O 0 0.00010176491196034476
of O 0 1.8325785333672684e-08
neurological B-Disease 1 0.9981462955474854
dysfunction I-Disease 0 0.0080350236967206
often O 0 1.101131630321106e-07
precipitated O 0 8.339520007893952e-08
by O 0 5.753322263046812e-10
drugs O 0 1.1828446000450299e-09
, O 0 4.200847170121591e-10
fasting O 0 2.1733786326194604e-08
, O 0 1.1342028427563378e-09
cyclical O 0 8.534255471204233e-07
hormonal O 0 7.145361450966448e-06
changes O 0 2.142763122492397e-08
, O 0 2.502000606696697e-09
or O 0 1.0108075265691241e-08
infectious B-Disease 0 1.5200980669760611e-05
diseases I-Disease 0 2.072359529847745e-05
. O 0 1.2286400874472747e-07

Skin O 1 0.999985933303833
photosensitivity O 1 0.9999064207077026
may O 0 0.009692279621958733
also O 0 6.400573937526133e-08
be O 0 1.5996295843478947e-08
present O 0 1.9226188641141562e-08
. O 0 4.1327897548626424e-08

The O 0 5.413644643681437e-08
seven O 0 8.816083862939195e-09
exons O 0 4.3004881433716946e-08
, O 0 4.0329092843016667e-10
the O 0 1.5312628942609763e-10
exon O 0 3.204885601348906e-08
/ O 0 2.6083181836611402e-08
intron O 0 1.153310790869e-06
boundaries O 0 1.7949032482533767e-08
and O 0 4.4012576916330204e-10
part O 0 3.6361541555507415e-10
of O 0 5.350341350518484e-11
3 O 0 7.19307280405701e-10
noncoding O 0 2.2206664951340827e-08
sequence O 0 4.6559309185845166e-10
of O 0 1.1186937660945251e-11
the O 0 6.45396514009633e-11
CPO O 0 4.5785007785070775e-08
gene O 0 2.6200992486735686e-09
were O 0 6.06806715985897e-10
systematically O 0 3.908794177220898e-09
analyzed O 0 2.93843260834592e-09
by O 0 4.7990531687469584e-11
an O 0 1.0015677176511417e-10
exon O 0 1.1342596195618171e-08
- O 0 4.1877314060911885e-08
by O 0 1.7424617304584444e-09
- O 0 3.201293736765365e-07
exon O 0 8.351034921361133e-07
denaturing O 0 1.2116034667997155e-05
gradient O 0 0.00010835186549229547
gel O 0 7.77347304392606e-06
electrophoresis O 0 4.1191131572304585e-07
( O 0 1.3111038921209683e-09
DGGE O 0 3.064935469865304e-07
) O 0 2.794217912605035e-10
strategy O 0 2.2253845433084507e-09
followed O 0 7.54257600821262e-10
by O 0 2.0757727134390613e-11
direct O 0 1.168617563829244e-10
sequencing O 0 6.017608078501269e-10
in O 0 1.205336386256306e-10
seven O 0 3.379985180629319e-10
unrelated O 0 1.922776426965811e-08
heterozygous O 0 2.3609102299815277e-06
HC B-Disease 0 0.0007430546684190631
patients O 0 0.0002074356161756441
from O 0 1.851952813325397e-09
France O 0 5.05852256083017e-07
, O 0 6.636033500484473e-09
Holland O 0 1.2777909432770684e-06
, O 0 1.5849961343405994e-09
and O 0 3.555713945502248e-09
Czech O 0 5.082873940409627e-06
Republic O 0 5.420515947207605e-08
. O 0 2.1892804014100875e-08

Seven O 0 9.280557833335479e-07
novel O 0 4.0685273461349425e-07
mutations O 0 6.493598334600392e-07
and O 0 2.7321374052036163e-09
two O 0 3.4949551586116456e-10
new O 0 2.3694066708657147e-09
polymorphisms O 0 2.7533419597602915e-06
were O 0 1.2767260670898395e-07
detected O 0 9.528034183858836e-07
. O 0 4.966892319657745e-08

Among O 0 4.389944194826967e-07
these O 0 4.693327060323327e-09
mutations O 0 4.120715502153871e-08
two O 0 1.3183534264271657e-09
are O 0 9.166432612950359e-10
missense O 0 8.818305445856822e-07
( O 0 1.3420294875388095e-09
G197W O 0 2.447864346777351e-07
, O 0 1.3511807228638872e-09
W427R O 0 2.9700277792699126e-08
) O 0 1.5889665971879907e-10
, O 0 4.246846277422556e-11
two O 0 8.879290358532188e-11
are O 0 3.196762576873624e-10
nonsense O 0 6.100415106402579e-08
( O 0 2.153051903430736e-10
Q306X O 0 4.9916611288836066e-08
, O 0 4.195530312056661e-10
Q385X O 0 1.1378609166001752e-08
) O 0 5.6657321195752175e-11
, O 0 8.649778809877162e-11
two O 0 1.0936889588419874e-10
are O 0 1.065882798689799e-10
small O 0 6.297732335625028e-10
deletions O 0 1.1965444457473495e-07
( O 0 7.672819046788959e-10
662de14bp O 0 2.7957941028944333e-07
; O 0 8.918299432281174e-10
1168del3bp O 0 2.98929379027868e-08
removing O 0 9.145091905971015e-10
a O 0 4.711262491241541e-10
glycine O 0 1.07409618976817e-08
at O 0 4.657441099453763e-10
position O 0 1.2716437680637682e-08
390 O 0 5.4042743613536e-09
) O 0 2.4678792343024725e-10
, O 0 1.3796862263770748e-10
and O 0 1.3087846084669508e-10
one O 0 2.792443776211684e-10
is O 0 1.5443679668436516e-10
a O 0 4.144579124343295e-10
splicing O 0 4.43194245747236e-08
mutation O 0 3.8457969253613555e-08
( O 0 2.1008111916742678e-10
IVS1 O 0 1.0831503232111572e-06
- O 0 2.7704968488251325e-06
15c O 0 3.7488573525479296e-06
- O 0 9.317947728959552e-07
- O 0 2.2349581740854774e-06
> O 0 6.834383015075218e-08
g O 0 3.2662211424394627e-07
) O 0 9.771095738075886e-11
which O 0 1.1438634067717501e-10
creates O 0 9.854237426054624e-10
a O 0 6.675014985191297e-10
new O 0 7.552234948526859e-10
acceptor O 0 3.849243590536844e-09
splice O 0 5.910994786972879e-07
site O 0 1.8400534429474646e-07
. O 0 3.043146179493306e-08

The O 0 5.473908260000826e-08
pathological O 0 2.0642988829422393e-07
significance O 0 2.955007127880549e-09
of O 0 3.3329172755003356e-11
the O 0 5.843463907195812e-11
point O 0 1.2620070544144824e-09
mutations O 0 1.2497529233712612e-08
G197W O 0 2.6461965063617754e-08
, O 0 2.573388446780456e-10
W427R O 0 3.608590404269307e-08
, O 0 2.270418297811716e-10
and O 0 8.342785490222937e-11
the O 0 4.329071476294466e-11
in O 0 2.4916743668335073e-10
- O 0 2.3458928808395285e-06
frame O 0 0.0008358258637599647
deletion O 0 4.788568617186684e-07
390delGly O 0 4.589180377934099e-07
were O 0 4.655631435923624e-09
assessed O 0 6.1821960883889915e-09
by O 0 1.0293400853900181e-10
their O 0 8.543235563429619e-11
respective O 0 1.925490183962708e-10
expression O 0 6.713830602578241e-10
in O 0 2.1310866266111006e-11
a O 0 1.4724073349459132e-10
prokaryotic O 0 3.3657804321407525e-10
system O 0 6.220050169369884e-11
using O 0 1.3770835860515973e-10
site O 0 2.102499951917025e-09
- O 0 2.986837444041157e-08
directed O 0 1.639351978610648e-07
mutagenesis O 0 3.96372615796281e-06
. O 0 2.670401855198179e-08

These O 0 1.0249510751236812e-07
mutations O 0 9.642158147471491e-07
resulted O 0 4.9589978345920827e-08
in O 0 4.003219700177141e-10
the O 0 1.0577856646154515e-10
absence O 0 1.9171797482897546e-09
or O 0 1.2939957438895533e-10
a O 0 3.901889034096939e-09
dramatic O 0 5.558540010497381e-07
decrease O 0 5.814909513901512e-07
of O 0 1.400184856947817e-09
CPO O 0 8.0739000622998e-06
activity O 0 6.42748858581399e-08
. O 0 2.8552129549552774e-08

The O 0 3.085837363414612e-08
two O 0 2.907845741972892e-09
polymorphisms O 0 2.6073439585161395e-07
were O 0 8.620273383996846e-09
localized O 0 1.1648516107243267e-07
in O 0 5.809917880128523e-09
noncoding O 0 2.2345224692799093e-07
part O 0 9.100651343629806e-10
of O 0 2.0444640771999367e-11
the O 0 1.681608498282916e-11
gene O 0 3.0452332322461473e-10
1 O 0 1.8308228544317018e-10
) O 0 4.941277942371869e-11
a O 0 1.0540126105240688e-08
C O 0 5.072014914730971e-07
/ O 0 2.0388834798268363e-07
G O 0 0.00041856677853502333
polymorphism O 0 1.95457450899994e-05
in O 0 4.199340875032931e-10
the O 0 1.975133667730944e-10
promotor O 0 1.3947300203653867e-07
region O 0 1.6805647984341476e-09
, O 0 2.1721414944497752e-10
142 O 0 1.9356467539921596e-09
bp O 0 5.4961081019655467e-08
upstream O 0 1.0193101918076763e-09
from O 0 1.0001088499023147e-11
the O 0 6.0810492925889026e-12
transcriptional O 0 1.8864632078674504e-09
initiation O 0 2.7294691506973834e-10
site O 0 1.4848934304367845e-09
( O 0 2.432585799461151e-10
- O 0 9.593017580300511e-08
142C O 0 1.3732078514294699e-06
/ O 0 4.7180300555282884e-08
G O 0 6.875108624626591e-07
) O 0 2.6351129611690283e-10
, O 0 3.419266536575094e-10
and O 0 4.6234882589146764e-10
2 O 0 3.0758096070115926e-10
) O 0 4.9300372811922344e-11
a O 0 2.332788184844503e-09
6 O 0 4.669290731840192e-09
bp O 0 2.586814105143276e-07
deletion O 0 3.511482660201182e-08
polymorphism O 0 3.4844259744204464e-07
in O 0 2.120311010100906e-10
the O 0 5.630257718380882e-11
3 O 0 3.7382996698198667e-10
noncoding O 0 2.4099730211446513e-08
part O 0 5.769343891515177e-10
of O 0 2.5195588670978708e-11
the O 0 1.2778766933507768e-10
CPO O 0 3.201477056791191e-07
gene O 0 1.2307482144535697e-08
, O 0 7.203713181525018e-10
574 O 0 1.3183515612524843e-08
bp O 0 9.995900285275638e-08
downstream O 0 2.3668094151219066e-09
of O 0 2.0304430012330066e-11
the O 0 3.1064248395829e-11
last O 0 2.442210211839324e-09
base O 0 1.756225276317025e-09
of O 0 1.1768483756946502e-11
the O 0 9.856976346256374e-11
normal O 0 4.949866294623462e-09
termination O 0 2.4053072422702826e-08
codon O 0 1.3864620562742402e-08
( O 0 4.3474765454298847e-10
+ O 0 8.84613271523449e-09
574 O 0 3.7892942117423445e-08
delATTCTT O 0 2.800651088818995e-07
) O 0 4.068839043469552e-09
. O 0 1.2419066663937883e-08

Five O 0 5.412126711235032e-07
intragenic O 0 5.04378067489597e-06
dimorphisms O 0 2.5038168587343534e-06
are O 0 4.783960338983206e-09
now O 0 4.349950177839901e-09
well O 0 1.818906247841312e-09
characterized O 0 4.2834280122860946e-08
and O 0 2.0683998958048733e-09
the O 0 3.0812352669329357e-10
high O 0 2.6560300625533273e-09
degree O 0 4.3003522964824015e-10
of O 0 3.817274621398248e-11
allelic O 0 1.6251554768587084e-07
heterogeneity O 0 4.4248139374758466e-07
in O 0 6.138510144637621e-09
HC B-Disease 0 0.0030030091293156147
is O 0 3.947826030525903e-07
demonstrated O 0 1.0367442371261859e-07
with O 0 1.2591958031826778e-10
seven O 0 1.2599717102990127e-10
new O 0 1.9428353023598355e-11
different O 0 1.3985926999859899e-11
mutations O 0 3.5010733201445987e-10
making O 0 6.120406265130995e-11
a O 0 2.88770396483784e-10
total O 0 1.45591400046996e-10
of O 0 9.504708131657935e-11
nineteen O 0 8.864547851317184e-08
CPO O 0 5.363895979826339e-06
gene B-Disease 0 1.2616005733434577e-06
defects I-Disease 0 0.013320766389369965
reported O 0 5.657933144220806e-08
so O 0 2.4681108268254093e-09
far O 0 5.4395492554704106e-09
. O 0 1.224178092229522e-09
. O 0 6.462027357656552e-09

Coincidence O 0 3.4587551454023924e-06
of O 0 3.20606385884048e-09
two O 0 9.34390897988635e-10
novel O 0 1.851176811840105e-08
arylsulfatase O 0 1.7889226455736207e-07
A O 0 1.0134078465284801e-08
alleles O 0 6.678751418576212e-08
and O 0 6.633224192142961e-09
mutation O 0 1.522899850670001e-07
459 O 0 1.1580815595380045e-07
+ O 0 6.822713061183094e-08
1G O 0 1.1678960618155543e-05
> O 0 4.7553601945082846e-08
A O 0 9.516091914463232e-09
within O 0 3.4549030303310246e-10
a O 0 5.079732634527545e-09
family O 0 4.2957168489010655e-08
with O 0 2.7544810876634074e-08
metachromatic B-Disease 1 0.9999994039535522
leukodystrophy I-Disease 1 0.9999980926513672
: O 0 1.6621138909655997e-09
molecular O 0 3.2878140210357287e-09
basis O 0 3.4067026977169235e-10
of O 0 3.083339972231869e-10
phenotypic O 0 6.4344581005570944e-06
heterogeneity O 0 2.6686491764849052e-05
. O 0 2.9186503525124863e-07

In O 0 7.37712610998642e-08
a O 0 1.3358651074213412e-08
family O 0 1.80431172225326e-08
with O 0 1.6981513972780249e-09
three O 0 1.2557360484777291e-08
siblings O 0 1.5235099226629245e-07
, O 0 7.220285480613597e-11
one O 0 2.1820908968628316e-10
developed O 0 4.772904738103989e-09
classical O 0 2.661569276085629e-08
late O 0 5.892561603104696e-07
infantile O 1 0.985782265663147
metachromatic B-Disease 1 0.9999996423721313
leukodystrophy I-Disease 1 0.9999994039535522
( O 0 1.6686939829924086e-07
MLD B-Disease 1 0.9999343156814575
) O 0 3.1482716433828273e-09
, O 0 1.6508031608353235e-09
fatal O 0 1.3779554137727246e-06
at O 0 1.7177229638676295e-09
age O 0 5.0032777920705485e-09
5 O 0 3.539397941398903e-10
years O 0 1.1862200111067978e-09
, O 0 1.7489104608969797e-10
with O 0 1.0405131201096651e-09
deficient O 0 4.4989637899561785e-06
arylsulfatase O 0 5.211030611462775e-07
A O 0 3.5209993143325846e-08
( O 0 6.074691305535396e-10
ARSA O 0 2.6477973733562976e-06
) O 0 2.6139282405246433e-10
activity O 0 9.222340113801408e-10
and O 0 5.893107113408291e-10
increased O 0 1.0292429131197878e-08
galactosylsulfatide O 0 2.107502587023191e-05
( O 0 2.491838557716619e-08
GS O 1 0.9999756813049316
) O 0 1.1458560322807898e-08
excretion O 0 2.0562410441016254e-07
. O 0 1.5457606750146624e-08

The O 0 2.8803027518620183e-08
two O 0 2.063356374648606e-09
other O 0 2.1146324968857044e-10
siblings O 0 2.51130085615614e-08
, O 0 4.6340301040892484e-10
apparently O 0 1.512449898655177e-07
healthy O 0 2.126719467199223e-09
at O 0 1.404485139300249e-10
12 O 0 1.5816069287577506e-10
( O 0 2.0538914319301327e-11
1 O 0 6.185708056882788e-10
/ O 0 5.092635202430529e-09
2 O 0 1.0080615231444767e-09
) O 0 8.186946953703256e-11
and O 0 9.229818576095283e-10
15 O 0 5.685708570624115e-10
years O 0 4.4094417006590447e-10
, O 0 1.1429234642035269e-10
respectively O 0 1.3488118399962445e-09
, O 0 1.8862321427004503e-10
and O 0 3.228528000498443e-10
their O 0 1.6884001141637128e-10
father O 0 5.3753488771235425e-08
, O 0 2.1223502122413862e-10
apparently O 0 2.254024167314128e-08
healthy O 0 7.227977660839713e-10
as O 0 1.3274793764228576e-10
well O 0 4.2705183833646743e-10
, O 0 3.356587230385344e-10
presented O 0 1.0870433442278227e-08
ARSA O 0 4.25799262302462e-05
and O 0 2.958867355573602e-07
GS O 1 0.9999516010284424
values O 0 2.989514857887343e-09
within O 0 4.185281635149529e-11
the O 0 6.947005470880896e-11
range O 0 7.95832022504328e-09
of O 0 1.1165765201326394e-08
MLD B-Disease 1 0.9999995231628418
patients O 1 0.9543540477752686
. O 0 6.675020358670736e-08

Mutation O 0 7.156442734412849e-05
screening O 0 9.103626439355139e-07
and O 0 3.3213838346313196e-09
sequence O 0 1.716465303225334e-09
analysis O 0 1.6646647393869785e-09
disclosed O 0 6.24715257302455e-09
the O 0 3.672164655688093e-11
involvement O 0 5.337501551849755e-10
of O 0 1.187112734502005e-11
three O 0 2.2010517020110143e-10
different O 0 4.99885910443254e-10
ARSA O 0 8.342991350218654e-06
mutations O 0 7.581352434726796e-08
being O 0 9.256986843730886e-10
the O 0 2.5768547018412136e-11
molecular O 0 1.439073527009782e-09
basis O 0 1.3306886148534147e-10
of O 0 8.628785880260281e-11
intrafamilial O 0 1.2144979336881079e-05
phenotypic O 0 2.180039882659912e-05
heterogeneity O 0 1.4351730897033121e-05
. O 0 2.0674885092830664e-07

The O 0 2.527739297875087e-07
late O 0 7.767105216771597e-07
infantile O 0 0.018004249781370163
patient O 1 0.5029031038284302
inherited O 0 1.1920576071133837e-05
from O 0 1.1913261488416538e-09
his O 0 1.1689174073126196e-08
mother O 0 1.4767709721752453e-08
the O 0 5.052545881678583e-11
frequent O 0 4.2587444681885245e-08
0 O 0 3.0938409167902137e-08
- O 0 2.1346734229155118e-06
type O 0 2.0154780941084027e-05
mutation O 0 2.9842755111531005e-07
459 O 0 4.1539848893989983e-08
+ O 0 1.0836525454749335e-08
1G O 0 1.5367070318461629e-06
> O 0 3.662789893610352e-08
A O 0 2.6280934761757635e-08
, O 0 7.174780214391774e-10
and O 0 3.32556593374278e-10
from O 0 6.778575617483185e-11
his O 0 1.2839907803652295e-08
father O 0 7.015631808826583e-08
a O 0 2.594958248280932e-09
novel O 0 1.8429751946769102e-08
, O 0 2.4006482912675153e-10
single O 0 1.6470854680150637e-09
basepair O 0 9.18558740181652e-08
microdeletion O 0 4.168605016729998e-08
of O 0 2.8057629136712947e-11
guanine O 0 1.4943319914806352e-09
at O 0 9.987825844159914e-11
nucleotide O 0 1.468758781264512e-09
7 O 0 7.25272508717012e-10
in O 0 3.734494102847208e-10
exon O 0 8.340983725929618e-08
1 O 0 9.086953411951981e-09
( O 0 1.1455473236665625e-09
7delG O 0 7.925707450340269e-07
) O 0 4.186323732113806e-09
. O 0 2.33842456509592e-08

The O 0 1.1962306700752379e-07
two O 0 8.29250623723965e-08
clinically O 0 0.00021252836450003088
unaffected O 0 4.100763544556685e-05
siblings O 0 4.4992631842433184e-07
carried O 0 1.6174423578263486e-08
the O 0 2.7706176242148217e-10
maternal O 0 4.075101571743289e-07
mutation O 0 1.3333543336102593e-07
459 O 0 8.135310736179235e-08
+ O 0 4.1387217208921356e-08
1G O 0 8.809573955659289e-06
> O 0 5.7043106238552355e-08
A O 0 3.064388209850222e-08
and O 0 3.269852832943343e-09
, O 0 8.169040444094833e-11
on O 0 1.5271685027684612e-09
their O 0 4.792743979464831e-10
paternal O 0 4.922189873468596e-07
allele O 0 3.2874833522100744e-08
, O 0 6.128980656328054e-11
a O 0 2.82949663699128e-10
novel O 0 6.5097789381241e-09
cytosine O 0 1.2960373219073063e-08
to O 0 4.063717973235015e-10
thymidine O 0 3.1238208464401396e-08
transition O 0 1.0147206408461784e-09
at O 0 1.0215869122864873e-10
nucleotide O 0 2.5712063589367062e-09
2435 O 0 1.0250059290228819e-07
in O 0 1.1416559919652514e-09
exon O 0 5.070983988275657e-08
8 O 0 4.95235941144756e-09
, O 0 2.4197996384422993e-10
resulting O 0 9.67948499130955e-10
in O 0 7.402076174223282e-11
substitution O 0 1.1240548491997515e-09
of O 0 1.055806275740423e-10
alanine O 0 2.600688731035916e-07
464 O 0 1.107868712324489e-07
by O 0 7.992395190115076e-09
valine O 0 1.3682399185199756e-05
( O 0 4.166401001981512e-09
A464V O 0 5.909613491894561e-07
) O 0 5.5696598444399115e-09
. O 0 2.9515611288388754e-08

The O 0 2.426853882298019e-07
fathers O 0 1.6671747289365157e-06
genotype O 0 1.1249292583670467e-05
thus O 0 3.974389173322379e-08
was O 0 2.1093418922646379e-07
7delG O 0 4.9943218982662074e-06
/ O 0 1.4445820397668285e-06
A464V O 0 3.62992591362854e-06
. O 0 5.5721066871683433e-08

Mutation O 0 0.0004997524665668607
A464V O 0 1.00885154097341e-05
was O 0 5.090554964226612e-07
not O 0 2.7705346905548822e-09
found O 0 6.446537748061587e-10
in O 0 4.633818051491545e-10
18 O 0 1.3694418043996848e-08
unrelated O 0 1.6586965330134262e-06
MLD B-Disease 1 0.9999998807907104
patients O 1 0.9985474944114685
and O 0 2.3564819429111594e-08
50 O 0 6.557733023271339e-09
controls O 0 4.672973773267586e-06
. O 0 1.0423534746450969e-07

A464V O 0 0.00012677547056227922
, O 0 5.422822013656514e-08
although O 0 4.446418344628e-09
clearly O 0 2.4458895353518528e-08
modifying O 0 4.7175440442970284e-08
ARSA O 0 0.00025366232148371637
and O 0 2.093622470056289e-06
GS O 1 0.9999946355819702
levels O 0 9.992660210400572e-08
, O 0 9.235859299572269e-10
apparently O 0 1.8566824522281422e-08
bears O 0 5.245751388827102e-09
little O 0 5.361397437120274e-10
significance O 0 6.938626340158294e-10
for O 0 3.776029489088728e-10
clinical O 0 5.650534973256072e-08
manifestation O 0 2.442507991418097e-07
of O 0 1.1688773504658911e-08
MLD B-Disease 1 0.9999922513961792
, O 0 1.521430093021081e-08
mimicking O 0 1.890261103199009e-07
the O 0 3.071268128707061e-09
frequent O 0 2.4508572096237913e-06
ARSA O 0 0.0016391807002946734
pseudodeficiency O 0 6.498986476799473e-05
allele O 0 1.390868146700086e-05
. O 0 6.887854198112109e-08

Our O 0 1.3335159110283712e-07
results O 0 4.274629716860545e-08
demonstrate O 0 4.289655741729348e-09
that O 0 1.5353865401301903e-10
in O 0 3.103292275929981e-11
certain O 0 5.018672699641513e-10
genetic O 0 1.2694850681782555e-07
conditions O 0 8.134399104164913e-05
MLD B-Disease 1 0.9999959468841553
- O 0 0.000194277978152968
like O 0 2.71370254267822e-07
ARSA O 0 0.0005048164166510105
and O 0 2.2608408301039162e-07
GS O 1 0.9999446868896484
values O 0 2.2530257659525432e-09
need O 0 2.2393324694558459e-10
not O 0 8.196915368685609e-11
be O 0 1.8847072513761276e-10
paralleled O 0 1.4416429827690536e-08
by O 0 3.168984186174839e-09
clinical O 0 1.5973024574122974e-06
disease O 0 1.0681345656848862e-06
, O 0 1.3923014130501343e-10
a O 0 5.149675685878208e-10
finding O 0 5.729449692459809e-10
with O 0 8.373238213899015e-10
serious O 0 2.762347435236734e-07
diagnostic O 0 2.0837389911321225e-06
and O 0 1.0007461526129191e-07
prognostic O 0 0.002360448706895113
implications O 0 1.6839368299770285e-06
. O 0 9.240113740816014e-08

Moreover O 0 1.4846618796582334e-05
, O 0 3.4136007798224455e-08
further O 0 3.252488056659786e-08
ARSA O 0 0.00011320867633912712
alleles O 0 4.867949883191613e-07
functionally O 0 2.2615199668507557e-07
similar O 0 4.050789037535196e-09
to O 0 3.6116460933044436e-09
A464V O 0 2.736937858571764e-07
might O 0 4.7840721606462466e-08
exist O 0 4.657814134390037e-10
which O 0 2.3944013438637057e-10
, O 0 1.1357262352795772e-10
together O 0 1.2614095878937803e-10
with O 0 5.264160773954529e-10
0 O 0 3.0679849771786394e-08
- O 0 1.2923212125315331e-05
type O 0 5.680196773028001e-05
mutations O 0 4.78275865134492e-07
, O 0 5.705687033952245e-10
may O 0 2.690796918614069e-08
cause O 0 1.1050976667092982e-07
pathological O 0 4.106180313101504e-06
ARSA O 0 0.07368676364421844
and O 0 4.192213509668363e-06
GS O 1 0.9999984502792358
levels O 0 1.1851621906089349e-08
, O 0 1.1357868812122973e-10
but O 0 6.634485738565843e-10
not O 0 1.1434102553664616e-09
clinical O 0 6.984373079887973e-09
outbreak O 0 1.0931311855699732e-08
of O 0 1.5889575766259156e-10
the O 0 3.849419893953154e-09
disease O 0 1.1801352002294152e-06
. O 0 2.214350702800516e-09
. O 0 7.991708628196648e-09

Human O 0 0.0001942124217748642
MLH1 O 1 0.9985606074333191
deficiency O 1 0.9965219497680664
predisposes O 0 0.0027834095526486635
to O 0 4.354196335043525e-06
hematological B-Disease 1 0.7480042576789856
malignancy I-Disease 0 0.10490007698535919
and O 0 1.2419087624948588e-06
neurofibromatosis B-Disease 1 0.8849078416824341
type I-Disease 0 8.036725193960592e-05
1 I-Disease 0 1.4596726316540298e-07
. O 0 8.947015572857708e-08

Heterozygous O 0 0.0010793311521410942
germ O 0 0.00012641295325011015
- O 0 0.0028128495905548334
line O 0 1.0938987543340772e-05
mutations O 0 2.01069141780863e-07
in O 0 3.5742137027838794e-10
the O 0 1.830190998752812e-10
DNA O 0 8.673945472992273e-08
mismatch O 0 1.3742952660322771e-06
repair O 0 6.344414487102767e-07
genes O 0 2.0337482808940877e-08
lead O 0 7.787949130033667e-08
to O 0 9.12267694275215e-07
hereditary B-Disease 1 0.9999831914901733
nonpolyposis I-Disease 1 0.9999994039535522
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 2.249327280878788e-06

The O 0 1.1420853525123675e-06
disease O 0 7.089638529578224e-05
susceptibility O 0 5.361777584766969e-05
of O 0 1.5323037283465624e-09
individuals O 0 7.85696663285762e-09
who O 0 4.931591774948174e-07
constitutionally O 0 6.138050707704679e-07
lack O 0 4.8786317208282526e-09
both O 0 9.208032669683064e-10
wild O 0 3.1393729837958517e-09
- O 0 1.8902635929407552e-05
type O 0 1.1331317182339262e-05
alleles O 0 5.734167274340507e-08
is O 0 5.6186988395268145e-09
unknown O 0 2.0463005512283416e-08
. O 0 5.206764797094365e-09

We O 0 3.3743529570529063e-07
have O 0 9.579062876241551e-09
identified O 0 5.963258775665281e-09
three O 0 2.1626993251810944e-10
offspring O 0 3.5400209430491714e-09
in O 0 2.7395563595433714e-10
a O 0 2.89541816300698e-07
hereditary B-Disease 1 0.9999854564666748
nonpolyposis I-Disease 1 0.9999995231628418
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
family O 0 2.236867294413969e-05
who O 0 8.818927312859159e-07
developed O 0 1.1796294074883917e-07
hematological B-Disease 0 6.361548003042117e-05
malignancy I-Disease 0 6.043889698048588e-06
at O 0 3.4808314564038767e-10
a O 0 1.6187933216116335e-09
very O 0 7.1275088053823765e-09
early O 0 1.2681800498626217e-08
age O 0 8.84491857533476e-09
, O 0 1.5267831443566138e-10
and O 0 2.2688338707776978e-10
at O 0 1.0597810129464591e-10
least O 0 3.1978480974359513e-10
two O 0 2.8614180469510586e-11
of O 0 5.148413813327313e-12
them O 0 2.642592533685928e-10
displayed O 0 1.99190282046402e-08
signs O 0 1.4626818867213842e-08
of O 0 6.063450852522578e-10
neurofibromatosis B-Disease 0 0.0014415108598768711
type I-Disease 0 1.9842336769215763e-06
1 I-Disease 0 5.607524755646409e-08
( O 0 8.86579520908981e-09
NF1 B-Disease 0 5.25566101714503e-05
) O 0 2.8384507189116448e-08
. O 0 5.447245499112796e-08

DNA O 0 2.3255604446603684e-06
sequence O 0 4.901868777551499e-08
analysis O 0 7.058539086557403e-09
and O 0 2.363701234742166e-09
allele O 0 5.649198797641475e-08
- O 0 2.2656275078247745e-08
specific O 0 1.1324345905450173e-09
amplification O 0 1.7752333292264666e-07
in O 0 1.2427400220005325e-09
two O 0 1.9462420564053673e-09
siblings O 0 4.1931425442953696e-08
revealed O 0 1.2105584090704724e-08
a O 0 8.15030976042408e-09
homozygous O 0 2.101131258314126e-06
MLH1 O 0 8.72260716278106e-05
mutation O 0 4.795199401996797e-07
( O 0 1.724255294099919e-09
C676T O 0 9.130588409789198e-07
- O 0 9.028448403114453e-06
- O 0 8.548879850422964e-05
> O 0 3.0041354648346896e-07
Arg226Stop O 0 8.232273103203624e-07
) O 0 1.7703641885802313e-09
. O 0 1.0362910529693181e-08

Thus O 0 1.3600483725895174e-06
, O 0 5.763077570719588e-09
a O 0 4.3908126023950445e-09
homozygous O 0 8.495538281749759e-07
germ O 0 1.574171051288431e-06
- O 0 0.0002765111858025193
line O 0 0.0002104931336361915
MLH1 O 0 0.0038188884500414133
mutation O 0 1.266212279915635e-06
and O 0 6.665539231676121e-09
consequent O 0 2.478508349668118e-06
mismatch O 0 0.011636344715952873
repair O 1 0.9901813864707947
deficiency O 1 0.9490950703620911
results O 0 3.7810924169434657e-08
in O 0 5.10030240263859e-10
a O 0 1.354730159164319e-07
mutator O 1 0.9610138535499573
phenotype O 1 0.8781430125236511
characterized O 0 1.3039143595960923e-06
by O 0 1.0536069794397918e-07
leukemia B-Disease 0 0.07128598541021347
and O 0 1.8207434777650633e-06
/ O 0 0.028747016564011574
or O 0 0.0027863862924277782
lymphoma B-Disease 1 1.0
associated O 0 9.266264896723442e-06
with O 0 5.1906251741229426e-08
neurofibromatosis B-Disease 1 0.7308399677276611
type I-Disease 0 1.3550364201364573e-05
1 I-Disease 0 2.7920151524085668e-08
. O 0 4.6882275839266185e-09
. O 0 2.0402833200705572e-08

Missense O 0 0.008095047436654568
mutations O 0 0.0030937923584133387
in O 0 3.07223650963806e-08
the O 0 7.982746685897268e-10
most O 0 3.1638006103840155e-10
ancient O 0 8.899297271325324e-11
residues O 0 8.420966146616138e-10
of O 0 2.2607117566852963e-11
the O 0 2.9148300439985064e-10
PAX6 O 0 2.09047834687226e-06
paired O 0 3.09024343891906e-08
domain O 0 2.2050026249331722e-09
underlie O 0 5.166307914805657e-08
a O 0 5.599569696812523e-09
spectrum O 0 1.3937858511781087e-07
of O 0 1.6781431799728352e-09
human O 0 7.342466119553137e-07
congenital B-Disease 1 0.9999910593032837
eye I-Disease 1 0.9999579191207886
malformations I-Disease 1 0.9998421669006348
. O 0 1.4606266631744802e-06

Mutations O 0 0.00020968308672308922
of O 0 6.669901964073688e-09
the O 0 1.8169851179195007e-09
human O 0 1.8768959719750455e-08
PAX6 O 0 0.00027105797198601067
gene O 0 1.5825531590962783e-05
underlie O 0 0.030857350677251816
aniridia B-Disease 1 0.9999997615814209
( O 0 1.4676332966701011e-06
congenital B-Disease 1 0.9999432563781738
absence I-Disease 0 2.5962453946704045e-06
of I-Disease 0 7.44583505962737e-10
the I-Disease 0 3.779331070319358e-09
iris I-Disease 0 2.037767626461573e-05
) O 0 8.00480903784262e-10
, O 0 3.707375795247714e-10
a O 0 8.075185853329003e-09
rare O 0 4.725622204659885e-07
dominant O 0 0.004158559255301952
malformation B-Disease 0 0.48392453789711
of I-Disease 0 3.759937916569811e-10
the I-Disease 0 6.053678003326013e-09
eye I-Disease 0 0.010880663990974426
. O 0 2.066575888193256e-07

The O 0 7.422700321058073e-08
spectrum O 0 3.642666115410975e-07
of O 0 1.8513737209957526e-09
PAX6 O 0 5.330241401679814e-05
mutations O 0 6.470438165706582e-06
in O 0 5.254655732755964e-08
aniridia B-Disease 1 0.9999997615814209
patients O 1 0.8179110884666443
is O 0 5.880579134753816e-09
highly O 0 4.136320619352318e-09
biased O 0 1.2402134075273352e-07
, O 0 2.776638086121608e-10
with O 0 1.8334858631341433e-10
92 O 0 1.701361895811715e-08
% O 0 2.7335420385576903e-11
of O 0 3.2829463973704787e-12
all O 0 1.1083997608629659e-10
reported O 0 7.84911780016273e-09
mutations O 0 7.80483944140542e-09
leading O 0 2.8319384615116405e-09
to O 0 3.213269428314902e-09
premature O 0 1.2171874175237463e-07
truncation O 0 5.466375441187665e-08
of O 0 1.0826679830433505e-10
the O 0 9.353747637552701e-11
protein O 0 2.584057856580557e-09
( O 0 1.1371958236194857e-10
nonsense O 0 3.2979023956158926e-08
, O 0 1.5802167907530418e-10
splicing O 0 4.825556843002232e-09
, O 0 1.0529987992669021e-10
insertions O 0 3.9612193525329076e-09
and O 0 3.9623201941729747e-10
deletions O 0 3.787008928668456e-09
) O 0 1.5449631851627288e-10
and O 0 1.0302126929317978e-09
just O 0 1.7554951936560315e-09
2 O 0 9.092878672234406e-10
% O 0 6.888579984209997e-11
leading O 0 1.6569724758941362e-10
to O 0 1.2169466823142017e-10
substitution O 0 4.416276233598637e-10
of O 0 4.0040346038772157e-11
one O 0 1.0000373862339984e-09
amino O 0 7.477430341573665e-10
acid O 0 4.172118650558332e-09
by O 0 8.069911405783614e-11
another O 0 1.1377996322892159e-09
( O 0 9.258117605881466e-10
missense O 0 1.0038677373813698e-06
) O 0 3.945106019642708e-09
. O 0 1.50153542932685e-08

The O 0 1.2920641268010513e-07
extraordinary O 0 7.293475334790855e-08
conservation O 0 5.066988606472478e-09
of O 0 2.4756438565809447e-10
the O 0 2.704682033893846e-10
PAX6 O 0 5.373513545237074e-07
protein O 0 8.658436634334521e-09
at O 0 1.0070790035232591e-10
the O 0 4.9803366292122675e-11
amino O 0 2.1347255074744e-09
acid O 0 1.93220994759713e-08
level O 0 1.8986162642065096e-10
amongst O 0 2.9003000001637247e-10
vertebrates O 0 8.878651702737272e-10
predicts O 0 2.1502799540940032e-08
that O 0 6.862722612410721e-10
pathological O 0 6.103953609226664e-08
missense O 0 8.560699029658281e-07
mutations O 0 9.834305103595398e-08
should O 0 7.327871198725688e-09
in O 0 1.4887721611067661e-10
fact O 0 1.1985328285391006e-09
be O 0 3.806460036059889e-09
common O 0 5.092807286999346e-10
even O 0 4.569625566830382e-09
though O 0 1.7358373627374135e-09
they O 0 2.4624108307946813e-10
are O 0 2.804896072350349e-11
hardly O 0 3.95303745293063e-09
ever O 0 7.866082896157423e-09
seen O 0 5.5584344238468475e-08
in O 0 2.8245063177223528e-08
aniridia B-Disease 1 0.999998927116394
patients O 0 0.06174718216061592
. O 0 3.388018043892771e-08

This O 0 4.5371120194204195e-08
indicates O 0 6.129526752829406e-08
that O 0 5.103873434997297e-10
there O 0 1.4510982693227703e-10
is O 0 1.922448034097357e-10
a O 0 2.260205356208189e-09
heavy O 0 1.4138260667095892e-05
ascertainment O 0 4.551327947410755e-06
bias O 0 7.68949121265905e-06
in O 0 2.67444150159335e-10
the O 0 4.426680549896034e-11
selection O 0 4.05773858958014e-10
of O 0 1.8575981031165867e-10
patients O 0 1.321957938671403e-07
for O 0 5.024630156391652e-10
PAX6 O 0 2.145546386600472e-05
mutation O 0 1.3899763473546045e-07
analysis O 0 7.793945488998588e-10
and O 0 1.2471371158007116e-10
that O 0 1.0243653147945508e-10
the O 0 7.149176389775747e-11
missing O 0 5.532815805509017e-08
PAX6 O 0 2.766223406069912e-05
missense O 0 2.0760486222570762e-05
mutations O 0 2.4401269911322743e-06
frequently O 0 8.687486570124747e-07
may O 0 6.147370754661097e-07
underlie O 0 7.6232522587815765e-06
phenotypes O 0 1.6610376405878924e-05
distinct O 0 2.6911511241678454e-08
from O 0 3.396803283095551e-09
textbook O 0 1.3407478036242537e-05
aniridia B-Disease 1 0.9999905824661255
. O 0 3.955853173920332e-07

Here O 0 4.3261977111797023e-07
we O 0 5.1356714436678885e-09
present O 0 4.771491535215944e-10
four O 0 9.089584085408831e-10
novel O 0 4.387834451335948e-08
PAX6 O 0 1.8585003999760374e-05
missense O 0 6.903018402226735e-06
mutations O 0 5.041165991315211e-07
, O 0 3.7576866618316274e-10
two O 0 1.872924593193659e-10
in O 0 3.3770081175887867e-10
association O 0 7.167640370120409e-10
with O 0 1.4939871562091867e-09
atypical O 0 0.0001145211499533616
phenotypes O 0 0.0005274150753393769
ectopia B-Disease 0 1.640121263335459e-05
pupillae I-Disease 0 1.2569754289870616e-05
( O 0 6.0447935545937526e-09
displaced B-Disease 0 3.70588168152608e-07
pupils I-Disease 0 7.169150961772175e-08
) O 0 7.907511090365915e-09
and O 0 4.432971309142886e-06
congenital B-Disease 1 0.9999589920043945
nystagmus I-Disease 0 0.03402986377477646
( O 0 2.4348847382782424e-09
searching B-Disease 0 3.945213222777966e-08
gaze I-Disease 0 1.8620892205944983e-06
) O 0 2.7713734085388353e-10
, O 0 2.036937285510021e-10
and O 0 2.69605476832524e-10
two O 0 2.517585862005234e-10
in O 0 2.352527894711187e-10
association O 0 1.6704557181945745e-10
with O 0 2.2943874578018608e-10
more O 0 1.024382001446611e-08
recognizable O 0 0.006716286763548851
aniridia B-Disease 1 0.999998927116394
phenotypes O 0 0.00022546554100699723
. O 0 3.828115424653333e-08

Strikingly O 0 0.04468913748860359
, O 0 3.2455222509497617e-08
all O 0 1.2959223971709122e-10
four O 0 2.474878912916978e-10
mutations O 0 6.48202558295452e-09
are O 0 1.400745075486043e-10
located O 0 9.499928621536924e-10
within O 0 5.5843333429672626e-11
the O 0 1.4244491697290584e-10
PAX6 O 0 2.1733553694502916e-06
paired O 0 6.445682743105863e-08
domain O 0 5.0609707535898e-09
and O 0 8.115899063909637e-10
affect O 0 1.3745440341494941e-09
amino O 0 7.380173139281965e-10
acids O 0 7.067237905999946e-10
which O 0 2.0486026763855136e-10
are O 0 3.581185695211708e-11
highly O 0 1.814926819942997e-10
conserved O 0 6.759174331349982e-10
in O 0 3.985633351133444e-11
all O 0 2.735252649377351e-11
known O 0 7.348358588288306e-10
paired O 0 7.847411609418486e-09
domain O 0 4.112735485506391e-09
proteins O 0 2.874231519456316e-09
. O 0 5.558134397176673e-09

Our O 0 3.0483198543151957e-07
results O 0 6.087699233603416e-08
support O 0 1.455178977316507e-09
the O 0 1.757652079437122e-10
hypothesis O 0 1.1646089426164963e-08
that O 0 1.0457573001998455e-10
the O 0 1.9604875015066803e-11
under O 0 6.354078374570804e-10
- O 0 8.881352897560646e-08
representation O 0 1.0901723968004262e-08
of O 0 1.691923684488117e-10
missense O 0 1.5052996786835138e-06
mutations O 0 3.005089155294627e-08
is O 0 1.5030159339346483e-09
caused O 0 2.5569859118945715e-08
by O 0 7.287460634941567e-10
ascertainment O 0 1.5823469539100188e-06
bias O 0 6.326013681245968e-05
and O 0 1.1985580306017596e-09
suggest O 0 1.0104697079071912e-09
that O 0 1.2279378902579907e-10
a O 0 4.873551562312173e-10
substantial O 0 1.0305493347573247e-08
burden O 0 3.3285076028732874e-07
of O 0 6.62996990641318e-10
PAX6 B-Disease 0 0.0007373213884420693
- I-Disease 0 0.0037314151413738728
related I-Disease 0 3.182798991474556e-06
disease I-Disease 0 2.8357770133879967e-05
remains O 0 9.434874925773329e-08
to O 0 4.99687624611056e-10
be O 0 1.0340199807501449e-09
uncovered O 0 3.8102609067891535e-08
. O 0 2.8742919155888558e-09
. O 0 9.28000876143642e-09

The O 0 1.014922830222531e-07
chromosomal O 0 5.120536570757395e-06
order O 0 1.1361477092464156e-08
of O 0 1.4682986770875317e-10
genes O 0 3.1164872904554386e-09
controlling O 0 1.7038688682191605e-08
the O 0 1.8422845193821757e-10
major O 0 6.678656516712067e-10
histocompatibility O 0 7.835240012354916e-08
complex O 0 4.1976773168528325e-09
, O 0 3.466461007128885e-10
properdin O 0 6.054950318912233e-08
factor O 0 7.903711463086438e-09
B O 0 5.258716484490833e-08
, O 0 1.1572437452755935e-09
and O 0 3.8817450587202984e-08
deficiency B-Disease 0 2.5250909629903617e-07
of I-Disease 0 1.9612466164997677e-11
the I-Disease 0 3.297155257153683e-11
second I-Disease 0 1.1659953003118062e-09
component I-Disease 0 1.778378333483488e-09
of I-Disease 0 9.62269153248485e-11
complement I-Disease 0 3.217723687498619e-08
. O 0 6.235917027197502e-08

The O 0 3.481910582081582e-08
relationship O 0 7.181383043786127e-09
of O 0 2.9023129385907787e-11
the O 0 3.805628728814625e-11
genes O 0 3.8765987642186417e-10
coding O 0 8.306084708920025e-09
for O 0 4.528893648991783e-10
HLA O 0 7.275080093904762e-08
to O 0 1.1086287443617948e-09
those O 0 3.817143823248159e-11
coding O 0 8.202503121168547e-10
for O 0 8.95166302194994e-11
properdin O 0 9.351939667112674e-08
Factor O 0 3.344312826669693e-09
B O 0 1.597105203643423e-08
allotypes O 0 2.1022006535531546e-07
and O 0 7.122100242895613e-09
for O 0 2.0002244305317163e-09
deficiency B-Disease 0 1.9597879941102292e-07
of I-Disease 0 1.576967376126781e-11
the I-Disease 0 2.691223979778279e-11
second I-Disease 0 1.3583590918742061e-09
component I-Disease 0 4.498177386125235e-10
of I-Disease 0 1.4374754858659244e-11
complement I-Disease 0 9.25695187170561e-10
( O 0 2.9753713381985847e-10
C2 O 0 1.414763062257407e-07
) O 0 2.415197764005228e-10
was O 0 9.3154941538387e-09
studied O 0 9.83009562638415e-10
in O 0 1.0725310223280715e-10
families O 0 2.507005436580556e-10
of O 0 2.2377738551071502e-10
patients O 0 2.6381089810456615e-06
with O 0 4.0661099376393395e-08
connective O 1 0.9946129322052002
tissue O 1 0.9998624324798584
disorders O 1 0.9856837391853333
. O 0 1.4386151292455907e-07

Patients O 1 0.9983972907066345
were O 0 3.196065279098548e-07
selected O 0 4.503836859015564e-09
because O 0 5.467996055941171e-10
they O 0 9.765622754898118e-10
were O 0 4.465132708020292e-09
heterozygous O 0 1.0091127222722207e-07
or O 0 1.2786526282226873e-09
homozygous O 0 4.4816888475907035e-06
for O 0 9.496558959654067e-06
C2 B-Disease 1 0.9999998807907104
deficiency I-Disease 1 0.9999992847442627
. O 0 5.068276891506684e-07

12 O 0 8.502135528942745e-07
families O 0 1.6502813338092892e-08
with O 0 3.783505730936554e-10
15 O 0 3.979894636074732e-09
matings O 0 4.910369625577005e-06
informative O 0 5.126209543959703e-06
for O 0 0.0002525599265936762
C2 B-Disease 1 1.0
deficiency I-Disease 1 0.9999997615814209
were O 0 1.1125739263206924e-07
found O 0 2.9084185726446776e-08
. O 0 1.4553406479933528e-08

Of O 0 4.607937142964147e-08
57 O 0 2.491998429832165e-07
informative O 0 5.4624980094786224e-08
meioses O 0 6.136991146377113e-07
, O 0 3.676055848611526e-10
two O 0 7.594221779205768e-11
crossovers O 0 1.413521832915876e-08
were O 0 3.3658980047590603e-09
noted O 0 3.0864539812824887e-09
between O 0 9.987335403138786e-10
the O 0 3.2119346542458516e-06
C2 B-Disease 1 1.0
deficiency I-Disease 1 0.9999946355819702
gene O 0 2.526130948865557e-08
and O 0 4.113086538026778e-10
the O 0 1.272792704565262e-10
HLA O 0 6.224539106369775e-07
- O 0 2.3987888653209666e-06
B O 0 1.2377439873034746e-07
gene O 0 1.6956851478511226e-09
, O 0 2.7875094593676764e-11
with O 0 9.396371701553274e-12
a O 0 1.651759701237765e-10
recombinant O 0 7.134823287735514e-10
fraction O 0 2.2749189199089415e-09
of O 0 1.2319917308545314e-10
0 O 0 2.2896859519505597e-08
. O 0 1.988881059844516e-08

035 O 0 0.02451527677476406
. O 0 2.534995110181626e-05

A O 0 2.8834028853452764e-06
lod O 0 0.0005180669249966741
score O 0 1.7149845632502547e-07
of O 0 4.924908258985283e-10
13 O 0 1.1433776148095376e-09
was O 0 3.706897011568344e-09
calculated O 0 7.081909281225762e-09
for O 0 7.01086300125553e-10
linkage O 0 5.349744697014103e-06
between O 0 7.793774420861155e-05
C2 B-Disease 1 1.0
deficiency I-Disease 1 0.9999994039535522
and O 0 3.469818210533049e-08
HLA O 0 7.649321673852683e-07
- O 0 7.353741011684178e-07
B O 0 3.5607918391633575e-08
at O 0 6.890524956171262e-11
a O 0 1.083962031245278e-09
maximum O 0 1.4037260243071614e-08
likelihood O 0 2.098345275314273e-09
value O 0 5.195609567576476e-11
of O 0 2.7942897561777924e-12
the O 0 1.6956413703694828e-11
recombinant O 0 6.78367473305741e-10
fraction O 0 1.7116759121194036e-09
of O 0 1.8923652922442358e-10
0 O 0 6.615764647222022e-08
. O 0 2.532383192033194e-08

04 O 0 0.0035126011352986097
. O 0 8.66453683556756e-06

18 O 0 3.7653928757208632e-06
families O 0 5.6407142068337635e-08
with O 0 1.0597814847912446e-09
21 O 0 4.699320044210253e-09
informative O 0 1.874842148197331e-08
matings O 0 8.320286042362568e-07
for O 0 2.114964203769887e-09
both O 0 1.0886362922235548e-09
properdin O 0 2.1702972219372896e-07
Factor O 0 1.2254005810063973e-08
B O 0 3.338380949458042e-08
allotype O 0 2.0964345992524613e-07
and O 0 6.459883739040606e-09
HLA O 0 7.53461677049927e-07
- O 0 1.9443512428551912e-05
B O 0 8.167609166775947e-07
were O 0 7.69951924439738e-09
found O 0 1.2061884824277058e-08
. O 0 8.865861822471288e-09

Of O 0 5.5791467445942544e-08
72 O 0 1.4483630650374835e-07
informative O 0 3.519220115322241e-08
meioses O 0 6.826305138929456e-07
, O 0 7.44069583724638e-10
three O 0 2.291715150981588e-10
recombinants O 0 1.4616811938594765e-07
were O 0 6.527571372316743e-09
found O 0 1.2018750439324322e-09
, O 0 8.203547563478963e-11
giving O 0 5.601615352124334e-11
a O 0 1.8257595435500207e-10
recombinant O 0 1.8819423797111767e-09
fraction O 0 2.739045656952044e-09
of O 0 1.657433912338746e-10
0 O 0 3.9006856411560875e-08
. O 0 3.163689399343639e-08

042 O 0 0.001991923665627837
. O 0 1.5180324226093944e-05

A O 0 2.7208102437725756e-06
lod O 0 0.0001417744206264615
score O 0 2.0109983722704783e-07
of O 0 3.4151473315979786e-10
16 O 0 1.521382797520232e-09
between O 0 8.514608462739659e-10
HLA O 0 7.142916160773893e-07
- O 0 2.4892081000871258e-06
B O 0 1.0477912582018689e-07
and O 0 6.484494607938984e-10
Factor O 0 5.265345381921804e-10
B O 0 6.009043040933193e-09
allotypes O 0 5.158686278150526e-08
was O 0 5.344023890074823e-09
calculated O 0 3.067819775992575e-09
at O 0 3.019332700526789e-11
a O 0 2.981722924122465e-10
maximum O 0 1.1130043553464475e-08
likelihood O 0 2.679088728640977e-09
value O 0 2.8833322882060308e-11
of O 0 2.199064715047161e-12
the O 0 5.734101127946589e-12
recombinant O 0 3.6541053516359057e-10
fraction O 0 2.3766939527547493e-09
of O 0 1.248608022530462e-10
0 O 0 1.0778229864172317e-08
. O 0 1.7743744251674798e-08

04 O 0 0.002491308841854334
. O 0 4.915542376693338e-06

A O 0 4.790107368535246e-07
crossover O 0 4.389316359265649e-07
was O 0 2.1938203076388163e-07
shown O 0 1.0418819584856465e-08
to O 0 7.262954682119016e-10
have O 0 1.423765438879343e-09
occurred O 0 5.991392937332307e-10
between O 0 2.6538196987169194e-11
genes O 0 1.4913101309410592e-10
for O 0 1.0020301949298371e-10
Factor O 0 1.7882799685509099e-09
B O 0 2.4383250973869508e-08
and O 0 4.845256640351181e-09
HLA O 0 1.8233604350825772e-06
- O 0 2.0661533199017867e-05
D O 0 8.270412763522472e-06
, O 0 3.60697693935208e-10
in O 0 9.073158196981623e-11
which O 0 2.1064534561077153e-09
HLA O 0 6.640884748776443e-07
- O 0 1.177038939204067e-05
D O 0 5.6516942095186096e-06
segregared O 0 9.410232451045886e-07
with O 0 6.719599099369589e-09
HLA O 0 8.985028898678138e-07
- O 0 9.540917744743638e-07
A O 0 1.6147551207268407e-07
and O 0 4.6725716629225644e-08
B O 0 1.8009907876148645e-07
. O 0 1.3355925254643353e-08

These O 0 9.017738022976118e-08
studies O 0 4.577092482804801e-09
suggest O 0 5.1347801566237194e-09
that O 0 8.867037659676669e-11
the O 0 2.2110818384546427e-11
genes O 0 2.769978413308394e-10
for O 0 3.2086622248073127e-10
Factor O 0 1.5640887696122263e-08
B O 0 2.5478477255092002e-05
and O 0 0.03660163655877113
C2 B-Disease 1 1.0
deficiency I-Disease 1 0.9999992847442627
are O 0 6.864084300950424e-10
located O 0 2.2351590023284018e-10
outside O 0 4.767216066348112e-10
those O 0 8.165363524215152e-11
for O 0 2.8417956876580774e-10
HLA O 0 4.5492740241570573e-07
, O 0 3.3206346006231513e-10
that O 0 3.9637317733598465e-11
the O 0 1.1136822367086019e-11
order O 0 1.3532587550546538e-10
of O 0 5.5591045655667415e-11
genese O 0 1.3267700182950648e-07
is O 0 3.390692837612619e-09
HLA O 0 8.968765285999325e-08
- O 0 3.778641399776461e-08
A O 0 3.50000846083276e-08
, O 0 1.0206758771502678e-09
- O 0 1.2016744221909903e-07
B O 0 1.4931652003724594e-07
, O 0 6.891947568199441e-10
- O 0 9.225198027706938e-08
D O 0 3.047592826987966e-07
, O 0 2.0161652902750404e-10
Factor O 0 1.690356854489039e-09
B O 0 8.61600355506198e-08
allotype O 0 2.5304108930868097e-05
, O 0 8.3607128544827e-06
C2 B-Disease 1 0.9999998807907104
deficiency I-Disease 1 0.9999991655349731
, O 0 2.0991929028379985e-10
that O 0 2.2748428141206034e-11
the O 0 6.783719419534151e-12
genes O 0 8.500816162104741e-10
coding O 0 1.3616676142191864e-07
for O 0 1.2989943343200139e-06
C2 B-Disease 1 0.9999995231628418
deficiency I-Disease 1 0.9999858140945435
and O 0 3.715362906220321e-09
Factor O 0 1.7943888597216073e-09
B O 0 1.5140598108587255e-08
allotypes O 0 1.8863065065488627e-07
are O 0 3.74367259414754e-10
approximately O 0 4.469885295232956e-10
3 O 0 6.255543860689272e-10
- O 0 1.7268388319280348e-07
- O 0 1.6094032844193862e-06
5 O 0 4.924704199993357e-09
centimorgans O 0 5.933445379469049e-08
from O 0 7.451997352525552e-11
the O 0 8.532634321323229e-11
HLA O 0 7.770115217908824e-08
- O 0 9.51157659301316e-08
A O 0 4.453898583278715e-08
and O 0 5.552243553808012e-09
HLA O 0 3.178241456680553e-07
- O 0 9.413337807018252e-07
B O 0 5.730165852924074e-08
loci O 0 1.6320468310127012e-09
, O 0 2.4867177761400683e-10
and O 0 8.827752417950308e-11
that O 0 1.0505594311149835e-10
the O 0 8.709642729254341e-11
apparent O 0 1.1536415200907868e-07
lack O 0 3.2476883404797263e-09
of O 0 8.984916283205635e-11
recombinants O 0 1.0868738087310703e-07
between O 0 1.0455777910145514e-10
the O 0 1.3275858190553436e-10
Factor O 0 3.934427894591863e-09
B O 0 1.280716190876774e-07
gene O 0 5.460955776470655e-07
and O 0 0.011404477059841156
C2 B-Disease 1 1.0
deficiency I-Disease 1 0.9999971389770508
gene O 0 3.293062533771263e-08
suggests O 0 4.182125756813093e-09
that O 0 1.448758751854129e-10
these O 0 1.0342911423155687e-11
two O 0 2.4880732890641966e-11
genes O 0 8.542425100621642e-10
lie O 0 2.9531154410733507e-08
in O 0 1.531700877244191e-10
close O 0 1.016274064902234e-09
proximity O 0 3.803876325036981e-09
to O 0 7.532745094351867e-09
one O 0 6.142257813479546e-09
another O 0 2.6525382779141182e-08
. O 0 5.61086288541901e-08

Distribution O 0 1.3114626540300378e-07
of O 0 1.7433328114435653e-09
emerin O 0 1.01546652331308e-06
and O 0 7.700914572694728e-09
lamins O 0 9.470579698245274e-07
in O 0 1.442802988194103e-09
the O 0 5.971381722424951e-10
heart O 0 4.345367301539227e-07
and O 0 1.9121182415204885e-09
implications O 0 1.1062571303455115e-08
for O 0 8.308001397949738e-09
Emery B-Disease 1 0.5725516676902771
- I-Disease 1 0.999816358089447
Dreifuss I-Disease 1 0.9999898672103882
muscular I-Disease 1 0.9999368190765381
dystrophy I-Disease 1 0.9998605251312256
. O 0 7.076010888340534e-07

Emerin O 0 0.00039815044146962464
is O 0 1.216892684396953e-07
a O 0 8.931683836976845e-09
nuclear O 0 1.079921929658667e-08
membrane O 0 1.3041013602332896e-08
protein O 0 8.195172540581552e-09
which O 0 8.966602460525053e-10
is O 0 4.201568259976085e-10
missing O 0 2.4825486111268447e-09
or O 0 3.3737437843406326e-10
defective O 0 1.2142037348894519e-06
in O 0 4.388595797877315e-08
Emery B-Disease 1 0.996648371219635
- I-Disease 1 0.9999797344207764
Dreifuss I-Disease 1 0.9999991655349731
muscular I-Disease 1 0.9999982118606567
dystrophy I-Disease 1 0.9999982118606567
( O 0 9.508490279586113e-07
EDMD B-Disease 1 0.9999939203262329
) O 0 1.3599493797755713e-07
. O 0 8.392720474148518e-08

It O 0 2.569786659023521e-07
is O 0 4.2892955853801595e-09
one O 0 4.2447914627707917e-10
member O 0 8.226847675318893e-11
of O 0 8.511790230980587e-12
a O 0 2.9428914860574196e-09
family O 0 1.1666811516874986e-08
of O 0 2.9177837923555217e-10
lamina O 0 8.242265607805166e-07
- O 0 5.569153472606558e-06
associated O 0 5.138385272829282e-09
proteins O 0 2.047005204230956e-10
which O 0 5.770422473183601e-10
includes O 0 7.86340881298031e-10
LAP1 O 0 3.1472941373067442e-06
, O 0 2.6446560497106475e-09
LAP2 O 0 4.150732820562553e-06
and O 0 2.738837956428597e-08
lamin O 0 0.00018818260286934674
B O 0 9.81803623290034e-06
receptor O 0 6.141627864053589e-07
( O 0 1.6704925442923013e-08
LBR O 0 7.492391159757972e-05
) O 0 1.4730688668862513e-08
. O 0 3.2322652998573176e-08

A O 0 1.413346012668626e-06
panel O 0 1.5249038654019387e-07
of O 0 9.272714263097726e-10
16 O 0 6.861312407124842e-09
monoclonal O 0 2.043298366061208e-07
antibodies O 0 1.670015308263828e-07
( O 0 6.17569884120428e-10
mAbs O 0 5.5171877733073416e-08
) O 0 3.2240604630473513e-10
has O 0 7.01243108025551e-09
been O 0 2.330075465906134e-09
mapped O 0 2.7255286028093906e-08
to O 0 9.848449833427253e-10
six O 0 8.172625076685591e-11
specific O 0 1.6280253187228588e-11
sites O 0 4.124994790188907e-11
throughout O 0 2.6251237295049634e-11
the O 0 1.1239036611099262e-11
emerin O 0 7.143064806314214e-09
molecule O 0 3.840859019721421e-10
using O 0 4.748865745085595e-10
phage O 0 1.4559598859875678e-08
- O 0 2.435499091291149e-08
displayed O 0 6.244126993237842e-09
peptide O 0 1.1490156603954915e-09
libraries O 0 1.2559743522988498e-10
and O 0 6.535811475361086e-11
has O 0 7.409454161333429e-10
been O 0 4.869797343154403e-10
used O 0 9.327633110345346e-10
to O 0 7.658139677957365e-10
localize O 0 2.4999820880111656e-07
emerin O 0 2.4886928713385714e-06
in O 0 1.3129982656678862e-09
human O 0 1.64221702902978e-09
and O 0 9.606087481017767e-09
rabbit O 0 1.7783740986487828e-05
heart O 0 3.176484824507497e-05
. O 0 3.612281673781581e-08

Several O 0 2.8330131840448303e-07
mAbs O 0 2.4662074338266393e-06
against O 0 1.192240528524735e-08
different O 0 4.462746561184616e-10
emerin O 0 2.628630966228229e-07
epitopes O 0 7.913389481473132e-07
did O 0 4.0190375472093365e-08
not O 0 6.94051927041528e-10
recognize O 0 1.2228059675933878e-09
intercalated O 0 5.675093284196464e-09
discs O 0 5.844364068252617e-07
in O 0 1.1230218976976403e-09
the O 0 5.432381766645733e-10
heart O 0 5.571329779741063e-07
, O 0 6.364218596566218e-10
though O 0 9.199466188825056e-10
they O 0 2.6046068080098905e-10
recognized O 0 3.2569913432922704e-10
cardiomyocyte O 0 4.963075994623978e-08
nuclei O 0 8.811073648473666e-09
strongly O 0 1.2947920069450447e-08
, O 0 1.2522810566295561e-10
both O 0 1.5484825921507905e-10
at O 0 8.846428450892674e-11
the O 0 1.558423390335406e-10
rim O 0 3.1559327595687137e-08
and O 0 3.0230007386222724e-09
in O 0 6.499229487921809e-10
intranuclear O 0 7.200957838904287e-07
spots O 0 7.47221875485593e-08
or O 0 1.0628908864163122e-09
channels O 0 5.736409747214566e-08
. O 0 2.112280483856921e-08

A O 0 2.588778670542524e-06
polyclonal O 0 8.473731577396393e-05
rabbit O 0 2.0631210645660758e-05
antiserum O 0 2.102299731632229e-05
against O 0 2.0539225431548402e-07
emerin O 0 4.289815933589125e-06
did O 0 1.0854691367967462e-07
recognize O 0 1.10806270825492e-08
both O 0 4.4849671199109764e-10
nuclear O 0 2.0504802300536085e-09
membrane O 0 1.0871263000922227e-08
and O 0 8.402771811688581e-10
intercalated O 0 7.734181295404596e-09
discs O 0 2.708957538288814e-07
but O 0 1.5214728366075292e-09
, O 0 2.4585611324567935e-11
after O 0 3.839275425354671e-11
affinity O 0 9.785605659118346e-11
purification O 0 2.5870106057368503e-10
against O 0 2.613673999452004e-10
a O 0 1.1023053581027398e-09
pure O 0 8.179634747307318e-09
- O 0 2.3242826330260868e-07
emerin O 0 1.464923343519331e-06
band O 0 6.9300196692267946e-09
on O 0 4.568525002746071e-10
a O 0 1.6451953133156394e-09
western O 0 9.284257806996266e-09
blot O 0 0.00010436109005240723
, O 0 7.50981776764803e-10
it O 0 8.916564708805197e-10
stained O 0 1.6760061498644063e-06
only O 0 1.9459005518029926e-09
the O 0 1.39186051573148e-10
nuclear O 0 6.7471859210854745e-09
membrane O 0 8.372654747290653e-08
. O 0 1.2436797369730357e-08

These O 0 5.455116180996811e-08
results O 0 2.1866261690206557e-08
would O 0 2.715098146310879e-09
not O 0 5.504842137682431e-10
be O 0 3.004484439017574e-10
expected O 0 4.820920107562188e-09
if O 0 1.136472249640974e-09
immunostaining O 0 6.703804444896377e-08
at O 0 1.3044033908560237e-10
intercalated O 0 3.1531754984825966e-09
discs O 0 1.22121051049362e-07
were O 0 3.429332817717068e-09
due O 0 2.4648635910118344e-10
to O 0 3.69666436350613e-10
a O 0 1.4797957303969156e-09
product O 0 1.2310856778441348e-09
of O 0 2.23003941701716e-11
the O 0 5.6092703398791244e-11
emerin O 0 6.455833556628932e-08
gene O 0 3.2830640428471725e-09
and O 0 6.012341735583959e-10
, O 0 1.1213475981097787e-10
therefore O 0 3.3871941362839664e-10
, O 0 7.098454463116965e-11
cast O 0 1.136676530677505e-08
some O 0 9.484900642675598e-10
doubt O 0 5.095821986600413e-09
upon O 0 1.42426709315302e-10
the O 0 3.464879425041367e-11
hypothesis O 0 9.318817717485217e-09
that O 0 1.604493315987554e-09
cardiac B-Disease 0 0.0007298572454601526
defects I-Disease 0 0.1607535481452942
in O 0 5.4565209239854084e-08
EDMD B-Disease 1 1.0
are O 0 4.2812065004227406e-08
caused O 0 9.559774127865239e-08
by O 0 5.829184912542473e-10
absence O 0 2.856436864817624e-09
of O 0 1.7538544228035136e-10
emerin O 0 1.1186974688826012e-06
from O 0 1.0495685431877178e-09
intercalated O 0 1.1817586198503705e-07
discs O 0 4.268489192327252e-06
. O 0 5.037493977511076e-08

Although O 0 3.1161525839706883e-06
emerin O 0 6.163870239106473e-06
was O 0 1.0124672655820177e-07
abundant O 0 2.346317806711795e-09
in O 0 3.035479367863303e-10
the O 0 1.6439273553547906e-10
membranes O 0 3.4977911678168994e-09
of O 0 1.1768332142114701e-10
cardiomyocyte O 0 4.21542324602342e-07
nuclei O 0 1.4955986671338906e-08
, O 0 1.6500718846845785e-10
it O 0 4.4841630408853916e-10
was O 0 1.3202091508901503e-07
absent O 0 3.604791576350408e-09
from O 0 2.993825326536026e-11
many O 0 1.3248538377474972e-10
non O 0 6.980693245672853e-10
- O 0 4.91943580982479e-07
myocyte O 0 3.787111199926585e-05
cells O 0 3.595770081687988e-08
in O 0 3.406865067834275e-10
the O 0 1.1704585078931018e-09
heart O 0 8.898094279174984e-07
. O 0 1.9246879645606896e-08

This O 0 8.861010591942886e-09
distribution O 0 2.787820641003691e-09
of O 0 4.964933672524374e-11
emerin O 0 1.7758733861228393e-07
was O 0 2.5433614325720555e-08
similar O 0 5.198426689112523e-10
to O 0 4.662044639225371e-10
that O 0 2.289006761913015e-10
of O 0 3.6277009174412456e-11
lamin O 0 1.0796994729389553e-06
A O 0 6.684499709308511e-08
, O 0 4.090687510949209e-10
a O 0 4.4198070203727013e-10
candidate O 0 6.583122935666097e-09
gene O 0 1.4201635423205516e-09
for O 0 1.0513250686683406e-10
an O 0 1.0507281711369387e-09
autosomal O 0 3.362070128787309e-05
form O 0 1.1524934251383456e-07
of O 0 1.30050450408703e-08
EDMD B-Disease 1 0.9999994039535522
. O 0 4.5326919462240767e-07

In O 0 6.806815804338839e-07
contrast O 0 1.0482044672244228e-06
, O 0 2.7772445676532698e-08
lamin O 0 8.251526014646515e-05
B1 O 0 0.0002409470616839826
was O 0 7.822128509360482e-07
absent O 0 2.4634326578620858e-08
from O 0 4.1025796648774815e-10
cardiomyocyte O 0 2.5121568114627735e-07
nuclei O 0 1.971966234748379e-08
, O 0 3.661305425506356e-10
showing O 0 8.734004630639447e-09
that O 0 7.005987345820586e-09
lamin O 0 5.966339085716754e-05
B1 O 0 3.032148742931895e-05
is O 0 2.6901592065087243e-09
not O 0 5.39506439523052e-10
essential O 0 1.524382703399496e-10
for O 0 8.44723110904333e-11
localization O 0 2.4022983602378645e-09
of O 0 6.363535393072439e-11
emerin O 0 1.4706019157983974e-07
to O 0 3.206155785306919e-09
the O 0 7.725611816944422e-10
nuclear O 0 8.500434489633335e-08
lamina O 0 2.8625415779970353e-06
. O 0 7.402793045230283e-08

Lamin O 1 0.8064441084861755
B1 O 1 0.9841744303703308
is O 0 2.910216608142946e-06
also O 0 9.729915007028467e-08
almost O 0 6.065293156609641e-09
completely O 0 6.801871421657779e-08
absent O 0 4.370244255369471e-08
from O 0 1.5262017205586176e-09
skeletal O 0 0.00010702901636250317
muscle O 0 0.000284853158518672
nuclei O 0 1.0333292266295757e-05
. O 0 9.110524246125351e-08

In O 0 9.695917242424912e-07
EDMD B-Disease 1 0.9999618530273438
, O 0 4.0508121301741085e-09
the O 0 7.89757009789227e-11
additional O 0 5.133151681491199e-10
absence O 0 4.510800621915223e-09
of O 0 6.110494887856532e-10
lamin O 0 0.007284948602318764
B1 O 0 0.004109248053282499
from O 0 9.657342481261821e-09
heart O 0 3.1616314117854927e-06
and O 0 1.862467335911333e-08
skeletal O 0 4.396427175379358e-05
muscle O 0 8.109413101919927e-06
nuclei O 0 2.6642948114385945e-07
which O 0 9.688410962382932e-09
already O 0 1.2153195783071169e-08
lack O 0 2.697259748885017e-09
emerin O 0 1.9421049728407525e-06
may O 0 4.756303795261374e-08
offer O 0 1.0367967595570349e-09
an O 0 1.7088727655156788e-10
alternative O 0 2.879092964036545e-09
explanation O 0 2.890515604647703e-09
of O 0 1.26788796475652e-11
why O 0 8.598478040688917e-10
these O 0 6.321630025007963e-11
tissues O 0 3.6942344738832844e-09
are O 0 2.467182291798764e-10
particularly O 0 7.993232742364853e-09
affected O 0 2.246071773015501e-08
. O 0 2.3370902990649256e-09
. O 0 8.782148341879292e-09

Genetic O 0 3.107114025624469e-05
mapping O 0 8.735256074032804e-07
of O 0 3.095196987601412e-09
the O 0 2.6218789361820427e-09
copper B-Disease 0 3.383388502697926e-07
toxicosis I-Disease 0 1.5814894140930846e-05
locus O 0 1.7356455828121398e-07
in O 0 2.407334775966774e-09
Bedlington O 0 4.756494718094473e-07
terriers O 0 3.450327028531319e-07
to O 0 7.821903125204699e-09
dog O 0 6.59242346046085e-07
chromosome O 0 5.634144031319011e-07
10 O 0 2.015220434969933e-09
, O 0 2.0541705836318869e-10
in O 0 1.2407216920529152e-10
a O 0 4.258449592953184e-09
region O 0 8.329850587074361e-09
syntenic O 0 1.4538585446643992e-06
to O 0 2.8789006734086797e-09
human O 0 1.877869193478432e-09
chromosome O 0 1.0661847227311227e-06
region O 0 3.820587579639323e-08
2p13 O 0 3.2227653719019145e-06
- O 0 2.671747552085435e-06
p16 O 0 1.8691652030611294e-06
. O 0 4.885105298058079e-08

Abnormal O 0 0.06697345525026321
hepatic B-Disease 1 0.9574382901191711
copper I-Disease 0 1.3632216905534733e-05
accumulation I-Disease 0 6.724691843373876e-07
is O 0 9.57930090805803e-09
recognized O 0 1.5361664162938382e-09
as O 0 2.0434134384572644e-09
an O 0 1.0778871484262709e-07
inherited B-Disease 1 1.0
disorder I-Disease 1 1.0
in O 0 4.5897973421915594e-08
man O 0 2.011002470680978e-05
, O 0 6.576054700779821e-10
mouse O 0 8.03069184485139e-08
, O 0 1.6399007707335045e-09
rat O 0 1.3106377991789486e-06
and O 0 4.934482600305046e-09
dog O 0 2.1646801542374305e-06
. O 0 2.099683626965998e-08

The O 0 8.190770017790783e-08
major O 0 1.1133971966614808e-08
cause O 0 8.003900830999555e-08
of O 0 1.0552229090521337e-09
hepatic B-Disease 0 8.649905794300139e-05
copper I-Disease 0 1.3729040801990777e-06
accumulation I-Disease 0 2.513883856636312e-08
in O 0 1.3943589616260965e-09
man O 0 3.1185169291347847e-07
is O 0 7.102900489996955e-10
a O 0 4.067069792057509e-09
dysfunctional O 0 4.786162435266306e-07
ATP7B O 0 5.777107617177535e-06
gene O 0 1.1899941654291979e-07
, O 0 8.48377990081417e-09
causing O 0 8.003730727068614e-07
Wilson B-Disease 0 8.430852176388726e-05
disease I-Disease 0 7.052027649478987e-05
( O 0 2.566450163499212e-08
WD B-Disease 0 0.0011660985182970762
) O 0 5.2304674369452187e-08
. O 0 6.629204563068924e-08

Mutations O 0 0.0005357688060030341
in O 0 3.100764800478828e-08
the O 0 3.223445399491709e-10
ATP7B O 0 3.2888354439819523e-07
genes O 0 6.511020611554841e-09
have O 0 4.1608023693129326e-09
also O 0 6.824310894160135e-09
been O 0 8.42652969623714e-09
demonstrated O 0 7.607408036847119e-09
in O 0 1.859065401621507e-10
mouse O 0 2.2429686907798896e-07
and O 0 2.833414924907629e-08
rat O 0 1.5823312423890457e-05
. O 0 6.978103783694678e-08

The O 0 1.627807932891301e-07
ATP7B O 0 4.62277967017144e-06
gene O 0 1.1305601077538086e-07
has O 0 2.0711247827875923e-08
been O 0 3.8279965863807774e-09
excluded O 0 1.4763310574039679e-09
in O 0 1.8333100662570878e-11
the O 0 5.485020077022895e-11
much O 0 2.222504402737968e-09
rarer O 0 1.234933506566449e-06
human O 0 1.5770959649330507e-08
copper B-Disease 0 1.0032446880359203e-05
overload I-Disease 0 0.003998054191470146
disease O 0 5.279310425976291e-05
non B-Disease 0 5.12636688654311e-08
- I-Disease 0 2.6642110242391936e-06
Indian I-Disease 0 1.164631697747609e-07
childhood I-Disease 0 1.6067274373199325e-06
cirrhosis I-Disease 0 9.294790288549848e-06
, O 0 1.39869538173798e-09
indicating O 0 3.754115951437598e-08
genetic O 0 1.624685808110371e-07
heterogeneity O 0 3.5537536859919783e-06
. O 0 9.94719329128202e-08

By O 0 9.330844363830693e-08
investigating O 0 4.2847844383686606e-08
the O 0 2.0013082302483554e-09
common O 0 2.8439348653819252e-08
autosomal O 0 0.11924772709608078
recessive O 1 0.9818544387817383
copper B-Disease 0 0.0033435949590057135
toxicosis I-Disease 0 0.016944052651524544
( O 0 8.729875489166261e-09
CT B-Disease 0 3.6025314329890534e-05
) O 0 1.7976193866786616e-09
in O 0 1.3341355797891197e-09
Bedlington O 0 2.9046276495137135e-07
terriers O 0 1.7001461571908294e-07
, O 0 5.442919448483963e-10
we O 0 2.346066396707869e-10
have O 0 1.341411981492513e-10
identified O 0 3.4329242226682766e-10
a O 0 2.7224864029840035e-10
new O 0 7.705318605388811e-10
locus O 0 1.545436312255788e-08
involved O 0 5.167605454658997e-09
in O 0 2.004644450437354e-08
progressive O 1 0.9969170093536377
liver B-Disease 1 1.0
disease I-Disease 1 0.9999997615814209
. O 0 7.159093229347491e-07

We O 0 3.120831877367891e-07
examined O 0 2.086967469949741e-07
whether O 0 7.3798389621515526e-09
the O 0 1.3124724640434238e-09
WD B-Disease 0 4.261728463461623e-06
gene O 0 8.04465827286549e-08
ATP7B O 0 6.68009079163312e-06
was O 0 1.1761729723502867e-07
also O 0 2.2421287049212424e-09
causative O 0 1.3517123420569988e-08
for O 0 5.704239303128134e-10
CT B-Disease 0 7.512276170018595e-06
by O 0 4.817029553016994e-10
investigating O 0 1.4720739072160427e-09
the O 0 1.58223448232242e-10
chromosomal O 0 2.7982696337858215e-07
co O 0 9.38347639589665e-08
- O 0 1.6516990797299513e-07
localization O 0 9.686917934459416e-08
of O 0 4.463257263775944e-10
ATP7B O 0 1.6593926375207957e-06
and O 0 2.1901478408636876e-09
C04107 O 0 1.4244343482516797e-08
, O 0 2.661412930315965e-11
using O 0 2.519161268477177e-10
fluorescence O 0 8.005851981351952e-09
in O 0 3.6481792586862127e-10
situ O 0 3.954547622697646e-08
hybridization O 0 1.036729901926492e-08
( O 0 4.5541440063523453e-10
FISH O 0 8.69424887639525e-09
) O 0 1.5785789342359635e-09
. O 0 8.991027478089109e-09

C04107 O 0 4.413402348291129e-05
is O 0 5.8436619099211384e-08
an O 0 1.6736234620395862e-09
anonymous O 0 5.8034723693367596e-09
microsatellite O 0 6.42667373540462e-07
marker O 0 5.837879939463164e-07
closely O 0 9.902252884330665e-08
linked O 0 5.676296837009431e-07
to O 0 7.37549399332238e-08
CT B-Disease 0 0.484317421913147
. O 0 4.1241600001740153e-07

However O 0 2.393652039245353e-06
, O 0 2.929446552002446e-08
BAC O 0 9.182957683151471e-07
clones O 0 4.6355726368574324e-08
containing O 0 1.434426710744674e-08
ATP7B O 0 1.846240479608241e-06
and O 0 2.6875692782368787e-09
C04107 O 0 4.1659980354324944e-08
mapped O 0 7.31900442474398e-08
to O 0 6.967870169738433e-10
the O 0 1.2177965580395522e-10
canine O 0 1.8494128539714438e-07
chromosome O 0 2.57910664913652e-06
regions O 0 2.2600984195264573e-08
CFA22q11 O 0 4.936071036354406e-06
and O 0 8.504420279109581e-09
CFA10q26 O 0 4.2660369103941775e-07
, O 0 1.4652108415447174e-09
respectively O 0 2.455761149988689e-09
, O 0 2.03782338226155e-10
demonstrating O 0 7.774436650009875e-10
that O 0 2.0354080643159023e-09
WD B-Disease 0 2.148602789020515e-06
cannot O 0 2.4155367484013368e-08
be O 0 2.2318021042355696e-10
homologous O 0 2.357973594158125e-09
to O 0 1.8069497897954534e-08
CT B-Disease 0 0.007087140344083309
. O 0 1.6350581688584498e-07

The O 0 2.0192003091779043e-07
copper O 0 1.6280812076274742e-07
transport O 0 1.0840224717867386e-08
genes O 0 7.049659078717241e-09
CTR1 O 0 1.3533900755646755e-06
and O 0 3.960169081551612e-09
CTR2 O 0 2.807057398968027e-06
were O 0 2.6351107962341302e-08
also O 0 8.026094455715338e-09
excluded O 0 2.143661248510398e-09
as O 0 1.6242761302631692e-10
candidate O 0 1.1229062124584743e-09
genes O 0 2.2733476212621895e-10
for O 0 3.1331981453774915e-10
CT B-Disease 0 0.00014598459529224783
since O 0 5.671630276538053e-09
they O 0 3.4972155726897824e-10
both O 0 2.2013876832538415e-10
mapped O 0 5.118326384945249e-08
to O 0 3.1783062848234067e-09
canine O 0 9.989284990297165e-07
chromosome O 0 1.3797575775242876e-05
region O 0 1.6511226874627027e-07
CFA11q22 O 0 4.7058259951882064e-05
. O 0 1.280074002352194e-07

2 O 0 6.1715404626738746e-06
- O 0 0.00016818495350889862
22 O 0 1.098835923585284e-06
. O 0 1.1230851271193387e-07

5 O 0 3.334784196340479e-05
. O 0 2.05855758395046e-06

A O 0 1.1479110071377363e-06
transcribed O 0 4.147616721184022e-07
sequence O 0 1.5228062366645645e-08
identified O 0 1.5665191810398937e-08
from O 0 1.518193487592967e-10
the O 0 2.429900725076095e-10
C04107 O 0 1.4929771907645772e-07
- O 0 2.432526287066139e-07
containing O 0 9.853869897824552e-08
BAC O 0 1.3899818895879434e-06
was O 0 2.7371982014301466e-08
found O 0 2.3046947683624808e-10
to O 0 8.382981808718881e-11
be O 0 8.966016817879563e-11
homologous O 0 1.989444303740484e-10
to O 0 3.243229296234773e-10
a O 0 3.1107327824742015e-09
gene O 0 2.170909496612694e-08
expressed O 0 5.73120129132576e-09
from O 0 1.2912049207614018e-10
human O 0 3.679998528127726e-10
chromosome O 0 8.722904709657087e-08
2p13 O 0 1.6279476255931513e-07
- O 0 9.73745244436941e-08
p16 O 0 1.1170775593427607e-07
, O 0 4.795203123464375e-10
a O 0 3.035909301729589e-09
region O 0 5.820943282941471e-09
devoid O 0 1.3387704278500223e-08
of O 0 2.0803943637237587e-11
any O 0 1.482314687661912e-10
positional O 0 3.785855824389728e-07
candidate O 0 6.895977833210054e-08
genes O 0 3.5041228585441786e-08
. O 0 2.1020959195539035e-08

Molecular O 0 1.982077492357348e-06
analysis O 0 3.9208405411272906e-08
of O 0 2.541099552999526e-10
the O 0 1.399329818685402e-10
APC B-Disease 0 1.0469917377520233e-08
gene O 0 2.3639987745127655e-09
in O 0 3.75859704471182e-10
205 O 0 7.2343393497931174e-09
families O 0 2.473596438790082e-09
: O 0 3.3802366461443967e-10
extended O 0 1.1229116125832661e-07
genotype O 0 0.0030230656266212463
- O 0 5.5079450248740613e-05
phenotype O 0 7.118858047761023e-05
correlations O 0 9.805798129036702e-08
in O 0 1.1198371119292005e-09
FAP B-Disease 0 2.724149510413554e-07
and O 0 4.526823360606613e-09
evidence O 0 2.745824678740405e-09
for O 0 9.702788572596432e-11
the O 0 5.576361594705759e-11
role O 0 4.404767939281129e-10
of O 0 5.922830281779312e-11
APC B-Disease 0 3.1972778202771224e-08
amino O 0 3.046815022500482e-09
acid O 0 1.4354256450133107e-08
changes O 0 1.1746569938964058e-08
in O 0 2.426241280772956e-06
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
predisposition O 1 0.9616767168045044
. O 0 1.9698671849255334e-07

BACKGROUND O 0 0.00026351053384132683
/ O 0 4.4930638978257775e-06
AIMS O 0 2.3479358901568048e-07
The O 0 1.2895121637157558e-09
development O 0 7.638184529312753e-10
of O 0 2.1063426913769945e-07
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 7.008583224887843e-08
a O 0 1.6616073850173052e-08
variable O 0 9.901610553697537e-08
range O 0 2.709278357215794e-09
of O 0 2.2069202021413048e-10
extracolonic O 0 2.6453431928530335e-05
manifestations O 0 9.777388640941354e-07
in O 0 3.8389521250792313e-07
familial B-Disease 1 0.9999991655349731
adenomatous I-Disease 1 0.9999144077301025
polyposis I-Disease 1 0.999998927116394
( O 0 5.359255439429944e-08
FAP B-Disease 0 1.0982994353980757e-06
) O 0 1.3757296413174913e-09
is O 0 6.377901540233211e-10
the O 0 7.240406191266757e-11
result O 0 3.4952818417366416e-10
of O 0 1.074655989197204e-11
the O 0 2.617500660662131e-10
dominant O 0 7.384417131106602e-07
inheritance O 0 1.538384594823583e-06
of O 0 1.4591937258501275e-07
adenomatous B-Disease 1 0.9999963045120239
polyposis I-Disease 1 0.9998453855514526
coli I-Disease 1 0.9999849796295166
( O 0 9.34903283678068e-08
APC B-Disease 0 7.969075568325934e-07
) O 0 2.1713557618596724e-09
gene O 0 1.0921333171154401e-07
mutations O 0 1.2051993962813867e-06
. O 0 3.80903308894176e-08

In O 0 3.3755238604271653e-08
this O 0 7.064677176593648e-10
study O 0 4.66277405575255e-10
, O 0 9.947520585029679e-11
direct O 0 8.571459653161639e-10
mutation O 0 2.9703279835757712e-08
analysis O 0 3.6707312189854235e-10
of O 0 8.874595502916804e-12
the O 0 4.569446557245449e-11
APC B-Disease 0 1.2383632785883947e-08
gene O 0 3.2420188755821755e-09
was O 0 9.932969113890522e-09
performed O 0 1.6680877790165027e-09
to O 0 3.518612901043383e-10
determine O 0 3.607792464777049e-08
genotype O 0 3.782426938414574e-05
- O 0 1.2169512046966702e-05
phenotype O 0 7.026318780845031e-05
correlations O 0 1.2315658182160405e-07
for O 0 5.519003032361525e-10
nine O 0 4.530986696948958e-09
extracolonic O 0 8.980882739706431e-07
manifestations O 0 3.141297355568895e-08
and O 0 8.533859174875147e-10
to O 0 6.673843144788805e-10
investigate O 0 2.5770159339799648e-08
the O 0 2.4805701936969626e-09
incidence O 0 1.7011205954986508e-06
of O 0 1.9534561468415035e-10
APC B-Disease 0 1.4890923694110825e-07
mutations O 0 4.494451033565383e-08
in O 0 9.789493660150583e-10
non O 0 3.816626019670366e-07
- O 1 0.9999047517776489
FAP O 1 0.9999953508377075
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 1.4845537634755601e-06

METHODS O 0 3.39410939886875e-06
The O 0 8.061966205730187e-09
APC B-Disease 0 1.1949467193517194e-07
gene O 0 2.9001759216384926e-08
was O 0 2.8555559694609656e-08
analysed O 0 1.7431109000654033e-08
in O 0 3.973468221118992e-10
190 O 0 6.604100377671784e-09
unrelated O 0 2.0566856662185273e-08
FAP B-Disease 0 3.9228009995895263e-07
and O 0 2.1229272562095503e-08
15 O 0 1.627617862709485e-08
non O 0 1.634827384577875e-07
- O 1 0.9998915195465088
FAP O 1 0.9999974966049194
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
patients O 0 0.11109017580747604
using O 0 3.5907806505974804e-08
denaturing O 0 9.986169970943592e-06
gradient O 0 0.0003387674514669925
gel O 0 2.796967464746558e-06
electrophoresis O 0 1.611701350157091e-07
, O 0 2.18501480797606e-10
the O 0 1.542783435726225e-11
protein O 0 8.570855136724731e-10
truncation O 0 5.0623249592263164e-08
test O 0 7.096136300788203e-08
, O 0 1.3237828888623682e-10
and O 0 1.1095610541467238e-10
direct O 0 3.3067502069883403e-09
sequencing O 0 8.102450976821274e-08
. O 0 3.68017047946978e-08

RESULTS O 0 5.380329821491614e-05
Chain O 0 2.071446942863986e-06
terminating O 0 2.4987426172629057e-07
signals O 0 8.624076741625686e-08
were O 0 5.5258100317701064e-09
only O 0 9.361676989172452e-10
identified O 0 5.452045037657172e-09
in O 0 6.192542589822381e-10
patients O 0 5.77439216442599e-08
belonging O 0 5.223035337564852e-10
to O 0 8.033977927368596e-10
the O 0 4.5410292193182045e-10
FAP B-Disease 0 2.3609597974427743e-06
group O 0 1.1774636021755214e-07
( O 0 5.625419574606383e-10
105 O 0 1.4265908987454168e-07
patients O 0 2.9611317586386576e-05
) O 0 5.9415512509986e-09
. O 0 1.9405051787657612e-08

Amino O 0 2.9472153073584195e-06
acid O 0 9.229278816746955e-07
changes O 0 7.268321500220054e-09
were O 0 2.4780590912598655e-09
identified O 0 3.1220559471023535e-09
in O 0 3.2962890750276586e-10
four O 0 2.440940249925916e-08
patients O 0 6.780815056117717e-07
, O 0 1.190228610115085e-10
three O 0 1.213905226338241e-10
of O 0 4.3085111867124937e-11
whom O 0 1.1639161634491302e-08
belonged O 0 7.968903315003217e-10
to O 0 1.263268517570637e-10
the O 0 1.2018286366100028e-10
non O 0 2.636225238106249e-09
- O 0 2.5046167593245627e-06
FAP O 0 2.3038322979118675e-05
group O 0 1.4790968634770252e-05
of O 0 1.2083851288480218e-06
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
patients O 1 0.9805099964141846
. O 0 2.3094477796803403e-07

Genotype O 1 0.9984886646270752
- O 1 0.9645368456840515
phenotype O 1 0.9834035038948059
correlations O 0 1.2680692634603474e-05
identified O 0 3.619648225594574e-07
significant O 0 5.807369696242404e-09
differences O 0 4.841240652808665e-08
in O 0 7.106871202644527e-10
the O 0 2.2605403660058698e-10
nature O 0 5.625065413461527e-10
of O 0 1.9007928911407568e-11
certain O 0 4.385152796437808e-10
extracolonic O 0 6.910750585120695e-07
manifestations O 0 4.426501476473277e-08
in O 0 2.115262631718906e-09
FAP B-Disease 0 1.9128079657093622e-05
patients O 0 0.000478218134958297
belonging O 0 3.5980185497663797e-09
to O 0 1.8271678614567577e-09
three O 0 2.559072731500578e-09
mutation O 0 1.390472164075618e-07
subgroups O 0 6.8705475086972e-08
. O 0 2.3918753200291576e-08

CONCLUSIONS O 0 0.00013677043898496777
Extended O 0 1.446183796360856e-05
genotype O 0 0.00652404734864831
- O 0 0.0029528725426644087
phenotype O 0 0.0009217127808369696
correlations O 0 1.7794182838315464e-07
made O 0 7.524489475940754e-09
in O 0 2.451389091717715e-10
this O 0 2.162451884224481e-10
study O 0 6.409975883414631e-10
may O 0 2.5848267970474126e-09
have O 0 1.2244297242780533e-10
the O 0 8.438257904919144e-12
potential O 0 4.9014219766219114e-11
to O 0 8.59255583351981e-11
determine O 0 3.0853283816689725e-10
the O 0 1.5336999031889675e-11
most O 0 2.902922000003194e-11
appropriate O 0 4.9290783260547144e-11
surveillance O 0 6.493657611628123e-09
and O 0 1.3166622236937542e-09
prophylactic O 0 2.375450094405096e-06
treatment O 0 0.00019071220594923943
regimens O 0 7.609347107973008e-07
for O 0 1.109536129639821e-09
those O 0 1.8075072549805782e-09
patients O 0 1.184012532462475e-07
with O 0 1.185896492117422e-09
mutations O 0 1.1032695823587346e-07
associated O 0 7.1423968961426e-09
with O 0 2.0462529448650457e-09
life O 0 9.733719963378462e-08
threatening O 0 6.414374638552545e-06
conditions O 0 9.738613698573317e-06
. O 0 2.451649265822198e-07

This O 0 5.216102039184989e-08
study O 0 1.7057939061260186e-08
also O 0 2.847537539096834e-09
provided O 0 5.452697182661836e-10
evidence O 0 1.040711627986468e-09
for O 0 6.635963306633741e-11
the O 0 1.9119568428482836e-10
pathological O 0 1.3985258817683643e-07
nature O 0 1.2754276523807562e-09
of O 0 4.332359124226137e-11
amino O 0 9.303877668287441e-10
acid O 0 7.345377195377978e-09
changes O 0 4.893428440233549e-10
in O 0 3.687530836238295e-10
APC O 0 7.934361434536186e-08
associated O 0 2.21544915746108e-09
with O 0 2.3867594012294546e-10
both O 0 1.0228782265642167e-09
FAP B-Disease 0 6.735281203873456e-07
and O 0 4.07325906337519e-08
non O 0 3.4557641015453555e-07
- O 1 0.9998378753662109
FAP O 1 0.9999970197677612
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
patients O 1 0.9995006322860718
. O 0 1.0776051162508793e-08
. O 0 1.5148396315112223e-08

Inherited B-Disease 1 0.999861478805542
colorectal I-Disease 1 1.0
polyposis I-Disease 1 0.9999287128448486
and O 0 0.39457467198371887
cancer B-Disease 1 0.762872040271759
risk O 0 1.2988266462343745e-07
of O 0 2.1557146345774214e-10
the O 0 1.2074031774389482e-09
APC O 0 1.2702422509391909e-06
I1307K O 0 3.400825562493992e-06
polymorphism O 0 5.2985164074925706e-05
. O 0 7.193668949412313e-08

Germ O 0 0.00046398781705647707
- O 0 0.012563486583530903
line O 0 7.890805136412382e-06
and O 0 2.722337244520645e-09
somatic O 0 4.627180771876738e-08
truncating O 0 1.2948937921919423e-07
mutations O 0 7.265123258548556e-08
of O 0 1.2704813590058706e-10
the O 0 2.0253924926105782e-10
APC B-Disease 0 3.434394457713097e-08
gene O 0 5.440659478495036e-09
are O 0 8.172188620259035e-11
thought O 0 1.1750641570884568e-09
to O 0 1.7464313328829917e-09
initiate O 0 1.144581074186135e-05
colorectal B-Disease 1 1.0
tumor I-Disease 0 0.009084544144570827
formation O 0 6.55265921523096e-08
in O 0 1.4859288910429314e-07
familial B-Disease 1 0.9999997615814209
adenomatous I-Disease 1 0.999998927116394
polyposis I-Disease 1 1.0
syndrome I-Disease 1 1.0
and O 0 5.636558853439055e-06
sporadic O 1 0.5130255818367004
colorectal O 1 1.0
carcinogenesis O 1 0.9653081297874451
, O 0 1.2759494438796537e-07
respectively O 0 9.618740648420498e-08
. O 0 2.159832668269246e-08

Recently O 0 5.648343176289927e-06
, O 0 8.637357495899778e-09
an O 0 1.551892614415351e-09
isoleucine O 0 2.6727804652182385e-05
- O 0 2.8399017537594773e-05
- O 0 3.1262494303518906e-05
> O 0 1.929194581862248e-07
lysine O 0 4.885044972979813e-07
polymorphism O 0 1.5191153579507954e-06
at O 0 2.334497484213216e-09
codon O 0 4.311789680855327e-08
1307 O 0 3.7229125382509665e-07
( O 0 5.690091176013823e-10
I1307K O 0 2.866119963584879e-08
) O 0 7.204534191451728e-11
of O 0 7.192653590781806e-12
the O 0 2.9656249678211566e-11
APC B-Disease 0 4.940717168722131e-09
gene O 0 1.7681235364719328e-09
has O 0 1.898273316314203e-09
been O 0 6.943909336420973e-10
identified O 0 6.111380290718671e-10
in O 0 3.25799005829186e-11
6 O 0 7.59274920714148e-10
% O 0 5.401198238663696e-11
- O 0 3.859008046447343e-08
7 O 0 9.322248750720519e-09
% O 0 4.5652474855994996e-11
of O 0 5.120034170941201e-12
the O 0 2.472293758604138e-10
Ashkenazi O 0 2.0214508822391508e-07
Jewish O 0 1.306999752870297e-08
population O 0 7.122561651584647e-09
. O 0 1.4815785043253982e-08

To O 0 3.5108203633171797e-07
assess O 0 3.098654417499347e-07
the O 0 2.347736893781871e-09
risk O 0 5.498118405000696e-09
of O 0 2.2820219672259334e-11
this O 0 1.800122967354767e-10
common O 0 2.3690631678618956e-09
APC B-Disease 0 2.2247094477734208e-07
allelic O 0 8.68909467044432e-07
variant O 0 0.00014564146113116294
in O 0 3.9084315517357027e-07
colorectal O 1 0.9999998807907104
carcinogenesis O 0 0.003809291636571288
, O 0 3.06993852561277e-09
we O 0 3.6742192621730396e-10
have O 0 1.655405673650634e-10
analyzed O 0 9.533599465427756e-10
a O 0 4.954719412531006e-10
large O 0 4.4321743497555133e-10
cohort O 0 1.115680348107162e-08
of O 0 2.2992151238465652e-10
unselected O 0 1.2563011750899022e-06
Ashkenazi O 0 3.620076256538596e-07
Jewish O 0 4.778916817826939e-09
subjects O 0 5.4865951781835065e-09
with O 0 3.2123381732418466e-09
adenomatous B-Disease 0 1.3806658898829482e-05
polyps I-Disease 0 5.5861688451841474e-05
and O 0 8.231254611246186e-08
. O 0 2.3223611478329076e-08
or O 0 0.00021257212210912257
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, I-Disease 0 1.004517002911598e-08
for O 0 3.758389433006215e-10
the O 0 2.613685268215704e-09
APC O 0 1.765945739862218e-06
I1307K O 0 3.2811769870022545e-06
polymorphism O 0 1.978708132810425e-05
. O 0 4.086144755888199e-08

The O 0 7.563328097148769e-08
APC O 0 5.880154958504136e-07
I1307K O 0 5.703276428903337e-07
allele O 0 4.63729747934849e-07
was O 0 1.607293675931487e-08
identified O 0 3.760435074440238e-09
in O 0 9.136091883021891e-11
48 O 0 1.7634016469258995e-09
( O 0 3.259774047914554e-11
10 O 0 1.2929152193308369e-10
. O 0 5.015225387761113e-11
1 O 0 1.8057283446282213e-10
% O 0 3.5239838824807634e-11
) O 0 2.0121380256421517e-11
of O 0 1.3517806318752434e-10
476 O 0 2.4560913516324945e-06
patients O 0 0.0010674119694158435
. O 0 3.283767213702049e-08

Compared O 0 1.1835652912850492e-05
with O 0 2.206584692743263e-09
the O 0 1.61291521805218e-10
frequency O 0 5.566752747654391e-08
in O 0 1.887700551428395e-10
two O 0 1.1143011513503609e-10
separate O 0 4.638044392990537e-10
population O 0 5.742348263559904e-10
control O 0 5.269899627791119e-09
groups O 0 2.732604975630437e-10
, O 0 1.025417042943566e-10
the O 0 2.0380877541192888e-10
APC O 0 1.3668407916611613e-07
I1307K O 0 3.110224326974276e-07
allele O 0 8.160252917832622e-08
is O 0 1.240913927169629e-09
associated O 0 6.630880289293373e-10
with O 0 6.359834880953485e-11
an O 0 5.345702769332661e-10
estimated O 0 5.466643582252573e-09
relative O 0 1.335732680018964e-08
risk O 0 4.798929698068832e-09
of O 0 2.254344488861193e-10
1 O 0 6.282034092919275e-08
. O 0 7.332781848390368e-08

5 O 0 6.9230864028213546e-06
- O 0 3.432769517530687e-05
1 O 0 5.166519940758008e-07
. O 0 8.925471917109462e-08

7 O 0 8.674367563799024e-06
for O 0 1.336496779913432e-06
colorectal B-Disease 1 0.9999996423721313
neoplasia I-Disease 0 0.014387311413884163
( O 0 4.431468880738976e-08
both O 0 8.265078577096574e-08
P O 0 2.1015819584135897e-05
= O 0 9.37744673024099e-08
. O 0 2.591590053668824e-09
01 O 0 7.415144409606e-08
) O 0 3.3746403449441686e-09
. O 0 1.5472943815098006e-08

Furthermore O 0 8.798414455668535e-06
, O 0 1.5561202104663607e-08
compared O 0 7.282323188917417e-09
with O 0 5.22755005949449e-10
noncarriers O 0 1.2053925502186758e-06
, O 0 1.6125623059082272e-09
APC O 0 3.070660525850144e-08
I1307K O 0 9.215578700150218e-08
carriers O 0 1.2664252757588201e-08
had O 0 4.010359599959656e-09
increased O 0 4.0501918485702504e-10
numbers O 0 1.1568723756738564e-10
of O 0 5.7040403650399085e-11
adenomas B-Disease 0 5.4272682064038236e-06
and O 0 0.004950700793415308
colorectal B-Disease 1 1.0
cancers I-Disease 1 0.9936192631721497
per O 0 1.0212897905148566e-06
patient O 0 0.000278806866845116
( O 0 3.903869227883661e-09
P O 0 8.78455557540292e-06
= O 0 3.6354503407665106e-08
. O 0 3.9971617682432736e-10
03 O 0 1.8888179909026803e-09
) O 0 3.155843641966527e-11
, O 0 6.117931855564862e-11
as O 0 1.8325348183356738e-10
well O 0 7.583206979022705e-11
as O 0 1.9595798594895797e-10
a O 0 3.758111599694303e-09
younger O 0 6.356024186970899e-07
age O 0 3.3932998633190437e-09
at O 0 7.029112847334318e-10
diagnosis O 0 3.4026650155283278e-06
. O 0 4.646194895485678e-08

We O 0 1.8527067879858805e-07
conclude O 0 2.888279482249345e-08
that O 0 8.489052238935813e-10
the O 0 1.7061761725667424e-10
APC O 0 2.6442590339570415e-08
I1307K O 0 8.883606739118477e-08
variant O 0 3.442534080022597e-07
leads O 0 1.2493073242580977e-08
to O 0 1.145882322362013e-08
increased O 0 4.1906423575710505e-06
adenoma B-Disease 1 0.9999933242797852
formation O 0 3.7035487565617586e-08
and O 0 1.31425359484183e-09
directly O 0 1.251192927043121e-09
contributes O 0 1.0196719024690992e-09
to O 0 5.816833681393518e-10
3 O 0 1.6391877855070902e-09
% O 0 1.954193890041367e-10
- O 0 5.631941846218069e-08
4 O 0 1.77301107129324e-08
% O 0 1.1311947906156306e-10
of O 0 9.266694182830104e-12
all O 0 7.058736928300391e-10
Ashkenazi O 0 2.8015298084937967e-05
Jewish O 0 0.0014411123702302575
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
. O 0 4.432060904946411e-07

The O 0 9.372296716492201e-08
estimated O 0 4.175289447516661e-08
relative O 0 3.921932290040786e-08
risk O 0 1.3359032990933883e-08
for O 0 1.0531640004529663e-09
carriers O 0 1.5115148244149168e-08
may O 0 7.973894433632722e-09
justify O 0 3.968918083074868e-09
specific O 0 1.8707324578315365e-10
clinical O 0 3.2813487482741266e-09
screening O 0 9.256104216426309e-10
for O 0 3.980953414139954e-11
the O 0 3.8949329872473015e-11
360 O 0 8.510651738902197e-09
, O 0 1.2343626121236184e-10
000 O 0 3.4646169266849824e-10
Americans O 0 5.291663218720544e-10
expected O 0 7.078029828910815e-10
to O 0 1.6243885125888369e-09
harbor O 0 1.1265542099181403e-07
this O 0 8.797467754284582e-10
allele O 0 3.047473384754085e-08
, O 0 1.031529583972457e-10
and O 0 1.0005176548366634e-10
genetic O 0 9.456467831014947e-10
testing O 0 7.928227518938513e-10
in O 0 4.726895264095532e-11
the O 0 2.5185643501290933e-11
setting O 0 6.390638573883223e-10
of O 0 7.131526619241768e-11
long O 0 1.7525554341091265e-08
- O 0 4.540117060969351e-06
term O 0 9.340958229131502e-08
- O 0 2.4666562126185454e-07
outcome O 0 4.108551010517658e-08
studies O 0 2.2830898283032752e-10
may O 0 1.046458142361928e-09
impact O 0 1.8174081128918829e-09
significantly O 0 6.988025802456832e-07
on O 0 0.33804020285606384
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
prevention O 0 4.410556755374273e-07
in O 0 9.45717171241256e-10
this O 0 6.518373618646933e-10
population O 0 3.6667162639503204e-09
. O 0 1.0545997852773326e-08

Localization O 0 1.531228917883709e-05
of O 0 5.882037523718964e-09
human O 0 1.0241104853037086e-08
BRCA1 O 0 4.034568235056213e-07
and O 0 3.841952977978735e-09
its O 0 1.9332411227424018e-09
loss O 0 2.1175068809498043e-07
in O 0 3.3728126958010307e-09
high O 0 2.1989900744756596e-07
- O 0 3.8769463571952656e-05
grade O 0 8.64880149720193e-08
, O 0 2.638529172926951e-09
non B-Disease 0 3.601535780717313e-08
- I-Disease 0 0.4847286343574524
inherited I-Disease 1 0.9858695268630981
breast I-Disease 1 0.9998863935470581
carcinomas I-Disease 1 0.9999995231628418
. O 0 2.9056132007099222e-06

Although O 0 1.0878159173444146e-06
the O 0 2.044084013164138e-09
link O 0 2.438673796234525e-08
between O 0 2.0065140660108227e-09
the O 0 1.597739007763721e-08
BRCA1 O 0 0.017820855602622032
tumour B-Disease 1 0.9999986886978149
- O 0 1.0090189789480064e-05
suppressor O 0 1.4433164324145764e-05
gene O 0 3.4245343272232276e-07
and O 0 1.2385079628529638e-07
hereditary B-Disease 1 0.9990954399108887
breast I-Disease 1 0.9999978542327881
and I-Disease 1 0.9999808073043823
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
is O 0 7.655620493096649e-08
established O 0 6.262671492507366e-10
, O 0 6.260147955572393e-11
the O 0 1.0850820242325199e-11
role O 0 3.2714794762078725e-10
, O 0 7.162197918075819e-11
if O 0 8.203625972980078e-11
any O 0 6.125824847380557e-11
, O 0 4.388413590850071e-11
of O 0 2.3029621612491447e-11
BRCA1 O 0 4.4810892774194144e-08
in O 0 7.113353239773801e-10
non B-Disease 0 1.5173149847669265e-08
- I-Disease 0 0.0208735428750515
familial I-Disease 1 0.8440164923667908
cancers I-Disease 1 0.836063027381897
is O 0 7.906308496785641e-08
unclear O 0 5.391653417063935e-07
. O 0 3.8817596248463815e-08

BRCA1 O 0 0.007772059179842472
mutations O 0 0.0003079966700170189
are O 0 2.498749118728938e-08
rare O 0 2.244063601608559e-08
in O 0 1.2195201293252467e-08
sporadic B-Disease 0 0.2521035969257355
cancers I-Disease 1 0.9909819960594177
, O 0 8.381295657500232e-09
but O 0 5.633539856830794e-09
loss O 0 7.73381270136042e-09
of O 0 8.750337954221976e-11
BRCA1 O 0 8.972818363872648e-07
resulting O 0 2.7394648327572213e-08
from O 0 6.84228063096981e-10
reduced O 0 4.892836003023149e-08
expression O 0 1.2006475813564066e-08
or O 0 4.6440992718110863e-10
incorrect O 0 2.9115879485175356e-08
subcellular O 0 2.777086649530247e-07
localization O 0 3.866729514356848e-08
is O 0 8.124697026268279e-10
postulated O 0 1.9364232883845034e-08
to O 0 9.269867651262587e-10
be O 0 4.765224881353447e-10
important O 0 9.889668944884633e-11
in O 0 4.303388478898995e-10
non B-Disease 0 1.2046342590110726e-08
- I-Disease 0 0.017360739409923553
familial I-Disease 1 0.9698649048805237
breast I-Disease 1 0.9999963045120239
and I-Disease 1 0.9977205395698547
ovarian I-Disease 1 1.0
cancers I-Disease 1 0.9999996423721313
. O 0 1.08860353975615e-06

Epigenetic O 0 0.00030161652830429375
loss O 0 0.0015627556713297963
, O 0 8.235164727921074e-08
however O 0 9.609679274547034e-09
, O 0 3.0877597700929016e-10
has O 0 6.6893561800895895e-09
not O 0 7.58568485803579e-10
received O 0 4.869741832003172e-10
general O 0 3.063146125636962e-10
acceptance O 0 2.0294306235513204e-09
due O 0 1.5738168546164388e-09
to O 0 2.2360300278023715e-09
controversy O 0 1.5361145244696672e-08
regarding O 0 1.1299748914339602e-09
the O 0 4.296794031688478e-10
subcellular O 0 1.880361395478758e-07
localization O 0 3.1913923947968215e-08
of O 0 1.201214544499507e-10
BRCA1 O 0 3.5869064163307485e-08
proteins O 0 6.980214184437727e-10
, O 0 2.834325552036887e-10
reports O 0 7.518531353056801e-10
of O 0 1.3579018118270447e-11
which O 0 7.327266571266478e-10
have O 0 9.56787005179649e-09
ranged O 0 4.165378086895544e-08
from O 0 9.46768913268059e-11
exclusively O 0 6.342744662823918e-10
nuclear O 0 1.0441115749770802e-09
, O 0 4.6695890210113333e-11
to O 0 1.868728227716332e-10
conditionally O 0 1.2672207105879352e-07
nuclear O 0 2.0147745694032437e-09
, O 0 4.2277726458594955e-11
to O 0 9.72910363383761e-11
the O 0 8.857554273378199e-11
ER O 0 4.157810735705425e-07
/ O 0 1.1888389828129675e-08
golgi O 0 1.4214602117590402e-07
, O 0 2.4081461824643213e-10
to O 0 3.829805916844009e-10
cytoplasmic O 0 1.0357772417535216e-08
invaginations O 0 6.982403988331498e-08
into O 0 4.766197436723019e-10
the O 0 1.9915437354800503e-10
nucleus O 0 2.8310433108913458e-08
. O 0 5.4901967416753905e-09

In O 0 4.651807827826815e-08
an O 0 1.1947872691209227e-09
attempt O 0 3.245720492373039e-08
to O 0 8.37531910491407e-09
resolve O 0 8.431243969653224e-08
this O 0 1.4578124263309178e-09
issue O 0 8.638427750895517e-09
, O 0 8.587443950380802e-11
we O 0 5.063872585142626e-11
have O 0 3.259452430182108e-10
comprehensively O 0 1.5956260313032544e-07
characterized O 0 1.0058805344215216e-07
19 O 0 7.4184227649709555e-09
anti O 0 3.400474781756202e-07
- O 0 0.00019881274783983827
BRCA1 O 0 0.0001518290227977559
antibodies O 0 2.1429159460240044e-06
. O 0 2.571654000860235e-08

These O 0 6.102638394622772e-08
reagents O 0 7.344917918317151e-08
detect O 0 2.3128002624162036e-07
a O 0 7.585370553897519e-09
220 O 0 1.6006275416202698e-08
- O 0 2.6914852924164734e-07
kD O 0 4.0703474724068656e-07
protein O 0 1.2504705715343789e-08
localized O 0 3.0916229576405385e-08
in O 0 1.5378719131486918e-10
discrete O 0 5.439455996736342e-09
nuclear O 0 1.0259776139776022e-08
foci O 0 2.0792001009795058e-07
in O 0 9.386529331578686e-10
all O 0 3.138018733750414e-10
epithelial O 0 4.836699645238696e-07
cell O 0 8.257495210273191e-06
lines O 0 6.112167625360598e-07
, O 0 1.5514893536572316e-10
including O 0 9.354674673778263e-11
those O 0 1.0672559364044432e-10
derived O 0 8.655889338626821e-10
from O 0 3.3993698966838792e-09
breast B-Disease 0 0.006916292477399111
malignancies I-Disease 0 0.00010795881098601967
. O 0 1.505232205545326e-07

Immunohistochemical O 0 0.0015908138593658805
staining O 0 8.408371650148183e-05
of O 0 3.24017825903411e-08
human O 0 1.2138465876887494e-07
breast O 0 0.0037374154198914766
specimens O 0 6.653030482084432e-07
also O 0 1.0565612029722615e-07
revealed O 0 1.785401622100835e-07
BRCA1 O 0 4.0787719512991316e-07
nuclear O 0 1.8274372237669922e-08
foci O 0 6.302430506366363e-07
in O 0 1.0297063646191873e-08
benign O 0 0.0033183118794113398
breast O 1 0.9658952355384827
, O 0 1.2406830762756726e-07
invasive B-Disease 0 0.0012454706011340022
lobular I-Disease 1 0.9998517036437988
cancers I-Disease 1 0.9998087286949158
and O 0 9.317698186350754e-07
low B-Disease 0 5.063336720922962e-05
- I-Disease 1 0.7941266894340515
grade I-Disease 0 7.96373060438782e-05
ductal I-Disease 1 0.9932758808135986
carcinomas I-Disease 1 0.9999996423721313
. O 0 6.953285264899023e-06

Conversely O 0 2.3492837499361485e-05
, O 0 1.8138765156550107e-08
BRCA1 O 0 3.4420813221913704e-07
expression O 0 2.840887880495302e-08
was O 0 6.891612258641544e-08
reduced O 0 5.6835749440153904e-09
or O 0 2.690229705670788e-10
undetectable O 0 5.1799804445806785e-09
in O 0 7.907458021705338e-11
the O 0 7.004376939567791e-11
majority O 0 3.609139431759445e-09
of O 0 3.178836360806514e-11
high O 0 2.5694085081795492e-08
- O 0 3.2851490686880425e-05
grade O 0 1.4209682319688e-07
, O 0 2.5104819556531766e-08
ductal B-Disease 0 0.007151945028454065
carcinomas I-Disease 1 0.9999997615814209
, O 0 4.407039178033756e-09
suggesting O 0 1.1412690348322485e-08
that O 0 5.059617724789689e-10
absence O 0 4.781184892443946e-10
of O 0 7.305270971480482e-11
BRCA1 O 0 1.1958964307723363e-07
may O 0 2.0442955772637106e-08
contribute O 0 6.400470708989303e-10
to O 0 1.0087000124059387e-09
the O 0 5.02656694045811e-10
pathogenesis O 0 6.195475688031138e-09
of O 0 1.011832111152966e-11
a O 0 2.822823086390258e-10
significant O 0 1.05643327419358e-09
percentage O 0 2.4390494068882163e-09
of O 0 3.1089991692212493e-10
sporadic B-Disease 0 0.006373302079737186
breast I-Disease 1 0.9999504089355469
cancers I-Disease 0 0.3461019694805145
. O 0 2.6984135814700494e-08
. O 0 2.6768068650540044e-08

